data_1iyv_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1iyv _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.4 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 52.4 p . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -138.06 141.28 40.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.321 -0.862 . . . . 0.0 109.478 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.8 tt -89.45 151.46 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.416 HD13 HG22 ' A' ' 4' ' ' ILE . 24.8 mm -115.79 107.8 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.51 ' NH1' ' HA2' ' A' ' 66' ' ' GLY . 0.0 OUTLIER -92.28 168.13 11.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.504 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 75.2 t -44.28 142.27 2.32 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.23 -170.64 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.447 2.098 . . . . 0.0 110.371 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.85 101.91 12.67 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.508 HD12 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.35 -61.66 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 109.253 -179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.75 12.5 6.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.02 -139.49 2.65 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 31.8 t0 -111.14 136.86 49.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -1.152 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -105.48 139.72 14.81 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.2 mt-10 -122.54 135.08 54.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.176 -1.19 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.403 HG22 HD12 ' A' ' 63' ' ' LEU . 13.3 t -81.52 130.64 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.91 . . . . 0.0 109.399 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.422 ' HA ' HD11 ' A' ' 16' ' ' ILE . 32.2 mm -97.05 -42.8 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.176 -0.953 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.39 151.5 15.38 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.881 . . . . 0.0 109.493 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 2.5 tp -110.87 110.26 20.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.422 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -101.98 49.76 0.85 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.882 . . . . 0.0 109.407 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.404 HG22 HD22 ' A' ' 32' ' ' LEU . 0.8 OUTLIER -146.89 157.47 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.66 173.64 7.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.21 -0.931 . . . . 0.0 109.524 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.438 ' HA ' HG13 ' A' ' 52' ' ' VAL . 15.0 t -85.05 147.27 26.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.14 7.8 63.75 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -85.04 130.62 34.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.43 111.48 20.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.453 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.437 HD11 HD13 ' A' ' 32' ' ' LEU . 3.1 mt -94.31 -171.42 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.3 -0.875 . . . . 0.0 109.185 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 29' ' ' GLU . 3.2 mt-10 -149.05 134.92 18.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.421 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' A' ' 29' ' ' GLU . 3.0 p -50.28 91.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.491 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.78 -60.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.348 -0.845 . . . . 0.0 109.534 179.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.429 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.7 tt0 -57.19 162.79 2.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.567 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -80.08 -179.11 52.31 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -143.43 -40.45 0.3 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -1.164 . . . . 0.0 109.567 179.962 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.8 m -158.63 173.65 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.171 -0.956 . . . . 0.0 109.523 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.1 t -132.27 104.7 8.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.268 -0.895 . . . . 0.0 109.494 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.435 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.93 164.75 14.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.431 ' CG ' ' N ' ' A' ' 37' ' ' SER . 14.5 tt0 -117.22 158.79 23.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.431 ' N ' ' CG ' ' A' ' 36' ' ' GLU . 2.3 t -130.12 179.76 5.7 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.308 -0.87 . . . . 0.0 109.449 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.19 -59.06 2.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 109.415 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.86 54.55 1.58 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.522 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.65 146.16 0.97 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 78.6 p -105.36 137.22 43.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.1 mmt -120.67 178.81 4.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.209 -0.932 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -138.42 161.4 37.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.892 . . . . 0.0 109.529 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 1.8 t -141.66 96.99 6.7 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.376 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 35.7 Cg_endo -77.56 -168.4 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.476 2.117 . . . . 0.0 110.452 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.454 ' O ' ' HA ' ' A' ' 28' ' ' VAL . 1.6 t -85.26 113.71 52.03 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.14 1.9 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.37 2.047 . . . . 0.0 110.256 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.476 ' CG ' HD23 ' A' ' 72' ' ' LEU . 0.5 OUTLIER -160.17 138.12 9.93 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.88 . . . . 0.0 109.334 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.9 102.19 11.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.184 -0.948 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.511 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -159.11 -167.82 20.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 14.4 p -110.59 138.28 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -1.137 . . . . 0.0 109.496 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.438 HG13 ' HA ' ' A' ' 22' ' ' THR . 61.6 t -56.29 122.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 109.527 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.59 -49.37 5.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.457 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 t -149.95 163.66 37.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 43.5 t -121.35 131.84 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.25 -0.906 . . . . 0.0 109.428 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.06 21.43 13.74 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.515 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 27.5 m -148.23 162.56 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 ttpt -123.73 155.13 38.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.453 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.417 ' HB3' ' HB2' ' A' ' 18' ' ' LEU . 1.7 pp -72.09 139.27 48.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.524 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.59 -13.85 57.2 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -82.79 148.78 27.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -1.162 . . . . 0.0 109.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -104.59 141.12 36.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.175 -0.953 . . . . 0.0 109.469 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.517 ' CD1' ' N ' ' A' ' 63' ' ' LEU . 1.5 mp -130.26 164.26 24.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -0.888 . . . . 0.0 109.531 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -115.32 154.11 29.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.987 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.3 OUTLIER -42.72 130.72 4.11 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.285 -0.884 . . . . 0.0 109.663 -179.939 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.51 ' HA2' ' NH1' ' A' ' 5' ' ' ARG . . . 107.83 -12.58 38.32 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -84.23 131.0 34.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -1.16 . . . . 0.0 109.471 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.26 147.13 48.49 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.289 -0.882 . . . . 0.0 109.448 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.515 ' HA ' ' CG1' ' A' ' 57' ' ' VAL . 19.8 mm -103.34 -71.46 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.229 -0.919 . . . . 0.0 109.457 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.448 HG21 ' O ' ' A' ' 69' ' ' ILE . 0.9 OUTLIER -142.15 171.14 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -0.912 . . . . 0.0 109.5 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -122.7 117.44 25.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.339 -0.851 . . . . 0.0 109.475 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.511 HD12 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -89.99 142.18 27.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.247 -0.908 . . . . 0.0 109.424 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.498 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -115.61 91.86 31.23 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.488 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.541 0 C-N-CA 122.597 2.198 . . . . 0.0 110.401 -179.953 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 80.6 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.33 164.24 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.452 HG23 ' HB3' ' A' ' 68' ' ' ALA . 57.0 mt -97.43 140.9 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -0.918 . . . . 0.0 109.456 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.431 HG22 HD11 ' A' ' 4' ' ' ILE . 77.0 mt -99.73 114.21 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.505 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.415 ' HA ' HD13 ' A' ' 69' ' ' ILE . 1.5 ptt180 -110.29 164.68 12.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.253 -0.904 . . . . 0.0 109.434 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 74.9 t -65.99 142.28 97.94 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.175 -0.953 . . . . 0.0 109.393 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.5 Cg_endo -78.16 -171.72 1.29 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.515 2.143 . . . . 0.0 110.39 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -68.04 112.86 5.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.414 ' O ' HG13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -110.18 -29.25 2.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.224 -0.923 . . . . 0.0 108.741 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.62 -47.34 2.32 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.74 -144.96 7.18 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -99.63 146.98 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.2 -1.176 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.02 148.35 18.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.428 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 44.2 tt0 -127.78 146.6 50.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -1.108 . . . . 0.0 109.424 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.449 HG21 HD22 ' A' ' 35' ' ' LEU . 3.6 t -84.33 156.96 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.182 -0.949 . . . . 0.0 109.489 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.439 HD11 ' O ' ' A' ' 34' ' ' VAL . 3.6 mp -123.79 -36.61 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.279 -0.888 . . . . 0.0 109.496 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -151.44 151.39 31.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.22 -0.925 . . . . 0.0 109.449 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.52 118.46 36.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.455 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 mt -90.26 30.55 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.498 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.47 ' CG1' HD12 ' A' ' 26' ' ' ILE . 31.8 m -149.69 156.66 7.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.404 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.3 OUTLIER -130.26 176.3 8.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.421 ' O ' HG22 ' A' ' 22' ' ' THR . 14.7 t -75.15 124.57 27.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.223 -0.923 . . . . 0.0 109.504 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.84 1.05 89.08 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.404 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -84.61 142.17 30.14 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.145 -1.209 . . . . 0.0 109.474 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 5.0 tt -108.66 121.38 44.9 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.207 -0.933 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.47 HD12 ' CG1' ' A' ' 20' ' ' VAL . 2.5 mt -90.29 -171.41 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.268 -0.895 . . . . 0.0 109.177 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -145.28 172.69 12.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.7 p -74.06 82.27 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 162.94 -58.55 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.298 -0.876 . . . . 0.0 109.48 179.918 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.41 ' C ' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -44.29 157.88 0.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.509 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.23 -153.56 0.99 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.52 ' CD2' ' HA ' ' A' ' 46' ' ' SER . 0.1 OUTLIER -159.87 -73.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -1.148 . . . . 0.0 109.517 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.439 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 25.8 m -135.37 135.09 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.439 ' O ' HD11 ' A' ' 16' ' ' ILE . 20.5 t -107.09 92.82 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.343 -0.848 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.449 HD22 HG21 ' A' ' 15' ' ' VAL . 0.4 OUTLIER -89.97 -173.69 3.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.945 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -130.41 167.58 18.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.4 m -126.61 172.25 10.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.57 -58.8 3.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 11.6 pttm -132.27 53.38 2.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.432 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.1 -166.58 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.249 -0.907 . . . . 0.0 109.46 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.8 155.68 38.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 4.5 mmt -138.71 145.55 40.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.471 ' CD ' ' N ' ' A' ' 44' ' ' VAL . 14.3 tm-20 -159.99 150.13 18.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.268 -0.895 . . . . 0.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.501 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 49.4 t -135.77 140.1 32.64 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.448 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.501 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.28 -168.65 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.442 2.095 . . . . 0.0 110.368 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.52 ' HA ' ' CD2' ' A' ' 32' ' ' LEU . 0.3 OUTLIER -85.52 113.38 50.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.6 Cg_endo -78.31 -3.17 13.16 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.256 1.971 . . . . 0.0 110.381 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.515 ' CB ' HD21 ' A' ' 72' ' ' LEU . 3.6 mtmm -160.37 130.92 5.44 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.344 -0.847 . . . . 0.0 109.406 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.51 90.67 7.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.439 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.426 ' O ' ' HG ' ' A' ' 25' ' ' LEU . . . -146.25 -166.24 11.98 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.5 p -109.97 160.26 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.28 -1.13 . . . . 0.0 109.482 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.0 t -76.04 123.6 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.967 . . . . 0.0 109.443 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -94.23 -49.41 5.74 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.495 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 t -158.35 118.21 3.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.465 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.8 t -87.66 133.17 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.431 ' O ' ' OG ' ' A' ' 56' ' ' SER . 8.2 t -113.31 29.18 8.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.496 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.422 HG23 HG21 ' A' ' 69' ' ' ILE . 35.6 m -149.47 175.6 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.44 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -136.5 157.57 46.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.467 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -68.22 138.87 55.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.448 -179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.45 -10.67 68.47 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.44 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 41.6 m-20 -80.9 144.95 31.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -1.144 . . . . 0.0 109.482 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.428 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 14.2 ptmt -110.52 148.09 32.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.3 mp -138.95 166.68 23.85 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.244 -0.91 . . . . 0.0 109.525 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 5.0 mtpt -99.58 148.4 24.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 23.8 pt-20 -42.81 142.76 0.82 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.666 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.83 -9.48 76.68 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.98 137.21 35.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -1.156 . . . . 0.0 109.516 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.452 ' HB3' HG23 ' A' ' 3' ' ' ILE . . . -67.81 176.83 2.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.422 HG21 HG23 ' A' ' 57' ' ' VAL . 2.1 mp -140.9 -67.24 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 30.1 pt -139.45 173.24 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 109.472 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -127.83 108.47 10.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.515 HD21 ' CB ' ' A' ' 48' ' ' LYS . 0.6 OUTLIER -90.09 142.24 27.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.436 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.402 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 60.6 tt0 -116.54 88.32 23.84 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HG3' ' HD2' ' A' ' 48' ' ' LYS . 35.7 Cg_endo . . . . . 0 C--N 1.31 -1.492 0 C-N-CA 122.652 2.235 . . . . 0.0 110.409 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.44 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 53.6 p . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -82.44 171.64 13.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 41.0 mm -107.0 143.91 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.514 ' CG2' ' HG3' ' A' ' 47' ' ' PRO . 38.8 mm -107.16 118.59 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.522 ' CG ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -103.73 -171.13 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.185 -0.947 . . . . 0.0 109.541 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.515 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 65.7 t -79.47 142.72 58.39 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.319 -0.863 . . . . 0.0 109.311 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.515 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.06 -168.79 0.65 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.599 2.199 . . . . 0.0 110.509 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -82.74 111.18 18.43 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.395 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.91 -10.93 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.935 . . . . 0.0 109.345 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.98 39.63 58.53 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.07 -153.72 24.88 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -89.34 174.15 7.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.289 -1.124 . . . . 0.0 109.497 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -147.51 104.8 0.3 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.463 ' N ' ' CD ' ' A' ' 14' ' ' GLU . 6.2 mp0 -92.82 112.92 25.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -1.153 . . . . 0.0 109.442 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.464 HG13 ' HA ' ' A' ' 59' ' ' LEU . 40.3 t -54.33 134.75 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.5 mm -108.56 -50.88 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.228 -0.92 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -144.19 153.03 41.68 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.454 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.495 HD22 ' CG2' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -120.82 116.08 24.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.924 . . . . 0.0 109.5 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.452 ' CD1' ' O ' ' A' ' 19' ' ' LEU . 1.3 pp -106.1 52.15 0.73 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.354 -0.841 . . . . 0.0 109.525 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.495 ' CG2' HD22 ' A' ' 18' ' ' LEU . 0.8 OUTLIER -140.2 169.54 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.415 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . 3.5 tptt -144.32 169.28 18.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.211 -0.931 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.427 ' O ' HG21 ' A' ' 22' ' ' THR . 15.2 t -84.11 132.56 34.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.427 ' C ' HG22 ' A' ' 51' ' ' VAL . . . 84.26 -1.43 88.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.415 ' CG ' ' HB3' ' A' ' 21' ' ' LYS . 5.7 m-20 -84.05 134.29 34.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.115 -1.227 . . . . 0.0 109.527 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.464 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -94.36 116.37 28.73 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.881 . . . . 0.0 109.41 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.462 ' CD1' HD13 ' A' ' 32' ' ' LEU . 2.1 mt -90.52 -171.35 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.228 -0.92 . . . . 0.0 109.157 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -146.37 159.47 43.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.95 83.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.88 . . . . 0.0 109.47 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 162.83 -32.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.3 -0.875 . . . . 0.0 109.518 179.914 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -76.28 148.64 37.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.493 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -60.44 -175.66 1.28 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -148.22 -68.59 0.23 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -1.105 . . . . 0.0 109.463 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -131.71 171.42 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.584 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 43' ' ' GLU . 75.4 t -134.14 92.72 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.419 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.4 mp -90.0 149.82 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -0.873 . . . . 0.0 109.423 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -115.17 139.1 50.21 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.24 -179.21 5.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 109.515 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -69.76 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -49.69 6.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.892 . . . . 0.0 109.47 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 173.89 173.63 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.28 -0.887 . . . . 0.0 109.447 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.65 128.94 34.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.294 -0.879 . . . . 0.0 109.501 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.7 mtt -127.2 105.73 8.76 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.45 ' HB3' HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -80.01 156.76 27.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 44.9 t -133.96 140.45 36.39 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.389 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.518 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.0 Cg_endo -78.44 -168.44 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.599 2.199 . . . . 0.0 110.434 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.425 ' HA ' HD11 ' A' ' 32' ' ' LEU . 7.7 t -85.23 129.93 53.84 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.404 -0.81 . . . . 0.0 109.332 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.514 ' HG3' ' CG2' ' A' ' 4' ' ' ILE . 36.0 Cg_endo -78.59 -1.88 11.98 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.366 2.044 . . . . 0.0 110.513 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.468 ' HD3' HD21 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.18 128.57 4.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.533 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.09 86.33 5.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 25' ' ' LEU . . . -146.62 -166.12 12.03 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.443 ' O ' HG11 ' A' ' 51' ' ' VAL . 7.0 p -104.88 139.47 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -1.167 . . . . 0.0 109.466 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 70.5 t -56.98 127.85 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' SER . 18.4 tptm -100.7 -15.91 17.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.202 -0.936 . . . . 0.0 109.485 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.412 ' CB ' ' O ' ' A' ' 53' ' ' LYS . 0.5 OUTLIER 171.12 145.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.464 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 76.1 t -101.11 142.19 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.458 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 61.6 m -121.84 13.58 10.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.89 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 10.8 m -147.76 166.99 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 109.504 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -125.52 171.23 10.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.464 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.464 ' HA ' HG13 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -79.03 118.78 21.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.933 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.51 -11.47 42.82 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -70.86 150.93 45.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.479 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 10.2 tttm -100.19 120.26 39.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.463 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.508 ' N ' HD21 ' A' ' 63' ' ' LEU . 4.0 mm? -131.14 143.93 51.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -105.04 153.21 21.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.46 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 4.3 pt-20 -42.9 143.63 0.7 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.66 -18.1 58.09 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' ' O ' ' A' ' 68' ' ' ALA . 7.7 m-20 -85.12 129.99 34.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -1.156 . . . . 0.0 109.526 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.522 ' HA ' ' CG ' ' A' ' 5' ' ' ARG . . . -48.5 175.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.458 ' CG1' HG21 ' A' ' 6' ' ' VAL . 21.9 mm -146.93 -47.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.463 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -158.68 -177.11 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.483 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -127.75 161.82 28.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.208 -0.933 . . . . 0.0 109.494 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.468 HD21 ' HD3' ' A' ' 48' ' ' LYS . 0.7 OUTLIER -143.15 135.8 27.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.392 -179.948 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 71.3 tt0 -114.68 90.24 21.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.2 Cg_endo . . . . . 0 C--N 1.309 -1.517 0 C-N-CA 122.557 2.171 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.438 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 18.3 p . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.447 ' O ' HD13 ' A' ' 4' ' ' ILE . 3.4 mt-10 -121.37 152.57 38.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.507 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.424 ' O ' HG21 ' A' ' 3' ' ' ILE . 14.7 tt -86.52 152.96 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.447 HD13 ' O ' ' A' ' 2' ' ' GLU . 5.2 mp -131.92 118.54 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.254 -0.904 . . . . 0.0 109.464 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.442 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.79 175.03 7.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.452 179.954 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.443 HG12 ' HD2' ' A' ' 7' ' ' PRO . 53.5 t -55.2 139.88 64.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.323 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.473 ' HG3' ' CG1' ' A' ' 44' ' ' VAL . 36.1 Cg_endo -78.59 -172.94 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.533 2.155 . . . . 0.0 110.359 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -85.11 110.66 19.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.8 -56.47 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.421 -179.917 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.96 -27.32 1.89 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . -179.8 118.42 0.59 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.51 ' O ' ' CD1' ' A' ' 9' ' ' ILE . 0.2 OUTLIER 49.76 -179.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.267 -1.137 . . . . 0.0 109.478 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.453 ' CA ' HD21 ' A' ' 35' ' ' LEU . . . -172.24 90.97 0.09 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.445 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 19.3 mt-10 -94.98 124.05 38.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.339 -1.095 . . . . 0.0 109.487 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.7 t -73.12 132.33 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.424 HG23 ' HB ' ' A' ' 34' ' ' VAL . 4.4 tt -92.34 -28.76 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -174.43 151.2 1.53 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.18 103.45 13.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.45 15.07 7.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.284 -0.885 . . . . 0.0 109.375 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.459 HG13 ' HG ' ' A' ' 32' ' ' LEU . 11.9 m -113.28 178.02 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.67 158.43 43.78 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.9 t -73.64 141.89 46.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.288 -0.883 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.463 ' O ' HG22 ' A' ' 51' ' ' VAL . . . 82.85 -6.61 69.55 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.14 135.62 36.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -1.141 . . . . 0.0 109.446 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.484 ' CD1' ' C ' ' A' ' 50' ' ' GLY . 22.4 tp -93.24 110.68 22.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.229 -0.92 . . . . 0.0 109.469 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.461 HD11 HD13 ' A' ' 32' ' ' LEU . 2.7 mt -91.27 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.248 -0.908 . . . . 0.0 109.201 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -139.36 -178.63 5.46 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.208 -0.933 . . . . 0.0 109.443 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 14.2 p -84.79 69.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.554 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 169.21 -40.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.366 -0.834 . . . . 0.0 109.435 179.884 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.8 OUTLIER -56.73 138.49 52.82 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 109.364 179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.462 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -69.5 166.05 49.15 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.518 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.42 -42.01 1.69 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.366 -1.079 . . . . 0.0 109.446 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 25.6 m -158.63 174.33 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.154 -0.966 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.424 ' HB ' HG23 ' A' ' 16' ' ' ILE . 70.7 t -128.77 102.53 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.227 -0.921 . . . . 0.0 109.449 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.453 HD21 ' CA ' ' A' ' 13' ' ' GLY . 3.5 mp -89.98 141.67 28.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.216 -0.928 . . . . 0.0 109.4 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.419 ' OE2' ' OG ' ' A' ' 41' ' ' SER . 6.0 tt0 -115.79 134.31 55.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.23 -0.919 . . . . 0.0 109.513 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.9 m -132.03 -177.77 4.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.894 . . . . 0.0 109.446 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.04 -16.54 60.2 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -84.16 -55.27 4.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.94 . . . . 0.0 109.439 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 177.15 -179.54 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.889 . . . . 0.0 109.454 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.419 ' OG ' ' OE2' ' A' ' 36' ' ' GLU . 2.4 m -95.84 103.72 15.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.5 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -93.78 -173.34 3.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.186 -0.946 . . . . 0.0 109.5 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -124.89 162.16 25.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.201 -0.937 . . . . 0.0 109.477 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.509 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.7 t -144.17 97.11 5.28 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.515 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.6 Cg_endo -77.43 -168.69 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.566 2.177 . . . . 0.0 110.476 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.456 ' HB3' HG23 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -85.3 135.24 39.21 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.411 -0.806 . . . . 0.0 109.307 179.89 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HG2' HG12 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.56 -4.63 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.466 2.111 . . . . 0.0 110.433 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 46' ' ' SER . 26.0 tttt -160.31 142.13 12.69 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.403 -0.81 . . . . 0.0 109.468 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.92 94.22 5.19 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.179 -0.951 . . . . 0.0 109.394 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.495 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -150.94 -174.7 22.15 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.463 HG22 ' O ' ' A' ' 23' ' ' GLY . 10.8 p -103.66 137.98 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -1.149 . . . . 0.0 109.522 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.8 t -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.05 -27.7 13.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.206 -0.934 . . . . 0.0 109.524 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -167.04 171.57 10.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.16 -0.963 . . . . 0.0 109.544 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 55.6 t -131.86 113.25 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 56' ' ' SER . 5.6 t -99.32 22.64 10.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.47 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 31.3 m -144.03 169.55 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.198 -0.939 . . . . 0.0 109.451 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.68 171.93 12.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.471 ' C ' ' CD1' ' A' ' 59' ' ' LEU . 4.0 pp -80.04 139.15 37.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.315 -0.866 . . . . 0.0 109.536 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.79 -11.14 62.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -70.53 137.46 50.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -1.16 . . . . 0.0 109.39 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.424 ' C ' HD21 ' A' ' 63' ' ' LEU . 18.7 mttm -98.5 117.18 32.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.27 -0.894 . . . . 0.0 109.46 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.456 ' N ' HD21 ' A' ' 63' ' ' LEU . 3.5 mm? -117.92 159.74 22.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.429 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.3 tttt -112.09 142.82 44.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 64' ' ' LYS . 9.7 mt-10 -42.84 129.78 4.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.306 -0.871 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 113.96 -19.95 17.63 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.417 ' HB3' HD13 ' A' ' 63' ' ' LEU . 26.8 m-20 -85.12 136.06 33.71 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.231 -1.158 . . . . 0.0 109.41 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -58.92 167.85 1.47 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.226 -0.921 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 39.1 mm -134.13 -67.28 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -144.9 -173.56 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -133.48 120.93 21.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.303 -0.873 . . . . 0.0 109.477 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.508 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 2.4 tt -94.05 135.47 35.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.433 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.438 ' OE2' ' HB3' ' A' ' 1' ' ' SER . 5.9 tt0 -114.45 89.17 17.26 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.157 -0.964 . . . . 0.0 109.499 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.508 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.308 -1.592 0 C-N-CA 122.564 2.176 . . . . 0.0 110.365 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.466 ' HB3' ' HB2' ' A' ' 73' ' ' GLU . 95.0 p . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -87.04 137.03 32.69 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -0.883 . . . . 0.0 109.472 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 3' ' ' ILE . 0.0 OUTLIER -101.87 121.49 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.4 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.547 ' CD1' ' CG ' ' A' ' 47' ' ' PRO . 49.8 mm -95.82 115.08 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.424 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.463 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 0.0 OUTLIER -112.4 160.24 17.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.203 -0.935 . . . . 0.0 109.686 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.508 HG13 ' N ' ' A' ' 65' ' ' GLU . 85.6 t -44.83 104.47 0.39 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.338 -0.851 . . . . 0.0 109.545 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.1 Cg_endo -77.58 -170.43 0.94 Allowed 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.433 2.089 . . . . 0.0 110.438 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -72.31 99.92 2.52 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.209 -0.932 . . . . 0.0 109.466 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.414 HD12 HG12 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.26 -10.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.372 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.41 -17.63 11.27 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.04 -119.28 0.81 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.37 170.0 9.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.07 120.14 1.07 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 6.2 mt-10 -100.58 122.46 43.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -1.158 . . . . 0.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.2 t -63.2 124.15 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.905 . . . . 0.0 109.509 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.3 mm -99.54 -18.06 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.34 -0.85 . . . . 0.0 109.454 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.98 149.06 1.83 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.53 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.421 HD22 HG21 ' A' ' 20' ' ' VAL . 6.6 tp -118.73 102.39 8.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.457 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -90.71 48.62 1.56 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.527 179.973 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.507 HG13 ' CD2' ' A' ' 32' ' ' LEU . 18.7 m -145.86 168.47 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.409 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.35 171.27 14.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.98 132.02 35.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.57 63.81 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.4 134.99 36.57 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.16 -1.2 . . . . 0.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.464 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -82.64 127.54 33.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.853 . . . . 0.0 109.429 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.493 ' CG2' ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -91.53 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.278 -0.889 . . . . 0.0 109.269 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 30' ' ' GLN . 1.2 tm-20 -142.57 136.68 29.49 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.204 -0.935 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.3 p -45.73 140.72 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.248 -0.907 . . . . 0.0 109.475 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.564 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 82.99 -43.69 0.11 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.64 -0.663 . . . . 0.0 109.9 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.523 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -47.35 133.82 12.12 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.035 -1.041 . . . . 0.0 109.482 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -68.34 162.32 49.74 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.7 OUTLIER -125.98 -38.53 2.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -1.158 . . . . 0.0 109.465 179.972 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 33.0 m -158.73 158.59 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.522 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.2 t -124.44 98.22 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.314 -0.866 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 1.9 mp -90.23 140.24 29.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.305 -0.872 . . . . 0.0 109.526 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -126.89 127.58 45.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.416 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.449 ' OG ' ' N ' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -102.99 174.87 5.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.893 . . . . 0.0 109.477 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' N ' ' OG ' ' A' ' 37' ' ' SER . . . -44.88 -34.48 2.38 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.6 pttt -156.21 50.87 0.52 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.254 -0.903 . . . . 0.0 109.524 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -158.56 91.72 1.09 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.32 129.62 40.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.421 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.9 mtm -149.25 174.46 12.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.259 -0.9 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 31.6 mp0 -127.97 164.58 22.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -143.9 96.92 5.43 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.57 -169.1 0.68 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.537 2.158 . . . . 0.0 110.478 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.493 ' HB2' ' CG2' ' A' ' 26' ' ' ILE . 19.0 t -85.55 126.24 67.11 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.436 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.547 ' CG ' ' CD1' ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.59 -2.2 12.26 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.44 2.093 . . . . 0.0 110.383 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.459 ' O ' ' HG ' ' A' ' 72' ' ' LEU . 3.3 tptt -160.16 127.35 4.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.386 -0.821 . . . . 0.0 109.432 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.7 88.66 1.74 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.209 -0.932 . . . . 0.0 109.469 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.473 ' HA3' ' CD1' ' A' ' 72' ' ' LEU . . . -144.99 -153.71 5.94 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.458 ' O ' HD23 ' A' ' 72' ' ' LEU . 5.9 p -108.45 151.65 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -1.127 . . . . 0.0 109.408 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.2 t -75.97 123.8 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.187 -0.946 . . . . 0.0 109.522 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -81.38 -59.13 2.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.285 -0.884 . . . . 0.0 109.489 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 31.3 p -161.29 126.3 3.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.457 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 57' ' ' VAL . 57.9 t -81.38 126.21 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.287 -0.883 . . . . 0.0 109.486 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 t -103.66 26.0 9.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.216 -0.927 . . . . 0.0 109.48 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 55' ' ' VAL . 15.6 m -148.72 164.87 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.887 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.437 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 9.2 tttt -132.89 164.12 27.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.522 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.34 138.18 55.21 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.454 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.14 -18.22 54.64 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.437 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 1.7 m-20 -82.87 143.61 30.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 109.437 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.18 136.99 41.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.215 -0.928 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.494 ' HG ' ' CD1' ' A' ' 69' ' ' ILE . 4.1 mm? -111.34 177.94 4.5 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.471 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.5 ttpp -139.39 152.21 46.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' N ' HG13 ' A' ' 6' ' ' VAL . 7.3 mt-10 -44.28 139.9 2.44 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.172 -0.955 . . . . 0.0 109.513 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.34 -47.52 3.65 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -48.75 130.19 17.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.298 -1.119 . . . . 0.0 109.521 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -60.44 161.99 6.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.326 -0.859 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.494 ' CD1' ' HG ' ' A' ' 63' ' ' LEU . 19.9 mm -135.41 -55.55 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.304 -0.872 . . . . 0.0 109.466 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' A' ' 69' ' ' ILE . 11.4 pt -156.57 -174.52 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.311 -0.868 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.405 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 0.6 OUTLIER -144.17 139.04 28.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.528 ' CD1' ' HD3' ' A' ' 74' ' ' PRO . 3.4 tm? -119.61 118.81 31.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.196 -0.94 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.466 ' HB2' ' HB3' ' A' ' 1' ' ' SER . 5.7 tt0 -111.74 94.91 25.78 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.528 ' HD3' ' CD1' ' A' ' 72' ' ' LEU . 35.5 Cg_endo . . . . . 0 C--N 1.308 -1.578 0 C-N-CA 122.616 2.211 . . . . 0.0 110.381 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 94.7 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -99.45 149.21 23.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.941 . . . . 0.0 109.426 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.2 tt -83.48 159.16 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.31 -0.868 . . . . 0.0 109.468 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.42 HD12 ' HG2' ' A' ' 47' ' ' PRO . 2.8 mp -131.18 111.62 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.192 -0.942 . . . . 0.0 109.407 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.36 170.13 10.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.538 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.524 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -44.19 142.32 2.25 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.419 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.524 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.27 171.51 16.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.554 2.169 . . . . 0.0 110.37 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -84.92 99.13 10.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.56 -11.19 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.258 -0.901 . . . . 0.0 109.396 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.88 -10.8 68.24 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -158.98 -161.32 11.02 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 -83.74 143.32 30.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -1.179 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.77 150.16 18.7 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.411 ' HG2' ' HG3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -129.44 119.17 23.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -1.154 . . . . 0.0 109.481 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.6 t -67.37 152.22 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.419 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 16' ' ' ILE . 49.3 mm -120.06 -34.24 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -175.47 137.91 0.39 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 109.452 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.566 ' N ' ' CD2' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.97 140.6 37.03 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 121.154 -0.966 . . . . 0.0 109.371 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.46 35.23 3.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 m -144.13 -179.7 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.432 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.27 -179.68 6.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 0.0 109.441 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.2 t -79.9 129.58 34.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.417 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.55 -0.13 61.22 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -81.35 133.29 35.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 109.489 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.419 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -89.78 107.82 19.32 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.461 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.445 HG23 ' HB3' ' A' ' 46' ' ' SER . 2.7 mt -91.88 -171.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.184 -0.948 . . . . 0.0 109.26 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.436 ' OE1' HG11 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -147.31 176.76 9.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.51 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.506 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.2 p -81.18 74.34 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.515 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.506 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.92 -27.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.313 -0.867 . . . . 0.0 109.402 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -72.99 136.01 45.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.24 176.18 2.85 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.504 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -137.15 -62.93 0.61 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -1.147 . . . . 0.0 109.452 180.0 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.461 HG11 ' CD2' ' A' ' 32' ' ' LEU . 16.5 m -137.66 172.03 15.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -125.69 105.95 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.246 -0.909 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.1 mp -97.95 153.61 18.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.84 149.98 39.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.6 m -126.65 177.96 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.99 -41.41 59.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.483 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -157.95 37.04 0.26 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -152.69 88.33 1.34 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.401 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.447 ' O ' ' HG2' ' A' ' 42' ' ' MET . 34.6 t -83.45 127.58 33.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.242 -0.911 . . . . 0.0 109.451 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.447 ' HG2' ' O ' ' A' ' 41' ' ' SER . 11.9 mtt -147.45 136.46 22.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.468 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -93.0 169.93 10.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.162 -0.961 . . . . 0.0 109.437 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 40.7 t -135.88 127.83 17.46 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.36 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.47 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.4 -168.15 0.58 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.43 2.086 . . . . 0.0 110.389 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.495 ' HA ' ' CD1' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -85.14 135.92 38.78 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.869 . . . . 0.0 109.19 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.42 ' HG2' HD12 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.43 -2.39 12.45 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.434 2.089 . . . . 0.0 110.533 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.455 ' HB3' HD23 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.03 140.53 11.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.376 -0.828 . . . . 0.0 109.4 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.68 95.95 9.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.487 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -160.71 -153.0 6.79 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.417 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 12.2 p -110.81 141.63 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -1.124 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 71.0 t -63.87 142.6 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.42 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -106.77 -55.35 2.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.31 118.87 7.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 t -84.87 106.73 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 p -90.16 9.2 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.459 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.518 ' CG1' HD11 ' A' ' 69' ' ' ILE . 20.6 m -124.87 158.27 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.451 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.8 tptp -137.43 -173.38 3.46 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.22 -0.925 . . . . 0.0 109.524 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.2 pp -85.05 134.36 34.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.441 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 77.23 9.08 87.0 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -84.87 145.46 27.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.244 -1.15 . . . . 0.0 109.438 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.42 ' O ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -107.41 132.48 53.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.521 -179.981 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -139.59 130.14 25.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.41 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 31.4 tttm -93.82 145.74 24.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.202 -0.936 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.446 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -42.86 124.29 3.05 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.353 -0.842 . . . . 0.0 109.638 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 123.46 -26.37 6.04 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 68' ' ' ALA . 1.2 m-20 -85.11 131.23 34.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -1.147 . . . . 0.0 109.442 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -49.66 178.55 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.284 -0.885 . . . . 0.0 109.509 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.518 HD11 ' CG1' ' A' ' 57' ' ' VAL . 23.1 mm -145.08 -65.21 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.237 -0.914 . . . . 0.0 109.414 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.433 HG21 ' O ' ' A' ' 69' ' ' ILE . 1.2 pt -151.51 177.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.478 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -143.48 140.42 30.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.496 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 1.3 tt -107.75 142.8 37.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.411 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -131.34 89.84 39.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.432 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.496 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.55 0 C-N-CA 122.59 2.193 . . . . 0.0 110.406 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 60.4 p . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.453 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 16.5 mt-10 -135.78 137.24 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.496 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.455 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 1.2 tt -82.14 151.94 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.452 HD13 ' HG3' ' A' ' 47' ' ' PRO . 17.5 mm -117.37 97.03 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.491 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.76 163.3 14.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.523 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 71.4 t -57.88 142.05 79.61 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.523 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.3 Cg_endo -77.98 -174.46 2.24 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.587 2.191 . . . . 0.0 110.386 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -58.78 103.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.463 ' CG2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -110.17 -37.75 3.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.238 -0.913 . . . . 0.0 108.767 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.85 52.98 21.65 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.89 -136.57 4.37 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -116.65 138.4 51.47 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.22 -1.165 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -110.74 118.93 5.1 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.01 130.91 47.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.278 -1.131 . . . . 0.0 109.476 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.3 t -80.67 147.31 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.469 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.4 mt -113.49 -57.02 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -0.942 . . . . 0.0 109.474 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -160.8 162.64 32.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.305 -0.872 . . . . 0.0 109.463 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.1 tp -101.2 141.53 33.94 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 12.7 mt -99.0 18.67 16.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.488 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.4 HG22 HG23 ' A' ' 52' ' ' VAL . 27.5 m -150.04 172.22 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.422 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -120.01 -178.29 3.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.459 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.22 113.92 19.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.501 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.31 0.5 65.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.84 145.89 27.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -1.138 . . . . 0.0 109.434 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.1 tp -89.81 132.27 35.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.184 -0.947 . . . . 0.0 109.449 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.501 HD11 ' CD1' ' A' ' 32' ' ' LEU . 2.7 mt -91.79 -171.41 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.184 -0.947 . . . . 0.0 109.135 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.526 ' CG ' ' HB2' ' A' ' 30' ' ' GLN . 0.1 OUTLIER -149.96 126.01 10.59 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.246 -0.908 . . . . 0.0 109.488 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.567 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 8.4 p -44.98 149.61 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.567 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 16.3 tt0 83.05 -43.67 0.11 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.666 -0.646 . . . . 0.0 109.8 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.526 ' HB2' ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -62.29 153.81 29.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.101 -0.999 . . . . 0.0 109.48 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -62.46 -176.94 3.03 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.501 ' CD1' HD11 ' A' ' 26' ' ' ILE . 10.0 tp -153.98 -56.88 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -1.176 . . . . 0.0 109.558 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.19 152.7 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.175 -0.953 . . . . 0.0 109.65 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.479 HG11 ' CG ' ' A' ' 43' ' ' GLU . 22.6 t -120.97 83.96 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.282 -0.886 . . . . 0.0 109.367 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.01 170.86 9.99 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -0.905 . . . . 0.0 109.478 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.516 ' CG ' ' O ' ' A' ' 40' ' ' ALA . 21.8 tt0 -114.08 154.22 28.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -104.7 -177.05 3.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -45.31 -37.69 5.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.314 -0.866 . . . . 0.0 109.446 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.427 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -158.74 63.52 0.42 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.516 ' O ' ' CG ' ' A' ' 36' ' ' GLU . . . 178.13 -167.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.425 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.8 m -135.85 116.36 13.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.243 -0.91 . . . . 0.0 109.455 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.454 ' HG2' ' O ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -116.78 132.68 56.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.164 -0.96 . . . . 0.0 109.43 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.479 ' CG ' HG11 ' A' ' 34' ' ' VAL . 2.0 mt-10 -112.57 161.59 16.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 3.4 t -139.31 140.3 25.52 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.279 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.529 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.31 -169.12 0.71 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.379 2.053 . . . . 0.0 110.38 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.464 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.53 134.71 39.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.32 -0.862 . . . . 0.0 109.302 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.452 ' HG3' HD13 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.68 -12.64 15.0 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.435 2.09 . . . . 0.0 110.233 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.457 ' HD2' HD23 ' A' ' 72' ' ' LEU . 1.3 ttmp? -160.64 132.11 5.75 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.7 84.54 2.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.4 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' A' ' 25' ' ' LEU . . . -135.21 -144.11 4.9 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.495 HG21 ' N ' ' A' ' 52' ' ' VAL . 11.3 p -118.74 157.24 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.495 ' N ' HG21 ' A' ' 51' ' ' VAL . 24.1 t -84.82 136.69 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.239 -0.913 . . . . 0.0 109.468 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.4 ' O ' ' OG ' ' A' ' 54' ' ' SER . 0.2 OUTLIER -89.38 -60.89 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.433 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 53' ' ' LYS . 3.8 m -175.36 157.62 2.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.16 -0.963 . . . . 0.0 109.501 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.464 ' HA ' HG21 ' A' ' 70' ' ' ILE . 3.5 t -87.11 121.38 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.44 ' O ' HG11 ' A' ' 57' ' ' VAL . 1.2 m -80.93 5.85 15.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.573 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.493 HG13 ' CD1' ' A' ' 63' ' ' LEU . 35.6 m -150.11 -172.26 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.444 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.4 OUTLIER -114.05 153.28 29.7 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.453 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -65.81 150.3 48.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.466 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 69.25 9.1 60.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.444 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 5.1 m-20 -84.99 154.79 21.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -101.92 123.18 45.4 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.898 . . . . 0.0 109.427 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.493 ' CD1' HG13 ' A' ' 57' ' ' VAL . 83.0 mt -123.2 152.72 40.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 109.453 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.8 ttpt -94.0 147.28 23.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.286 -0.883 . . . . 0.0 109.509 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.463 ' HB3' ' CG2' ' A' ' 9' ' ' ILE . 10.7 pt-20 -43.05 139.59 1.72 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.35 -0.844 . . . . 0.0 109.605 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.55 -4.61 79.83 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.04 143.37 29.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -1.106 . . . . 0.0 109.452 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -74.98 157.74 34.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.312 -0.868 . . . . 0.0 109.461 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.41 HD12 HG21 ' A' ' 6' ' ' VAL . 3.2 mp -131.07 -51.77 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.94 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.464 HG21 ' HA ' ' A' ' 55' ' ' VAL . 3.0 pt -147.4 -179.69 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.455 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 22.9 tt0 -150.06 129.24 12.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.224 -0.923 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.514 ' HG ' ' N ' ' A' ' 73' ' ' GLU . 0.6 OUTLIER -95.82 145.07 25.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.473 179.931 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.514 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -112.4 93.32 22.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.328 -0.858 . . . . 0.0 109.404 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.562 0 C-N-CA 122.631 2.221 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 26.9 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -92.87 169.41 10.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.89 . . . . 0.0 109.476 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.7 mt -106.48 146.58 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.875 . . . . 0.0 109.439 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.46 ' O ' HD11 ' A' ' 69' ' ' ILE . 27.9 mm -104.93 114.68 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.452 ' HA ' HD11 ' A' ' 69' ' ' ILE . 6.0 ptp180 -107.07 177.71 4.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.238 -0.914 . . . . 0.0 109.459 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.52 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 72.6 t -73.77 142.06 79.77 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.219 -0.926 . . . . 0.0 109.459 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.52 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 36.0 Cg_endo -78.45 -170.15 0.92 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.497 2.131 . . . . 0.0 110.441 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -85.02 102.86 13.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.164 -0.96 . . . . 0.0 109.423 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.3 -49.03 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.352 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.63 30.28 2.44 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' OE1' ' A' ' 65' ' ' GLU . . . 168.3 -166.19 39.34 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -94.95 115.65 27.72 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.264 -1.139 . . . . 0.0 109.531 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.38 168.39 54.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.451 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 4.6 tt0 -142.99 117.27 9.58 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.2 -1.177 . . . . 0.0 109.496 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.44 ' CG1' HD11 ' A' ' 18' ' ' LEU . 62.4 t -62.52 119.78 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.47 ' CG1' ' O ' ' A' ' 34' ' ' VAL . 2.1 pt -113.99 -20.26 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.421 ' N ' HG13 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -155.41 136.76 14.02 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.299 -0.875 . . . . 0.0 109.499 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.44 HD11 ' CG1' ' A' ' 15' ' ' VAL . 0.2 OUTLIER -129.09 123.57 32.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.937 . . . . 0.0 109.4 -179.965 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.492 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -125.22 63.13 1.17 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 0.0 109.478 -179.923 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.441 HG13 ' HG ' ' A' ' 32' ' ' LEU . 16.7 m -144.96 169.24 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.22 160.07 42.04 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.508 ' CG2' ' O ' ' A' ' 53' ' ' LYS . 94.8 m -84.5 133.85 34.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.495 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.85 -10.77 73.81 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -81.1 136.42 35.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -1.137 . . . . 0.0 109.505 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.56 115.96 22.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 109.5 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 32' ' ' LEU . 2.4 mt -91.02 -171.54 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.187 -0.945 . . . . 0.0 109.234 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.67 174.87 10.81 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 12.0 p -84.98 76.22 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.42 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 167.21 -41.98 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.431 -0.793 . . . . 0.0 109.251 179.867 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.526 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 61.5 tt0 -59.65 146.44 41.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.478 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -74.19 168.17 54.4 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 5.0 tp -128.46 -43.79 1.41 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -1.154 . . . . 0.0 109.567 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 15.7 m -158.56 159.08 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' A' ' 16' ' ' ILE . 62.9 t -124.37 103.47 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.184 -0.947 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.08 163.08 15.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -118.05 145.29 44.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.447 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -121.69 -177.39 3.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.915 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.36 -56.01 9.25 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -143.98 59.77 1.36 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 109.523 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . 170.42 112.01 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 33.8 t -100.73 115.15 29.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.483 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 26.2 ttp -102.98 154.73 18.94 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.178 -0.952 . . . . 0.0 109.403 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.452 ' O ' HG21 ' A' ' 44' ' ' VAL . 12.5 mt-10 -100.6 169.61 8.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 69.9 t -146.12 99.57 4.27 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.526 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.4 Cg_endo -77.13 -167.96 0.53 Allowed 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.432 2.088 . . . . 0.0 110.479 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 2.6 t -84.82 125.98 69.5 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.348 -0.845 . . . . 0.0 109.385 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.427 ' CG ' HD11 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.54 -1.16 11.35 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.382 2.055 . . . . 0.0 110.404 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 46' ' ' SER . 4.7 tttt -160.15 140.95 12.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.304 -0.872 . . . . 0.0 109.574 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.67 102.84 12.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 0.0 109.402 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.507 ' CA ' ' CD1' ' A' ' 72' ' ' LEU . . . -152.92 -168.93 17.54 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.469 ' CG1' ' O ' ' A' ' 51' ' ' VAL . 7.4 p -104.18 120.19 54.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -1.105 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.44 HG13 ' HA ' ' A' ' 22' ' ' THR . 50.9 t -49.09 142.36 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.508 ' O ' ' CG2' ' A' ' 22' ' ' THR . 3.1 ttpp -104.87 -59.77 1.7 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.01 140.99 14.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.7 t -90.37 126.36 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.506 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.6 m -100.38 20.47 14.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.251 -0.906 . . . . 0.0 109.394 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.426 ' CG2' HG21 ' A' ' 69' ' ' ILE . 1.4 m -143.62 163.39 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -120.1 141.47 49.77 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.474 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.413 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 2.1 pp -60.26 128.37 36.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.466 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.39 -21.9 21.04 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -83.43 158.45 22.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.187 -1.184 . . . . 0.0 109.502 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 5.8 pttt -86.8 165.11 16.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.02 110.66 10.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.324 -0.86 . . . . 0.0 109.45 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.84 136.28 36.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.232 -0.918 . . . . 0.0 109.282 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' O ' ' A' ' 11' ' ' GLY . 1.8 mt-10 -48.85 149.04 1.94 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.31 -0.869 . . . . 0.0 109.958 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.79 -14.66 46.75 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.64 141.62 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.198 -1.178 . . . . 0.0 109.621 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -74.61 176.07 7.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 109.342 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.46 HD11 ' O ' ' A' ' 4' ' ' ILE . 2.9 mp -139.37 -64.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.156 -0.965 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.415 HG22 HG23 ' A' ' 69' ' ' ILE . 2.3 pp -139.18 173.59 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.605 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -129.31 137.51 51.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.874 . . . . 0.0 109.428 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.52 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 3.5 tt -108.52 137.88 45.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.893 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.448 ' OE1' ' HD3' ' A' ' 53' ' ' LYS . 0.5 OUTLIER -113.38 92.17 22.19 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.52 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.501 0 C-N-CA 122.598 2.198 . . . . 0.0 110.391 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.514 ' CB ' ' HG2' ' A' ' 73' ' ' GLU . 53.2 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.271 0.558 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 1' ' ' SER . 2.0 mm-40 -154.09 148.81 26.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.231 -0.918 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.7 mp -80.05 143.1 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.412 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.453 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 2.1 mp -114.82 97.88 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.428 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.07 176.67 6.69 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.0 t -65.68 142.43 98.21 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.529 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.7 Cg_endo -78.24 -178.68 4.8 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.528 2.152 . . . . 0.0 110.374 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -85.05 96.64 9.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.22 -0.925 . . . . 0.0 109.41 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.99 -17.64 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.31 -0.869 . . . . 0.0 109.299 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.29 -8.95 62.46 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.82 -133.14 3.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -113.6 170.8 7.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -134.06 108.44 0.73 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.3 OUTLIER -99.8 120.33 39.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -1.112 . . . . 0.0 109.371 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.2 t -67.26 123.31 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.88 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.512 ' CG2' ' O ' ' A' ' 34' ' ' VAL . 8.3 tp -103.37 -25.19 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.196 -0.94 . . . . 0.0 109.494 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.432 ' N ' HG21 ' A' ' 16' ' ' ILE . 38.0 tt0 -178.62 138.83 0.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.424 HD11 ' O ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -102.75 152.47 21.2 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.304 -0.872 . . . . 0.0 109.399 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -112.06 27.29 9.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.46 HG23 HD12 ' A' ' 32' ' ' LEU . 24.3 m -149.98 167.48 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.97 -167.59 1.94 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 80.3 m -84.96 130.34 34.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.79 2.16 87.98 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -84.61 135.3 34.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.191 -1.182 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.425 HD11 ' HB ' ' A' ' 51' ' ' VAL . 12.4 tp -89.24 127.84 35.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.221 -0.924 . . . . 0.0 109.493 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.524 HD12 ' CD2' ' A' ' 32' ' ' LEU . 3.7 mt -98.5 -171.22 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.285 -0.885 . . . . 0.0 109.148 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 40.0 mm-40 -140.81 164.99 28.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.492 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 14.7 p -80.47 75.62 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -0.901 . . . . 0.0 109.404 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 2.4 mt-10 162.7 -31.01 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.283 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 6.2 tt0 -71.01 151.0 45.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.449 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.468 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.4 165.94 51.35 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.524 ' CD2' HD12 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -125.84 -49.54 1.61 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -1.124 . . . . 0.0 109.559 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 32' ' ' LEU . 27.5 m -146.74 158.11 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.482 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.512 ' O ' ' CG2' ' A' ' 16' ' ' ILE . 82.6 t -126.05 88.25 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.14 -0.975 . . . . 0.0 109.439 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -90.04 152.34 21.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.541 -179.943 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.53 -178.92 5.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.495 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.418 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -140.87 175.9 9.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.458 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.4 -49.94 9.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.514 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -147.09 32.92 0.9 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.77 169.1 25.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.865 . . . . 0.0 109.464 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 58.7 m -123.56 135.3 53.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.3 mmt -133.59 135.63 44.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' N ' ' A' ' 44' ' ' VAL . 24.9 tt0 -106.92 166.03 10.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.515 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 6.4 t -145.9 111.64 4.48 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.314 -0.866 . . . . 0.0 109.283 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.5 Cg_endo -77.26 -169.11 0.68 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.364 2.043 . . . . 0.0 110.437 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.462 ' HB2' HD11 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -85.46 130.44 51.36 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 -179.92 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.88 -6.6 15.21 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.417 2.078 . . . . 0.0 110.482 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' HD23 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.37 149.26 17.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.529 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 74' ' ' PRO . . . -79.85 96.43 6.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.481 ' HA3' ' CD2' ' A' ' 72' ' ' LEU . . . -144.78 177.11 23.5 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.425 ' HB ' HD11 ' A' ' 25' ' ' LEU . 7.3 p -104.12 137.83 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -1.148 . . . . 0.0 109.483 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.3 129.62 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.455 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.77 -18.14 10.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.301 -0.874 . . . . 0.0 109.44 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -164.88 150.05 9.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.195 -0.941 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 57' ' ' VAL . 61.0 t -129.88 117.93 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.413 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.409 ' C ' HG11 ' A' ' 57' ' ' VAL . 0.3 OUTLIER -102.07 15.4 29.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.419 179.95 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.441 HG23 HG21 ' A' ' 69' ' ' ILE . 33.3 m -138.71 161.73 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.478 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.93 -165.0 1.8 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.86 123.99 28.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.33 -3.96 86.55 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.88 135.52 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.15 -1.206 . . . . 0.0 109.392 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -107.8 125.06 50.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.9 mp -131.35 154.02 49.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.46 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -111.03 150.37 29.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.45 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.7 OUTLIER -42.88 141.46 1.1 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 109.643 -179.825 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.14 -26.47 23.76 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.07 137.33 33.12 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -1.183 . . . . 0.0 109.546 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.431 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -64.57 164.18 12.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.507 ' CD1' HG21 ' A' ' 6' ' ' VAL . 44.2 mm -122.25 -68.24 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.122 -0.986 . . . . 0.0 109.534 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.407 HD11 ' N ' ' A' ' 71' ' ' GLU . 1.6 pp -138.91 179.87 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.237 -0.914 . . . . 0.0 109.471 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.407 ' N ' HD11 ' A' ' 70' ' ' ILE . 46.3 tt0 -134.03 127.83 33.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.481 ' CD2' ' HA3' ' A' ' 50' ' ' GLY . 1.9 tp -107.03 123.91 48.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.514 ' HG2' ' CB ' ' A' ' 1' ' ' SER . 0.0 OUTLIER -120.92 91.4 47.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.301 -0.874 . . . . 0.0 109.424 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.446 ' HB3' ' HA2' ' A' ' 50' ' ' GLY . 35.2 Cg_endo . . . . . 0 C--N 1.308 -1.593 0 C-N-CA 122.644 2.229 . . . . 0.0 110.395 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.44 ' HB3' ' HD3' ' A' ' 74' ' ' PRO . 83.4 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.418 ' OE2' ' HG3' ' A' ' 48' ' ' LYS . 20.2 pt-20 -155.9 172.51 18.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.433 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.534 ' CD1' ' CG ' ' A' ' 71' ' ' GLU . 16.7 mm -116.52 134.39 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.304 -0.873 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -98.0 110.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.402 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.45 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -110.44 169.56 8.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.21 -0.931 . . . . 0.0 109.573 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 65' ' ' GLU . 51.6 t -43.58 106.03 0.47 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.893 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.43 -170.5 0.95 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.486 2.124 . . . . 0.0 110.41 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -75.68 100.45 4.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.506 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.437 HD12 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.05 -24.81 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.286 -0.883 . . . . 0.0 109.313 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.9 -30.76 4.75 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -173.56 169.43 42.51 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -48.07 113.53 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.488 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.25 149.41 16.86 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.453 ' OE2' ' O ' ' A' ' 60' ' ' GLY . 55.8 tt0 -115.27 126.37 54.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -1.144 . . . . 0.0 109.548 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.418 ' O ' ' HA2' ' A' ' 60' ' ' GLY . 40.6 t -55.93 148.41 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 36' ' ' GLU . 50.4 mt -120.41 -50.4 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -159.3 143.55 15.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.286 -0.883 . . . . 0.0 109.413 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.561 ' N ' ' CD2' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.84 155.2 18.5 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.297 -0.877 . . . . 0.0 109.384 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.435 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -122.83 35.83 4.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -146.13 -179.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.452 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.35 176.12 8.39 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.191 -0.943 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.1 m -77.6 148.41 35.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.445 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.457 ' O ' HG22 ' A' ' 51' ' ' VAL . . . 68.49 7.53 53.43 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -85.01 143.1 29.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 0.0 109.515 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -102.21 116.02 31.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.446 179.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.411 HG23 ' HB2' ' A' ' 46' ' ' SER . 0.8 OUTLIER -92.92 -171.57 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.194 -0.941 . . . . 0.0 109.245 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -140.56 172.91 12.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.186 -0.946 . . . . 0.0 109.391 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.515 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.1 p -78.86 77.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.52 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.99 -41.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.312 -0.868 . . . . 0.0 109.485 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -61.43 146.6 47.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -63.13 -174.67 2.68 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.514 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -147.54 -71.9 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.147 -1.207 . . . . 0.0 109.518 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 m -131.52 175.84 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.943 . . . . 0.0 109.576 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 43' ' ' GLU . 87.8 t -132.24 99.73 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.345 -0.847 . . . . 0.0 109.421 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.19 153.37 17.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.881 . . . . 0.0 109.486 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.489 ' HB2' ' CD1' ' A' ' 16' ' ' ILE . 1.5 tt0 -107.8 153.1 23.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.347 -0.845 . . . . 0.0 109.395 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.66 -179.37 3.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.462 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.45 -22.97 66.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 10.2 pttp -159.39 65.47 0.39 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.419 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.471 ' CB ' ' O ' ' A' ' 39' ' ' LYS . . . 166.62 174.6 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.176 -0.953 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.4 m -154.95 93.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.397 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 55.7 mtp -116.65 138.82 51.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.275 -0.891 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.435 ' HB3' HG21 ' A' ' 34' ' ' VAL . 4.3 pt-20 -95.36 -176.31 3.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.24 -0.913 . . . . 0.0 109.389 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 68.0 t -143.33 139.38 16.49 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.92 -168.14 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.554 2.169 . . . . 0.0 110.373 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.411 ' HB2' HG23 ' A' ' 26' ' ' ILE . 28.0 t -85.04 124.31 72.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.247 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.434 ' HD3' HD11 ' A' ' 32' ' ' LEU . 35.8 Cg_endo -78.17 0.37 9.95 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.366 2.044 . . . . 0.0 110.434 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.515 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 3.5 mmtm -160.15 121.36 3.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.248 -0.908 . . . . 0.0 109.517 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.15 83.91 1.01 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.497 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -150.14 -170.03 16.96 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 23' ' ' GLY . 8.0 p -95.94 148.59 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -1.145 . . . . 0.0 109.531 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.42 ' N ' HG21 ' A' ' 51' ' ' VAL . 34.0 t -75.94 137.69 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.472 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.432 ' HB3' ' O ' ' A' ' 71' ' ' GLU . 0.0 OUTLIER -90.73 -46.21 8.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.462 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.49 144.14 0.12 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.155 -0.965 . . . . 0.0 109.445 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 57' ' ' VAL . 5.1 t -86.3 112.87 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.496 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.8 m -90.82 15.75 10.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.518 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.432 ' O ' HG13 ' A' ' 55' ' ' VAL . 2.8 m -139.55 157.65 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.81 147.04 28.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.02 140.21 56.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.453 ' O ' ' OE2' ' A' ' 14' ' ' GLU . . . 90.7 -11.31 72.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -73.23 140.99 47.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -1.134 . . . . 0.0 109.434 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.449 ' HG2' ' HB2' ' A' ' 14' ' ' GLU . 0.4 OUTLIER -98.38 133.78 42.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -140.11 162.3 35.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.454 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.7 tmtt? -128.71 159.71 34.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.464 ' N ' ' CG1' ' A' ' 6' ' ' VAL . 8.6 mt-10 -42.7 111.83 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.426 -0.796 . . . . 0.0 109.695 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.94 -33.85 2.15 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -84.22 142.51 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -1.149 . . . . 0.0 109.405 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' HD12 ' A' ' 69' ' ' ILE . . . -78.26 159.54 28.42 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.391 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.454 HD12 ' O ' ' A' ' 68' ' ' ALA . 34.5 mm -123.7 -60.72 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.511 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.406 HG21 ' HA ' ' A' ' 55' ' ' VAL . 11.3 pt -142.54 -176.47 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 109.49 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.534 ' CG ' ' CD1' ' A' ' 3' ' ' ILE . 1.7 tm-20 -138.16 108.04 6.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.241 -0.912 . . . . 0.0 109.475 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.515 ' CD1' ' O ' ' A' ' 48' ' ' LYS . 4.4 tt -89.94 140.99 29.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.453 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -110.22 157.89 36.73 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 0.0 109.499 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.453 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.534 0 C-N-CA 122.57 2.18 . . . . 0.0 110.45 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 79.5 p . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -123.2 178.59 5.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.465 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.402 ' HA ' ' HG2' ' A' ' 71' ' ' GLU . 7.0 mt -120.15 127.71 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.197 -0.939 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.449 HD11 HD13 ' A' ' 70' ' ' ILE . 3.3 mt -98.98 126.62 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.439 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -111.03 161.01 16.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.518 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 72.8 t -50.23 142.08 14.85 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.346 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.518 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.22 -170.31 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.632 2.221 . . . . 0.0 110.493 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.95 102.32 10.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.388 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.441 HG13 ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -104.3 -10.76 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 109.382 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.16 35.85 91.04 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.5 -173.48 43.79 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -82.96 172.88 12.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -1.153 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.51 146.71 18.69 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.408 ' C ' HD12 ' A' ' 35' ' ' LEU . 25.0 tt0 -132.03 118.24 19.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.288 -1.125 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.584 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 9.8 t -67.84 141.17 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.206 -0.934 . . . . 0.0 109.538 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.425 ' CG1' ' HB2' ' A' ' 36' ' ' GLU . 30.3 mm -112.22 -51.27 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.268 -0.895 . . . . 0.0 109.444 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -150.05 140.93 22.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.553 ' CD2' ' CG2' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -101.83 149.09 24.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.502 179.946 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.69 50.77 1.66 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.269 -0.894 . . . . 0.0 109.533 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.553 ' CG2' ' CD2' ' A' ' 18' ' ' LEU . 0.9 OUTLIER -150.05 163.27 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.248 -0.908 . . . . 0.0 109.455 -179.956 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.29 165.39 23.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.221 -0.924 . . . . 0.0 109.441 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.514 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 72.4 m -81.16 141.25 34.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 109.513 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.3 -10.83 69.74 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 1.0 OUTLIER -82.86 133.65 35.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.494 179.975 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.462 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.5 OUTLIER -85.97 117.58 24.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.512 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.4 mt -90.01 -171.57 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -147.78 166.38 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -0.933 . . . . 0.0 109.479 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 12.8 p -77.72 79.05 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.449 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 163.0 -35.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.517 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -70.0 140.55 52.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.2 -0.937 . . . . 0.0 109.437 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.479 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -68.45 165.05 47.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -128.01 -40.49 1.68 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -1.15 . . . . 0.0 109.506 -179.97 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.462 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.0 m -157.27 174.49 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.482 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.71 104.3 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.438 HD12 ' HA ' ' A' ' 15' ' ' VAL . 4.5 mm? -89.96 152.55 21.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.256 -0.903 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.425 ' HB2' ' CG1' ' A' ' 16' ' ' ILE . 0.3 OUTLIER -131.74 116.19 16.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 -179.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.61 -172.62 3.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.47 -57.38 8.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.268 -0.895 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.3 mttt -140.4 49.66 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -154.88 104.67 2.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.339 -0.851 . . . . 0.0 109.478 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.97 119.28 31.56 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.87 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 5.4 ptp -136.51 162.35 33.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.325 -0.859 . . . . 0.0 109.418 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -106.42 172.36 6.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 22.9 t -142.75 95.89 6.25 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.409 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.517 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.9 Cg_endo -77.47 -168.73 0.63 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.481 2.12 . . . . 0.0 110.52 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.512 ' CB ' HG23 ' A' ' 26' ' ' ILE . 11.6 t -85.42 130.68 50.52 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.356 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.413 ' HG3' HG22 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.61 -3.04 12.99 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.401 2.067 . . . . 0.0 110.43 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -160.3 145.77 15.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 -179.997 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.93 93.22 8.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.475 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.492 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -143.52 -155.14 6.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.9 p -117.04 142.3 31.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.307 -1.114 . . . . 0.0 109.465 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.514 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 55.0 t -65.37 110.29 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.441 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.58 -35.38 27.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.494 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.8 t -169.86 158.13 7.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.552 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.408 ' CG1' HG21 ' A' ' 57' ' ' VAL . 77.7 t -117.44 115.23 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.14 17.87 20.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.551 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.408 HG21 ' CG1' ' A' ' 55' ' ' VAL . 29.2 m -123.1 162.23 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 109.483 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 tptt -134.26 172.58 12.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.436 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -81.86 124.33 29.61 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.156 -0.965 . . . . 0.0 109.513 179.959 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 98.33 -9.55 63.0 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -75.87 153.93 36.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -1.176 . . . . 0.0 109.482 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -99.3 121.11 40.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.584 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 11.1 mt -102.59 95.16 6.05 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.428 ' O ' ' C ' ' A' ' 65' ' ' GLU . 26.8 ttpt -85.43 138.64 32.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 109.386 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.441 ' HB3' HG13 ' A' ' 9' ' ' ILE . 11.5 pt-20 -43.06 150.63 0.16 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.67 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.26 -26.37 13.79 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -85.17 146.02 27.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.437 ' O ' HD12 ' A' ' 69' ' ' ILE . . . -61.64 -175.15 0.05 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.274 -0.891 . . . . 0.0 109.404 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.474 ' CD1' HG22 ' A' ' 6' ' ' VAL . 39.8 mm -146.95 -70.37 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.538 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.449 HD13 HD11 ' A' ' 4' ' ' ILE . 0.8 OUTLIER -143.96 -172.33 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.214 -0.929 . . . . 0.0 109.451 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.402 ' HG2' ' HA ' ' A' ' 3' ' ' ILE . 9.6 mt-10 -137.81 105.05 5.46 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.205 -0.935 . . . . 0.0 109.585 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.492 HD12 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -90.63 135.14 33.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.179 -0.951 . . . . 0.0 109.484 179.893 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.401 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 27.7 tt0 -113.45 91.33 19.79 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.459 ' HD3' HD22 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.507 0 C-N-CA 122.635 2.223 . . . . 0.0 110.423 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 31.3 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -122.87 155.92 35.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.406 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.407 HG13 ' HG2' ' A' ' 71' ' ' GLU . 2.1 mp -117.12 146.89 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.486 HG13 ' CG ' ' A' ' 47' ' ' PRO . 37.9 mm -124.46 112.95 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -100.8 172.83 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.8 t -61.89 142.26 95.09 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.399 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.528 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.16 -171.24 1.15 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.505 2.137 . . . . 0.0 110.431 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -85.01 102.82 13.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.417 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.76 -40.19 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.282 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.9 29.85 30.62 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.84 -128.52 0.96 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.488 ' OD2' ' CE ' ' A' ' 62' ' ' LYS . 18.3 p-10 -136.31 135.81 39.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.202 -1.176 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.59 111.43 2.55 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -101.25 133.85 45.19 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -1.158 . . . . 0.0 109.46 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.8 t -72.18 140.01 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.534 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.467 HG22 HD11 ' A' ' 16' ' ' ILE . 20.1 mt -100.8 -39.34 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.372 -0.83 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -164.64 -173.94 3.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.506 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.4 tp -136.7 102.05 4.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.448 HD11 ' O ' ' A' ' 19' ' ' LEU . 1.2 pp -95.88 29.33 2.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.417 HG12 ' HA ' ' A' ' 32' ' ' LEU . 34.2 m -133.23 159.54 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -125.4 174.87 7.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -84.99 141.0 30.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.488 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.457 ' HA2' HG23 ' A' ' 51' ' ' VAL . . . 76.6 8.59 86.16 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.95 131.99 34.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.254 -1.145 . . . . 0.0 109.441 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.459 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.3 OUTLIER -86.01 111.7 20.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.507 HD11 HG22 ' A' ' 26' ' ' ILE . 2.7 mt -91.36 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.288 -0.883 . . . . 0.0 109.25 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -147.56 -174.51 4.56 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.925 . . . . 0.0 109.446 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.4 p -84.83 72.76 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.9 -40.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.459 179.955 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.525 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.6 tt0 -54.11 142.49 25.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.469 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.62 168.32 54.61 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.519 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -129.31 -40.26 1.46 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.234 -1.157 . . . . 0.0 109.56 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.513 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 13.0 m -161.01 176.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.112 -0.993 . . . . 0.0 109.534 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.9 t -131.9 97.9 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.422 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.07 146.25 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.439 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.95 177.84 6.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.0 m -136.33 160.91 37.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.87 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.11 -28.85 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.214 -0.929 . . . . 0.0 109.405 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -160.02 52.62 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 176.93 -166.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.174 -0.954 . . . . 0.0 109.476 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.2 t -152.73 140.8 20.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.46 150.53 42.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -0.893 . . . . 0.0 109.509 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.456 ' O ' HG21 ' A' ' 44' ' ' VAL . 4.8 pm0 -98.14 169.71 9.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 55.5 t -146.47 98.39 4.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.235 -0.915 . . . . 0.0 109.422 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.63 -169.05 0.67 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.437 2.091 . . . . 0.0 110.412 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.4 134.17 40.92 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.454 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.486 ' CG ' HG13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.96 -5.37 14.53 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.425 2.083 . . . . 0.0 110.399 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.469 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -160.41 144.99 14.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.326 -0.859 . . . . 0.0 109.513 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.5 99.18 3.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.421 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.437 ' CA ' HD13 ' A' ' 72' ' ' LEU . . . -153.79 175.65 32.02 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.459 ' HB ' HD21 ' A' ' 25' ' ' LEU . 11.3 p -95.78 145.16 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -1.131 . . . . 0.0 109.574 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -63.87 114.24 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.45 ' HD2' ' HB2' ' A' ' 73' ' ' GLU . 2.8 tttp -85.21 -56.74 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.5 m -143.86 127.44 17.02 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.498 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 t -96.23 128.78 47.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.448 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.9 m -119.59 34.0 5.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.425 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.54 157.5 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.47 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -141.08 149.53 41.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.918 . . . . 0.0 109.46 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.77 128.58 35.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.497 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.1 -23.2 29.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -80.78 148.89 29.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.184 -1.186 . . . . 0.0 109.489 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.488 ' CE ' ' OD2' ' A' ' 12' ' ' ASP . 3.1 tttt -103.14 112.99 26.11 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.916 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.478 HD21 ' CB ' ' A' ' 67' ' ' ASP . 12.6 mt -102.01 135.32 43.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.287 -0.883 . . . . 0.0 109.434 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -100.51 152.47 20.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.31 -0.869 . . . . 0.0 109.439 -179.956 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.9 pt-20 -42.88 150.49 0.16 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.55 -17.58 51.45 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.478 ' CB ' HD21 ' A' ' 63' ' ' LEU . 1.1 m-20 -84.0 131.21 34.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -1.131 . . . . 0.0 109.436 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -57.4 159.78 4.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.238 -0.914 . . . . 0.0 109.475 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 70' ' ' ILE . 33.0 mm -117.6 -58.15 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.486 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.462 HG22 HG21 ' A' ' 69' ' ' ILE . 2.4 pp -158.36 -177.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.239 -0.913 . . . . 0.0 109.43 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.407 ' HG2' HG13 ' A' ' 3' ' ' ILE . 57.5 mt-10 -133.58 127.46 33.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -99.5 142.47 30.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.484 -179.954 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HB2' ' HD2' ' A' ' 53' ' ' LYS . 0.2 OUTLIER -118.85 90.06 39.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.186 -0.946 . . . . 0.0 109.47 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.523 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.533 0 C-N-CA 122.625 2.217 . . . . 0.0 110.413 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 96.5 p . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.244 0.545 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -93.31 140.7 29.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 109.52 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.421 HG21 ' N ' ' A' ' 4' ' ' ILE . 18.0 mm -80.44 160.35 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.421 ' N ' HG21 ' A' ' 3' ' ' ILE . 96.6 mt -122.97 96.6 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.333 -0.855 . . . . 0.0 109.415 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.482 ' C ' ' CD1' ' A' ' 69' ' ' ILE . 0.1 OUTLIER -92.01 -178.76 5.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.289 -0.882 . . . . 0.0 109.558 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 75.8 t -70.93 142.7 88.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.369 -0.832 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.532 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.03 -170.02 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.494 2.13 . . . . 0.0 110.377 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.85 104.12 14.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.252 -0.905 . . . . 0.0 109.477 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.19 -41.68 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.208 -0.932 . . . . 0.0 109.273 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.88 -21.04 12.69 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.77 -142.25 3.91 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 3.1 m-20 -102.84 165.94 10.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.289 -1.124 . . . . 0.0 109.415 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.33 165.44 21.25 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -146.44 121.39 10.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.199 -1.177 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.428 HG12 ' CD1' ' A' ' 18' ' ' LEU . 21.6 t -70.23 149.49 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' ' OE1' ' A' ' 17' ' ' GLU . 69.1 mt -127.15 -40.01 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.284 -0.885 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -156.51 126.44 6.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.489 -179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.428 ' CD1' HG12 ' A' ' 15' ' ' VAL . 0.7 OUTLIER -102.41 141.53 35.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.428 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.407 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -132.61 61.54 1.67 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.498 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.78 164.42 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.466 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 28.6 mmtt -122.98 157.2 33.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 13.3 t -84.74 128.9 34.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.96 -9.17 73.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.466 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 1.6 m-20 -83.53 136.8 34.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -1.157 . . . . 0.0 109.551 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -86.18 126.5 34.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.491 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.443 HG23 ' HB2' ' A' ' 46' ' ' SER . 2.2 mt -90.33 -171.32 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.294 -0.879 . . . . 0.0 109.193 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -137.39 156.12 48.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.205 -0.934 . . . . 0.0 109.467 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.6 p -79.03 82.08 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.85 -35.89 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.395 -0.816 . . . . 0.0 109.433 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -71.59 152.13 43.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.44 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.492 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.32 -169.31 0.29 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.502 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.1 tp -153.31 -70.18 0.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -1.154 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.449 HG22 HD12 ' A' ' 35' ' ' LEU . 17.7 m -134.02 173.56 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 43' ' ' GLU . 97.1 t -133.73 102.33 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.449 HD12 HG22 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -109.29 170.07 8.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.311 -0.868 . . . . 0.0 109.525 179.935 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.85 137.25 51.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.482 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.64 176.89 5.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.21 -0.931 . . . . 0.0 109.5 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.55 -45.82 13.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.403 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.466 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 1.4 mttm -152.3 67.55 0.84 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.492 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' A' ' 39' ' ' LYS . . . 167.66 99.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.208 -0.932 . . . . 0.0 109.479 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.5 t -80.02 126.53 31.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.452 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -147.2 159.46 43.61 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -0.875 . . . . 0.0 109.512 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.441 ' HB3' HG21 ' A' ' 34' ' ' VAL . 3.5 pt-20 -109.4 169.3 8.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.39 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.502 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 94.7 t -132.5 139.36 34.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.405 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.492 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.97 -168.23 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.432 0 C-N-CA 122.549 2.166 . . . . 0.0 110.361 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.443 ' HB2' HG23 ' A' ' 26' ' ' ILE . 1.0 OUTLIER -85.16 113.55 50.93 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.385 -0.822 . . . . 0.0 109.365 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 36.0 Cg_endo -77.87 3.37 7.02 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.332 2.021 . . . . 0.0 110.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.502 ' HB3' ' CD2' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -160.02 110.28 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.465 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.2 90.62 1.6 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.939 . . . . 0.0 109.601 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.52 ' HA3' ' CD2' ' A' ' 72' ' ' LEU . . . -143.69 -157.73 7.29 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 11.1 p -111.48 128.53 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -1.148 . . . . 0.0 109.509 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.478 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 48.8 t -58.27 134.83 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.474 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.87 -33.28 7.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.291 -0.881 . . . . 0.0 109.458 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 173.27 144.31 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.509 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 57' ' ' VAL . 52.2 t -99.68 135.11 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.6 m -105.63 16.19 25.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.346 -0.846 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 55' ' ' VAL . 1.5 m -136.47 157.34 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.443 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -110.37 167.17 10.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.02 137.2 38.84 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.493 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.1 -11.07 68.41 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -79.21 148.4 32.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.5 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -82.64 165.37 20.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -148.77 113.42 5.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -86.03 137.78 32.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.241 -0.912 . . . . 0.0 109.455 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 64' ' ' LYS . 25.7 pt-20 -42.88 151.41 0.13 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 109.672 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.08 -18.2 41.99 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -85.0 141.68 30.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.262 -1.14 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.19 172.42 9.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.482 ' CD1' ' C ' ' A' ' 5' ' ' ARG . 2.0 mp -134.76 -58.49 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.431 HG21 ' HA ' ' A' ' 55' ' ' VAL . 7.4 pt -147.23 -179.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.461 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -131.18 117.33 18.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.52 ' CD2' ' HA3' ' A' ' 50' ' ' GLY . 0.7 OUTLIER -97.54 147.08 24.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -0.863 . . . . 0.0 109.486 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.514 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 2.5 tp10 -120.09 89.7 43.24 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo . . . . . 0 C--N 1.308 -1.571 0 C-N-CA 122.651 2.234 . . . . 0.0 110.375 -179.936 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.403 ' HG3' HD12 ' A' ' 4' ' ' ILE . 11.4 tp10 -86.69 111.01 20.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.253 -0.904 . . . . 0.0 109.285 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.407 ' O ' HD12 ' A' ' 4' ' ' ILE . 2.2 tt -79.96 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.448 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.453 HG21 HD11 ' A' ' 4' ' ' ILE . 40.2 mm -122.78 122.77 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.564 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -92.11 -176.13 4.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.554 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.573 ' CG2' ' CD1' ' A' ' 69' ' ' ILE . 53.4 t -74.75 139.99 74.31 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.347 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.442 ' HD2' HG12 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.39 -174.37 2.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.549 2.166 . . . . 0.0 110.438 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -85.19 108.88 17.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.413 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.79 -7.27 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.281 -0.887 . . . . 0.0 109.396 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.58 21.95 13.54 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 150.2 -133.53 4.4 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -85.54 170.85 12.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.243 -1.151 . . . . 0.0 109.464 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -141.05 148.25 19.9 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.419 ' HG3' ' HA ' ' A' ' 62' ' ' LYS . 1.0 OUTLIER -135.73 130.43 34.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -1.17 . . . . 0.0 109.484 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.444 ' HB ' ' HA2' ' A' ' 60' ' ' GLY . 38.2 t -70.1 147.2 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.439 HD12 ' HB2' ' A' ' 36' ' ' GLU . 42.7 mt -118.95 -53.91 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.326 -0.859 . . . . 0.0 109.558 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -134.34 133.81 41.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.431 ' CD1' HG13 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -115.24 102.47 9.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.496 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -93.66 41.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 m -143.74 156.08 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.533 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.07 -176.83 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.9 m -84.08 133.92 34.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.482 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.2 5.38 89.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.94 135.49 34.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -1.175 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.57 115.7 27.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.269 -0.895 . . . . 0.0 109.471 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.456 HD11 ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -90.46 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.322 -0.861 . . . . 0.0 109.219 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.437 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 1.8 mt-10 -135.37 177.68 7.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 14.3 p -85.4 59.89 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.588 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 3.3 tt0 167.5 -32.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.249 -0.907 . . . . 0.0 109.228 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -52.35 145.41 11.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.414 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -69.03 171.03 39.88 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -130.11 -56.04 1.11 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -1.156 . . . . 0.0 109.546 -179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.431 HG13 ' CD1' ' A' ' 18' ' ' LEU . 36.0 m -151.56 -176.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.496 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -139.01 97.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.418 HD22 HG21 ' A' ' 15' ' ' VAL . 3.1 mt -90.08 158.9 17.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.439 ' HB2' HD12 ' A' ' 16' ' ' ILE . 2.0 tt0 -123.27 153.04 40.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.408 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.6 m -130.25 -176.58 4.0 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.464 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.98 -34.62 65.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.249 -0.907 . . . . 0.0 109.484 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -159.9 61.19 0.36 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.402 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 177.14 88.21 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.421 ' HB3' ' CG ' ' A' ' 36' ' ' GLU . 99.6 p -105.1 112.97 26.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.383 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.2 mtt -130.02 -175.5 3.64 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.479 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.418 ' C ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -114.23 162.19 16.87 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.25 -0.906 . . . . 0.0 109.504 -179.943 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 59.2 t -137.53 117.57 10.35 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.33 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.96 -168.69 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.28 1.987 . . . . 0.0 110.434 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.479 ' CA ' HD11 ' A' ' 32' ' ' LEU . 6.0 t -85.27 138.08 36.7 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.402 -0.811 . . . . 0.0 109.328 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.82 -4.82 14.3 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.417 2.078 . . . . 0.0 110.478 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.523 ' HB3' ' CD2' ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.35 128.1 4.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -0.859 . . . . 0.0 109.521 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.437 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . . . -70.86 98.51 1.58 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.903 . . . . 0.0 109.501 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.428 ' C ' HD13 ' A' ' 72' ' ' LEU . . . -152.12 -135.98 2.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.42 ' N ' HD13 ' A' ' 72' ' ' LEU . 10.0 p -132.27 151.36 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.189 -1.183 . . . . 0.0 109.439 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.413 ' N ' HG21 ' A' ' 51' ' ' VAL . 16.5 t -73.49 119.95 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -91.97 -43.21 9.57 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.916 . . . . 0.0 109.407 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.8 t -149.48 142.84 25.23 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 21.0 t -105.02 106.79 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.86 10.56 13.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.288 -0.883 . . . . 0.0 109.436 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.2 m -124.98 177.73 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.305 -0.872 . . . . 0.0 109.5 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.465 ' CB ' ' CG ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -128.48 -156.02 0.73 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.87 80.67 9.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.444 ' HA2' ' HB ' ' A' ' 15' ' ' VAL . . . 74.89 46.22 18.03 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.465 ' CG ' ' CB ' ' A' ' 58' ' ' LYS . 4.9 m-20 -84.96 172.24 11.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.296 -1.12 . . . . 0.0 109.435 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.419 ' HA ' ' HG3' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -97.62 145.3 26.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.196 -0.94 . . . . 0.0 109.447 -179.92 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.92 -172.52 4.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.467 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -138.45 147.08 42.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.86 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.474 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 4.2 pt-20 -45.39 148.86 0.6 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.273 -0.892 . . . . 0.0 109.694 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 5' ' ' ARG . . . 85.86 -43.51 3.25 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 68' ' ' ALA . 0.9 OUTLIER -50.76 134.46 24.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -1.128 . . . . 0.0 109.602 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -48.21 174.04 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -0.886 . . . . 0.0 109.535 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.573 ' CD1' ' CG2' ' A' ' 6' ' ' VAL . 26.9 mm -143.51 -58.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.238 -0.914 . . . . 0.0 109.498 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.432 ' C ' ' CD1' ' A' ' 70' ' ' ILE . 2.4 pp -150.98 179.56 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.482 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -145.56 97.25 2.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.511 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD2' ' HB3' ' A' ' 48' ' ' LYS . 0.4 OUTLIER -90.76 124.86 35.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.238 -0.914 . . . . 0.0 109.433 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.517 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 37.1 tt0 -91.42 140.99 25.6 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.254 -0.903 . . . . 0.0 109.374 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.6 Cg_endo . . . . . 0 C--N 1.31 -1.455 0 C-N-CA 122.486 2.124 . . . . 0.0 110.373 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.416 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 23.4 p . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -126.77 147.55 49.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 109.403 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.49 HG13 ' CG ' ' A' ' 71' ' ' GLU . 3.5 mp -85.11 162.88 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.211 -0.931 . . . . 0.0 109.484 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.454 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 3.0 mp -127.75 104.27 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.469 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 4.3 ptp85 -93.03 -172.44 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.145 -0.972 . . . . 0.0 109.473 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.519 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 42.0 t -73.99 136.59 76.4 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.297 -0.877 . . . . 0.0 109.389 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.436 ' HD2' HG12 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.94 -176.61 3.38 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.481 2.121 . . . . 0.0 110.383 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -85.18 101.21 12.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.183 -0.948 . . . . 0.0 109.322 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.71 -45.95 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.249 -0.907 . . . . 0.0 109.259 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.78 16.07 11.25 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.7 -159.42 16.64 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 7.5 m-20 -104.31 119.82 39.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -1.167 . . . . 0.0 109.516 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.4 151.62 23.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.5 mp0 -131.58 119.82 22.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.246 -1.149 . . . . 0.0 109.442 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.465 ' CG2' HD13 ' A' ' 63' ' ' LEU . 39.8 t -65.37 134.67 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.495 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.2 mm -115.19 -52.74 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.438 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -129.09 123.47 32.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.499 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HG ' HG23 ' A' ' 20' ' ' VAL . 5.9 tp -99.84 115.37 29.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.893 . . . . 0.0 109.465 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -113.55 57.18 0.68 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.482 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.443 HG12 ' HG ' ' A' ' 32' ' ' LEU . 29.3 m -139.73 158.44 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.263 -0.898 . . . . 0.0 109.435 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.26 162.6 33.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -0.956 . . . . 0.0 109.46 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.413 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 0.2 OUTLIER -84.93 125.61 32.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.259 -0.901 . . . . 0.0 109.512 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.501 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.03 -8.95 67.88 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -78.63 132.05 36.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -1.138 . . . . 0.0 109.5 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.462 HD11 ' N ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -85.35 115.71 23.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.497 ' CD1' HD12 ' A' ' 32' ' ' LEU . 2.6 mt -91.99 -171.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.3 -0.875 . . . . 0.0 109.211 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 20.0 pt-20 -146.3 172.33 13.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.415 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 11.6 p -81.12 74.83 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.211 -0.93 . . . . 0.0 109.357 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.4 tm-20 167.87 -39.37 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.332 -0.855 . . . . 0.0 109.299 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -62.47 144.64 55.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.393 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.478 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -72.32 164.34 54.51 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 2.6 tp -124.61 -38.37 2.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -1.166 . . . . 0.0 109.398 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.487 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 9.3 m -157.77 167.26 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.9 t -131.47 105.04 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.468 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.449 ' CD1' HG22 ' A' ' 33' ' ' VAL . 9.8 mp -90.23 148.69 22.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -138.56 116.78 11.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.547 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.0 m -100.1 -175.74 3.03 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.26 -0.9 . . . . 0.0 109.449 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.79 -42.22 16.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -154.62 57.45 0.69 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -167.87 97.12 0.45 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.926 . . . . 0.0 109.51 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.5 m -99.7 120.64 40.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.436 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 17.2 mtp -128.63 134.25 48.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.443 ' O ' HG21 ' A' ' 44' ' ' VAL . 26.0 tt0 -91.56 162.73 14.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.2 -0.937 . . . . 0.0 109.387 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -144.45 99.17 4.91 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.33 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.42 -168.6 0.61 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.526 2.151 . . . . 0.0 110.477 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 1.1 t -85.34 127.45 63.64 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.22 -0.925 . . . . 0.0 109.377 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.43 -2.51 12.56 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.345 2.03 . . . . 0.0 110.43 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 2.4 mtmt -160.19 143.11 13.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.389 -0.819 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.81 97.95 7.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.458 ' O ' HD11 ' A' ' 25' ' ' LEU . . . -147.0 -172.51 17.34 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.501 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 2.5 p -104.63 127.47 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.456 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.413 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 50.5 t -50.57 133.91 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 18.1 tttt -101.99 -58.8 1.81 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -0.922 . . . . 0.0 109.496 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.56 153.87 36.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 109.474 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.452 ' HA ' HG21 ' A' ' 70' ' ' ILE . 9.1 t -103.16 131.68 51.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.266 -0.896 . . . . 0.0 109.493 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.0 m -113.62 19.83 16.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.244 -0.91 . . . . 0.0 109.462 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.441 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 17.8 m -132.71 -178.62 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.945 . . . . 0.0 109.396 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.6 ttpt -138.91 158.6 43.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.472 ' CD1' ' O ' ' A' ' 59' ' ' LEU . 3.4 pp -76.68 123.02 25.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.243 -0.911 . . . . 0.0 109.492 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.97 -8.35 73.28 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -78.01 144.16 36.91 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.268 -1.136 . . . . 0.0 109.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 62' ' ' LYS . 1.8 pptp? -91.13 122.91 34.18 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.24 -0.913 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.465 HD13 ' CG2' ' A' ' 15' ' ' VAL . 19.2 mt -102.74 152.14 21.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.895 . . . . 0.0 109.442 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -122.54 152.45 40.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.436 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.519 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 77.2 mt-10 -47.7 148.11 1.64 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.245 -0.909 . . . . 0.0 109.725 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.03 -40.19 3.09 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -61.97 131.6 50.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -1.158 . . . . 0.0 109.549 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.469 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -62.1 -174.88 0.06 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.454 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 44.2 mm -146.45 -64.99 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.874 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.516 ' CD1' HD22 ' A' ' 32' ' ' LEU . 2.8 pt -148.56 -172.45 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.297 -0.877 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.49 ' CG ' HG13 ' A' ' 3' ' ' ILE . 1.7 tt0 -142.99 117.48 9.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.589 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.519 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 0.5 OUTLIER -95.47 137.38 34.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.382 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.436 ' O ' HG13 ' A' ' 51' ' ' VAL . 3.4 tt0 -115.71 85.84 14.81 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.519 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.539 0 C-N-CA 122.654 2.236 . . . . 0.0 110.371 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.455 HD11 ' HG2' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.463 ' O ' HD13 ' A' ' 69' ' ' ILE . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.453 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.56 ' CG2' ' CB ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.458 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.445 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.464 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.521 HD23 ' CB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.523 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.47 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.42 HG11 ' OG ' ' A' ' 41' ' ' SER . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.542 ' CD2' ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.42 ' OG ' HG11 ' A' ' 34' ' ' VAL . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.436 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.508 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.523 ' CB ' HG23 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.521 ' O ' ' CG ' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.519 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.521 ' CB ' HD23 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.464 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 57' ' ' VAL . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.428 ' C ' HG11 ' A' ' 57' ' ' VAL . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.425 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.56 ' CB ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.453 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.464 HD13 HD23 ' A' ' 32' ' ' LEU . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.455 ' HG2' HD11 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.519 HD12 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.3 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.455 HD11 ' HG2' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.463 ' O ' HD13 ' A' ' 69' ' ' ILE . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.453 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.56 ' CG2' ' CB ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.458 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.445 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.464 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.521 HD23 ' CB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.523 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.47 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.42 HG11 ' OG ' ' A' ' 41' ' ' SER . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.542 ' CD2' ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.42 ' OG ' HG11 ' A' ' 34' ' ' VAL . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.436 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.508 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.523 ' CB ' HG23 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.521 ' O ' ' CG ' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.519 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.521 ' CB ' HD23 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.464 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 57' ' ' VAL . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.428 ' C ' HG11 ' A' ' 57' ' ' VAL . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.425 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.56 ' CB ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.453 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.464 HD13 HD23 ' A' ' 32' ' ' LEU . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.455 ' HG2' HD11 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.519 HD12 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.3 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.409 ' O ' ' HG2' ' A' ' 2' ' ' GLU . 48.4 p . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.295 0.569 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.409 ' HG2' ' O ' ' A' ' 1' ' ' SER . 14.0 mt-10 -145.28 145.35 31.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.464 HG21 ' N ' ' A' ' 4' ' ' ILE . 21.2 mt -85.13 148.89 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.197 -0.939 . . . . 0.0 109.45 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.465 HG12 ' HG3' ' A' ' 47' ' ' PRO . 2.3 mp -116.14 108.01 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 1.2 ptp85 -98.71 176.73 5.53 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 78.9 t -74.04 142.43 79.36 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.319 -0.863 . . . . 0.0 109.359 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.532 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.82 -171.53 1.22 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.463 2.109 . . . . 0.0 110.435 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -85.03 104.88 15.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.59 -31.13 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.226 -0.921 . . . . 0.0 109.215 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.68 -11.41 59.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.03 145.07 15.09 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -45.96 151.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.505 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.17 119.9 3.58 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -86.77 129.01 35.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.479 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.3 t -76.5 131.94 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.413 ' HB ' ' O ' ' A' ' 34' ' ' VAL . 39.5 mt -95.04 -51.17 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.169 -0.957 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -174.07 163.5 3.96 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.474 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.417 HD21 HG21 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -108.41 139.21 43.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 109.449 -179.99 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.7 15.11 11.68 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.417 HG21 HD21 ' A' ' 18' ' ' LEU . 1.9 m -149.87 164.22 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.887 . . . . 0.0 109.527 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -114.9 -163.87 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.337 -0.852 . . . . 0.0 109.493 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.4 t -84.96 139.86 31.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.302 -0.874 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.01 8.37 61.2 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.423 ' C ' HG22 ' A' ' 51' ' ' VAL . 11.7 m-20 -84.95 133.02 34.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.207 -1.173 . . . . 0.0 109.522 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 1.1 tp -79.98 125.49 29.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.268 -0.895 . . . . 0.0 109.475 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.447 HG23 ' HB3' ' A' ' 46' ' ' SER . 2.7 mt -92.04 -171.41 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.251 -0.906 . . . . 0.0 109.204 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.16 175.39 9.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 11.6 p -85.15 64.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.505 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.88 -43.68 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.496 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.9 tt0 -45.25 149.59 0.5 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.518 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.462 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -74.39 166.89 54.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.517 ' N ' ' HA ' ' A' ' 45' ' ' PRO . 0.4 OUTLIER -126.94 -37.5 2.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -1.175 . . . . 0.0 109.561 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.442 HG21 ' HB ' ' A' ' 44' ' ' VAL . 23.5 m -152.85 154.32 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.561 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.422 HG23 ' OE2' ' A' ' 43' ' ' GLU . 60.5 t -125.74 91.93 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.307 -0.871 . . . . 0.0 109.419 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.414 ' CD1' HG22 ' A' ' 33' ' ' VAL . 6.3 mp -89.98 153.75 20.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.51 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -143.36 134.46 25.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.274 -0.891 . . . . 0.0 109.467 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.61 174.24 7.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.881 . . . . 0.0 109.547 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.0 -13.18 57.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.46 -56.27 3.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -0.935 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -164.72 -149.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.927 . . . . 0.0 109.401 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.7 p -136.34 144.59 44.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -136.85 -175.97 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.422 ' OE2' HG23 ' A' ' 34' ' ' VAL . 6.4 tt0 -150.24 162.18 40.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.52 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 38.2 t -147.5 101.37 3.76 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.262 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.517 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.6 Cg_endo -77.2 -168.94 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.399 2.066 . . . . 0.0 110.506 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 3.8 t -85.28 132.52 44.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.441 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.465 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.87 -5.28 14.55 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 C-N-CA 122.489 2.126 . . . . 0.0 110.402 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' A' ' 46' ' ' SER . 5.6 tptt -160.23 144.71 14.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.35 -0.844 . . . . 0.0 109.491 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.95 91.05 4.17 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.501 ' N ' HD23 ' A' ' 72' ' ' LEU . . . -139.69 -135.19 3.22 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.509 ' N ' ' CD1' ' A' ' 72' ' ' LEU . 7.2 p -149.08 150.57 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -1.178 . . . . 0.0 109.535 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.407 ' N ' HG21 ' A' ' 51' ' ' VAL . 58.0 t -73.01 129.45 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.407 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 3.5 tttp -113.63 -27.59 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.266 -0.896 . . . . 0.0 109.564 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -154.61 128.28 8.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.176 -0.953 . . . . 0.0 109.508 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.8 t -113.08 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.465 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.37 34.79 4.95 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.418 HG12 ' HA ' ' A' ' 69' ' ' ILE . 3.4 m -140.75 170.18 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.26 -0.9 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.434 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -132.59 157.77 43.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.926 . . . . 0.0 109.454 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -83.09 131.79 35.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.496 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.81 -11.48 68.72 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.434 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.7 OUTLIER -81.65 163.93 22.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -1.182 . . . . 0.0 109.435 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 mttt -104.13 120.24 40.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.475 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -105.47 137.28 43.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.467 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -101.47 140.32 35.93 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.278 -0.888 . . . . 0.0 109.469 179.964 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.464 ' HA ' HG13 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -42.76 151.6 0.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.29 -0.881 . . . . 0.0 109.675 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.09 -24.54 21.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.47 134.49 34.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.289 -1.124 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -59.23 179.23 0.11 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.513 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.507 ' CD1' HG21 ' A' ' 6' ' ' VAL . 31.8 mm -134.73 -67.63 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.178 -0.951 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.82 -172.1 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.442 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -144.62 136.48 25.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.514 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.509 ' CD1' ' N ' ' A' ' 51' ' ' VAL . 1.3 tp -113.01 112.32 23.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.407 ' OE1' ' HE2' ' A' ' 53' ' ' LYS . 23.7 tt0 -113.78 90.38 18.48 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.8 Cg_endo . . . . . 0 C--N 1.309 -1.547 0 C-N-CA 122.612 2.208 . . . . 0.0 110.484 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 48.6 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -97.02 175.75 6.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.473 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mp -104.76 146.97 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.493 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.2 mt -104.25 99.26 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.428 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -91.26 165.62 13.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.344 -0.847 . . . . 0.0 109.458 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.8 t -55.0 142.22 57.05 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.888 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.14 -172.58 1.53 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.489 2.126 . . . . 0.0 110.387 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -84.03 104.33 14.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.902 . . . . 0.0 109.503 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.79 -41.42 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.297 -0.877 . . . . 0.0 109.354 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.69 10.73 52.5 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -146.04 -125.14 1.68 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.65 123.67 38.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.15 . . . . 0.0 109.393 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.68 147.43 50.94 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.07 101.79 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -1.119 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.436 HG13 ' HA ' ' A' ' 59' ' ' LEU . 38.4 t -48.44 149.76 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.492 HD12 ' CA ' ' A' ' 36' ' ' GLU . 43.9 mt -127.16 -62.22 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 109.454 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -150.11 149.74 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.457 ' CD2' HG21 ' A' ' 20' ' ' VAL . 2.8 tp -119.47 138.84 52.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.453 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -127.98 54.35 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.516 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.457 HG21 ' CD2' ' A' ' 18' ' ' LEU . 15.3 m -144.42 159.8 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.17 -0.956 . . . . 0.0 109.399 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.494 ' CB ' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -111.37 -171.18 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 109.548 179.954 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.4 m -85.18 119.39 25.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.78 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 52' ' ' VAL . . . 72.37 2.17 53.64 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.639 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.494 ' CG ' ' CB ' ' A' ' 21' ' ' LYS . 2.1 m-20 -69.7 129.44 39.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.299 . . . . 0.0 109.123 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.0 OUTLIER -90.93 144.14 25.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.413 -0.805 . . . . 0.0 109.728 -179.697 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.525 ' CD1' ' HA3' ' A' ' 50' ' ' GLY . 1.3 mt -114.58 -170.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.411 ' H ' ' CG2' ' A' ' 26' ' ' ILE . 0.2 OUTLIER -100.46 172.45 7.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.079 -1.013 . . . . 0.0 109.405 179.963 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.497 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 14.8 p -83.89 68.64 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.497 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 163.03 -29.73 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -60.13 151.59 26.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.517 179.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -67.06 163.61 44.84 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.509 HD21 ' CD1' ' A' ' 70' ' ' ILE . 0.2 OUTLIER -125.75 -38.81 2.18 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.537 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 32' ' ' LEU . 28.7 m -152.23 171.64 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.422 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 60.7 t -127.91 95.67 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.309 -0.87 . . . . 0.0 109.417 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 mt -89.88 162.14 15.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.922 . . . . 0.0 109.558 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.492 ' CA ' HD12 ' A' ' 16' ' ' ILE . 8.2 tt0 -114.99 164.13 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -135.43 -177.07 4.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -56.49 -44.06 80.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -0.886 . . . . 0.0 109.471 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.47 48.42 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -176.0 124.03 0.19 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.522 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.0 125.68 32.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.342 -0.849 . . . . 0.0 109.484 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.437 ' SD ' ' HG2' ' A' ' 7' ' ' PRO . 2.3 ptm -115.98 129.9 56.58 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -96.64 167.18 11.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.208 -0.933 . . . . 0.0 109.415 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 2.7 t -144.37 100.1 4.86 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.242 -0.911 . . . . 0.0 109.366 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.2 Cg_endo -77.68 -170.03 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.411 2.074 . . . . 0.0 110.359 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.459 ' HB2' HD13 ' A' ' 32' ' ' LEU . 6.3 t -85.96 142.66 36.61 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.432 -0.792 . . . . 0.0 109.364 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.461 ' O ' ' HG3' ' A' ' 48' ' ' LYS . 35.7 Cg_endo -78.37 -10.94 16.07 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.484 2.122 . . . . 0.0 110.174 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' HG3' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.37 -91.73 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.559 -0.713 . . . . 0.0 109.121 179.887 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.442 ' HB2' HD22 ' A' ' 25' ' ' LEU . . . -85.2 -92.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.29 -0.882 . . . . 0.0 109.229 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.525 ' HA3' ' CD1' ' A' ' 26' ' ' ILE . . . 139.98 41.04 0.08 OUTLIER Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.519 ' CG1' ' O ' ' A' ' 51' ' ' VAL . 7.1 p -95.56 115.15 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.1 -1.235 . . . . 0.0 109.346 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.468 ' O ' ' HA2' ' A' ' 23' ' ' GLY . 40.6 t -69.26 116.15 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.443 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -108.21 -25.25 11.16 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.174 -0.954 . . . . 0.0 109.513 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.85 123.33 1.73 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.514 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 90.1 t -112.58 135.27 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.464 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -126.38 39.73 3.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.484 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 27.1 m -149.91 167.23 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.2 tttt -125.39 167.99 14.18 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.436 ' HA ' HG13 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -84.43 87.42 7.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.6 -11.87 4.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.42 ' O ' HG22 ' A' ' 15' ' ' VAL . 32.9 m-20 -75.45 146.67 40.5 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -1.118 . . . . 0.0 109.566 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.403 ' C ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -105.14 146.62 28.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.209 -0.932 . . . . 0.0 109.484 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.403 ' HG ' ' C ' ' A' ' 62' ' ' LYS . 13.8 mt -141.47 178.42 7.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.477 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' GLU . 8.7 tttp -118.58 149.32 41.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.181 -0.949 . . . . 0.0 109.537 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.3 pt-20 -42.71 150.33 0.16 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.337 -0.852 . . . . 0.0 109.627 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.68 -15.33 55.41 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -82.28 132.26 35.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -1.148 . . . . 0.0 109.544 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -63.85 161.59 15.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.432 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.484 ' HA ' ' CG1' ' A' ' 57' ' ' VAL . 43.9 mm -128.01 -59.71 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.887 . . . . 0.0 109.522 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.509 ' CD1' HD21 ' A' ' 32' ' ' LEU . 3.4 pt -141.44 -171.94 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.51 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.8 109.2 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.602 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.519 HD13 ' N ' ' A' ' 50' ' ' GLY . 2.0 tt -90.02 145.42 25.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.3 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.448 ' O ' HD22 ' A' ' 72' ' ' LEU . 1.4 mt-10 -106.09 146.27 32.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.448 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 36.1 Cg_endo . . . . . 0 C--N 1.309 -1.508 0 C-N-CA 122.587 2.191 . . . . 0.0 110.431 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.449 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 2.5 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mt-10 -125.2 169.19 12.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.24 -0.913 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mt -99.61 137.34 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.446 HD11 HG22 ' A' ' 4' ' ' ILE . 31.6 mm -113.82 119.05 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.239 -0.913 . . . . 0.0 109.485 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.455 ' C ' ' CD1' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -106.23 -177.96 3.51 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.476 -179.927 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.518 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.6 t -81.0 142.27 51.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.355 -0.841 . . . . 0.0 109.342 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.518 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.07 -170.74 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.607 2.205 . . . . 0.0 110.433 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -84.51 104.69 14.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.224 -0.923 . . . . 0.0 109.437 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.438 HD13 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.97 -21.65 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.281 -0.887 . . . . 0.0 109.295 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.78 21.63 76.29 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.0 -165.92 25.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -97.2 140.34 31.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -1.168 . . . . 0.0 109.459 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -111.14 105.17 1.83 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.8 mm-40 -97.22 130.22 44.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.422 HG23 ' CD2' ' A' ' 35' ' ' LEU . 60.3 t -72.91 119.42 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.496 ' CG2' ' O ' ' A' ' 34' ' ' VAL . 1.6 tt -112.55 -24.33 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.451 ' N ' HG21 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -145.99 140.44 26.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.51 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.412 HD22 HG21 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -132.55 127.37 34.96 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.473 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.7 47.32 1.82 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.897 . . . . 0.0 109.414 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.516 ' CG1' HD12 ' A' ' 32' ' ' LEU . 3.2 m -150.07 158.19 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.6 mmtt -138.05 -174.0 3.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.9 m -84.4 141.18 31.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.481 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.7 1.83 62.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.89 130.27 34.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -1.196 . . . . 0.0 109.485 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -86.12 119.3 26.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.88 . . . . 0.0 109.387 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.518 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.4 mt -90.01 -171.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.209 -0.932 . . . . 0.0 109.201 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -150.17 163.34 38.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.433 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.49 147.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.161 -0.962 . . . . 0.0 109.411 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 83.07 -43.61 0.11 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.688 -0.632 . . . . 0.0 109.863 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.524 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -55.41 144.27 26.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.078 -1.014 . . . . 0.0 109.43 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.478 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -69.32 172.38 38.27 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -133.04 -51.84 0.9 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.542 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.9 m -153.6 175.75 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.141 -0.974 . . . . 0.0 109.617 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.496 ' O ' ' CG2' ' A' ' 16' ' ' ILE . 84.4 t -130.8 94.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.87 . . . . 0.0 109.425 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 13.2 mt -90.14 151.86 21.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -106.05 112.02 24.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.291 -0.881 . . . . 0.0 109.432 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.64 -172.12 3.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -0.907 . . . . 0.0 109.525 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.32 6.64 13.67 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.51 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.454 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -112.47 -36.89 5.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.178 -0.951 . . . . 0.0 109.518 179.93 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' A' ' 39' ' ' LYS . . . 174.44 -152.37 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.243 -0.911 . . . . 0.0 109.429 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 8.3 t -106.05 112.55 25.64 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.251 -0.906 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -106.95 151.81 24.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.46 ' HG3' HG21 ' A' ' 34' ' ' VAL . 40.1 tt0 -110.31 150.43 28.77 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.176 -0.952 . . . . 0.0 109.452 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.8 t -132.73 118.24 15.51 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.897 . . . . 0.0 109.261 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.1 Cg_endo -77.7 -168.65 0.63 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.33 2.02 . . . . 0.0 110.451 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.518 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -85.35 126.32 67.34 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.345 -0.847 . . . . 0.0 109.339 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.44 -0.9 11.12 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.377 2.052 . . . . 0.0 110.374 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.18 127.31 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.76 99.54 5.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 109.46 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.508 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -155.93 -137.79 2.42 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.464 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 9.5 p -137.19 146.94 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.202 -1.176 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 52.2 t -69.73 133.39 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.303 -0.873 . . . . 0.0 109.518 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -110.79 -58.23 2.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.313 -0.867 . . . . 0.0 109.482 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 14.1 m -124.52 164.95 18.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.43 ' HA ' HG21 ' A' ' 70' ' ' ILE . 53.7 t -124.74 118.98 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.268 -0.895 . . . . 0.0 109.452 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.21 15.25 27.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.409 HG13 HD13 ' A' ' 63' ' ' LEU . 21.0 m -149.85 173.44 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.241 -0.912 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 tptt -134.47 173.67 11.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.253 -0.905 . . . . 0.0 109.46 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.73 124.29 31.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.65 -10.71 57.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.74 165.35 21.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -1.093 . . . . 0.0 109.571 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 165.12 13.06 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.409 HD13 HG13 ' A' ' 57' ' ' VAL . 5.3 mt -149.35 104.97 3.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.8 OUTLIER -86.99 137.89 31.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 10.3 pt-20 -42.77 151.57 0.12 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.19 -19.75 37.31 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -84.87 144.9 28.1 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.246 -1.15 . . . . 0.0 109.483 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -72.56 -178.8 2.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.477 HD13 ' N ' ' A' ' 6' ' ' VAL . 2.0 mp -139.82 -68.08 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.412 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.43 HG21 ' HA ' ' A' ' 55' ' ' VAL . 1.0 OUTLIER -148.9 -177.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.448 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -132.89 117.83 18.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 50' ' ' GLY . 2.8 tt -93.78 143.33 26.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.204 -0.935 . . . . 0.0 109.526 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -113.53 91.03 19.15 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.363 -0.836 . . . . 0.0 109.381 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.603 0 C-N-CA 122.668 2.246 . . . . 0.0 110.441 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 76.8 p . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.284 0.564 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.6 mt-10 -139.37 160.61 39.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.48 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.5 mp -85.17 136.07 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.905 . . . . 0.0 109.528 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.466 HD11 ' HG2' ' A' ' 47' ' ' PRO . 10.3 mt -105.49 120.21 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.92 168.55 10.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.189 -0.944 . . . . 0.0 109.486 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 78.3 t -49.68 142.48 12.17 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.268 -0.895 . . . . 0.0 109.322 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.69 -174.72 2.34 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.462 2.108 . . . . 0.0 110.393 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.91 100.86 8.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.41 -14.91 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.272 -0.892 . . . . 0.0 109.291 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.38 -21.26 32.87 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -128.82 -145.5 5.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.95 142.3 30.63 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -1.163 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.15 103.29 2.13 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.1 mt-10 -101.7 119.75 39.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.296 -1.12 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.496 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 39.7 t -78.83 131.93 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.464 179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 34' ' ' VAL . 8.8 mm -108.93 -40.48 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.9 . . . . 0.0 109.498 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' A' ' 16' ' ' ILE . 64.9 mt-10 -157.17 -177.77 6.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.426 -179.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.3 tp -137.03 145.96 44.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.471 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -136.8 36.35 2.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.554 -179.95 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.7 m -149.94 156.61 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.29 -0.881 . . . . 0.0 109.558 179.976 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.24 175.71 5.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.181 -0.949 . . . . 0.0 109.469 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.417 ' HA ' HG13 ' A' ' 52' ' ' VAL . 5.6 m -84.95 146.39 27.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.546 -179.933 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.48 3.32 86.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.02 133.14 34.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -1.165 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.486 ' CD2' ' HB ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -83.65 108.12 16.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.197 -0.939 . . . . 0.0 109.432 -179.991 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.46 HG23 ' HB3' ' A' ' 46' ' ' SER . 2.8 mt -92.53 -171.4 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 15.1 mt-10 -147.03 -178.95 6.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.421 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 12.4 p -82.7 73.67 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.87 -42.36 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.334 -0.853 . . . . 0.0 109.435 179.836 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 -50.81 135.69 23.49 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.174 -0.954 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -52.88 179.99 0.08 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -146.24 -67.99 0.28 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.21 -1.171 . . . . 0.0 109.535 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.9 m -133.01 169.63 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.47 ' CG2' ' HG2' ' A' ' 43' ' ' GLU . 24.4 t -119.09 79.2 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.261 -0.899 . . . . 0.0 109.452 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.496 ' CD2' ' HA ' ' A' ' 15' ' ' VAL . 5.9 mt -90.05 151.73 21.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.53 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.414 ' HG3' ' OG ' ' A' ' 41' ' ' SER . 2.3 tm-20 -140.79 141.84 34.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.33 -0.857 . . . . 0.0 109.495 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.03 -177.95 3.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -0.896 . . . . 0.0 109.523 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.95 -12.46 37.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.278 -0.889 . . . . 0.0 109.472 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.51 -67.96 0.77 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.264 -0.897 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.19 175.41 14.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -0.937 . . . . 0.0 109.461 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.414 ' OG ' ' HG3' ' A' ' 36' ' ' GLU . 0.9 OUTLIER -95.01 137.21 34.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 109.473 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.22 124.83 11.76 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.916 . . . . 0.0 109.5 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.47 ' HG2' ' CG2' ' A' ' 34' ' ' VAL . 7.1 mt-10 -84.52 166.86 16.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.488 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.496 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 54.1 t -137.03 134.59 19.09 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.24 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.23 -168.4 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.412 2.075 . . . . 0.0 110.316 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.46 ' HB3' HG23 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -85.1 130.88 50.4 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.302 -0.874 . . . . 0.0 109.353 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.466 ' HG2' HD11 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.53 -1.48 11.64 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.416 2.078 . . . . 0.0 110.394 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.448 ' O ' ' OG ' ' A' ' 46' ' ' SER . 33.6 ttmt -160.28 140.69 11.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 109.561 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.09 101.21 12.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.925 . . . . 0.0 109.493 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.508 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -158.58 -162.35 11.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.486 ' HB ' ' CD2' ' A' ' 25' ' ' LEU . 9.9 p -111.03 129.17 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.295 -1.12 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.417 HG13 ' HA ' ' A' ' 22' ' ' THR . 46.8 t -54.02 138.63 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.49 179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.12 -35.67 4.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 t -174.78 149.48 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.175 -0.953 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.1 t -108.53 148.45 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.452 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.424 ' O ' HG11 ' A' ' 57' ' ' VAL . 59.4 m -113.35 18.22 17.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 179.901 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.424 HG11 ' O ' ' A' ' 56' ' ' SER . 30.2 m -147.12 158.47 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.503 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.429 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -120.17 -175.21 2.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 -179.946 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.414 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -77.04 147.75 36.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.265 -0.897 . . . . 0.0 109.416 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.33 11.62 53.05 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.429 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -84.74 132.25 34.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.186 -1.185 . . . . 0.0 109.492 179.997 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.56 118.37 36.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.1 mp -122.6 162.55 21.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.1 tttp -102.75 146.79 27.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.431 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.5 OUTLIER -42.9 148.04 0.27 Allowed 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.312 -0.868 . . . . 0.0 109.661 -179.877 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.7 -8.07 74.0 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 1.2 m-20 -83.96 140.18 32.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -1.103 . . . . 0.0 109.487 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.36 164.16 0.21 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.422 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.45 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 17.7 mm -141.13 -54.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.182 -0.948 . . . . 0.0 109.449 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -150.65 -178.23 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.931 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -139.43 135.61 33.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 50' ' ' GLY . 1.5 tt -116.44 146.76 42.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 23.6 tt0 -118.35 88.62 33.73 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.486 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.529 0 C-N-CA 122.568 2.178 . . . . 0.0 110.466 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.4 p . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.43 161.81 16.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.34 -0.85 . . . . 0.0 109.459 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.486 ' N ' ' CD1' ' A' ' 3' ' ' ILE . 3.2 mp -110.74 139.26 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.903 . . . . 0.0 109.466 -179.978 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.418 HG21 ' N ' ' A' ' 5' ' ' ARG . 3.2 mt -111.19 138.27 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.228 -0.92 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.445 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 3.0 ptt180 -121.55 166.66 13.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.3 t -48.5 142.2 8.68 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.244 -0.91 . . . . 0.0 109.36 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.09 -171.45 1.21 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.483 2.122 . . . . 0.0 110.423 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.09 101.54 12.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.11 -26.36 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.24 -0.912 . . . . 0.0 109.255 -179.922 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 34.9 5.47 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 153.04 -133.58 4.09 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -118.08 168.2 10.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -1.112 . . . . 0.0 109.463 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.1 128.61 2.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.461 ' OE2' ' O ' ' A' ' 15' ' ' VAL . 3.3 tm-20 -89.2 134.65 33.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -1.144 . . . . 0.0 109.427 179.956 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.461 ' O ' ' OE2' ' A' ' 14' ' ' GLU . 19.2 t -74.72 156.57 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.505 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -115.56 -58.49 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.492 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.71 161.91 41.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.0 111.54 20.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -0.88 . . . . 0.0 109.472 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.415 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -95.16 32.91 1.62 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 179.988 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.415 HG11 ' O ' ' A' ' 19' ' ' LEU . 34.6 m -144.03 161.98 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.467 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.426 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.24 -177.07 4.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.205 -0.934 . . . . 0.0 109.469 179.999 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.0 m -81.34 143.18 32.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.234 -0.916 . . . . 0.0 109.504 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.422 ' HA2' HG23 ' A' ' 51' ' ' VAL . . . 82.94 2.58 90.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.426 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 22.7 m-20 -85.07 139.45 31.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -1.198 . . . . 0.0 109.435 -179.961 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.448 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 6.8 tt -103.43 108.97 20.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.517 HG23 ' CB ' ' A' ' 46' ' ' SER . 0.9 OUTLIER -90.15 -171.39 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.212 -0.93 . . . . 0.0 109.234 179.985 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.413 ' O ' ' HB3' ' A' ' 46' ' ' SER . 2.4 pt-20 -138.22 -178.28 5.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.119 -0.988 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.532 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.9 p -82.27 74.57 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.48 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER 162.91 -55.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.901 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 29' ' ' GLU . 1.4 tt0 -44.41 141.01 2.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.87 . . . . 0.0 109.494 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.466 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.77 178.67 32.1 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.521 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -141.35 -42.18 0.37 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -1.169 . . . . 0.0 109.453 179.926 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG2' ' HB ' ' A' ' 44' ' ' VAL . 20.3 m -152.04 155.29 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 -179.986 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' HG12 ' A' ' 16' ' ' ILE . 58.7 t -114.84 107.75 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.232 -0.918 . . . . 0.0 109.451 -179.903 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.8 mp -98.11 -178.38 4.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -147.54 140.08 24.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.938 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.4 p -107.07 -177.67 3.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.58 -65.45 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.238 -0.913 . . . . 0.0 109.425 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 mppt? -129.54 55.91 1.74 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.496 -179.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -170.85 -161.56 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.278 -0.889 . . . . 0.0 109.512 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.09 149.73 30.71 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.296 -0.877 . . . . 0.0 109.448 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 69.5 mmm -146.06 104.42 3.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -0.947 . . . . 0.0 109.383 -179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.95 171.98 13.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -0.921 . . . . 0.0 109.538 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.9 t -146.15 98.48 4.35 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.263 -0.898 . . . . 0.0 109.389 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.466 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 35.5 Cg_endo -77.5 -168.09 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.492 2.128 . . . . 0.0 110.527 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.517 ' CB ' HG23 ' A' ' 26' ' ' ILE . 6.5 t -85.09 113.65 51.37 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.45 -179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.4 Cg_endo -78.06 3.01 7.41 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.364 2.043 . . . . 0.0 110.329 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.515 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 6.0 mttt -160.01 114.94 2.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.312 -0.868 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.1 91.95 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.944 . . . . 0.0 109.533 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.532 ' CA ' ' CD1' ' A' ' 72' ' ' LEU . . . -155.39 -171.86 22.41 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.422 HG23 ' HA2' ' A' ' 23' ' ' GLY . 10.9 p -100.77 155.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -1.185 . . . . 0.0 109.517 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.2 t -81.37 138.62 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -0.923 . . . . 0.0 109.536 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -104.34 -66.9 0.93 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -137.92 148.7 45.55 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.474 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.0 t -101.65 133.65 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 179.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -112.87 13.98 19.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.142 -0.974 . . . . 0.0 109.567 179.962 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.447 HG12 HD12 ' A' ' 69' ' ' ILE . 2.0 m -137.46 158.77 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.219 -0.926 . . . . 0.0 109.478 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.15 158.68 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.238 -0.914 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.8 pp -82.68 137.64 34.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.931 . . . . 0.0 109.53 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.95 -14.52 65.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -83.68 168.07 16.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.14 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -97.38 140.77 31.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -0.855 . . . . 0.0 109.442 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.41 HD13 ' CG2' ' A' ' 15' ' ' VAL . 6.5 mt -123.97 116.05 22.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.497 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 65' ' ' GLU . 4.3 tttt -90.48 139.69 30.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.303 -0.873 . . . . 0.0 109.472 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 64' ' ' LYS . 15.6 pt-20 -42.76 149.19 0.2 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.313 -0.867 . . . . 0.0 109.645 -179.896 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.71 -14.88 58.88 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.445 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 91.6 m-20 -85.01 140.06 31.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.285 -1.126 . . . . 0.0 109.471 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.421 ' O ' HD12 ' A' ' 69' ' ' ILE . . . -62.37 -179.43 0.24 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.213 -0.929 . . . . 0.0 109.506 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.494 HD11 HG21 ' A' ' 69' ' ' ILE . 28.6 mm -147.95 -72.19 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.447 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.4 HG21 ' C ' ' A' ' 69' ' ' ILE . 3.8 pt -142.37 -172.52 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.932 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -140.29 112.2 7.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.532 ' CD1' ' CA ' ' A' ' 50' ' ' GLY . 3.6 tt -90.06 141.96 28.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -113.24 91.69 20.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.21 -0.932 . . . . 0.0 109.535 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.515 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.1 Cg_endo . . . . . 0 C--N 1.308 -1.56 0 C-N-CA 122.602 2.201 . . . . 0.0 110.35 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 68.8 p . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -147.42 150.48 34.74 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.439 HD13 ' O ' ' A' ' 70' ' ' ILE . 1.4 tp -93.03 130.73 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.6 mm -93.81 124.22 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.388 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.461 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 3.5 ptt-85 -118.52 159.16 24.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.523 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 84.3 t -43.33 103.51 0.32 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.344 -0.847 . . . . 0.0 109.442 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.9 Cg_endo -77.78 -169.54 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.511 2.14 . . . . 0.0 110.45 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -68.26 99.7 0.95 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.283 -0.886 . . . . 0.0 109.413 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.483 HD13 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.0 -43.0 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.305 -179.877 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.55 34.61 0.65 Allowed Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 147.21 -132.74 4.45 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -101.5 135.27 43.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.65 115.78 4.31 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.458 ' HG2' ' CB ' ' A' ' 62' ' ' LYS . 12.9 mt-10 -112.36 104.32 12.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -1.152 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -54.17 136.23 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.515 -179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.444 HG12 ' O ' ' A' ' 14' ' ' GLU . 29.2 mm -128.04 -37.42 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.83 155.27 43.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.455 HD21 HG21 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -117.59 123.59 46.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.991 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.489 HD11 ' N ' ' A' ' 32' ' ' LEU . 6.3 mt -93.77 9.36 37.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.535 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.468 ' CG2' HD12 ' A' ' 32' ' ' LEU . 4.7 m -146.42 175.42 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -139.31 -164.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.272 -0.892 . . . . 0.0 109.49 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.422 ' HA ' HG13 ' A' ' 52' ' ' VAL . 26.4 m -84.83 139.41 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.918 . . . . 0.0 109.509 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.87 10.56 51.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -85.04 134.72 34.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.195 -1.179 . . . . 0.0 109.454 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.445 HD23 ' HB ' ' A' ' 51' ' ' VAL . 0.4 OUTLIER -88.24 118.25 27.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.448 HG23 ' HB2' ' A' ' 46' ' ' SER . 3.7 mt -97.04 -171.41 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.239 -0.913 . . . . 0.0 109.234 -179.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -147.81 153.99 39.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 6.3 p -72.03 84.35 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.248 -0.907 . . . . 0.0 109.506 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.79 -32.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.336 -0.853 . . . . 0.0 109.473 179.877 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -78.66 153.27 31.14 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.233 -0.917 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.38 -160.07 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.01 -72.74 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -1.166 . . . . 0.0 109.459 179.983 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.515 HG22 ' CD1' ' A' ' 35' ' ' LEU . 8.5 m -119.45 150.92 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.455 HG23 ' OE1' ' A' ' 43' ' ' GLU . 23.9 t -117.91 83.22 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.515 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -91.13 147.52 23.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.44 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.39 152.84 21.13 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.169 -0.957 . . . . 0.0 109.411 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -98.72 -175.62 3.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.28 -0.888 . . . . 0.0 109.481 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.61 94.78 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.6 mttm -142.4 48.33 1.56 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.413 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -177.13 -158.76 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.51 152.94 37.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.388 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtp -159.26 142.47 14.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.455 ' OE1' HG23 ' A' ' 34' ' ' VAL . 24.0 mt-10 -132.65 162.8 30.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.7 t -131.02 140.08 37.57 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.309 -0.869 . . . . 0.0 109.345 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.499 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.21 -168.59 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.581 2.188 . . . . 0.0 110.421 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.448 ' HB2' HG23 ' A' ' 26' ' ' ILE . 28.9 t -85.27 113.64 51.6 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.398 -0.814 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.03 0.49 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.348 2.032 . . . . 0.0 110.425 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.453 ' O ' HD23 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.09 104.75 1.51 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.338 -0.851 . . . . 0.0 109.491 179.951 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.35 101.87 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.467 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.522 ' HA3' ' CD2' ' A' ' 72' ' ' LEU . . . -159.36 -150.19 5.75 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.867 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.445 ' HB ' HD23 ' A' ' 25' ' ' LEU . 8.1 p -116.51 132.35 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -1.14 . . . . 0.0 109.478 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.422 HG13 ' HA ' ' A' ' 22' ' ' THR . 63.7 t -56.3 126.84 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.01 -50.1 5.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.163 -0.96 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -169.64 153.26 4.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.349 -0.844 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.404 HG12 ' CG2' ' A' ' 70' ' ' ILE . 25.9 t -111.69 136.34 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.301 -0.874 . . . . 0.0 109.457 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -94.79 17.4 13.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.271 -0.893 . . . . 0.0 109.471 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.472 HG13 ' CD2' ' A' ' 63' ' ' LEU . 1.6 m -145.28 176.88 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.274 -0.891 . . . . 0.0 109.386 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.434 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -112.34 -178.91 3.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.19 -0.944 . . . . 0.0 109.522 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -82.3 136.85 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.93 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.41 18.08 76.65 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 4.4 m-20 -83.68 144.14 29.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.458 ' CB ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -103.66 120.94 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.515 179.961 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.472 ' CD2' HG13 ' A' ' 57' ' ' VAL . 1.3 mp -121.73 175.57 6.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.907 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' GLU . 3.5 tttp -118.31 145.75 44.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.523 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 3.2 pt-20 -42.85 137.48 2.3 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.341 -0.849 . . . . 0.0 109.584 -179.884 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.53 -25.93 16.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -84.89 140.76 30.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -1.124 . . . . 0.0 109.448 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -65.04 -174.11 0.14 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.423 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 28.7 mm -143.3 -65.33 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.264 -0.897 . . . . 0.0 109.49 -179.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.439 ' O ' HD13 ' A' ' 3' ' ' ILE . 1.8 pt -141.95 -175.11 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.899 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.434 ' HB2' HD13 ' A' ' 3' ' ' ILE . 1.8 tt0 -149.56 114.37 5.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.296 -0.877 . . . . 0.0 109.498 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.522 ' CD2' ' HA3' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -93.27 148.02 22.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.423 -179.911 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.406 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 3.6 tt0 -132.91 91.22 29.67 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.493 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HD3' HD22 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.308 -1.553 0 C-N-CA 122.627 2.218 . . . . 0.0 110.44 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 89.1 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -122.35 151.07 41.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 4.3 mp -90.94 154.36 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.513 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.443 HG22 ' HG3' ' A' ' 47' ' ' PRO . 4.1 mp -120.81 107.57 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.407 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -101.55 170.64 8.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.385 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -61.26 142.27 93.6 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.374 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.08 -169.77 0.83 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.561 2.174 . . . . 0.0 110.458 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -82.88 105.15 13.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.416 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.461 HD13 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.8 -59.5 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.389 -179.954 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.04 -11.68 10.78 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.05 -141.28 4.22 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.411 ' OD1' ' HE2' ' A' ' 64' ' ' LYS . 0.1 OUTLIER -98.66 164.17 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -1.127 . . . . 0.0 109.516 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.59 95.47 0.47 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -97.0 126.16 41.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.282 -1.128 . . . . 0.0 109.428 -179.953 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.2 t -77.09 133.6 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.93 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.428 HD12 ' HB2' ' A' ' 36' ' ' GLU . 19.2 mt -121.38 -37.58 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.395 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.56 137.6 43.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.192 -0.942 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.441 HD22 HG22 ' A' ' 20' ' ' VAL . 0.5 OUTLIER -122.43 119.29 30.56 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.45 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.4 OUTLIER -117.81 50.34 1.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.431 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 19' ' ' LEU . 3.8 m -147.36 159.34 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -148.74 -176.3 5.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.427 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.5 m -84.63 126.47 33.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.449 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.88 6.9 64.94 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.457 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 57.2 m-20 -83.66 131.9 34.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.46 HD11 ' HB ' ' A' ' 51' ' ' VAL . 7.2 tp -92.94 106.48 18.43 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.534 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.513 ' CD1' HD13 ' A' ' 32' ' ' LEU . 2.8 mt -91.77 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.215 -0.928 . . . . 0.0 109.151 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -144.7 176.51 9.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.925 . . . . 0.0 109.412 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.532 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 14.4 p -81.96 72.95 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.205 -0.934 . . . . 0.0 109.535 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.83 -44.57 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.331 -0.856 . . . . 0.0 109.397 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -51.13 142.42 12.53 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.209 -0.932 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -60.61 175.47 4.68 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.521 HD11 ' CA ' ' A' ' 46' ' ' SER . 0.6 OUTLIER -138.51 -62.24 0.57 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.358 -179.979 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.412 HG22 ' HG ' ' A' ' 35' ' ' LEU . 35.9 m -136.38 159.86 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.932 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 65.1 t -114.66 84.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 7.3 mt -94.68 159.55 15.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.46 ' HG2' ' HA ' ' A' ' 41' ' ' SER . 0.3 OUTLIER -124.15 161.23 26.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.913 . . . . 0.0 109.49 -179.96 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -139.44 172.02 13.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.465 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.02 -13.39 62.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.312 -0.867 . . . . 0.0 109.54 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.449 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 2.2 mptt -87.42 -38.84 15.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 39' ' ' LYS . . . 174.07 -174.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.514 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.46 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 0.0 OUTLIER -99.15 134.98 41.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.237 -0.915 . . . . 0.0 109.453 -179.975 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.464 ' O ' ' HG3' ' A' ' 42' ' ' MET . 0.4 OUTLIER -155.16 132.26 10.89 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.449 -179.959 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.402 ' C ' HG21 ' A' ' 44' ' ' VAL . 4.1 pt-20 -94.53 -179.71 4.99 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.5 t -144.36 128.94 9.24 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.224 -0.923 . . . . 0.0 109.304 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.476 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.5 -168.62 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.334 2.023 . . . . 0.0 110.326 179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.521 ' CA ' HD11 ' A' ' 32' ' ' LEU . 1.9 t -85.31 136.41 37.83 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.362 -0.836 . . . . 0.0 109.359 179.891 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.459 ' O ' ' CG ' ' A' ' 48' ' ' LYS . 36.1 Cg_endo -78.73 -5.73 14.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.516 2.144 . . . . 0.0 110.495 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.33 139.17 10.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 109.488 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.86 101.57 8.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.444 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.471 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -157.7 -147.75 4.91 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.46 ' HB ' HD11 ' A' ' 25' ' ' LEU . 14.5 p -126.66 152.02 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.219 -1.165 . . . . 0.0 109.502 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 54.3 t -68.66 140.47 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.249 -0.907 . . . . 0.0 109.459 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -109.04 -53.88 2.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -0.933 . . . . 0.0 109.457 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.87 177.95 7.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 57' ' ' VAL . 92.9 t -124.35 125.15 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.446 ' O ' HG11 ' A' ' 57' ' ' VAL . 21.6 t -105.53 1.67 27.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.198 -0.939 . . . . 0.0 109.645 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 55' ' ' VAL . 3.3 m -147.28 176.3 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.481 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.481 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -129.79 150.4 51.11 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.488 -179.943 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -61.79 140.67 58.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.889 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.75 -11.96 60.64 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.481 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 8.0 m-20 -78.01 152.62 32.97 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.194 -1.18 . . . . 0.0 109.444 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.419 ' O ' ' HG2' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -114.11 146.26 40.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.971 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.44 HD21 ' HB3' ' A' ' 67' ' ' ASP . 2.2 mp -147.75 -178.41 6.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -120.22 149.74 41.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.459 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.441 ' CD ' ' N ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -42.87 149.17 0.21 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.839 . . . . 0.0 109.591 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.69 -14.29 65.34 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.44 ' HB3' HD21 ' A' ' 63' ' ' LEU . 51.6 m-20 -84.65 137.73 33.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.25 -1.147 . . . . 0.0 109.491 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.436 ' O ' HG13 ' A' ' 69' ' ' ILE . . . -66.25 176.93 1.59 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.436 HG13 ' O ' ' A' ' 68' ' ' ALA . 2.3 mp -142.1 -61.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.253 -0.904 . . . . 0.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -142.9 -172.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.199 -0.938 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -142.41 106.94 4.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.291 -0.881 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.471 HD12 ' N ' ' A' ' 50' ' ' GLY . 2.7 tt -91.18 135.58 33.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.203 -0.936 . . . . 0.0 109.49 179.929 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.52 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 20.6 tt0 -116.66 142.11 29.15 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.227 -0.921 . . . . 0.0 109.423 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 36.0 Cg_endo . . . . . 0 C--N 1.309 -1.519 0 C-N-CA 122.568 2.179 . . . . 0.0 110.403 179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.454 ' HB3' ' HG3' ' A' ' 73' ' ' GLU . 9.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -128.12 133.42 48.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.484 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.1 tp -79.95 140.27 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.436 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 4' ' ' ILE . 4.4 mp -101.61 142.41 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 179.991 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.451 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -113.95 179.74 3.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.854 . . . . 0.0 109.478 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.474 HG11 ' HD2' ' A' ' 7' ' ' PRO . 49.1 t -61.35 134.4 93.35 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 109.292 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.474 ' HD2' HG11 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -170.04 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.457 2.105 . . . . 0.0 110.483 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -79.93 101.41 8.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.473 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.24 -49.73 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.284 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.64 -17.37 6.89 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.938 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.42 -171.88 28.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.83 148.88 42.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -1.159 . . . . 0.0 109.53 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.53 150.23 18.54 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.444 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.9 OUTLIER -118.38 142.33 47.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.176 -1.19 . . . . 0.0 109.465 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.479 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -76.48 135.41 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.521 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 80.5 mt -100.33 -38.33 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.447 -179.926 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -172.47 170.12 5.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.533 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 tp -117.15 125.16 50.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.45 HD11 ' O ' ' A' ' 19' ' ' LEU . 1.1 pp -104.7 31.25 4.85 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.497 ' CG2' HD21 ' A' ' 32' ' ' LEU . 17.2 m -150.0 166.67 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.6 mtmt -128.51 179.06 5.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.902 . . . . 0.0 109.498 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 35.1 m -84.96 141.63 30.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.89 63.34 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -84.89 138.45 32.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -1.22 . . . . 0.0 109.502 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -79.98 131.11 35.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 109.431 179.911 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.463 HD12 HD12 ' A' ' 32' ' ' LEU . 2.4 mt -92.95 -171.56 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.176 -0.952 . . . . 0.0 109.278 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.465 ' HB2' ' HG3' ' A' ' 30' ' ' GLN . 0.7 OUTLIER -126.98 175.84 7.78 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.206 -0.933 . . . . 0.0 109.433 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.465 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 8.3 p -76.55 124.46 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.497 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 4.1 mt-10 63.05 11.92 5.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.245 -0.909 . . . . 0.0 109.656 179.859 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.465 ' HG3' ' HB2' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -74.13 122.57 22.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.356 179.923 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.497 ' CA ' ' HA ' ' A' ' 45' ' ' PRO . . . -43.19 152.88 0.28 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.86 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.497 HD21 ' CG2' ' A' ' 20' ' ' VAL . 0.5 OUTLIER -132.56 -39.25 1.01 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -1.153 . . . . 0.0 109.496 179.943 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 32' ' ' LEU . 33.6 m -140.92 165.1 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.174 -0.954 . . . . 0.0 109.528 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -130.59 95.51 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.444 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.92 163.57 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 21.2 tt0 -122.94 123.45 40.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.892 . . . . 0.0 109.515 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -79.91 -173.82 4.08 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.58 -42.1 32.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.539 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.81 18.48 0.69 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.34 -169.74 1.85 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -158.04 101.75 1.78 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.531 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.432 ' N ' ' SD ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -114.34 143.16 45.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.212 -0.93 . . . . 0.0 109.452 -179.984 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.422 ' C ' HG21 ' A' ' 44' ' ' VAL . 12.1 pt-20 -100.97 164.07 11.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.281 -0.887 . . . . 0.0 109.521 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.449 ' HB ' HG21 ' A' ' 33' ' ' VAL . 46.3 t -135.07 102.88 10.81 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.362 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.497 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -77.4 -169.58 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.419 2.079 . . . . 0.0 110.428 -179.823 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.73 139.52 35.39 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.473 179.906 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -78.96 -10.65 15.28 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.409 2.072 . . . . 0.0 110.328 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -160.5 146.84 15.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.477 -0.764 . . . . 0.0 109.364 179.962 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.97 116.95 17.17 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -0.946 . . . . 0.0 109.399 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.538 ' CA ' ' CD1' ' A' ' 72' ' ' LEU . . . -164.36 -149.25 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.4 p -126.34 145.43 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -1.113 . . . . 0.0 109.433 -179.945 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.7 t -65.13 140.41 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.891 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.2 tptp -117.16 -47.11 2.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.401 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.49 163.61 32.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 80.4 t -121.52 118.19 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.0 t -108.22 22.59 15.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.557 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.5 m -144.13 160.35 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.532 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.437 ' O ' HG13 ' A' ' 15' ' ' VAL . 0.0 OUTLIER -136.67 169.2 18.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -0.903 . . . . 0.0 109.442 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.42 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -84.97 103.08 13.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.218 -0.926 . . . . 0.0 109.476 -179.955 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.1 -14.06 19.14 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.57 138.62 38.46 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.198 -1.178 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -80.48 152.83 28.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -0.868 . . . . 0.0 109.44 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.479 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 63.2 mt -140.97 136.53 32.27 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 14.3 tttm -105.87 149.05 26.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 0.0 109.486 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.0 OUTLIER -42.88 147.31 0.32 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.37 -0.831 . . . . 0.0 109.583 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 82.57 -4.34 78.79 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 2.5 m-20 -83.09 130.87 35.16 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.289 -1.124 . . . . 0.0 109.423 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.451 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -50.5 178.34 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.26 -0.9 . . . . 0.0 109.475 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.455 HG23 HG22 ' A' ' 70' ' ' ILE . 29.5 mm -146.97 -71.48 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.461 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.455 HG22 HG23 ' A' ' 69' ' ' ILE . 0.8 OUTLIER -138.81 -174.58 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.489 180.0 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -150.0 102.0 3.07 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.907 . . . . 0.0 109.507 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.538 ' CD1' ' CA ' ' A' ' 50' ' ' GLY . 4.0 tt -91.3 129.01 37.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.289 -0.882 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.513 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -90.07 144.96 32.07 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.367 -179.97 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.513 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.53 0 C-N-CA 122.623 2.215 . . . . 0.0 110.432 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 84.6 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -107.8 147.26 31.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.504 ' CD1' ' HB3' ' A' ' 68' ' ' ALA . 13.8 tt -79.93 169.13 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -0.883 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.472 ' O ' ' CD1' ' A' ' 69' ' ' ILE . 24.6 mm -125.39 119.78 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 -179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 3.9 ptm180 -94.93 163.83 13.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.491 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 86.9 t -69.25 140.03 90.25 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.379 -179.903 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.491 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.73 -168.7 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.589 2.193 . . . . 0.0 110.432 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -75.19 117.67 17.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 109.268 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.447 HD13 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -108.57 -47.26 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 109.482 -179.736 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 149.61 -38.9 0.92 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . 172.29 117.64 0.45 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.92 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' A' ' 11' ' ' GLY . 0.7 OUTLIER 50.33 178.66 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -1.091 . . . . 0.0 109.623 179.892 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.35 111.69 0.36 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.456 ' HB2' ' HD3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -95.95 137.12 35.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.283 -1.128 . . . . 0.0 109.539 179.963 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.401 HG21 ' CD2' ' A' ' 35' ' ' LEU . 59.9 t -85.12 134.97 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.556 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.439 ' O ' ' HB2' ' A' ' 17' ' ' GLU . 44.6 mt -104.31 -30.63 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.204 -0.935 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.439 ' HB2' ' O ' ' A' ' 16' ' ' ILE . 0.5 OUTLIER 175.22 131.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.545 179.976 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.12 172.08 7.02 Favored 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -145.32 63.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.473 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.0 m -146.36 158.92 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.534 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HB2' ' CG ' ' A' ' 24' ' ' ASP . 75.9 mttt -123.47 167.75 13.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.875 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.0 t -79.12 126.82 31.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.42 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 89.29 9.36 67.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.411 ' CG ' ' HB2' ' A' ' 21' ' ' LYS . 0.8 OUTLIER -85.02 135.06 34.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.158 -1.201 . . . . 0.0 109.506 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.7 tt -97.25 104.37 16.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -0.916 . . . . 0.0 109.475 179.959 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.432 HD11 ' CD2' ' A' ' 32' ' ' LEU . 2.7 mt -91.89 -171.45 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.2 -0.937 . . . . 0.0 109.246 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -137.94 176.5 8.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 11.1 p -81.39 79.07 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.455 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 167.49 -55.9 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.42 -0.8 . . . . 0.0 109.319 179.874 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.66 145.79 0.85 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.946 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.34 -162.74 0.09 OUTLIER Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.03 -71.77 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 109.516 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.452 ' O ' ' HB2' ' A' ' 43' ' ' GLU . 9.5 m -129.9 170.24 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.406 HG23 ' HB3' ' A' ' 43' ' ' GLU . 77.2 t -129.53 92.12 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 180.0 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.422 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.5 OUTLIER -97.04 169.83 9.56 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 179.999 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -103.12 178.74 4.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.247 -0.908 . . . . 0.0 109.486 -180.0 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -139.57 -173.09 3.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.28 -0.888 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -53.65 -57.61 10.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.932 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.43 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 2.2 mttt -138.45 58.46 1.66 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.246 -0.909 . . . . 0.0 109.526 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.43 ' HB1' ' O ' ' A' ' 39' ' ' LYS . . . 173.95 174.17 0.16 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.0 127.88 39.23 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.248 -0.907 . . . . 0.0 109.44 -179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.5 mtt -138.19 142.97 40.01 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.452 ' HB2' ' O ' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -105.97 164.12 12.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.284 -0.885 . . . . 0.0 109.352 179.969 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.5 t -122.31 137.83 28.19 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.309 179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.3 Cg_endo -79.13 -167.99 0.57 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.465 2.11 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.05 116.35 65.05 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.395 -0.816 . . . . 0.0 109.36 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.445 ' HG2' HG22 ' A' ' 4' ' ' ILE . 35.8 Cg_endo -77.77 4.54 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.381 2.054 . . . . 0.0 110.45 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.517 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.01 111.68 2.0 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.522 -179.976 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.45 95.89 2.3 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.307 -0.871 . . . . 0.0 109.435 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.497 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -164.29 -164.08 18.73 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.42 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 14.9 p -100.91 133.82 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.229 -1.16 . . . . 0.0 109.519 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 80.4 t -58.82 147.88 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 -30.75 6.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -169.6 159.38 8.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.2 t -116.66 106.74 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.137 -0.977 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.91 21.88 8.08 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.261 -0.899 . . . . 0.0 109.417 179.955 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.439 HG23 HG21 ' A' ' 69' ' ' ILE . 15.8 m -144.1 160.51 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.57 171.15 12.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 179.966 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.07 119.2 22.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.424 -179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.77 -10.02 48.4 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.17 159.93 33.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.269 -1.136 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.456 ' HD3' ' HB2' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -113.52 135.07 54.29 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.507 179.958 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -142.68 155.05 44.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.175 -0.953 . . . . 0.0 109.456 179.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -104.43 147.96 26.98 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.522 -179.933 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 64' ' ' LYS . 4.1 pt-20 -43.04 141.24 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.77 -8.89 73.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 132.06 34.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -1.169 . . . . 0.0 109.519 179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.504 ' HB3' ' CD1' ' A' ' 3' ' ' ILE . . . -56.08 156.1 5.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.396 -0.815 . . . . 0.0 109.44 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.481 ' CG1' HG21 ' A' ' 6' ' ' VAL . 1.4 mp -129.82 -43.8 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.489 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.452 HG21 ' O ' ' A' ' 69' ' ' ILE . 4.9 pt -159.9 -173.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.6 tt0 -135.66 159.0 42.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.252 -0.905 . . . . 0.0 109.474 180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.517 ' CD1' ' O ' ' A' ' 48' ' ' LYS . 8.0 tt -140.54 145.32 36.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -116.68 87.77 22.58 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.906 . . . . 0.0 109.447 -179.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.508 ' N ' HD22 ' A' ' 72' ' ' LEU . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.552 0 C-N-CA 122.622 2.215 . . . . 0.0 110.458 179.974 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 86.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -141.86 144.7 33.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.45 HD11 ' HG2' ' A' ' 71' ' ' GLU . 32.6 mm -90.45 136.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.488 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 mt -110.57 124.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.403 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 11.6 ptt180 -105.18 171.45 7.31 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.907 . . . . 0.0 109.489 -179.945 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.531 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.0 t -62.13 142.48 95.57 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.531 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.3 Cg_endo -78.56 -170.38 0.97 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.496 2.13 . . . . 0.0 110.375 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -84.9 110.74 19.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.392 179.927 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.59 -10.08 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.298 -0.876 . . . . 0.0 109.389 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.8 26.62 74.45 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.906 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 12' ' ' ASP . . . 171.61 160.55 20.41 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -44.45 155.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.239 -1.153 . . . . 0.0 109.485 -179.996 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.65 109.28 1.45 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -101.72 114.41 28.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -1.159 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.423 HG21 HD22 ' A' ' 35' ' ' LEU . 14.3 t -60.24 129.93 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.891 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.1 mt -104.86 -35.57 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.243 -0.91 . . . . 0.0 109.502 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.436 ' HA ' ' HB2' ' A' ' 59' ' ' LEU . 6.5 tp10 -165.37 135.47 3.64 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.48 127.49 55.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -0.923 . . . . 0.0 109.411 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.449 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -116.03 57.68 0.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.444 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.509 HG12 ' CD2' ' A' ' 32' ' ' LEU . 35.6 m -137.19 157.24 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -129.93 157.51 42.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.511 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.446 HG22 ' O ' ' A' ' 22' ' ' THR . 12.1 t -80.64 128.98 34.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 109.419 179.939 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.71 -8.92 79.09 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -82.26 132.61 35.23 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.229 -1.16 . . . . 0.0 109.427 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.417 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -79.9 125.63 29.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.264 -0.897 . . . . 0.0 109.488 -179.959 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.52 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.7 mt -92.52 -171.38 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.276 -0.89 . . . . 0.0 109.201 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -142.2 159.68 41.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.119 -0.988 . . . . 0.0 109.477 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.3 p -81.41 79.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.244 -0.91 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.75 -36.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.397 179.893 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.507 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 39.6 tt0 -67.33 155.47 38.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -0.925 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.465 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -77.32 168.4 54.53 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.525 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 1.3 tt -129.5 -40.5 1.42 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.263 -1.14 . . . . 0.0 109.49 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.408 ' CG1' ' C ' ' A' ' 32' ' ' LEU . 5.2 m -154.7 166.84 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.506 -179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.4 t -134.66 96.55 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.325 179.931 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.46 HD13 HG22 ' A' ' 44' ' ' VAL . 0.4 OUTLIER -94.62 163.83 13.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.564 -179.947 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -105.42 173.87 6.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.407 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.1 m -135.32 -174.13 3.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -44.73 -42.58 7.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 109.441 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 ttpp -158.89 39.76 0.22 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.485 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -151.0 -156.9 0.76 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.84 107.26 2.1 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' MET . . . . . 0.424 ' HG3' ' N ' ' A' ' 43' ' ' GLU . 2.4 ttm -100.2 149.66 23.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.456 ' O ' HG21 ' A' ' 44' ' ' VAL . 10.6 mt-10 -113.2 164.51 13.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.525 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.6 t -143.9 101.74 4.93 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.25 -0.906 . . . . 0.0 109.269 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.514 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.4 Cg_endo -77.16 -168.75 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.393 2.062 . . . . 0.0 110.55 -179.824 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.52 ' CB ' HG23 ' A' ' 26' ' ' ILE . 1.6 t -85.26 117.64 69.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.272 -0.892 . . . . 0.0 109.502 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.12 3.35 7.13 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.332 2.021 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.44 ' HG2' ' CD1' ' A' ' 72' ' ' LEU . 1.8 tptt -159.88 131.2 5.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.892 . . . . 0.0 109.415 179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.41 88.36 7.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.818 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.451 ' HA3' HD13 ' A' ' 72' ' ' LEU . . . -140.05 -152.35 5.81 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.415 ' O ' HG11 ' A' ' 51' ' ' VAL . 9.9 p -113.59 129.99 68.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -1.169 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.4 t -55.55 126.75 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.09 -44.68 9.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.44 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 54.7 p -171.82 138.44 1.07 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 57' ' ' VAL . 4.8 t -92.98 117.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 109.539 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.22 13.52 18.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 55' ' ' VAL . 2.8 m -140.83 172.09 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.73 151.74 44.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.436 ' HB2' ' HA ' ' A' ' 17' ' ' GLU . 1.6 pp -56.83 139.91 49.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.87 -7.53 81.56 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -70.57 -179.95 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.212 -1.169 . . . . 0.0 109.438 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -153.12 115.74 4.48 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.186 -0.946 . . . . 0.0 109.441 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mp -131.3 -175.05 3.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.473 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.3 tttp -118.56 144.65 45.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.467 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 1.6 pt-20 -42.82 141.23 1.13 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.302 -0.874 . . . . 0.0 109.585 -179.861 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.76 -22.62 36.52 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -78.79 138.14 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.46 179.99 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.44 170.12 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.433 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.407 ' CD1' HG21 ' A' ' 6' ' ' VAL . 27.7 mm -139.11 -59.56 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.43 ' CD1' HD12 ' A' ' 32' ' ' LEU . 2.3 pt -143.44 -173.75 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.268 -0.895 . . . . 0.0 109.409 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.45 ' HG2' HD11 ' A' ' 3' ' ' ILE . 13.8 mt-10 -139.07 113.16 8.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.491 ' C ' ' CD1' ' A' ' 72' ' ' LEU . 3.4 tm? -90.05 119.92 30.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -111.14 95.42 25.16 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.202 -0.936 . . . . 0.0 109.451 -179.926 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.469 ' HD3' ' CD1' ' A' ' 72' ' ' LEU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.527 0 C-N-CA 122.594 2.196 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.45 ' HB3' ' HG2' ' A' ' 73' ' ' GLU . 24.8 p . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -157.19 140.61 15.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.453 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.463 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 2.9 mt -80.48 154.56 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.93 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.405 ' N ' HG21 ' A' ' 3' ' ' ILE . 64.5 mt -122.25 97.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.571 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.72 -172.36 3.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.914 . . . . 0.0 109.379 179.968 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.452 HG12 ' HD2' ' A' ' 7' ' ' PRO . 54.6 t -80.88 139.09 49.86 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.128 -0.983 . . . . 0.0 109.284 -179.957 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.452 ' HD2' HG12 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.56 -169.89 0.87 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.499 2.133 . . . . 0.0 110.399 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -81.69 104.11 11.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.847 . . . . 0.0 109.37 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.498 ' CG2' ' OG ' ' A' ' 37' ' ' SER . 0.0 OUTLIER -105.77 -42.71 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.989 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.77 -23.37 6.28 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.95 -140.29 4.0 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.2 p30 -99.29 153.08 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.185 -1.185 . . . . 0.0 109.401 179.883 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -107.69 105.95 2.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.9 mt-10 -99.96 137.64 38.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -1.145 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 99.6 t -76.5 127.22 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.49 -179.934 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 83.7 mt -107.8 -35.47 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.356 -0.84 . . . . 0.0 109.368 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -152.09 127.36 9.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.506 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.417 HD21 ' O ' ' A' ' 18' ' ' LEU . 3.9 tt -110.14 126.07 53.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.893 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.95 54.56 1.51 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.502 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.511 HG13 ' CD1' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -148.55 162.59 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.511 -179.943 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.425 ' HD2' ' O ' ' A' ' 20' ' ' VAL . 4.0 tptp -141.29 176.75 8.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.6 m -81.76 144.91 30.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.207 -0.933 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.414 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 69.29 8.07 58.43 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -85.02 132.61 34.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -1.151 . . . . 0.0 109.515 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.482 ' CD1' ' O ' ' A' ' 26' ' ' ILE . 0.7 OUTLIER -88.48 118.9 28.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 179.855 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.51 HG23 ' CB ' ' A' ' 46' ' ' SER . 3.2 mt -95.62 -171.33 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 O-C-N 121.222 -0.924 . . . . 0.0 109.328 -179.784 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -145.47 167.69 22.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.397 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 12.6 p -83.83 72.73 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.934 . . . . 0.0 109.522 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.476 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 170.82 -35.03 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.334 -0.854 . . . . 0.0 109.459 179.826 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -72.67 153.76 41.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.47 179.985 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.45 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.75 175.06 44.94 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.534 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -134.85 -44.84 0.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 109.501 179.965 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.441 HG21 ' HB ' ' A' ' 44' ' ' VAL . 2.1 m -153.91 170.88 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.227 -0.92 . . . . 0.0 109.513 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 94.0 t -129.75 76.87 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.23 -0.918 . . . . 0.0 109.444 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 4.9 mp -89.91 135.13 33.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.471 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.402 ' CG ' ' HA ' ' A' ' 41' ' ' SER . 5.0 tm-20 -111.43 140.36 46.09 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.895 . . . . 0.0 109.492 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.498 ' OG ' ' CG2' ' A' ' 9' ' ' ILE . 1.4 m -112.52 173.7 6.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.532 179.989 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.89 -13.51 25.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -84.26 -45.44 12.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 178.94 165.21 0.88 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.402 ' HA ' ' CG ' ' A' ' 36' ' ' GLU . 8.5 t -81.48 118.56 22.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.541 179.919 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 23.9 mtm -121.63 -178.97 3.95 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 109.415 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.7 174.29 10.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.286 -0.884 . . . . 0.0 109.484 -179.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.1 t -149.21 103.05 3.32 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.212 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.466 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.6 Cg_endo -77.39 -168.64 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.343 2.029 . . . . 0.0 110.407 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.51 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.42 113.57 51.48 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.43 -179.905 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.7 Cg_endo -78.18 0.36 9.96 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.343 2.028 . . . . 0.0 110.308 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.44 ' O ' HD12 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.12 131.15 5.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.314 -0.866 . . . . 0.0 109.397 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.59 108.11 5.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.862 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.524 ' HA3' ' CD1' ' A' ' 72' ' ' LEU . . . -160.86 -172.76 28.6 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.414 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 9.8 p -104.87 150.92 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 109.494 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.88 130.78 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.421 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.422 ' O ' ' HB2' ' A' ' 54' ' ' SER . 0.3 OUTLIER -86.51 -42.59 13.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 109.448 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 53' ' ' LYS . 4.8 t -179.51 139.95 0.14 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.183 -0.948 . . . . 0.0 109.566 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.407 HG13 ' O ' ' A' ' 57' ' ' VAL . 9.0 t -80.87 109.53 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.88 . . . . 0.0 109.423 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.8 p -89.5 7.84 34.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.299 -0.875 . . . . 0.0 109.632 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.474 ' CG1' HD23 ' A' ' 63' ' ' LEU . 2.8 m -139.03 -177.59 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.941 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.5 tptp -131.87 171.27 13.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -0.916 . . . . 0.0 109.499 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.421 HD13 ' O ' ' A' ' 59' ' ' LEU . 2.7 pp -84.56 132.33 34.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.899 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.63 74.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -81.38 141.58 33.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -1.158 . . . . 0.0 109.402 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.417 ' C ' ' CD1' ' A' ' 63' ' ' LEU . 10.8 pttp -99.73 151.61 21.04 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.195 -0.941 . . . . 0.0 109.465 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.474 HD23 ' CG1' ' A' ' 57' ' ' VAL . 6.0 mp -138.17 168.9 18.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.238 -0.914 . . . . 0.0 109.504 179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -107.11 146.66 30.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.467 -179.974 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.431 ' N ' ' HD2' ' A' ' 64' ' ' LYS . 5.4 mt-10 -42.96 138.9 1.89 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.292 -0.88 . . . . 0.0 109.635 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.79 -6.44 73.58 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.418 ' O ' HD13 ' A' ' 69' ' ' ILE . 0.6 OUTLIER -83.12 145.73 29.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -1.176 . . . . 0.0 109.48 179.987 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -81.15 163.57 23.01 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.437 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.457 HG21 ' CG2' ' A' ' 57' ' ' VAL . 4.3 mp -133.85 -55.57 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.18 -0.95 . . . . 0.0 109.546 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.46 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 18.1 pt -145.96 -173.42 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.269 -0.894 . . . . 0.0 109.49 -179.93 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.463 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 1.0 OUTLIER -146.49 155.63 42.67 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.235 -0.915 . . . . 0.0 109.505 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.524 ' CD1' ' HA3' ' A' ' 50' ' ' GLY . 4.5 tt -130.69 126.74 37.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HG2' ' HB3' ' A' ' 1' ' ' SER . 0.1 OUTLIER -96.71 149.33 35.65 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.238 -0.914 . . . . 0.0 109.54 -179.959 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.409 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.51 0 C-N-CA 122.633 2.222 . . . . 0.0 110.412 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 1' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 65.6 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.61 172.59 13.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.8 mt -100.5 155.5 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.907 . . . . 0.0 109.486 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.455 HD13 ' HG2' ' A' ' 47' ' ' PRO . 36.2 mm -118.17 91.75 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.895 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -95.33 175.8 6.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.488 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.4 t -84.25 142.33 40.78 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -169.44 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.517 2.145 . . . . 0.0 110.433 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -78.55 105.41 9.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -0.873 . . . . 0.0 109.411 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.478 ' CD1' HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.46 -11.07 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.307 -179.859 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.16 -14.99 56.16 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -144.92 -176.29 18.8 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.967 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -71.06 142.59 50.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -1.148 . . . . 0.0 109.472 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.92 107.55 3.25 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -99.61 113.42 25.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.459 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.0 t -68.91 131.81 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -0.934 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.435 HG22 HD11 ' A' ' 16' ' ' ILE . 19.5 mm -116.94 -22.16 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -0.897 . . . . 0.0 109.431 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.93 138.04 19.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.293 -0.879 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.8 tp -113.48 101.97 9.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 0.6 OUTLIER -108.84 56.65 0.62 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.3 m -134.28 160.28 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.224 -0.922 . . . . 0.0 109.453 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.442 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 1.2 mtpp -137.43 156.98 47.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.27 -0.894 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.1 m -84.55 129.65 34.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.47 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.404 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 84.31 -9.4 64.27 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.997 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.442 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 0.9 OUTLIER -77.41 131.87 38.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -1.205 . . . . 0.0 109.462 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.0 OUTLIER -85.95 120.57 27.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.217 -0.927 . . . . 0.0 109.467 179.961 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.538 HD11 HG22 ' A' ' 26' ' ' ILE . 2.8 mt -92.26 -171.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.229 -0.92 . . . . 0.0 109.204 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.408 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 11.0 mt-10 -145.44 163.02 35.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.2 p -78.14 79.57 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.367 -0.833 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.81 -34.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.471 179.924 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.453 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 28.4 tt0 -70.35 141.07 52.29 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.318 -0.864 . . . . 0.0 109.499 -179.988 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.491 ' CA ' ' HA ' ' A' ' 45' ' ' PRO . . . -51.32 -177.17 0.03 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.502 ' N ' ' O ' ' A' ' 44' ' ' VAL . 3.8 tp -151.41 -67.78 0.18 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.198 -1.178 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.445 HG22 ' CD1' ' A' ' 35' ' ' LEU . 28.5 m -135.07 138.66 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.512 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 42.2 t -97.64 89.12 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.439 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.445 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.9 OUTLIER -89.89 150.36 22.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.206 -0.934 . . . . 0.0 109.481 179.965 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.44 ' HG3' ' HB2' ' A' ' 41' ' ' SER . 2.0 tt0 -115.24 167.23 11.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.303 -0.873 . . . . 0.0 109.547 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.96 -172.6 3.88 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.48 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -84.52 10.31 11.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.509 179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.426 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 5.4 mttp -121.0 -30.83 4.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.333 -0.854 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.426 ' CB ' ' O ' ' A' ' 39' ' ' LYS . . . 169.75 -171.78 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.321 -0.862 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.44 ' HB2' ' HG3' ' A' ' 36' ' ' GLU . 10.5 t -103.96 134.07 47.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.181 -0.949 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtt -138.73 107.2 5.84 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.251 -0.906 . . . . 0.0 109.487 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.29 166.04 21.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.182 -0.949 . . . . 0.0 109.465 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 72.0 t -136.38 142.15 38.49 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.305 -0.872 . . . . 0.0 109.342 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.527 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 35.8 Cg_endo -77.96 -168.27 0.59 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.512 2.142 . . . . 0.0 110.448 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.515 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -85.21 124.09 72.45 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.374 -0.829 . . . . 0.0 109.392 -179.913 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.455 ' HG2' HD13 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -78.45 0.55 9.83 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.306 2.004 . . . . 0.0 110.29 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.427 ' HE3' ' HG3' ' A' ' 74' ' ' PRO . 0.4 OUTLIER -160.15 116.73 2.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.941 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.408 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . . . -75.76 80.93 2.7 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.467 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.518 ' HA3' ' CD1' ' A' ' 72' ' ' LEU . . . -136.37 -159.71 8.51 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 51' ' ' VAL . 11.7 p -103.4 124.1 57.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.201 -1.176 . . . . 0.0 109.519 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.2 t -49.94 140.02 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.7 tptm -96.94 -70.22 0.73 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.201 -0.937 . . . . 0.0 109.442 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 52.0 p -158.32 135.23 9.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 20.9 t -83.31 117.45 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 8.9 t -94.21 19.99 8.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.453 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.428 HG23 HG21 ' A' ' 69' ' ' ILE . 0.7 OUTLIER -143.06 179.58 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.292 -0.88 . . . . 0.0 109.441 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.514 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -130.0 167.39 18.33 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.537 -179.978 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.22 151.63 35.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.48 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.29 9.0 80.77 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.514 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 4.4 m-20 -85.04 150.77 24.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.215 -1.167 . . . . 0.0 109.487 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -112.44 104.99 13.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -110.35 173.56 6.27 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.333 -0.855 . . . . 0.0 109.487 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 18.2 ttpt -108.57 142.04 39.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.925 . . . . 0.0 109.499 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 12.7 pt-20 -42.79 138.58 1.91 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.336 -0.852 . . . . 0.0 109.628 -179.884 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.27 -12.86 61.86 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.408 ' O ' ' HA ' ' A' ' 5' ' ' ARG . 4.3 m-20 -79.87 153.56 28.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -1.16 . . . . 0.0 109.423 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.427 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -83.09 161.91 21.51 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.222 -0.924 . . . . 0.0 109.508 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.448 ' CD1' HG21 ' A' ' 6' ' ' VAL . 2.8 mp -132.68 -54.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.23 -0.918 . . . . 0.0 109.481 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.401 HG21 ' CG2' ' A' ' 69' ' ' ILE . 36.4 pt -144.06 -172.37 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.915 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -138.02 115.39 11.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.23 -0.919 . . . . 0.0 109.474 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.518 ' CD1' ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 137.62 32.19 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.294 -0.878 . . . . 0.0 109.365 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.509 ' N ' HD12 ' A' ' 72' ' ' LEU . 10.7 tt0 -111.41 95.12 25.04 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.352 -0.842 . . . . 0.0 109.342 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.7 Cg_endo . . . . . 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.206 . . . . 0.0 110.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.4 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 52.4 p . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -138.06 141.28 40.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.321 -0.862 . . . . 0.0 109.478 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.8 tt -89.45 151.46 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.416 HD13 HG22 ' A' ' 4' ' ' ILE . 24.8 mm -115.79 107.8 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.51 ' NH1' ' HA2' ' A' ' 66' ' ' GLY . 0.0 OUTLIER -92.28 168.13 11.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.504 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 75.2 t -44.28 142.27 2.32 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.23 -170.64 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.447 2.098 . . . . 0.0 110.371 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.85 101.91 12.67 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.508 HD12 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.35 -61.66 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 109.253 -179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.75 12.5 6.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.02 -139.49 2.65 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 31.8 t0 -111.14 136.86 49.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -1.152 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -105.48 139.72 14.81 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.2 mt-10 -122.54 135.08 54.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.176 -1.19 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.403 HG22 HD12 ' A' ' 63' ' ' LEU . 13.3 t -81.52 130.64 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.91 . . . . 0.0 109.399 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.422 ' HA ' HD11 ' A' ' 16' ' ' ILE . 32.2 mm -97.05 -42.8 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.176 -0.953 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.39 151.5 15.38 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.881 . . . . 0.0 109.493 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 2.5 tp -110.87 110.26 20.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.422 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -101.98 49.76 0.85 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.882 . . . . 0.0 109.407 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.404 HG22 HD22 ' A' ' 32' ' ' LEU . 0.8 OUTLIER -146.89 157.47 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.66 173.64 7.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.21 -0.931 . . . . 0.0 109.524 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.438 ' HA ' HG13 ' A' ' 52' ' ' VAL . 15.0 t -85.05 147.27 26.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.14 7.8 63.75 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -85.04 130.62 34.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.43 111.48 20.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.453 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.437 HD11 HD13 ' A' ' 32' ' ' LEU . 3.1 mt -94.31 -171.42 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.3 -0.875 . . . . 0.0 109.185 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.514 ' O ' ' N ' ' A' ' 29' ' ' GLU . 3.2 mt-10 -149.05 134.92 18.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.421 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' A' ' 29' ' ' GLU . 3.0 p -50.28 91.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.491 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.78 -60.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.348 -0.845 . . . . 0.0 109.534 179.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.429 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.7 tt0 -57.19 162.79 2.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.567 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -80.08 -179.11 52.31 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -143.43 -40.45 0.3 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -1.164 . . . . 0.0 109.567 179.962 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.8 m -158.63 173.65 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.171 -0.956 . . . . 0.0 109.523 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.1 t -132.27 104.7 8.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.268 -0.895 . . . . 0.0 109.494 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.435 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.93 164.75 14.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.431 ' CG ' ' N ' ' A' ' 37' ' ' SER . 14.5 tt0 -117.22 158.79 23.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.431 ' N ' ' CG ' ' A' ' 36' ' ' GLU . 2.3 t -130.12 179.76 5.7 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.308 -0.87 . . . . 0.0 109.449 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.19 -59.06 2.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 109.415 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.86 54.55 1.58 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.522 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.65 146.16 0.97 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 78.6 p -105.36 137.22 43.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.1 mmt -120.67 178.81 4.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.209 -0.932 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -138.42 161.4 37.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.892 . . . . 0.0 109.529 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 1.8 t -141.66 96.99 6.7 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.376 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 35.7 Cg_endo -77.56 -168.4 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.476 2.117 . . . . 0.0 110.452 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.454 ' O ' ' HA ' ' A' ' 28' ' ' VAL . 1.6 t -85.26 113.71 52.03 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.14 1.9 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.37 2.047 . . . . 0.0 110.256 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.476 ' CG ' HD23 ' A' ' 72' ' ' LEU . 0.5 OUTLIER -160.17 138.12 9.93 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.88 . . . . 0.0 109.334 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.9 102.19 11.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.184 -0.948 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.511 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -159.11 -167.82 20.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 14.4 p -110.59 138.28 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -1.137 . . . . 0.0 109.496 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.438 HG13 ' HA ' ' A' ' 22' ' ' THR . 61.6 t -56.29 122.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 109.527 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.59 -49.37 5.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.457 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 t -149.95 163.66 37.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 43.5 t -121.35 131.84 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.25 -0.906 . . . . 0.0 109.428 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.06 21.43 13.74 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.515 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 27.5 m -148.23 162.56 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 ttpt -123.73 155.13 38.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.453 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.417 ' HB3' ' HB2' ' A' ' 18' ' ' LEU . 1.7 pp -72.09 139.27 48.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.524 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.59 -13.85 57.2 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -82.79 148.78 27.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -1.162 . . . . 0.0 109.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -104.59 141.12 36.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.175 -0.953 . . . . 0.0 109.469 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.517 ' CD1' ' N ' ' A' ' 63' ' ' LEU . 1.5 mp -130.26 164.26 24.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -0.888 . . . . 0.0 109.531 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -115.32 154.11 29.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.987 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.3 OUTLIER -42.72 130.72 4.11 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.285 -0.884 . . . . 0.0 109.663 -179.939 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.51 ' HA2' ' NH1' ' A' ' 5' ' ' ARG . . . 107.83 -12.58 38.32 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -84.23 131.0 34.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -1.16 . . . . 0.0 109.471 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.26 147.13 48.49 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.289 -0.882 . . . . 0.0 109.448 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.515 ' HA ' ' CG1' ' A' ' 57' ' ' VAL . 19.8 mm -103.34 -71.46 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.229 -0.919 . . . . 0.0 109.457 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.448 HG21 ' O ' ' A' ' 69' ' ' ILE . 0.9 OUTLIER -142.15 171.14 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -0.912 . . . . 0.0 109.5 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -122.7 117.44 25.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.339 -0.851 . . . . 0.0 109.475 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.511 HD12 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -89.99 142.18 27.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.247 -0.908 . . . . 0.0 109.424 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.498 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -115.61 91.86 31.23 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.488 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.43 ' O ' ' CB ' ' A' ' 75' ' ' ALA . 35.4 Cg_endo -78.07 2.91 7.5 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.597 2.198 . . . . 0.0 110.401 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.43 ' CB ' ' O ' ' A' ' 74' ' ' PRO . . . 70.26 -169.07 0.16 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.474 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -74.17 -49.26 24.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.359 -0.838 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -146.36 170.57 27.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -141.67 145.94 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -1.162 . . . . 0.0 109.455 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.47 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 80.6 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.33 164.24 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.452 HG23 ' HB3' ' A' ' 68' ' ' ALA . 57.0 mt -97.43 140.9 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -0.918 . . . . 0.0 109.456 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.431 HG22 HD11 ' A' ' 4' ' ' ILE . 77.0 mt -99.73 114.21 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.505 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.415 ' HA ' HD13 ' A' ' 69' ' ' ILE . 1.5 ptt180 -110.29 164.68 12.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.253 -0.904 . . . . 0.0 109.434 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 74.9 t -65.99 142.28 97.94 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.175 -0.953 . . . . 0.0 109.393 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.5 Cg_endo -78.16 -171.72 1.29 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.515 2.143 . . . . 0.0 110.39 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -68.04 112.86 5.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.414 ' O ' HG13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -110.18 -29.25 2.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.224 -0.923 . . . . 0.0 108.741 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.62 -47.34 2.32 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.74 -144.96 7.18 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -99.63 146.98 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.2 -1.176 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.02 148.35 18.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.428 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 44.2 tt0 -127.78 146.6 50.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -1.108 . . . . 0.0 109.424 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.449 HG21 HD22 ' A' ' 35' ' ' LEU . 3.6 t -84.33 156.96 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.182 -0.949 . . . . 0.0 109.489 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.439 HD11 ' O ' ' A' ' 34' ' ' VAL . 3.6 mp -123.79 -36.61 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.279 -0.888 . . . . 0.0 109.496 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -151.44 151.39 31.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.22 -0.925 . . . . 0.0 109.449 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.52 118.46 36.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.455 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 mt -90.26 30.55 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.498 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.47 ' CG1' HD12 ' A' ' 26' ' ' ILE . 31.8 m -149.69 156.66 7.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.404 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.3 OUTLIER -130.26 176.3 8.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.421 ' O ' HG22 ' A' ' 22' ' ' THR . 14.7 t -75.15 124.57 27.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.223 -0.923 . . . . 0.0 109.504 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.84 1.05 89.08 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.404 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -84.61 142.17 30.14 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.145 -1.209 . . . . 0.0 109.474 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.46 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 5.0 tt -108.66 121.38 44.9 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.207 -0.933 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.47 HD12 ' CG1' ' A' ' 20' ' ' VAL . 2.5 mt -90.29 -171.41 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.268 -0.895 . . . . 0.0 109.177 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -145.28 172.69 12.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.7 p -74.06 82.27 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 162.94 -58.55 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.298 -0.876 . . . . 0.0 109.48 179.918 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.41 ' C ' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -44.29 157.88 0.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.509 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.23 -153.56 0.99 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.52 ' CD2' ' HA ' ' A' ' 46' ' ' SER . 0.1 OUTLIER -159.87 -73.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -1.148 . . . . 0.0 109.517 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.439 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 25.8 m -135.37 135.09 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.439 ' O ' HD11 ' A' ' 16' ' ' ILE . 20.5 t -107.09 92.82 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.343 -0.848 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.449 HD22 HG21 ' A' ' 15' ' ' VAL . 0.4 OUTLIER -89.97 -173.69 3.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.945 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -130.41 167.58 18.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.4 m -126.61 172.25 10.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.57 -58.8 3.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 11.6 pttm -132.27 53.38 2.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.432 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.1 -166.58 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.249 -0.907 . . . . 0.0 109.46 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.8 155.68 38.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 4.5 mmt -138.71 145.55 40.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.471 ' CD ' ' N ' ' A' ' 44' ' ' VAL . 14.3 tm-20 -159.99 150.13 18.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.268 -0.895 . . . . 0.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.501 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 49.4 t -135.77 140.1 32.64 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.448 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.501 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.28 -168.65 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.442 2.095 . . . . 0.0 110.368 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.52 ' HA ' ' CD2' ' A' ' 32' ' ' LEU . 0.3 OUTLIER -85.52 113.38 50.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.6 Cg_endo -78.31 -3.17 13.16 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.256 1.971 . . . . 0.0 110.381 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.515 ' CB ' HD21 ' A' ' 72' ' ' LEU . 3.6 mtmm -160.37 130.92 5.44 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.344 -0.847 . . . . 0.0 109.406 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.51 90.67 7.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.439 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.426 ' O ' ' HG ' ' A' ' 25' ' ' LEU . . . -146.25 -166.24 11.98 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.5 p -109.97 160.26 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.28 -1.13 . . . . 0.0 109.482 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.0 t -76.04 123.6 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.967 . . . . 0.0 109.443 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -94.23 -49.41 5.74 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.495 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 t -158.35 118.21 3.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.465 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.8 t -87.66 133.17 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.431 ' O ' ' OG ' ' A' ' 56' ' ' SER . 8.2 t -113.31 29.18 8.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.496 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.422 HG23 HG21 ' A' ' 69' ' ' ILE . 35.6 m -149.47 175.6 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.44 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -136.5 157.57 46.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.467 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -68.22 138.87 55.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.448 -179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.45 -10.67 68.47 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.44 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 41.6 m-20 -80.9 144.95 31.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -1.144 . . . . 0.0 109.482 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.428 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 14.2 ptmt -110.52 148.09 32.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.3 mp -138.95 166.68 23.85 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.244 -0.91 . . . . 0.0 109.525 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 5.0 mtpt -99.58 148.4 24.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 23.8 pt-20 -42.81 142.76 0.82 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.666 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.83 -9.48 76.68 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.98 137.21 35.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -1.156 . . . . 0.0 109.516 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.452 ' HB3' HG23 ' A' ' 3' ' ' ILE . . . -67.81 176.83 2.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.422 HG21 HG23 ' A' ' 57' ' ' VAL . 2.1 mp -140.9 -67.24 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 30.1 pt -139.45 173.24 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 109.472 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -127.83 108.47 10.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.515 HD21 ' CB ' ' A' ' 48' ' ' LYS . 0.6 OUTLIER -90.09 142.24 27.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.436 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.402 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 60.6 tt0 -116.54 88.32 23.84 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HG3' ' HD2' ' A' ' 48' ' ' LYS . 35.7 Cg_endo -78.11 71.4 6.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.652 2.235 . . . . 0.0 110.409 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . 49.6 -172.05 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.242 -0.911 . . . . 0.0 109.421 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 60.63 36.69 19.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -98.05 130.65 10.31 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -51.35 104.62 0.08 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -1.118 . . . . 0.0 109.474 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.481 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.44 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 53.6 p . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -82.44 171.64 13.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 41.0 mm -107.0 143.91 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.514 ' CG2' ' HG3' ' A' ' 47' ' ' PRO . 38.8 mm -107.16 118.59 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.522 ' CG ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -103.73 -171.13 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.185 -0.947 . . . . 0.0 109.541 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.515 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 65.7 t -79.47 142.72 58.39 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.319 -0.863 . . . . 0.0 109.311 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.515 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.06 -168.79 0.65 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.599 2.199 . . . . 0.0 110.509 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -82.74 111.18 18.43 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.395 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.91 -10.93 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.935 . . . . 0.0 109.345 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.98 39.63 58.53 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.07 -153.72 24.88 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -89.34 174.15 7.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.289 -1.124 . . . . 0.0 109.497 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -147.51 104.8 0.3 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.463 ' N ' ' CD ' ' A' ' 14' ' ' GLU . 6.2 mp0 -92.82 112.92 25.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -1.153 . . . . 0.0 109.442 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.464 HG13 ' HA ' ' A' ' 59' ' ' LEU . 40.3 t -54.33 134.75 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.5 mm -108.56 -50.88 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.228 -0.92 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -144.19 153.03 41.68 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.454 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.495 HD22 ' CG2' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -120.82 116.08 24.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.924 . . . . 0.0 109.5 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.452 ' CD1' ' O ' ' A' ' 19' ' ' LEU . 1.3 pp -106.1 52.15 0.73 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.354 -0.841 . . . . 0.0 109.525 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.495 ' CG2' HD22 ' A' ' 18' ' ' LEU . 0.8 OUTLIER -140.2 169.54 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.415 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . 3.5 tptt -144.32 169.28 18.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.211 -0.931 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.427 ' O ' HG21 ' A' ' 22' ' ' THR . 15.2 t -84.11 132.56 34.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.427 ' C ' HG22 ' A' ' 51' ' ' VAL . . . 84.26 -1.43 88.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.415 ' CG ' ' HB3' ' A' ' 21' ' ' LYS . 5.7 m-20 -84.05 134.29 34.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.115 -1.227 . . . . 0.0 109.527 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.464 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -94.36 116.37 28.73 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.881 . . . . 0.0 109.41 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.462 ' CD1' HD13 ' A' ' 32' ' ' LEU . 2.1 mt -90.52 -171.35 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.228 -0.92 . . . . 0.0 109.157 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -146.37 159.47 43.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.95 83.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.88 . . . . 0.0 109.47 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 162.83 -32.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.3 -0.875 . . . . 0.0 109.518 179.914 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -76.28 148.64 37.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.493 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -60.44 -175.66 1.28 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -148.22 -68.59 0.23 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -1.105 . . . . 0.0 109.463 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -131.71 171.42 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.584 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 43' ' ' GLU . 75.4 t -134.14 92.72 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.419 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.4 mp -90.0 149.82 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -0.873 . . . . 0.0 109.423 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -115.17 139.1 50.21 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.24 -179.21 5.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 109.515 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -69.76 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.17 -49.69 6.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.892 . . . . 0.0 109.47 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 173.89 173.63 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.28 -0.887 . . . . 0.0 109.447 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.65 128.94 34.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.294 -0.879 . . . . 0.0 109.501 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.7 mtt -127.2 105.73 8.76 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.45 ' HB3' HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -80.01 156.76 27.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 44.9 t -133.96 140.45 36.39 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.389 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.518 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.0 Cg_endo -78.44 -168.44 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.599 2.199 . . . . 0.0 110.434 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.425 ' HA ' HD11 ' A' ' 32' ' ' LEU . 7.7 t -85.23 129.93 53.84 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.404 -0.81 . . . . 0.0 109.332 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.514 ' HG3' ' CG2' ' A' ' 4' ' ' ILE . 36.0 Cg_endo -78.59 -1.88 11.98 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.366 2.044 . . . . 0.0 110.513 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.468 ' HD3' HD21 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.18 128.57 4.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.533 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.09 86.33 5.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 25' ' ' LEU . . . -146.62 -166.12 12.03 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.443 ' O ' HG11 ' A' ' 51' ' ' VAL . 7.0 p -104.88 139.47 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -1.167 . . . . 0.0 109.466 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 70.5 t -56.98 127.85 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' SER . 18.4 tptm -100.7 -15.91 17.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.202 -0.936 . . . . 0.0 109.485 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.412 ' CB ' ' O ' ' A' ' 53' ' ' LYS . 0.5 OUTLIER 171.12 145.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.464 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 76.1 t -101.11 142.19 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.458 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 61.6 m -121.84 13.58 10.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.89 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 10.8 m -147.76 166.99 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 109.504 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -125.52 171.23 10.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.464 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.464 ' HA ' HG13 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -79.03 118.78 21.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.933 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.51 -11.47 42.82 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -70.86 150.93 45.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.479 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 10.2 tttm -100.19 120.26 39.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.463 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.508 ' N ' HD21 ' A' ' 63' ' ' LEU . 4.0 mm? -131.14 143.93 51.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -105.04 153.21 21.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.46 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 4.3 pt-20 -42.9 143.63 0.7 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.66 -18.1 58.09 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' ' O ' ' A' ' 68' ' ' ALA . 7.7 m-20 -85.12 129.99 34.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -1.156 . . . . 0.0 109.526 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.522 ' HA ' ' CG ' ' A' ' 5' ' ' ARG . . . -48.5 175.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.458 ' CG1' HG21 ' A' ' 6' ' ' VAL . 21.9 mm -146.93 -47.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.463 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -158.68 -177.11 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.483 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -127.75 161.82 28.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.208 -0.933 . . . . 0.0 109.494 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.468 HD21 ' HD3' ' A' ' 48' ' ' LYS . 0.7 OUTLIER -143.15 135.8 27.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.392 -179.948 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 71.3 tt0 -114.68 90.24 21.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.2 Cg_endo -78.07 111.31 3.06 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.557 2.171 . . . . 0.0 110.403 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.418 ' O ' ' C ' ' A' ' 76' ' ' ALA . . . -123.9 -79.6 0.61 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.19 -0.943 . . . . 0.0 109.508 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 75' ' ' ALA . . . 44.71 81.65 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.434 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.19 -138.86 14.93 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.456 ' O ' ' HB3' ' A' ' 79' ' ' ARG . . . -168.96 166.91 11.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.325 -1.103 . . . . 0.0 109.49 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' A' ' 78' ' ' ALA . 14.8 ttp180 . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.413 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.438 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 18.3 p . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.447 ' O ' HD13 ' A' ' 4' ' ' ILE . 3.4 mt-10 -121.37 152.57 38.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.507 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.424 ' O ' HG21 ' A' ' 3' ' ' ILE . 14.7 tt -86.52 152.96 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.447 HD13 ' O ' ' A' ' 2' ' ' GLU . 5.2 mp -131.92 118.54 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.254 -0.904 . . . . 0.0 109.464 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.442 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.79 175.03 7.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.452 179.954 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.443 HG12 ' HD2' ' A' ' 7' ' ' PRO . 53.5 t -55.2 139.88 64.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.323 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.473 ' HG3' ' CG1' ' A' ' 44' ' ' VAL . 36.1 Cg_endo -78.59 -172.94 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.533 2.155 . . . . 0.0 110.359 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -85.11 110.66 19.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.51 ' CD1' ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.8 -56.47 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.421 -179.917 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.96 -27.32 1.89 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . -179.8 118.42 0.59 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.51 ' O ' ' CD1' ' A' ' 9' ' ' ILE . 0.2 OUTLIER 49.76 -179.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.267 -1.137 . . . . 0.0 109.478 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.453 ' CA ' HD21 ' A' ' 35' ' ' LEU . . . -172.24 90.97 0.09 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.445 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 19.3 mt-10 -94.98 124.05 38.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.339 -1.095 . . . . 0.0 109.487 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.7 t -73.12 132.33 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.424 HG23 ' HB ' ' A' ' 34' ' ' VAL . 4.4 tt -92.34 -28.76 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -174.43 151.2 1.53 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.18 103.45 13.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.45 15.07 7.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.284 -0.885 . . . . 0.0 109.375 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.459 HG13 ' HG ' ' A' ' 32' ' ' LEU . 11.9 m -113.28 178.02 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.67 158.43 43.78 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.9 t -73.64 141.89 46.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.288 -0.883 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.463 ' O ' HG22 ' A' ' 51' ' ' VAL . . . 82.85 -6.61 69.55 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.14 135.62 36.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -1.141 . . . . 0.0 109.446 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.484 ' CD1' ' C ' ' A' ' 50' ' ' GLY . 22.4 tp -93.24 110.68 22.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.229 -0.92 . . . . 0.0 109.469 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.461 HD11 HD13 ' A' ' 32' ' ' LEU . 2.7 mt -91.27 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.248 -0.908 . . . . 0.0 109.201 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -139.36 -178.63 5.46 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.208 -0.933 . . . . 0.0 109.443 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 14.2 p -84.79 69.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.554 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 169.21 -40.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.366 -0.834 . . . . 0.0 109.435 179.884 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.8 OUTLIER -56.73 138.49 52.82 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 109.364 179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.462 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -69.5 166.05 49.15 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.518 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -127.42 -42.01 1.69 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.366 -1.079 . . . . 0.0 109.446 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 25.6 m -158.63 174.33 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.154 -0.966 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.424 ' HB ' HG23 ' A' ' 16' ' ' ILE . 70.7 t -128.77 102.53 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.227 -0.921 . . . . 0.0 109.449 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.453 HD21 ' CA ' ' A' ' 13' ' ' GLY . 3.5 mp -89.98 141.67 28.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.216 -0.928 . . . . 0.0 109.4 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.419 ' OE2' ' OG ' ' A' ' 41' ' ' SER . 6.0 tt0 -115.79 134.31 55.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.23 -0.919 . . . . 0.0 109.513 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.9 m -132.03 -177.77 4.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.894 . . . . 0.0 109.446 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.04 -16.54 60.2 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -84.16 -55.27 4.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.94 . . . . 0.0 109.439 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 177.15 -179.54 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.889 . . . . 0.0 109.454 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.419 ' OG ' ' OE2' ' A' ' 36' ' ' GLU . 2.4 m -95.84 103.72 15.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.5 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -93.78 -173.34 3.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.186 -0.946 . . . . 0.0 109.5 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -124.89 162.16 25.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.201 -0.937 . . . . 0.0 109.477 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.509 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.7 t -144.17 97.11 5.28 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.515 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.6 Cg_endo -77.43 -168.69 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.566 2.177 . . . . 0.0 110.476 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.456 ' HB3' HG23 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -85.3 135.24 39.21 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.411 -0.806 . . . . 0.0 109.307 179.89 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HG2' HG12 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.56 -4.63 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.466 2.111 . . . . 0.0 110.433 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 46' ' ' SER . 26.0 tttt -160.31 142.13 12.69 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.403 -0.81 . . . . 0.0 109.468 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.92 94.22 5.19 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.179 -0.951 . . . . 0.0 109.394 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.495 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -150.94 -174.7 22.15 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.463 HG22 ' O ' ' A' ' 23' ' ' GLY . 10.8 p -103.66 137.98 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -1.149 . . . . 0.0 109.522 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.8 t -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.05 -27.7 13.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.206 -0.934 . . . . 0.0 109.524 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -167.04 171.57 10.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.16 -0.963 . . . . 0.0 109.544 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 55.6 t -131.86 113.25 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 56' ' ' SER . 5.6 t -99.32 22.64 10.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.47 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 31.3 m -144.03 169.55 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.198 -0.939 . . . . 0.0 109.451 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.68 171.93 12.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.471 ' C ' ' CD1' ' A' ' 59' ' ' LEU . 4.0 pp -80.04 139.15 37.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.315 -0.866 . . . . 0.0 109.536 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.79 -11.14 62.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -70.53 137.46 50.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -1.16 . . . . 0.0 109.39 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.424 ' C ' HD21 ' A' ' 63' ' ' LEU . 18.7 mttm -98.5 117.18 32.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.27 -0.894 . . . . 0.0 109.46 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.456 ' N ' HD21 ' A' ' 63' ' ' LEU . 3.5 mm? -117.92 159.74 22.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.429 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.3 tttt -112.09 142.82 44.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 64' ' ' LYS . 9.7 mt-10 -42.84 129.78 4.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.306 -0.871 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 113.96 -19.95 17.63 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.417 ' HB3' HD13 ' A' ' 63' ' ' LEU . 26.8 m-20 -85.12 136.06 33.71 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.231 -1.158 . . . . 0.0 109.41 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -58.92 167.85 1.47 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.226 -0.921 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 39.1 mm -134.13 -67.28 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -144.9 -173.56 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -133.48 120.93 21.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.303 -0.873 . . . . 0.0 109.477 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.508 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 2.4 tt -94.05 135.47 35.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.433 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.438 ' OE2' ' HB3' ' A' ' 1' ' ' SER . 5.9 tt0 -114.45 89.17 17.26 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.157 -0.964 . . . . 0.0 109.499 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.508 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.4 Cg_endo -78.28 173.24 14.13 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.564 2.176 . . . . 0.0 110.365 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -137.89 -54.0 0.65 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.501 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -174.87 133.3 0.34 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.426 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.28 81.98 0.2 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -87.51 134.31 33.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -1.178 . . . . 0.0 109.447 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.446 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.466 ' HB3' ' HB2' ' A' ' 73' ' ' GLU . 95.0 p . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -87.04 137.03 32.69 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -0.883 . . . . 0.0 109.472 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 3' ' ' ILE . 0.0 OUTLIER -101.87 121.49 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.4 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.547 ' CD1' ' CG ' ' A' ' 47' ' ' PRO . 49.8 mm -95.82 115.08 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.424 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.463 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 0.0 OUTLIER -112.4 160.24 17.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.203 -0.935 . . . . 0.0 109.686 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.508 HG13 ' N ' ' A' ' 65' ' ' GLU . 85.6 t -44.83 104.47 0.39 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.338 -0.851 . . . . 0.0 109.545 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.1 Cg_endo -77.58 -170.43 0.94 Allowed 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.433 2.089 . . . . 0.0 110.438 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -72.31 99.92 2.52 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.209 -0.932 . . . . 0.0 109.466 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.414 HD12 HG12 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.26 -10.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.372 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.41 -17.63 11.27 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.04 -119.28 0.81 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.37 170.0 9.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.07 120.14 1.07 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 6.2 mt-10 -100.58 122.46 43.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -1.158 . . . . 0.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.2 t -63.2 124.15 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.905 . . . . 0.0 109.509 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.3 mm -99.54 -18.06 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.34 -0.85 . . . . 0.0 109.454 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.98 149.06 1.83 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.53 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.421 HD22 HG21 ' A' ' 20' ' ' VAL . 6.6 tp -118.73 102.39 8.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.457 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -90.71 48.62 1.56 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.527 179.973 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.507 HG13 ' CD2' ' A' ' 32' ' ' LEU . 18.7 m -145.86 168.47 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.409 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.35 171.27 14.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.98 132.02 35.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.57 63.81 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.4 134.99 36.57 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.16 -1.2 . . . . 0.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.464 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -82.64 127.54 33.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.853 . . . . 0.0 109.429 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.493 ' CG2' ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -91.53 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.278 -0.889 . . . . 0.0 109.269 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 30' ' ' GLN . 1.2 tm-20 -142.57 136.68 29.49 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.204 -0.935 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.3 p -45.73 140.72 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.248 -0.907 . . . . 0.0 109.475 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.564 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 82.99 -43.69 0.11 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.64 -0.663 . . . . 0.0 109.9 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.523 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -47.35 133.82 12.12 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.035 -1.041 . . . . 0.0 109.482 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -68.34 162.32 49.74 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.7 OUTLIER -125.98 -38.53 2.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -1.158 . . . . 0.0 109.465 179.972 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 33.0 m -158.73 158.59 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.522 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.2 t -124.44 98.22 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.314 -0.866 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 1.9 mp -90.23 140.24 29.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.305 -0.872 . . . . 0.0 109.526 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -126.89 127.58 45.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.416 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.449 ' OG ' ' N ' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -102.99 174.87 5.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.893 . . . . 0.0 109.477 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' N ' ' OG ' ' A' ' 37' ' ' SER . . . -44.88 -34.48 2.38 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.6 pttt -156.21 50.87 0.52 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.254 -0.903 . . . . 0.0 109.524 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -158.56 91.72 1.09 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.32 129.62 40.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.421 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.9 mtm -149.25 174.46 12.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.259 -0.9 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 31.6 mp0 -127.97 164.58 22.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -143.9 96.92 5.43 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.57 -169.1 0.68 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.537 2.158 . . . . 0.0 110.478 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.493 ' HB2' ' CG2' ' A' ' 26' ' ' ILE . 19.0 t -85.55 126.24 67.11 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.436 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.547 ' CG ' ' CD1' ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.59 -2.2 12.26 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.44 2.093 . . . . 0.0 110.383 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.459 ' O ' ' HG ' ' A' ' 72' ' ' LEU . 3.3 tptt -160.16 127.35 4.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.386 -0.821 . . . . 0.0 109.432 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.7 88.66 1.74 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.209 -0.932 . . . . 0.0 109.469 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.473 ' HA3' ' CD1' ' A' ' 72' ' ' LEU . . . -144.99 -153.71 5.94 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.458 ' O ' HD23 ' A' ' 72' ' ' LEU . 5.9 p -108.45 151.65 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -1.127 . . . . 0.0 109.408 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.2 t -75.97 123.8 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.187 -0.946 . . . . 0.0 109.522 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -81.38 -59.13 2.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.285 -0.884 . . . . 0.0 109.489 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 31.3 p -161.29 126.3 3.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.457 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 57' ' ' VAL . 57.9 t -81.38 126.21 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.287 -0.883 . . . . 0.0 109.486 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 t -103.66 26.0 9.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.216 -0.927 . . . . 0.0 109.48 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 55' ' ' VAL . 15.6 m -148.72 164.87 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.887 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.437 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 9.2 tttt -132.89 164.12 27.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.522 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.34 138.18 55.21 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.454 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.14 -18.22 54.64 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.437 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 1.7 m-20 -82.87 143.61 30.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 109.437 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.18 136.99 41.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.215 -0.928 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.494 ' HG ' ' CD1' ' A' ' 69' ' ' ILE . 4.1 mm? -111.34 177.94 4.5 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.471 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.5 ttpp -139.39 152.21 46.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' N ' HG13 ' A' ' 6' ' ' VAL . 7.3 mt-10 -44.28 139.9 2.44 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.172 -0.955 . . . . 0.0 109.513 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.34 -47.52 3.65 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -48.75 130.19 17.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.298 -1.119 . . . . 0.0 109.521 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -60.44 161.99 6.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.326 -0.859 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.494 ' CD1' ' HG ' ' A' ' 63' ' ' LEU . 19.9 mm -135.41 -55.55 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.304 -0.872 . . . . 0.0 109.466 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' A' ' 69' ' ' ILE . 11.4 pt -156.57 -174.52 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.311 -0.868 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.405 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 0.6 OUTLIER -144.17 139.04 28.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.528 ' CD1' ' HD3' ' A' ' 74' ' ' PRO . 3.4 tm? -119.61 118.81 31.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.196 -0.94 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.466 ' HB2' ' HB3' ' A' ' 1' ' ' SER . 5.7 tt0 -111.74 94.91 25.78 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.528 ' HD3' ' CD1' ' A' ' 72' ' ' LEU . 35.5 Cg_endo -78.05 2.74 7.66 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.616 2.211 . . . . 0.0 110.381 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -87.82 164.57 15.85 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.213 -0.93 . . . . 0.0 109.576 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -91.66 108.83 20.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.457 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -94.28 -139.47 9.85 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -158.03 24.04 0.26 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.2 -1.176 . . . . 0.0 109.486 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.451 -179.986 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 94.7 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -99.45 149.21 23.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.941 . . . . 0.0 109.426 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.2 tt -83.48 159.16 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.31 -0.868 . . . . 0.0 109.468 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.42 HD12 ' HG2' ' A' ' 47' ' ' PRO . 2.8 mp -131.18 111.62 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.192 -0.942 . . . . 0.0 109.407 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.36 170.13 10.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.538 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.524 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -44.19 142.32 2.25 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.419 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.524 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.27 171.51 16.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.554 2.169 . . . . 0.0 110.37 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -84.92 99.13 10.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.56 -11.19 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.258 -0.901 . . . . 0.0 109.396 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.88 -10.8 68.24 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -158.98 -161.32 11.02 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 -83.74 143.32 30.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -1.179 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.77 150.16 18.7 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.411 ' HG2' ' HG3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -129.44 119.17 23.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -1.154 . . . . 0.0 109.481 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.6 t -67.37 152.22 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.419 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 16' ' ' ILE . 49.3 mm -120.06 -34.24 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -175.47 137.91 0.39 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 109.452 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.566 ' N ' ' CD2' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.97 140.6 37.03 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 121.154 -0.966 . . . . 0.0 109.371 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.46 35.23 3.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 m -144.13 -179.7 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.432 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.27 -179.68 6.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 0.0 109.441 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.2 t -79.9 129.58 34.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.417 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.55 -0.13 61.22 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -81.35 133.29 35.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 109.489 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.419 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -89.78 107.82 19.32 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.461 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.445 HG23 ' HB3' ' A' ' 46' ' ' SER . 2.7 mt -91.88 -171.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.184 -0.948 . . . . 0.0 109.26 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.436 ' OE1' HG11 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -147.31 176.76 9.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.51 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.506 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.2 p -81.18 74.34 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.515 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.506 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.92 -27.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.313 -0.867 . . . . 0.0 109.402 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -72.99 136.01 45.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.24 176.18 2.85 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.504 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -137.15 -62.93 0.61 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -1.147 . . . . 0.0 109.452 180.0 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.461 HG11 ' CD2' ' A' ' 32' ' ' LEU . 16.5 m -137.66 172.03 15.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -125.69 105.95 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.246 -0.909 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.1 mp -97.95 153.61 18.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.84 149.98 39.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.6 m -126.65 177.96 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.99 -41.41 59.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.483 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -157.95 37.04 0.26 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -152.69 88.33 1.34 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.401 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.447 ' O ' ' HG2' ' A' ' 42' ' ' MET . 34.6 t -83.45 127.58 33.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.242 -0.911 . . . . 0.0 109.451 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.447 ' HG2' ' O ' ' A' ' 41' ' ' SER . 11.9 mtt -147.45 136.46 22.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.468 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -93.0 169.93 10.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.162 -0.961 . . . . 0.0 109.437 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 40.7 t -135.88 127.83 17.46 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.36 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.47 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.4 -168.15 0.58 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.43 2.086 . . . . 0.0 110.389 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.495 ' HA ' ' CD1' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -85.14 135.92 38.78 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.869 . . . . 0.0 109.19 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.42 ' HG2' HD12 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.43 -2.39 12.45 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.434 2.089 . . . . 0.0 110.533 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.455 ' HB3' HD23 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.03 140.53 11.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.376 -0.828 . . . . 0.0 109.4 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.68 95.95 9.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.487 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -160.71 -153.0 6.79 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.417 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 12.2 p -110.81 141.63 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -1.124 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 71.0 t -63.87 142.6 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.42 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -106.77 -55.35 2.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.31 118.87 7.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 13.1 t -84.87 106.73 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 p -90.16 9.2 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.459 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.518 ' CG1' HD11 ' A' ' 69' ' ' ILE . 20.6 m -124.87 158.27 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.451 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.8 tptp -137.43 -173.38 3.46 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.22 -0.925 . . . . 0.0 109.524 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.2 pp -85.05 134.36 34.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.441 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 77.23 9.08 87.0 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -84.87 145.46 27.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.244 -1.15 . . . . 0.0 109.438 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.42 ' O ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -107.41 132.48 53.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.521 -179.981 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -139.59 130.14 25.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.41 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 31.4 tttm -93.82 145.74 24.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.202 -0.936 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.446 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -42.86 124.29 3.05 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.353 -0.842 . . . . 0.0 109.638 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 123.46 -26.37 6.04 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 68' ' ' ALA . 1.2 m-20 -85.11 131.23 34.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -1.147 . . . . 0.0 109.442 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -49.66 178.55 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.284 -0.885 . . . . 0.0 109.509 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.518 HD11 ' CG1' ' A' ' 57' ' ' VAL . 23.1 mm -145.08 -65.21 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.237 -0.914 . . . . 0.0 109.414 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.433 HG21 ' O ' ' A' ' 69' ' ' ILE . 1.2 pt -151.51 177.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.478 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -143.48 140.42 30.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.496 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 1.3 tt -107.75 142.8 37.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.411 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -131.34 89.84 39.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.432 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.496 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.05 91.08 1.21 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.59 2.193 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -152.87 -54.16 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.248 -0.907 . . . . 0.0 109.419 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -160.42 146.39 15.21 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.472 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.59 -100.86 0.01 OUTLIER Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.84 178.31 8.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.472 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.487 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 60.4 p . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.453 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 16.5 mt-10 -135.78 137.24 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.496 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.455 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 1.2 tt -82.14 151.94 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.452 HD13 ' HG3' ' A' ' 47' ' ' PRO . 17.5 mm -117.37 97.03 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.491 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.76 163.3 14.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.523 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 71.4 t -57.88 142.05 79.61 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.523 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.3 Cg_endo -77.98 -174.46 2.24 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.587 2.191 . . . . 0.0 110.386 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -58.78 103.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.463 ' CG2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -110.17 -37.75 3.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.238 -0.913 . . . . 0.0 108.767 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.85 52.98 21.65 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.89 -136.57 4.37 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -116.65 138.4 51.47 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.22 -1.165 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -110.74 118.93 5.1 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.01 130.91 47.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.278 -1.131 . . . . 0.0 109.476 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.3 t -80.67 147.31 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.469 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.4 mt -113.49 -57.02 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -0.942 . . . . 0.0 109.474 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -160.8 162.64 32.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.305 -0.872 . . . . 0.0 109.463 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.1 tp -101.2 141.53 33.94 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 12.7 mt -99.0 18.67 16.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.488 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.4 HG22 HG23 ' A' ' 52' ' ' VAL . 27.5 m -150.04 172.22 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.422 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -120.01 -178.29 3.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.459 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.22 113.92 19.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.501 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.31 0.5 65.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.84 145.89 27.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -1.138 . . . . 0.0 109.434 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.1 tp -89.81 132.27 35.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.184 -0.947 . . . . 0.0 109.449 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.501 HD11 ' CD1' ' A' ' 32' ' ' LEU . 2.7 mt -91.79 -171.41 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.184 -0.947 . . . . 0.0 109.135 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.526 ' CG ' ' HB2' ' A' ' 30' ' ' GLN . 0.1 OUTLIER -149.96 126.01 10.59 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.246 -0.908 . . . . 0.0 109.488 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.567 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 8.4 p -44.98 149.61 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.567 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 16.3 tt0 83.05 -43.67 0.11 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.666 -0.646 . . . . 0.0 109.8 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.526 ' HB2' ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -62.29 153.81 29.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.101 -0.999 . . . . 0.0 109.48 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -62.46 -176.94 3.03 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.501 ' CD1' HD11 ' A' ' 26' ' ' ILE . 10.0 tp -153.98 -56.88 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -1.176 . . . . 0.0 109.558 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.19 152.7 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.175 -0.953 . . . . 0.0 109.65 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.479 HG11 ' CG ' ' A' ' 43' ' ' GLU . 22.6 t -120.97 83.96 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.282 -0.886 . . . . 0.0 109.367 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.01 170.86 9.99 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -0.905 . . . . 0.0 109.478 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.516 ' CG ' ' O ' ' A' ' 40' ' ' ALA . 21.8 tt0 -114.08 154.22 28.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -104.7 -177.05 3.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -45.31 -37.69 5.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.314 -0.866 . . . . 0.0 109.446 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.427 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -158.74 63.52 0.42 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.516 ' O ' ' CG ' ' A' ' 36' ' ' GLU . . . 178.13 -167.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.425 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.8 m -135.85 116.36 13.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.243 -0.91 . . . . 0.0 109.455 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.454 ' HG2' ' O ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -116.78 132.68 56.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.164 -0.96 . . . . 0.0 109.43 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.479 ' CG ' HG11 ' A' ' 34' ' ' VAL . 2.0 mt-10 -112.57 161.59 16.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 3.4 t -139.31 140.3 25.52 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.279 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.529 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.31 -169.12 0.71 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.379 2.053 . . . . 0.0 110.38 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.464 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.53 134.71 39.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.32 -0.862 . . . . 0.0 109.302 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.452 ' HG3' HD13 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.68 -12.64 15.0 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.435 2.09 . . . . 0.0 110.233 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.457 ' HD2' HD23 ' A' ' 72' ' ' LEU . 1.3 ttmp? -160.64 132.11 5.75 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.7 84.54 2.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.4 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' A' ' 25' ' ' LEU . . . -135.21 -144.11 4.9 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.495 HG21 ' N ' ' A' ' 52' ' ' VAL . 11.3 p -118.74 157.24 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.495 ' N ' HG21 ' A' ' 51' ' ' VAL . 24.1 t -84.82 136.69 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.239 -0.913 . . . . 0.0 109.468 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.4 ' O ' ' OG ' ' A' ' 54' ' ' SER . 0.2 OUTLIER -89.38 -60.89 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.433 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 53' ' ' LYS . 3.8 m -175.36 157.62 2.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.16 -0.963 . . . . 0.0 109.501 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.464 ' HA ' HG21 ' A' ' 70' ' ' ILE . 3.5 t -87.11 121.38 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.44 ' O ' HG11 ' A' ' 57' ' ' VAL . 1.2 m -80.93 5.85 15.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.573 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.493 HG13 ' CD1' ' A' ' 63' ' ' LEU . 35.6 m -150.11 -172.26 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.444 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.4 OUTLIER -114.05 153.28 29.7 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.453 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -65.81 150.3 48.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.466 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 69.25 9.1 60.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.444 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 5.1 m-20 -84.99 154.79 21.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -101.92 123.18 45.4 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.898 . . . . 0.0 109.427 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.493 ' CD1' HG13 ' A' ' 57' ' ' VAL . 83.0 mt -123.2 152.72 40.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 109.453 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.8 ttpt -94.0 147.28 23.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.286 -0.883 . . . . 0.0 109.509 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.463 ' HB3' ' CG2' ' A' ' 9' ' ' ILE . 10.7 pt-20 -43.05 139.59 1.72 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.35 -0.844 . . . . 0.0 109.605 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.55 -4.61 79.83 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.04 143.37 29.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -1.106 . . . . 0.0 109.452 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -74.98 157.74 34.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.312 -0.868 . . . . 0.0 109.461 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.41 HD12 HG21 ' A' ' 6' ' ' VAL . 3.2 mp -131.07 -51.77 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.94 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.464 HG21 ' HA ' ' A' ' 55' ' ' VAL . 3.0 pt -147.4 -179.69 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.455 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 22.9 tt0 -150.06 129.24 12.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.224 -0.923 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.514 ' HG ' ' N ' ' A' ' 73' ' ' GLU . 0.6 OUTLIER -95.82 145.07 25.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.473 179.931 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.514 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -112.4 93.32 22.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.328 -0.858 . . . . 0.0 109.404 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.465 ' O ' ' N ' ' A' ' 76' ' ' ALA . 35.6 Cg_endo -77.97 -170.33 0.94 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.631 2.221 . . . . 0.0 110.461 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.42 ' C ' ' O ' ' A' ' 74' ' ' PRO . . . -43.69 97.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.865 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 74' ' ' PRO . . . -81.63 -14.1 57.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -165.6 -76.85 0.03 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -161.76 94.93 0.97 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.221 -1.164 . . . . 0.0 109.528 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 26.9 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -92.87 169.41 10.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.89 . . . . 0.0 109.476 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.7 mt -106.48 146.58 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.875 . . . . 0.0 109.439 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.46 ' O ' HD11 ' A' ' 69' ' ' ILE . 27.9 mm -104.93 114.68 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.452 ' HA ' HD11 ' A' ' 69' ' ' ILE . 6.0 ptp180 -107.07 177.71 4.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.238 -0.914 . . . . 0.0 109.459 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.52 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 72.6 t -73.77 142.06 79.77 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.219 -0.926 . . . . 0.0 109.459 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.52 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 36.0 Cg_endo -78.45 -170.15 0.92 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.497 2.131 . . . . 0.0 110.441 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -85.02 102.86 13.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.164 -0.96 . . . . 0.0 109.423 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.3 -49.03 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.352 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.63 30.28 2.44 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' OE1' ' A' ' 65' ' ' GLU . . . 168.3 -166.19 39.34 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -94.95 115.65 27.72 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.264 -1.139 . . . . 0.0 109.531 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.38 168.39 54.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.451 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 4.6 tt0 -142.99 117.27 9.58 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.2 -1.177 . . . . 0.0 109.496 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.44 ' CG1' HD11 ' A' ' 18' ' ' LEU . 62.4 t -62.52 119.78 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.47 ' CG1' ' O ' ' A' ' 34' ' ' VAL . 2.1 pt -113.99 -20.26 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.421 ' N ' HG13 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -155.41 136.76 14.02 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.299 -0.875 . . . . 0.0 109.499 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.44 HD11 ' CG1' ' A' ' 15' ' ' VAL . 0.2 OUTLIER -129.09 123.57 32.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.937 . . . . 0.0 109.4 -179.965 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.492 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -125.22 63.13 1.17 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 0.0 109.478 -179.923 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.441 HG13 ' HG ' ' A' ' 32' ' ' LEU . 16.7 m -144.96 169.24 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.22 160.07 42.04 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.508 ' CG2' ' O ' ' A' ' 53' ' ' LYS . 94.8 m -84.5 133.85 34.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.495 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.85 -10.77 73.81 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -81.1 136.42 35.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -1.137 . . . . 0.0 109.505 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.56 115.96 22.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 109.5 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 32' ' ' LEU . 2.4 mt -91.02 -171.54 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.187 -0.945 . . . . 0.0 109.234 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.67 174.87 10.81 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 12.0 p -84.98 76.22 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.42 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 167.21 -41.98 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.431 -0.793 . . . . 0.0 109.251 179.867 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.526 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 61.5 tt0 -59.65 146.44 41.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.478 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -74.19 168.17 54.4 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 5.0 tp -128.46 -43.79 1.41 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -1.154 . . . . 0.0 109.567 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 15.7 m -158.56 159.08 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' A' ' 16' ' ' ILE . 62.9 t -124.37 103.47 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.184 -0.947 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.08 163.08 15.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -118.05 145.29 44.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.447 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -121.69 -177.39 3.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.915 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.36 -56.01 9.25 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -143.98 59.77 1.36 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 109.523 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . 170.42 112.01 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 33.8 t -100.73 115.15 29.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.483 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 26.2 ttp -102.98 154.73 18.94 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.178 -0.952 . . . . 0.0 109.403 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' O ' HG21 ' A' ' 44' ' ' VAL . 12.5 mt-10 -100.6 169.61 8.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 69.9 t -146.12 99.57 4.27 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.526 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.4 Cg_endo -77.13 -167.96 0.53 Allowed 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.432 2.088 . . . . 0.0 110.479 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 2.6 t -84.82 125.98 69.5 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.348 -0.845 . . . . 0.0 109.385 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.427 ' CG ' HD11 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.54 -1.16 11.35 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.382 2.055 . . . . 0.0 110.404 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 46' ' ' SER . 4.7 tttt -160.15 140.95 12.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.304 -0.872 . . . . 0.0 109.574 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.67 102.84 12.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 0.0 109.402 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.507 ' CA ' ' CD1' ' A' ' 72' ' ' LEU . . . -152.92 -168.93 17.54 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.469 ' CG1' ' O ' ' A' ' 51' ' ' VAL . 7.4 p -104.18 120.19 54.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -1.105 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.44 HG13 ' HA ' ' A' ' 22' ' ' THR . 50.9 t -49.09 142.36 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.508 ' O ' ' CG2' ' A' ' 22' ' ' THR . 3.1 ttpp -104.87 -59.77 1.7 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.01 140.99 14.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 10.7 t -90.37 126.36 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.506 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.6 m -100.38 20.47 14.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.251 -0.906 . . . . 0.0 109.394 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.426 ' CG2' HG21 ' A' ' 69' ' ' ILE . 1.4 m -143.62 163.39 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -120.1 141.47 49.77 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.474 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.413 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 2.1 pp -60.26 128.37 36.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.466 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.39 -21.9 21.04 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -83.43 158.45 22.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.187 -1.184 . . . . 0.0 109.502 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 5.8 pttt -86.8 165.11 16.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.02 110.66 10.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.324 -0.86 . . . . 0.0 109.45 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.84 136.28 36.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.232 -0.918 . . . . 0.0 109.282 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' O ' ' A' ' 11' ' ' GLY . 1.8 mt-10 -48.85 149.04 1.94 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.31 -0.869 . . . . 0.0 109.958 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.79 -14.66 46.75 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.64 141.62 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.198 -1.178 . . . . 0.0 109.621 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -74.61 176.07 7.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 109.342 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.46 HD11 ' O ' ' A' ' 4' ' ' ILE . 2.9 mp -139.37 -64.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.156 -0.965 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.415 HG22 HG23 ' A' ' 69' ' ' ILE . 2.3 pp -139.18 173.59 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.605 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -129.31 137.51 51.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.874 . . . . 0.0 109.428 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.52 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 3.5 tt -108.52 137.88 45.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.893 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.448 ' OE1' ' HD3' ' A' ' 53' ' ' LYS . 0.5 OUTLIER -113.38 92.17 22.19 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.52 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.4 Cg_endo -78.05 75.05 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.598 2.198 . . . . 0.0 110.391 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . 53.7 97.95 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.399 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -107.25 16.11 24.36 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.454 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.16 -106.13 0.22 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -87.42 -166.77 1.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.32 -1.106 . . . . 0.0 109.404 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.2 mtm180 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.049 -0.976 . . . . 0.0 109.467 179.917 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.514 ' CB ' ' HG2' ' A' ' 73' ' ' GLU . 53.2 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.271 0.558 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 1' ' ' SER . 2.0 mm-40 -154.09 148.81 26.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.231 -0.918 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.7 mp -80.05 143.1 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.412 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.453 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 2.1 mp -114.82 97.88 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.428 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.07 176.67 6.69 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.0 t -65.68 142.43 98.21 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.529 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.7 Cg_endo -78.24 -178.68 4.8 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.528 2.152 . . . . 0.0 110.374 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -85.05 96.64 9.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.22 -0.925 . . . . 0.0 109.41 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.99 -17.64 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.31 -0.869 . . . . 0.0 109.299 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.29 -8.95 62.46 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.82 -133.14 3.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -113.6 170.8 7.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -134.06 108.44 0.73 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.3 OUTLIER -99.8 120.33 39.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -1.112 . . . . 0.0 109.371 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.2 t -67.26 123.31 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.88 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.512 ' CG2' ' O ' ' A' ' 34' ' ' VAL . 8.3 tp -103.37 -25.19 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.196 -0.94 . . . . 0.0 109.494 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.432 ' N ' HG21 ' A' ' 16' ' ' ILE . 38.0 tt0 -178.62 138.83 0.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.424 HD11 ' O ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -102.75 152.47 21.2 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.304 -0.872 . . . . 0.0 109.399 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -112.06 27.29 9.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.46 HG23 HD12 ' A' ' 32' ' ' LEU . 24.3 m -149.98 167.48 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.97 -167.59 1.94 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 80.3 m -84.96 130.34 34.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.79 2.16 87.98 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -84.61 135.3 34.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.191 -1.182 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.425 HD11 ' HB ' ' A' ' 51' ' ' VAL . 12.4 tp -89.24 127.84 35.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.221 -0.924 . . . . 0.0 109.493 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.524 HD12 ' CD2' ' A' ' 32' ' ' LEU . 3.7 mt -98.5 -171.22 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.285 -0.885 . . . . 0.0 109.148 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 40.0 mm-40 -140.81 164.99 28.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.492 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 14.7 p -80.47 75.62 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -0.901 . . . . 0.0 109.404 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 2.4 mt-10 162.7 -31.01 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.283 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 6.2 tt0 -71.01 151.0 45.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.449 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.468 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.4 165.94 51.35 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.524 ' CD2' HD12 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -125.84 -49.54 1.61 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -1.124 . . . . 0.0 109.559 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 32' ' ' LEU . 27.5 m -146.74 158.11 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.482 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.512 ' O ' ' CG2' ' A' ' 16' ' ' ILE . 82.6 t -126.05 88.25 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.14 -0.975 . . . . 0.0 109.439 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -90.04 152.34 21.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.541 -179.943 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.53 -178.92 5.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.495 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.418 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -140.87 175.9 9.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.458 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.4 -49.94 9.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.514 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -147.09 32.92 0.9 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.77 169.1 25.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.865 . . . . 0.0 109.464 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 58.7 m -123.56 135.3 53.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.3 mmt -133.59 135.63 44.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' N ' ' A' ' 44' ' ' VAL . 24.9 tt0 -106.92 166.03 10.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.515 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 6.4 t -145.9 111.64 4.48 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.314 -0.866 . . . . 0.0 109.283 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.5 Cg_endo -77.26 -169.11 0.68 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.364 2.043 . . . . 0.0 110.437 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.462 ' HB2' HD11 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -85.46 130.44 51.36 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 -179.92 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.88 -6.6 15.21 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.417 2.078 . . . . 0.0 110.482 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' HD23 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.37 149.26 17.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.529 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 74' ' ' PRO . . . -79.85 96.43 6.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.481 ' HA3' ' CD2' ' A' ' 72' ' ' LEU . . . -144.78 177.11 23.5 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.425 ' HB ' HD11 ' A' ' 25' ' ' LEU . 7.3 p -104.12 137.83 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -1.148 . . . . 0.0 109.483 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.3 129.62 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.455 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.77 -18.14 10.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.301 -0.874 . . . . 0.0 109.44 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -164.88 150.05 9.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.195 -0.941 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 57' ' ' VAL . 61.0 t -129.88 117.93 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.413 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.409 ' C ' HG11 ' A' ' 57' ' ' VAL . 0.3 OUTLIER -102.07 15.4 29.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.419 179.95 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.441 HG23 HG21 ' A' ' 69' ' ' ILE . 33.3 m -138.71 161.73 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.478 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.93 -165.0 1.8 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.86 123.99 28.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.33 -3.96 86.55 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.88 135.52 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.15 -1.206 . . . . 0.0 109.392 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -107.8 125.06 50.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.9 mp -131.35 154.02 49.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.46 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -111.03 150.37 29.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.45 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.7 OUTLIER -42.88 141.46 1.1 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 109.643 -179.825 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.14 -26.47 23.76 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.07 137.33 33.12 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -1.183 . . . . 0.0 109.546 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.431 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -64.57 164.18 12.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.507 ' CD1' HG21 ' A' ' 6' ' ' VAL . 44.2 mm -122.25 -68.24 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.122 -0.986 . . . . 0.0 109.534 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.407 HD11 ' N ' ' A' ' 71' ' ' GLU . 1.6 pp -138.91 179.87 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.237 -0.914 . . . . 0.0 109.471 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.407 ' N ' HD11 ' A' ' 70' ' ' ILE . 46.3 tt0 -134.03 127.83 33.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.481 ' CD2' ' HA3' ' A' ' 50' ' ' GLY . 1.9 tp -107.03 123.91 48.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.514 ' HG2' ' CB ' ' A' ' 1' ' ' SER . 0.0 OUTLIER -120.92 91.4 47.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.301 -0.874 . . . . 0.0 109.424 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.446 ' HB3' ' HA2' ' A' ' 50' ' ' GLY . 35.2 Cg_endo -77.99 98.16 1.19 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.644 2.229 . . . . 0.0 110.395 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.441 ' O ' ' O ' ' A' ' 74' ' ' PRO . . . 61.13 120.72 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -112.94 94.69 5.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.464 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -104.94 -49.3 1.01 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -50.45 -23.95 2.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.252 -1.146 . . . . 0.0 109.521 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.9 ttt180 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.504 179.99 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.44 ' HB3' ' HD3' ' A' ' 74' ' ' PRO . 83.4 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.418 ' OE2' ' HG3' ' A' ' 48' ' ' LYS . 20.2 pt-20 -155.9 172.51 18.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.433 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.534 ' CD1' ' CG ' ' A' ' 71' ' ' GLU . 16.7 mm -116.52 134.39 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.304 -0.873 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -98.0 110.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.402 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.45 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -110.44 169.56 8.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.21 -0.931 . . . . 0.0 109.573 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 65' ' ' GLU . 51.6 t -43.58 106.03 0.47 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.893 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.43 -170.5 0.95 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.486 2.124 . . . . 0.0 110.41 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -75.68 100.45 4.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.506 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.437 HD12 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.05 -24.81 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.286 -0.883 . . . . 0.0 109.313 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.9 -30.76 4.75 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -173.56 169.43 42.51 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -48.07 113.53 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.488 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.25 149.41 16.86 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.453 ' OE2' ' O ' ' A' ' 60' ' ' GLY . 55.8 tt0 -115.27 126.37 54.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -1.144 . . . . 0.0 109.548 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.418 ' O ' ' HA2' ' A' ' 60' ' ' GLY . 40.6 t -55.93 148.41 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 36' ' ' GLU . 50.4 mt -120.41 -50.4 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -159.3 143.55 15.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.286 -0.883 . . . . 0.0 109.413 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.561 ' N ' ' CD2' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.84 155.2 18.5 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.297 -0.877 . . . . 0.0 109.384 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.435 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -122.83 35.83 4.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -146.13 -179.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.452 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.35 176.12 8.39 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.191 -0.943 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.1 m -77.6 148.41 35.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.445 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.457 ' O ' HG22 ' A' ' 51' ' ' VAL . . . 68.49 7.53 53.43 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -85.01 143.1 29.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 0.0 109.515 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -102.21 116.02 31.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.446 179.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.411 HG23 ' HB2' ' A' ' 46' ' ' SER . 0.8 OUTLIER -92.92 -171.57 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.194 -0.941 . . . . 0.0 109.245 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -140.56 172.91 12.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.186 -0.946 . . . . 0.0 109.391 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.515 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.1 p -78.86 77.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.52 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.99 -41.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.312 -0.868 . . . . 0.0 109.485 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -61.43 146.6 47.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -63.13 -174.67 2.68 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.514 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -147.54 -71.9 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.147 -1.207 . . . . 0.0 109.518 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 m -131.52 175.84 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.943 . . . . 0.0 109.576 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 43' ' ' GLU . 87.8 t -132.24 99.73 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.345 -0.847 . . . . 0.0 109.421 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.19 153.37 17.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.881 . . . . 0.0 109.486 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.489 ' HB2' ' CD1' ' A' ' 16' ' ' ILE . 1.5 tt0 -107.8 153.1 23.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.347 -0.845 . . . . 0.0 109.395 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.66 -179.37 3.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.462 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.45 -22.97 66.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.471 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 10.2 pttp -159.39 65.47 0.39 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.419 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.471 ' CB ' ' O ' ' A' ' 39' ' ' LYS . . . 166.62 174.6 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.176 -0.953 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.4 m -154.95 93.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.397 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 55.7 mtp -116.65 138.82 51.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.275 -0.891 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.435 ' HB3' HG21 ' A' ' 34' ' ' VAL . 4.3 pt-20 -95.36 -176.31 3.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.24 -0.913 . . . . 0.0 109.389 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 68.0 t -143.33 139.38 16.49 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.92 -168.14 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.554 2.169 . . . . 0.0 110.373 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.411 ' HB2' HG23 ' A' ' 26' ' ' ILE . 28.0 t -85.04 124.31 72.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.247 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.434 ' HD3' HD11 ' A' ' 32' ' ' LEU . 35.8 Cg_endo -78.17 0.37 9.95 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.366 2.044 . . . . 0.0 110.434 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.515 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 3.5 mmtm -160.15 121.36 3.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.248 -0.908 . . . . 0.0 109.517 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.15 83.91 1.01 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.497 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -150.14 -170.03 16.96 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 23' ' ' GLY . 8.0 p -95.94 148.59 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -1.145 . . . . 0.0 109.531 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.42 ' N ' HG21 ' A' ' 51' ' ' VAL . 34.0 t -75.94 137.69 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.472 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.432 ' HB3' ' O ' ' A' ' 71' ' ' GLU . 0.0 OUTLIER -90.73 -46.21 8.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.462 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.49 144.14 0.12 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.155 -0.965 . . . . 0.0 109.445 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 57' ' ' VAL . 5.1 t -86.3 112.87 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.496 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.8 m -90.82 15.75 10.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.518 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.432 ' O ' HG13 ' A' ' 55' ' ' VAL . 2.8 m -139.55 157.65 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.81 147.04 28.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.02 140.21 56.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.453 ' O ' ' OE2' ' A' ' 14' ' ' GLU . . . 90.7 -11.31 72.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -73.23 140.99 47.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -1.134 . . . . 0.0 109.434 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.449 ' HG2' ' HB2' ' A' ' 14' ' ' GLU . 0.4 OUTLIER -98.38 133.78 42.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -140.11 162.3 35.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.454 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.7 tmtt? -128.71 159.71 34.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.464 ' N ' ' CG1' ' A' ' 6' ' ' VAL . 8.6 mt-10 -42.7 111.83 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.426 -0.796 . . . . 0.0 109.695 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.94 -33.85 2.15 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -84.22 142.51 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -1.149 . . . . 0.0 109.405 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' HD12 ' A' ' 69' ' ' ILE . . . -78.26 159.54 28.42 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.391 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.454 HD12 ' O ' ' A' ' 68' ' ' ALA . 34.5 mm -123.7 -60.72 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.511 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.406 HG21 ' HA ' ' A' ' 55' ' ' VAL . 11.3 pt -142.54 -176.47 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 109.49 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.534 ' CG ' ' CD1' ' A' ' 3' ' ' ILE . 1.7 tm-20 -138.16 108.04 6.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.241 -0.912 . . . . 0.0 109.475 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.515 ' CD1' ' O ' ' A' ' 48' ' ' LYS . 4.4 tt -89.94 140.99 29.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.453 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -110.22 157.89 36.73 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 0.0 109.499 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.453 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 35.9 Cg_endo -77.97 117.48 4.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.57 2.18 . . . . 0.0 110.45 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -149.99 87.94 1.5 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.429 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -93.59 40.71 1.07 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.12 -30.55 8.2 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 56.34 20.64 4.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -1.148 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 40.7 mtp85 . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.982 -1.008 . . . . 0.0 109.484 179.969 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 79.5 p . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -123.2 178.59 5.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.465 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.402 ' HA ' ' HG2' ' A' ' 71' ' ' GLU . 7.0 mt -120.15 127.71 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.197 -0.939 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.449 HD11 HD13 ' A' ' 70' ' ' ILE . 3.3 mt -98.98 126.62 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.439 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -111.03 161.01 16.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.518 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 72.8 t -50.23 142.08 14.85 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.346 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.518 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.22 -170.31 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.632 2.221 . . . . 0.0 110.493 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.95 102.32 10.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.388 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.441 HG13 ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -104.3 -10.76 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 109.382 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.16 35.85 91.04 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.5 -173.48 43.79 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -82.96 172.88 12.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -1.153 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.51 146.71 18.69 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.408 ' C ' HD12 ' A' ' 35' ' ' LEU . 25.0 tt0 -132.03 118.24 19.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.288 -1.125 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.584 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 9.8 t -67.84 141.17 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.206 -0.934 . . . . 0.0 109.538 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.425 ' CG1' ' HB2' ' A' ' 36' ' ' GLU . 30.3 mm -112.22 -51.27 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.268 -0.895 . . . . 0.0 109.444 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -150.05 140.93 22.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.553 ' CD2' ' CG2' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -101.83 149.09 24.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.502 179.946 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.69 50.77 1.66 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.269 -0.894 . . . . 0.0 109.533 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.553 ' CG2' ' CD2' ' A' ' 18' ' ' LEU . 0.9 OUTLIER -150.05 163.27 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.248 -0.908 . . . . 0.0 109.455 -179.956 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.29 165.39 23.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.221 -0.924 . . . . 0.0 109.441 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.514 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 72.4 m -81.16 141.25 34.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 109.513 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.3 -10.83 69.74 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 1.0 OUTLIER -82.86 133.65 35.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.494 179.975 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.462 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.5 OUTLIER -85.97 117.58 24.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.512 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.4 mt -90.01 -171.57 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -147.78 166.38 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -0.933 . . . . 0.0 109.479 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 12.8 p -77.72 79.05 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.449 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 163.0 -35.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.517 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -70.0 140.55 52.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.2 -0.937 . . . . 0.0 109.437 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.479 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -68.45 165.05 47.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -128.01 -40.49 1.68 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -1.15 . . . . 0.0 109.506 -179.97 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.462 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.0 m -157.27 174.49 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.482 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.71 104.3 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.438 HD12 ' HA ' ' A' ' 15' ' ' VAL . 4.5 mm? -89.96 152.55 21.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.256 -0.903 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.425 ' HB2' ' CG1' ' A' ' 16' ' ' ILE . 0.3 OUTLIER -131.74 116.19 16.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 -179.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.61 -172.62 3.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.47 -57.38 8.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.268 -0.895 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.3 mttt -140.4 49.66 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -154.88 104.67 2.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.339 -0.851 . . . . 0.0 109.478 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.97 119.28 31.56 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.87 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 5.4 ptp -136.51 162.35 33.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.325 -0.859 . . . . 0.0 109.418 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -106.42 172.36 6.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 22.9 t -142.75 95.89 6.25 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.409 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.517 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.9 Cg_endo -77.47 -168.73 0.63 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.481 2.12 . . . . 0.0 110.52 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.512 ' CB ' HG23 ' A' ' 26' ' ' ILE . 11.6 t -85.42 130.68 50.52 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.356 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.413 ' HG3' HG22 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.61 -3.04 12.99 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.401 2.067 . . . . 0.0 110.43 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -160.3 145.77 15.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 -179.997 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.93 93.22 8.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.475 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.492 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -143.52 -155.14 6.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.9 p -117.04 142.3 31.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.307 -1.114 . . . . 0.0 109.465 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.514 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 55.0 t -65.37 110.29 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.441 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.58 -35.38 27.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.494 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.8 t -169.86 158.13 7.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.552 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.408 ' CG1' HG21 ' A' ' 57' ' ' VAL . 77.7 t -117.44 115.23 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.14 17.87 20.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.551 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.408 HG21 ' CG1' ' A' ' 55' ' ' VAL . 29.2 m -123.1 162.23 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 109.483 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 tptt -134.26 172.58 12.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.436 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -81.86 124.33 29.61 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.156 -0.965 . . . . 0.0 109.513 179.959 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 98.33 -9.55 63.0 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -75.87 153.93 36.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -1.176 . . . . 0.0 109.482 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -99.3 121.11 40.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.584 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 11.1 mt -102.59 95.16 6.05 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.428 ' O ' ' C ' ' A' ' 65' ' ' GLU . 26.8 ttpt -85.43 138.64 32.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 109.386 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.441 ' HB3' HG13 ' A' ' 9' ' ' ILE . 11.5 pt-20 -43.06 150.63 0.16 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.67 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.26 -26.37 13.79 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -85.17 146.02 27.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.437 ' O ' HD12 ' A' ' 69' ' ' ILE . . . -61.64 -175.15 0.05 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.274 -0.891 . . . . 0.0 109.404 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.474 ' CD1' HG22 ' A' ' 6' ' ' VAL . 39.8 mm -146.95 -70.37 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.538 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.449 HD13 HD11 ' A' ' 4' ' ' ILE . 0.8 OUTLIER -143.96 -172.33 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.214 -0.929 . . . . 0.0 109.451 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.402 ' HG2' ' HA ' ' A' ' 3' ' ' ILE . 9.6 mt-10 -137.81 105.05 5.46 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.205 -0.935 . . . . 0.0 109.585 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.492 HD12 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -90.63 135.14 33.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.179 -0.951 . . . . 0.0 109.484 179.893 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.401 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 27.7 tt0 -113.45 91.33 19.79 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.459 ' HD3' HD22 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -78.02 -18.29 13.06 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.635 2.223 . . . . 0.0 110.423 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -59.34 -66.01 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.413 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 65.46 -168.85 0.21 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.447 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.94 18.45 24.8 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -114.07 -74.38 0.62 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.329 -1.101 . . . . 0.0 109.464 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.2 mtt85 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.423 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 31.3 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -122.87 155.92 35.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.406 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.407 HG13 ' HG2' ' A' ' 71' ' ' GLU . 2.1 mp -117.12 146.89 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.486 HG13 ' CG ' ' A' ' 47' ' ' PRO . 37.9 mm -124.46 112.95 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -100.8 172.83 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.8 t -61.89 142.26 95.09 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.399 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.528 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.16 -171.24 1.15 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.505 2.137 . . . . 0.0 110.431 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -85.01 102.82 13.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.417 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.76 -40.19 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.282 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.9 29.85 30.62 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.84 -128.52 0.96 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.488 ' OD2' ' CE ' ' A' ' 62' ' ' LYS . 18.3 p-10 -136.31 135.81 39.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.202 -1.176 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.59 111.43 2.55 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -101.25 133.85 45.19 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -1.158 . . . . 0.0 109.46 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.8 t -72.18 140.01 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.534 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.467 HG22 HD11 ' A' ' 16' ' ' ILE . 20.1 mt -100.8 -39.34 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.372 -0.83 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -164.64 -173.94 3.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.506 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.4 tp -136.7 102.05 4.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.448 HD11 ' O ' ' A' ' 19' ' ' LEU . 1.2 pp -95.88 29.33 2.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.417 HG12 ' HA ' ' A' ' 32' ' ' LEU . 34.2 m -133.23 159.54 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -125.4 174.87 7.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -84.99 141.0 30.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.488 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.457 ' HA2' HG23 ' A' ' 51' ' ' VAL . . . 76.6 8.59 86.16 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.95 131.99 34.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.254 -1.145 . . . . 0.0 109.441 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.459 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.3 OUTLIER -86.01 111.7 20.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.507 HD11 HG22 ' A' ' 26' ' ' ILE . 2.7 mt -91.36 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.288 -0.883 . . . . 0.0 109.25 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -147.56 -174.51 4.56 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.925 . . . . 0.0 109.446 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.4 p -84.83 72.76 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.9 -40.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.459 179.955 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.525 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.6 tt0 -54.11 142.49 25.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.469 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.62 168.32 54.61 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.519 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -129.31 -40.26 1.46 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.234 -1.157 . . . . 0.0 109.56 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.513 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 13.0 m -161.01 176.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.112 -0.993 . . . . 0.0 109.534 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.9 t -131.9 97.9 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.422 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.07 146.25 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.439 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.95 177.84 6.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.0 m -136.33 160.91 37.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.87 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.11 -28.85 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.214 -0.929 . . . . 0.0 109.405 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.0 tttm -160.02 52.62 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 176.93 -166.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.174 -0.954 . . . . 0.0 109.476 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.2 t -152.73 140.8 20.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.46 150.53 42.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -0.893 . . . . 0.0 109.509 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.456 ' O ' HG21 ' A' ' 44' ' ' VAL . 4.8 pm0 -98.14 169.71 9.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 55.5 t -146.47 98.39 4.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.235 -0.915 . . . . 0.0 109.422 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.63 -169.05 0.67 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.437 2.091 . . . . 0.0 110.412 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.4 134.17 40.92 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.454 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.486 ' CG ' HG13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.96 -5.37 14.53 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.425 2.083 . . . . 0.0 110.399 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.469 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -160.41 144.99 14.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.326 -0.859 . . . . 0.0 109.513 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.5 99.18 3.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.421 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.437 ' CA ' HD13 ' A' ' 72' ' ' LEU . . . -153.79 175.65 32.02 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.459 ' HB ' HD21 ' A' ' 25' ' ' LEU . 11.3 p -95.78 145.16 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -1.131 . . . . 0.0 109.574 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -63.87 114.24 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.45 ' HD2' ' HB2' ' A' ' 73' ' ' GLU . 2.8 tttp -85.21 -56.74 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.5 m -143.86 127.44 17.02 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.498 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 t -96.23 128.78 47.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.448 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.9 m -119.59 34.0 5.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.425 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.54 157.5 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.47 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -141.08 149.53 41.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.918 . . . . 0.0 109.46 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.77 128.58 35.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.497 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.1 -23.2 29.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -80.78 148.89 29.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.184 -1.186 . . . . 0.0 109.489 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.488 ' CE ' ' OD2' ' A' ' 12' ' ' ASP . 3.1 tttt -103.14 112.99 26.11 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.916 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.478 HD21 ' CB ' ' A' ' 67' ' ' ASP . 12.6 mt -102.01 135.32 43.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.287 -0.883 . . . . 0.0 109.434 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -100.51 152.47 20.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.31 -0.869 . . . . 0.0 109.439 -179.956 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.9 pt-20 -42.88 150.49 0.16 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.55 -17.58 51.45 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.478 ' CB ' HD21 ' A' ' 63' ' ' LEU . 1.1 m-20 -84.0 131.21 34.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -1.131 . . . . 0.0 109.436 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -57.4 159.78 4.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.238 -0.914 . . . . 0.0 109.475 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 70' ' ' ILE . 33.0 mm -117.6 -58.15 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.486 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.462 HG22 HG21 ' A' ' 69' ' ' ILE . 2.4 pp -158.36 -177.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.239 -0.913 . . . . 0.0 109.43 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.407 ' HG2' HG13 ' A' ' 3' ' ' ILE . 57.5 mt-10 -133.58 127.46 33.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -99.5 142.47 30.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.484 -179.954 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HB2' ' HD2' ' A' ' 53' ' ' LYS . 0.2 OUTLIER -118.85 90.06 39.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.186 -0.946 . . . . 0.0 109.47 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.523 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.9 Cg_endo -78.26 174.57 12.24 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.625 2.217 . . . . 0.0 110.413 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -69.92 -170.86 0.36 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 109.422 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -96.94 25.96 4.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.435 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -45.54 -38.45 7.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -89.39 -176.73 5.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.281 -1.129 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.472 ' HB3' ' CZ ' ' A' ' 79' ' ' ARG . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.484 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 96.5 p . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.244 0.545 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -93.31 140.7 29.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 109.52 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.421 HG21 ' N ' ' A' ' 4' ' ' ILE . 18.0 mm -80.44 160.35 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.421 ' N ' HG21 ' A' ' 3' ' ' ILE . 96.6 mt -122.97 96.6 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.333 -0.855 . . . . 0.0 109.415 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.482 ' C ' ' CD1' ' A' ' 69' ' ' ILE . 0.1 OUTLIER -92.01 -178.76 5.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.289 -0.882 . . . . 0.0 109.558 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 75.8 t -70.93 142.7 88.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.369 -0.832 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.532 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.03 -170.02 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.494 2.13 . . . . 0.0 110.377 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.85 104.12 14.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.252 -0.905 . . . . 0.0 109.477 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.19 -41.68 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.208 -0.932 . . . . 0.0 109.273 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.88 -21.04 12.69 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.77 -142.25 3.91 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 3.1 m-20 -102.84 165.94 10.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.289 -1.124 . . . . 0.0 109.415 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.33 165.44 21.25 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -146.44 121.39 10.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.199 -1.177 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.428 HG12 ' CD1' ' A' ' 18' ' ' LEU . 21.6 t -70.23 149.49 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' ' OE1' ' A' ' 17' ' ' GLU . 69.1 mt -127.15 -40.01 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.284 -0.885 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -156.51 126.44 6.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.489 -179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.428 ' CD1' HG12 ' A' ' 15' ' ' VAL . 0.7 OUTLIER -102.41 141.53 35.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.428 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.407 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -132.61 61.54 1.67 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.498 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.78 164.42 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.466 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 28.6 mmtt -122.98 157.2 33.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 13.3 t -84.74 128.9 34.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.96 -9.17 73.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.466 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 1.6 m-20 -83.53 136.8 34.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -1.157 . . . . 0.0 109.551 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -86.18 126.5 34.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.491 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.443 HG23 ' HB2' ' A' ' 46' ' ' SER . 2.2 mt -90.33 -171.32 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.294 -0.879 . . . . 0.0 109.193 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -137.39 156.12 48.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.205 -0.934 . . . . 0.0 109.467 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.6 p -79.03 82.08 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.85 -35.89 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.395 -0.816 . . . . 0.0 109.433 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -71.59 152.13 43.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.44 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.492 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.32 -169.31 0.29 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.502 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.1 tp -153.31 -70.18 0.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -1.154 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.449 HG22 HD12 ' A' ' 35' ' ' LEU . 17.7 m -134.02 173.56 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 43' ' ' GLU . 97.1 t -133.73 102.33 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.449 HD12 HG22 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -109.29 170.07 8.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.311 -0.868 . . . . 0.0 109.525 179.935 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.85 137.25 51.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.482 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.64 176.89 5.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.21 -0.931 . . . . 0.0 109.5 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.55 -45.82 13.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.403 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.466 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 1.4 mttm -152.3 67.55 0.84 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.492 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' A' ' 39' ' ' LYS . . . 167.66 99.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.208 -0.932 . . . . 0.0 109.479 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.5 t -80.02 126.53 31.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.452 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -147.2 159.46 43.61 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -0.875 . . . . 0.0 109.512 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.441 ' HB3' HG21 ' A' ' 34' ' ' VAL . 3.5 pt-20 -109.4 169.3 8.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.39 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.502 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 94.7 t -132.5 139.36 34.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.405 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.492 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.97 -168.23 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.432 0 C-N-CA 122.549 2.166 . . . . 0.0 110.361 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.443 ' HB2' HG23 ' A' ' 26' ' ' ILE . 1.0 OUTLIER -85.16 113.55 50.93 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.385 -0.822 . . . . 0.0 109.365 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 36.0 Cg_endo -77.87 3.37 7.02 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.332 2.021 . . . . 0.0 110.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.502 ' HB3' ' CD2' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -160.02 110.28 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.465 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.2 90.62 1.6 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.939 . . . . 0.0 109.601 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.52 ' HA3' ' CD2' ' A' ' 72' ' ' LEU . . . -143.69 -157.73 7.29 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 11.1 p -111.48 128.53 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -1.148 . . . . 0.0 109.509 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.478 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 48.8 t -58.27 134.83 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.474 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.87 -33.28 7.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.291 -0.881 . . . . 0.0 109.458 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 173.27 144.31 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.509 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 57' ' ' VAL . 52.2 t -99.68 135.11 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.6 m -105.63 16.19 25.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.346 -0.846 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 55' ' ' VAL . 1.5 m -136.47 157.34 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.443 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -110.37 167.17 10.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.02 137.2 38.84 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.493 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.1 -11.07 68.41 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -79.21 148.4 32.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.5 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -82.64 165.37 20.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -148.77 113.42 5.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -86.03 137.78 32.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.241 -0.912 . . . . 0.0 109.455 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 64' ' ' LYS . 25.7 pt-20 -42.88 151.41 0.13 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 109.672 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.08 -18.2 41.99 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -85.0 141.68 30.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.262 -1.14 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.19 172.42 9.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.482 ' CD1' ' C ' ' A' ' 5' ' ' ARG . 2.0 mp -134.76 -58.49 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.431 HG21 ' HA ' ' A' ' 55' ' ' VAL . 7.4 pt -147.23 -179.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.461 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -131.18 117.33 18.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.52 ' CD2' ' HA3' ' A' ' 50' ' ' GLY . 0.7 OUTLIER -97.54 147.08 24.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -0.863 . . . . 0.0 109.486 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.514 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 2.5 tp10 -120.09 89.7 43.24 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.13 173.4 13.97 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.651 2.234 . . . . 0.0 110.375 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.477 ' O ' ' CB ' ' A' ' 76' ' ' ALA . . . -60.32 -84.97 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.164 -0.96 . . . . 0.0 109.447 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 75' ' ' ALA . . . 75.39 -168.3 0.09 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.285 -0.884 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.81 153.77 52.44 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.04 119.17 12.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -1.186 . . . . 0.0 109.467 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.403 ' HG3' HD12 ' A' ' 4' ' ' ILE . 11.4 tp10 -86.69 111.01 20.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.253 -0.904 . . . . 0.0 109.285 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.407 ' O ' HD12 ' A' ' 4' ' ' ILE . 2.2 tt -79.96 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.448 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.453 HG21 HD11 ' A' ' 4' ' ' ILE . 40.2 mm -122.78 122.77 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.564 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -92.11 -176.13 4.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.554 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.573 ' CG2' ' CD1' ' A' ' 69' ' ' ILE . 53.4 t -74.75 139.99 74.31 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.347 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.442 ' HD2' HG12 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.39 -174.37 2.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.549 2.166 . . . . 0.0 110.438 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -85.19 108.88 17.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.413 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.79 -7.27 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.281 -0.887 . . . . 0.0 109.396 -179.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.58 21.95 13.54 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 150.2 -133.53 4.4 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -85.54 170.85 12.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.243 -1.151 . . . . 0.0 109.464 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -141.05 148.25 19.9 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.419 ' HG3' ' HA ' ' A' ' 62' ' ' LYS . 1.0 OUTLIER -135.73 130.43 34.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -1.17 . . . . 0.0 109.484 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.444 ' HB ' ' HA2' ' A' ' 60' ' ' GLY . 38.2 t -70.1 147.2 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.439 HD12 ' HB2' ' A' ' 36' ' ' GLU . 42.7 mt -118.95 -53.91 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.326 -0.859 . . . . 0.0 109.558 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -134.34 133.81 41.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.431 ' CD1' HG13 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -115.24 102.47 9.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.496 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -93.66 41.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 m -143.74 156.08 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.533 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.07 -176.83 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.9 m -84.08 133.92 34.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.482 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.2 5.38 89.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.94 135.49 34.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -1.175 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.57 115.7 27.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.269 -0.895 . . . . 0.0 109.471 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.456 HD11 ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -90.46 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.322 -0.861 . . . . 0.0 109.219 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.437 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 1.8 mt-10 -135.37 177.68 7.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.478 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 14.3 p -85.4 59.89 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.588 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 3.3 tt0 167.5 -32.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.249 -0.907 . . . . 0.0 109.228 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -52.35 145.41 11.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.414 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -69.03 171.03 39.88 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -130.11 -56.04 1.11 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -1.156 . . . . 0.0 109.546 -179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.431 HG13 ' CD1' ' A' ' 18' ' ' LEU . 36.0 m -151.56 -176.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.496 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -139.01 97.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.418 HD22 HG21 ' A' ' 15' ' ' VAL . 3.1 mt -90.08 158.9 17.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.439 ' HB2' HD12 ' A' ' 16' ' ' ILE . 2.0 tt0 -123.27 153.04 40.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.408 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.6 m -130.25 -176.58 4.0 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.464 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.98 -34.62 65.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.249 -0.907 . . . . 0.0 109.484 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -159.9 61.19 0.36 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.402 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 177.14 88.21 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 109.491 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.421 ' HB3' ' CG ' ' A' ' 36' ' ' GLU . 99.6 p -105.1 112.97 26.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.383 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.2 mtt -130.02 -175.5 3.64 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.479 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.418 ' C ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -114.23 162.19 16.87 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.25 -0.906 . . . . 0.0 109.504 -179.943 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 59.2 t -137.53 117.57 10.35 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.33 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.96 -168.69 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.28 1.987 . . . . 0.0 110.434 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.479 ' CA ' HD11 ' A' ' 32' ' ' LEU . 6.0 t -85.27 138.08 36.7 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.402 -0.811 . . . . 0.0 109.328 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.82 -4.82 14.3 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.417 2.078 . . . . 0.0 110.478 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.523 ' HB3' ' CD2' ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.35 128.1 4.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -0.859 . . . . 0.0 109.521 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.437 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . . . -70.86 98.51 1.58 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.903 . . . . 0.0 109.501 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.428 ' C ' HD13 ' A' ' 72' ' ' LEU . . . -152.12 -135.98 2.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.42 ' N ' HD13 ' A' ' 72' ' ' LEU . 10.0 p -132.27 151.36 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.189 -1.183 . . . . 0.0 109.439 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.413 ' N ' HG21 ' A' ' 51' ' ' VAL . 16.5 t -73.49 119.95 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -91.97 -43.21 9.57 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.916 . . . . 0.0 109.407 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.8 t -149.48 142.84 25.23 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 21.0 t -105.02 106.79 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.86 10.56 13.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.288 -0.883 . . . . 0.0 109.436 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.2 m -124.98 177.73 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.305 -0.872 . . . . 0.0 109.5 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.465 ' CB ' ' CG ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -128.48 -156.02 0.73 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.87 80.67 9.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.444 ' HA2' ' HB ' ' A' ' 15' ' ' VAL . . . 74.89 46.22 18.03 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.465 ' CG ' ' CB ' ' A' ' 58' ' ' LYS . 4.9 m-20 -84.96 172.24 11.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.296 -1.12 . . . . 0.0 109.435 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.419 ' HA ' ' HG3' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -97.62 145.3 26.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.196 -0.94 . . . . 0.0 109.447 -179.92 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.92 -172.52 4.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.467 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -138.45 147.08 42.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.86 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.474 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 4.2 pt-20 -45.39 148.86 0.6 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.273 -0.892 . . . . 0.0 109.694 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 5' ' ' ARG . . . 85.86 -43.51 3.25 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 68' ' ' ALA . 0.9 OUTLIER -50.76 134.46 24.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -1.128 . . . . 0.0 109.602 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -48.21 174.04 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -0.886 . . . . 0.0 109.535 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.573 ' CD1' ' CG2' ' A' ' 6' ' ' VAL . 26.9 mm -143.51 -58.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.238 -0.914 . . . . 0.0 109.498 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.432 ' C ' ' CD1' ' A' ' 70' ' ' ILE . 2.4 pp -150.98 179.56 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.482 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -145.56 97.25 2.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.511 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD2' ' HB3' ' A' ' 48' ' ' LYS . 0.4 OUTLIER -90.76 124.86 35.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.238 -0.914 . . . . 0.0 109.433 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.517 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 37.1 tt0 -91.42 140.99 25.6 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.254 -0.903 . . . . 0.0 109.374 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.6 Cg_endo -78.38 -54.97 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.486 2.124 . . . . 0.0 110.373 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . 178.9 168.99 0.92 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -142.3 -57.29 0.45 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.4 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 64.88 161.75 0.61 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -98.41 172.25 7.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.485 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.4 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 5.4 ttt180 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.464 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.416 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 23.4 p . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -126.77 147.55 49.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 109.403 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.49 HG13 ' CG ' ' A' ' 71' ' ' GLU . 3.5 mp -85.11 162.88 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.211 -0.931 . . . . 0.0 109.484 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.454 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 3.0 mp -127.75 104.27 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.469 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 4.3 ptp85 -93.03 -172.44 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.145 -0.972 . . . . 0.0 109.473 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.519 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 42.0 t -73.99 136.59 76.4 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.297 -0.877 . . . . 0.0 109.389 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.436 ' HD2' HG12 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.94 -176.61 3.38 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.481 2.121 . . . . 0.0 110.383 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -85.18 101.21 12.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.183 -0.948 . . . . 0.0 109.322 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.71 -45.95 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.249 -0.907 . . . . 0.0 109.259 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.78 16.07 11.25 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.7 -159.42 16.64 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 7.5 m-20 -104.31 119.82 39.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -1.167 . . . . 0.0 109.516 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.4 151.62 23.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.5 mp0 -131.58 119.82 22.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.246 -1.149 . . . . 0.0 109.442 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.465 ' CG2' HD13 ' A' ' 63' ' ' LEU . 39.8 t -65.37 134.67 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.495 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.2 mm -115.19 -52.74 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.438 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -129.09 123.47 32.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.499 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HG ' HG23 ' A' ' 20' ' ' VAL . 5.9 tp -99.84 115.37 29.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.893 . . . . 0.0 109.465 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -113.55 57.18 0.68 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.482 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.443 HG12 ' HG ' ' A' ' 32' ' ' LEU . 29.3 m -139.73 158.44 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.263 -0.898 . . . . 0.0 109.435 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.26 162.6 33.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -0.956 . . . . 0.0 109.46 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.413 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 0.2 OUTLIER -84.93 125.61 32.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.259 -0.901 . . . . 0.0 109.512 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.501 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.03 -8.95 67.88 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -78.63 132.05 36.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -1.138 . . . . 0.0 109.5 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.462 HD11 ' N ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -85.35 115.71 23.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.497 ' CD1' HD12 ' A' ' 32' ' ' LEU . 2.6 mt -91.99 -171.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.3 -0.875 . . . . 0.0 109.211 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 20.0 pt-20 -146.3 172.33 13.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.415 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 11.6 p -81.12 74.83 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.211 -0.93 . . . . 0.0 109.357 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.4 tm-20 167.87 -39.37 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.332 -0.855 . . . . 0.0 109.299 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -62.47 144.64 55.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.393 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.478 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -72.32 164.34 54.51 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 2.6 tp -124.61 -38.37 2.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -1.166 . . . . 0.0 109.398 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.487 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 9.3 m -157.77 167.26 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.9 t -131.47 105.04 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.468 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.449 ' CD1' HG22 ' A' ' 33' ' ' VAL . 9.8 mp -90.23 148.69 22.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -138.56 116.78 11.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.547 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.0 m -100.1 -175.74 3.03 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.26 -0.9 . . . . 0.0 109.449 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.79 -42.22 16.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -154.62 57.45 0.69 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -167.87 97.12 0.45 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.926 . . . . 0.0 109.51 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.5 m -99.7 120.64 40.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.436 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 17.2 mtp -128.63 134.25 48.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.443 ' O ' HG21 ' A' ' 44' ' ' VAL . 26.0 tt0 -91.56 162.73 14.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.2 -0.937 . . . . 0.0 109.387 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -144.45 99.17 4.91 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.33 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.42 -168.6 0.61 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.526 2.151 . . . . 0.0 110.477 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 1.1 t -85.34 127.45 63.64 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.22 -0.925 . . . . 0.0 109.377 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.43 -2.51 12.56 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.345 2.03 . . . . 0.0 110.43 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 2.4 mtmt -160.19 143.11 13.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.389 -0.819 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.81 97.95 7.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.458 ' O ' HD11 ' A' ' 25' ' ' LEU . . . -147.0 -172.51 17.34 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.501 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 2.5 p -104.63 127.47 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.456 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.413 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 50.5 t -50.57 133.91 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 18.1 tttt -101.99 -58.8 1.81 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -0.922 . . . . 0.0 109.496 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.56 153.87 36.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 109.474 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.452 ' HA ' HG21 ' A' ' 70' ' ' ILE . 9.1 t -103.16 131.68 51.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.266 -0.896 . . . . 0.0 109.493 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.0 m -113.62 19.83 16.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.244 -0.91 . . . . 0.0 109.462 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.441 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 17.8 m -132.71 -178.62 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.945 . . . . 0.0 109.396 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.6 ttpt -138.91 158.6 43.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.472 ' CD1' ' O ' ' A' ' 59' ' ' LEU . 3.4 pp -76.68 123.02 25.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.243 -0.911 . . . . 0.0 109.492 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.97 -8.35 73.28 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -78.01 144.16 36.91 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.268 -1.136 . . . . 0.0 109.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 62' ' ' LYS . 1.8 pptp? -91.13 122.91 34.18 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.24 -0.913 . . . . 0.0 109.507 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.465 HD13 ' CG2' ' A' ' 15' ' ' VAL . 19.2 mt -102.74 152.14 21.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.895 . . . . 0.0 109.442 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -122.54 152.45 40.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.436 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.519 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 77.2 mt-10 -47.7 148.11 1.64 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.245 -0.909 . . . . 0.0 109.725 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.03 -40.19 3.09 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -61.97 131.6 50.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -1.158 . . . . 0.0 109.549 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.469 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -62.1 -174.88 0.06 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.454 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 44.2 mm -146.45 -64.99 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.874 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.516 ' CD1' HD22 ' A' ' 32' ' ' LEU . 2.8 pt -148.56 -172.45 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.297 -0.877 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.49 ' CG ' HG13 ' A' ' 3' ' ' ILE . 1.7 tt0 -142.99 117.48 9.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.589 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.519 ' CD2' ' HD3' ' A' ' 74' ' ' PRO . 0.5 OUTLIER -95.47 137.38 34.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.382 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.436 ' O ' HG13 ' A' ' 51' ' ' VAL . 3.4 tt0 -115.71 85.84 14.81 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.519 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.08 131.83 11.18 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.654 2.236 . . . . 0.0 110.371 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -138.31 110.49 7.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.217 -0.927 . . . . 0.0 109.516 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -141.81 95.5 2.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 109.478 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 148.06 157.14 7.35 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 67.28 19.83 10.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.316 -1.109 . . . . 0.0 109.486 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.444 -179.929 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.455 HD11 ' HG2' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.463 ' O ' HD13 ' A' ' 69' ' ' ILE . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.453 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.56 ' CG2' ' CB ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.458 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.445 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.464 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.521 HD23 ' CB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.523 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.47 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.42 HG11 ' OG ' ' A' ' 41' ' ' SER . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.542 ' CD2' ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.42 ' OG ' HG11 ' A' ' 34' ' ' VAL . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.436 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.508 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.523 ' CB ' HG23 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.521 ' O ' ' CG ' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.519 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.521 ' CB ' HD23 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.464 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 57' ' ' VAL . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.428 ' C ' HG11 ' A' ' 57' ' ' VAL . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.425 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.56 ' CB ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.453 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.464 HD13 HD23 ' A' ' 32' ' ' LEU . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.455 ' HG2' HD11 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.519 HD12 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.3 Cg_endo -78.19 131.14 10.62 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -92.45 123.69 35.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.11 -63.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.54 76.87 0.07 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -99.88 134.51 42.68 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.226 -1.161 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.456 -179.994 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.455 HD11 ' HG2' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.463 ' O ' HD13 ' A' ' 69' ' ' ILE . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.453 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.56 ' CG2' ' CB ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.458 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.445 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.464 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.521 HD23 ' CB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.523 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.47 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.42 HG11 ' OG ' ' A' ' 41' ' ' SER . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.542 ' CD2' ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.42 ' OG ' HG11 ' A' ' 34' ' ' VAL . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.436 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.508 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.523 ' CB ' HG23 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.521 ' O ' ' CG ' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.519 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.521 ' CB ' HD23 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.464 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 57' ' ' VAL . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.428 ' C ' HG11 ' A' ' 57' ' ' VAL . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.425 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.56 ' CB ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.453 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.464 HD13 HD23 ' A' ' 32' ' ' LEU . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.455 ' HG2' HD11 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.519 HD12 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.3 Cg_endo -78.19 131.14 10.62 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -92.45 123.69 35.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.11 -63.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.54 76.87 0.07 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -99.88 134.51 42.68 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.226 -1.161 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.456 -179.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.409 ' O ' ' HG2' ' A' ' 2' ' ' GLU . 48.4 p . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.295 0.569 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.409 ' HG2' ' O ' ' A' ' 1' ' ' SER . 14.0 mt-10 -145.28 145.35 31.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.464 HG21 ' N ' ' A' ' 4' ' ' ILE . 21.2 mt -85.13 148.89 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.197 -0.939 . . . . 0.0 109.45 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.465 HG12 ' HG3' ' A' ' 47' ' ' PRO . 2.3 mp -116.14 108.01 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 1.2 ptp85 -98.71 176.73 5.53 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 78.9 t -74.04 142.43 79.36 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.319 -0.863 . . . . 0.0 109.359 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.532 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.82 -171.53 1.22 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.463 2.109 . . . . 0.0 110.435 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -85.03 104.88 15.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.59 -31.13 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.226 -0.921 . . . . 0.0 109.215 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.68 -11.41 59.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.03 145.07 15.09 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -45.96 151.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.505 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.17 119.9 3.58 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -86.77 129.01 35.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.479 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.3 t -76.5 131.94 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.413 ' HB ' ' O ' ' A' ' 34' ' ' VAL . 39.5 mt -95.04 -51.17 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.169 -0.957 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -174.07 163.5 3.96 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.474 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.417 HD21 HG21 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -108.41 139.21 43.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 109.449 -179.99 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.7 15.11 11.68 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.417 HG21 HD21 ' A' ' 18' ' ' LEU . 1.9 m -149.87 164.22 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.887 . . . . 0.0 109.527 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -114.9 -163.87 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.337 -0.852 . . . . 0.0 109.493 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.4 t -84.96 139.86 31.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.302 -0.874 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.01 8.37 61.2 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.423 ' C ' HG22 ' A' ' 51' ' ' VAL . 11.7 m-20 -84.95 133.02 34.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.207 -1.173 . . . . 0.0 109.522 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 1.1 tp -79.98 125.49 29.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.268 -0.895 . . . . 0.0 109.475 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.447 HG23 ' HB3' ' A' ' 46' ' ' SER . 2.7 mt -92.04 -171.41 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.251 -0.906 . . . . 0.0 109.204 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.16 175.39 9.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 11.6 p -85.15 64.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.505 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.88 -43.68 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.496 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.9 tt0 -45.25 149.59 0.5 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.518 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.462 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -74.39 166.89 54.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.517 ' N ' ' HA ' ' A' ' 45' ' ' PRO . 0.4 OUTLIER -126.94 -37.5 2.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -1.175 . . . . 0.0 109.561 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.442 HG21 ' HB ' ' A' ' 44' ' ' VAL . 23.5 m -152.85 154.32 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.561 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.422 HG23 ' OE2' ' A' ' 43' ' ' GLU . 60.5 t -125.74 91.93 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.307 -0.871 . . . . 0.0 109.419 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.414 ' CD1' HG22 ' A' ' 33' ' ' VAL . 6.3 mp -89.98 153.75 20.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.51 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -143.36 134.46 25.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.274 -0.891 . . . . 0.0 109.467 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.61 174.24 7.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.881 . . . . 0.0 109.547 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.0 -13.18 57.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.46 -56.27 3.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -0.935 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -164.72 -149.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.927 . . . . 0.0 109.401 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.7 p -136.34 144.59 44.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -136.85 -175.97 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.422 ' OE2' HG23 ' A' ' 34' ' ' VAL . 6.4 tt0 -150.24 162.18 40.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.52 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 38.2 t -147.5 101.37 3.76 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.262 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.517 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.6 Cg_endo -77.2 -168.94 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.399 2.066 . . . . 0.0 110.506 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 3.8 t -85.28 132.52 44.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.441 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.465 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.87 -5.28 14.55 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 C-N-CA 122.489 2.126 . . . . 0.0 110.402 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' A' ' 46' ' ' SER . 5.6 tptt -160.23 144.71 14.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.35 -0.844 . . . . 0.0 109.491 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.95 91.05 4.17 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.501 ' N ' HD23 ' A' ' 72' ' ' LEU . . . -139.69 -135.19 3.22 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.509 ' N ' ' CD1' ' A' ' 72' ' ' LEU . 7.2 p -149.08 150.57 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -1.178 . . . . 0.0 109.535 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.407 ' N ' HG21 ' A' ' 51' ' ' VAL . 58.0 t -73.01 129.45 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.407 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 3.5 tttp -113.63 -27.59 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.266 -0.896 . . . . 0.0 109.564 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -154.61 128.28 8.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.176 -0.953 . . . . 0.0 109.508 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.8 t -113.08 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.465 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.37 34.79 4.95 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.418 HG12 ' HA ' ' A' ' 69' ' ' ILE . 3.4 m -140.75 170.18 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.26 -0.9 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.434 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -132.59 157.77 43.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.926 . . . . 0.0 109.454 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -83.09 131.79 35.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.496 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.81 -11.48 68.72 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.434 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.7 OUTLIER -81.65 163.93 22.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -1.182 . . . . 0.0 109.435 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 mttt -104.13 120.24 40.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.475 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -105.47 137.28 43.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.467 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -101.47 140.32 35.93 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.278 -0.888 . . . . 0.0 109.469 179.964 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.464 ' HA ' HG13 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -42.76 151.6 0.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.29 -0.881 . . . . 0.0 109.675 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.09 -24.54 21.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.47 134.49 34.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.289 -1.124 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -59.23 179.23 0.11 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.513 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.507 ' CD1' HG21 ' A' ' 6' ' ' VAL . 31.8 mm -134.73 -67.63 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.178 -0.951 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.82 -172.1 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.442 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -144.62 136.48 25.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.514 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.509 ' CD1' ' N ' ' A' ' 51' ' ' VAL . 1.3 tp -113.01 112.32 23.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.407 ' OE1' ' HE2' ' A' ' 53' ' ' LYS . 23.7 tt0 -113.78 90.38 18.48 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.8 Cg_endo -78.1 -85.54 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.612 2.208 . . . . 0.0 110.484 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.404 ' CB ' ' O ' ' A' ' 74' ' ' PRO . . . 170.39 67.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.425 ' O ' ' O ' ' A' ' 77' ' ' GLY . . . -77.13 147.97 36.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . -47.44 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 179.81 -161.51 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -1.171 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.928 -1.034 . . . . 0.0 109.409 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 48.6 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -97.02 175.75 6.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.473 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mp -104.76 146.97 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.493 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.2 mt -104.25 99.26 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.428 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -91.26 165.62 13.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.344 -0.847 . . . . 0.0 109.458 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.8 t -55.0 142.22 57.05 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.888 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.14 -172.58 1.53 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.489 2.126 . . . . 0.0 110.387 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -84.03 104.33 14.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.902 . . . . 0.0 109.503 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.79 -41.42 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.297 -0.877 . . . . 0.0 109.354 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.69 10.73 52.5 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -146.04 -125.14 1.68 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.65 123.67 38.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.15 . . . . 0.0 109.393 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.68 147.43 50.94 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.07 101.79 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -1.119 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.436 HG13 ' HA ' ' A' ' 59' ' ' LEU . 38.4 t -48.44 149.76 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.492 HD12 ' CA ' ' A' ' 36' ' ' GLU . 43.9 mt -127.16 -62.22 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 109.454 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -150.11 149.74 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.457 ' CD2' HG21 ' A' ' 20' ' ' VAL . 2.8 tp -119.47 138.84 52.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.453 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -127.98 54.35 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.516 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.457 HG21 ' CD2' ' A' ' 18' ' ' LEU . 15.3 m -144.42 159.8 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.17 -0.956 . . . . 0.0 109.399 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.494 ' CB ' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -111.37 -171.18 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 109.548 179.954 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.4 m -85.18 119.39 25.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.78 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 52' ' ' VAL . . . 72.37 2.17 53.64 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.639 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.494 ' CG ' ' CB ' ' A' ' 21' ' ' LYS . 2.1 m-20 -69.7 129.44 39.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.299 . . . . 0.0 109.123 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.0 OUTLIER -90.93 144.14 25.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.413 -0.805 . . . . 0.0 109.728 -179.697 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.525 ' CD1' ' HA3' ' A' ' 50' ' ' GLY . 1.3 mt -114.58 -170.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.411 ' H ' ' CG2' ' A' ' 26' ' ' ILE . 0.2 OUTLIER -100.46 172.45 7.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.079 -1.013 . . . . 0.0 109.405 179.963 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.497 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 14.8 p -83.89 68.64 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.497 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 163.03 -29.73 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -60.13 151.59 26.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.517 179.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -67.06 163.61 44.84 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.509 HD21 ' CD1' ' A' ' 70' ' ' ILE . 0.2 OUTLIER -125.75 -38.81 2.18 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.537 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 32' ' ' LEU . 28.7 m -152.23 171.64 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.422 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 60.7 t -127.91 95.67 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.309 -0.87 . . . . 0.0 109.417 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 mt -89.88 162.14 15.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.922 . . . . 0.0 109.558 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.492 ' CA ' HD12 ' A' ' 16' ' ' ILE . 8.2 tt0 -114.99 164.13 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -135.43 -177.07 4.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -56.49 -44.06 80.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -0.886 . . . . 0.0 109.471 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.47 48.42 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -176.0 124.03 0.19 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.522 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.0 125.68 32.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.342 -0.849 . . . . 0.0 109.484 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.437 ' SD ' ' HG2' ' A' ' 7' ' ' PRO . 2.3 ptm -115.98 129.9 56.58 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -96.64 167.18 11.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.208 -0.933 . . . . 0.0 109.415 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 2.7 t -144.37 100.1 4.86 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.242 -0.911 . . . . 0.0 109.366 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.2 Cg_endo -77.68 -170.03 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.411 2.074 . . . . 0.0 110.359 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.459 ' HB2' HD13 ' A' ' 32' ' ' LEU . 6.3 t -85.96 142.66 36.61 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.432 -0.792 . . . . 0.0 109.364 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.461 ' O ' ' HG3' ' A' ' 48' ' ' LYS . 35.7 Cg_endo -78.37 -10.94 16.07 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.484 2.122 . . . . 0.0 110.174 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' HG3' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.37 -91.73 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.559 -0.713 . . . . 0.0 109.121 179.887 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.442 ' HB2' HD22 ' A' ' 25' ' ' LEU . . . -85.2 -92.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.29 -0.882 . . . . 0.0 109.229 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.525 ' HA3' ' CD1' ' A' ' 26' ' ' ILE . . . 139.98 41.04 0.08 OUTLIER Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.519 ' CG1' ' O ' ' A' ' 51' ' ' VAL . 7.1 p -95.56 115.15 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.1 -1.235 . . . . 0.0 109.346 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.468 ' O ' ' HA2' ' A' ' 23' ' ' GLY . 40.6 t -69.26 116.15 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.443 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -108.21 -25.25 11.16 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.174 -0.954 . . . . 0.0 109.513 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.85 123.33 1.73 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.514 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 90.1 t -112.58 135.27 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.464 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -126.38 39.73 3.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.484 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 27.1 m -149.91 167.23 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.2 tttt -125.39 167.99 14.18 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.436 ' HA ' HG13 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -84.43 87.42 7.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.999 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.6 -11.87 4.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.42 ' O ' HG22 ' A' ' 15' ' ' VAL . 32.9 m-20 -75.45 146.67 40.5 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -1.118 . . . . 0.0 109.566 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.403 ' C ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -105.14 146.62 28.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.209 -0.932 . . . . 0.0 109.484 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.403 ' HG ' ' C ' ' A' ' 62' ' ' LYS . 13.8 mt -141.47 178.42 7.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.477 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' GLU . 8.7 tttp -118.58 149.32 41.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.181 -0.949 . . . . 0.0 109.537 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.3 pt-20 -42.71 150.33 0.16 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.337 -0.852 . . . . 0.0 109.627 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.68 -15.33 55.41 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -82.28 132.26 35.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -1.148 . . . . 0.0 109.544 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -63.85 161.59 15.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.432 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.484 ' HA ' ' CG1' ' A' ' 57' ' ' VAL . 43.9 mm -128.01 -59.71 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.887 . . . . 0.0 109.522 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.509 ' CD1' HD21 ' A' ' 32' ' ' LEU . 3.4 pt -141.44 -171.94 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.51 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -145.8 109.2 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.602 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.519 HD13 ' N ' ' A' ' 50' ' ' GLY . 2.0 tt -90.02 145.42 25.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.3 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.448 ' O ' HD22 ' A' ' 72' ' ' LEU . 1.4 mt-10 -106.09 146.27 32.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.52 ' O ' ' CB ' ' A' ' 75' ' ' ALA . 36.1 Cg_endo -78.34 -22.39 9.61 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.587 2.191 . . . . 0.0 110.431 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 74' ' ' PRO . . . 76.08 50.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.496 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -137.2 78.97 1.72 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -167.39 -92.11 0.08 OUTLIER Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -53.45 178.03 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.51 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.6 mtm105 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.429 -179.987 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.449 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 2.5 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mt-10 -125.2 169.19 12.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.24 -0.913 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mt -99.61 137.34 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.446 HD11 HG22 ' A' ' 4' ' ' ILE . 31.6 mm -113.82 119.05 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.239 -0.913 . . . . 0.0 109.485 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.455 ' C ' ' CD1' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -106.23 -177.96 3.51 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.476 -179.927 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.518 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.6 t -81.0 142.27 51.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.355 -0.841 . . . . 0.0 109.342 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.518 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.07 -170.74 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.607 2.205 . . . . 0.0 110.433 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -84.51 104.69 14.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.224 -0.923 . . . . 0.0 109.437 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.438 HD13 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.97 -21.65 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.281 -0.887 . . . . 0.0 109.295 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.78 21.63 76.29 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.0 -165.92 25.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -97.2 140.34 31.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -1.168 . . . . 0.0 109.459 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -111.14 105.17 1.83 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.8 mm-40 -97.22 130.22 44.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.422 HG23 ' CD2' ' A' ' 35' ' ' LEU . 60.3 t -72.91 119.42 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.496 ' CG2' ' O ' ' A' ' 34' ' ' VAL . 1.6 tt -112.55 -24.33 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.451 ' N ' HG21 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -145.99 140.44 26.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.51 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.412 HD22 HG21 ' A' ' 20' ' ' VAL . 0.3 OUTLIER -132.55 127.37 34.96 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.473 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.7 47.32 1.82 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.897 . . . . 0.0 109.414 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.516 ' CG1' HD12 ' A' ' 32' ' ' LEU . 3.2 m -150.07 158.19 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.6 mmtt -138.05 -174.0 3.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.9 m -84.4 141.18 31.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.481 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.7 1.83 62.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.89 130.27 34.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -1.196 . . . . 0.0 109.485 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -86.12 119.3 26.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.88 . . . . 0.0 109.387 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.518 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.4 mt -90.01 -171.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.209 -0.932 . . . . 0.0 109.201 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -150.17 163.34 38.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.433 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.49 147.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.161 -0.962 . . . . 0.0 109.411 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 83.07 -43.61 0.11 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.688 -0.632 . . . . 0.0 109.863 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.524 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -55.41 144.27 26.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.078 -1.014 . . . . 0.0 109.43 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.478 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -69.32 172.38 38.27 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -133.04 -51.84 0.9 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.542 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.9 m -153.6 175.75 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.141 -0.974 . . . . 0.0 109.617 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.496 ' O ' ' CG2' ' A' ' 16' ' ' ILE . 84.4 t -130.8 94.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.87 . . . . 0.0 109.425 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 13.2 mt -90.14 151.86 21.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -106.05 112.02 24.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.291 -0.881 . . . . 0.0 109.432 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.64 -172.12 3.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -0.907 . . . . 0.0 109.525 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.32 6.64 13.67 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.51 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.454 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -112.47 -36.89 5.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.178 -0.951 . . . . 0.0 109.518 179.93 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' A' ' 39' ' ' LYS . . . 174.44 -152.37 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.243 -0.911 . . . . 0.0 109.429 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 8.3 t -106.05 112.55 25.64 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.251 -0.906 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -106.95 151.81 24.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.46 ' HG3' HG21 ' A' ' 34' ' ' VAL . 40.1 tt0 -110.31 150.43 28.77 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.176 -0.952 . . . . 0.0 109.452 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.8 t -132.73 118.24 15.51 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.897 . . . . 0.0 109.261 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.1 Cg_endo -77.7 -168.65 0.63 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.33 2.02 . . . . 0.0 110.451 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.518 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -85.35 126.32 67.34 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.345 -0.847 . . . . 0.0 109.339 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.44 -0.9 11.12 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.377 2.052 . . . . 0.0 110.374 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.18 127.31 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.76 99.54 5.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 109.46 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.508 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -155.93 -137.79 2.42 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.464 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 9.5 p -137.19 146.94 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.202 -1.176 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 52.2 t -69.73 133.39 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.303 -0.873 . . . . 0.0 109.518 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -110.79 -58.23 2.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.313 -0.867 . . . . 0.0 109.482 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 14.1 m -124.52 164.95 18.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.43 ' HA ' HG21 ' A' ' 70' ' ' ILE . 53.7 t -124.74 118.98 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.268 -0.895 . . . . 0.0 109.452 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.21 15.25 27.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.409 HG13 HD13 ' A' ' 63' ' ' LEU . 21.0 m -149.85 173.44 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.241 -0.912 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 tptt -134.47 173.67 11.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.253 -0.905 . . . . 0.0 109.46 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.73 124.29 31.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.65 -10.71 57.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.74 165.35 21.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -1.093 . . . . 0.0 109.571 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 165.12 13.06 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.409 HD13 HG13 ' A' ' 57' ' ' VAL . 5.3 mt -149.35 104.97 3.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.8 OUTLIER -86.99 137.89 31.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 10.3 pt-20 -42.77 151.57 0.12 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.19 -19.75 37.31 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -84.87 144.9 28.1 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.246 -1.15 . . . . 0.0 109.483 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -72.56 -178.8 2.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.477 HD13 ' N ' ' A' ' 6' ' ' VAL . 2.0 mp -139.82 -68.08 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.412 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.43 HG21 ' HA ' ' A' ' 55' ' ' VAL . 1.0 OUTLIER -148.9 -177.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.448 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -132.89 117.83 18.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 50' ' ' GLY . 2.8 tt -93.78 143.33 26.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.204 -0.935 . . . . 0.0 109.526 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -113.53 91.03 19.15 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.363 -0.836 . . . . 0.0 109.381 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.02 177.9 8.23 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.668 2.246 . . . . 0.0 110.441 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -170.76 153.08 3.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.27 -0.894 . . . . 0.0 109.385 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -93.25 155.07 17.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.392 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.34 -48.15 5.18 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 47.13 55.72 7.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -1.168 . . . . 0.0 109.495 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.482 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 76.8 p . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.284 0.564 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.6 mt-10 -139.37 160.61 39.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.48 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.5 mp -85.17 136.07 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.905 . . . . 0.0 109.528 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.466 HD11 ' HG2' ' A' ' 47' ' ' PRO . 10.3 mt -105.49 120.21 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.92 168.55 10.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.189 -0.944 . . . . 0.0 109.486 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 78.3 t -49.68 142.48 12.17 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.268 -0.895 . . . . 0.0 109.322 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.69 -174.72 2.34 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.462 2.108 . . . . 0.0 110.393 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.91 100.86 8.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.41 -14.91 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.272 -0.892 . . . . 0.0 109.291 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.38 -21.26 32.87 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -128.82 -145.5 5.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.95 142.3 30.63 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -1.163 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.15 103.29 2.13 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.1 mt-10 -101.7 119.75 39.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.296 -1.12 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.496 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . 39.7 t -78.83 131.93 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.464 179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 34' ' ' VAL . 8.8 mm -108.93 -40.48 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.9 . . . . 0.0 109.498 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.422 ' HG3' ' O ' ' A' ' 16' ' ' ILE . 64.9 mt-10 -157.17 -177.77 6.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.426 -179.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.3 tp -137.03 145.96 44.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.471 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 HD13 ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -136.8 36.35 2.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.554 -179.95 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.7 m -149.94 156.61 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.29 -0.881 . . . . 0.0 109.558 179.976 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.24 175.71 5.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.181 -0.949 . . . . 0.0 109.469 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.417 ' HA ' HG13 ' A' ' 52' ' ' VAL . 5.6 m -84.95 146.39 27.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.546 -179.933 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.48 3.32 86.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.02 133.14 34.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -1.165 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.486 ' CD2' ' HB ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -83.65 108.12 16.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.197 -0.939 . . . . 0.0 109.432 -179.991 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.46 HG23 ' HB3' ' A' ' 46' ' ' SER . 2.8 mt -92.53 -171.4 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 15.1 mt-10 -147.03 -178.95 6.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.421 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 12.4 p -82.7 73.67 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.87 -42.36 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.334 -0.853 . . . . 0.0 109.435 179.836 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.6 tt0 -50.81 135.69 23.49 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.174 -0.954 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -52.88 179.99 0.08 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -146.24 -67.99 0.28 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.21 -1.171 . . . . 0.0 109.535 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.9 m -133.01 169.63 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.47 ' CG2' ' HG2' ' A' ' 43' ' ' GLU . 24.4 t -119.09 79.2 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.261 -0.899 . . . . 0.0 109.452 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.496 ' CD2' ' HA ' ' A' ' 15' ' ' VAL . 5.9 mt -90.05 151.73 21.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.53 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.414 ' HG3' ' OG ' ' A' ' 41' ' ' SER . 2.3 tm-20 -140.79 141.84 34.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.33 -0.857 . . . . 0.0 109.495 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.03 -177.95 3.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -0.896 . . . . 0.0 109.523 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.95 -12.46 37.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.278 -0.889 . . . . 0.0 109.472 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.51 -67.96 0.77 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.264 -0.897 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.19 175.41 14.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -0.937 . . . . 0.0 109.461 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.414 ' OG ' ' HG3' ' A' ' 36' ' ' GLU . 0.9 OUTLIER -95.01 137.21 34.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 109.473 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.22 124.83 11.76 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.916 . . . . 0.0 109.5 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.47 ' HG2' ' CG2' ' A' ' 34' ' ' VAL . 7.1 mt-10 -84.52 166.86 16.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.488 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.496 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 54.1 t -137.03 134.59 19.09 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.24 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.23 -168.4 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.412 2.075 . . . . 0.0 110.316 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.46 ' HB3' HG23 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -85.1 130.88 50.4 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.302 -0.874 . . . . 0.0 109.353 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.466 ' HG2' HD11 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.53 -1.48 11.64 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.416 2.078 . . . . 0.0 110.394 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.448 ' O ' ' OG ' ' A' ' 46' ' ' SER . 33.6 ttmt -160.28 140.69 11.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 109.561 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.09 101.21 12.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.925 . . . . 0.0 109.493 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.508 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -158.58 -162.35 11.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.486 ' HB ' ' CD2' ' A' ' 25' ' ' LEU . 9.9 p -111.03 129.17 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.295 -1.12 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.417 HG13 ' HA ' ' A' ' 22' ' ' THR . 46.8 t -54.02 138.63 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.49 179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.12 -35.67 4.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 t -174.78 149.48 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.175 -0.953 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.1 t -108.53 148.45 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.452 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.424 ' O ' HG11 ' A' ' 57' ' ' VAL . 59.4 m -113.35 18.22 17.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 179.901 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.424 HG11 ' O ' ' A' ' 56' ' ' SER . 30.2 m -147.12 158.47 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.503 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.429 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -120.17 -175.21 2.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 -179.946 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.414 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -77.04 147.75 36.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.265 -0.897 . . . . 0.0 109.416 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.33 11.62 53.05 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.429 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -84.74 132.25 34.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.186 -1.185 . . . . 0.0 109.492 179.997 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.56 118.37 36.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.1 mp -122.6 162.55 21.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.1 tttp -102.75 146.79 27.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.431 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.5 OUTLIER -42.9 148.04 0.27 Allowed 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.312 -0.868 . . . . 0.0 109.661 -179.877 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.7 -8.07 74.0 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 1.2 m-20 -83.96 140.18 32.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -1.103 . . . . 0.0 109.487 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.36 164.16 0.21 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.422 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.45 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 17.7 mm -141.13 -54.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.182 -0.948 . . . . 0.0 109.449 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -150.65 -178.23 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.931 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -139.43 135.61 33.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.508 HD12 ' N ' ' A' ' 50' ' ' GLY . 1.5 tt -116.44 146.76 42.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 23.6 tt0 -118.35 88.62 33.73 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.486 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.9 Cg_endo -77.95 106.76 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.568 2.178 . . . . 0.0 110.466 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -99.64 178.62 4.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.253 -0.904 . . . . 0.0 109.461 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -160.67 143.03 12.76 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 179.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -142.57 140.75 10.12 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -69.9 103.76 2.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.184 -1.186 . . . . 0.0 109.443 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.452 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.4 p . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 20.9 mp0 -89.43 161.81 16.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.34 -0.85 . . . . 0.0 109.459 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.486 ' N ' ' CD1' ' A' ' 3' ' ' ILE . 3.2 mp -110.74 139.26 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.903 . . . . 0.0 109.466 -179.978 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.418 HG21 ' N ' ' A' ' 5' ' ' ARG . 3.2 mt -111.19 138.27 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.228 -0.92 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.445 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 3.0 ptt180 -121.55 166.66 13.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.3 t -48.5 142.2 8.68 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.244 -0.91 . . . . 0.0 109.36 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.526 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.09 -171.45 1.21 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.483 2.122 . . . . 0.0 110.423 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.09 101.54 12.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.11 -26.36 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.24 -0.912 . . . . 0.0 109.255 -179.922 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 34.9 5.47 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 153.04 -133.58 4.09 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -118.08 168.2 10.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -1.112 . . . . 0.0 109.463 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.1 128.61 2.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.461 ' OE2' ' O ' ' A' ' 15' ' ' VAL . 3.3 tm-20 -89.2 134.65 33.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -1.144 . . . . 0.0 109.427 179.956 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.461 ' O ' ' OE2' ' A' ' 14' ' ' GLU . 19.2 t -74.72 156.57 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.505 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -115.56 -58.49 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.492 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.71 161.91 41.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.0 111.54 20.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -0.88 . . . . 0.0 109.472 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.415 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -95.16 32.91 1.62 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 179.988 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.415 HG11 ' O ' ' A' ' 19' ' ' LEU . 34.6 m -144.03 161.98 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.467 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.426 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.24 -177.07 4.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.205 -0.934 . . . . 0.0 109.469 179.999 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.0 m -81.34 143.18 32.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.234 -0.916 . . . . 0.0 109.504 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.422 ' HA2' HG23 ' A' ' 51' ' ' VAL . . . 82.94 2.58 90.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.426 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 22.7 m-20 -85.07 139.45 31.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -1.198 . . . . 0.0 109.435 -179.961 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.448 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 6.8 tt -103.43 108.97 20.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.517 HG23 ' CB ' ' A' ' 46' ' ' SER . 0.9 OUTLIER -90.15 -171.39 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.212 -0.93 . . . . 0.0 109.234 179.985 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.413 ' O ' ' HB3' ' A' ' 46' ' ' SER . 2.4 pt-20 -138.22 -178.28 5.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.119 -0.988 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.532 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 9.9 p -82.27 74.57 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.48 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER 162.91 -55.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.901 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 29' ' ' GLU . 1.4 tt0 -44.41 141.01 2.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.87 . . . . 0.0 109.494 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.466 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.77 178.67 32.1 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.521 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -141.35 -42.18 0.37 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -1.169 . . . . 0.0 109.453 179.926 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.521 ' CG2' ' HB ' ' A' ' 44' ' ' VAL . 20.3 m -152.04 155.29 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 -179.986 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' HG12 ' A' ' 16' ' ' ILE . 58.7 t -114.84 107.75 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.232 -0.918 . . . . 0.0 109.451 -179.903 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.8 mp -98.11 -178.38 4.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -147.54 140.08 24.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.938 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.4 p -107.07 -177.67 3.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.58 -65.45 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.238 -0.913 . . . . 0.0 109.425 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 mppt? -129.54 55.91 1.74 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.496 -179.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -170.85 -161.56 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.278 -0.889 . . . . 0.0 109.512 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.09 149.73 30.71 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.296 -0.877 . . . . 0.0 109.448 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 69.5 mmm -146.06 104.42 3.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -0.947 . . . . 0.0 109.383 -179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.95 171.98 13.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -0.921 . . . . 0.0 109.538 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.9 t -146.15 98.48 4.35 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.263 -0.898 . . . . 0.0 109.389 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.466 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 35.5 Cg_endo -77.5 -168.09 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.492 2.128 . . . . 0.0 110.527 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.517 ' CB ' HG23 ' A' ' 26' ' ' ILE . 6.5 t -85.09 113.65 51.37 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.45 -179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.4 Cg_endo -78.06 3.01 7.41 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.364 2.043 . . . . 0.0 110.329 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.515 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 6.0 mttt -160.01 114.94 2.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.312 -0.868 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.1 91.95 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.944 . . . . 0.0 109.533 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.532 ' CA ' ' CD1' ' A' ' 72' ' ' LEU . . . -155.39 -171.86 22.41 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.422 HG23 ' HA2' ' A' ' 23' ' ' GLY . 10.9 p -100.77 155.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -1.185 . . . . 0.0 109.517 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.2 t -81.37 138.62 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -0.923 . . . . 0.0 109.536 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -104.34 -66.9 0.93 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -137.92 148.7 45.55 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.474 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 12.0 t -101.65 133.65 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 179.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -112.87 13.98 19.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.142 -0.974 . . . . 0.0 109.567 179.962 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.447 HG12 HD12 ' A' ' 69' ' ' ILE . 2.0 m -137.46 158.77 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.219 -0.926 . . . . 0.0 109.478 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.15 158.68 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.238 -0.914 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.8 pp -82.68 137.64 34.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.931 . . . . 0.0 109.53 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.95 -14.52 65.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -83.68 168.07 16.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.14 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -97.38 140.77 31.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -0.855 . . . . 0.0 109.442 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.41 HD13 ' CG2' ' A' ' 15' ' ' VAL . 6.5 mt -123.97 116.05 22.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.497 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 65' ' ' GLU . 4.3 tttt -90.48 139.69 30.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.303 -0.873 . . . . 0.0 109.472 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 64' ' ' LYS . 15.6 pt-20 -42.76 149.19 0.2 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.313 -0.867 . . . . 0.0 109.645 -179.896 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.71 -14.88 58.88 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.445 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 91.6 m-20 -85.01 140.06 31.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.285 -1.126 . . . . 0.0 109.471 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.421 ' O ' HD12 ' A' ' 69' ' ' ILE . . . -62.37 -179.43 0.24 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.213 -0.929 . . . . 0.0 109.506 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.494 HD11 HG21 ' A' ' 69' ' ' ILE . 28.6 mm -147.95 -72.19 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.447 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.4 HG21 ' C ' ' A' ' 69' ' ' ILE . 3.8 pt -142.37 -172.52 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.932 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -140.29 112.2 7.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.532 ' CD1' ' CA ' ' A' ' 50' ' ' GLY . 3.6 tt -90.06 141.96 28.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -113.24 91.69 20.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.21 -0.932 . . . . 0.0 109.535 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.515 ' HD3' ' CD2' ' A' ' 72' ' ' LEU . 35.1 Cg_endo -78.13 115.24 3.71 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.602 2.201 . . . . 0.0 110.35 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -77.6 -81.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.31 -0.869 . . . . 0.0 109.46 179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 118.63 14.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.468 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -153.78 -135.49 2.13 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -105.57 72.56 0.97 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.245 -1.15 . . . . 0.0 109.544 179.944 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.451 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 68.8 p . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -147.42 150.48 34.74 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.439 HD13 ' O ' ' A' ' 70' ' ' ILE . 1.4 tp -93.03 130.73 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.6 mm -93.81 124.22 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.388 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.461 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 3.5 ptt-85 -118.52 159.16 24.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.523 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 84.3 t -43.33 103.51 0.32 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.344 -0.847 . . . . 0.0 109.442 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.9 Cg_endo -77.78 -169.54 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.511 2.14 . . . . 0.0 110.45 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -68.26 99.7 0.95 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.283 -0.886 . . . . 0.0 109.413 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.483 HD13 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.0 -43.0 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.305 -179.877 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.55 34.61 0.65 Allowed Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 147.21 -132.74 4.45 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -101.5 135.27 43.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.65 115.78 4.31 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.458 ' HG2' ' CB ' ' A' ' 62' ' ' LYS . 12.9 mt-10 -112.36 104.32 12.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -1.152 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -54.17 136.23 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.515 -179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.444 HG12 ' O ' ' A' ' 14' ' ' GLU . 29.2 mm -128.04 -37.42 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.83 155.27 43.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.455 HD21 HG21 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -117.59 123.59 46.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.991 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.489 HD11 ' N ' ' A' ' 32' ' ' LEU . 6.3 mt -93.77 9.36 37.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.535 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.468 ' CG2' HD12 ' A' ' 32' ' ' LEU . 4.7 m -146.42 175.42 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -139.31 -164.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.272 -0.892 . . . . 0.0 109.49 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.422 ' HA ' HG13 ' A' ' 52' ' ' VAL . 26.4 m -84.83 139.41 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.918 . . . . 0.0 109.509 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.87 10.56 51.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -85.04 134.72 34.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.195 -1.179 . . . . 0.0 109.454 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.445 HD23 ' HB ' ' A' ' 51' ' ' VAL . 0.4 OUTLIER -88.24 118.25 27.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.448 HG23 ' HB2' ' A' ' 46' ' ' SER . 3.7 mt -97.04 -171.41 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.239 -0.913 . . . . 0.0 109.234 -179.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -147.81 153.99 39.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 6.3 p -72.03 84.35 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.248 -0.907 . . . . 0.0 109.506 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.79 -32.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.336 -0.853 . . . . 0.0 109.473 179.877 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -78.66 153.27 31.14 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.233 -0.917 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.38 -160.07 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.01 -72.74 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -1.166 . . . . 0.0 109.459 179.983 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.515 HG22 ' CD1' ' A' ' 35' ' ' LEU . 8.5 m -119.45 150.92 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.455 HG23 ' OE1' ' A' ' 43' ' ' GLU . 23.9 t -117.91 83.22 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.515 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -91.13 147.52 23.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.44 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.39 152.84 21.13 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.169 -0.957 . . . . 0.0 109.411 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -98.72 -175.62 3.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.28 -0.888 . . . . 0.0 109.481 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.61 94.78 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.6 mttm -142.4 48.33 1.56 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.413 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -177.13 -158.76 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.51 152.94 37.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.388 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtp -159.26 142.47 14.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.455 ' OE1' HG23 ' A' ' 34' ' ' VAL . 24.0 mt-10 -132.65 162.8 30.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.7 t -131.02 140.08 37.57 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.309 -0.869 . . . . 0.0 109.345 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.499 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.21 -168.59 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.581 2.188 . . . . 0.0 110.421 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.448 ' HB2' HG23 ' A' ' 26' ' ' ILE . 28.9 t -85.27 113.64 51.6 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.398 -0.814 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.03 0.49 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.348 2.032 . . . . 0.0 110.425 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.453 ' O ' HD23 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.09 104.75 1.51 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.338 -0.851 . . . . 0.0 109.491 179.951 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.35 101.87 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.467 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.522 ' HA3' ' CD2' ' A' ' 72' ' ' LEU . . . -159.36 -150.19 5.75 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.867 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.445 ' HB ' HD23 ' A' ' 25' ' ' LEU . 8.1 p -116.51 132.35 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -1.14 . . . . 0.0 109.478 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.422 HG13 ' HA ' ' A' ' 22' ' ' THR . 63.7 t -56.3 126.84 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.01 -50.1 5.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.163 -0.96 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -169.64 153.26 4.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.349 -0.844 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.404 HG12 ' CG2' ' A' ' 70' ' ' ILE . 25.9 t -111.69 136.34 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.301 -0.874 . . . . 0.0 109.457 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -94.79 17.4 13.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.271 -0.893 . . . . 0.0 109.471 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.472 HG13 ' CD2' ' A' ' 63' ' ' LEU . 1.6 m -145.28 176.88 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.274 -0.891 . . . . 0.0 109.386 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.434 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -112.34 -178.91 3.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.19 -0.944 . . . . 0.0 109.522 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -82.3 136.85 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.93 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.41 18.08 76.65 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 4.4 m-20 -83.68 144.14 29.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.458 ' CB ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -103.66 120.94 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.515 179.961 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.472 ' CD2' HG13 ' A' ' 57' ' ' VAL . 1.3 mp -121.73 175.57 6.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.907 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' GLU . 3.5 tttp -118.31 145.75 44.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.523 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 3.2 pt-20 -42.85 137.48 2.3 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.341 -0.849 . . . . 0.0 109.584 -179.884 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.53 -25.93 16.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -84.89 140.76 30.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -1.124 . . . . 0.0 109.448 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -65.04 -174.11 0.14 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.423 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 28.7 mm -143.3 -65.33 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.264 -0.897 . . . . 0.0 109.49 -179.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.439 ' O ' HD13 ' A' ' 3' ' ' ILE . 1.8 pt -141.95 -175.11 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.899 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.434 ' HB2' HD13 ' A' ' 3' ' ' ILE . 1.8 tt0 -149.56 114.37 5.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.296 -0.877 . . . . 0.0 109.498 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.522 ' CD2' ' HA3' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -93.27 148.02 22.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.423 -179.911 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.406 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 3.6 tt0 -132.91 91.22 29.67 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.493 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HD3' HD22 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -77.96 176.41 10.02 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.627 2.218 . . . . 0.0 110.44 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -80.37 179.37 7.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.201 -0.937 . . . . 0.0 109.501 -179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -172.7 107.81 0.18 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.18 -0.95 . . . . 0.0 109.471 179.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 78' ' ' ALA . . . 87.31 78.22 1.25 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' A' ' 77' ' ' GLY . . . 71.24 115.27 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -1.136 . . . . 0.0 109.489 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.419 -179.989 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 89.1 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -122.35 151.07 41.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 4.3 mp -90.94 154.36 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.513 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.443 HG22 ' HG3' ' A' ' 47' ' ' PRO . 4.1 mp -120.81 107.57 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.407 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -101.55 170.64 8.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.385 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -61.26 142.27 93.6 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.374 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.08 -169.77 0.83 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.561 2.174 . . . . 0.0 110.458 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -82.88 105.15 13.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.416 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.461 HD13 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.8 -59.5 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.389 -179.954 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.04 -11.68 10.78 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.05 -141.28 4.22 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.411 ' OD1' ' HE2' ' A' ' 64' ' ' LYS . 0.1 OUTLIER -98.66 164.17 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -1.127 . . . . 0.0 109.516 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.59 95.47 0.47 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -97.0 126.16 41.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.282 -1.128 . . . . 0.0 109.428 -179.953 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.2 t -77.09 133.6 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.93 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.428 HD12 ' HB2' ' A' ' 36' ' ' GLU . 19.2 mt -121.38 -37.58 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.395 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.56 137.6 43.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.192 -0.942 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.441 HD22 HG22 ' A' ' 20' ' ' VAL . 0.5 OUTLIER -122.43 119.29 30.56 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.45 ' O ' HG11 ' A' ' 20' ' ' VAL . 0.4 OUTLIER -117.81 50.34 1.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.431 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 19' ' ' LEU . 3.8 m -147.36 159.34 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -148.74 -176.3 5.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.427 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.5 m -84.63 126.47 33.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.449 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.88 6.9 64.94 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.457 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 57.2 m-20 -83.66 131.9 34.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.46 HD11 ' HB ' ' A' ' 51' ' ' VAL . 7.2 tp -92.94 106.48 18.43 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.534 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.513 ' CD1' HD13 ' A' ' 32' ' ' LEU . 2.8 mt -91.77 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.215 -0.928 . . . . 0.0 109.151 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -144.7 176.51 9.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.925 . . . . 0.0 109.412 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.532 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 14.4 p -81.96 72.95 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.205 -0.934 . . . . 0.0 109.535 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.83 -44.57 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.331 -0.856 . . . . 0.0 109.397 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -51.13 142.42 12.53 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.209 -0.932 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -60.61 175.47 4.68 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.521 HD11 ' CA ' ' A' ' 46' ' ' SER . 0.6 OUTLIER -138.51 -62.24 0.57 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.358 -179.979 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.412 HG22 ' HG ' ' A' ' 35' ' ' LEU . 35.9 m -136.38 159.86 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.932 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 65.1 t -114.66 84.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 7.3 mt -94.68 159.55 15.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.46 ' HG2' ' HA ' ' A' ' 41' ' ' SER . 0.3 OUTLIER -124.15 161.23 26.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.913 . . . . 0.0 109.49 -179.96 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -139.44 172.02 13.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.465 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.02 -13.39 62.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.312 -0.867 . . . . 0.0 109.54 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.449 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 2.2 mptt -87.42 -38.84 15.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 39' ' ' LYS . . . 174.07 -174.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.514 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.46 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 0.0 OUTLIER -99.15 134.98 41.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.237 -0.915 . . . . 0.0 109.453 -179.975 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.464 ' O ' ' HG3' ' A' ' 42' ' ' MET . 0.4 OUTLIER -155.16 132.26 10.89 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.449 -179.959 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.402 ' C ' HG21 ' A' ' 44' ' ' VAL . 4.1 pt-20 -94.53 -179.71 4.99 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.5 t -144.36 128.94 9.24 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.224 -0.923 . . . . 0.0 109.304 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.476 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.5 -168.62 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.334 2.023 . . . . 0.0 110.326 179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.521 ' CA ' HD11 ' A' ' 32' ' ' LEU . 1.9 t -85.31 136.41 37.83 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.362 -0.836 . . . . 0.0 109.359 179.891 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.459 ' O ' ' CG ' ' A' ' 48' ' ' LYS . 36.1 Cg_endo -78.73 -5.73 14.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.516 2.144 . . . . 0.0 110.495 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.33 139.17 10.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 109.488 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.86 101.57 8.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.444 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.471 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -157.7 -147.75 4.91 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.46 ' HB ' HD11 ' A' ' 25' ' ' LEU . 14.5 p -126.66 152.02 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.219 -1.165 . . . . 0.0 109.502 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 54.3 t -68.66 140.47 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.249 -0.907 . . . . 0.0 109.459 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -109.04 -53.88 2.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -0.933 . . . . 0.0 109.457 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.87 177.95 7.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 57' ' ' VAL . 92.9 t -124.35 125.15 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.446 ' O ' HG11 ' A' ' 57' ' ' VAL . 21.6 t -105.53 1.67 27.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.198 -0.939 . . . . 0.0 109.645 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 55' ' ' VAL . 3.3 m -147.28 176.3 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.481 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.481 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -129.79 150.4 51.11 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.488 -179.943 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -61.79 140.67 58.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.889 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.75 -11.96 60.64 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.481 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 8.0 m-20 -78.01 152.62 32.97 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.194 -1.18 . . . . 0.0 109.444 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.419 ' O ' ' HG2' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -114.11 146.26 40.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.971 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.44 HD21 ' HB3' ' A' ' 67' ' ' ASP . 2.2 mp -147.75 -178.41 6.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -120.22 149.74 41.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.459 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.441 ' CD ' ' N ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -42.87 149.17 0.21 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.839 . . . . 0.0 109.591 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.69 -14.29 65.34 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.44 ' HB3' HD21 ' A' ' 63' ' ' LEU . 51.6 m-20 -84.65 137.73 33.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.25 -1.147 . . . . 0.0 109.491 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.436 ' O ' HG13 ' A' ' 69' ' ' ILE . . . -66.25 176.93 1.59 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.436 HG13 ' O ' ' A' ' 68' ' ' ALA . 2.3 mp -142.1 -61.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.253 -0.904 . . . . 0.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -142.9 -172.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.199 -0.938 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -142.41 106.94 4.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.291 -0.881 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.471 HD12 ' N ' ' A' ' 50' ' ' GLY . 2.7 tt -91.18 135.58 33.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.203 -0.936 . . . . 0.0 109.49 179.929 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.52 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 20.6 tt0 -116.66 142.11 29.15 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.227 -0.921 . . . . 0.0 109.423 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 36.0 Cg_endo -78.27 100.02 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.568 2.179 . . . . 0.0 110.403 179.942 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.427 ' O ' ' CB ' ' A' ' 76' ' ' ALA . . . -81.36 161.63 23.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.231 -0.918 . . . . 0.0 109.412 -179.939 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.427 ' CB ' ' O ' ' A' ' 75' ' ' ALA . . . 69.89 19.55 6.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.164 -0.96 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -159.82 133.76 3.44 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.998 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -174.28 145.04 0.98 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -1.163 . . . . 0.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.8 mtp180 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.471 -179.953 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.454 ' HB3' ' HG3' ' A' ' 73' ' ' GLU . 9.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -128.12 133.42 48.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.484 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.1 tp -79.95 140.27 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.436 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 4' ' ' ILE . 4.4 mp -101.61 142.41 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 179.991 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.451 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -113.95 179.74 3.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.854 . . . . 0.0 109.478 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.474 HG11 ' HD2' ' A' ' 7' ' ' PRO . 49.1 t -61.35 134.4 93.35 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 109.292 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.474 ' HD2' HG11 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -170.04 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.457 2.105 . . . . 0.0 110.483 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -79.93 101.41 8.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.473 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -104.24 -49.73 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.284 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.64 -17.37 6.89 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.938 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.42 -171.88 28.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.83 148.88 42.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -1.159 . . . . 0.0 109.53 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.53 150.23 18.54 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.444 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.9 OUTLIER -118.38 142.33 47.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.176 -1.19 . . . . 0.0 109.465 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.479 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -76.48 135.41 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.521 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 80.5 mt -100.33 -38.33 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.447 -179.926 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -172.47 170.12 5.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.533 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 tp -117.15 125.16 50.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.45 HD11 ' O ' ' A' ' 19' ' ' LEU . 1.1 pp -104.7 31.25 4.85 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.497 ' CG2' HD21 ' A' ' 32' ' ' LEU . 17.2 m -150.0 166.67 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.6 mtmt -128.51 179.06 5.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.902 . . . . 0.0 109.498 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 35.1 m -84.96 141.63 30.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.89 63.34 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -84.89 138.45 32.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -1.22 . . . . 0.0 109.502 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -79.98 131.11 35.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 109.431 179.911 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.463 HD12 HD12 ' A' ' 32' ' ' LEU . 2.4 mt -92.95 -171.56 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.176 -0.952 . . . . 0.0 109.278 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.465 ' HB2' ' HG3' ' A' ' 30' ' ' GLN . 0.7 OUTLIER -126.98 175.84 7.78 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.206 -0.933 . . . . 0.0 109.433 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.465 ' O ' ' HB2' ' A' ' 29' ' ' GLU . 8.3 p -76.55 124.46 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.497 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 4.1 mt-10 63.05 11.92 5.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.245 -0.909 . . . . 0.0 109.656 179.859 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.465 ' HG3' ' HB2' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -74.13 122.57 22.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.356 179.923 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.497 ' CA ' ' HA ' ' A' ' 45' ' ' PRO . . . -43.19 152.88 0.28 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.86 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.497 HD21 ' CG2' ' A' ' 20' ' ' VAL . 0.5 OUTLIER -132.56 -39.25 1.01 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -1.153 . . . . 0.0 109.496 179.943 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 32' ' ' LEU . 33.6 m -140.92 165.1 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.174 -0.954 . . . . 0.0 109.528 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -130.59 95.51 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.444 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.92 163.57 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 21.2 tt0 -122.94 123.45 40.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.892 . . . . 0.0 109.515 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -79.91 -173.82 4.08 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.47 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.58 -42.1 32.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.539 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.81 18.48 0.69 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.34 -169.74 1.85 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -158.04 101.75 1.78 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.531 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.432 ' N ' ' SD ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -114.34 143.16 45.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.212 -0.93 . . . . 0.0 109.452 -179.984 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.422 ' C ' HG21 ' A' ' 44' ' ' VAL . 12.1 pt-20 -100.97 164.07 11.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.281 -0.887 . . . . 0.0 109.521 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.449 ' HB ' HG21 ' A' ' 33' ' ' VAL . 46.3 t -135.07 102.88 10.81 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.362 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.497 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -77.4 -169.58 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.419 2.079 . . . . 0.0 110.428 -179.823 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.73 139.52 35.39 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.473 179.906 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -78.96 -10.65 15.28 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.409 2.072 . . . . 0.0 110.328 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -160.5 146.84 15.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.477 -0.764 . . . . 0.0 109.364 179.962 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.97 116.95 17.17 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -0.946 . . . . 0.0 109.399 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.538 ' CA ' ' CD1' ' A' ' 72' ' ' LEU . . . -164.36 -149.25 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.4 p -126.34 145.43 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -1.113 . . . . 0.0 109.433 -179.945 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.7 t -65.13 140.41 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.891 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.2 tptp -117.16 -47.11 2.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.401 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.49 163.61 32.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 80.4 t -121.52 118.19 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.0 t -108.22 22.59 15.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.557 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.5 m -144.13 160.35 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.532 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.437 ' O ' HG13 ' A' ' 15' ' ' VAL . 0.0 OUTLIER -136.67 169.2 18.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -0.903 . . . . 0.0 109.442 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.42 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -84.97 103.08 13.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.218 -0.926 . . . . 0.0 109.476 -179.955 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.1 -14.06 19.14 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.57 138.62 38.46 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.198 -1.178 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -80.48 152.83 28.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -0.868 . . . . 0.0 109.44 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.479 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 63.2 mt -140.97 136.53 32.27 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 14.3 tttm -105.87 149.05 26.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 0.0 109.486 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.0 OUTLIER -42.88 147.31 0.32 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.37 -0.831 . . . . 0.0 109.583 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 82.57 -4.34 78.79 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 2.5 m-20 -83.09 130.87 35.16 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.289 -1.124 . . . . 0.0 109.423 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.451 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -50.5 178.34 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.26 -0.9 . . . . 0.0 109.475 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.455 HG23 HG22 ' A' ' 70' ' ' ILE . 29.5 mm -146.97 -71.48 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.461 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.455 HG22 HG23 ' A' ' 69' ' ' ILE . 0.8 OUTLIER -138.81 -174.58 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.489 180.0 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -150.0 102.0 3.07 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.907 . . . . 0.0 109.507 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.538 ' CD1' ' CA ' ' A' ' 50' ' ' GLY . 4.0 tt -91.3 129.01 37.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.289 -0.882 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.513 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -90.07 144.96 32.07 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.367 -179.97 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.513 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.5 Cg_endo -78.02 151.87 27.63 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.623 2.215 . . . . 0.0 110.432 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -85.59 -45.54 11.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.902 . . . . 0.0 109.461 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 48.57 -171.62 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.465 -179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -118.81 -71.46 0.37 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 46.35 41.7 9.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.362 -1.081 . . . . 0.0 109.476 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.479 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 84.6 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -107.8 147.26 31.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.504 ' CD1' ' HB3' ' A' ' 68' ' ' ALA . 13.8 tt -79.93 169.13 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -0.883 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.472 ' O ' ' CD1' ' A' ' 69' ' ' ILE . 24.6 mm -125.39 119.78 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 -179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 3.9 ptm180 -94.93 163.83 13.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.491 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 86.9 t -69.25 140.03 90.25 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.379 -179.903 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.491 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.73 -168.7 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.589 2.193 . . . . 0.0 110.432 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -75.19 117.67 17.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 109.268 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.447 HD13 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -108.57 -47.26 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 109.482 -179.736 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 149.61 -38.9 0.92 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . 172.29 117.64 0.45 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.92 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' A' ' 11' ' ' GLY . 0.7 OUTLIER 50.33 178.66 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -1.091 . . . . 0.0 109.623 179.892 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.35 111.69 0.36 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.456 ' HB2' ' HD3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -95.95 137.12 35.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.283 -1.128 . . . . 0.0 109.539 179.963 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.401 HG21 ' CD2' ' A' ' 35' ' ' LEU . 59.9 t -85.12 134.97 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.556 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.439 ' O ' ' HB2' ' A' ' 17' ' ' GLU . 44.6 mt -104.31 -30.63 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.204 -0.935 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.439 ' HB2' ' O ' ' A' ' 16' ' ' ILE . 0.5 OUTLIER 175.22 131.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.545 179.976 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.12 172.08 7.02 Favored 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -145.32 63.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.473 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.0 m -146.36 158.92 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.534 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HB2' ' CG ' ' A' ' 24' ' ' ASP . 75.9 mttt -123.47 167.75 13.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.875 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 11.0 t -79.12 126.82 31.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.42 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 89.29 9.36 67.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.411 ' CG ' ' HB2' ' A' ' 21' ' ' LYS . 0.8 OUTLIER -85.02 135.06 34.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.158 -1.201 . . . . 0.0 109.506 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.7 tt -97.25 104.37 16.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -0.916 . . . . 0.0 109.475 179.959 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.432 HD11 ' CD2' ' A' ' 32' ' ' LEU . 2.7 mt -91.89 -171.45 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.2 -0.937 . . . . 0.0 109.246 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -137.94 176.5 8.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 11.1 p -81.39 79.07 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.455 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 167.49 -55.9 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.42 -0.8 . . . . 0.0 109.319 179.874 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.66 145.79 0.85 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.946 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -59.34 -162.74 0.09 OUTLIER Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.03 -71.77 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 109.516 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.452 ' O ' ' HB2' ' A' ' 43' ' ' GLU . 9.5 m -129.9 170.24 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.406 HG23 ' HB3' ' A' ' 43' ' ' GLU . 77.2 t -129.53 92.12 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 180.0 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.422 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.5 OUTLIER -97.04 169.83 9.56 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 179.999 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -103.12 178.74 4.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.247 -0.908 . . . . 0.0 109.486 -180.0 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -139.57 -173.09 3.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.28 -0.888 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -53.65 -57.61 10.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.932 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.43 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 2.2 mttt -138.45 58.46 1.66 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.246 -0.909 . . . . 0.0 109.526 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.43 ' HB1' ' O ' ' A' ' 39' ' ' LYS . . . 173.95 174.17 0.16 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.0 127.88 39.23 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.248 -0.907 . . . . 0.0 109.44 -179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.5 mtt -138.19 142.97 40.01 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' HB2' ' O ' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -105.97 164.12 12.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.284 -0.885 . . . . 0.0 109.352 179.969 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.5 t -122.31 137.83 28.19 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.309 179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 36.3 Cg_endo -79.13 -167.99 0.57 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.465 2.11 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.05 116.35 65.05 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.395 -0.816 . . . . 0.0 109.36 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.445 ' HG2' HG22 ' A' ' 4' ' ' ILE . 35.8 Cg_endo -77.77 4.54 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.381 2.054 . . . . 0.0 110.45 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.517 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.01 111.68 2.0 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.522 -179.976 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.45 95.89 2.3 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.307 -0.871 . . . . 0.0 109.435 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.497 ' N ' HD12 ' A' ' 72' ' ' LEU . . . -164.29 -164.08 18.73 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.42 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 14.9 p -100.91 133.82 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.229 -1.16 . . . . 0.0 109.519 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 80.4 t -58.82 147.88 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 -30.75 6.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -169.6 159.38 8.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.2 t -116.66 106.74 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.137 -0.977 . . . . 0.0 109.47 -179.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.91 21.88 8.08 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.261 -0.899 . . . . 0.0 109.417 179.955 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.439 HG23 HG21 ' A' ' 69' ' ' ILE . 15.8 m -144.1 160.51 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.57 171.15 12.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 179.966 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.07 119.2 22.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.424 -179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.77 -10.02 48.4 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.17 159.93 33.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.269 -1.136 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.456 ' HD3' ' HB2' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -113.52 135.07 54.29 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.507 179.958 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -142.68 155.05 44.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.175 -0.953 . . . . 0.0 109.456 179.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.426 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -104.43 147.96 26.98 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.522 -179.933 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 64' ' ' LYS . 4.1 pt-20 -43.04 141.24 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.77 -8.89 73.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 132.06 34.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -1.169 . . . . 0.0 109.519 179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.504 ' HB3' ' CD1' ' A' ' 3' ' ' ILE . . . -56.08 156.1 5.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.396 -0.815 . . . . 0.0 109.44 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.481 ' CG1' HG21 ' A' ' 6' ' ' VAL . 1.4 mp -129.82 -43.8 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.489 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.452 HG21 ' O ' ' A' ' 69' ' ' ILE . 4.9 pt -159.9 -173.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.6 tt0 -135.66 159.0 42.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.252 -0.905 . . . . 0.0 109.474 180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.517 ' CD1' ' O ' ' A' ' 48' ' ' LYS . 8.0 tt -140.54 145.32 36.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -116.68 87.77 22.58 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.906 . . . . 0.0 109.447 -179.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.508 ' N ' HD22 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.05 137.52 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.622 2.215 . . . . 0.0 110.458 179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -117.38 173.0 6.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -136.75 -44.92 0.59 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.369 -0.832 . . . . 0.0 109.459 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -168.6 72.06 0.14 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -95.78 18.38 13.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.206 -1.173 . . . . 0.0 109.381 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.424 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 86.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -141.86 144.7 33.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.45 HD11 ' HG2' ' A' ' 71' ' ' GLU . 32.6 mm -90.45 136.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.488 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 mt -110.57 124.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.403 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 11.6 ptt180 -105.18 171.45 7.31 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.907 . . . . 0.0 109.489 -179.945 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.531 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 77.0 t -62.13 142.48 95.57 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.531 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.3 Cg_endo -78.56 -170.38 0.97 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.496 2.13 . . . . 0.0 110.375 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -84.9 110.74 19.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.392 179.927 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.59 -10.08 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.298 -0.876 . . . . 0.0 109.389 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.8 26.62 74.45 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.906 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 12' ' ' ASP . . . 171.61 160.55 20.41 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -44.45 155.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.239 -1.153 . . . . 0.0 109.485 -179.996 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.65 109.28 1.45 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -101.72 114.41 28.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -1.159 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.423 HG21 HD22 ' A' ' 35' ' ' LEU . 14.3 t -60.24 129.93 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.891 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.1 mt -104.86 -35.57 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.243 -0.91 . . . . 0.0 109.502 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.436 ' HA ' ' HB2' ' A' ' 59' ' ' LEU . 6.5 tp10 -165.37 135.47 3.64 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.48 127.49 55.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -0.923 . . . . 0.0 109.411 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.449 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -116.03 57.68 0.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.444 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.509 HG12 ' CD2' ' A' ' 32' ' ' LEU . 35.6 m -137.19 157.24 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -129.93 157.51 42.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.511 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.446 HG22 ' O ' ' A' ' 22' ' ' THR . 12.1 t -80.64 128.98 34.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 109.419 179.939 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.71 -8.92 79.09 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -82.26 132.61 35.23 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.229 -1.16 . . . . 0.0 109.427 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.417 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -79.9 125.63 29.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.264 -0.897 . . . . 0.0 109.488 -179.959 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.52 HG23 ' CB ' ' A' ' 46' ' ' SER . 2.7 mt -92.52 -171.38 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.276 -0.89 . . . . 0.0 109.201 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -142.2 159.68 41.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.119 -0.988 . . . . 0.0 109.477 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 13.3 p -81.41 79.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.244 -0.91 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.75 -36.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.397 179.893 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.507 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 39.6 tt0 -67.33 155.47 38.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -0.925 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.465 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -77.32 168.4 54.53 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.525 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 1.3 tt -129.5 -40.5 1.42 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.263 -1.14 . . . . 0.0 109.49 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.408 ' CG1' ' C ' ' A' ' 32' ' ' LEU . 5.2 m -154.7 166.84 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.506 -179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.4 t -134.66 96.55 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.325 179.931 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.46 HD13 HG22 ' A' ' 44' ' ' VAL . 0.4 OUTLIER -94.62 163.83 13.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.564 -179.947 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -105.42 173.87 6.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.407 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.1 m -135.32 -174.13 3.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -44.73 -42.58 7.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 109.441 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 ttpp -158.89 39.76 0.22 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.485 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -151.0 -156.9 0.76 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.84 107.26 2.1 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' MET . . . . . 0.424 ' HG3' ' N ' ' A' ' 43' ' ' GLU . 2.4 ttm -100.2 149.66 23.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.456 ' O ' HG21 ' A' ' 44' ' ' VAL . 10.6 mt-10 -113.2 164.51 13.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.525 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.6 t -143.9 101.74 4.93 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.25 -0.906 . . . . 0.0 109.269 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.514 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.4 Cg_endo -77.16 -168.75 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.393 2.062 . . . . 0.0 110.55 -179.824 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.52 ' CB ' HG23 ' A' ' 26' ' ' ILE . 1.6 t -85.26 117.64 69.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.272 -0.892 . . . . 0.0 109.502 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.12 3.35 7.13 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.332 2.021 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.44 ' HG2' ' CD1' ' A' ' 72' ' ' LEU . 1.8 tptt -159.88 131.2 5.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.892 . . . . 0.0 109.415 179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.41 88.36 7.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.818 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.451 ' HA3' HD13 ' A' ' 72' ' ' LEU . . . -140.05 -152.35 5.81 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.415 ' O ' HG11 ' A' ' 51' ' ' VAL . 9.9 p -113.59 129.99 68.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -1.169 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.4 t -55.55 126.75 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.09 -44.68 9.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.44 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 54.7 p -171.82 138.44 1.07 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 57' ' ' VAL . 4.8 t -92.98 117.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 109.539 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.22 13.52 18.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 55' ' ' VAL . 2.8 m -140.83 172.09 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.73 151.74 44.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.436 ' HB2' ' HA ' ' A' ' 17' ' ' GLU . 1.6 pp -56.83 139.91 49.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.87 -7.53 81.56 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -70.57 -179.95 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.212 -1.169 . . . . 0.0 109.438 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -153.12 115.74 4.48 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.186 -0.946 . . . . 0.0 109.441 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mp -131.3 -175.05 3.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.473 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.3 tttp -118.56 144.65 45.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.467 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 1.6 pt-20 -42.82 141.23 1.13 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.302 -0.874 . . . . 0.0 109.585 -179.861 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.76 -22.62 36.52 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -78.79 138.14 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.46 179.99 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.44 170.12 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.433 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.407 ' CD1' HG21 ' A' ' 6' ' ' VAL . 27.7 mm -139.11 -59.56 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.43 ' CD1' HD12 ' A' ' 32' ' ' LEU . 2.3 pt -143.44 -173.75 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.268 -0.895 . . . . 0.0 109.409 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.45 ' HG2' HD11 ' A' ' 3' ' ' ILE . 13.8 mt-10 -139.07 113.16 8.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.491 ' C ' ' CD1' ' A' ' 72' ' ' LEU . 3.4 tm? -90.05 119.92 30.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -111.14 95.42 25.16 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.202 -0.936 . . . . 0.0 109.451 -179.926 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.469 ' HD3' ' CD1' ' A' ' 72' ' ' LEU . 35.5 Cg_endo -77.74 173.67 13.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.594 2.196 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -165.2 -179.84 5.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.465 -179.928 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -79.4 -41.59 27.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.21 -0.931 . . . . 0.0 109.48 179.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -153.76 113.43 0.57 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -45.91 -74.18 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.25 -1.147 . . . . 0.0 109.462 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.451 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.45 ' HB3' ' HG2' ' A' ' 73' ' ' GLU . 24.8 p . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -157.19 140.61 15.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.453 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.463 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 2.9 mt -80.48 154.56 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.93 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.405 ' N ' HG21 ' A' ' 3' ' ' ILE . 64.5 mt -122.25 97.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.571 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.72 -172.36 3.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.914 . . . . 0.0 109.379 179.968 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.452 HG12 ' HD2' ' A' ' 7' ' ' PRO . 54.6 t -80.88 139.09 49.86 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.128 -0.983 . . . . 0.0 109.284 -179.957 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.452 ' HD2' HG12 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.56 -169.89 0.87 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.499 2.133 . . . . 0.0 110.399 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -81.69 104.11 11.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.847 . . . . 0.0 109.37 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.498 ' CG2' ' OG ' ' A' ' 37' ' ' SER . 0.0 OUTLIER -105.77 -42.71 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.989 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.77 -23.37 6.28 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.95 -140.29 4.0 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.2 p30 -99.29 153.08 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.185 -1.185 . . . . 0.0 109.401 179.883 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -107.69 105.95 2.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.9 mt-10 -99.96 137.64 38.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -1.145 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 99.6 t -76.5 127.22 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.49 -179.934 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 83.7 mt -107.8 -35.47 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.356 -0.84 . . . . 0.0 109.368 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -152.09 127.36 9.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.506 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.417 HD21 ' O ' ' A' ' 18' ' ' LEU . 3.9 tt -110.14 126.07 53.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.893 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.95 54.56 1.51 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.502 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.511 HG13 ' CD1' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -148.55 162.59 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.511 -179.943 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.425 ' HD2' ' O ' ' A' ' 20' ' ' VAL . 4.0 tptp -141.29 176.75 8.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.6 m -81.76 144.91 30.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.207 -0.933 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.414 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 69.29 8.07 58.43 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -85.02 132.61 34.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -1.151 . . . . 0.0 109.515 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.482 ' CD1' ' O ' ' A' ' 26' ' ' ILE . 0.7 OUTLIER -88.48 118.9 28.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 179.855 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.51 HG23 ' CB ' ' A' ' 46' ' ' SER . 3.2 mt -95.62 -171.33 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 O-C-N 121.222 -0.924 . . . . 0.0 109.328 -179.784 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -145.47 167.69 22.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.397 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 12.6 p -83.83 72.73 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.934 . . . . 0.0 109.522 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.476 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 170.82 -35.03 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.334 -0.854 . . . . 0.0 109.459 179.826 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -72.67 153.76 41.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.47 179.985 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.45 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.75 175.06 44.94 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.534 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -134.85 -44.84 0.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 109.501 179.965 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.441 HG21 ' HB ' ' A' ' 44' ' ' VAL . 2.1 m -153.91 170.88 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.227 -0.92 . . . . 0.0 109.513 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 94.0 t -129.75 76.87 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.23 -0.918 . . . . 0.0 109.444 -179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 4.9 mp -89.91 135.13 33.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.471 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.402 ' CG ' ' HA ' ' A' ' 41' ' ' SER . 5.0 tm-20 -111.43 140.36 46.09 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.895 . . . . 0.0 109.492 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.498 ' OG ' ' CG2' ' A' ' 9' ' ' ILE . 1.4 m -112.52 173.7 6.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.532 179.989 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.89 -13.51 25.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -84.26 -45.44 12.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . 178.94 165.21 0.88 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.402 ' HA ' ' CG ' ' A' ' 36' ' ' GLU . 8.5 t -81.48 118.56 22.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.541 179.919 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 23.9 mtm -121.63 -178.97 3.95 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 109.415 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.7 174.29 10.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.286 -0.884 . . . . 0.0 109.484 -179.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.1 t -149.21 103.05 3.32 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.212 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.466 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.6 Cg_endo -77.39 -168.64 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.343 2.029 . . . . 0.0 110.407 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.51 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.42 113.57 51.48 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.43 -179.905 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.7 Cg_endo -78.18 0.36 9.96 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.343 2.028 . . . . 0.0 110.308 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.44 ' O ' HD12 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.12 131.15 5.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.314 -0.866 . . . . 0.0 109.397 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.59 108.11 5.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.862 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.524 ' HA3' ' CD1' ' A' ' 72' ' ' LEU . . . -160.86 -172.76 28.6 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.414 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 9.8 p -104.87 150.92 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 109.494 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.88 130.78 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.421 179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.422 ' O ' ' HB2' ' A' ' 54' ' ' SER . 0.3 OUTLIER -86.51 -42.59 13.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 109.448 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 53' ' ' LYS . 4.8 t -179.51 139.95 0.14 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.183 -0.948 . . . . 0.0 109.566 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.407 HG13 ' O ' ' A' ' 57' ' ' VAL . 9.0 t -80.87 109.53 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.88 . . . . 0.0 109.423 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.8 p -89.5 7.84 34.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.299 -0.875 . . . . 0.0 109.632 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.474 ' CG1' HD23 ' A' ' 63' ' ' LEU . 2.8 m -139.03 -177.59 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.941 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.5 tptp -131.87 171.27 13.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -0.916 . . . . 0.0 109.499 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.421 HD13 ' O ' ' A' ' 59' ' ' LEU . 2.7 pp -84.56 132.33 34.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.899 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.63 74.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -81.38 141.58 33.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -1.158 . . . . 0.0 109.402 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.417 ' C ' ' CD1' ' A' ' 63' ' ' LEU . 10.8 pttp -99.73 151.61 21.04 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.195 -0.941 . . . . 0.0 109.465 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.474 HD23 ' CG1' ' A' ' 57' ' ' VAL . 6.0 mp -138.17 168.9 18.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.238 -0.914 . . . . 0.0 109.504 179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -107.11 146.66 30.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.467 -179.974 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.431 ' N ' ' HD2' ' A' ' 64' ' ' LYS . 5.4 mt-10 -42.96 138.9 1.89 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.292 -0.88 . . . . 0.0 109.635 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.79 -6.44 73.58 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.418 ' O ' HD13 ' A' ' 69' ' ' ILE . 0.6 OUTLIER -83.12 145.73 29.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -1.176 . . . . 0.0 109.48 179.987 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -81.15 163.57 23.01 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.437 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.457 HG21 ' CG2' ' A' ' 57' ' ' VAL . 4.3 mp -133.85 -55.57 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.18 -0.95 . . . . 0.0 109.546 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.46 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 18.1 pt -145.96 -173.42 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.269 -0.894 . . . . 0.0 109.49 -179.93 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.463 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 1.0 OUTLIER -146.49 155.63 42.67 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.235 -0.915 . . . . 0.0 109.505 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.524 ' CD1' ' HA3' ' A' ' 50' ' ' GLY . 4.5 tt -130.69 126.74 37.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HG2' ' HB3' ' A' ' 1' ' ' SER . 0.1 OUTLIER -96.71 149.33 35.65 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.238 -0.914 . . . . 0.0 109.54 -179.959 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.509 ' O ' ' CB ' ' A' ' 75' ' ' ALA . 35.5 Cg_endo -78.15 -27.38 5.61 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.633 2.222 . . . . 0.0 110.412 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 74' ' ' PRO . . . 75.25 137.29 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.17 -0.956 . . . . 0.0 109.438 179.972 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' A' ' 75' ' ' ALA . . . 75.81 17.08 2.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -112.43 79.48 0.26 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -55.63 107.68 0.36 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 0.0 109.486 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.514 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 65.6 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.61 172.59 13.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.8 mt -100.5 155.5 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.907 . . . . 0.0 109.486 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.455 HD13 ' HG2' ' A' ' 47' ' ' PRO . 36.2 mm -118.17 91.75 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.895 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -95.33 175.8 6.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.488 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HD2' ' A' ' 7' ' ' PRO . 76.4 t -84.25 142.33 40.78 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -169.44 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.517 2.145 . . . . 0.0 110.433 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -78.55 105.41 9.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -0.873 . . . . 0.0 109.411 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.478 ' CD1' HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.46 -11.07 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.307 -179.859 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.16 -14.99 56.16 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -144.92 -176.29 18.8 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.967 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -71.06 142.59 50.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -1.148 . . . . 0.0 109.472 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.92 107.55 3.25 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -99.61 113.42 25.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.459 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.0 t -68.91 131.81 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -0.934 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.435 HG22 HD11 ' A' ' 16' ' ' ILE . 19.5 mm -116.94 -22.16 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -0.897 . . . . 0.0 109.431 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.93 138.04 19.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.293 -0.879 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.8 tp -113.48 101.97 9.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 0.6 OUTLIER -108.84 56.65 0.62 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.3 m -134.28 160.28 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.224 -0.922 . . . . 0.0 109.453 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.442 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 1.2 mtpp -137.43 156.98 47.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.27 -0.894 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.1 m -84.55 129.65 34.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.47 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.404 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 84.31 -9.4 64.27 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.997 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.442 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 0.9 OUTLIER -77.41 131.87 38.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -1.205 . . . . 0.0 109.462 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.0 OUTLIER -85.95 120.57 27.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.217 -0.927 . . . . 0.0 109.467 179.961 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.538 HD11 HG22 ' A' ' 26' ' ' ILE . 2.8 mt -92.26 -171.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.229 -0.92 . . . . 0.0 109.204 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.408 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 11.0 mt-10 -145.44 163.02 35.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.2 p -78.14 79.57 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.367 -0.833 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.81 -34.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.471 179.924 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.453 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 28.4 tt0 -70.35 141.07 52.29 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.318 -0.864 . . . . 0.0 109.499 -179.988 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.491 ' CA ' ' HA ' ' A' ' 45' ' ' PRO . . . -51.32 -177.17 0.03 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.502 ' N ' ' O ' ' A' ' 44' ' ' VAL . 3.8 tp -151.41 -67.78 0.18 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.198 -1.178 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.445 HG22 ' CD1' ' A' ' 35' ' ' LEU . 28.5 m -135.07 138.66 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.512 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 42.2 t -97.64 89.12 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.439 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.445 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.9 OUTLIER -89.89 150.36 22.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.206 -0.934 . . . . 0.0 109.481 179.965 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.44 ' HG3' ' HB2' ' A' ' 41' ' ' SER . 2.0 tt0 -115.24 167.23 11.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.303 -0.873 . . . . 0.0 109.547 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.96 -172.6 3.88 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.48 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -84.52 10.31 11.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.509 179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.426 ' O ' ' CB ' ' A' ' 40' ' ' ALA . 5.4 mttp -121.0 -30.83 4.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.333 -0.854 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.426 ' CB ' ' O ' ' A' ' 39' ' ' LYS . . . 169.75 -171.78 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.321 -0.862 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.44 ' HB2' ' HG3' ' A' ' 36' ' ' GLU . 10.5 t -103.96 134.07 47.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.181 -0.949 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtt -138.73 107.2 5.84 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.251 -0.906 . . . . 0.0 109.487 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.29 166.04 21.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.182 -0.949 . . . . 0.0 109.465 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 72.0 t -136.38 142.15 38.49 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.305 -0.872 . . . . 0.0 109.342 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.527 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 35.8 Cg_endo -77.96 -168.27 0.59 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.512 2.142 . . . . 0.0 110.448 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.515 ' CB ' HG23 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -85.21 124.09 72.45 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.374 -0.829 . . . . 0.0 109.392 -179.913 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.455 ' HG2' HD13 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -78.45 0.55 9.83 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.306 2.004 . . . . 0.0 110.29 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.427 ' HE3' ' HG3' ' A' ' 74' ' ' PRO . 0.4 OUTLIER -160.15 116.73 2.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.941 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.408 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . . . -75.76 80.93 2.7 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.467 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.518 ' HA3' ' CD1' ' A' ' 72' ' ' LEU . . . -136.37 -159.71 8.51 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 51' ' ' VAL . 11.7 p -103.4 124.1 57.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.201 -1.176 . . . . 0.0 109.519 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.2 t -49.94 140.02 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.7 tptm -96.94 -70.22 0.73 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.201 -0.937 . . . . 0.0 109.442 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 52.0 p -158.32 135.23 9.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 20.9 t -83.31 117.45 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 8.9 t -94.21 19.99 8.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.453 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.428 HG23 HG21 ' A' ' 69' ' ' ILE . 0.7 OUTLIER -143.06 179.58 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.292 -0.88 . . . . 0.0 109.441 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.514 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -130.0 167.39 18.33 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.537 -179.978 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.22 151.63 35.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.48 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.29 9.0 80.77 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.514 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 4.4 m-20 -85.04 150.77 24.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.215 -1.167 . . . . 0.0 109.487 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -112.44 104.99 13.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -110.35 173.56 6.27 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.333 -0.855 . . . . 0.0 109.487 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 18.2 ttpt -108.57 142.04 39.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.925 . . . . 0.0 109.499 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 12.7 pt-20 -42.79 138.58 1.91 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.336 -0.852 . . . . 0.0 109.628 -179.884 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.27 -12.86 61.86 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.408 ' O ' ' HA ' ' A' ' 5' ' ' ARG . 4.3 m-20 -79.87 153.56 28.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -1.16 . . . . 0.0 109.423 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.427 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -83.09 161.91 21.51 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.222 -0.924 . . . . 0.0 109.508 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.448 ' CD1' HG21 ' A' ' 6' ' ' VAL . 2.8 mp -132.68 -54.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.23 -0.918 . . . . 0.0 109.481 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.401 HG21 ' CG2' ' A' ' 69' ' ' ILE . 36.4 pt -144.06 -172.37 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.915 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -138.02 115.39 11.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.23 -0.919 . . . . 0.0 109.474 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.518 ' CD1' ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 137.62 32.19 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.294 -0.878 . . . . 0.0 109.365 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.509 ' N ' HD12 ' A' ' 72' ' ' LEU . 10.7 tt0 -111.41 95.12 25.04 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.352 -0.842 . . . . 0.0 109.342 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.7 Cg_endo -77.67 125.88 7.8 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.206 . . . . 0.0 110.489 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -168.07 82.47 0.18 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.304 -0.872 . . . . 0.0 109.364 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 78' ' ' ALA . . . -89.36 122.06 32.22 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 -179.97 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.457 ' O ' ' HB1' ' A' ' 78' ' ' ALA . . . 43.32 -98.71 0.01 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' A' ' 77' ' ' GLY . . . 61.59 22.57 13.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -1.152 . . . . 0.0 109.462 -179.914 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.5 ttt180 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.44 179.956 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 52.4 p . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -138.06 141.28 40.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.321 -0.862 . . . . 0.0 109.478 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.575 HD12 ' CG ' ' A' ' 71' ' ' GLU . 3.8 tt -89.45 151.46 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.516 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.8 mm -115.79 107.8 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.527 ' NH1' ' HA2' ' A' ' 66' ' ' GLY . 0.0 OUTLIER -92.28 168.13 11.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.504 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.75 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.2 t -44.28 142.27 2.32 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.75 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.23 -170.64 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.447 2.098 . . . . 0.0 110.371 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.85 101.91 12.67 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.542 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.35 -61.66 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 109.253 -179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.75 12.5 6.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.02 -139.49 2.65 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 31.8 t0 -111.14 136.86 49.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -1.152 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -105.48 139.72 14.81 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.443 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.2 mt-10 -122.54 135.08 54.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.176 -1.19 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.401 HG23 ' CD1' ' A' ' 63' ' ' LEU . 13.3 t -81.52 130.64 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.91 . . . . 0.0 109.399 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -97.05 -42.8 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.176 -0.953 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.39 151.5 15.38 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.881 . . . . 0.0 109.493 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 2.5 tp -110.87 110.26 20.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.421 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -101.98 49.76 0.85 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.882 . . . . 0.0 109.407 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.506 HG11 ' HG ' ' A' ' 32' ' ' LEU . 0.8 OUTLIER -146.89 157.47 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.4 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -122.66 173.64 7.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.21 -0.931 . . . . 0.0 109.524 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.402 ' HA ' HG11 ' A' ' 52' ' ' VAL . 15.0 t -85.05 147.27 26.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 71.14 7.8 63.75 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 6.0 m-20 -85.04 130.62 34.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.43 111.48 20.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.453 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 27' ' ' GLU . 3.1 mt -94.31 -171.42 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.3 -0.875 . . . . 0.0 109.185 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.73 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.2 mt-10 -149.05 134.92 18.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.421 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.565 HG13 ' O ' ' A' ' 28' ' ' VAL . 3.0 p -50.28 91.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.491 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.78 -60.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.348 -0.845 . . . . 0.0 109.534 179.863 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.429 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.1 tt0 -57.19 162.79 2.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.567 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.456 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -80.08 -179.11 52.31 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -143.43 -40.45 0.3 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -1.164 . . . . 0.0 109.567 179.962 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.8 m -158.63 173.65 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.171 -0.956 . . . . 0.0 109.523 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 16' ' ' ILE . 88.1 t -132.27 104.7 8.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.268 -0.895 . . . . 0.0 109.494 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.93 164.75 14.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.431 ' CG ' ' N ' ' A' ' 37' ' ' SER . 14.5 tt0 -117.22 158.79 23.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.431 ' N ' ' CG ' ' A' ' 36' ' ' GLU . 2.3 t -130.12 179.76 5.7 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.308 -0.87 . . . . 0.0 109.449 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.19 -59.06 2.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 109.415 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.86 54.55 1.58 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.522 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.65 146.16 0.97 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 78.6 p -105.36 137.22 43.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.1 mmt -120.67 178.81 4.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.209 -0.932 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -138.42 161.4 37.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.892 . . . . 0.0 109.529 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 1.8 t -141.66 96.99 6.7 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.376 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.7 Cg_endo -77.56 -168.4 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.476 2.117 . . . . 0.0 110.452 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 28' ' ' VAL . 1.6 t -85.26 113.71 52.03 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.14 1.9 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.37 2.047 . . . . 0.0 110.256 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.8 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.5 OUTLIER -160.17 138.12 9.93 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.88 . . . . 0.0 109.334 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.9 102.19 11.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.184 -0.948 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.921 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -159.11 -167.82 20.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.467 HG22 ' HA2' ' A' ' 23' ' ' GLY . 14.4 p -110.59 138.28 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -1.137 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.402 HG11 ' HA ' ' A' ' 22' ' ' THR . 61.6 t -56.29 122.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 109.527 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.59 -49.37 5.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.457 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 t -149.95 163.66 37.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.578 HG12 ' H ' ' A' ' 57' ' ' VAL . 43.5 t -121.35 131.84 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.25 -0.906 . . . . 0.0 109.428 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.06 21.43 13.74 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.614 HG11 ' HA ' ' A' ' 69' ' ' ILE . 27.5 m -148.23 162.56 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 ttpt -123.73 155.13 38.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.453 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.458 ' HB3' ' HB2' ' A' ' 18' ' ' LEU . 1.7 pp -72.09 139.27 48.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.524 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.59 -13.85 57.2 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -82.79 148.78 27.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -1.162 . . . . 0.0 109.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.448 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 pttp -104.59 141.12 36.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.175 -0.953 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.781 ' N ' HD12 ' A' ' 63' ' ' LEU . 1.5 mp -130.26 164.26 24.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -0.888 . . . . 0.0 109.531 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -115.32 154.11 29.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.987 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.3 OUTLIER -42.72 130.72 4.11 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.285 -0.884 . . . . 0.0 109.663 -179.939 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.527 ' HA2' ' NH1' ' A' ' 5' ' ' ARG . . . 107.83 -12.58 38.32 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -84.23 131.0 34.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -1.16 . . . . 0.0 109.471 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.26 147.13 48.49 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.289 -0.882 . . . . 0.0 109.448 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.723 HG22 HG23 ' A' ' 70' ' ' ILE . 19.8 mm -103.34 -71.46 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.229 -0.919 . . . . 0.0 109.457 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.723 HG23 HG22 ' A' ' 69' ' ' ILE . 0.9 OUTLIER -142.15 171.14 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -0.912 . . . . 0.0 109.5 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.575 ' CG ' HD12 ' A' ' 3' ' ' ILE . 2.6 mp0 -122.7 117.44 25.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.339 -0.851 . . . . 0.0 109.475 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.921 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -89.99 142.18 27.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.247 -0.908 . . . . 0.0 109.424 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.506 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -115.61 91.86 31.23 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.488 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.526 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.541 0 C-N-CA 122.597 2.198 . . . . 0.0 110.401 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 80.6 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.33 164.24 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 57.0 mt -97.43 140.9 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -0.918 . . . . 0.0 109.456 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.73 114.21 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.505 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.744 ' HA ' HD12 ' A' ' 69' ' ' ILE . 1.5 ptt180 -110.29 164.68 12.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.253 -0.904 . . . . 0.0 109.434 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.746 HG13 ' HD2' ' A' ' 7' ' ' PRO . 74.9 t -65.99 142.28 97.94 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.175 -0.953 . . . . 0.0 109.393 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.746 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.5 Cg_endo -78.16 -171.72 1.29 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.515 2.143 . . . . 0.0 110.39 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -68.04 112.86 5.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.427 ' O ' HG13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -110.18 -29.25 2.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.224 -0.923 . . . . 0.0 108.741 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.62 -47.34 2.32 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.74 -144.96 7.18 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -99.63 146.98 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.2 -1.176 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.02 148.35 18.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 44.2 tt0 -127.78 146.6 50.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -1.108 . . . . 0.0 109.424 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.734 HG22 HD23 ' A' ' 35' ' ' LEU . 3.6 t -84.33 156.96 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.182 -0.949 . . . . 0.0 109.489 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.675 HD11 ' HB2' ' A' ' 36' ' ' GLU . 3.6 mp -123.79 -36.61 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.279 -0.888 . . . . 0.0 109.496 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -151.44 151.39 31.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.22 -0.925 . . . . 0.0 109.449 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 1.011 HD12 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -108.52 118.46 36.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.455 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 mt -90.26 30.55 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.498 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 1.011 HG22 HD12 ' A' ' 18' ' ' LEU . 31.8 m -149.69 156.66 7.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.429 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.3 OUTLIER -130.26 176.3 8.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 22' ' ' THR . 14.7 t -75.15 124.57 27.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.223 -0.923 . . . . 0.0 109.504 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.84 1.05 89.08 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.429 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -84.61 142.17 30.14 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.145 -1.209 . . . . 0.0 109.474 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 5.0 tt -108.66 121.38 44.9 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.207 -0.933 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.718 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.5 mt -90.29 -171.41 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.268 -0.895 . . . . 0.0 109.177 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -145.28 172.69 12.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.749 HG13 ' O ' ' A' ' 28' ' ' VAL . 9.7 p -74.06 82.27 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 162.94 -58.55 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.298 -0.876 . . . . 0.0 109.48 179.918 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.41 ' C ' ' O ' ' A' ' 29' ' ' GLU . 0.7 OUTLIER -44.29 157.88 0.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.509 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.23 -153.56 0.99 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.755 HD23 ' CA ' ' A' ' 46' ' ' SER . 0.1 OUTLIER -159.87 -73.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -1.148 . . . . 0.0 109.517 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.436 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 25.8 m -135.37 135.09 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HG3' ' A' ' 43' ' ' GLU . 20.5 t -107.09 92.82 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.343 -0.848 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.734 HD23 HG22 ' A' ' 15' ' ' VAL . 0.4 OUTLIER -89.97 -173.69 3.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.945 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.675 ' HB2' HD11 ' A' ' 16' ' ' ILE . 8.7 tt0 -130.41 167.58 18.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.4 m -126.61 172.25 10.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.57 -58.8 3.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 11.6 pttm -132.27 53.38 2.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.432 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.1 -166.58 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.249 -0.907 . . . . 0.0 109.46 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.8 155.68 38.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 4.5 mmt -138.71 145.55 40.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HG3' HG22 ' A' ' 34' ' ' VAL . 14.3 tm-20 -159.99 150.13 18.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.268 -0.895 . . . . 0.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.548 HG13 ' HD2' ' A' ' 45' ' ' PRO . 49.4 t -135.77 140.1 32.64 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.448 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.548 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.28 -168.65 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.442 2.095 . . . . 0.0 110.368 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.755 ' CA ' HD23 ' A' ' 32' ' ' LEU . 0.3 OUTLIER -85.52 113.38 50.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.481 ' O ' ' HG2' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -78.31 -3.17 13.16 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.256 1.971 . . . . 0.0 110.381 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.641 ' CB ' HD22 ' A' ' 72' ' ' LEU . 3.6 mtmm -160.37 130.92 5.44 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.344 -0.847 . . . . 0.0 109.406 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.51 90.67 7.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.439 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.486 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -146.25 -166.24 11.98 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.5 p -109.97 160.26 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.28 -1.13 . . . . 0.0 109.482 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.428 ' N ' HG22 ' A' ' 51' ' ' VAL . 55.0 t -76.04 123.6 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.967 . . . . 0.0 109.443 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -94.23 -49.41 5.74 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.495 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 t -158.35 118.21 3.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.465 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.92 HG13 HG22 ' A' ' 70' ' ' ILE . 5.8 t -87.66 133.17 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 56' ' ' SER . 8.2 t -113.31 29.18 8.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.496 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.445 HG11 ' HA ' ' A' ' 69' ' ' ILE . 35.6 m -149.47 175.6 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -136.5 157.57 46.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.467 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.447 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -68.22 138.87 55.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.448 -179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.45 -10.67 68.47 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.441 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 41.6 m-20 -80.9 144.95 31.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -1.144 . . . . 0.0 109.482 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 14.2 ptmt -110.52 148.09 32.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 63' ' ' LEU . 4.3 mp -138.95 166.68 23.85 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.244 -0.91 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 5.0 mtpt -99.58 148.4 24.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 23.8 pt-20 -42.81 142.76 0.82 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.666 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.83 -9.48 76.68 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.98 137.21 35.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -1.156 . . . . 0.0 109.516 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -67.81 176.83 2.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.844 HG22 HG23 ' A' ' 70' ' ' ILE . 2.1 mp -140.9 -67.24 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.92 HG22 HG13 ' A' ' 55' ' ' VAL . 30.1 pt -139.45 173.24 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 109.472 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -127.83 108.47 10.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.641 HD22 ' CB ' ' A' ' 48' ' ' LYS . 0.6 OUTLIER -90.09 142.24 27.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.436 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.407 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 60.6 tt0 -116.54 88.32 23.84 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HG3' ' HD2' ' A' ' 48' ' ' LYS . 35.7 Cg_endo . . . . . 0 C--N 1.31 -1.492 0 C-N-CA 122.652 2.235 . . . . 0.0 110.409 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 53.6 p . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -82.44 171.64 13.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 41.0 mm -107.0 143.91 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.859 HG21 ' HG3' ' A' ' 47' ' ' PRO . 38.8 mm -107.16 118.59 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.53 ' CG ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -103.73 -171.13 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.185 -0.947 . . . . 0.0 109.541 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.752 HG13 ' HD2' ' A' ' 7' ' ' PRO . 65.7 t -79.47 142.72 58.39 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.319 -0.863 . . . . 0.0 109.311 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.752 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.06 -168.79 0.65 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.599 2.199 . . . . 0.0 110.509 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -82.74 111.18 18.43 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.395 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.91 -10.93 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.935 . . . . 0.0 109.345 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.98 39.63 58.53 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.07 -153.72 24.88 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -89.34 174.15 7.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.289 -1.124 . . . . 0.0 109.497 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -147.51 104.8 0.3 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.463 ' N ' ' CD ' ' A' ' 14' ' ' GLU . 6.2 mp0 -92.82 112.92 25.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -1.153 . . . . 0.0 109.442 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 40.3 t -54.33 134.75 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.5 mm -108.56 -50.88 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.228 -0.92 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -144.19 153.03 41.68 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.454 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.85 HD23 HG23 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -120.82 116.08 24.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.924 . . . . 0.0 109.5 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.767 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.3 pp -106.1 52.15 0.73 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.354 -0.841 . . . . 0.0 109.525 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.85 HG23 HD23 ' A' ' 18' ' ' LEU . 0.8 OUTLIER -140.2 169.54 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . 3.5 tptt -144.32 169.28 18.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.211 -0.931 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.435 HG23 ' O ' ' A' ' 22' ' ' THR . 15.2 t -84.11 132.56 34.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 84.26 -1.43 88.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.44 ' CG ' ' HB3' ' A' ' 21' ' ' LYS . 5.7 m-20 -84.05 134.29 34.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.115 -1.227 . . . . 0.0 109.527 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -94.36 116.37 28.73 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.881 . . . . 0.0 109.41 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.1 mt -90.52 -171.35 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.228 -0.92 . . . . 0.0 109.157 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.6 mt-10 -146.37 159.47 43.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 28' ' ' VAL . 7.5 p -72.95 83.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.88 . . . . 0.0 109.47 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 162.83 -32.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.3 -0.875 . . . . 0.0 109.518 179.914 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.413 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 39.4 tt0 -76.28 148.64 37.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.462 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.44 -175.66 1.28 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.888 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.9 OUTLIER -148.22 -68.59 0.23 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -1.105 . . . . 0.0 109.463 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -131.71 171.42 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.584 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 43' ' ' GLU . 75.4 t -134.14 92.72 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.419 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.4 mp -90.0 149.82 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -0.873 . . . . 0.0 109.423 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -115.17 139.1 50.21 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.24 -179.21 5.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 109.515 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -69.76 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -92.17 -49.69 6.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.892 . . . . 0.0 109.47 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.528 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.89 173.63 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.28 -0.887 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.65 128.94 34.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.294 -0.879 . . . . 0.0 109.501 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.7 mtt -127.2 105.73 8.76 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -80.01 156.76 27.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.547 HG13 ' HD2' ' A' ' 45' ' ' PRO . 44.9 t -133.96 140.45 36.39 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.389 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.547 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.0 Cg_endo -78.44 -168.44 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.599 2.199 . . . . 0.0 110.434 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.888 ' HA ' HD13 ' A' ' 32' ' ' LEU . 7.7 t -85.23 129.93 53.84 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.404 -0.81 . . . . 0.0 109.332 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.859 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.0 Cg_endo -78.59 -1.88 11.98 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.366 2.044 . . . . 0.0 110.513 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.729 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.18 128.57 4.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.533 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.09 86.33 5.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.794 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -146.62 -166.12 12.03 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.456 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.0 p -104.88 139.47 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -1.167 . . . . 0.0 109.466 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 70.5 t -56.98 127.85 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' SER . 18.4 tptm -100.7 -15.91 17.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.202 -0.936 . . . . 0.0 109.485 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.412 ' CB ' ' O ' ' A' ' 53' ' ' LYS . 0.5 OUTLIER 171.12 145.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.464 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.559 HG12 ' H ' ' A' ' 57' ' ' VAL . 76.1 t -101.11 142.19 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.458 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 61.6 m -121.84 13.58 10.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.89 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 69' ' ' ILE . 10.8 m -147.76 166.99 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 109.504 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -125.52 171.23 10.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.464 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -79.03 118.78 21.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.51 -11.47 42.82 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -70.86 150.93 45.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.968 ' C ' HD22 ' A' ' 63' ' ' LEU . 10.2 tttm -100.19 120.26 39.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.463 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.968 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.0 mm? -131.14 143.93 51.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -105.04 153.21 21.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.479 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 4.3 pt-20 -42.9 143.63 0.7 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.66 -18.1 58.09 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' ' O ' ' A' ' 68' ' ' ALA . 7.7 m-20 -85.12 129.99 34.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -1.156 . . . . 0.0 109.526 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.53 ' HA ' ' CG ' ' A' ' 5' ' ' ARG . . . -48.5 175.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.599 ' O ' HG23 ' A' ' 70' ' ' ILE . 21.9 mm -146.93 -47.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.463 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 69' ' ' ILE . 0.6 OUTLIER -158.68 -177.11 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.483 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -127.75 161.82 28.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.208 -0.933 . . . . 0.0 109.494 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.794 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.7 OUTLIER -143.15 135.8 27.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.392 -179.948 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 71.3 tt0 -114.68 90.24 21.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.2 Cg_endo . . . . . 0 C--N 1.309 -1.517 0 C-N-CA 122.557 2.171 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.451 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 18.3 p . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -121.37 152.57 38.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.507 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.7 tt -86.52 152.96 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.821 HG21 ' HG3' ' A' ' 47' ' ' PRO . 5.2 mp -131.92 118.54 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.254 -0.904 . . . . 0.0 109.464 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.79 175.03 7.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.452 179.954 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.654 HG13 ' HD2' ' A' ' 7' ' ' PRO . 53.5 t -55.2 139.88 64.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.323 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.654 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.1 Cg_endo -78.59 -172.94 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.533 2.155 . . . . 0.0 110.359 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -85.11 110.66 19.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 1.009 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.8 -56.47 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.421 -179.917 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.96 -27.32 1.89 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . -179.8 118.42 0.59 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 1.009 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.2 OUTLIER 49.76 -179.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.267 -1.137 . . . . 0.0 109.478 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.762 ' C ' HD23 ' A' ' 35' ' ' LEU . . . -172.24 90.97 0.09 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 19.3 mt-10 -94.98 124.05 38.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.339 -1.095 . . . . 0.0 109.487 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.7 t -73.12 132.33 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.464 HG22 ' O ' ' A' ' 34' ' ' VAL . 4.4 tt -92.34 -28.76 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -174.43 151.2 1.53 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.41 HD23 ' CG2' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -104.18 103.45 13.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.45 15.07 7.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.284 -0.885 . . . . 0.0 109.375 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.838 HG11 ' HG ' ' A' ' 32' ' ' LEU . 11.9 m -113.28 178.02 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.67 158.43 43.78 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.9 t -73.64 141.89 46.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.288 -0.883 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 82.85 -6.61 69.55 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.14 135.62 36.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -1.141 . . . . 0.0 109.446 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.89 HD12 ' C ' ' A' ' 50' ' ' GLY . 22.4 tp -93.24 110.68 22.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.229 -0.92 . . . . 0.0 109.469 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.816 HG23 ' OE1' ' A' ' 30' ' ' GLN . 2.7 mt -91.27 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.248 -0.908 . . . . 0.0 109.201 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 tm-20 -139.36 -178.63 5.46 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.208 -0.933 . . . . 0.0 109.443 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.2 p -84.79 69.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.554 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.491 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 169.21 -40.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.366 -0.834 . . . . 0.0 109.435 179.884 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.816 ' OE1' HG23 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -56.73 138.49 52.82 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 109.364 179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.44 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -69.5 166.05 49.15 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.838 ' HG ' HG11 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -127.42 -42.01 1.69 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.366 -1.079 . . . . 0.0 109.446 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 25.6 m -158.63 174.33 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.154 -0.966 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.464 ' O ' HG22 ' A' ' 16' ' ' ILE . 70.7 t -128.77 102.53 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.227 -0.921 . . . . 0.0 109.449 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.762 HD23 ' C ' ' A' ' 13' ' ' GLY . 3.5 mp -89.98 141.67 28.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.216 -0.928 . . . . 0.0 109.4 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.407 ' OE2' ' OG ' ' A' ' 41' ' ' SER . 6.0 tt0 -115.79 134.31 55.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.23 -0.919 . . . . 0.0 109.513 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.9 m -132.03 -177.77 4.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.894 . . . . 0.0 109.446 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.04 -16.54 60.2 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.467 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.8 mttt -84.16 -55.27 4.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.94 . . . . 0.0 109.439 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.467 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.15 -179.54 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.889 . . . . 0.0 109.454 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.407 ' OG ' ' OE2' ' A' ' 36' ' ' GLU . 2.4 m -95.84 103.72 15.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.5 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -93.78 -173.34 3.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.186 -0.946 . . . . 0.0 109.5 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -124.89 162.16 25.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.201 -0.937 . . . . 0.0 109.477 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 35' ' ' LEU . 18.7 t -144.17 97.11 5.28 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.515 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.6 Cg_endo -77.43 -168.69 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.566 2.177 . . . . 0.0 110.476 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.3 135.24 39.21 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.411 -0.806 . . . . 0.0 109.307 179.89 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.821 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.56 -4.63 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.466 2.111 . . . . 0.0 110.433 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 46' ' ' SER . 26.0 tttt -160.31 142.13 12.69 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.403 -0.81 . . . . 0.0 109.468 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.92 94.22 5.19 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.179 -0.951 . . . . 0.0 109.394 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.897 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.94 -174.7 22.15 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 23' ' ' GLY . 10.8 p -103.66 137.98 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -1.149 . . . . 0.0 109.522 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.8 t -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.05 -27.7 13.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.206 -0.934 . . . . 0.0 109.524 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -167.04 171.57 10.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.16 -0.963 . . . . 0.0 109.544 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.787 ' HA ' HG22 ' A' ' 70' ' ' ILE . 55.6 t -131.86 113.25 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 56' ' ' SER . 5.6 t -99.32 22.64 10.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.47 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.414 ' H ' HG12 ' A' ' 55' ' ' VAL . 31.3 m -144.03 169.55 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.198 -0.939 . . . . 0.0 109.451 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.68 171.93 12.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.728 ' O ' HD12 ' A' ' 59' ' ' LEU . 4.0 pp -80.04 139.15 37.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.315 -0.866 . . . . 0.0 109.536 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.79 -11.14 62.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -70.53 137.46 50.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -1.16 . . . . 0.0 109.39 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.544 ' O ' HD22 ' A' ' 63' ' ' LEU . 18.7 mttm -98.5 117.18 32.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.27 -0.894 . . . . 0.0 109.46 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.722 HD12 ' CB ' ' A' ' 67' ' ' ASP . 3.5 mm? -117.92 159.74 22.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.429 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.3 tttt -112.09 142.82 44.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 64' ' ' LYS . 9.7 mt-10 -42.84 129.78 4.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.306 -0.871 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 113.96 -19.95 17.63 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.722 ' CB ' HD12 ' A' ' 63' ' ' LEU . 26.8 m-20 -85.12 136.06 33.71 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.231 -1.158 . . . . 0.0 109.41 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -58.92 167.85 1.47 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.226 -0.921 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.51 HD11 ' CG2' ' A' ' 6' ' ' VAL . 39.1 mm -134.13 -67.28 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.787 HG22 ' HA ' ' A' ' 55' ' ' VAL . 0.7 OUTLIER -144.9 -173.56 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.459 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -133.48 120.93 21.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.303 -0.873 . . . . 0.0 109.477 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.976 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.4 tt -94.05 135.47 35.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.433 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.451 ' OE2' ' HB3' ' A' ' 1' ' ' SER . 5.9 tt0 -114.45 89.17 17.26 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.157 -0.964 . . . . 0.0 109.499 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.976 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.308 -1.592 0 C-N-CA 122.564 2.176 . . . . 0.0 110.365 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.469 ' HB3' ' HB2' ' A' ' 73' ' ' GLU . 95.0 p . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -87.04 137.03 32.69 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -0.883 . . . . 0.0 109.472 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.765 HD13 ' N ' ' A' ' 4' ' ' ILE . 0.0 OUTLIER -101.87 121.49 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.4 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.765 ' N ' HD13 ' A' ' 3' ' ' ILE . 49.8 mm -95.82 115.08 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.424 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.444 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -112.4 160.24 17.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.203 -0.935 . . . . 0.0 109.686 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.8 HG13 HD11 ' A' ' 9' ' ' ILE . 85.6 t -44.83 104.47 0.39 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.338 -0.851 . . . . 0.0 109.545 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.1 Cg_endo -77.58 -170.43 0.94 Allowed 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.433 2.089 . . . . 0.0 110.438 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -72.31 99.92 2.52 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.209 -0.932 . . . . 0.0 109.466 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.8 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.26 -10.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.372 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.41 -17.63 11.27 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.04 -119.28 0.81 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.37 170.0 9.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.07 120.14 1.07 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 6.2 mt-10 -100.58 122.46 43.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -1.158 . . . . 0.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.2 t -63.2 124.15 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.905 . . . . 0.0 109.509 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.3 mm -99.54 -18.06 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.34 -0.85 . . . . 0.0 109.454 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.98 149.06 1.83 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.53 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.924 ' HG ' HG22 ' A' ' 20' ' ' VAL . 6.6 tp -118.73 102.39 8.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.545 ' H ' HD23 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -90.71 48.62 1.56 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.527 179.973 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.924 HG22 ' HG ' ' A' ' 18' ' ' LEU . 18.7 m -145.86 168.47 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.409 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.35 171.27 14.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.98 132.02 35.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.554 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 79.57 -4.57 63.81 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.4 134.99 36.57 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.16 -1.2 . . . . 0.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -82.64 127.54 33.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.853 . . . . 0.0 109.429 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.792 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -91.53 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.278 -0.889 . . . . 0.0 109.269 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.715 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.2 tm-20 -142.57 136.68 29.49 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.204 -0.935 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.661 HG13 ' HG3' ' A' ' 29' ' ' GLU . 9.3 p -45.73 140.72 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.248 -0.907 . . . . 0.0 109.475 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.661 ' HG3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER 82.99 -43.69 0.11 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.64 -0.663 . . . . 0.0 109.9 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.523 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -47.35 133.82 12.12 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.035 -1.041 . . . . 0.0 109.482 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.34 162.32 49.74 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.902 ' CD2' HG11 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -125.98 -38.53 2.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -1.158 . . . . 0.0 109.465 179.972 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.705 HG12 HD12 ' A' ' 18' ' ' LEU . 33.0 m -158.73 158.59 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.522 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.2 t -124.44 98.22 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.314 -0.866 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 1.9 mp -90.23 140.24 29.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.305 -0.872 . . . . 0.0 109.526 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -126.89 127.58 45.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.416 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.627 ' HB3' ' HB3' ' A' ' 40' ' ' ALA . 0.3 OUTLIER -102.99 174.87 5.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.893 . . . . 0.0 109.477 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' N ' ' OG ' ' A' ' 37' ' ' SER . . . -44.88 -34.48 2.38 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.6 pttt -156.21 50.87 0.52 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.254 -0.903 . . . . 0.0 109.524 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.627 ' HB3' ' HB3' ' A' ' 37' ' ' SER . . . -158.56 91.72 1.09 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.32 129.62 40.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.421 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.9 mtm -149.25 174.46 12.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.259 -0.9 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 31.6 mp0 -127.97 164.58 22.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -143.9 96.92 5.43 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.57 -169.1 0.68 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.537 2.158 . . . . 0.0 110.478 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.792 ' HB2' HG21 ' A' ' 26' ' ' ILE . 19.0 t -85.55 126.24 67.11 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.436 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.547 ' CG ' ' CD1' ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.59 -2.2 12.26 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.44 2.093 . . . . 0.0 110.383 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.593 ' HB3' HD12 ' A' ' 72' ' ' LEU . 3.3 tptt -160.16 127.35 4.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.386 -0.821 . . . . 0.0 109.432 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.7 88.66 1.74 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.209 -0.932 . . . . 0.0 109.469 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -144.99 -153.71 5.94 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.674 ' O ' HD22 ' A' ' 72' ' ' LEU . 5.9 p -108.45 151.65 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -1.127 . . . . 0.0 109.408 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.2 t -75.97 123.8 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.187 -0.946 . . . . 0.0 109.522 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -81.38 -59.13 2.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.285 -0.884 . . . . 0.0 109.489 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 31.3 p -161.29 126.3 3.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.457 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.69 HG12 ' H ' ' A' ' 57' ' ' VAL . 57.9 t -81.38 126.21 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.287 -0.883 . . . . 0.0 109.486 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 t -103.66 26.0 9.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.216 -0.927 . . . . 0.0 109.48 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.69 ' H ' HG12 ' A' ' 55' ' ' VAL . 15.6 m -148.72 164.87 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.887 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.451 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 9.2 tttt -132.89 164.12 27.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.522 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.34 138.18 55.21 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.454 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.14 -18.22 54.64 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.451 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 1.7 m-20 -82.87 143.61 30.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 109.437 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.577 ' C ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -102.18 136.99 41.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.215 -0.928 . . . . 0.0 109.438 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.1 mm? -111.34 177.94 4.5 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.471 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.449 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.5 ttpp -139.39 152.21 46.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 7.3 mt-10 -44.28 139.9 2.44 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.172 -0.955 . . . . 0.0 109.513 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.34 -47.52 3.65 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -48.75 130.19 17.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.298 -1.119 . . . . 0.0 109.521 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -60.44 161.99 6.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.326 -0.859 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.787 HD11 HG23 ' A' ' 6' ' ' VAL . 19.9 mm -135.41 -55.55 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.304 -0.872 . . . . 0.0 109.466 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.672 HG23 HG22 ' A' ' 69' ' ' ILE . 11.4 pt -156.57 -174.52 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.311 -0.868 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 0.6 OUTLIER -144.17 139.04 28.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.856 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -119.61 118.81 31.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.196 -0.94 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.516 ' N ' HD13 ' A' ' 72' ' ' LEU . 5.7 tt0 -111.74 94.91 25.78 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.575 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo . . . . . 0 C--N 1.308 -1.578 0 C-N-CA 122.616 2.211 . . . . 0.0 110.381 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 94.7 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -99.45 149.21 23.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.941 . . . . 0.0 109.426 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.2 tt -83.48 159.16 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.31 -0.868 . . . . 0.0 109.468 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.18 111.62 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.192 -0.942 . . . . 0.0 109.407 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.466 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.36 170.13 10.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.538 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -44.19 142.32 2.25 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.419 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.27 171.51 16.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.554 2.169 . . . . 0.0 110.37 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -84.92 99.13 10.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.56 -11.19 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.258 -0.901 . . . . 0.0 109.396 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.88 -10.8 68.24 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -158.98 -161.32 11.02 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 -83.74 143.32 30.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -1.179 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.77 150.16 18.7 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -129.44 119.17 23.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -1.154 . . . . 0.0 109.481 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.6 t -67.37 152.22 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.419 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.404 HD12 HG23 ' A' ' 16' ' ' ILE . 49.3 mm -120.06 -34.24 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -175.47 137.91 0.39 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 109.452 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.97 140.6 37.03 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 121.154 -0.966 . . . . 0.0 109.371 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.46 35.23 3.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 m -144.13 -179.7 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.432 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.27 -179.68 6.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 0.0 109.441 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.472 HG23 ' O ' ' A' ' 22' ' ' THR . 14.2 t -79.9 129.58 34.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.41 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.55 -0.13 61.22 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -81.35 133.29 35.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 109.489 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -89.78 107.82 19.32 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.461 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.724 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.88 -171.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.184 -0.948 . . . . 0.0 109.26 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -147.31 176.76 9.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.51 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.748 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.2 p -81.18 74.34 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.515 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.506 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.92 -27.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.313 -0.867 . . . . 0.0 109.402 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -72.99 136.01 45.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.456 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.24 176.18 2.85 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.973 HD23 HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -137.15 -62.93 0.61 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -1.147 . . . . 0.0 109.452 180.0 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.973 HG13 HD23 ' A' ' 32' ' ' LEU . 16.5 m -137.66 172.03 15.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -125.69 105.95 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.246 -0.909 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.1 mp -97.95 153.61 18.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.84 149.98 39.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.6 m -126.65 177.96 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.99 -41.41 59.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.483 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -157.95 37.04 0.26 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -152.69 88.33 1.34 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.401 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.465 ' O ' ' HG2' ' A' ' 42' ' ' MET . 34.6 t -83.45 127.58 33.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.242 -0.911 . . . . 0.0 109.451 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 41' ' ' SER . 11.9 mtt -147.45 136.46 22.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.468 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -93.0 169.93 10.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.162 -0.961 . . . . 0.0 109.437 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 40.7 t -135.88 127.83 17.46 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.36 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.456 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.4 -168.15 0.58 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.43 2.086 . . . . 0.0 110.389 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.529 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.1 OUTLIER -85.14 135.92 38.78 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.869 . . . . 0.0 109.19 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.43 -2.39 12.45 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.434 2.089 . . . . 0.0 110.533 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.775 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.03 140.53 11.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.376 -0.828 . . . . 0.0 109.4 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.68 95.95 9.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.773 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.71 -153.0 6.79 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 73' ' ' GLU . 12.2 p -110.81 141.63 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -1.124 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 71.0 t -63.87 142.6 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.42 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -106.77 -55.35 2.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.31 118.87 7.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 70' ' ' ILE . 13.1 t -84.87 106.73 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 p -90.16 9.2 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.459 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.809 HG11 HG23 ' A' ' 69' ' ' ILE . 20.6 m -124.87 158.27 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.451 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.403 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 2.8 tptp -137.43 -173.38 3.46 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.22 -0.925 . . . . 0.0 109.524 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.453 ' N ' HD21 ' A' ' 18' ' ' LEU . 2.2 pp -85.05 134.36 34.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 77.23 9.08 87.0 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.403 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 37.0 m-20 -84.87 145.46 27.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.244 -1.15 . . . . 0.0 109.438 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -107.41 132.48 53.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.521 -179.981 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.427 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -139.59 130.14 25.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.41 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 31.4 tttm -93.82 145.74 24.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.202 -0.936 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.463 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -42.86 124.29 3.05 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.353 -0.842 . . . . 0.0 109.638 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 123.46 -26.37 6.04 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 68' ' ' ALA . 1.2 m-20 -85.11 131.23 34.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -1.147 . . . . 0.0 109.442 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -49.66 178.55 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.284 -0.885 . . . . 0.0 109.509 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.809 HG23 HG11 ' A' ' 57' ' ' VAL . 23.1 mm -145.08 -65.21 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.237 -0.914 . . . . 0.0 109.414 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.591 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.2 pt -151.51 177.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.478 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -143.48 140.42 30.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.942 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.3 tt -107.75 142.8 37.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.411 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.431 ' O ' HG12 ' A' ' 51' ' ' VAL . 1.3 tp10 -131.34 89.84 39.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.432 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.942 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.55 0 C-N-CA 122.59 2.193 . . . . 0.0 110.406 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 60.4 p . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 16.5 mt-10 -135.78 137.24 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.496 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.618 HD11 ' HB1' ' A' ' 68' ' ' ALA . 1.2 tt -82.14 151.94 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.5 mm -117.37 97.03 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.76 163.3 14.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.843 HG23 HD11 ' A' ' 69' ' ' ILE . 71.4 t -57.88 142.05 79.61 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.737 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -77.98 -174.46 2.24 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.587 2.191 . . . . 0.0 110.386 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -58.78 103.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.602 HG23 ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -110.17 -37.75 3.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.238 -0.913 . . . . 0.0 108.767 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.85 52.98 21.65 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.89 -136.57 4.37 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -116.65 138.4 51.47 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.22 -1.165 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -110.74 118.93 5.1 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.01 130.91 47.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.278 -1.131 . . . . 0.0 109.476 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.3 t -80.67 147.31 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.469 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.838 HD12 HG12 ' A' ' 34' ' ' VAL . 60.4 mt -113.49 -57.02 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -0.942 . . . . 0.0 109.474 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -160.8 162.64 32.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.305 -0.872 . . . . 0.0 109.463 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.1 tp -101.2 141.53 33.94 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.721 HD12 ' N ' ' A' ' 32' ' ' LEU . 12.7 mt -99.0 18.67 16.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.488 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -150.04 172.22 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.422 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -120.01 -178.29 3.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.459 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.22 113.92 19.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.501 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.31 0.5 65.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.84 145.89 27.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -1.138 . . . . 0.0 109.434 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.469 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.1 tp -89.81 132.27 35.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.184 -0.947 . . . . 0.0 109.449 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.822 HD13 ' CD1' ' A' ' 32' ' ' LEU . 2.7 mt -91.79 -171.41 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.184 -0.947 . . . . 0.0 109.135 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -149.96 126.01 10.59 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.246 -0.908 . . . . 0.0 109.488 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.567 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 8.4 p -44.98 149.61 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.567 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 16.3 tt0 83.05 -43.67 0.11 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.666 -0.646 . . . . 0.0 109.8 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.546 ' HB2' ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -62.29 153.81 29.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.101 -0.999 . . . . 0.0 109.48 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.476 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -62.46 -176.94 3.03 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.822 ' CD1' HD13 ' A' ' 26' ' ' ILE . 10.0 tp -153.98 -56.88 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -1.176 . . . . 0.0 109.558 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.19 152.7 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.175 -0.953 . . . . 0.0 109.65 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.838 HG12 HD12 ' A' ' 16' ' ' ILE . 22.6 t -120.97 83.96 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.282 -0.886 . . . . 0.0 109.367 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.01 170.86 9.99 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -0.905 . . . . 0.0 109.478 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.516 ' CG ' ' O ' ' A' ' 40' ' ' ALA . 21.8 tt0 -114.08 154.22 28.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -104.7 -177.05 3.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -45.31 -37.69 5.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.314 -0.866 . . . . 0.0 109.446 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -158.74 63.52 0.42 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.516 ' O ' ' CG ' ' A' ' 36' ' ' GLU . . . 178.13 -167.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.425 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.8 m -135.85 116.36 13.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.243 -0.91 . . . . 0.0 109.455 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.465 ' O ' ' HG2' ' A' ' 42' ' ' MET . 0.0 OUTLIER -116.78 132.68 56.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.164 -0.96 . . . . 0.0 109.43 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.569 ' HG2' HG22 ' A' ' 34' ' ' VAL . 2.0 mt-10 -112.57 161.59 16.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 3.4 t -139.31 140.3 25.52 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.279 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.31 -169.12 0.71 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.379 2.053 . . . . 0.0 110.38 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.754 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.53 134.71 39.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.32 -0.862 . . . . 0.0 109.302 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.582 ' HD3' HD22 ' A' ' 32' ' ' LEU . 36.2 Cg_endo -78.68 -12.64 15.0 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.435 2.09 . . . . 0.0 110.233 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.453 ' CD ' ' HB3' ' A' ' 74' ' ' PRO . 1.3 ttmp? -160.64 132.11 5.75 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.7 84.54 2.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.4 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.742 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -135.21 -144.11 4.9 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' VAL . 11.3 p -118.74 157.24 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.404 ' N ' HG22 ' A' ' 51' ' ' VAL . 24.1 t -84.82 136.69 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.239 -0.913 . . . . 0.0 109.468 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.38 -60.89 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.433 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.8 m -175.36 157.62 2.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.16 -0.963 . . . . 0.0 109.501 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 57' ' ' VAL . 3.5 t -87.11 121.38 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 m -80.93 5.85 15.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.573 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.871 HG11 HD11 ' A' ' 63' ' ' LEU . 35.6 m -150.11 -172.26 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.436 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.4 OUTLIER -114.05 153.28 29.7 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.453 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -65.81 150.3 48.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.466 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 69.25 9.1 60.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.436 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 5.1 m-20 -84.99 154.79 21.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -101.92 123.18 45.4 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.898 . . . . 0.0 109.427 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 57' ' ' VAL . 83.0 mt -123.2 152.72 40.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 109.453 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.8 ttpt -94.0 147.28 23.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.286 -0.883 . . . . 0.0 109.509 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.602 ' HB3' HG23 ' A' ' 9' ' ' ILE . 10.7 pt-20 -43.05 139.59 1.72 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.35 -0.844 . . . . 0.0 109.605 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.55 -4.61 79.83 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.04 143.37 29.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -1.106 . . . . 0.0 109.452 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.618 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -74.98 157.74 34.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.312 -0.868 . . . . 0.0 109.461 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.843 HD11 HG23 ' A' ' 6' ' ' VAL . 3.2 mp -131.07 -51.77 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.94 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.0 pt -147.4 -179.69 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 2' ' ' GLU . 22.9 tt0 -150.06 129.24 12.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.224 -0.923 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.742 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -95.82 145.07 25.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.473 179.931 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.52 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -112.4 93.32 22.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.328 -0.858 . . . . 0.0 109.404 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.56 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.562 0 C-N-CA 122.631 2.221 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 26.9 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -92.87 169.41 10.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.89 . . . . 0.0 109.476 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.7 mt -106.48 146.58 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.875 . . . . 0.0 109.439 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.595 HD12 ' HG2' ' A' ' 47' ' ' PRO . 27.9 mm -104.93 114.68 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.566 ' HA ' HD12 ' A' ' 69' ' ' ILE . 6.0 ptp180 -107.07 177.71 4.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.238 -0.914 . . . . 0.0 109.459 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 72.6 t -73.77 142.06 79.77 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.219 -0.926 . . . . 0.0 109.459 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.0 Cg_endo -78.45 -170.15 0.92 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.497 2.131 . . . . 0.0 110.441 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -85.02 102.86 13.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.164 -0.96 . . . . 0.0 109.423 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.529 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.3 -49.03 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.352 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.63 30.28 2.44 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' OE1' ' A' ' 65' ' ' GLU . . . 168.3 -166.19 39.34 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -94.95 115.65 27.72 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.264 -1.139 . . . . 0.0 109.531 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.38 168.39 54.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 4.6 tt0 -142.99 117.27 9.58 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.2 -1.177 . . . . 0.0 109.496 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.556 HG11 ' HA ' ' A' ' 59' ' ' LEU . 62.4 t -62.52 119.78 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 34' ' ' VAL . 2.1 pt -113.99 -20.26 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.416 ' N ' HG13 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -155.41 136.76 14.02 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.299 -0.875 . . . . 0.0 109.499 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.425 HD13 HG11 ' A' ' 15' ' ' VAL . 0.2 OUTLIER -129.09 123.57 32.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.937 . . . . 0.0 109.4 -179.965 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.492 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -125.22 63.13 1.17 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 0.0 109.478 -179.923 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.608 HG11 ' HG ' ' A' ' 32' ' ' LEU . 16.7 m -144.96 169.24 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.22 160.07 42.04 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 53' ' ' LYS . 94.8 m -84.5 133.85 34.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.495 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.85 -10.77 73.81 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -81.1 136.42 35.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -1.137 . . . . 0.0 109.505 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.56 115.96 22.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 109.5 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -91.02 -171.54 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.187 -0.945 . . . . 0.0 109.234 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 mt-10 -145.67 174.87 10.81 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.736 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.0 p -84.98 76.22 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.42 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 167.21 -41.98 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.431 -0.793 . . . . 0.0 109.251 179.867 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.526 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 61.5 tt0 -59.65 146.44 41.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.19 168.17 54.4 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.608 ' HG ' HG11 ' A' ' 20' ' ' VAL . 5.0 tp -128.46 -43.79 1.41 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -1.154 . . . . 0.0 109.567 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.526 HG13 ' C ' ' A' ' 32' ' ' LEU . 15.7 m -158.56 159.08 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 16' ' ' ILE . 62.9 t -124.37 103.47 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.184 -0.947 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.08 163.08 15.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -118.05 145.29 44.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -121.69 -177.39 3.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.915 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.36 -56.01 9.25 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.582 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -143.98 59.77 1.36 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 109.523 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.582 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 170.42 112.01 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 33.8 t -100.73 115.15 29.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.483 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 26.2 ttp -102.98 154.73 18.94 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.178 -0.952 . . . . 0.0 109.403 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -100.6 169.61 8.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 69.9 t -146.12 99.57 4.27 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.526 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.4 Cg_endo -77.13 -167.96 0.53 Allowed 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.432 2.088 . . . . 0.0 110.479 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 2.6 t -84.82 125.98 69.5 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.348 -0.845 . . . . 0.0 109.385 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.595 ' HG2' HD12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.54 -1.16 11.35 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.382 2.055 . . . . 0.0 110.404 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 46' ' ' SER . 4.7 tttt -160.15 140.95 12.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.304 -0.872 . . . . 0.0 109.574 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.67 102.84 12.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 0.0 109.402 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 1.002 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -152.92 -168.93 17.54 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.63 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.4 p -104.18 120.19 54.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -1.105 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 50.9 t -49.09 142.36 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.532 ' O ' HG23 ' A' ' 22' ' ' THR . 3.1 ttpp -104.87 -59.77 1.7 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.01 140.99 14.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.572 HG12 ' H ' ' A' ' 57' ' ' VAL . 10.7 t -90.37 126.36 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.506 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.6 m -100.38 20.47 14.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.251 -0.906 . . . . 0.0 109.394 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.795 HG21 HG23 ' A' ' 69' ' ' ILE . 1.4 m -143.62 163.39 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -120.1 141.47 49.77 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.474 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.556 ' HA ' HG11 ' A' ' 15' ' ' VAL . 2.1 pp -60.26 128.37 36.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.466 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.39 -21.9 21.04 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -83.43 158.45 22.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.187 -1.184 . . . . 0.0 109.502 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 5.8 pttt -86.8 165.11 16.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.574 HD21 HG11 ' A' ' 57' ' ' VAL . 0.3 OUTLIER -132.02 110.66 10.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.324 -0.86 . . . . 0.0 109.45 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.84 136.28 36.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.232 -0.918 . . . . 0.0 109.282 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' O ' ' A' ' 11' ' ' GLY . 1.8 mt-10 -48.85 149.04 1.94 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.31 -0.869 . . . . 0.0 109.958 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.79 -14.66 46.75 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.64 141.62 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.198 -1.178 . . . . 0.0 109.621 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -74.61 176.07 7.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 109.342 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.882 HG22 HG23 ' A' ' 70' ' ' ILE . 2.9 mp -139.37 -64.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.156 -0.965 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.882 HG23 HG22 ' A' ' 69' ' ' ILE . 2.3 pp -139.18 173.59 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.605 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -129.31 137.51 51.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.874 . . . . 0.0 109.428 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.002 HD11 ' CA ' ' A' ' 50' ' ' GLY . 3.5 tt -108.52 137.88 45.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.893 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -113.38 92.17 22.19 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.975 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.501 0 C-N-CA 122.598 2.198 . . . . 0.0 110.391 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.529 ' CB ' ' HG2' ' A' ' 73' ' ' GLU . 53.2 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.271 0.558 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 1' ' ' SER . 2.0 mm-40 -154.09 148.81 26.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.231 -0.918 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.7 mp -80.05 143.1 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.412 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.477 HD13 HD11 ' A' ' 70' ' ' ILE . 2.1 mp -114.82 97.88 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.428 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.07 176.67 6.69 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.735 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.0 t -65.68 142.43 98.21 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.735 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.7 Cg_endo -78.24 -178.68 4.8 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.528 2.152 . . . . 0.0 110.374 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -85.05 96.64 9.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.22 -0.925 . . . . 0.0 109.41 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.99 -17.64 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.31 -0.869 . . . . 0.0 109.299 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.29 -8.95 62.46 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.82 -133.14 3.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -113.6 170.8 7.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -134.06 108.44 0.73 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.471 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.3 OUTLIER -99.8 120.33 39.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -1.112 . . . . 0.0 109.371 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.2 t -67.26 123.31 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.88 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.954 HG22 ' O ' ' A' ' 34' ' ' VAL . 8.3 tp -103.37 -25.19 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.196 -0.94 . . . . 0.0 109.494 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -178.62 138.83 0.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.485 HD12 ' H ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -102.75 152.47 21.2 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.304 -0.872 . . . . 0.0 109.399 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.682 HD12 ' C ' ' A' ' 32' ' ' LEU . 0.7 OUTLIER -112.06 27.29 9.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.446 HG21 HD11 ' A' ' 32' ' ' LEU . 24.3 m -149.98 167.48 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.529 ' O ' HG21 ' A' ' 52' ' ' VAL . 0.0 OUTLIER -132.97 -167.59 1.94 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 80.3 m -84.96 130.34 34.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.447 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 79.79 2.16 87.98 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -84.61 135.3 34.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.191 -1.182 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.4 tp -89.24 127.84 35.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.221 -0.924 . . . . 0.0 109.493 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.012 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -98.5 -171.22 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.285 -0.885 . . . . 0.0 109.148 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 40.0 mm-40 -140.81 164.99 28.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.492 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.7 p -80.47 75.62 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -0.901 . . . . 0.0 109.404 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 2.4 mt-10 162.7 -31.01 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.283 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 6.2 tt0 -71.01 151.0 45.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.449 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.445 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -70.4 165.94 51.35 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 1.012 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -125.84 -49.54 1.61 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -1.124 . . . . 0.0 109.559 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.428 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.5 m -146.74 158.11 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.482 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.954 ' O ' HG22 ' A' ' 16' ' ' ILE . 82.6 t -126.05 88.25 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.14 -0.975 . . . . 0.0 109.439 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.471 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -90.04 152.34 21.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.541 -179.943 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.53 -178.92 5.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.495 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.418 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -140.87 175.9 9.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.458 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.4 -49.94 9.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.514 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -147.09 32.92 0.9 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.77 169.1 25.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.865 . . . . 0.0 109.464 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 58.7 m -123.56 135.3 53.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.3 mmt -133.59 135.63 44.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' N ' ' A' ' 44' ' ' VAL . 24.9 tt0 -106.92 166.03 10.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.515 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 6.4 t -145.9 111.64 4.48 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.314 -0.866 . . . . 0.0 109.283 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.5 Cg_endo -77.26 -169.11 0.68 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.364 2.043 . . . . 0.0 110.437 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.5 OUTLIER -85.46 130.44 51.36 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 -179.92 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.405 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.88 -6.6 15.21 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.417 2.078 . . . . 0.0 110.482 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -160.37 149.26 17.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.529 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.433 ' O ' ' HB3' ' A' ' 74' ' ' PRO . . . -79.85 96.43 6.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.762 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -144.78 177.11 23.5 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.447 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.3 p -104.12 137.83 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -1.148 . . . . 0.0 109.483 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.529 HG21 ' O ' ' A' ' 21' ' ' LYS . 49.0 t -53.3 129.62 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.455 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.77 -18.14 10.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.301 -0.874 . . . . 0.0 109.44 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -164.88 150.05 9.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.195 -0.941 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.458 HG12 ' H ' ' A' ' 57' ' ' VAL . 61.0 t -129.88 117.93 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.413 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.07 15.4 29.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.419 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 69' ' ' ILE . 33.3 m -138.71 161.73 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.478 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.93 -165.0 1.8 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.86 123.99 28.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.33 -3.96 86.55 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.88 135.52 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.15 -1.206 . . . . 0.0 109.392 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -107.8 125.06 50.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.533 HD23 ' HB3' ' A' ' 67' ' ' ASP . 1.9 mp -131.35 154.02 49.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.46 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -111.03 150.37 29.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.469 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.7 OUTLIER -42.88 141.46 1.1 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 109.643 -179.825 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.14 -26.47 23.76 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.533 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -85.07 137.33 33.12 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -1.183 . . . . 0.0 109.546 -179.911 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -64.57 164.18 12.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 70' ' ' ILE . 44.2 mm -122.25 -68.24 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.122 -0.986 . . . . 0.0 109.534 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 69' ' ' ILE . 1.6 pp -138.91 179.87 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.237 -0.914 . . . . 0.0 109.471 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.433 ' N ' HD12 ' A' ' 70' ' ' ILE . 46.3 tt0 -134.03 127.83 33.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.762 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.9 tp -107.03 123.91 48.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.529 ' HG2' ' CB ' ' A' ' 1' ' ' SER . 0.0 OUTLIER -120.92 91.4 47.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.301 -0.874 . . . . 0.0 109.424 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.468 ' HD2' ' CA ' ' A' ' 1' ' ' SER . 35.2 Cg_endo . . . . . 0 C--N 1.308 -1.593 0 C-N-CA 122.644 2.229 . . . . 0.0 110.395 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.475 ' HB3' ' HD3' ' A' ' 74' ' ' PRO . 83.4 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.445 ' OE2' ' HG3' ' A' ' 48' ' ' LYS . 20.2 pt-20 -155.9 172.51 18.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.433 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.846 HD13 ' HG2' ' A' ' 71' ' ' GLU . 16.7 mm -116.52 134.39 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.304 -0.873 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -98.0 110.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.402 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.47 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -110.44 169.56 8.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.21 -0.931 . . . . 0.0 109.573 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG13 HD11 ' A' ' 9' ' ' ILE . 51.6 t -43.58 106.03 0.47 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.893 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.43 -170.5 0.95 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.486 2.124 . . . . 0.0 110.41 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -75.68 100.45 4.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.506 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.614 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.05 -24.81 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.286 -0.883 . . . . 0.0 109.313 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.9 -30.76 4.75 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -173.56 169.43 42.51 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -48.07 113.53 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.488 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.25 149.41 16.86 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.475 ' HB2' ' HG2' ' A' ' 62' ' ' LYS . 55.8 tt0 -115.27 126.37 54.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -1.144 . . . . 0.0 109.548 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.406 ' O ' ' HA2' ' A' ' 60' ' ' GLY . 40.6 t -55.93 148.41 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.883 HD11 ' HB2' ' A' ' 36' ' ' GLU . 50.4 mt -120.41 -50.4 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -159.3 143.55 15.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.286 -0.883 . . . . 0.0 109.413 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.771 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.84 155.2 18.5 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.297 -0.877 . . . . 0.0 109.384 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.612 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -122.83 35.83 4.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -146.13 -179.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.452 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.35 176.12 8.39 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.191 -0.943 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.1 m -77.6 148.41 35.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.445 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 68.49 7.53 53.43 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -85.01 143.1 29.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 0.0 109.515 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -102.21 116.02 31.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.446 179.954 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.8 OUTLIER -92.92 -171.57 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.194 -0.941 . . . . 0.0 109.245 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 mt-10 -140.56 172.91 12.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.186 -0.946 . . . . 0.0 109.391 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.691 HG13 ' O ' ' A' ' 28' ' ' VAL . 7.1 p -78.86 77.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.52 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.99 -41.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.312 -0.868 . . . . 0.0 109.485 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -61.43 146.6 47.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.464 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -63.13 -174.67 2.68 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.642 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -147.54 -71.9 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.147 -1.207 . . . . 0.0 109.518 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.506 HG13 HD22 ' A' ' 32' ' ' LEU . 8.0 m -131.52 175.84 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.943 . . . . 0.0 109.576 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.876 HG22 ' HB3' ' A' ' 43' ' ' GLU . 87.8 t -132.24 99.73 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.345 -0.847 . . . . 0.0 109.421 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.19 153.37 17.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.881 . . . . 0.0 109.486 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.883 ' HB2' HD11 ' A' ' 16' ' ' ILE . 1.5 tt0 -107.8 153.1 23.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.347 -0.845 . . . . 0.0 109.395 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.66 -179.37 3.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.462 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.45 -22.97 66.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.653 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 10.2 pttp -159.39 65.47 0.39 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.419 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 166.62 174.6 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.176 -0.953 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.4 m -154.95 93.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.397 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 55.7 mtp -116.65 138.82 51.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.275 -0.891 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.876 ' HB3' HG22 ' A' ' 34' ' ' VAL . 4.3 pt-20 -95.36 -176.31 3.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.24 -0.913 . . . . 0.0 109.389 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' A' ' 45' ' ' PRO . 68.0 t -143.33 139.38 16.49 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.1 Cg_endo -78.92 -168.14 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.554 2.169 . . . . 0.0 110.373 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.642 ' HA ' HD12 ' A' ' 32' ' ' LEU . 28.0 t -85.04 124.31 72.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.247 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HD3' HD12 ' A' ' 32' ' ' LEU . 35.8 Cg_endo -78.17 0.37 9.95 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.366 2.044 . . . . 0.0 110.434 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.646 ' HB3' HD13 ' A' ' 72' ' ' LEU . 3.5 mmtm -160.15 121.36 3.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.248 -0.908 . . . . 0.0 109.517 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.15 83.91 1.01 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.14 -170.03 16.96 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 23' ' ' GLY . 8.0 p -95.94 148.59 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -1.145 . . . . 0.0 109.531 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.0 t -75.94 137.69 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.472 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.454 ' HB3' ' O ' ' A' ' 71' ' ' GLU . 0.0 OUTLIER -90.73 -46.21 8.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.462 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.49 144.14 0.12 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.155 -0.965 . . . . 0.0 109.445 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.459 ' HA ' HG22 ' A' ' 70' ' ' ILE . 5.1 t -86.3 112.87 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.496 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.8 m -90.82 15.75 10.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.518 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.652 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.55 157.65 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.81 147.04 28.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.588 ' HB3' HD21 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -60.02 140.21 56.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.453 ' O ' ' OE2' ' A' ' 14' ' ' GLU . . . 90.7 -11.31 72.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -73.23 140.99 47.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -1.134 . . . . 0.0 109.434 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 14' ' ' GLU . 0.4 OUTLIER -98.38 133.78 42.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -140.11 162.3 35.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.454 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.7 tmtt? -128.71 159.71 34.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.557 ' N ' HG11 ' A' ' 6' ' ' VAL . 8.6 mt-10 -42.7 111.83 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.426 -0.796 . . . . 0.0 109.695 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.94 -33.85 2.15 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -84.22 142.51 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -1.149 . . . . 0.0 109.405 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.633 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -78.26 159.54 28.42 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.391 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.652 HG23 HG21 ' A' ' 57' ' ' VAL . 34.5 mm -123.7 -60.72 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.511 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.555 HG23 HG22 ' A' ' 69' ' ' ILE . 11.3 pt -142.54 -176.47 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 109.49 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.846 ' HG2' HD13 ' A' ' 3' ' ' ILE . 1.7 tm-20 -138.16 108.04 6.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.241 -0.912 . . . . 0.0 109.475 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.725 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.4 tt -89.94 140.99 29.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.468 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -110.22 157.89 36.73 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 0.0 109.499 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.475 ' HD3' ' HB3' ' A' ' 1' ' ' SER . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.534 0 C-N-CA 122.57 2.18 . . . . 0.0 110.45 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 79.5 p . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -123.2 178.59 5.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.465 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 71' ' ' GLU . 7.0 mt -120.15 127.71 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.197 -0.939 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.447 HG21 ' HG3' ' A' ' 47' ' ' PRO . 3.3 mt -98.98 126.62 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.439 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -111.03 161.01 16.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.903 HG23 HD11 ' A' ' 69' ' ' ILE . 72.8 t -50.23 142.08 14.85 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.346 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.73 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.22 -170.31 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.632 2.221 . . . . 0.0 110.493 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.95 102.32 10.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.388 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.84 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.3 -10.76 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 109.382 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.16 35.85 91.04 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.5 -173.48 43.79 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -82.96 172.88 12.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -1.153 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.51 146.71 18.69 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.496 ' O ' HD13 ' A' ' 35' ' ' LEU . 25.0 tt0 -132.03 118.24 19.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.288 -1.125 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.71 ' CG2' HD11 ' A' ' 63' ' ' LEU . 9.8 t -67.84 141.17 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.206 -0.934 . . . . 0.0 109.538 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.437 ' CG1' ' HB2' ' A' ' 36' ' ' GLU . 30.3 mm -112.22 -51.27 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.268 -0.895 . . . . 0.0 109.444 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -150.05 140.93 22.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.657 HD23 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -101.83 149.09 24.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.502 179.946 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.472 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.6 OUTLIER -140.69 50.77 1.66 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.269 -0.894 . . . . 0.0 109.533 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.845 HG21 ' CD2' ' A' ' 32' ' ' LEU . 0.9 OUTLIER -150.05 163.27 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.248 -0.908 . . . . 0.0 109.455 -179.956 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.29 165.39 23.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.221 -0.924 . . . . 0.0 109.441 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.524 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 72.4 m -81.16 141.25 34.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 109.513 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.3 -10.83 69.74 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 1.0 OUTLIER -82.86 133.65 35.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.494 179.975 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.5 OUTLIER -85.97 117.58 24.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -90.01 -171.57 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.719 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.6 pt-20 -147.78 166.38 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -0.933 . . . . 0.0 109.479 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.8 p -77.72 79.05 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.449 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 163.0 -35.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.517 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -70.0 140.55 52.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.2 -0.937 . . . . 0.0 109.437 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.45 165.05 47.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -128.01 -40.49 1.68 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -1.15 . . . . 0.0 109.506 -179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.478 HG12 ' HG ' ' A' ' 18' ' ' LEU . 30.0 m -157.27 174.49 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.482 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.71 104.3 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 14' ' ' GLU . 4.5 mm? -89.96 152.55 21.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.256 -0.903 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.437 ' HB2' ' CG1' ' A' ' 16' ' ' ILE . 0.3 OUTLIER -131.74 116.19 16.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 -179.974 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.61 -172.62 3.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.47 -57.38 8.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.268 -0.895 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.3 mttt -140.4 49.66 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -154.88 104.67 2.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.339 -0.851 . . . . 0.0 109.478 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.97 119.28 31.56 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.87 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 5.4 ptp -136.51 162.35 33.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.325 -0.859 . . . . 0.0 109.418 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -106.42 172.36 6.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 22.9 t -142.75 95.89 6.25 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.409 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.517 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.9 Cg_endo -77.47 -168.73 0.63 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.481 2.12 . . . . 0.0 110.52 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.527 ' HB2' HG21 ' A' ' 26' ' ' ILE . 11.6 t -85.42 130.68 50.52 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.356 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.447 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.61 -3.04 12.99 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.401 2.067 . . . . 0.0 110.43 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -160.3 145.77 15.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 -179.997 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.93 93.22 8.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.475 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.864 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -143.52 -155.14 6.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.9 p -117.04 142.3 31.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.307 -1.114 . . . . 0.0 109.465 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.524 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 55.0 t -65.37 110.29 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.441 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.58 -35.38 27.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.494 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.8 t -169.86 158.13 7.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.552 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.41 HG12 ' H ' ' A' ' 57' ' ' VAL . 77.7 t -117.44 115.23 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.14 17.87 20.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.551 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.431 HG13 ' O ' ' A' ' 69' ' ' ILE . 29.2 m -123.1 162.23 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 109.483 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 tptt -134.26 172.58 12.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.442 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -81.86 124.33 29.61 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.156 -0.965 . . . . 0.0 109.513 179.959 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 98.33 -9.55 63.0 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -75.87 153.93 36.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -1.176 . . . . 0.0 109.482 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -99.3 121.11 40.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.71 HD11 ' CG2' ' A' ' 15' ' ' VAL . 11.1 mt -102.59 95.16 6.05 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.428 ' O ' ' C ' ' A' ' 65' ' ' GLU . 26.8 ttpt -85.43 138.64 32.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 109.386 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.473 ' HB3' HG13 ' A' ' 9' ' ' ILE . 11.5 pt-20 -43.06 150.63 0.16 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.67 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.26 -26.37 13.79 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -85.17 146.02 27.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.502 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -61.64 -175.15 0.05 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.274 -0.891 . . . . 0.0 109.404 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.903 HD11 HG23 ' A' ' 6' ' ' VAL . 39.8 mm -146.95 -70.37 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.538 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -143.96 -172.33 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.214 -0.929 . . . . 0.0 109.451 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.422 ' HG2' ' HA ' ' A' ' 3' ' ' ILE . 9.6 mt-10 -137.81 105.05 5.46 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.205 -0.935 . . . . 0.0 109.585 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.864 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -90.63 135.14 33.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.179 -0.951 . . . . 0.0 109.484 179.893 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.409 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 27.7 tt0 -113.45 91.33 19.79 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.504 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.507 0 C-N-CA 122.635 2.223 . . . . 0.0 110.423 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.411 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 31.3 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -122.87 155.92 35.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.406 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 4' ' ' ILE . 2.1 mp -117.12 146.89 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 37.9 mm -124.46 112.95 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -100.8 172.83 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.745 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.8 t -61.89 142.26 95.09 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.399 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.745 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.16 -171.24 1.15 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.505 2.137 . . . . 0.0 110.431 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -85.01 102.82 13.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.417 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.486 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.76 -40.19 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.282 -179.925 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.9 29.85 30.62 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.84 -128.52 0.96 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.488 ' OD2' ' CE ' ' A' ' 62' ' ' LYS . 18.3 p-10 -136.31 135.81 39.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.202 -1.176 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.59 111.43 2.55 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.401 ' HG3' ' CG ' ' A' ' 62' ' ' LYS . 3.0 tt0 -101.25 133.85 45.19 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -1.158 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.8 t -72.18 140.01 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.534 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.704 HD12 HG12 ' A' ' 34' ' ' VAL . 20.1 mt -100.8 -39.34 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.372 -0.83 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -164.64 -173.94 3.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.506 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.4 tp -136.7 102.05 4.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.442 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.2 pp -95.88 29.33 2.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.479 HG11 ' HG ' ' A' ' 32' ' ' LEU . 34.2 m -133.23 159.54 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -125.4 174.87 7.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -84.99 141.0 30.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.488 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.456 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 76.6 8.59 86.16 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.95 131.99 34.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.254 -1.145 . . . . 0.0 109.441 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.457 HD22 ' HA ' ' A' ' 25' ' ' LEU . 0.3 OUTLIER -86.01 111.7 20.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.716 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.36 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.288 -0.883 . . . . 0.0 109.25 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 31.8 mt-10 -147.56 -174.51 4.56 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.925 . . . . 0.0 109.446 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.4 p -84.83 72.76 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.9 -40.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.459 179.955 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.525 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.6 tt0 -54.11 142.49 25.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.62 168.32 54.61 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.66 ' O ' HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -129.31 -40.26 1.46 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.234 -1.157 . . . . 0.0 109.56 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 32' ' ' LEU . 13.0 m -161.01 176.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.112 -0.993 . . . . 0.0 109.534 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.704 HG12 HD12 ' A' ' 16' ' ' ILE . 98.9 t -131.9 97.9 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.422 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.07 146.25 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.439 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.95 177.84 6.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.0 m -136.33 160.91 37.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.87 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.11 -28.85 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.214 -0.929 . . . . 0.0 109.405 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.471 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 3.0 tttm -160.02 52.62 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 176.93 -166.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.174 -0.954 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.2 t -152.73 140.8 20.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.46 150.53 42.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -0.893 . . . . 0.0 109.509 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -98.14 169.71 9.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 55.5 t -146.47 98.39 4.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.235 -0.915 . . . . 0.0 109.422 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.63 -169.05 0.67 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.437 2.091 . . . . 0.0 110.412 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.4 134.17 40.92 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.454 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.489 ' HG2' HG13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.96 -5.37 14.53 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.425 2.083 . . . . 0.0 110.399 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.469 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -160.41 144.99 14.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.326 -0.859 . . . . 0.0 109.513 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.5 99.18 3.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.421 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.862 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -153.79 175.65 32.02 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.456 HG22 ' HA2' ' A' ' 23' ' ' GLY . 11.3 p -95.78 145.16 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -1.131 . . . . 0.0 109.574 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -63.87 114.24 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' A' ' 73' ' ' GLU . 2.8 tttp -85.21 -56.74 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.5 m -143.86 127.44 17.02 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.498 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 t -96.23 128.78 47.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.448 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.9 m -119.59 34.0 5.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.425 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.676 HG13 ' O ' ' A' ' 69' ' ' ILE . 27.2 m -137.54 157.5 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.47 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -141.08 149.53 41.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.918 . . . . 0.0 109.46 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.77 128.58 35.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.497 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.1 -23.2 29.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -80.78 148.89 29.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.184 -1.186 . . . . 0.0 109.489 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.488 ' CE ' ' OD2' ' A' ' 12' ' ' ASP . 3.1 tttt -103.14 112.99 26.11 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.916 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.744 HD22 ' HB3' ' A' ' 67' ' ' ASP . 12.6 mt -102.01 135.32 43.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.287 -0.883 . . . . 0.0 109.434 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -100.51 152.47 20.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.31 -0.869 . . . . 0.0 109.439 -179.956 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.9 pt-20 -42.88 150.49 0.16 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.55 -17.58 51.45 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.744 ' HB3' HD22 ' A' ' 63' ' ' LEU . 1.1 m-20 -84.0 131.21 34.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -1.131 . . . . 0.0 109.436 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -57.4 159.78 4.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.238 -0.914 . . . . 0.0 109.475 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.726 HD11 ' CG2' ' A' ' 6' ' ' VAL . 33.0 mm -117.6 -58.15 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.486 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 69' ' ' ILE . 2.4 pp -158.36 -177.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.239 -0.913 . . . . 0.0 109.43 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.424 ' HG2' HG13 ' A' ' 3' ' ' ILE . 57.5 mt-10 -133.58 127.46 33.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.971 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -99.5 142.47 30.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.484 -179.954 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.481 ' HB2' ' HD2' ' A' ' 53' ' ' LYS . 0.2 OUTLIER -118.85 90.06 39.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.186 -0.946 . . . . 0.0 109.47 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.971 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.533 0 C-N-CA 122.625 2.217 . . . . 0.0 110.413 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 96.5 p . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.244 0.545 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -93.31 140.7 29.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 109.52 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.448 HD13 ' HG3' ' A' ' 71' ' ' GLU . 18.0 mm -80.44 160.35 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 96.6 mt -122.97 96.6 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.333 -0.855 . . . . 0.0 109.415 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.655 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -92.01 -178.76 5.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.289 -0.882 . . . . 0.0 109.558 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.731 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.8 t -70.93 142.7 88.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.369 -0.832 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.03 -170.02 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.494 2.13 . . . . 0.0 110.377 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.85 104.12 14.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.252 -0.905 . . . . 0.0 109.477 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.585 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.19 -41.68 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.208 -0.932 . . . . 0.0 109.273 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.88 -21.04 12.69 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.77 -142.25 3.91 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 3.1 m-20 -102.84 165.94 10.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.289 -1.124 . . . . 0.0 109.415 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.33 165.44 21.25 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -146.44 121.39 10.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.199 -1.177 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.559 HG23 HD13 ' A' ' 63' ' ' LEU . 21.6 t -70.23 149.49 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' ' OE1' ' A' ' 17' ' ' GLU . 69.1 mt -127.15 -40.01 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.284 -0.885 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -156.51 126.44 6.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.489 -179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.427 HD13 HG11 ' A' ' 15' ' ' VAL . 0.7 OUTLIER -102.41 141.53 35.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.428 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.732 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -132.61 61.54 1.67 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.498 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.78 164.42 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 28.6 mmtt -122.98 157.2 33.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 22' ' ' THR . 13.3 t -84.74 128.9 34.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.96 -9.17 73.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.472 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 1.6 m-20 -83.53 136.8 34.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -1.157 . . . . 0.0 109.551 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.448 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -86.18 126.5 34.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.491 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.2 mt -90.33 -171.32 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.294 -0.879 . . . . 0.0 109.193 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 5.6 mt-10 -137.39 156.12 48.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.205 -0.934 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.735 HG13 ' O ' ' A' ' 28' ' ' VAL . 9.6 p -79.03 82.08 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.85 -35.89 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.395 -0.816 . . . . 0.0 109.433 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -71.59 152.13 43.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.44 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.47 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.32 -169.31 0.29 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.536 HD11 ' CD1' ' A' ' 26' ' ' ILE . 8.1 tp -153.31 -70.18 0.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -1.154 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.7 m -134.02 173.56 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.486 HG22 ' HB3' ' A' ' 43' ' ' GLU . 97.1 t -133.73 102.33 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.29 170.07 8.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.311 -0.868 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.85 137.25 51.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.482 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.64 176.89 5.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.21 -0.931 . . . . 0.0 109.5 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.55 -45.82 13.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.403 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.4 mttm -152.3 67.55 0.84 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.492 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 167.66 99.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.208 -0.932 . . . . 0.0 109.479 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.5 t -80.02 126.53 31.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.452 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -147.2 159.46 43.61 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -0.875 . . . . 0.0 109.512 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.486 ' HB3' HG22 ' A' ' 34' ' ' VAL . 3.5 pt-20 -109.4 169.3 8.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.39 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' A' ' 45' ' ' PRO . 94.7 t -132.5 139.36 34.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.405 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.97 -168.23 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.432 0 C-N-CA 122.549 2.166 . . . . 0.0 110.361 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.4 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.0 OUTLIER -85.16 113.55 50.93 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.385 -0.822 . . . . 0.0 109.365 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 36.0 Cg_endo -77.87 3.37 7.02 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.332 2.021 . . . . 0.0 110.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 1.024 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -160.02 110.28 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.465 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.2 90.62 1.6 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.939 . . . . 0.0 109.601 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.83 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -143.69 -157.73 7.29 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 73' ' ' GLU . 11.1 p -111.48 128.53 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -1.148 . . . . 0.0 109.509 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 48.8 t -58.27 134.83 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.474 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.87 -33.28 7.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.291 -0.881 . . . . 0.0 109.458 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 173.27 144.31 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.509 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 57' ' ' VAL . 52.2 t -99.68 135.11 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.6 m -105.63 16.19 25.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.346 -0.846 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 1.009 HG11 HD21 ' A' ' 63' ' ' LEU . 1.5 m -136.47 157.34 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.443 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -110.37 167.17 10.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.02 137.2 38.84 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.493 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.1 -11.07 68.41 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -79.21 148.4 32.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.5 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.712 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 mttp -82.64 165.37 20.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 HG11 ' A' ' 57' ' ' VAL . 3.4 mp -148.77 113.42 5.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -86.03 137.78 32.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.241 -0.912 . . . . 0.0 109.455 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 64' ' ' LYS . 25.7 pt-20 -42.88 151.41 0.13 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 109.672 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.08 -18.2 41.99 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -85.0 141.68 30.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.262 -1.14 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.19 172.42 9.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.914 HG22 HG23 ' A' ' 70' ' ' ILE . 2.0 mp -134.76 -58.49 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.914 HG23 HG22 ' A' ' 69' ' ' ILE . 7.4 pt -147.23 -179.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.461 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.448 ' HG3' HD13 ' A' ' 3' ' ' ILE . 32.4 tt0 -131.18 117.33 18.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.024 HD22 ' HB3' ' A' ' 48' ' ' LYS . 0.7 OUTLIER -97.54 147.08 24.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -0.863 . . . . 0.0 109.486 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.522 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 2.5 tp10 -120.09 89.7 43.24 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo . . . . . 0 C--N 1.308 -1.571 0 C-N-CA 122.651 2.234 . . . . 0.0 110.375 -179.936 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -86.69 111.01 20.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.253 -0.904 . . . . 0.0 109.285 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.679 HD12 ' OE2' ' A' ' 71' ' ' GLU . 2.2 tt -79.96 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.448 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 40.2 mm -122.78 122.77 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.564 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -92.11 -176.13 4.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.554 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.986 ' CG2' HD11 ' A' ' 69' ' ' ILE . 53.4 t -74.75 139.99 74.31 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.347 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.648 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.39 -174.37 2.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.549 2.166 . . . . 0.0 110.438 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -85.19 108.88 17.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.413 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.415 ' CD1' ' HA3' ' A' ' 13' ' ' GLY . 0.0 OUTLIER -104.79 -7.27 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.281 -0.887 . . . . 0.0 109.396 -179.768 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.58 21.95 13.54 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 150.2 -133.53 4.4 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -85.54 170.85 12.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.243 -1.151 . . . . 0.0 109.464 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.415 ' HA3' ' CD1' ' A' ' 9' ' ' ILE . . . -141.05 148.25 19.9 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.454 ' HG3' ' HA ' ' A' ' 62' ' ' LYS . 1.0 OUTLIER -135.73 130.43 34.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -1.17 . . . . 0.0 109.484 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.53 ' HA ' HD23 ' A' ' 35' ' ' LEU . 38.2 t -70.1 147.2 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.899 HD11 ' HB2' ' A' ' 36' ' ' GLU . 42.7 mt -118.95 -53.91 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.326 -0.859 . . . . 0.0 109.558 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -134.34 133.81 41.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.402 HD12 ' CG1' ' A' ' 33' ' ' VAL . 0.4 OUTLIER -115.24 102.47 9.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.496 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.487 ' H ' HD23 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -93.66 41.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 m -143.74 156.08 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.533 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.405 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.07 -176.83 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.9 m -84.08 133.92 34.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.482 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.2 5.38 89.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.405 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.3 m-20 -84.94 135.49 34.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -1.175 . . . . 0.0 109.532 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.57 115.7 27.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.269 -0.895 . . . . 0.0 109.471 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.712 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.6 mt -90.46 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.322 -0.861 . . . . 0.0 109.219 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.712 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.8 mt-10 -135.37 177.68 7.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.645 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.3 p -85.4 59.89 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.588 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 3.3 tt0 167.5 -32.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.249 -0.907 . . . . 0.0 109.228 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 1.9 tm0? -52.35 145.41 11.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.414 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.449 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.03 171.03 39.88 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.54 ' CD1' HD13 ' A' ' 26' ' ' ILE . 0.6 OUTLIER -130.11 -56.04 1.11 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -1.156 . . . . 0.0 109.546 -179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 18' ' ' LEU . 36.0 m -151.56 -176.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.496 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.503 HG12 HD12 ' A' ' 16' ' ' ILE . 46.2 t -139.01 97.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 15' ' ' VAL . 3.1 mt -90.08 158.9 17.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.899 ' HB2' HD11 ' A' ' 16' ' ' ILE . 2.0 tt0 -123.27 153.04 40.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.408 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.6 m -130.25 -176.58 4.0 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.464 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.98 -34.62 65.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.249 -0.907 . . . . 0.0 109.484 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 20.9 tttp -159.9 61.19 0.36 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.402 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.14 88.21 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 109.491 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.436 ' HB3' ' CG ' ' A' ' 36' ' ' GLU . 99.6 p -105.1 112.97 26.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.383 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.2 mtt -130.02 -175.5 3.64 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.479 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -114.23 162.19 16.87 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.25 -0.906 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 59.2 t -137.53 117.57 10.35 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.33 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.96 -168.69 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.28 1.987 . . . . 0.0 110.434 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.497 ' HA ' HD13 ' A' ' 32' ' ' LEU . 6.0 t -85.27 138.08 36.7 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.402 -0.811 . . . . 0.0 109.328 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.82 -4.82 14.3 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.417 2.078 . . . . 0.0 110.478 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.573 ' O ' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.35 128.1 4.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -0.859 . . . . 0.0 109.521 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.86 98.51 1.58 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.903 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.491 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -152.12 -135.98 2.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.0 p -132.27 151.36 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.189 -1.183 . . . . 0.0 109.439 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.5 t -73.49 119.95 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -91.97 -43.21 9.57 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.916 . . . . 0.0 109.407 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.8 t -149.48 142.84 25.23 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 57' ' ' VAL . 21.0 t -105.02 106.79 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.86 10.56 13.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.288 -0.883 . . . . 0.0 109.436 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.426 ' H ' HG12 ' A' ' 55' ' ' VAL . 17.2 m -124.98 177.73 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.305 -0.872 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.479 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -128.48 -156.02 0.73 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.87 80.67 9.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.43 ' HA2' ' HB ' ' A' ' 15' ' ' VAL . . . 74.89 46.22 18.03 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 4.9 m-20 -84.96 172.24 11.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.296 -1.12 . . . . 0.0 109.435 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.454 ' HA ' ' HG3' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -97.62 145.3 26.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.196 -0.94 . . . . 0.0 109.447 -179.92 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.92 -172.52 4.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.467 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -138.45 147.08 42.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.86 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.485 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 4.2 pt-20 -45.39 148.86 0.6 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.273 -0.892 . . . . 0.0 109.694 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 5' ' ' ARG . . . 85.86 -43.51 3.25 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 68' ' ' ALA . 0.9 OUTLIER -50.76 134.46 24.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -1.128 . . . . 0.0 109.602 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -48.21 174.04 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -0.886 . . . . 0.0 109.535 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.986 HD11 ' CG2' ' A' ' 6' ' ' VAL . 26.9 mm -143.51 -58.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.238 -0.914 . . . . 0.0 109.498 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.656 ' C ' HD12 ' A' ' 70' ' ' ILE . 2.4 pp -150.98 179.56 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.482 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.679 ' OE2' HD12 ' A' ' 3' ' ' ILE . 22.3 mt-10 -145.56 97.25 2.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.511 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 48' ' ' LYS . 0.4 OUTLIER -90.76 124.86 35.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.238 -0.914 . . . . 0.0 109.433 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.527 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 37.1 tt0 -91.42 140.99 25.6 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.254 -0.903 . . . . 0.0 109.374 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.6 Cg_endo . . . . . 0 C--N 1.31 -1.455 0 C-N-CA 122.486 2.124 . . . . 0.0 110.373 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.433 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 23.4 p . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -126.77 147.55 49.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 109.403 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.531 HG22 ' N ' ' A' ' 4' ' ' ILE . 3.5 mp -85.11 162.88 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.211 -0.931 . . . . 0.0 109.484 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.531 ' N ' HG22 ' A' ' 3' ' ' ILE . 3.0 mp -127.75 104.27 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 4.3 ptp85 -93.03 -172.44 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.145 -0.972 . . . . 0.0 109.473 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 42.0 t -73.99 136.59 76.4 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.297 -0.877 . . . . 0.0 109.389 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.51 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.94 -176.61 3.38 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.481 2.121 . . . . 0.0 110.383 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -85.18 101.21 12.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.183 -0.948 . . . . 0.0 109.322 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.71 -45.95 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.249 -0.907 . . . . 0.0 109.259 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.78 16.07 11.25 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.7 -159.42 16.64 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 7.5 m-20 -104.31 119.82 39.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -1.167 . . . . 0.0 109.516 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.4 151.62 23.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.5 mp0 -131.58 119.82 22.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.246 -1.149 . . . . 0.0 109.442 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.8 t -65.37 134.67 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.495 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 16' ' ' ILE . 18.2 mm -115.19 -52.74 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.438 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -129.09 123.47 32.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.499 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.709 ' HG ' HG22 ' A' ' 20' ' ' VAL . 5.9 tp -99.84 115.37 29.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.893 . . . . 0.0 109.465 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -113.55 57.18 0.68 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.482 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.777 HG11 ' HG ' ' A' ' 32' ' ' LEU . 29.3 m -139.73 158.44 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.263 -0.898 . . . . 0.0 109.435 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.26 162.6 33.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -0.956 . . . . 0.0 109.46 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.423 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 0.2 OUTLIER -84.93 125.61 32.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.259 -0.901 . . . . 0.0 109.512 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.489 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.03 -8.95 67.88 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -78.63 132.05 36.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -1.138 . . . . 0.0 109.5 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.573 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -85.35 115.71 23.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.75 ' CD1' HD11 ' A' ' 32' ' ' LEU . 2.6 mt -91.99 -171.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.3 -0.875 . . . . 0.0 109.211 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 20.0 pt-20 -146.3 172.33 13.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.733 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.6 p -81.12 74.83 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.211 -0.93 . . . . 0.0 109.357 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.4 tm-20 167.87 -39.37 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.332 -0.855 . . . . 0.0 109.299 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.9 OUTLIER -62.47 144.64 55.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.393 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.32 164.34 54.51 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.777 ' HG ' HG11 ' A' ' 20' ' ' VAL . 2.6 tp -124.61 -38.37 2.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -1.166 . . . . 0.0 109.398 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.502 HG13 ' C ' ' A' ' 32' ' ' LEU . 9.3 m -157.77 167.26 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.582 HG22 ' HG3' ' A' ' 43' ' ' GLU . 97.9 t -131.47 105.04 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.468 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.511 HD12 ' N ' ' A' ' 35' ' ' LEU . 9.8 mp -90.23 148.69 22.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -138.56 116.78 11.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.547 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.0 m -100.1 -175.74 3.03 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.26 -0.9 . . . . 0.0 109.449 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.79 -42.22 16.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -154.62 57.45 0.69 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -167.87 97.12 0.45 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.926 . . . . 0.0 109.51 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.5 m -99.7 120.64 40.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.436 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 17.2 mtp -128.63 134.25 48.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.582 ' HG3' HG22 ' A' ' 34' ' ' VAL . 26.0 tt0 -91.56 162.73 14.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.2 -0.937 . . . . 0.0 109.387 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -144.45 99.17 4.91 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.33 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.528 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.7 Cg_endo -77.42 -168.6 0.61 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.526 2.151 . . . . 0.0 110.477 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 1.1 t -85.34 127.45 63.64 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.22 -0.925 . . . . 0.0 109.377 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.43 -2.51 12.56 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.345 2.03 . . . . 0.0 110.43 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 2.4 mtmt -160.19 143.11 13.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.389 -0.819 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.81 97.95 7.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -147.0 -172.51 17.34 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' O ' ' A' ' 73' ' ' GLU . 2.5 p -104.63 127.47 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.456 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.423 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 50.5 t -50.57 133.91 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.411 ' HG2' ' OG ' ' A' ' 54' ' ' SER . 18.1 tttt -101.99 -58.8 1.81 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -0.922 . . . . 0.0 109.496 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.411 ' OG ' ' HG2' ' A' ' 53' ' ' LYS . 0.7 OUTLIER -150.56 153.87 36.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 109.474 -179.969 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' A' ' 70' ' ' ILE . 9.1 t -103.16 131.68 51.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.266 -0.896 . . . . 0.0 109.493 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.0 m -113.62 19.83 16.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.244 -0.91 . . . . 0.0 109.462 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.671 HG11 HG23 ' A' ' 69' ' ' ILE . 17.8 m -132.71 -178.62 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.945 . . . . 0.0 109.396 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.6 ttpt -138.91 158.6 43.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 59' ' ' LEU . 3.4 pp -76.68 123.02 25.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.243 -0.911 . . . . 0.0 109.492 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.97 -8.35 73.28 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -78.01 144.16 36.91 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.268 -1.136 . . . . 0.0 109.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -91.13 122.91 34.18 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.24 -0.913 . . . . 0.0 109.507 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.81 HD13 ' CD1' ' A' ' 69' ' ' ILE . 19.2 mt -102.74 152.14 21.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.895 . . . . 0.0 109.442 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -122.54 152.45 40.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.436 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.53 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 77.2 mt-10 -47.7 148.11 1.64 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.245 -0.909 . . . . 0.0 109.725 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.03 -40.19 3.09 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -61.97 131.6 50.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -1.158 . . . . 0.0 109.549 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.573 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -62.1 -174.88 0.06 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.81 ' CD1' HD13 ' A' ' 63' ' ' LEU . 44.2 mm -146.45 -64.99 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.874 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.661 HD11 ' CD2' ' A' ' 32' ' ' LEU . 2.8 pt -148.56 -172.45 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.297 -0.877 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 3' ' ' ILE . 1.7 tt0 -142.99 117.48 9.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.589 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.896 HD23 ' HD3' ' A' ' 74' ' ' PRO . 0.5 OUTLIER -95.47 137.38 34.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.382 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.52 ' O ' HG12 ' A' ' 51' ' ' VAL . 3.4 tt0 -115.71 85.84 14.81 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.896 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.539 0 C-N-CA 122.654 2.236 . . . . 0.0 110.371 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.422 ' O ' ' HG2' ' A' ' 2' ' ' GLU . 48.4 p . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.295 0.569 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 1' ' ' SER . 14.0 mt-10 -145.28 145.35 31.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.2 mt -85.13 148.89 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.197 -0.939 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.517 HD13 HD11 ' A' ' 70' ' ' ILE . 2.3 mp -116.14 108.01 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 1.2 ptp85 -98.71 176.73 5.53 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.836 HG23 HD11 ' A' ' 69' ' ' ILE . 78.9 t -74.04 142.43 79.36 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.319 -0.863 . . . . 0.0 109.359 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.738 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.82 -171.53 1.22 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.463 2.109 . . . . 0.0 110.435 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -85.03 104.88 15.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.462 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.59 -31.13 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.226 -0.921 . . . . 0.0 109.215 -179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.68 -11.41 59.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.03 145.07 15.09 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -45.96 151.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.505 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.17 119.9 3.58 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -86.77 129.01 35.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.479 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.3 t -76.5 131.94 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.857 HD11 ' HB2' ' A' ' 36' ' ' GLU . 39.5 mt -95.04 -51.17 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.169 -0.957 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -174.07 163.5 3.96 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.474 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.717 HD23 HG23 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -108.41 139.21 43.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 109.449 -179.99 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.7 15.11 11.68 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.717 HG23 HD23 ' A' ' 18' ' ' LEU . 1.9 m -149.87 164.22 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.887 . . . . 0.0 109.527 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -114.9 -163.87 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.337 -0.852 . . . . 0.0 109.493 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.4 t -84.96 139.86 31.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.302 -0.874 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.01 8.37 61.2 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.449 ' C ' HG23 ' A' ' 51' ' ' VAL . 11.7 m-20 -84.95 133.02 34.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.207 -1.173 . . . . 0.0 109.522 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 1.1 tp -79.98 125.49 29.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.268 -0.895 . . . . 0.0 109.475 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.747 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.04 -171.41 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.251 -0.906 . . . . 0.0 109.204 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.722 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.4 mt-10 -135.16 175.39 9.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.432 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.6 p -85.15 64.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.505 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.88 -43.68 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.496 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.9 tt0 -45.25 149.59 0.5 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.518 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.442 ' N ' ' HG2' ' A' ' 30' ' ' GLN . . . -74.39 166.89 54.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.823 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -126.94 -37.5 2.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -1.175 . . . . 0.0 109.561 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.624 HG22 ' HB ' ' A' ' 44' ' ' VAL . 23.5 m -152.85 154.32 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.561 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.592 HG22 ' OE2' ' A' ' 43' ' ' GLU . 60.5 t -125.74 91.93 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.307 -0.871 . . . . 0.0 109.419 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mp -89.98 153.75 20.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.51 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.857 ' HB2' HD11 ' A' ' 16' ' ' ILE . 38.3 tt0 -143.36 134.46 25.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.274 -0.891 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.61 174.24 7.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.881 . . . . 0.0 109.547 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.0 -13.18 57.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.46 -56.27 3.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -0.935 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -164.72 -149.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.927 . . . . 0.0 109.401 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.7 p -136.34 144.59 44.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -136.85 -175.97 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.592 ' OE2' HG22 ' A' ' 34' ' ' VAL . 6.4 tt0 -150.24 162.18 40.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.52 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.624 ' HB ' HG22 ' A' ' 33' ' ' VAL . 38.2 t -147.5 101.37 3.76 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.262 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.525 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.6 Cg_endo -77.2 -168.94 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.399 2.066 . . . . 0.0 110.506 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.823 ' HA ' HD12 ' A' ' 32' ' ' LEU . 3.8 t -85.28 132.52 44.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.441 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.503 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.87 -5.28 14.55 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 C-N-CA 122.489 2.126 . . . . 0.0 110.402 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' A' ' 46' ' ' SER . 5.6 tptt -160.23 144.71 14.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.35 -0.844 . . . . 0.0 109.491 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.95 91.05 4.17 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.791 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -139.69 -135.19 3.22 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.554 ' N ' HD11 ' A' ' 72' ' ' LEU . 7.2 p -149.08 150.57 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -1.178 . . . . 0.0 109.535 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.0 t -73.01 129.45 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 3.5 tttp -113.63 -27.59 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.266 -0.896 . . . . 0.0 109.564 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -154.61 128.28 8.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.176 -0.953 . . . . 0.0 109.508 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.553 HG12 ' H ' ' A' ' 57' ' ' VAL . 75.8 t -113.08 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.465 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.37 34.79 4.95 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.553 ' H ' HG12 ' A' ' 55' ' ' VAL . 3.4 m -140.75 170.18 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.26 -0.9 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.443 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -132.59 157.77 43.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.926 . . . . 0.0 109.454 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -83.09 131.79 35.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.496 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.81 -11.48 68.72 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.443 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.7 OUTLIER -81.65 163.93 22.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -1.182 . . . . 0.0 109.435 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 mttt -104.13 120.24 40.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.475 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.434 HD13 ' HA ' ' A' ' 63' ' ' LEU . 1.2 mm? -105.47 137.28 43.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.467 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -101.47 140.32 35.93 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.278 -0.888 . . . . 0.0 109.469 179.964 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.2 OUTLIER -42.76 151.6 0.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.29 -0.881 . . . . 0.0 109.675 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.09 -24.54 21.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.47 134.49 34.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.289 -1.124 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.49 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -59.23 179.23 0.11 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.513 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.836 HD11 HG23 ' A' ' 6' ' ' VAL . 31.8 mm -134.73 -67.63 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.178 -0.951 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.748 HG23 HG22 ' A' ' 69' ' ' ILE . 2.6 pp -147.82 -172.1 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.73 ' N ' HD12 ' A' ' 70' ' ' ILE . 14.5 mt-10 -144.62 136.48 25.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.791 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.3 tp -113.01 112.32 23.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 53' ' ' LYS . 23.7 tt0 -113.78 90.38 18.48 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.493 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.8 Cg_endo . . . . . 0 C--N 1.309 -1.547 0 C-N-CA 122.612 2.208 . . . . 0.0 110.484 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 48.6 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -97.02 175.75 6.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.473 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.561 ' H ' HD12 ' A' ' 3' ' ' ILE . 3.7 mp -104.76 146.97 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.2 mt -104.25 99.26 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.44 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -91.26 165.62 13.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.344 -0.847 . . . . 0.0 109.458 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.8 t -55.0 142.22 57.05 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.888 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.14 -172.58 1.53 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.489 2.126 . . . . 0.0 110.387 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -84.03 104.33 14.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.902 . . . . 0.0 109.503 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.465 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.79 -41.42 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.297 -0.877 . . . . 0.0 109.354 -179.929 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.69 10.73 52.5 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -146.04 -125.14 1.68 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.65 123.67 38.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.15 . . . . 0.0 109.393 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.68 147.43 50.94 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.07 101.79 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -1.119 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.734 HG11 ' O ' ' A' ' 58' ' ' LYS . 38.4 t -48.44 149.76 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.8 HD12 HG12 ' A' ' 34' ' ' VAL . 43.9 mt -127.16 -62.22 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 109.454 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -150.11 149.74 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.777 ' CD1' HG12 ' A' ' 33' ' ' VAL . 2.8 tp -119.47 138.84 52.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 HG13 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -127.98 54.35 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.516 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.621 HG13 HD12 ' A' ' 19' ' ' LEU . 15.3 m -144.42 159.8 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.17 -0.956 . . . . 0.0 109.399 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.494 ' CB ' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -111.37 -171.18 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 109.548 179.954 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.4 m -85.18 119.39 25.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.78 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.479 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 72.37 2.17 53.64 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.639 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.494 ' CG ' ' CB ' ' A' ' 21' ' ' LYS . 2.1 m-20 -69.7 129.44 39.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.299 . . . . 0.0 109.123 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.908 HD21 ' HB1' ' A' ' 49' ' ' ALA . 1.0 OUTLIER -90.93 144.14 25.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.413 -0.805 . . . . 0.0 109.728 -179.697 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.987 HD12 ' CA ' ' A' ' 50' ' ' GLY . 1.3 mt -114.58 -170.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.776 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -100.46 172.45 7.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.079 -1.013 . . . . 0.0 109.405 179.963 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.743 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.8 p -83.89 68.64 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.497 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 163.03 -29.73 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -60.13 151.59 26.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.517 179.959 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -67.06 163.61 44.84 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.705 HD22 ' CD1' ' A' ' 70' ' ' ILE . 0.2 OUTLIER -125.75 -38.81 2.18 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.537 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.777 HG12 ' CD1' ' A' ' 18' ' ' LEU . 28.7 m -152.23 171.64 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.8 HG12 HD12 ' A' ' 16' ' ' ILE . 60.7 t -127.91 95.67 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.309 -0.87 . . . . 0.0 109.417 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 mt -89.88 162.14 15.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.922 . . . . 0.0 109.558 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.53 ' CA ' HD11 ' A' ' 16' ' ' ILE . 8.2 tt0 -114.99 164.13 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -135.43 -177.07 4.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -56.49 -44.06 80.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -0.886 . . . . 0.0 109.471 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.47 48.42 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -176.0 124.03 0.19 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.522 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.0 125.68 32.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.342 -0.849 . . . . 0.0 109.484 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.462 ' SD ' ' HG2' ' A' ' 7' ' ' PRO . 2.3 ptm -115.98 129.9 56.58 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -96.64 167.18 11.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.208 -0.933 . . . . 0.0 109.415 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 2.7 t -144.37 100.1 4.86 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.242 -0.911 . . . . 0.0 109.366 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.2 Cg_endo -77.68 -170.03 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.411 2.074 . . . . 0.0 110.359 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.458 ' HB2' HD12 ' A' ' 32' ' ' LEU . 6.3 t -85.96 142.66 36.61 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.432 -0.792 . . . . 0.0 109.364 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.617 ' HD2' HD13 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.37 -10.94 16.07 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.484 2.122 . . . . 0.0 110.174 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.37 -91.73 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.559 -0.713 . . . . 0.0 109.121 179.887 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.908 ' HB1' HD21 ' A' ' 25' ' ' LEU . . . -85.2 -92.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.29 -0.882 . . . . 0.0 109.229 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.987 ' CA ' HD12 ' A' ' 26' ' ' ILE . . . 139.98 41.04 0.08 OUTLIER Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.1 p -95.56 115.15 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.1 -1.235 . . . . 0.0 109.346 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' A' ' 23' ' ' GLY . 40.6 t -69.26 116.15 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.443 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -108.21 -25.25 11.16 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.174 -0.954 . . . . 0.0 109.513 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.85 123.33 1.73 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.514 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 70' ' ' ILE . 90.1 t -112.58 135.27 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.464 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -126.38 39.73 3.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.52 HG11 HG23 ' A' ' 69' ' ' ILE . 27.1 m -149.91 167.23 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.734 ' O ' HG11 ' A' ' 15' ' ' VAL . 4.2 tttt -125.39 167.99 14.18 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.43 87.42 7.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.6 -11.87 4.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -75.45 146.67 40.5 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -1.118 . . . . 0.0 109.566 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.407 ' C ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -105.14 146.62 28.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.209 -0.932 . . . . 0.0 109.484 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 62' ' ' LYS . 13.8 mt -141.47 178.42 7.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.477 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' GLU . 8.7 tttp -118.58 149.32 41.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.181 -0.949 . . . . 0.0 109.537 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.3 pt-20 -42.71 150.33 0.16 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.337 -0.852 . . . . 0.0 109.627 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.68 -15.33 55.41 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -82.28 132.26 35.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -1.148 . . . . 0.0 109.544 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -63.85 161.59 15.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.432 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.52 HG23 HG11 ' A' ' 57' ' ' VAL . 43.9 mm -128.01 -59.71 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.887 . . . . 0.0 109.522 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.705 ' CD1' HD22 ' A' ' 32' ' ' LEU . 3.4 pt -141.44 -171.94 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.51 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 3' ' ' ILE . 1.7 mt-10 -145.8 109.2 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.602 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.668 HD23 ' C ' ' A' ' 72' ' ' LEU . 2.0 tt -90.02 145.42 25.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.3 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.47 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 1.4 mt-10 -106.09 146.27 32.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.47 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 36.1 Cg_endo . . . . . 0 C--N 1.309 -1.508 0 C-N-CA 122.587 2.191 . . . . 0.0 110.431 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.485 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 2.5 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mt-10 -125.2 169.19 12.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.24 -0.913 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mt -99.61 137.34 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.535 HG21 ' HG3' ' A' ' 47' ' ' PRO . 31.6 mm -113.82 119.05 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.239 -0.913 . . . . 0.0 109.485 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.701 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -106.23 -177.96 3.51 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.476 -179.927 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.6 t -81.0 142.27 51.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.355 -0.841 . . . . 0.0 109.342 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.07 -170.74 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.607 2.205 . . . . 0.0 110.433 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -84.51 104.69 14.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.224 -0.923 . . . . 0.0 109.437 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.97 -21.65 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.281 -0.887 . . . . 0.0 109.295 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.78 21.63 76.29 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.0 -165.92 25.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -97.2 140.34 31.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -1.168 . . . . 0.0 109.459 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -111.14 105.17 1.83 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.8 mm-40 -97.22 130.22 44.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.542 ' HA ' HD23 ' A' ' 35' ' ' LEU . 60.3 t -72.91 119.42 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.981 HG22 ' O ' ' A' ' 34' ' ' VAL . 1.6 tt -112.55 -24.33 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -145.99 140.44 26.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.51 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.55 127.37 34.96 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.54 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -120.7 47.32 1.82 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.897 . . . . 0.0 109.414 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.465 HG11 ' CD1' ' A' ' 32' ' ' LEU . 3.2 m -150.07 158.19 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.6 mmtt -138.05 -174.0 3.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.9 m -84.4 141.18 31.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.481 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.7 1.83 62.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.89 130.27 34.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -1.196 . . . . 0.0 109.485 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -86.12 119.3 26.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.88 . . . . 0.0 109.387 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.053 HD13 HD21 ' A' ' 32' ' ' LEU . 2.4 mt -90.01 -171.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.209 -0.932 . . . . 0.0 109.201 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.717 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -150.17 163.34 38.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.433 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.49 147.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.161 -0.962 . . . . 0.0 109.411 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 83.07 -43.61 0.11 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.688 -0.632 . . . . 0.0 109.863 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.524 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -55.41 144.27 26.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.078 -1.014 . . . . 0.0 109.43 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.32 172.38 38.27 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 1.053 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -133.04 -51.84 0.9 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.542 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.9 m -153.6 175.75 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.141 -0.974 . . . . 0.0 109.617 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.981 ' O ' HG22 ' A' ' 16' ' ' ILE . 84.4 t -130.8 94.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.87 . . . . 0.0 109.425 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.542 HD23 ' HA ' ' A' ' 15' ' ' VAL . 13.2 mt -90.14 151.86 21.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -106.05 112.02 24.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.291 -0.881 . . . . 0.0 109.432 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.64 -172.12 3.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -0.907 . . . . 0.0 109.525 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.32 6.64 13.67 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.51 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -112.47 -36.89 5.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.178 -0.951 . . . . 0.0 109.518 179.93 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.524 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.44 -152.37 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.243 -0.911 . . . . 0.0 109.429 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 8.3 t -106.05 112.55 25.64 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.251 -0.906 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -106.95 151.81 24.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -110.31 150.43 28.77 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.176 -0.952 . . . . 0.0 109.452 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.8 t -132.73 118.24 15.51 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.897 . . . . 0.0 109.261 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.1 Cg_endo -77.7 -168.65 0.63 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.33 2.02 . . . . 0.0 110.451 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.518 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -85.35 126.32 67.34 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.345 -0.847 . . . . 0.0 109.339 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.535 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.9 Cg_endo -78.44 -0.9 11.12 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.377 2.052 . . . . 0.0 110.374 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.499 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.18 127.31 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.76 99.54 5.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 109.46 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.902 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.93 -137.79 2.42 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 9.5 p -137.19 146.94 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.202 -1.176 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 52.2 t -69.73 133.39 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.303 -0.873 . . . . 0.0 109.518 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.404 ' CD ' ' HB2' ' A' ' 73' ' ' GLU . 0.3 OUTLIER -110.79 -58.23 2.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.313 -0.867 . . . . 0.0 109.482 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 14.1 m -124.52 164.95 18.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.498 ' HA ' HG22 ' A' ' 70' ' ' ILE . 53.7 t -124.74 118.98 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.268 -0.895 . . . . 0.0 109.452 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.21 15.25 27.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.448 HG11 HD11 ' A' ' 63' ' ' LEU . 21.0 m -149.85 173.44 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.241 -0.912 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.42 ' HB3' ' OD2' ' A' ' 61' ' ' ASP . 6.0 tptt -134.47 173.67 11.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.253 -0.905 . . . . 0.0 109.46 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.73 124.29 31.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.65 -10.71 57.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.42 ' OD2' ' HB3' ' A' ' 58' ' ' LYS . 3.0 m-20 -81.74 165.35 21.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -1.093 . . . . 0.0 109.571 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 165.12 13.06 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.499 ' HA ' HD23 ' A' ' 63' ' ' LEU . 5.3 mt -149.35 104.97 3.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.8 OUTLIER -86.99 137.89 31.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 10.3 pt-20 -42.77 151.57 0.12 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.19 -19.75 37.31 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -84.87 144.9 28.1 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.246 -1.15 . . . . 0.0 109.483 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -72.56 -178.8 2.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.701 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.0 mp -139.82 -68.08 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.412 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.498 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.0 OUTLIER -148.9 -177.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.448 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -132.89 117.83 18.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.987 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.8 tt -93.78 143.33 26.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.204 -0.935 . . . . 0.0 109.526 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.404 ' HB2' ' CD ' ' A' ' 53' ' ' LYS . 0.1 OUTLIER -113.53 91.03 19.15 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.363 -0.836 . . . . 0.0 109.381 179.988 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.987 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.603 0 C-N-CA 122.668 2.246 . . . . 0.0 110.441 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 76.8 p . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.284 0.564 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.6 mt-10 -139.37 160.61 39.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.48 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.519 ' H ' HD12 ' A' ' 3' ' ' ILE . 2.5 mp -85.17 136.07 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.905 . . . . 0.0 109.528 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.751 HD13 ' HG2' ' A' ' 47' ' ' PRO . 10.3 mt -105.49 120.21 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.92 168.55 10.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.189 -0.944 . . . . 0.0 109.486 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 78.3 t -49.68 142.48 12.17 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.268 -0.895 . . . . 0.0 109.322 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.69 -174.72 2.34 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.462 2.108 . . . . 0.0 110.393 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.91 100.86 8.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.712 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.41 -14.91 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.272 -0.892 . . . . 0.0 109.291 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.38 -21.26 32.87 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -128.82 -145.5 5.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.95 142.3 30.63 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -1.163 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.15 103.29 2.13 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.458 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.1 mt-10 -101.7 119.75 39.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.296 -1.12 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.97 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.7 t -78.83 131.93 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.464 179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.442 ' O ' ' HG3' ' A' ' 17' ' ' GLU . 8.8 mm -108.93 -40.48 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.9 . . . . 0.0 109.498 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.442 ' HG3' ' O ' ' A' ' 16' ' ' ILE . 64.9 mt-10 -157.17 -177.77 6.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.426 -179.967 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.501 HD12 HG12 ' A' ' 33' ' ' VAL . 11.3 tp -137.03 145.96 44.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.471 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.467 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -136.8 36.35 2.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.554 -179.95 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 32' ' ' LEU . 3.7 m -149.94 156.61 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.29 -0.881 . . . . 0.0 109.558 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.24 175.71 5.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.181 -0.949 . . . . 0.0 109.469 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.6 m -84.95 146.39 27.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.546 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.525 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 78.48 3.32 86.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.02 133.14 34.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -1.165 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.602 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -83.65 108.12 16.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.197 -0.939 . . . . 0.0 109.432 -179.991 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.53 -171.4 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.1 mt-10 -147.03 -178.95 6.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.421 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.725 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.4 p -82.7 73.67 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.87 -42.36 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.334 -0.853 . . . . 0.0 109.435 179.836 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.43 ' HB3' HG22 ' A' ' 26' ' ' ILE . 18.6 tt0 -50.81 135.69 23.49 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.174 -0.954 . . . . 0.0 109.455 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.467 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -52.88 179.99 0.08 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.592 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -146.24 -67.99 0.28 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.21 -1.171 . . . . 0.0 109.535 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.501 HG12 HD12 ' A' ' 18' ' ' LEU . 30.9 m -133.01 169.63 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.523 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.9 HG22 ' HG2' ' A' ' 43' ' ' GLU . 24.4 t -119.09 79.2 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.261 -0.899 . . . . 0.0 109.452 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.97 HD23 ' HA ' ' A' ' 15' ' ' VAL . 5.9 mt -90.05 151.73 21.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.53 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.424 ' HG3' ' OG ' ' A' ' 41' ' ' SER . 2.3 tm-20 -140.79 141.84 34.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.33 -0.857 . . . . 0.0 109.495 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.03 -177.95 3.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -0.896 . . . . 0.0 109.523 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.95 -12.46 37.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.278 -0.889 . . . . 0.0 109.472 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.51 -67.96 0.77 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.264 -0.897 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.19 175.41 14.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -0.937 . . . . 0.0 109.461 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.424 ' OG ' ' HG3' ' A' ' 36' ' ' GLU . 0.9 OUTLIER -95.01 137.21 34.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 109.473 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.22 124.83 11.76 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.916 . . . . 0.0 109.5 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.9 ' HG2' HG22 ' A' ' 34' ' ' VAL . 7.1 mt-10 -84.52 166.86 16.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.488 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.496 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 54.1 t -137.03 134.59 19.09 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.24 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.23 -168.4 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.412 2.075 . . . . 0.0 110.316 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.1 130.88 50.4 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.302 -0.874 . . . . 0.0 109.353 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.751 ' HG2' HD13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.53 -1.48 11.64 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.416 2.078 . . . . 0.0 110.394 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.755 ' HD2' HD22 ' A' ' 72' ' ' LEU . 33.6 ttmt -160.28 140.69 11.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 109.561 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.09 101.21 12.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.925 . . . . 0.0 109.493 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.909 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -158.58 -162.35 11.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.525 HG22 ' HA2' ' A' ' 23' ' ' GLY . 9.9 p -111.03 129.17 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.295 -1.12 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -54.02 138.63 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.49 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.12 -35.67 4.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 t -174.78 149.48 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.175 -0.953 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.772 HG13 HG22 ' A' ' 70' ' ' ILE . 11.1 t -108.53 148.45 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.452 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 59.4 m -113.35 18.22 17.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.641 ' H ' HG12 ' A' ' 55' ' ' VAL . 30.2 m -147.12 158.47 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.503 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.448 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -120.17 -175.21 2.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 -179.946 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.484 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -77.04 147.75 36.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.265 -0.897 . . . . 0.0 109.416 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.33 11.62 53.05 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.448 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -84.74 132.25 34.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.186 -1.185 . . . . 0.0 109.492 179.997 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.56 118.37 36.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.561 HD23 ' HB3' ' A' ' 67' ' ' ASP . 3.1 mp -122.6 162.55 21.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.1 tttp -102.75 146.79 27.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.431 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.5 OUTLIER -42.9 148.04 0.27 Allowed 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.312 -0.868 . . . . 0.0 109.661 -179.877 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.7 -8.07 74.0 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.561 ' HB3' HD23 ' A' ' 63' ' ' LEU . 1.2 m-20 -83.96 140.18 32.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -1.103 . . . . 0.0 109.487 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.408 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.36 164.16 0.21 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.422 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.596 HG22 HG23 ' A' ' 70' ' ' ILE . 17.7 mm -141.13 -54.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.182 -0.948 . . . . 0.0 109.449 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG13 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -150.65 -178.23 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.931 . . . . 0.0 109.585 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -139.43 135.61 33.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.93 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.5 tt -116.44 146.76 42.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 23.6 tt0 -118.35 88.62 33.73 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.486 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.93 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.529 0 C-N-CA 122.568 2.178 . . . . 0.0 110.466 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.4 p . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 3' ' ' ILE . 20.9 mp0 -89.43 161.81 16.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.34 -0.85 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.741 ' N ' HD12 ' A' ' 3' ' ' ILE . 3.2 mp -110.74 139.26 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.903 . . . . 0.0 109.466 -179.978 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -111.19 138.27 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.228 -0.92 . . . . 0.0 109.451 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.448 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 3.0 ptt180 -121.55 166.66 13.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.734 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.3 t -48.5 142.2 8.68 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.244 -0.91 . . . . 0.0 109.36 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.734 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.09 -171.45 1.21 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.483 2.122 . . . . 0.0 110.423 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.09 101.54 12.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.492 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.11 -26.36 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.24 -0.912 . . . . 0.0 109.255 -179.922 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 34.9 5.47 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 153.04 -133.58 4.09 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -118.08 168.2 10.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -1.112 . . . . 0.0 109.463 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.1 128.61 2.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.461 ' OE2' ' O ' ' A' ' 15' ' ' VAL . 3.3 tm-20 -89.2 134.65 33.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -1.144 . . . . 0.0 109.427 179.956 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.461 ' O ' ' OE2' ' A' ' 14' ' ' GLU . 19.2 t -74.72 156.57 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.505 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -115.56 -58.49 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.492 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.71 161.91 41.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.0 111.54 20.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -0.88 . . . . 0.0 109.472 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.16 32.91 1.62 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.03 161.98 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.467 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.426 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.24 -177.07 4.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.205 -0.934 . . . . 0.0 109.469 179.999 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.0 m -81.34 143.18 32.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.234 -0.916 . . . . 0.0 109.504 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.58 90.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.426 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 22.7 m-20 -85.07 139.45 31.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -1.198 . . . . 0.0 109.435 -179.961 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.542 ' O ' HD23 ' A' ' 25' ' ' LEU . 6.8 tt -103.43 108.97 20.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.9 OUTLIER -90.15 -171.39 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.212 -0.93 . . . . 0.0 109.234 179.985 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.4 pt-20 -138.22 -178.28 5.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.119 -0.988 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 28' ' ' VAL . 9.9 p -82.27 74.57 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.48 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER 162.91 -55.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.901 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 29' ' ' GLU . 1.4 tt0 -44.41 141.01 2.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.87 . . . . 0.0 109.494 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.455 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -70.77 178.67 32.1 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.521 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -141.35 -42.18 0.37 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -1.169 . . . . 0.0 109.453 179.926 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.6 HG22 ' HB ' ' A' ' 44' ' ' VAL . 20.3 m -152.04 155.29 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 -179.986 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 16' ' ' ILE . 58.7 t -114.84 107.75 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.232 -0.918 . . . . 0.0 109.451 -179.903 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 15' ' ' VAL . 1.8 mp -98.11 -178.38 4.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -147.54 140.08 24.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.938 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.4 p -107.07 -177.67 3.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.58 -65.45 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.238 -0.913 . . . . 0.0 109.425 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 mppt? -129.54 55.91 1.74 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.496 -179.952 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -170.85 -161.56 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.278 -0.889 . . . . 0.0 109.512 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.09 149.73 30.71 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.296 -0.877 . . . . 0.0 109.448 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' HG22 ' A' ' 9' ' ' ILE . 69.5 mmm -146.06 104.42 3.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -0.947 . . . . 0.0 109.383 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.95 171.98 13.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -0.921 . . . . 0.0 109.538 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.6 ' HB ' HG22 ' A' ' 33' ' ' VAL . 48.9 t -146.15 98.48 4.35 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.263 -0.898 . . . . 0.0 109.389 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.5 Cg_endo -77.5 -168.09 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.492 2.128 . . . . 0.0 110.527 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.489 ' CB ' ' HB ' ' A' ' 26' ' ' ILE . 6.5 t -85.09 113.65 51.37 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.45 -179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.4 Cg_endo -78.06 3.01 7.41 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.364 2.043 . . . . 0.0 110.329 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.588 ' O ' HD13 ' A' ' 72' ' ' LEU . 6.0 mttt -160.01 114.94 2.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.312 -0.868 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.1 91.95 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.944 . . . . 0.0 109.533 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 1.01 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.39 -171.86 22.41 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 10.9 p -100.77 155.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -1.185 . . . . 0.0 109.517 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.2 t -81.37 138.62 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -0.923 . . . . 0.0 109.536 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -104.34 -66.9 0.93 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -137.92 148.7 45.55 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.474 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.56 HG12 ' H ' ' A' ' 57' ' ' VAL . 12.0 t -101.65 133.65 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -112.87 13.98 19.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.142 -0.974 . . . . 0.0 109.567 179.962 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.6 HG11 HD13 ' A' ' 69' ' ' ILE . 2.0 m -137.46 158.77 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.219 -0.926 . . . . 0.0 109.478 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.15 158.68 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.238 -0.914 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.8 pp -82.68 137.64 34.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.931 . . . . 0.0 109.53 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.95 -14.52 65.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -83.68 168.07 16.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.14 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.795 ' O ' HD23 ' A' ' 63' ' ' LEU . 8.5 mtmt -97.38 140.77 31.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -0.855 . . . . 0.0 109.442 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 62' ' ' LYS . 6.5 mt -123.97 116.05 22.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.497 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 65' ' ' GLU . 4.3 tttt -90.48 139.69 30.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.303 -0.873 . . . . 0.0 109.472 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.445 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 15.6 pt-20 -42.76 149.19 0.2 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.313 -0.867 . . . . 0.0 109.645 -179.896 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.71 -14.88 58.88 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 91.6 m-20 -85.01 140.06 31.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.285 -1.126 . . . . 0.0 109.471 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -62.37 -179.43 0.24 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.213 -0.929 . . . . 0.0 109.506 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.684 HG22 HG23 ' A' ' 70' ' ' ILE . 28.6 mm -147.95 -72.19 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.447 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.684 HG23 HG22 ' A' ' 69' ' ' ILE . 3.8 pt -142.37 -172.52 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.932 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -140.29 112.2 7.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.011 HD23 ' HD3' ' A' ' 74' ' ' PRO . 3.6 tt -90.06 141.96 28.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -113.24 91.69 20.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.21 -0.932 . . . . 0.0 109.535 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 1.011 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.1 Cg_endo . . . . . 0 C--N 1.308 -1.56 0 C-N-CA 122.602 2.201 . . . . 0.0 110.35 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 68.8 p . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -147.42 150.48 34.74 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.635 HD12 ' HB2' ' A' ' 71' ' ' GLU . 1.4 tp -93.03 130.73 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.6 mm -93.81 124.22 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.388 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 3.5 ptt-85 -118.52 159.16 24.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 9' ' ' ILE . 84.3 t -43.33 103.51 0.32 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.344 -0.847 . . . . 0.0 109.442 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.472 ' O ' HG12 ' A' ' 9' ' ' ILE . 35.9 Cg_endo -77.78 -169.54 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.511 2.14 . . . . 0.0 110.45 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -68.26 99.7 0.95 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.283 -0.886 . . . . 0.0 109.413 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.883 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.0 -43.0 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.305 -179.877 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.55 34.61 0.65 Allowed Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 147.21 -132.74 4.45 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -101.5 135.27 43.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.65 115.78 4.31 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.476 ' HG2' ' CB ' ' A' ' 62' ' ' LYS . 12.9 mt-10 -112.36 104.32 12.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -1.152 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.649 ' O ' HD13 ' A' ' 16' ' ' ILE . 42.7 t -54.17 136.23 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.515 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.649 HD13 ' O ' ' A' ' 15' ' ' VAL . 29.2 mm -128.04 -37.42 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.83 155.27 43.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.59 123.59 46.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 32' ' ' LEU . 6.3 mt -93.77 9.36 37.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.535 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.7 m -146.42 175.42 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 179.949 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.423 ' O ' HG21 ' A' ' 52' ' ' VAL . 5.2 ttpp -139.31 -164.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.272 -0.892 . . . . 0.0 109.49 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.4 m -84.83 139.41 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.918 . . . . 0.0 109.509 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.87 10.56 51.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -85.04 134.72 34.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.195 -1.179 . . . . 0.0 109.454 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.629 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -88.24 118.25 27.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.804 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -97.04 -171.41 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.239 -0.913 . . . . 0.0 109.234 -179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.707 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.3 tt0 -147.81 153.99 39.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 28' ' ' VAL . 6.3 p -72.03 84.35 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.248 -0.907 . . . . 0.0 109.506 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.79 -32.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.336 -0.853 . . . . 0.0 109.473 179.877 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -78.66 153.27 31.14 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.233 -0.917 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.463 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.38 -160.07 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.804 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -160.01 -72.74 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -1.166 . . . . 0.0 109.459 179.983 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.54 HG21 HD11 ' A' ' 35' ' ' LEU . 8.5 m -119.45 150.92 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.792 HG22 ' OE1' ' A' ' 43' ' ' GLU . 23.9 t -117.91 83.22 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.54 HD11 HG21 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -91.13 147.52 23.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.44 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.39 152.84 21.13 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.169 -0.957 . . . . 0.0 109.411 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -98.72 -175.62 3.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.28 -0.888 . . . . 0.0 109.481 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.61 94.78 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.6 mttm -142.4 48.33 1.56 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.413 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -177.13 -158.76 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.51 152.94 37.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.388 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtp -159.26 142.47 14.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.792 ' OE1' HG22 ' A' ' 34' ' ' VAL . 24.0 mt-10 -132.65 162.8 30.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.7 t -131.02 140.08 37.57 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.309 -0.869 . . . . 0.0 109.345 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.515 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.21 -168.59 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.581 2.188 . . . . 0.0 110.421 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.483 ' HB2' HG21 ' A' ' 26' ' ' ILE . 28.9 t -85.27 113.64 51.6 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.398 -0.814 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.03 0.49 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.348 2.032 . . . . 0.0 110.425 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.76 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.09 104.75 1.51 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.338 -0.851 . . . . 0.0 109.491 179.951 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.35 101.87 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.467 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.943 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -159.36 -150.19 5.75 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.867 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.524 ' HB ' HD21 ' A' ' 25' ' ' LEU . 8.1 p -116.51 132.35 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -1.14 . . . . 0.0 109.478 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 21' ' ' LYS . 63.7 t -56.3 126.84 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.01 -50.1 5.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.163 -0.96 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -169.64 153.26 4.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.349 -0.844 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.753 HG12 ' H ' ' A' ' 57' ' ' VAL . 25.9 t -111.69 136.34 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.301 -0.874 . . . . 0.0 109.457 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -94.79 17.4 13.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.271 -0.893 . . . . 0.0 109.471 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.788 HG11 HD22 ' A' ' 63' ' ' LEU . 1.6 m -145.28 176.88 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.274 -0.891 . . . . 0.0 109.386 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -112.34 -178.91 3.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.19 -0.944 . . . . 0.0 109.522 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -82.3 136.85 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.93 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.41 18.08 76.65 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 4.4 m-20 -83.68 144.14 29.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -103.66 120.94 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.515 179.961 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.788 HD22 HG11 ' A' ' 57' ' ' VAL . 1.3 mp -121.73 175.57 6.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.907 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' GLU . 3.5 tttp -118.31 145.75 44.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 3.2 pt-20 -42.85 137.48 2.3 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.341 -0.849 . . . . 0.0 109.584 -179.884 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.53 -25.93 16.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -84.89 140.76 30.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -1.124 . . . . 0.0 109.448 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -65.04 -174.11 0.14 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.423 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 69' ' ' ILE . 28.7 mm -143.3 -65.33 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.264 -0.897 . . . . 0.0 109.49 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.699 ' CG2' HG13 ' A' ' 55' ' ' VAL . 1.8 pt -141.95 -175.11 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.899 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.635 ' HB2' HD12 ' A' ' 3' ' ' ILE . 1.8 tt0 -149.56 114.37 5.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.296 -0.877 . . . . 0.0 109.498 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.943 HD21 ' HA3' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -93.27 148.02 22.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.423 -179.911 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.413 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 3.6 tt0 -132.91 91.22 29.67 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.493 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.839 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.308 -1.553 0 C-N-CA 122.627 2.218 . . . . 0.0 110.44 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 89.1 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -122.35 151.07 41.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.476 ' C ' HD12 ' A' ' 4' ' ' ILE . 4.3 mp -90.94 154.36 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.513 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.1 mp -120.81 107.57 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.479 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -101.55 170.64 8.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.385 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.719 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -61.26 142.27 93.6 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.374 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.719 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.08 -169.77 0.83 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.561 2.174 . . . . 0.0 110.458 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -82.88 105.15 13.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.416 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.8 -59.5 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.389 -179.954 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.04 -11.68 10.78 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.05 -141.28 4.22 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.414 ' OD1' ' HE2' ' A' ' 64' ' ' LYS . 0.1 OUTLIER -98.66 164.17 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -1.127 . . . . 0.0 109.516 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.59 95.47 0.47 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -97.0 126.16 41.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.282 -1.128 . . . . 0.0 109.428 -179.953 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.643 HG22 ' CD2' ' A' ' 35' ' ' LEU . 19.2 t -77.09 133.6 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.93 . . . . 0.0 109.512 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.559 HD11 ' HB2' ' A' ' 36' ' ' GLU . 19.2 mt -121.38 -37.58 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.395 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.56 137.6 43.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.192 -0.942 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.423 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -122.43 119.29 30.56 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -117.81 50.34 1.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.431 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -147.36 159.34 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -148.74 -176.3 5.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.427 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.5 m -84.63 126.47 33.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.449 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.88 6.9 64.94 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 180.0 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 57.2 m-20 -83.66 131.9 34.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.46 HD12 ' HB ' ' A' ' 51' ' ' VAL . 7.2 tp -92.94 106.48 18.43 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.534 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.714 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -91.77 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.215 -0.928 . . . . 0.0 109.151 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.714 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.7 mt-10 -144.7 176.51 9.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.925 . . . . 0.0 109.412 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.768 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.4 p -81.96 72.95 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.205 -0.934 . . . . 0.0 109.535 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.83 -44.57 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.331 -0.856 . . . . 0.0 109.397 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -51.13 142.42 12.53 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.209 -0.932 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.457 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.61 175.47 4.68 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.724 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.6 OUTLIER -138.51 -62.24 0.57 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.358 -179.979 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.38 159.86 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.932 . . . . 0.0 109.457 -179.943 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 65.1 t -114.66 84.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.643 ' CD2' HG22 ' A' ' 15' ' ' VAL . 7.3 mt -94.68 159.55 15.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.559 ' HB2' HD11 ' A' ' 16' ' ' ILE . 0.3 OUTLIER -124.15 161.23 26.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.913 . . . . 0.0 109.49 -179.96 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -139.44 172.02 13.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.465 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.02 -13.39 62.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.312 -0.867 . . . . 0.0 109.54 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.535 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mptt -87.42 -38.84 15.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.535 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.07 -174.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.514 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.49 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 0.0 OUTLIER -99.15 134.98 41.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.237 -0.915 . . . . 0.0 109.453 -179.975 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.447 ' O ' ' HG3' ' A' ' 42' ' ' MET . 0.4 OUTLIER -155.16 132.26 10.89 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.449 -179.959 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -94.53 -179.71 4.99 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.5 t -144.36 128.94 9.24 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.224 -0.923 . . . . 0.0 109.304 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.457 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.5 -168.62 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.334 2.023 . . . . 0.0 110.326 179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.724 ' HA ' HD13 ' A' ' 32' ' ' LEU . 1.9 t -85.31 136.41 37.83 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.362 -0.836 . . . . 0.0 109.359 179.891 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HG2' HG12 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.73 -5.73 14.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.516 2.144 . . . . 0.0 110.495 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.33 139.17 10.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 109.488 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.86 101.57 8.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.444 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.849 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -157.7 -147.75 4.91 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 14.5 p -126.66 152.02 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.219 -1.165 . . . . 0.0 109.502 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 54.3 t -68.66 140.47 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.249 -0.907 . . . . 0.0 109.459 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -109.04 -53.88 2.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -0.933 . . . . 0.0 109.457 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.87 177.95 7.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 57' ' ' VAL . 92.9 t -124.35 125.15 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 21.6 t -105.53 1.67 27.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.198 -0.939 . . . . 0.0 109.645 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 55' ' ' VAL . 3.3 m -147.28 176.3 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.481 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.481 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -129.79 150.4 51.11 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.488 -179.943 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.667 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -61.79 140.67 58.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.889 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.75 -11.96 60.64 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.481 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 8.0 m-20 -78.01 152.62 32.97 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.194 -1.18 . . . . 0.0 109.444 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.426 ' O ' ' HG2' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -114.11 146.26 40.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.971 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.2 mp -147.75 -178.41 6.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -120.22 149.74 41.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.459 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.441 ' N ' ' CD ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -42.87 149.17 0.21 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.839 . . . . 0.0 109.591 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.69 -14.29 65.34 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -84.65 137.73 33.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.25 -1.147 . . . . 0.0 109.491 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.43 ' O ' HG13 ' A' ' 69' ' ' ILE . . . -66.25 176.93 1.59 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.479 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.3 mp -142.1 -61.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.253 -0.904 . . . . 0.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -142.9 -172.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.199 -0.938 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -142.41 106.94 4.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.291 -0.881 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.849 HD11 ' N ' ' A' ' 50' ' ' GLY . 2.7 tt -91.18 135.58 33.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.203 -0.936 . . . . 0.0 109.49 179.929 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.524 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 20.6 tt0 -116.66 142.11 29.15 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.227 -0.921 . . . . 0.0 109.423 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 36.0 Cg_endo . . . . . 0 C--N 1.309 -1.519 0 C-N-CA 122.568 2.179 . . . . 0.0 110.403 179.942 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.463 ' HB3' ' HG3' ' A' ' 73' ' ' GLU . 9.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -128.12 133.42 48.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.484 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.492 HD12 ' HB2' ' A' ' 71' ' ' GLU . 2.1 tp -79.95 140.27 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.436 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.68 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.4 mp -101.61 142.41 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 179.991 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -113.95 179.74 3.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.854 . . . . 0.0 109.478 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.68 ' CG1' HD11 ' A' ' 9' ' ' ILE . 49.1 t -61.35 134.4 93.35 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 109.292 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.418 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -170.04 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.457 2.105 . . . . 0.0 110.483 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -79.93 101.41 8.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.473 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.68 HD11 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.24 -49.73 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.284 -179.938 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.64 -17.37 6.89 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.938 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.42 -171.88 28.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.83 148.88 42.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -1.159 . . . . 0.0 109.53 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.53 150.23 18.54 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.9 OUTLIER -118.38 142.33 47.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.176 -1.19 . . . . 0.0 109.465 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.479 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -76.48 135.41 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.521 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.84 HD12 HG12 ' A' ' 34' ' ' VAL . 80.5 mt -100.33 -38.33 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.447 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -172.47 170.12 5.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.533 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 tp -117.15 125.16 50.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.444 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.1 pp -104.7 31.25 4.85 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' CD2' ' A' ' 32' ' ' LEU . 17.2 m -150.0 166.67 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.6 mtmt -128.51 179.06 5.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.902 . . . . 0.0 109.498 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 35.1 m -84.96 141.63 30.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.89 63.34 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -84.89 138.45 32.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -1.22 . . . . 0.0 109.502 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -79.98 131.11 35.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 109.431 179.911 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.84 HD13 HD11 ' A' ' 32' ' ' LEU . 2.4 mt -92.95 -171.56 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.176 -0.952 . . . . 0.0 109.278 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.7 OUTLIER -126.98 175.84 7.78 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.206 -0.933 . . . . 0.0 109.433 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 28' ' ' VAL . 8.3 p -76.55 124.46 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.497 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 4.1 mt-10 63.05 11.92 5.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.245 -0.909 . . . . 0.0 109.656 179.859 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.473 ' HG3' ' HB2' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -74.13 122.57 22.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.356 179.923 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.464 ' N ' ' HB3' ' A' ' 45' ' ' PRO . . . -43.19 152.88 0.28 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.86 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.84 HD11 HD13 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -132.56 -39.25 1.01 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -1.153 . . . . 0.0 109.496 179.943 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -140.92 165.1 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.174 -0.954 . . . . 0.0 109.528 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.84 HG12 HD12 ' A' ' 16' ' ' ILE . 78.4 t -130.59 95.51 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.92 163.57 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.711 ' HB2' HD11 ' A' ' 16' ' ' ILE . 21.2 tt0 -122.94 123.45 40.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.892 . . . . 0.0 109.515 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.443 ' HB2' ' HB3' ' A' ' 40' ' ' ALA . 0.4 OUTLIER -79.91 -173.82 4.08 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.58 -42.1 32.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.539 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.81 18.48 0.69 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' HB2' ' A' ' 37' ' ' SER . . . -120.34 -169.74 1.85 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -158.04 101.75 1.78 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.531 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.432 ' N ' ' SD ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -114.34 143.16 45.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.212 -0.93 . . . . 0.0 109.452 -179.984 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -100.97 164.07 11.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.281 -0.887 . . . . 0.0 109.521 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.07 102.88 10.81 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.362 179.951 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.464 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -77.4 -169.58 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.419 2.079 . . . . 0.0 110.428 -179.823 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.73 139.52 35.39 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.473 179.906 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.437 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.4 Cg_endo -78.96 -10.65 15.28 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.409 2.072 . . . . 0.0 110.328 179.841 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.484 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.5 146.84 15.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.477 -0.764 . . . . 0.0 109.364 179.962 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.97 116.95 17.17 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -0.946 . . . . 0.0 109.399 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 1.003 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -164.36 -149.25 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.4 p -126.34 145.43 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -1.113 . . . . 0.0 109.433 -179.945 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.7 t -65.13 140.41 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.891 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.2 tptp -117.16 -47.11 2.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.401 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.49 163.61 32.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 80.4 t -121.52 118.19 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.0 t -108.22 22.59 15.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.557 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.409 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 34.5 m -144.13 160.35 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.532 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.67 169.2 18.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -0.903 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.424 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -84.97 103.08 13.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.218 -0.926 . . . . 0.0 109.476 -179.955 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.1 -14.06 19.14 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.57 138.62 38.46 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.198 -1.178 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -80.48 152.83 28.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -0.868 . . . . 0.0 109.44 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.479 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 63.2 mt -140.97 136.53 32.27 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 14.3 tttm -105.87 149.05 26.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 0.0 109.486 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.0 OUTLIER -42.88 147.31 0.32 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.37 -0.831 . . . . 0.0 109.583 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 82.57 -4.34 78.79 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 2.5 m-20 -83.09 130.87 35.16 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.289 -1.124 . . . . 0.0 109.423 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -50.5 178.34 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.26 -0.9 . . . . 0.0 109.475 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.433 HG22 HG23 ' A' ' 70' ' ' ILE . 29.5 mm -146.97 -71.48 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.461 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.433 HG23 HG22 ' A' ' 69' ' ' ILE . 0.8 OUTLIER -138.81 -174.58 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.489 180.0 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.492 ' HB2' HD12 ' A' ' 3' ' ' ILE . 0.3 OUTLIER -150.0 102.0 3.07 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.907 . . . . 0.0 109.507 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 1.003 HD11 ' CA ' ' A' ' 50' ' ' GLY . 4.0 tt -91.3 129.01 37.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.289 -0.882 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.534 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -90.07 144.96 32.07 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.367 -179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.53 0 C-N-CA 122.623 2.215 . . . . 0.0 110.432 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 84.6 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -107.8 147.26 31.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.587 HD11 ' HB1' ' A' ' 68' ' ' ALA . 13.8 tt -79.93 169.13 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -0.883 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.937 ' O ' HD12 ' A' ' 69' ' ' ILE . 24.6 mm -125.39 119.78 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 -179.938 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.537 ' C ' HD11 ' A' ' 69' ' ' ILE . 3.9 ptm180 -94.93 163.83 13.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.648 ' N ' HD11 ' A' ' 69' ' ' ILE . 86.9 t -69.25 140.03 90.25 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.379 -179.903 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.573 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.73 -168.7 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.589 2.193 . . . . 0.0 110.432 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -75.19 117.67 17.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 109.268 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.448 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -108.57 -47.26 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 109.482 -179.736 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 149.61 -38.9 0.92 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.996 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . 172.29 117.64 0.45 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.92 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' A' ' 11' ' ' GLY . 0.7 OUTLIER 50.33 178.66 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -1.091 . . . . 0.0 109.623 179.892 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.35 111.69 0.36 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.439 ' HB2' ' HD3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -95.95 137.12 35.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.283 -1.128 . . . . 0.0 109.539 179.963 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.539 HG22 HD23 ' A' ' 35' ' ' LEU . 59.9 t -85.12 134.97 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.556 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.707 HD11 ' HG3' ' A' ' 36' ' ' GLU . 44.6 mt -104.31 -30.63 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.204 -0.935 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.423 ' HB2' ' O ' ' A' ' 16' ' ' ILE . 0.5 OUTLIER 175.22 131.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.545 179.976 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.491 HD12 ' H ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -103.12 172.08 7.02 Favored 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -145.32 63.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.473 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.411 HG11 ' CD1' ' A' ' 32' ' ' LEU . 18.0 m -146.36 158.92 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.534 179.972 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.432 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 75.9 mttt -123.47 167.75 13.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.875 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 22' ' ' THR . 11.0 t -79.12 126.82 31.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.428 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 89.29 9.36 67.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' OD1' ' HB2' ' A' ' 21' ' ' LYS . 0.8 OUTLIER -85.02 135.06 34.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.158 -1.201 . . . . 0.0 109.506 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.446 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.7 tt -97.25 104.37 16.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -0.916 . . . . 0.0 109.475 179.959 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.7 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.89 -171.45 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.2 -0.937 . . . . 0.0 109.246 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.7 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.7 mt-10 -137.94 176.5 8.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.749 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.1 p -81.39 79.07 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.455 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 167.49 -55.9 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.42 -0.8 . . . . 0.0 109.319 179.874 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.447 ' OE1' HG23 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -44.66 145.79 0.85 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.946 . . . . 0.0 109.497 179.965 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.45 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.34 -162.74 0.09 OUTLIER Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.03 -71.77 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 109.516 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.464 ' O ' ' HB2' ' A' ' 43' ' ' GLU . 9.5 m -129.9 170.24 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.975 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.453 HG22 ' HB3' ' A' ' 43' ' ' GLU . 77.2 t -129.53 92.12 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 180.0 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.539 HD23 HG22 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -97.04 169.83 9.56 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 179.999 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.707 ' HG3' HD11 ' A' ' 16' ' ' ILE . 0.9 OUTLIER -103.12 178.74 4.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.247 -0.908 . . . . 0.0 109.486 -180.0 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -139.57 -173.09 3.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.28 -0.888 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -53.65 -57.61 10.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.932 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mttt -138.45 58.46 1.66 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.246 -0.909 . . . . 0.0 109.526 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.95 174.17 0.16 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.0 127.88 39.23 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.248 -0.907 . . . . 0.0 109.44 -179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.5 mtt -138.19 142.97 40.01 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -105.97 164.12 12.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.284 -0.885 . . . . 0.0 109.352 179.969 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.5 t -122.31 137.83 28.19 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.309 179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.3 Cg_endo -79.13 -167.99 0.57 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.465 2.11 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.05 116.35 65.05 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.395 -0.816 . . . . 0.0 109.36 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' HG21 ' A' ' 4' ' ' ILE . 35.8 Cg_endo -77.77 4.54 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.381 2.054 . . . . 0.0 110.45 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.679 ' HB3' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.01 111.68 2.0 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.522 -179.976 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.45 95.89 2.3 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.307 -0.871 . . . . 0.0 109.435 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.975 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -164.29 -164.08 18.73 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.428 HG23 ' C ' ' A' ' 23' ' ' GLY . 14.9 p -100.91 133.82 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.229 -1.16 . . . . 0.0 109.519 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 80.4 t -58.82 147.88 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 -30.75 6.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -169.6 159.38 8.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.532 ' HA ' HG22 ' A' ' 70' ' ' ILE . 75.2 t -116.66 106.74 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.137 -0.977 . . . . 0.0 109.47 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.91 21.88 8.08 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.261 -0.899 . . . . 0.0 109.417 179.955 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.525 HG21 HG22 ' A' ' 69' ' ' ILE . 15.8 m -144.1 160.51 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.57 171.15 12.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 179.966 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.07 119.2 22.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.424 -179.963 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.77 -10.02 48.4 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.17 159.93 33.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.269 -1.136 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.868 ' O ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -113.52 135.07 54.29 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.507 179.958 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.868 HD12 ' O ' ' A' ' 62' ' ' LYS . 1.2 mp -142.68 155.05 44.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.175 -0.953 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.437 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.43 147.96 26.98 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.522 -179.933 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 64' ' ' LYS . 4.1 pt-20 -43.04 141.24 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.77 -8.89 73.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.494 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -84.49 132.06 34.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -1.169 . . . . 0.0 109.519 179.974 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.587 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -56.08 156.1 5.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.396 -0.815 . . . . 0.0 109.44 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.937 HD12 ' O ' ' A' ' 4' ' ' ILE . 1.4 mp -129.82 -43.8 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.489 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 69' ' ' ILE . 4.9 pt -159.9 -173.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.6 tt0 -135.66 159.0 42.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.252 -0.905 . . . . 0.0 109.474 180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.975 HD11 ' N ' ' A' ' 50' ' ' GLY . 8.0 tt -140.54 145.32 36.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -116.68 87.77 22.58 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.906 . . . . 0.0 109.447 -179.979 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.883 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.552 0 C-N-CA 122.622 2.215 . . . . 0.0 110.458 179.974 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.461 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 86.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -141.86 144.7 33.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.6 mm -90.45 136.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.488 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 mt -110.57 124.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.403 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 11.6 ptt180 -105.18 171.45 7.31 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.907 . . . . 0.0 109.489 -179.945 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.0 t -62.13 142.48 95.57 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -78.56 -170.38 0.97 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.496 2.13 . . . . 0.0 110.375 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -84.9 110.74 19.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.392 179.927 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.59 -10.08 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.298 -0.876 . . . . 0.0 109.389 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.8 26.62 74.45 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.906 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 12' ' ' ASP . . . 171.61 160.55 20.41 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -44.45 155.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.239 -1.153 . . . . 0.0 109.485 -179.996 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.65 109.28 1.45 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -101.72 114.41 28.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -1.159 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 15' ' ' VAL . 14.3 t -60.24 129.93 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.891 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.1 mt -104.86 -35.57 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.243 -0.91 . . . . 0.0 109.502 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.465 ' HA ' ' HB2' ' A' ' 59' ' ' LEU . 6.5 tp10 -165.37 135.47 3.64 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.48 127.49 55.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -0.923 . . . . 0.0 109.411 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -116.03 57.68 0.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.444 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.81 HG11 ' CD2' ' A' ' 32' ' ' LEU . 35.6 m -137.19 157.24 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -129.93 157.51 42.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.511 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' THR . 12.1 t -80.64 128.98 34.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 109.419 179.939 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.71 -8.92 79.09 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -82.26 132.61 35.23 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.229 -1.16 . . . . 0.0 109.427 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -79.9 125.63 29.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.264 -0.897 . . . . 0.0 109.488 -179.959 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.784 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.52 -171.38 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.276 -0.89 . . . . 0.0 109.201 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.72 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 pm0 -142.2 159.68 41.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.119 -0.988 . . . . 0.0 109.477 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.783 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.3 p -81.41 79.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.244 -0.91 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.75 -36.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.397 179.893 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.507 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 39.6 tt0 -67.33 155.47 38.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -0.925 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.441 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -77.32 168.4 54.53 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.81 ' CD2' HG11 ' A' ' 20' ' ' VAL . 1.3 tt -129.5 -40.5 1.42 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.263 -1.14 . . . . 0.0 109.49 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.659 HG22 ' HB ' ' A' ' 44' ' ' VAL . 5.2 m -154.7 166.84 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.506 -179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.4 t -134.66 96.55 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.325 179.931 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -94.62 163.83 13.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.564 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -105.42 173.87 6.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.407 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.1 m -135.32 -174.13 3.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -44.73 -42.58 7.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 109.441 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 ttpp -158.89 39.76 0.22 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.485 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -151.0 -156.9 0.76 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.84 107.26 2.1 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' GLU . 2.4 ttm -100.2 149.66 23.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' MET . 10.6 mt-10 -113.2 164.51 13.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.659 ' HB ' HG22 ' A' ' 33' ' ' VAL . 21.6 t -143.9 101.74 4.93 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.25 -0.906 . . . . 0.0 109.269 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.536 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.4 Cg_endo -77.16 -168.75 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.393 2.062 . . . . 0.0 110.55 -179.824 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.784 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.6 t -85.26 117.64 69.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.272 -0.892 . . . . 0.0 109.502 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.12 3.35 7.13 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.332 2.021 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.703 ' HG2' HD12 ' A' ' 72' ' ' LEU . 1.8 tptt -159.88 131.2 5.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.892 . . . . 0.0 109.415 179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.41 88.36 7.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.818 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.836 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -140.05 -152.35 5.81 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 73' ' ' GLU . 9.9 p -113.59 129.99 68.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -1.169 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.4 t -55.55 126.75 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.09 -44.68 9.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.44 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 54.7 p -171.82 138.44 1.07 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.614 ' HA ' HG22 ' A' ' 70' ' ' ILE . 4.8 t -92.98 117.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 109.539 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.22 13.52 18.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.479 ' H ' HG12 ' A' ' 55' ' ' VAL . 2.8 m -140.83 172.09 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.73 151.74 44.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.465 ' HB2' ' HA ' ' A' ' 17' ' ' GLU . 1.6 pp -56.83 139.91 49.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.87 -7.53 81.56 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -70.57 -179.95 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.212 -1.169 . . . . 0.0 109.438 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -153.12 115.74 4.48 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.186 -0.946 . . . . 0.0 109.441 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mp -131.3 -175.05 3.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.473 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.3 tttp -118.56 144.65 45.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 1.6 pt-20 -42.82 141.23 1.13 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.302 -0.874 . . . . 0.0 109.585 -179.861 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.76 -22.62 36.52 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -78.79 138.14 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.46 179.99 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.44 170.12 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.433 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.653 HD11 ' CG2' ' A' ' 6' ' ' VAL . 27.7 mm -139.11 -59.56 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.614 HG22 ' HA ' ' A' ' 55' ' ' VAL . 2.3 pt -143.44 -173.75 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.268 -0.895 . . . . 0.0 109.409 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -139.07 113.16 8.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.836 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 119.92 30.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.592 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -111.14 95.42 25.16 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.202 -0.936 . . . . 0.0 109.451 -179.926 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.5 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.527 0 C-N-CA 122.594 2.196 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.484 ' HB3' ' HG2' ' A' ' 73' ' ' GLU . 24.8 p . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -157.19 140.61 15.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.453 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.5 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 2.9 mt -80.48 154.56 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.93 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.5 mt -122.25 97.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.571 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.72 -172.36 3.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.914 . . . . 0.0 109.379 179.968 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.714 HG11 HD11 ' A' ' 9' ' ' ILE . 54.6 t -80.88 139.09 49.86 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.128 -0.983 . . . . 0.0 109.284 -179.957 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.625 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.56 -169.89 0.87 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.499 2.133 . . . . 0.0 110.399 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -81.69 104.11 11.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.847 . . . . 0.0 109.37 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.714 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.77 -42.71 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.989 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.77 -23.37 6.28 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.95 -140.29 4.0 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.2 p30 -99.29 153.08 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.185 -1.185 . . . . 0.0 109.401 179.883 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -107.69 105.95 2.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.99 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.447 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.9 mt-10 -99.96 137.64 38.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -1.145 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 99.6 t -76.5 127.22 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.49 -179.934 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.407 HD11 ' CB ' ' A' ' 36' ' ' GLU . 83.7 mt -107.8 -35.47 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.356 -0.84 . . . . 0.0 109.368 -179.952 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -152.09 127.36 9.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.506 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.409 ' O ' HD23 ' A' ' 18' ' ' LEU . 3.9 tt -110.14 126.07 53.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.893 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.95 54.56 1.51 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.502 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.855 HG11 ' CD1' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -148.55 162.59 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.511 -179.943 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.556 ' O ' HG21 ' A' ' 52' ' ' VAL . 4.0 tptp -141.29 176.75 8.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.6 m -81.76 144.91 30.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.207 -0.933 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.404 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 69.29 8.07 58.43 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -85.02 132.61 34.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -1.151 . . . . 0.0 109.515 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.636 HD13 ' N ' ' A' ' 26' ' ' ILE . 0.7 OUTLIER -88.48 118.9 28.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 179.855 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.959 HD13 HD21 ' A' ' 32' ' ' LEU . 3.2 mt -95.62 -171.33 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 O-C-N 121.222 -0.924 . . . . 0.0 109.328 -179.784 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.3 pt-20 -145.47 167.69 22.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.397 179.975 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.742 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.6 p -83.83 72.73 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.934 . . . . 0.0 109.522 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.486 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 170.82 -35.03 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.334 -0.854 . . . . 0.0 109.459 179.826 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -72.67 153.76 41.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.47 179.985 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.75 175.06 44.94 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -134.85 -44.84 0.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 109.501 179.965 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.443 HG23 ' HB ' ' A' ' 44' ' ' VAL . 2.1 m -153.91 170.88 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.227 -0.92 . . . . 0.0 109.513 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 34' ' ' VAL . 94.0 t -129.75 76.87 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.23 -0.918 . . . . 0.0 109.444 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 4.9 mp -89.91 135.13 33.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.471 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.407 ' CB ' HD11 ' A' ' 16' ' ' ILE . 5.0 tm-20 -111.43 140.36 46.09 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.895 . . . . 0.0 109.492 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.707 ' OG ' HG21 ' A' ' 9' ' ' ILE . 1.4 m -112.52 173.7 6.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.532 179.989 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.89 -13.51 25.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 21.2 mttt -84.26 -45.44 12.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 178.94 165.21 0.88 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.407 ' HA ' ' CG ' ' A' ' 36' ' ' GLU . 8.5 t -81.48 118.56 22.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.541 179.919 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 23.9 mtm -121.63 -178.97 3.95 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 109.415 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.7 174.29 10.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.286 -0.884 . . . . 0.0 109.484 -179.957 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.1 t -149.21 103.05 3.32 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.212 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.465 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.6 Cg_endo -77.39 -168.64 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.343 2.029 . . . . 0.0 110.407 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.438 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.42 113.57 51.48 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.43 -179.905 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.7 Cg_endo -78.18 0.36 9.96 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.343 2.028 . . . . 0.0 110.308 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.47 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.12 131.15 5.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.314 -0.866 . . . . 0.0 109.397 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.59 108.11 5.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.862 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.96 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.86 -172.76 28.6 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 9.8 p -104.87 150.92 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 109.494 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.556 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.1 t -68.88 130.78 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 54' ' ' SER . 0.3 OUTLIER -86.51 -42.59 13.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 109.448 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 53' ' ' LYS . 4.8 t -179.51 139.95 0.14 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.183 -0.948 . . . . 0.0 109.566 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 57' ' ' VAL . 9.0 t -80.87 109.53 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.88 . . . . 0.0 109.423 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.8 p -89.5 7.84 34.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.299 -0.875 . . . . 0.0 109.632 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.996 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.03 -177.59 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.941 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.5 tptp -131.87 171.27 13.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -0.916 . . . . 0.0 109.499 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.402 HD12 ' C ' ' A' ' 59' ' ' LEU . 2.7 pp -84.56 132.33 34.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.899 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.63 74.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -81.38 141.58 33.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -1.158 . . . . 0.0 109.402 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.876 ' C ' HD12 ' A' ' 63' ' ' LEU . 10.8 pttp -99.73 151.61 21.04 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.195 -0.941 . . . . 0.0 109.465 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.876 HD12 ' C ' ' A' ' 62' ' ' LYS . 6.0 mp -138.17 168.9 18.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.238 -0.914 . . . . 0.0 109.504 179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -107.11 146.66 30.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.467 -179.974 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.434 ' N ' ' HD2' ' A' ' 64' ' ' LYS . 5.4 mt-10 -42.96 138.9 1.89 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.292 -0.88 . . . . 0.0 109.635 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.79 -6.44 73.58 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.12 145.73 29.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -1.176 . . . . 0.0 109.48 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.536 ' C ' HD12 ' A' ' 69' ' ' ILE . . . -81.15 163.57 23.01 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.437 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.996 HG23 HG21 ' A' ' 57' ' ' VAL . 4.3 mp -133.85 -55.57 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.18 -0.95 . . . . 0.0 109.546 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.779 HG23 HG22 ' A' ' 69' ' ' ILE . 18.1 pt -145.96 -173.42 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.269 -0.894 . . . . 0.0 109.49 -179.93 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.5 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 1.0 OUTLIER -146.49 155.63 42.67 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.235 -0.915 . . . . 0.0 109.505 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.96 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.5 tt -130.69 126.74 37.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.484 ' HG2' ' HB3' ' A' ' 1' ' ' SER . 0.1 OUTLIER -96.71 149.33 35.65 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.238 -0.914 . . . . 0.0 109.54 -179.959 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.51 0 C-N-CA 122.633 2.222 . . . . 0.0 110.412 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 1' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 65.6 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.61 172.59 13.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.8 mt -100.5 155.5 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.907 . . . . 0.0 109.486 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.681 HD12 ' HG2' ' A' ' 47' ' ' PRO . 36.2 mm -118.17 91.75 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.895 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.443 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -95.33 175.8 6.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.488 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.891 HG11 HD11 ' A' ' 9' ' ' ILE . 76.4 t -84.25 142.33 40.78 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -169.44 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.517 2.145 . . . . 0.0 110.433 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -78.55 105.41 9.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -0.873 . . . . 0.0 109.411 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.891 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.46 -11.07 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.307 -179.859 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.16 -14.99 56.16 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -144.92 -176.29 18.8 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.967 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -71.06 142.59 50.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -1.148 . . . . 0.0 109.472 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.92 107.55 3.25 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -99.61 113.42 25.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.459 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.0 t -68.91 131.81 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -0.934 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 19.5 mm -116.94 -22.16 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -0.897 . . . . 0.0 109.431 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.93 138.04 19.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.293 -0.879 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.499 ' HG ' HG22 ' A' ' 20' ' ' VAL . 12.8 tp -113.48 101.97 9.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 0.6 OUTLIER -108.84 56.65 0.62 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.499 HG22 ' HG ' ' A' ' 18' ' ' LEU . 2.3 m -134.28 160.28 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.224 -0.922 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.463 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 1.2 mtpp -137.43 156.98 47.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.27 -0.894 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.1 m -84.55 129.65 34.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.47 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.451 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 84.31 -9.4 64.27 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.997 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.463 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 0.9 OUTLIER -77.41 131.87 38.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -1.205 . . . . 0.0 109.462 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.0 OUTLIER -85.95 120.57 27.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.217 -0.927 . . . . 0.0 109.467 179.961 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.26 -171.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.229 -0.92 . . . . 0.0 109.204 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 11.0 mt-10 -145.44 163.02 35.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.693 HG13 ' O ' ' A' ' 28' ' ' VAL . 7.2 p -78.14 79.57 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.367 -0.833 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.81 -34.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.471 179.924 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 14.3 tt0 -70.35 141.07 52.29 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.318 -0.864 . . . . 0.0 109.499 -179.988 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.474 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -51.32 -177.17 0.03 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.661 HD13 ' HA ' ' A' ' 46' ' ' SER . 3.8 tp -151.41 -67.78 0.18 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.198 -1.178 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.07 138.66 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.512 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 42.2 t -97.64 89.12 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.439 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.89 150.36 22.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.206 -0.934 . . . . 0.0 109.481 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 41' ' ' SER . 2.0 tt0 -115.24 167.23 11.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.303 -0.873 . . . . 0.0 109.547 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.96 -172.6 3.88 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.48 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -84.52 10.31 11.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.509 179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 5.4 mttp -121.0 -30.83 4.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.333 -0.854 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 169.75 -171.78 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.321 -0.862 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 36' ' ' GLU . 10.5 t -103.96 134.07 47.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.181 -0.949 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtt -138.73 107.2 5.84 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.251 -0.906 . . . . 0.0 109.487 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.29 166.04 21.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.182 -0.949 . . . . 0.0 109.465 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 45' ' ' PRO . 72.0 t -136.38 142.15 38.49 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.305 -0.872 . . . . 0.0 109.342 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 44' ' ' VAL . 35.8 Cg_endo -77.96 -168.27 0.59 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.512 2.142 . . . . 0.0 110.448 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.661 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.8 OUTLIER -85.21 124.09 72.45 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.374 -0.829 . . . . 0.0 109.392 -179.913 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.681 ' HG2' HD12 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -78.45 0.55 9.83 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.306 2.004 . . . . 0.0 110.29 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.466 ' HE3' ' HG3' ' A' ' 74' ' ' PRO . 0.4 OUTLIER -160.15 116.73 2.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.941 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.76 80.93 2.7 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.467 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.996 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -136.37 -159.71 8.51 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 51' ' ' VAL . 11.7 p -103.4 124.1 57.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.201 -1.176 . . . . 0.0 109.519 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.2 t -49.94 140.02 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.455 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.7 tptm -96.94 -70.22 0.73 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.201 -0.937 . . . . 0.0 109.442 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 52.0 p -158.32 135.23 9.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 57' ' ' VAL . 20.9 t -83.31 117.45 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 8.9 t -94.21 19.99 8.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.453 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.833 HG21 HG23 ' A' ' 69' ' ' ILE . 0.7 OUTLIER -143.06 179.58 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.292 -0.88 . . . . 0.0 109.441 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.514 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -130.0 167.39 18.33 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.537 -179.978 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.22 151.63 35.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.48 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.29 9.0 80.77 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.514 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 4.4 m-20 -85.04 150.77 24.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.215 -1.167 . . . . 0.0 109.487 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -112.44 104.99 13.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.491 ' HA ' HD13 ' A' ' 63' ' ' LEU . 3.2 mm? -110.35 173.56 6.27 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.333 -0.855 . . . . 0.0 109.487 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 18.2 ttpt -108.57 142.04 39.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.925 . . . . 0.0 109.499 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 12.7 pt-20 -42.79 138.58 1.91 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.336 -0.852 . . . . 0.0 109.628 -179.884 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.27 -12.86 61.86 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.458 ' CG ' HD12 ' A' ' 63' ' ' LEU . 4.3 m-20 -79.87 153.56 28.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -1.16 . . . . 0.0 109.423 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -83.09 161.91 21.51 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.222 -0.924 . . . . 0.0 109.508 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.95 HG22 HG23 ' A' ' 70' ' ' ILE . 2.8 mp -132.68 -54.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.23 -0.918 . . . . 0.0 109.481 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.95 HG23 HG22 ' A' ' 69' ' ' ILE . 36.4 pt -144.06 -172.37 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.915 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -138.02 115.39 11.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.23 -0.919 . . . . 0.0 109.474 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.996 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 137.62 32.19 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.294 -0.878 . . . . 0.0 109.365 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.942 ' N ' HD13 ' A' ' 72' ' ' LEU . 10.7 tt0 -111.41 95.12 25.04 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.352 -0.842 . . . . 0.0 109.342 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.7 Cg_endo . . . . . 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.206 . . . . 0.0 110.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 52.4 p . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -138.06 141.28 40.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.321 -0.862 . . . . 0.0 109.478 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.575 HD12 ' CG ' ' A' ' 71' ' ' GLU . 3.8 tt -89.45 151.46 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.516 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.8 mm -115.79 107.8 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.527 ' NH1' ' HA2' ' A' ' 66' ' ' GLY . 0.0 OUTLIER -92.28 168.13 11.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.504 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.75 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.2 t -44.28 142.27 2.32 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.75 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.23 -170.64 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.447 2.098 . . . . 0.0 110.371 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.85 101.91 12.67 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.542 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.35 -61.66 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 109.253 -179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.75 12.5 6.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.02 -139.49 2.65 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 31.8 t0 -111.14 136.86 49.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -1.152 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -105.48 139.72 14.81 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.443 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.2 mt-10 -122.54 135.08 54.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.176 -1.19 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.401 HG23 ' CD1' ' A' ' 63' ' ' LEU . 13.3 t -81.52 130.64 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.91 . . . . 0.0 109.399 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -97.05 -42.8 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.176 -0.953 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.39 151.5 15.38 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.881 . . . . 0.0 109.493 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 2.5 tp -110.87 110.26 20.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.421 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -101.98 49.76 0.85 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.882 . . . . 0.0 109.407 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.506 HG11 ' HG ' ' A' ' 32' ' ' LEU . 0.8 OUTLIER -146.89 157.47 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.4 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -122.66 173.64 7.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.21 -0.931 . . . . 0.0 109.524 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.402 ' HA ' HG11 ' A' ' 52' ' ' VAL . 15.0 t -85.05 147.27 26.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 71.14 7.8 63.75 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 6.0 m-20 -85.04 130.62 34.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.43 111.48 20.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.453 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 27' ' ' GLU . 3.1 mt -94.31 -171.42 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.3 -0.875 . . . . 0.0 109.185 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.73 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.2 mt-10 -149.05 134.92 18.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.421 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.565 HG13 ' O ' ' A' ' 28' ' ' VAL . 3.0 p -50.28 91.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.491 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.78 -60.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.348 -0.845 . . . . 0.0 109.534 179.863 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.429 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.1 tt0 -57.19 162.79 2.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.567 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.456 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -80.08 -179.11 52.31 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -143.43 -40.45 0.3 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -1.164 . . . . 0.0 109.567 179.962 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.8 m -158.63 173.65 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.171 -0.956 . . . . 0.0 109.523 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 16' ' ' ILE . 88.1 t -132.27 104.7 8.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.268 -0.895 . . . . 0.0 109.494 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.93 164.75 14.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.431 ' CG ' ' N ' ' A' ' 37' ' ' SER . 14.5 tt0 -117.22 158.79 23.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.431 ' N ' ' CG ' ' A' ' 36' ' ' GLU . 2.3 t -130.12 179.76 5.7 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.308 -0.87 . . . . 0.0 109.449 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.19 -59.06 2.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 109.415 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.86 54.55 1.58 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.522 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.65 146.16 0.97 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 78.6 p -105.36 137.22 43.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.1 mmt -120.67 178.81 4.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.209 -0.932 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -138.42 161.4 37.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.892 . . . . 0.0 109.529 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 1.8 t -141.66 96.99 6.7 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.376 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.7 Cg_endo -77.56 -168.4 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.476 2.117 . . . . 0.0 110.452 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 28' ' ' VAL . 1.6 t -85.26 113.71 52.03 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.14 1.9 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.37 2.047 . . . . 0.0 110.256 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.8 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.5 OUTLIER -160.17 138.12 9.93 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.88 . . . . 0.0 109.334 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.9 102.19 11.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.184 -0.948 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.921 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -159.11 -167.82 20.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.467 HG22 ' HA2' ' A' ' 23' ' ' GLY . 14.4 p -110.59 138.28 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -1.137 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.402 HG11 ' HA ' ' A' ' 22' ' ' THR . 61.6 t -56.29 122.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 109.527 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.59 -49.37 5.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.457 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 t -149.95 163.66 37.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.578 HG12 ' H ' ' A' ' 57' ' ' VAL . 43.5 t -121.35 131.84 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.25 -0.906 . . . . 0.0 109.428 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.06 21.43 13.74 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.614 HG11 ' HA ' ' A' ' 69' ' ' ILE . 27.5 m -148.23 162.56 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 ttpt -123.73 155.13 38.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.453 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.458 ' HB3' ' HB2' ' A' ' 18' ' ' LEU . 1.7 pp -72.09 139.27 48.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.524 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.59 -13.85 57.2 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -82.79 148.78 27.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -1.162 . . . . 0.0 109.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.448 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 pttp -104.59 141.12 36.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.175 -0.953 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.781 ' N ' HD12 ' A' ' 63' ' ' LEU . 1.5 mp -130.26 164.26 24.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -0.888 . . . . 0.0 109.531 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -115.32 154.11 29.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.987 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.3 OUTLIER -42.72 130.72 4.11 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.285 -0.884 . . . . 0.0 109.663 -179.939 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.527 ' HA2' ' NH1' ' A' ' 5' ' ' ARG . . . 107.83 -12.58 38.32 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -84.23 131.0 34.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -1.16 . . . . 0.0 109.471 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.26 147.13 48.49 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.289 -0.882 . . . . 0.0 109.448 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.723 HG22 HG23 ' A' ' 70' ' ' ILE . 19.8 mm -103.34 -71.46 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.229 -0.919 . . . . 0.0 109.457 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.723 HG23 HG22 ' A' ' 69' ' ' ILE . 0.9 OUTLIER -142.15 171.14 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -0.912 . . . . 0.0 109.5 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.575 ' CG ' HD12 ' A' ' 3' ' ' ILE . 2.6 mp0 -122.7 117.44 25.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.339 -0.851 . . . . 0.0 109.475 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.921 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -89.99 142.18 27.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.247 -0.908 . . . . 0.0 109.424 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.506 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -115.61 91.86 31.23 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.488 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.61 ' O ' ' HB3' ' A' ' 75' ' ' ALA . 35.4 Cg_endo -78.07 2.91 7.5 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.597 2.198 . . . . 0.0 110.401 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 74' ' ' PRO . . . 70.26 -169.07 0.16 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.474 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -74.17 -49.26 24.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.359 -0.838 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -146.36 170.57 27.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -141.67 145.94 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -1.162 . . . . 0.0 109.455 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.47 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 80.6 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.33 164.24 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 57.0 mt -97.43 140.9 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -0.918 . . . . 0.0 109.456 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.73 114.21 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.505 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.744 ' HA ' HD12 ' A' ' 69' ' ' ILE . 1.5 ptt180 -110.29 164.68 12.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.253 -0.904 . . . . 0.0 109.434 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.746 HG13 ' HD2' ' A' ' 7' ' ' PRO . 74.9 t -65.99 142.28 97.94 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.175 -0.953 . . . . 0.0 109.393 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.746 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.5 Cg_endo -78.16 -171.72 1.29 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.515 2.143 . . . . 0.0 110.39 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -68.04 112.86 5.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.427 ' O ' HG13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -110.18 -29.25 2.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.224 -0.923 . . . . 0.0 108.741 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.62 -47.34 2.32 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.74 -144.96 7.18 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -99.63 146.98 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.2 -1.176 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.02 148.35 18.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 44.2 tt0 -127.78 146.6 50.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -1.108 . . . . 0.0 109.424 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.734 HG22 HD23 ' A' ' 35' ' ' LEU . 3.6 t -84.33 156.96 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.182 -0.949 . . . . 0.0 109.489 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.675 HD11 ' HB2' ' A' ' 36' ' ' GLU . 3.6 mp -123.79 -36.61 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.279 -0.888 . . . . 0.0 109.496 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -151.44 151.39 31.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.22 -0.925 . . . . 0.0 109.449 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 1.011 HD12 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -108.52 118.46 36.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.455 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 mt -90.26 30.55 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.498 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 1.011 HG22 HD12 ' A' ' 18' ' ' LEU . 31.8 m -149.69 156.66 7.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.429 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.3 OUTLIER -130.26 176.3 8.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 22' ' ' THR . 14.7 t -75.15 124.57 27.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.223 -0.923 . . . . 0.0 109.504 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.84 1.05 89.08 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.429 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -84.61 142.17 30.14 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.145 -1.209 . . . . 0.0 109.474 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 5.0 tt -108.66 121.38 44.9 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.207 -0.933 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.718 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.5 mt -90.29 -171.41 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.268 -0.895 . . . . 0.0 109.177 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -145.28 172.69 12.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.749 HG13 ' O ' ' A' ' 28' ' ' VAL . 9.7 p -74.06 82.27 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 162.94 -58.55 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.298 -0.876 . . . . 0.0 109.48 179.918 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.41 ' C ' ' O ' ' A' ' 29' ' ' GLU . 0.7 OUTLIER -44.29 157.88 0.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.509 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.23 -153.56 0.99 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.755 HD23 ' CA ' ' A' ' 46' ' ' SER . 0.1 OUTLIER -159.87 -73.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -1.148 . . . . 0.0 109.517 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.436 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 25.8 m -135.37 135.09 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HG3' ' A' ' 43' ' ' GLU . 20.5 t -107.09 92.82 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.343 -0.848 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.734 HD23 HG22 ' A' ' 15' ' ' VAL . 0.4 OUTLIER -89.97 -173.69 3.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.945 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.675 ' HB2' HD11 ' A' ' 16' ' ' ILE . 8.7 tt0 -130.41 167.58 18.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.4 m -126.61 172.25 10.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.57 -58.8 3.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 11.6 pttm -132.27 53.38 2.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.432 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.1 -166.58 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.249 -0.907 . . . . 0.0 109.46 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.8 155.68 38.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 4.5 mmt -138.71 145.55 40.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HG3' HG22 ' A' ' 34' ' ' VAL . 14.3 tm-20 -159.99 150.13 18.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.268 -0.895 . . . . 0.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.548 HG13 ' HD2' ' A' ' 45' ' ' PRO . 49.4 t -135.77 140.1 32.64 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.448 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.548 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.28 -168.65 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.442 2.095 . . . . 0.0 110.368 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.755 ' CA ' HD23 ' A' ' 32' ' ' LEU . 0.3 OUTLIER -85.52 113.38 50.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.481 ' O ' ' HG2' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -78.31 -3.17 13.16 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.256 1.971 . . . . 0.0 110.381 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.641 ' CB ' HD22 ' A' ' 72' ' ' LEU . 3.6 mtmm -160.37 130.92 5.44 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.344 -0.847 . . . . 0.0 109.406 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.51 90.67 7.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.439 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.486 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -146.25 -166.24 11.98 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.5 p -109.97 160.26 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.28 -1.13 . . . . 0.0 109.482 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.428 ' N ' HG22 ' A' ' 51' ' ' VAL . 55.0 t -76.04 123.6 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.967 . . . . 0.0 109.443 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -94.23 -49.41 5.74 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.495 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 t -158.35 118.21 3.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.465 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.92 HG13 HG22 ' A' ' 70' ' ' ILE . 5.8 t -87.66 133.17 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 56' ' ' SER . 8.2 t -113.31 29.18 8.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.496 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.445 HG11 ' HA ' ' A' ' 69' ' ' ILE . 35.6 m -149.47 175.6 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -136.5 157.57 46.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.467 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.447 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -68.22 138.87 55.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.448 -179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.45 -10.67 68.47 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.441 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 41.6 m-20 -80.9 144.95 31.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -1.144 . . . . 0.0 109.482 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 14.2 ptmt -110.52 148.09 32.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 63' ' ' LEU . 4.3 mp -138.95 166.68 23.85 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.244 -0.91 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 5.0 mtpt -99.58 148.4 24.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 23.8 pt-20 -42.81 142.76 0.82 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.666 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.83 -9.48 76.68 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.98 137.21 35.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -1.156 . . . . 0.0 109.516 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -67.81 176.83 2.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.844 HG22 HG23 ' A' ' 70' ' ' ILE . 2.1 mp -140.9 -67.24 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.92 HG22 HG13 ' A' ' 55' ' ' VAL . 30.1 pt -139.45 173.24 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 109.472 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -127.83 108.47 10.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.641 HD22 ' CB ' ' A' ' 48' ' ' LYS . 0.6 OUTLIER -90.09 142.24 27.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.436 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.407 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 60.6 tt0 -116.54 88.32 23.84 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HG3' ' HD2' ' A' ' 48' ' ' LYS . 35.7 Cg_endo -78.11 71.4 6.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.652 2.235 . . . . 0.0 110.409 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.407 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . 49.6 -172.05 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.242 -0.911 . . . . 0.0 109.421 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 60.63 36.69 19.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -98.05 130.65 10.31 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -51.35 104.62 0.08 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -1.118 . . . . 0.0 109.474 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.481 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 53.6 p . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -82.44 171.64 13.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 41.0 mm -107.0 143.91 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.859 HG21 ' HG3' ' A' ' 47' ' ' PRO . 38.8 mm -107.16 118.59 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.53 ' CG ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -103.73 -171.13 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.185 -0.947 . . . . 0.0 109.541 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.752 HG13 ' HD2' ' A' ' 7' ' ' PRO . 65.7 t -79.47 142.72 58.39 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.319 -0.863 . . . . 0.0 109.311 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.752 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.06 -168.79 0.65 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.599 2.199 . . . . 0.0 110.509 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -82.74 111.18 18.43 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.395 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.91 -10.93 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.935 . . . . 0.0 109.345 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.98 39.63 58.53 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.07 -153.72 24.88 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -89.34 174.15 7.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.289 -1.124 . . . . 0.0 109.497 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -147.51 104.8 0.3 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.463 ' N ' ' CD ' ' A' ' 14' ' ' GLU . 6.2 mp0 -92.82 112.92 25.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -1.153 . . . . 0.0 109.442 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 40.3 t -54.33 134.75 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.5 mm -108.56 -50.88 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.228 -0.92 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -144.19 153.03 41.68 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.454 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.85 HD23 HG23 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -120.82 116.08 24.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.924 . . . . 0.0 109.5 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.767 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.3 pp -106.1 52.15 0.73 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.354 -0.841 . . . . 0.0 109.525 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.85 HG23 HD23 ' A' ' 18' ' ' LEU . 0.8 OUTLIER -140.2 169.54 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . 3.5 tptt -144.32 169.28 18.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.211 -0.931 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.435 HG23 ' O ' ' A' ' 22' ' ' THR . 15.2 t -84.11 132.56 34.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 84.26 -1.43 88.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.44 ' CG ' ' HB3' ' A' ' 21' ' ' LYS . 5.7 m-20 -84.05 134.29 34.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.115 -1.227 . . . . 0.0 109.527 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -94.36 116.37 28.73 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.881 . . . . 0.0 109.41 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.1 mt -90.52 -171.35 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.228 -0.92 . . . . 0.0 109.157 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.6 mt-10 -146.37 159.47 43.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 28' ' ' VAL . 7.5 p -72.95 83.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.88 . . . . 0.0 109.47 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 162.83 -32.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.3 -0.875 . . . . 0.0 109.518 179.914 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.413 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 39.4 tt0 -76.28 148.64 37.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.462 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.44 -175.66 1.28 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.888 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.9 OUTLIER -148.22 -68.59 0.23 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -1.105 . . . . 0.0 109.463 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -131.71 171.42 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.584 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 43' ' ' GLU . 75.4 t -134.14 92.72 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.419 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.4 mp -90.0 149.82 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -0.873 . . . . 0.0 109.423 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -115.17 139.1 50.21 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.24 -179.21 5.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 109.515 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -69.76 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -92.17 -49.69 6.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.892 . . . . 0.0 109.47 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.528 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.89 173.63 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.28 -0.887 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.65 128.94 34.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.294 -0.879 . . . . 0.0 109.501 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.7 mtt -127.2 105.73 8.76 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -80.01 156.76 27.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.547 HG13 ' HD2' ' A' ' 45' ' ' PRO . 44.9 t -133.96 140.45 36.39 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.389 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.547 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.0 Cg_endo -78.44 -168.44 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.599 2.199 . . . . 0.0 110.434 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.888 ' HA ' HD13 ' A' ' 32' ' ' LEU . 7.7 t -85.23 129.93 53.84 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.404 -0.81 . . . . 0.0 109.332 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.859 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.0 Cg_endo -78.59 -1.88 11.98 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.366 2.044 . . . . 0.0 110.513 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.729 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.18 128.57 4.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.533 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.09 86.33 5.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.794 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -146.62 -166.12 12.03 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.456 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.0 p -104.88 139.47 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -1.167 . . . . 0.0 109.466 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 70.5 t -56.98 127.85 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' SER . 18.4 tptm -100.7 -15.91 17.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.202 -0.936 . . . . 0.0 109.485 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.412 ' CB ' ' O ' ' A' ' 53' ' ' LYS . 0.5 OUTLIER 171.12 145.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.464 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.559 HG12 ' H ' ' A' ' 57' ' ' VAL . 76.1 t -101.11 142.19 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.458 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 61.6 m -121.84 13.58 10.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.89 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 69' ' ' ILE . 10.8 m -147.76 166.99 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 109.504 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -125.52 171.23 10.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.464 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -79.03 118.78 21.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.51 -11.47 42.82 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -70.86 150.93 45.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.968 ' C ' HD22 ' A' ' 63' ' ' LEU . 10.2 tttm -100.19 120.26 39.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.463 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.968 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.0 mm? -131.14 143.93 51.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -105.04 153.21 21.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.479 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 4.3 pt-20 -42.9 143.63 0.7 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.66 -18.1 58.09 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' ' O ' ' A' ' 68' ' ' ALA . 7.7 m-20 -85.12 129.99 34.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -1.156 . . . . 0.0 109.526 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.53 ' HA ' ' CG ' ' A' ' 5' ' ' ARG . . . -48.5 175.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.599 ' O ' HG23 ' A' ' 70' ' ' ILE . 21.9 mm -146.93 -47.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.463 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 69' ' ' ILE . 0.6 OUTLIER -158.68 -177.11 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.483 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -127.75 161.82 28.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.208 -0.933 . . . . 0.0 109.494 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.794 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.7 OUTLIER -143.15 135.8 27.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.392 -179.948 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 71.3 tt0 -114.68 90.24 21.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.2 Cg_endo -78.07 111.31 3.06 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.557 2.171 . . . . 0.0 110.403 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.418 ' O ' ' C ' ' A' ' 76' ' ' ALA . . . -123.9 -79.6 0.61 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.19 -0.943 . . . . 0.0 109.508 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 75' ' ' ALA . . . 44.71 81.65 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.434 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.19 -138.86 14.93 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.46 ' O ' ' HB3' ' A' ' 79' ' ' ARG . . . -168.96 166.91 11.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.325 -1.103 . . . . 0.0 109.49 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.46 ' HB3' ' O ' ' A' ' 78' ' ' ALA . 14.8 ttp180 . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.413 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.451 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 18.3 p . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -121.37 152.57 38.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.507 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.7 tt -86.52 152.96 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.821 HG21 ' HG3' ' A' ' 47' ' ' PRO . 5.2 mp -131.92 118.54 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.254 -0.904 . . . . 0.0 109.464 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.79 175.03 7.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.452 179.954 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.654 HG13 ' HD2' ' A' ' 7' ' ' PRO . 53.5 t -55.2 139.88 64.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.323 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.654 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.1 Cg_endo -78.59 -172.94 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.533 2.155 . . . . 0.0 110.359 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -85.11 110.66 19.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 1.009 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.8 -56.47 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.421 -179.917 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.96 -27.32 1.89 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . -179.8 118.42 0.59 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 1.009 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.2 OUTLIER 49.76 -179.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.267 -1.137 . . . . 0.0 109.478 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.762 ' C ' HD23 ' A' ' 35' ' ' LEU . . . -172.24 90.97 0.09 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 19.3 mt-10 -94.98 124.05 38.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.339 -1.095 . . . . 0.0 109.487 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.7 t -73.12 132.33 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.464 HG22 ' O ' ' A' ' 34' ' ' VAL . 4.4 tt -92.34 -28.76 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -174.43 151.2 1.53 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.41 HD23 ' CG2' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -104.18 103.45 13.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.45 15.07 7.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.284 -0.885 . . . . 0.0 109.375 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.838 HG11 ' HG ' ' A' ' 32' ' ' LEU . 11.9 m -113.28 178.02 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.67 158.43 43.78 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.9 t -73.64 141.89 46.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.288 -0.883 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 82.85 -6.61 69.55 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.14 135.62 36.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -1.141 . . . . 0.0 109.446 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.89 HD12 ' C ' ' A' ' 50' ' ' GLY . 22.4 tp -93.24 110.68 22.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.229 -0.92 . . . . 0.0 109.469 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.816 HG23 ' OE1' ' A' ' 30' ' ' GLN . 2.7 mt -91.27 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.248 -0.908 . . . . 0.0 109.201 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 tm-20 -139.36 -178.63 5.46 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.208 -0.933 . . . . 0.0 109.443 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.2 p -84.79 69.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.554 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.491 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 169.21 -40.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.366 -0.834 . . . . 0.0 109.435 179.884 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.816 ' OE1' HG23 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -56.73 138.49 52.82 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 109.364 179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.44 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -69.5 166.05 49.15 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.838 ' HG ' HG11 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -127.42 -42.01 1.69 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.366 -1.079 . . . . 0.0 109.446 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 25.6 m -158.63 174.33 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.154 -0.966 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.464 ' O ' HG22 ' A' ' 16' ' ' ILE . 70.7 t -128.77 102.53 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.227 -0.921 . . . . 0.0 109.449 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.762 HD23 ' C ' ' A' ' 13' ' ' GLY . 3.5 mp -89.98 141.67 28.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.216 -0.928 . . . . 0.0 109.4 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.407 ' OE2' ' OG ' ' A' ' 41' ' ' SER . 6.0 tt0 -115.79 134.31 55.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.23 -0.919 . . . . 0.0 109.513 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.9 m -132.03 -177.77 4.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.894 . . . . 0.0 109.446 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.04 -16.54 60.2 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.8 mttt -84.16 -55.27 4.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.94 . . . . 0.0 109.439 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.467 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.15 -179.54 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.889 . . . . 0.0 109.454 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.407 ' OG ' ' OE2' ' A' ' 36' ' ' GLU . 2.4 m -95.84 103.72 15.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.5 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -93.78 -173.34 3.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.186 -0.946 . . . . 0.0 109.5 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -124.89 162.16 25.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.201 -0.937 . . . . 0.0 109.477 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 35' ' ' LEU . 18.7 t -144.17 97.11 5.28 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.515 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.6 Cg_endo -77.43 -168.69 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.566 2.177 . . . . 0.0 110.476 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.3 135.24 39.21 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.411 -0.806 . . . . 0.0 109.307 179.89 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.821 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.56 -4.63 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.466 2.111 . . . . 0.0 110.433 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 46' ' ' SER . 26.0 tttt -160.31 142.13 12.69 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.403 -0.81 . . . . 0.0 109.468 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.92 94.22 5.19 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.179 -0.951 . . . . 0.0 109.394 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.897 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.94 -174.7 22.15 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 23' ' ' GLY . 10.8 p -103.66 137.98 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -1.149 . . . . 0.0 109.522 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.8 t -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.05 -27.7 13.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.206 -0.934 . . . . 0.0 109.524 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -167.04 171.57 10.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.16 -0.963 . . . . 0.0 109.544 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.787 ' HA ' HG22 ' A' ' 70' ' ' ILE . 55.6 t -131.86 113.25 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 56' ' ' SER . 5.6 t -99.32 22.64 10.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.47 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.414 ' H ' HG12 ' A' ' 55' ' ' VAL . 31.3 m -144.03 169.55 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.198 -0.939 . . . . 0.0 109.451 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.68 171.93 12.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.728 ' O ' HD12 ' A' ' 59' ' ' LEU . 4.0 pp -80.04 139.15 37.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.315 -0.866 . . . . 0.0 109.536 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.79 -11.14 62.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -70.53 137.46 50.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -1.16 . . . . 0.0 109.39 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.544 ' O ' HD22 ' A' ' 63' ' ' LEU . 18.7 mttm -98.5 117.18 32.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.27 -0.894 . . . . 0.0 109.46 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.722 HD12 ' CB ' ' A' ' 67' ' ' ASP . 3.5 mm? -117.92 159.74 22.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.429 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.3 tttt -112.09 142.82 44.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 64' ' ' LYS . 9.7 mt-10 -42.84 129.78 4.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.306 -0.871 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 113.96 -19.95 17.63 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.722 ' CB ' HD12 ' A' ' 63' ' ' LEU . 26.8 m-20 -85.12 136.06 33.71 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.231 -1.158 . . . . 0.0 109.41 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -58.92 167.85 1.47 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.226 -0.921 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.51 HD11 ' CG2' ' A' ' 6' ' ' VAL . 39.1 mm -134.13 -67.28 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.787 HG22 ' HA ' ' A' ' 55' ' ' VAL . 0.7 OUTLIER -144.9 -173.56 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.459 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -133.48 120.93 21.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.303 -0.873 . . . . 0.0 109.477 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.976 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.4 tt -94.05 135.47 35.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.433 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.451 ' OE2' ' HB3' ' A' ' 1' ' ' SER . 5.9 tt0 -114.45 89.17 17.26 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.157 -0.964 . . . . 0.0 109.499 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.976 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo -78.28 173.24 14.13 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.564 2.176 . . . . 0.0 110.365 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -137.89 -54.0 0.65 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.501 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -174.87 133.3 0.34 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.426 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.28 81.98 0.2 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -87.51 134.31 33.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -1.178 . . . . 0.0 109.447 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.446 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.469 ' HB3' ' HB2' ' A' ' 73' ' ' GLU . 95.0 p . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -87.04 137.03 32.69 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -0.883 . . . . 0.0 109.472 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.765 HD13 ' N ' ' A' ' 4' ' ' ILE . 0.0 OUTLIER -101.87 121.49 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.4 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.765 ' N ' HD13 ' A' ' 3' ' ' ILE . 49.8 mm -95.82 115.08 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.424 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.444 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -112.4 160.24 17.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.203 -0.935 . . . . 0.0 109.686 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.8 HG13 HD11 ' A' ' 9' ' ' ILE . 85.6 t -44.83 104.47 0.39 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.338 -0.851 . . . . 0.0 109.545 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.1 Cg_endo -77.58 -170.43 0.94 Allowed 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.433 2.089 . . . . 0.0 110.438 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -72.31 99.92 2.52 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.209 -0.932 . . . . 0.0 109.466 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.8 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.26 -10.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.372 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.41 -17.63 11.27 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.04 -119.28 0.81 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.37 170.0 9.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.07 120.14 1.07 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 6.2 mt-10 -100.58 122.46 43.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -1.158 . . . . 0.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.2 t -63.2 124.15 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.905 . . . . 0.0 109.509 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.3 mm -99.54 -18.06 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.34 -0.85 . . . . 0.0 109.454 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.98 149.06 1.83 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.53 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.924 ' HG ' HG22 ' A' ' 20' ' ' VAL . 6.6 tp -118.73 102.39 8.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.545 ' H ' HD23 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -90.71 48.62 1.56 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.527 179.973 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.924 HG22 ' HG ' ' A' ' 18' ' ' LEU . 18.7 m -145.86 168.47 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.409 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.35 171.27 14.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.98 132.02 35.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.554 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 79.57 -4.57 63.81 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.4 134.99 36.57 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.16 -1.2 . . . . 0.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -82.64 127.54 33.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.853 . . . . 0.0 109.429 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.792 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -91.53 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.278 -0.889 . . . . 0.0 109.269 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.715 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.2 tm-20 -142.57 136.68 29.49 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.204 -0.935 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.661 HG13 ' HG3' ' A' ' 29' ' ' GLU . 9.3 p -45.73 140.72 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.248 -0.907 . . . . 0.0 109.475 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.661 ' HG3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER 82.99 -43.69 0.11 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.64 -0.663 . . . . 0.0 109.9 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.523 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -47.35 133.82 12.12 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.035 -1.041 . . . . 0.0 109.482 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.34 162.32 49.74 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.902 ' CD2' HG11 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -125.98 -38.53 2.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -1.158 . . . . 0.0 109.465 179.972 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.705 HG12 HD12 ' A' ' 18' ' ' LEU . 33.0 m -158.73 158.59 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.522 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.2 t -124.44 98.22 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.314 -0.866 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 1.9 mp -90.23 140.24 29.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.305 -0.872 . . . . 0.0 109.526 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -126.89 127.58 45.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.416 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.627 ' HB3' ' HB3' ' A' ' 40' ' ' ALA . 0.3 OUTLIER -102.99 174.87 5.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.893 . . . . 0.0 109.477 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' N ' ' OG ' ' A' ' 37' ' ' SER . . . -44.88 -34.48 2.38 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.6 pttt -156.21 50.87 0.52 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.254 -0.903 . . . . 0.0 109.524 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.627 ' HB3' ' HB3' ' A' ' 37' ' ' SER . . . -158.56 91.72 1.09 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.32 129.62 40.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.421 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.9 mtm -149.25 174.46 12.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.259 -0.9 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 31.6 mp0 -127.97 164.58 22.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -143.9 96.92 5.43 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.57 -169.1 0.68 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.537 2.158 . . . . 0.0 110.478 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.792 ' HB2' HG21 ' A' ' 26' ' ' ILE . 19.0 t -85.55 126.24 67.11 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.436 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.547 ' CG ' ' CD1' ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.59 -2.2 12.26 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.44 2.093 . . . . 0.0 110.383 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.593 ' HB3' HD12 ' A' ' 72' ' ' LEU . 3.3 tptt -160.16 127.35 4.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.386 -0.821 . . . . 0.0 109.432 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.7 88.66 1.74 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.209 -0.932 . . . . 0.0 109.469 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -144.99 -153.71 5.94 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.674 ' O ' HD22 ' A' ' 72' ' ' LEU . 5.9 p -108.45 151.65 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -1.127 . . . . 0.0 109.408 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.2 t -75.97 123.8 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.187 -0.946 . . . . 0.0 109.522 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -81.38 -59.13 2.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.285 -0.884 . . . . 0.0 109.489 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 31.3 p -161.29 126.3 3.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.457 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.69 HG12 ' H ' ' A' ' 57' ' ' VAL . 57.9 t -81.38 126.21 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.287 -0.883 . . . . 0.0 109.486 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 t -103.66 26.0 9.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.216 -0.927 . . . . 0.0 109.48 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.69 ' H ' HG12 ' A' ' 55' ' ' VAL . 15.6 m -148.72 164.87 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.887 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.451 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 9.2 tttt -132.89 164.12 27.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.522 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.34 138.18 55.21 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.454 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.14 -18.22 54.64 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.451 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 1.7 m-20 -82.87 143.61 30.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 109.437 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.577 ' C ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -102.18 136.99 41.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.215 -0.928 . . . . 0.0 109.438 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.1 mm? -111.34 177.94 4.5 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.471 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.449 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.5 ttpp -139.39 152.21 46.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 7.3 mt-10 -44.28 139.9 2.44 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.172 -0.955 . . . . 0.0 109.513 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.34 -47.52 3.65 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -48.75 130.19 17.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.298 -1.119 . . . . 0.0 109.521 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -60.44 161.99 6.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.326 -0.859 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.787 HD11 HG23 ' A' ' 6' ' ' VAL . 19.9 mm -135.41 -55.55 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.304 -0.872 . . . . 0.0 109.466 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.672 HG23 HG22 ' A' ' 69' ' ' ILE . 11.4 pt -156.57 -174.52 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.311 -0.868 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 0.6 OUTLIER -144.17 139.04 28.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.856 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -119.61 118.81 31.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.196 -0.94 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.516 ' N ' HD13 ' A' ' 72' ' ' LEU . 5.7 tt0 -111.74 94.91 25.78 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.575 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo -78.05 2.74 7.66 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.616 2.211 . . . . 0.0 110.381 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -87.82 164.57 15.85 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.213 -0.93 . . . . 0.0 109.576 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -91.66 108.83 20.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.457 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -94.28 -139.47 9.85 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -158.03 24.04 0.26 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.2 -1.176 . . . . 0.0 109.486 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.451 -179.986 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 94.7 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -99.45 149.21 23.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.941 . . . . 0.0 109.426 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.2 tt -83.48 159.16 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.31 -0.868 . . . . 0.0 109.468 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.18 111.62 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.192 -0.942 . . . . 0.0 109.407 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.466 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.36 170.13 10.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.538 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -44.19 142.32 2.25 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.419 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.27 171.51 16.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.554 2.169 . . . . 0.0 110.37 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -84.92 99.13 10.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.56 -11.19 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.258 -0.901 . . . . 0.0 109.396 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.88 -10.8 68.24 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -158.98 -161.32 11.02 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 -83.74 143.32 30.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -1.179 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.77 150.16 18.7 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -129.44 119.17 23.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -1.154 . . . . 0.0 109.481 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.6 t -67.37 152.22 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.419 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.404 HD12 HG23 ' A' ' 16' ' ' ILE . 49.3 mm -120.06 -34.24 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -175.47 137.91 0.39 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 109.452 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.97 140.6 37.03 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 121.154 -0.966 . . . . 0.0 109.371 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.46 35.23 3.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 m -144.13 -179.7 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.432 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.27 -179.68 6.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 0.0 109.441 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.472 HG23 ' O ' ' A' ' 22' ' ' THR . 14.2 t -79.9 129.58 34.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.41 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.55 -0.13 61.22 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -81.35 133.29 35.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 109.489 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -89.78 107.82 19.32 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.461 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.724 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.88 -171.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.184 -0.948 . . . . 0.0 109.26 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -147.31 176.76 9.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.51 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.748 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.2 p -81.18 74.34 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.515 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.506 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.92 -27.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.313 -0.867 . . . . 0.0 109.402 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -72.99 136.01 45.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.456 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.24 176.18 2.85 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.973 HD23 HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -137.15 -62.93 0.61 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -1.147 . . . . 0.0 109.452 180.0 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.973 HG13 HD23 ' A' ' 32' ' ' LEU . 16.5 m -137.66 172.03 15.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -125.69 105.95 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.246 -0.909 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.1 mp -97.95 153.61 18.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.84 149.98 39.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.6 m -126.65 177.96 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.99 -41.41 59.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.483 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -157.95 37.04 0.26 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -152.69 88.33 1.34 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.401 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.465 ' O ' ' HG2' ' A' ' 42' ' ' MET . 34.6 t -83.45 127.58 33.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.242 -0.911 . . . . 0.0 109.451 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 41' ' ' SER . 11.9 mtt -147.45 136.46 22.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.468 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -93.0 169.93 10.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.162 -0.961 . . . . 0.0 109.437 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 40.7 t -135.88 127.83 17.46 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.36 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.456 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.4 -168.15 0.58 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.43 2.086 . . . . 0.0 110.389 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.529 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.1 OUTLIER -85.14 135.92 38.78 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.869 . . . . 0.0 109.19 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.43 -2.39 12.45 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.434 2.089 . . . . 0.0 110.533 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.775 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.03 140.53 11.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.376 -0.828 . . . . 0.0 109.4 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.68 95.95 9.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.773 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.71 -153.0 6.79 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 73' ' ' GLU . 12.2 p -110.81 141.63 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -1.124 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 71.0 t -63.87 142.6 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.42 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -106.77 -55.35 2.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.31 118.87 7.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 70' ' ' ILE . 13.1 t -84.87 106.73 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 p -90.16 9.2 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.459 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.809 HG11 HG23 ' A' ' 69' ' ' ILE . 20.6 m -124.87 158.27 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.451 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.403 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 2.8 tptp -137.43 -173.38 3.46 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.22 -0.925 . . . . 0.0 109.524 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.453 ' N ' HD21 ' A' ' 18' ' ' LEU . 2.2 pp -85.05 134.36 34.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 77.23 9.08 87.0 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.403 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 37.0 m-20 -84.87 145.46 27.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.244 -1.15 . . . . 0.0 109.438 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -107.41 132.48 53.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.521 -179.981 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.427 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -139.59 130.14 25.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.41 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 31.4 tttm -93.82 145.74 24.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.202 -0.936 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.463 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -42.86 124.29 3.05 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.353 -0.842 . . . . 0.0 109.638 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 123.46 -26.37 6.04 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 68' ' ' ALA . 1.2 m-20 -85.11 131.23 34.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -1.147 . . . . 0.0 109.442 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -49.66 178.55 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.284 -0.885 . . . . 0.0 109.509 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.809 HG23 HG11 ' A' ' 57' ' ' VAL . 23.1 mm -145.08 -65.21 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.237 -0.914 . . . . 0.0 109.414 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.591 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.2 pt -151.51 177.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.478 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -143.48 140.42 30.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.942 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.3 tt -107.75 142.8 37.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.411 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.431 ' O ' HG12 ' A' ' 51' ' ' VAL . 1.3 tp10 -131.34 89.84 39.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.432 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.942 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.05 91.08 1.21 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.59 2.193 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -152.87 -54.16 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.248 -0.907 . . . . 0.0 109.419 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -160.42 146.39 15.21 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.472 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.59 -100.86 0.01 OUTLIER Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.84 178.31 8.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.472 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.487 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 60.4 p . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 16.5 mt-10 -135.78 137.24 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.496 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.618 HD11 ' HB1' ' A' ' 68' ' ' ALA . 1.2 tt -82.14 151.94 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.5 mm -117.37 97.03 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.76 163.3 14.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.843 HG23 HD11 ' A' ' 69' ' ' ILE . 71.4 t -57.88 142.05 79.61 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.737 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -77.98 -174.46 2.24 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.587 2.191 . . . . 0.0 110.386 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -58.78 103.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.602 HG23 ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -110.17 -37.75 3.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.238 -0.913 . . . . 0.0 108.767 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.85 52.98 21.65 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.89 -136.57 4.37 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -116.65 138.4 51.47 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.22 -1.165 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -110.74 118.93 5.1 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.01 130.91 47.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.278 -1.131 . . . . 0.0 109.476 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.3 t -80.67 147.31 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.469 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.838 HD12 HG12 ' A' ' 34' ' ' VAL . 60.4 mt -113.49 -57.02 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -0.942 . . . . 0.0 109.474 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -160.8 162.64 32.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.305 -0.872 . . . . 0.0 109.463 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.1 tp -101.2 141.53 33.94 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.721 HD12 ' N ' ' A' ' 32' ' ' LEU . 12.7 mt -99.0 18.67 16.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.488 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -150.04 172.22 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.422 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -120.01 -178.29 3.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.459 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.22 113.92 19.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.501 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.31 0.5 65.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.84 145.89 27.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -1.138 . . . . 0.0 109.434 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.469 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.1 tp -89.81 132.27 35.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.184 -0.947 . . . . 0.0 109.449 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.822 HD13 ' CD1' ' A' ' 32' ' ' LEU . 2.7 mt -91.79 -171.41 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.184 -0.947 . . . . 0.0 109.135 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -149.96 126.01 10.59 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.246 -0.908 . . . . 0.0 109.488 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.567 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 8.4 p -44.98 149.61 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.567 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 16.3 tt0 83.05 -43.67 0.11 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.666 -0.646 . . . . 0.0 109.8 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.546 ' HB2' ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -62.29 153.81 29.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.101 -0.999 . . . . 0.0 109.48 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.476 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -62.46 -176.94 3.03 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.822 ' CD1' HD13 ' A' ' 26' ' ' ILE . 10.0 tp -153.98 -56.88 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -1.176 . . . . 0.0 109.558 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.19 152.7 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.175 -0.953 . . . . 0.0 109.65 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.838 HG12 HD12 ' A' ' 16' ' ' ILE . 22.6 t -120.97 83.96 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.282 -0.886 . . . . 0.0 109.367 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.01 170.86 9.99 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -0.905 . . . . 0.0 109.478 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.516 ' CG ' ' O ' ' A' ' 40' ' ' ALA . 21.8 tt0 -114.08 154.22 28.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -104.7 -177.05 3.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -45.31 -37.69 5.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.314 -0.866 . . . . 0.0 109.446 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -158.74 63.52 0.42 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.516 ' O ' ' CG ' ' A' ' 36' ' ' GLU . . . 178.13 -167.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.425 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.8 m -135.85 116.36 13.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.243 -0.91 . . . . 0.0 109.455 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.465 ' O ' ' HG2' ' A' ' 42' ' ' MET . 0.0 OUTLIER -116.78 132.68 56.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.164 -0.96 . . . . 0.0 109.43 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.569 ' HG2' HG22 ' A' ' 34' ' ' VAL . 2.0 mt-10 -112.57 161.59 16.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 3.4 t -139.31 140.3 25.52 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.279 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.31 -169.12 0.71 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.379 2.053 . . . . 0.0 110.38 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.754 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.53 134.71 39.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.32 -0.862 . . . . 0.0 109.302 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.582 ' HD3' HD22 ' A' ' 32' ' ' LEU . 36.2 Cg_endo -78.68 -12.64 15.0 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.435 2.09 . . . . 0.0 110.233 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.453 ' CD ' ' HB3' ' A' ' 74' ' ' PRO . 1.3 ttmp? -160.64 132.11 5.75 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.7 84.54 2.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.4 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.742 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -135.21 -144.11 4.9 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' VAL . 11.3 p -118.74 157.24 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.404 ' N ' HG22 ' A' ' 51' ' ' VAL . 24.1 t -84.82 136.69 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.239 -0.913 . . . . 0.0 109.468 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.38 -60.89 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.433 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.8 m -175.36 157.62 2.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.16 -0.963 . . . . 0.0 109.501 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 57' ' ' VAL . 3.5 t -87.11 121.38 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 m -80.93 5.85 15.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.573 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.871 HG11 HD11 ' A' ' 63' ' ' LEU . 35.6 m -150.11 -172.26 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.436 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.4 OUTLIER -114.05 153.28 29.7 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.453 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -65.81 150.3 48.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.466 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 69.25 9.1 60.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.436 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 5.1 m-20 -84.99 154.79 21.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -101.92 123.18 45.4 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.898 . . . . 0.0 109.427 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 57' ' ' VAL . 83.0 mt -123.2 152.72 40.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 109.453 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.8 ttpt -94.0 147.28 23.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.286 -0.883 . . . . 0.0 109.509 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.602 ' HB3' HG23 ' A' ' 9' ' ' ILE . 10.7 pt-20 -43.05 139.59 1.72 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.35 -0.844 . . . . 0.0 109.605 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.55 -4.61 79.83 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.04 143.37 29.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -1.106 . . . . 0.0 109.452 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.618 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -74.98 157.74 34.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.312 -0.868 . . . . 0.0 109.461 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.843 HD11 HG23 ' A' ' 6' ' ' VAL . 3.2 mp -131.07 -51.77 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.94 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.0 pt -147.4 -179.69 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 2' ' ' GLU . 22.9 tt0 -150.06 129.24 12.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.224 -0.923 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.742 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -95.82 145.07 25.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.473 179.931 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.52 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -112.4 93.32 22.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.328 -0.858 . . . . 0.0 109.404 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.56 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -77.97 -170.33 0.94 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.631 2.221 . . . . 0.0 110.461 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.42 ' C ' ' O ' ' A' ' 74' ' ' PRO . . . -43.69 97.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.865 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 74' ' ' PRO . . . -81.63 -14.1 57.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -165.6 -76.85 0.03 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -161.76 94.93 0.97 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.221 -1.164 . . . . 0.0 109.528 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 26.9 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -92.87 169.41 10.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.89 . . . . 0.0 109.476 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.7 mt -106.48 146.58 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.875 . . . . 0.0 109.439 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.595 HD12 ' HG2' ' A' ' 47' ' ' PRO . 27.9 mm -104.93 114.68 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.566 ' HA ' HD12 ' A' ' 69' ' ' ILE . 6.0 ptp180 -107.07 177.71 4.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.238 -0.914 . . . . 0.0 109.459 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 72.6 t -73.77 142.06 79.77 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.219 -0.926 . . . . 0.0 109.459 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.0 Cg_endo -78.45 -170.15 0.92 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.497 2.131 . . . . 0.0 110.441 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -85.02 102.86 13.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.164 -0.96 . . . . 0.0 109.423 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.529 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.3 -49.03 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.352 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.63 30.28 2.44 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' OE1' ' A' ' 65' ' ' GLU . . . 168.3 -166.19 39.34 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -94.95 115.65 27.72 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.264 -1.139 . . . . 0.0 109.531 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.38 168.39 54.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 4.6 tt0 -142.99 117.27 9.58 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.2 -1.177 . . . . 0.0 109.496 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.556 HG11 ' HA ' ' A' ' 59' ' ' LEU . 62.4 t -62.52 119.78 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 34' ' ' VAL . 2.1 pt -113.99 -20.26 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.416 ' N ' HG13 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -155.41 136.76 14.02 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.299 -0.875 . . . . 0.0 109.499 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.425 HD13 HG11 ' A' ' 15' ' ' VAL . 0.2 OUTLIER -129.09 123.57 32.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.937 . . . . 0.0 109.4 -179.965 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.492 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -125.22 63.13 1.17 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 0.0 109.478 -179.923 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.608 HG11 ' HG ' ' A' ' 32' ' ' LEU . 16.7 m -144.96 169.24 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.22 160.07 42.04 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 53' ' ' LYS . 94.8 m -84.5 133.85 34.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.495 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.85 -10.77 73.81 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -81.1 136.42 35.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -1.137 . . . . 0.0 109.505 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.56 115.96 22.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 109.5 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -91.02 -171.54 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.187 -0.945 . . . . 0.0 109.234 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 mt-10 -145.67 174.87 10.81 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.736 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.0 p -84.98 76.22 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.42 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 167.21 -41.98 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.431 -0.793 . . . . 0.0 109.251 179.867 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.526 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 61.5 tt0 -59.65 146.44 41.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.19 168.17 54.4 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.608 ' HG ' HG11 ' A' ' 20' ' ' VAL . 5.0 tp -128.46 -43.79 1.41 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -1.154 . . . . 0.0 109.567 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.526 HG13 ' C ' ' A' ' 32' ' ' LEU . 15.7 m -158.56 159.08 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 16' ' ' ILE . 62.9 t -124.37 103.47 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.184 -0.947 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.08 163.08 15.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -118.05 145.29 44.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -121.69 -177.39 3.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.915 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.36 -56.01 9.25 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.582 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -143.98 59.77 1.36 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 109.523 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.582 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 170.42 112.01 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 33.8 t -100.73 115.15 29.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.483 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 26.2 ttp -102.98 154.73 18.94 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.178 -0.952 . . . . 0.0 109.403 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -100.6 169.61 8.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 69.9 t -146.12 99.57 4.27 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.526 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.4 Cg_endo -77.13 -167.96 0.53 Allowed 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.432 2.088 . . . . 0.0 110.479 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 2.6 t -84.82 125.98 69.5 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.348 -0.845 . . . . 0.0 109.385 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.595 ' HG2' HD12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.54 -1.16 11.35 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.382 2.055 . . . . 0.0 110.404 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 46' ' ' SER . 4.7 tttt -160.15 140.95 12.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.304 -0.872 . . . . 0.0 109.574 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.67 102.84 12.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 0.0 109.402 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 1.002 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -152.92 -168.93 17.54 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.63 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.4 p -104.18 120.19 54.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -1.105 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 50.9 t -49.09 142.36 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.532 ' O ' HG23 ' A' ' 22' ' ' THR . 3.1 ttpp -104.87 -59.77 1.7 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.01 140.99 14.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.572 HG12 ' H ' ' A' ' 57' ' ' VAL . 10.7 t -90.37 126.36 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.506 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.6 m -100.38 20.47 14.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.251 -0.906 . . . . 0.0 109.394 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.795 HG21 HG23 ' A' ' 69' ' ' ILE . 1.4 m -143.62 163.39 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -120.1 141.47 49.77 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.474 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.556 ' HA ' HG11 ' A' ' 15' ' ' VAL . 2.1 pp -60.26 128.37 36.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.466 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.39 -21.9 21.04 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -83.43 158.45 22.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.187 -1.184 . . . . 0.0 109.502 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 5.8 pttt -86.8 165.11 16.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.574 HD21 HG11 ' A' ' 57' ' ' VAL . 0.3 OUTLIER -132.02 110.66 10.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.324 -0.86 . . . . 0.0 109.45 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.84 136.28 36.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.232 -0.918 . . . . 0.0 109.282 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' O ' ' A' ' 11' ' ' GLY . 1.8 mt-10 -48.85 149.04 1.94 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.31 -0.869 . . . . 0.0 109.958 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.79 -14.66 46.75 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.64 141.62 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.198 -1.178 . . . . 0.0 109.621 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -74.61 176.07 7.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 109.342 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.882 HG22 HG23 ' A' ' 70' ' ' ILE . 2.9 mp -139.37 -64.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.156 -0.965 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.882 HG23 HG22 ' A' ' 69' ' ' ILE . 2.3 pp -139.18 173.59 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.605 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -129.31 137.51 51.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.874 . . . . 0.0 109.428 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.002 HD11 ' CA ' ' A' ' 50' ' ' GLY . 3.5 tt -108.52 137.88 45.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.893 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -113.38 92.17 22.19 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.975 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo -78.05 75.05 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.598 2.198 . . . . 0.0 110.391 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . 53.7 97.95 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.399 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -107.25 16.11 24.36 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.454 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.16 -106.13 0.22 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -87.42 -166.77 1.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.32 -1.106 . . . . 0.0 109.404 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.2 mtm180 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.049 -0.976 . . . . 0.0 109.467 179.917 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.529 ' CB ' ' HG2' ' A' ' 73' ' ' GLU . 53.2 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.271 0.558 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 1' ' ' SER . 2.0 mm-40 -154.09 148.81 26.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.231 -0.918 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.7 mp -80.05 143.1 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.412 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.477 HD13 HD11 ' A' ' 70' ' ' ILE . 2.1 mp -114.82 97.88 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.428 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.07 176.67 6.69 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.735 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.0 t -65.68 142.43 98.21 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.735 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.7 Cg_endo -78.24 -178.68 4.8 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.528 2.152 . . . . 0.0 110.374 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -85.05 96.64 9.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.22 -0.925 . . . . 0.0 109.41 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.99 -17.64 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.31 -0.869 . . . . 0.0 109.299 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.29 -8.95 62.46 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.82 -133.14 3.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -113.6 170.8 7.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -134.06 108.44 0.73 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.471 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.3 OUTLIER -99.8 120.33 39.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -1.112 . . . . 0.0 109.371 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.2 t -67.26 123.31 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.88 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.954 HG22 ' O ' ' A' ' 34' ' ' VAL . 8.3 tp -103.37 -25.19 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.196 -0.94 . . . . 0.0 109.494 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -178.62 138.83 0.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.485 HD12 ' H ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -102.75 152.47 21.2 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.304 -0.872 . . . . 0.0 109.399 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.682 HD12 ' C ' ' A' ' 32' ' ' LEU . 0.7 OUTLIER -112.06 27.29 9.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.446 HG21 HD11 ' A' ' 32' ' ' LEU . 24.3 m -149.98 167.48 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.529 ' O ' HG21 ' A' ' 52' ' ' VAL . 0.0 OUTLIER -132.97 -167.59 1.94 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 80.3 m -84.96 130.34 34.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.447 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 79.79 2.16 87.98 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -84.61 135.3 34.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.191 -1.182 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.4 tp -89.24 127.84 35.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.221 -0.924 . . . . 0.0 109.493 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.012 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -98.5 -171.22 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.285 -0.885 . . . . 0.0 109.148 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 40.0 mm-40 -140.81 164.99 28.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.492 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.7 p -80.47 75.62 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -0.901 . . . . 0.0 109.404 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 2.4 mt-10 162.7 -31.01 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.283 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 6.2 tt0 -71.01 151.0 45.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.449 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.445 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -70.4 165.94 51.35 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 1.012 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -125.84 -49.54 1.61 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -1.124 . . . . 0.0 109.559 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.428 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.5 m -146.74 158.11 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.482 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.954 ' O ' HG22 ' A' ' 16' ' ' ILE . 82.6 t -126.05 88.25 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.14 -0.975 . . . . 0.0 109.439 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.471 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -90.04 152.34 21.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.541 -179.943 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.53 -178.92 5.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.495 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.418 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -140.87 175.9 9.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.458 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.4 -49.94 9.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.514 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -147.09 32.92 0.9 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.77 169.1 25.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.865 . . . . 0.0 109.464 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 58.7 m -123.56 135.3 53.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.3 mmt -133.59 135.63 44.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' N ' ' A' ' 44' ' ' VAL . 24.9 tt0 -106.92 166.03 10.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.515 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 6.4 t -145.9 111.64 4.48 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.314 -0.866 . . . . 0.0 109.283 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.5 Cg_endo -77.26 -169.11 0.68 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.364 2.043 . . . . 0.0 110.437 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.5 OUTLIER -85.46 130.44 51.36 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 -179.92 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.405 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.88 -6.6 15.21 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.417 2.078 . . . . 0.0 110.482 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -160.37 149.26 17.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.529 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.433 ' O ' ' HB3' ' A' ' 74' ' ' PRO . . . -79.85 96.43 6.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.762 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -144.78 177.11 23.5 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.447 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.3 p -104.12 137.83 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -1.148 . . . . 0.0 109.483 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.529 HG21 ' O ' ' A' ' 21' ' ' LYS . 49.0 t -53.3 129.62 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.455 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.77 -18.14 10.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.301 -0.874 . . . . 0.0 109.44 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -164.88 150.05 9.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.195 -0.941 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.458 HG12 ' H ' ' A' ' 57' ' ' VAL . 61.0 t -129.88 117.93 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.413 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.07 15.4 29.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.419 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 69' ' ' ILE . 33.3 m -138.71 161.73 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.478 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.93 -165.0 1.8 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.86 123.99 28.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.33 -3.96 86.55 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.88 135.52 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.15 -1.206 . . . . 0.0 109.392 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -107.8 125.06 50.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.533 HD23 ' HB3' ' A' ' 67' ' ' ASP . 1.9 mp -131.35 154.02 49.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.46 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -111.03 150.37 29.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.469 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.7 OUTLIER -42.88 141.46 1.1 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 109.643 -179.825 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.14 -26.47 23.76 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.533 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -85.07 137.33 33.12 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -1.183 . . . . 0.0 109.546 -179.911 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -64.57 164.18 12.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 70' ' ' ILE . 44.2 mm -122.25 -68.24 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.122 -0.986 . . . . 0.0 109.534 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 69' ' ' ILE . 1.6 pp -138.91 179.87 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.237 -0.914 . . . . 0.0 109.471 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.433 ' N ' HD12 ' A' ' 70' ' ' ILE . 46.3 tt0 -134.03 127.83 33.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.762 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.9 tp -107.03 123.91 48.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.884 ' OE1' ' HB2' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -120.92 91.4 47.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.301 -0.874 . . . . 0.0 109.424 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.468 ' HD2' ' CA ' ' A' ' 1' ' ' SER . 35.2 Cg_endo -77.99 98.16 1.19 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.644 2.229 . . . . 0.0 110.395 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.441 ' O ' ' O ' ' A' ' 74' ' ' PRO . . . 61.13 120.72 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.884 ' HB2' ' OE1' ' A' ' 73' ' ' GLU . . . -112.94 94.69 5.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -104.94 -49.3 1.01 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -50.45 -23.95 2.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.252 -1.146 . . . . 0.0 109.521 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.9 ttt180 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.504 179.99 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.475 ' HB3' ' HD3' ' A' ' 74' ' ' PRO . 83.4 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.445 ' OE2' ' HG3' ' A' ' 48' ' ' LYS . 20.2 pt-20 -155.9 172.51 18.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.433 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.846 HD13 ' HG2' ' A' ' 71' ' ' GLU . 16.7 mm -116.52 134.39 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.304 -0.873 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -98.0 110.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.402 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.47 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -110.44 169.56 8.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.21 -0.931 . . . . 0.0 109.573 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.614 HG13 HD11 ' A' ' 9' ' ' ILE . 51.6 t -43.58 106.03 0.47 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.893 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.43 -170.5 0.95 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.486 2.124 . . . . 0.0 110.41 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -75.68 100.45 4.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.506 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.614 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.05 -24.81 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.286 -0.883 . . . . 0.0 109.313 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.9 -30.76 4.75 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -173.56 169.43 42.51 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -48.07 113.53 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.488 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.25 149.41 16.86 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.475 ' HB2' ' HG2' ' A' ' 62' ' ' LYS . 55.8 tt0 -115.27 126.37 54.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -1.144 . . . . 0.0 109.548 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.406 ' O ' ' HA2' ' A' ' 60' ' ' GLY . 40.6 t -55.93 148.41 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.883 HD11 ' HB2' ' A' ' 36' ' ' GLU . 50.4 mt -120.41 -50.4 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -159.3 143.55 15.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.286 -0.883 . . . . 0.0 109.413 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.771 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.84 155.2 18.5 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.297 -0.877 . . . . 0.0 109.384 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.612 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -122.83 35.83 4.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -146.13 -179.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.452 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.35 176.12 8.39 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.191 -0.943 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.1 m -77.6 148.41 35.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.445 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 68.49 7.53 53.43 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -85.01 143.1 29.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 0.0 109.515 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -102.21 116.02 31.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.446 179.954 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.8 OUTLIER -92.92 -171.57 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.194 -0.941 . . . . 0.0 109.245 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 mt-10 -140.56 172.91 12.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.186 -0.946 . . . . 0.0 109.391 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.691 HG13 ' O ' ' A' ' 28' ' ' VAL . 7.1 p -78.86 77.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.52 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.99 -41.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.312 -0.868 . . . . 0.0 109.485 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -61.43 146.6 47.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.464 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -63.13 -174.67 2.68 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.642 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -147.54 -71.9 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.147 -1.207 . . . . 0.0 109.518 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.506 HG13 HD22 ' A' ' 32' ' ' LEU . 8.0 m -131.52 175.84 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.943 . . . . 0.0 109.576 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.876 HG22 ' HB3' ' A' ' 43' ' ' GLU . 87.8 t -132.24 99.73 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.345 -0.847 . . . . 0.0 109.421 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.19 153.37 17.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.881 . . . . 0.0 109.486 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.883 ' HB2' HD11 ' A' ' 16' ' ' ILE . 1.5 tt0 -107.8 153.1 23.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.347 -0.845 . . . . 0.0 109.395 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.66 -179.37 3.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.462 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.45 -22.97 66.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.653 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 10.2 pttp -159.39 65.47 0.39 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.419 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 166.62 174.6 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.176 -0.953 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.4 m -154.95 93.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.397 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 55.7 mtp -116.65 138.82 51.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.275 -0.891 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.876 ' HB3' HG22 ' A' ' 34' ' ' VAL . 4.3 pt-20 -95.36 -176.31 3.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.24 -0.913 . . . . 0.0 109.389 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' A' ' 45' ' ' PRO . 68.0 t -143.33 139.38 16.49 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.1 Cg_endo -78.92 -168.14 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.554 2.169 . . . . 0.0 110.373 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.642 ' HA ' HD12 ' A' ' 32' ' ' LEU . 28.0 t -85.04 124.31 72.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.247 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HD3' HD12 ' A' ' 32' ' ' LEU . 35.8 Cg_endo -78.17 0.37 9.95 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.366 2.044 . . . . 0.0 110.434 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.646 ' HB3' HD13 ' A' ' 72' ' ' LEU . 3.5 mmtm -160.15 121.36 3.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.248 -0.908 . . . . 0.0 109.517 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.15 83.91 1.01 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.14 -170.03 16.96 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 23' ' ' GLY . 8.0 p -95.94 148.59 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -1.145 . . . . 0.0 109.531 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.0 t -75.94 137.69 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.472 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.454 ' HB3' ' O ' ' A' ' 71' ' ' GLU . 0.0 OUTLIER -90.73 -46.21 8.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.462 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.49 144.14 0.12 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.155 -0.965 . . . . 0.0 109.445 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.459 ' HA ' HG22 ' A' ' 70' ' ' ILE . 5.1 t -86.3 112.87 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.496 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.8 m -90.82 15.75 10.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.518 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.652 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.55 157.65 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.81 147.04 28.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.588 ' HB3' HD21 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -60.02 140.21 56.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.453 ' O ' ' OE2' ' A' ' 14' ' ' GLU . . . 90.7 -11.31 72.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -73.23 140.99 47.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -1.134 . . . . 0.0 109.434 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 14' ' ' GLU . 0.4 OUTLIER -98.38 133.78 42.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -140.11 162.3 35.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.454 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.7 tmtt? -128.71 159.71 34.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.557 ' N ' HG11 ' A' ' 6' ' ' VAL . 8.6 mt-10 -42.7 111.83 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.426 -0.796 . . . . 0.0 109.695 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.94 -33.85 2.15 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -84.22 142.51 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -1.149 . . . . 0.0 109.405 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.633 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -78.26 159.54 28.42 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.391 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.652 HG23 HG21 ' A' ' 57' ' ' VAL . 34.5 mm -123.7 -60.72 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.511 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.555 HG23 HG22 ' A' ' 69' ' ' ILE . 11.3 pt -142.54 -176.47 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 109.49 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.846 ' HG2' HD13 ' A' ' 3' ' ' ILE . 1.7 tm-20 -138.16 108.04 6.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.241 -0.912 . . . . 0.0 109.475 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.725 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.4 tt -89.94 140.99 29.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.468 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -110.22 157.89 36.73 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 0.0 109.499 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.475 ' HD3' ' HB3' ' A' ' 1' ' ' SER . 35.9 Cg_endo -77.97 117.48 4.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.57 2.18 . . . . 0.0 110.45 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -149.99 87.94 1.5 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.429 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -93.59 40.71 1.07 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.12 -30.55 8.2 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 56.34 20.64 4.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -1.148 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 40.7 mtp85 . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.982 -1.008 . . . . 0.0 109.484 179.969 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 79.5 p . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -123.2 178.59 5.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.465 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 71' ' ' GLU . 7.0 mt -120.15 127.71 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.197 -0.939 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.447 HG21 ' HG3' ' A' ' 47' ' ' PRO . 3.3 mt -98.98 126.62 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.439 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -111.03 161.01 16.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.903 HG23 HD11 ' A' ' 69' ' ' ILE . 72.8 t -50.23 142.08 14.85 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.346 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.73 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.22 -170.31 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.632 2.221 . . . . 0.0 110.493 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.95 102.32 10.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.388 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.84 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.3 -10.76 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 109.382 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.16 35.85 91.04 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.5 -173.48 43.79 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -82.96 172.88 12.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -1.153 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.51 146.71 18.69 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.496 ' O ' HD13 ' A' ' 35' ' ' LEU . 25.0 tt0 -132.03 118.24 19.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.288 -1.125 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.71 ' CG2' HD11 ' A' ' 63' ' ' LEU . 9.8 t -67.84 141.17 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.206 -0.934 . . . . 0.0 109.538 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.437 ' CG1' ' HB2' ' A' ' 36' ' ' GLU . 30.3 mm -112.22 -51.27 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.268 -0.895 . . . . 0.0 109.444 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -150.05 140.93 22.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.657 HD23 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -101.83 149.09 24.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.502 179.946 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.472 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.6 OUTLIER -140.69 50.77 1.66 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.269 -0.894 . . . . 0.0 109.533 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.845 HG21 ' CD2' ' A' ' 32' ' ' LEU . 0.9 OUTLIER -150.05 163.27 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.248 -0.908 . . . . 0.0 109.455 -179.956 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.29 165.39 23.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.221 -0.924 . . . . 0.0 109.441 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.524 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 72.4 m -81.16 141.25 34.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 109.513 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.3 -10.83 69.74 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 1.0 OUTLIER -82.86 133.65 35.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.494 179.975 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.5 OUTLIER -85.97 117.58 24.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -90.01 -171.57 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.719 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.6 pt-20 -147.78 166.38 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -0.933 . . . . 0.0 109.479 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.8 p -77.72 79.05 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.449 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 163.0 -35.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.517 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -70.0 140.55 52.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.2 -0.937 . . . . 0.0 109.437 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.45 165.05 47.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -128.01 -40.49 1.68 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -1.15 . . . . 0.0 109.506 -179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.478 HG12 ' HG ' ' A' ' 18' ' ' LEU . 30.0 m -157.27 174.49 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.482 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.71 104.3 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 14' ' ' GLU . 4.5 mm? -89.96 152.55 21.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.256 -0.903 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.437 ' HB2' ' CG1' ' A' ' 16' ' ' ILE . 0.3 OUTLIER -131.74 116.19 16.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 -179.974 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.61 -172.62 3.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.47 -57.38 8.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.268 -0.895 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.3 mttt -140.4 49.66 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -154.88 104.67 2.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.339 -0.851 . . . . 0.0 109.478 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.97 119.28 31.56 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.87 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 5.4 ptp -136.51 162.35 33.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.325 -0.859 . . . . 0.0 109.418 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -106.42 172.36 6.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 22.9 t -142.75 95.89 6.25 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.409 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.517 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.9 Cg_endo -77.47 -168.73 0.63 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.481 2.12 . . . . 0.0 110.52 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.527 ' HB2' HG21 ' A' ' 26' ' ' ILE . 11.6 t -85.42 130.68 50.52 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.356 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.447 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.61 -3.04 12.99 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.401 2.067 . . . . 0.0 110.43 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -160.3 145.77 15.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 -179.997 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.93 93.22 8.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.475 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.864 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -143.52 -155.14 6.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.9 p -117.04 142.3 31.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.307 -1.114 . . . . 0.0 109.465 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.524 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 55.0 t -65.37 110.29 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.441 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.58 -35.38 27.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.494 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.8 t -169.86 158.13 7.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.552 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.41 HG12 ' H ' ' A' ' 57' ' ' VAL . 77.7 t -117.44 115.23 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.14 17.87 20.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.551 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.431 HG13 ' O ' ' A' ' 69' ' ' ILE . 29.2 m -123.1 162.23 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 109.483 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 tptt -134.26 172.58 12.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.442 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -81.86 124.33 29.61 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.156 -0.965 . . . . 0.0 109.513 179.959 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 98.33 -9.55 63.0 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -75.87 153.93 36.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -1.176 . . . . 0.0 109.482 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -99.3 121.11 40.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.71 HD11 ' CG2' ' A' ' 15' ' ' VAL . 11.1 mt -102.59 95.16 6.05 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.428 ' O ' ' C ' ' A' ' 65' ' ' GLU . 26.8 ttpt -85.43 138.64 32.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 109.386 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.473 ' HB3' HG13 ' A' ' 9' ' ' ILE . 11.5 pt-20 -43.06 150.63 0.16 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.67 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.26 -26.37 13.79 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -85.17 146.02 27.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.502 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -61.64 -175.15 0.05 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.274 -0.891 . . . . 0.0 109.404 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.903 HD11 HG23 ' A' ' 6' ' ' VAL . 39.8 mm -146.95 -70.37 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.538 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -143.96 -172.33 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.214 -0.929 . . . . 0.0 109.451 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.422 ' HG2' ' HA ' ' A' ' 3' ' ' ILE . 9.6 mt-10 -137.81 105.05 5.46 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.205 -0.935 . . . . 0.0 109.585 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.864 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -90.63 135.14 33.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.179 -0.951 . . . . 0.0 109.484 179.893 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.409 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 27.7 tt0 -113.45 91.33 19.79 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.504 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -78.02 -18.29 13.06 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.635 2.223 . . . . 0.0 110.423 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.516 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . -59.34 -66.01 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.413 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 65.46 -168.85 0.21 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.447 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.94 18.45 24.8 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -114.07 -74.38 0.62 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.329 -1.101 . . . . 0.0 109.464 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.2 mtt85 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.423 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.411 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 31.3 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -122.87 155.92 35.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.406 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 4' ' ' ILE . 2.1 mp -117.12 146.89 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 37.9 mm -124.46 112.95 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -100.8 172.83 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.745 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.8 t -61.89 142.26 95.09 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.399 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.745 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.16 -171.24 1.15 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.505 2.137 . . . . 0.0 110.431 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -85.01 102.82 13.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.417 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.486 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.76 -40.19 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.282 -179.925 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.9 29.85 30.62 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.84 -128.52 0.96 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.488 ' OD2' ' CE ' ' A' ' 62' ' ' LYS . 18.3 p-10 -136.31 135.81 39.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.202 -1.176 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.59 111.43 2.55 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.401 ' HG3' ' CG ' ' A' ' 62' ' ' LYS . 3.0 tt0 -101.25 133.85 45.19 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -1.158 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.8 t -72.18 140.01 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.534 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.704 HD12 HG12 ' A' ' 34' ' ' VAL . 20.1 mt -100.8 -39.34 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.372 -0.83 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -164.64 -173.94 3.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.506 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.4 tp -136.7 102.05 4.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.442 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.2 pp -95.88 29.33 2.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.479 HG11 ' HG ' ' A' ' 32' ' ' LEU . 34.2 m -133.23 159.54 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -125.4 174.87 7.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -84.99 141.0 30.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.488 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.456 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 76.6 8.59 86.16 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.95 131.99 34.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.254 -1.145 . . . . 0.0 109.441 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.457 HD22 ' HA ' ' A' ' 25' ' ' LEU . 0.3 OUTLIER -86.01 111.7 20.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.716 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.36 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.288 -0.883 . . . . 0.0 109.25 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 31.8 mt-10 -147.56 -174.51 4.56 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.925 . . . . 0.0 109.446 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.4 p -84.83 72.76 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.9 -40.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.459 179.955 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.525 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.6 tt0 -54.11 142.49 25.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.62 168.32 54.61 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.66 ' O ' HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -129.31 -40.26 1.46 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.234 -1.157 . . . . 0.0 109.56 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 32' ' ' LEU . 13.0 m -161.01 176.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.112 -0.993 . . . . 0.0 109.534 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.704 HG12 HD12 ' A' ' 16' ' ' ILE . 98.9 t -131.9 97.9 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.422 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.07 146.25 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.439 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.95 177.84 6.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.0 m -136.33 160.91 37.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.87 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.11 -28.85 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.214 -0.929 . . . . 0.0 109.405 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.471 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 3.0 tttm -160.02 52.62 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 176.93 -166.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.174 -0.954 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.2 t -152.73 140.8 20.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.46 150.53 42.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -0.893 . . . . 0.0 109.509 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -98.14 169.71 9.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 55.5 t -146.47 98.39 4.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.235 -0.915 . . . . 0.0 109.422 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.63 -169.05 0.67 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.437 2.091 . . . . 0.0 110.412 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.4 134.17 40.92 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.454 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.489 ' HG2' HG13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.96 -5.37 14.53 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.425 2.083 . . . . 0.0 110.399 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.469 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -160.41 144.99 14.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.326 -0.859 . . . . 0.0 109.513 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.5 99.18 3.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.421 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.862 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -153.79 175.65 32.02 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.456 HG22 ' HA2' ' A' ' 23' ' ' GLY . 11.3 p -95.78 145.16 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -1.131 . . . . 0.0 109.574 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -63.87 114.24 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' A' ' 73' ' ' GLU . 2.8 tttp -85.21 -56.74 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.5 m -143.86 127.44 17.02 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.498 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 t -96.23 128.78 47.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.448 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.9 m -119.59 34.0 5.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.425 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.676 HG13 ' O ' ' A' ' 69' ' ' ILE . 27.2 m -137.54 157.5 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.47 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -141.08 149.53 41.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.918 . . . . 0.0 109.46 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.77 128.58 35.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.497 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.1 -23.2 29.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -80.78 148.89 29.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.184 -1.186 . . . . 0.0 109.489 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.488 ' CE ' ' OD2' ' A' ' 12' ' ' ASP . 3.1 tttt -103.14 112.99 26.11 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.916 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.744 HD22 ' HB3' ' A' ' 67' ' ' ASP . 12.6 mt -102.01 135.32 43.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.287 -0.883 . . . . 0.0 109.434 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -100.51 152.47 20.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.31 -0.869 . . . . 0.0 109.439 -179.956 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.9 pt-20 -42.88 150.49 0.16 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.55 -17.58 51.45 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.744 ' HB3' HD22 ' A' ' 63' ' ' LEU . 1.1 m-20 -84.0 131.21 34.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -1.131 . . . . 0.0 109.436 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -57.4 159.78 4.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.238 -0.914 . . . . 0.0 109.475 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.726 HD11 ' CG2' ' A' ' 6' ' ' VAL . 33.0 mm -117.6 -58.15 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.486 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 69' ' ' ILE . 2.4 pp -158.36 -177.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.239 -0.913 . . . . 0.0 109.43 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.424 ' HG2' HG13 ' A' ' 3' ' ' ILE . 57.5 mt-10 -133.58 127.46 33.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.971 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -99.5 142.47 30.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.484 -179.954 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.481 ' HB2' ' HD2' ' A' ' 53' ' ' LYS . 0.2 OUTLIER -118.85 90.06 39.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.186 -0.946 . . . . 0.0 109.47 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.971 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -78.26 174.57 12.24 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.625 2.217 . . . . 0.0 110.413 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -69.92 -170.86 0.36 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 109.422 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -96.94 25.96 4.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.435 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -45.54 -38.45 7.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -89.39 -176.73 5.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.281 -1.129 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.474 ' CZ ' ' HB3' ' A' ' 79' ' ' ARG . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.484 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 96.5 p . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.244 0.545 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -93.31 140.7 29.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 109.52 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.448 HD13 ' HG3' ' A' ' 71' ' ' GLU . 18.0 mm -80.44 160.35 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 96.6 mt -122.97 96.6 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.333 -0.855 . . . . 0.0 109.415 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.655 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -92.01 -178.76 5.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.289 -0.882 . . . . 0.0 109.558 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.731 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.8 t -70.93 142.7 88.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.369 -0.832 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.03 -170.02 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.494 2.13 . . . . 0.0 110.377 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.85 104.12 14.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.252 -0.905 . . . . 0.0 109.477 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.585 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.19 -41.68 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.208 -0.932 . . . . 0.0 109.273 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.88 -21.04 12.69 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.77 -142.25 3.91 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 3.1 m-20 -102.84 165.94 10.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.289 -1.124 . . . . 0.0 109.415 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.33 165.44 21.25 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -146.44 121.39 10.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.199 -1.177 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.559 HG23 HD13 ' A' ' 63' ' ' LEU . 21.6 t -70.23 149.49 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' ' OE1' ' A' ' 17' ' ' GLU . 69.1 mt -127.15 -40.01 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.284 -0.885 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -156.51 126.44 6.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.489 -179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.427 HD13 HG11 ' A' ' 15' ' ' VAL . 0.7 OUTLIER -102.41 141.53 35.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.428 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.732 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -132.61 61.54 1.67 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.498 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.78 164.42 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 28.6 mmtt -122.98 157.2 33.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 22' ' ' THR . 13.3 t -84.74 128.9 34.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.96 -9.17 73.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.472 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 1.6 m-20 -83.53 136.8 34.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -1.157 . . . . 0.0 109.551 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.448 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -86.18 126.5 34.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.491 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.2 mt -90.33 -171.32 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.294 -0.879 . . . . 0.0 109.193 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 5.6 mt-10 -137.39 156.12 48.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.205 -0.934 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.735 HG13 ' O ' ' A' ' 28' ' ' VAL . 9.6 p -79.03 82.08 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.85 -35.89 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.395 -0.816 . . . . 0.0 109.433 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -71.59 152.13 43.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.44 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.47 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.32 -169.31 0.29 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.536 HD11 ' CD1' ' A' ' 26' ' ' ILE . 8.1 tp -153.31 -70.18 0.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -1.154 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.7 m -134.02 173.56 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.486 HG22 ' HB3' ' A' ' 43' ' ' GLU . 97.1 t -133.73 102.33 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.29 170.07 8.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.311 -0.868 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.85 137.25 51.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.482 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.64 176.89 5.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.21 -0.931 . . . . 0.0 109.5 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.55 -45.82 13.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.403 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.4 mttm -152.3 67.55 0.84 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.492 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 167.66 99.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.208 -0.932 . . . . 0.0 109.479 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.5 t -80.02 126.53 31.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.452 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -147.2 159.46 43.61 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -0.875 . . . . 0.0 109.512 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.486 ' HB3' HG22 ' A' ' 34' ' ' VAL . 3.5 pt-20 -109.4 169.3 8.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.39 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' A' ' 45' ' ' PRO . 94.7 t -132.5 139.36 34.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.405 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.97 -168.23 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.432 0 C-N-CA 122.549 2.166 . . . . 0.0 110.361 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.4 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.0 OUTLIER -85.16 113.55 50.93 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.385 -0.822 . . . . 0.0 109.365 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 36.0 Cg_endo -77.87 3.37 7.02 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.332 2.021 . . . . 0.0 110.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 1.024 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -160.02 110.28 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.465 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.2 90.62 1.6 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.939 . . . . 0.0 109.601 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.83 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -143.69 -157.73 7.29 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 73' ' ' GLU . 11.1 p -111.48 128.53 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -1.148 . . . . 0.0 109.509 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 48.8 t -58.27 134.83 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.474 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.87 -33.28 7.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.291 -0.881 . . . . 0.0 109.458 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 173.27 144.31 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.509 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 57' ' ' VAL . 52.2 t -99.68 135.11 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.6 m -105.63 16.19 25.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.346 -0.846 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 1.009 HG11 HD21 ' A' ' 63' ' ' LEU . 1.5 m -136.47 157.34 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.443 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -110.37 167.17 10.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.02 137.2 38.84 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.493 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.1 -11.07 68.41 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -79.21 148.4 32.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.5 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.712 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 mttp -82.64 165.37 20.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 HG11 ' A' ' 57' ' ' VAL . 3.4 mp -148.77 113.42 5.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -86.03 137.78 32.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.241 -0.912 . . . . 0.0 109.455 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 64' ' ' LYS . 25.7 pt-20 -42.88 151.41 0.13 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 109.672 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.08 -18.2 41.99 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -85.0 141.68 30.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.262 -1.14 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.19 172.42 9.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.914 HG22 HG23 ' A' ' 70' ' ' ILE . 2.0 mp -134.76 -58.49 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.914 HG23 HG22 ' A' ' 69' ' ' ILE . 7.4 pt -147.23 -179.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.461 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.448 ' HG3' HD13 ' A' ' 3' ' ' ILE . 32.4 tt0 -131.18 117.33 18.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.024 HD22 ' HB3' ' A' ' 48' ' ' LYS . 0.7 OUTLIER -97.54 147.08 24.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -0.863 . . . . 0.0 109.486 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.522 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 2.5 tp10 -120.09 89.7 43.24 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.13 173.4 13.97 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.651 2.234 . . . . 0.0 110.375 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.702 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . -60.32 -84.97 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.164 -0.96 . . . . 0.0 109.447 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.702 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 75.39 -168.3 0.09 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.285 -0.884 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.81 153.77 52.44 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.04 119.17 12.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -1.186 . . . . 0.0 109.467 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -86.69 111.01 20.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.253 -0.904 . . . . 0.0 109.285 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.679 HD12 ' OE2' ' A' ' 71' ' ' GLU . 2.2 tt -79.96 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.448 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 40.2 mm -122.78 122.77 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.564 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -92.11 -176.13 4.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.554 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.986 ' CG2' HD11 ' A' ' 69' ' ' ILE . 53.4 t -74.75 139.99 74.31 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.347 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.648 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.39 -174.37 2.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.549 2.166 . . . . 0.0 110.438 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -85.19 108.88 17.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.413 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.415 ' CD1' ' HA3' ' A' ' 13' ' ' GLY . 0.0 OUTLIER -104.79 -7.27 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.281 -0.887 . . . . 0.0 109.396 -179.768 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.58 21.95 13.54 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 150.2 -133.53 4.4 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -85.54 170.85 12.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.243 -1.151 . . . . 0.0 109.464 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.415 ' HA3' ' CD1' ' A' ' 9' ' ' ILE . . . -141.05 148.25 19.9 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.454 ' HG3' ' HA ' ' A' ' 62' ' ' LYS . 1.0 OUTLIER -135.73 130.43 34.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -1.17 . . . . 0.0 109.484 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.53 ' HA ' HD23 ' A' ' 35' ' ' LEU . 38.2 t -70.1 147.2 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.899 HD11 ' HB2' ' A' ' 36' ' ' GLU . 42.7 mt -118.95 -53.91 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.326 -0.859 . . . . 0.0 109.558 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -134.34 133.81 41.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.402 HD12 ' CG1' ' A' ' 33' ' ' VAL . 0.4 OUTLIER -115.24 102.47 9.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.496 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.487 ' H ' HD23 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -93.66 41.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 m -143.74 156.08 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.533 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.405 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.07 -176.83 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.9 m -84.08 133.92 34.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.482 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.2 5.38 89.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.405 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.3 m-20 -84.94 135.49 34.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -1.175 . . . . 0.0 109.532 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.57 115.7 27.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.269 -0.895 . . . . 0.0 109.471 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.712 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.6 mt -90.46 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.322 -0.861 . . . . 0.0 109.219 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.712 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.8 mt-10 -135.37 177.68 7.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.645 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.3 p -85.4 59.89 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.588 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 3.3 tt0 167.5 -32.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.249 -0.907 . . . . 0.0 109.228 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 1.9 tm0? -52.35 145.41 11.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.414 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.449 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.03 171.03 39.88 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.54 ' CD1' HD13 ' A' ' 26' ' ' ILE . 0.6 OUTLIER -130.11 -56.04 1.11 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -1.156 . . . . 0.0 109.546 -179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 18' ' ' LEU . 36.0 m -151.56 -176.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.496 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.503 HG12 HD12 ' A' ' 16' ' ' ILE . 46.2 t -139.01 97.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 15' ' ' VAL . 3.1 mt -90.08 158.9 17.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.899 ' HB2' HD11 ' A' ' 16' ' ' ILE . 2.0 tt0 -123.27 153.04 40.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.408 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.6 m -130.25 -176.58 4.0 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.464 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.98 -34.62 65.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.249 -0.907 . . . . 0.0 109.484 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 20.9 tttp -159.9 61.19 0.36 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.402 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.14 88.21 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 109.491 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.436 ' HB3' ' CG ' ' A' ' 36' ' ' GLU . 99.6 p -105.1 112.97 26.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.383 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.2 mtt -130.02 -175.5 3.64 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.479 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -114.23 162.19 16.87 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.25 -0.906 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 59.2 t -137.53 117.57 10.35 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.33 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.96 -168.69 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.28 1.987 . . . . 0.0 110.434 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.497 ' HA ' HD13 ' A' ' 32' ' ' LEU . 6.0 t -85.27 138.08 36.7 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.402 -0.811 . . . . 0.0 109.328 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.82 -4.82 14.3 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.417 2.078 . . . . 0.0 110.478 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.573 ' O ' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.35 128.1 4.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -0.859 . . . . 0.0 109.521 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.86 98.51 1.58 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.903 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.491 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -152.12 -135.98 2.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.0 p -132.27 151.36 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.189 -1.183 . . . . 0.0 109.439 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.5 t -73.49 119.95 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -91.97 -43.21 9.57 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.916 . . . . 0.0 109.407 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.8 t -149.48 142.84 25.23 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 57' ' ' VAL . 21.0 t -105.02 106.79 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.86 10.56 13.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.288 -0.883 . . . . 0.0 109.436 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.426 ' H ' HG12 ' A' ' 55' ' ' VAL . 17.2 m -124.98 177.73 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.305 -0.872 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.479 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -128.48 -156.02 0.73 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.87 80.67 9.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.43 ' HA2' ' HB ' ' A' ' 15' ' ' VAL . . . 74.89 46.22 18.03 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 4.9 m-20 -84.96 172.24 11.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.296 -1.12 . . . . 0.0 109.435 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.454 ' HA ' ' HG3' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -97.62 145.3 26.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.196 -0.94 . . . . 0.0 109.447 -179.92 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.92 -172.52 4.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.467 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -138.45 147.08 42.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.86 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.485 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 4.2 pt-20 -45.39 148.86 0.6 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.273 -0.892 . . . . 0.0 109.694 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 5' ' ' ARG . . . 85.86 -43.51 3.25 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 68' ' ' ALA . 0.9 OUTLIER -50.76 134.46 24.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -1.128 . . . . 0.0 109.602 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -48.21 174.04 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -0.886 . . . . 0.0 109.535 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.986 HD11 ' CG2' ' A' ' 6' ' ' VAL . 26.9 mm -143.51 -58.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.238 -0.914 . . . . 0.0 109.498 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.656 ' C ' HD12 ' A' ' 70' ' ' ILE . 2.4 pp -150.98 179.56 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.482 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.679 ' OE2' HD12 ' A' ' 3' ' ' ILE . 22.3 mt-10 -145.56 97.25 2.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.511 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 48' ' ' LYS . 0.4 OUTLIER -90.76 124.86 35.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.238 -0.914 . . . . 0.0 109.433 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.527 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 37.1 tt0 -91.42 140.99 25.6 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.254 -0.903 . . . . 0.0 109.374 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.6 Cg_endo -78.38 -54.97 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.486 2.124 . . . . 0.0 110.373 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.433 ' HB2' ' O ' ' A' ' 74' ' ' PRO . . . 178.9 168.99 0.92 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.47 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -142.3 -57.29 0.45 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.4 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 64.88 161.75 0.61 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -98.41 172.25 7.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.485 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.415 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 5.4 ttt180 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.464 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.433 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 23.4 p . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -126.77 147.55 49.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 109.403 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.531 HG22 ' N ' ' A' ' 4' ' ' ILE . 3.5 mp -85.11 162.88 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.211 -0.931 . . . . 0.0 109.484 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.531 ' N ' HG22 ' A' ' 3' ' ' ILE . 3.0 mp -127.75 104.27 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 4.3 ptp85 -93.03 -172.44 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.145 -0.972 . . . . 0.0 109.473 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 42.0 t -73.99 136.59 76.4 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.297 -0.877 . . . . 0.0 109.389 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.51 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.94 -176.61 3.38 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.481 2.121 . . . . 0.0 110.383 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -85.18 101.21 12.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.183 -0.948 . . . . 0.0 109.322 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.71 -45.95 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.249 -0.907 . . . . 0.0 109.259 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.78 16.07 11.25 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.7 -159.42 16.64 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 7.5 m-20 -104.31 119.82 39.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -1.167 . . . . 0.0 109.516 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.4 151.62 23.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.5 mp0 -131.58 119.82 22.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.246 -1.149 . . . . 0.0 109.442 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.8 t -65.37 134.67 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.495 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 16' ' ' ILE . 18.2 mm -115.19 -52.74 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.438 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -129.09 123.47 32.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.499 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.709 ' HG ' HG22 ' A' ' 20' ' ' VAL . 5.9 tp -99.84 115.37 29.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.893 . . . . 0.0 109.465 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -113.55 57.18 0.68 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.482 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.777 HG11 ' HG ' ' A' ' 32' ' ' LEU . 29.3 m -139.73 158.44 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.263 -0.898 . . . . 0.0 109.435 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.26 162.6 33.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -0.956 . . . . 0.0 109.46 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.423 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 0.2 OUTLIER -84.93 125.61 32.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.259 -0.901 . . . . 0.0 109.512 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.489 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.03 -8.95 67.88 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -78.63 132.05 36.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -1.138 . . . . 0.0 109.5 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.573 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -85.35 115.71 23.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.75 ' CD1' HD11 ' A' ' 32' ' ' LEU . 2.6 mt -91.99 -171.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.3 -0.875 . . . . 0.0 109.211 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 20.0 pt-20 -146.3 172.33 13.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.733 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.6 p -81.12 74.83 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.211 -0.93 . . . . 0.0 109.357 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.4 tm-20 167.87 -39.37 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.332 -0.855 . . . . 0.0 109.299 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.9 OUTLIER -62.47 144.64 55.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.393 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.32 164.34 54.51 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.777 ' HG ' HG11 ' A' ' 20' ' ' VAL . 2.6 tp -124.61 -38.37 2.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -1.166 . . . . 0.0 109.398 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.502 HG13 ' C ' ' A' ' 32' ' ' LEU . 9.3 m -157.77 167.26 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.582 HG22 ' HG3' ' A' ' 43' ' ' GLU . 97.9 t -131.47 105.04 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.468 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.511 HD12 ' N ' ' A' ' 35' ' ' LEU . 9.8 mp -90.23 148.69 22.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -138.56 116.78 11.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.547 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.0 m -100.1 -175.74 3.03 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.26 -0.9 . . . . 0.0 109.449 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.79 -42.22 16.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -154.62 57.45 0.69 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -167.87 97.12 0.45 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.926 . . . . 0.0 109.51 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.5 m -99.7 120.64 40.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.436 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 17.2 mtp -128.63 134.25 48.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.582 ' HG3' HG22 ' A' ' 34' ' ' VAL . 26.0 tt0 -91.56 162.73 14.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.2 -0.937 . . . . 0.0 109.387 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -144.45 99.17 4.91 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.33 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.528 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.7 Cg_endo -77.42 -168.6 0.61 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.526 2.151 . . . . 0.0 110.477 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 1.1 t -85.34 127.45 63.64 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.22 -0.925 . . . . 0.0 109.377 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.43 -2.51 12.56 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.345 2.03 . . . . 0.0 110.43 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 2.4 mtmt -160.19 143.11 13.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.389 -0.819 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.81 97.95 7.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -147.0 -172.51 17.34 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' O ' ' A' ' 73' ' ' GLU . 2.5 p -104.63 127.47 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.456 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.423 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 50.5 t -50.57 133.91 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.411 ' HG2' ' OG ' ' A' ' 54' ' ' SER . 18.1 tttt -101.99 -58.8 1.81 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -0.922 . . . . 0.0 109.496 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.411 ' OG ' ' HG2' ' A' ' 53' ' ' LYS . 0.7 OUTLIER -150.56 153.87 36.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 109.474 -179.969 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' A' ' 70' ' ' ILE . 9.1 t -103.16 131.68 51.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.266 -0.896 . . . . 0.0 109.493 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.0 m -113.62 19.83 16.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.244 -0.91 . . . . 0.0 109.462 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.671 HG11 HG23 ' A' ' 69' ' ' ILE . 17.8 m -132.71 -178.62 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.945 . . . . 0.0 109.396 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.6 ttpt -138.91 158.6 43.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 59' ' ' LEU . 3.4 pp -76.68 123.02 25.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.243 -0.911 . . . . 0.0 109.492 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.97 -8.35 73.28 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -78.01 144.16 36.91 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.268 -1.136 . . . . 0.0 109.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -91.13 122.91 34.18 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.24 -0.913 . . . . 0.0 109.507 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.81 HD13 ' CD1' ' A' ' 69' ' ' ILE . 19.2 mt -102.74 152.14 21.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.895 . . . . 0.0 109.442 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -122.54 152.45 40.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.436 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.53 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 77.2 mt-10 -47.7 148.11 1.64 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.245 -0.909 . . . . 0.0 109.725 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.03 -40.19 3.09 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -61.97 131.6 50.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -1.158 . . . . 0.0 109.549 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.573 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -62.1 -174.88 0.06 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.81 ' CD1' HD13 ' A' ' 63' ' ' LEU . 44.2 mm -146.45 -64.99 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.874 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.661 HD11 ' CD2' ' A' ' 32' ' ' LEU . 2.8 pt -148.56 -172.45 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.297 -0.877 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 3' ' ' ILE . 1.7 tt0 -142.99 117.48 9.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.589 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.896 HD23 ' HD3' ' A' ' 74' ' ' PRO . 0.5 OUTLIER -95.47 137.38 34.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.382 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.52 ' O ' HG12 ' A' ' 51' ' ' VAL . 3.4 tt0 -115.71 85.84 14.81 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.896 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.08 131.83 11.18 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.654 2.236 . . . . 0.0 110.371 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -138.31 110.49 7.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.217 -0.927 . . . . 0.0 109.516 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -141.81 95.5 2.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 109.478 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.557 ' O ' ' HB3' ' A' ' 78' ' ' ALA . . . 148.06 157.14 7.35 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 77' ' ' GLY . . . 67.28 19.83 10.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.316 -1.109 . . . . 0.0 109.486 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.444 -179.929 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo -78.19 131.14 10.62 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -92.45 123.69 35.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.11 -63.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.54 76.87 0.07 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -99.88 134.51 42.68 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.226 -1.161 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.456 -179.994 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.71 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo -78.19 131.14 10.62 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -92.45 123.69 35.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.11 -63.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.54 76.87 0.07 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -99.88 134.51 42.68 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.226 -1.161 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.456 -179.994 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.422 ' O ' ' HG2' ' A' ' 2' ' ' GLU . 48.4 p . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.295 0.569 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 1' ' ' SER . 14.0 mt-10 -145.28 145.35 31.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.2 mt -85.13 148.89 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.197 -0.939 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.517 HD13 HD11 ' A' ' 70' ' ' ILE . 2.3 mp -116.14 108.01 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 1.2 ptp85 -98.71 176.73 5.53 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.836 HG23 HD11 ' A' ' 69' ' ' ILE . 78.9 t -74.04 142.43 79.36 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.319 -0.863 . . . . 0.0 109.359 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.738 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.82 -171.53 1.22 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.463 2.109 . . . . 0.0 110.435 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -85.03 104.88 15.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.462 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.59 -31.13 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.226 -0.921 . . . . 0.0 109.215 -179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.68 -11.41 59.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.03 145.07 15.09 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -45.96 151.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.505 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.17 119.9 3.58 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -86.77 129.01 35.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.479 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.3 t -76.5 131.94 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.857 HD11 ' HB2' ' A' ' 36' ' ' GLU . 39.5 mt -95.04 -51.17 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.169 -0.957 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -174.07 163.5 3.96 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.474 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.717 HD23 HG23 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -108.41 139.21 43.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 109.449 -179.99 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.7 15.11 11.68 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.717 HG23 HD23 ' A' ' 18' ' ' LEU . 1.9 m -149.87 164.22 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.887 . . . . 0.0 109.527 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -114.9 -163.87 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.337 -0.852 . . . . 0.0 109.493 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.4 t -84.96 139.86 31.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.302 -0.874 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.01 8.37 61.2 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.449 ' C ' HG23 ' A' ' 51' ' ' VAL . 11.7 m-20 -84.95 133.02 34.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.207 -1.173 . . . . 0.0 109.522 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 1.1 tp -79.98 125.49 29.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.268 -0.895 . . . . 0.0 109.475 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.747 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.04 -171.41 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.251 -0.906 . . . . 0.0 109.204 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.722 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.4 mt-10 -135.16 175.39 9.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.432 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.6 p -85.15 64.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.505 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.88 -43.68 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.496 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.9 tt0 -45.25 149.59 0.5 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.518 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.442 ' N ' ' HG2' ' A' ' 30' ' ' GLN . . . -74.39 166.89 54.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.823 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -126.94 -37.5 2.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -1.175 . . . . 0.0 109.561 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.624 HG22 ' HB ' ' A' ' 44' ' ' VAL . 23.5 m -152.85 154.32 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.561 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.592 HG22 ' OE2' ' A' ' 43' ' ' GLU . 60.5 t -125.74 91.93 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.307 -0.871 . . . . 0.0 109.419 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mp -89.98 153.75 20.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.51 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.857 ' HB2' HD11 ' A' ' 16' ' ' ILE . 38.3 tt0 -143.36 134.46 25.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.274 -0.891 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.61 174.24 7.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.881 . . . . 0.0 109.547 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.0 -13.18 57.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.46 -56.27 3.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -0.935 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -164.72 -149.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.927 . . . . 0.0 109.401 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.7 p -136.34 144.59 44.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -136.85 -175.97 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.592 ' OE2' HG22 ' A' ' 34' ' ' VAL . 6.4 tt0 -150.24 162.18 40.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.52 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.624 ' HB ' HG22 ' A' ' 33' ' ' VAL . 38.2 t -147.5 101.37 3.76 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.262 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.525 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.6 Cg_endo -77.2 -168.94 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.399 2.066 . . . . 0.0 110.506 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.823 ' HA ' HD12 ' A' ' 32' ' ' LEU . 3.8 t -85.28 132.52 44.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.441 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.503 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.87 -5.28 14.55 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 C-N-CA 122.489 2.126 . . . . 0.0 110.402 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' A' ' 46' ' ' SER . 5.6 tptt -160.23 144.71 14.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.35 -0.844 . . . . 0.0 109.491 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.95 91.05 4.17 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.791 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -139.69 -135.19 3.22 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.554 ' N ' HD11 ' A' ' 72' ' ' LEU . 7.2 p -149.08 150.57 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -1.178 . . . . 0.0 109.535 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.0 t -73.01 129.45 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 3.5 tttp -113.63 -27.59 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.266 -0.896 . . . . 0.0 109.564 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -154.61 128.28 8.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.176 -0.953 . . . . 0.0 109.508 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.553 HG12 ' H ' ' A' ' 57' ' ' VAL . 75.8 t -113.08 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.465 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.37 34.79 4.95 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.553 ' H ' HG12 ' A' ' 55' ' ' VAL . 3.4 m -140.75 170.18 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.26 -0.9 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.443 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -132.59 157.77 43.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.926 . . . . 0.0 109.454 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -83.09 131.79 35.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.496 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.81 -11.48 68.72 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.443 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.7 OUTLIER -81.65 163.93 22.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -1.182 . . . . 0.0 109.435 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 mttt -104.13 120.24 40.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.475 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.434 HD13 ' HA ' ' A' ' 63' ' ' LEU . 1.2 mm? -105.47 137.28 43.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.467 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -101.47 140.32 35.93 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.278 -0.888 . . . . 0.0 109.469 179.964 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.2 OUTLIER -42.76 151.6 0.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.29 -0.881 . . . . 0.0 109.675 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.09 -24.54 21.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.47 134.49 34.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.289 -1.124 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.49 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -59.23 179.23 0.11 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.513 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.836 HD11 HG23 ' A' ' 6' ' ' VAL . 31.8 mm -134.73 -67.63 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.178 -0.951 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.748 HG23 HG22 ' A' ' 69' ' ' ILE . 2.6 pp -147.82 -172.1 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.73 ' N ' HD12 ' A' ' 70' ' ' ILE . 14.5 mt-10 -144.62 136.48 25.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.791 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.3 tp -113.01 112.32 23.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 53' ' ' LYS . 23.7 tt0 -113.78 90.38 18.48 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.602 ' O ' ' HB2' ' A' ' 75' ' ' ALA . 35.8 Cg_endo -78.1 -85.54 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.612 2.208 . . . . 0.0 110.484 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.602 ' HB2' ' O ' ' A' ' 74' ' ' PRO . . . 170.39 67.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.425 ' O ' ' O ' ' A' ' 77' ' ' GLY . . . -77.13 147.97 36.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . -47.44 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 77' ' ' GLY . . . 179.81 -161.51 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -1.171 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.928 -1.034 . . . . 0.0 109.409 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 48.6 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -97.02 175.75 6.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.473 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.561 ' H ' HD12 ' A' ' 3' ' ' ILE . 3.7 mp -104.76 146.97 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.2 mt -104.25 99.26 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.44 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -91.26 165.62 13.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.344 -0.847 . . . . 0.0 109.458 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.8 t -55.0 142.22 57.05 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.888 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.14 -172.58 1.53 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.489 2.126 . . . . 0.0 110.387 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -84.03 104.33 14.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.902 . . . . 0.0 109.503 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.465 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.79 -41.42 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.297 -0.877 . . . . 0.0 109.354 -179.929 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.69 10.73 52.5 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -146.04 -125.14 1.68 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.65 123.67 38.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.15 . . . . 0.0 109.393 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.68 147.43 50.94 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.07 101.79 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -1.119 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.734 HG11 ' O ' ' A' ' 58' ' ' LYS . 38.4 t -48.44 149.76 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.8 HD12 HG12 ' A' ' 34' ' ' VAL . 43.9 mt -127.16 -62.22 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 109.454 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -150.11 149.74 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.777 ' CD1' HG12 ' A' ' 33' ' ' VAL . 2.8 tp -119.47 138.84 52.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 HG13 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -127.98 54.35 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.516 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.621 HG13 HD12 ' A' ' 19' ' ' LEU . 15.3 m -144.42 159.8 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.17 -0.956 . . . . 0.0 109.399 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.494 ' CB ' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -111.37 -171.18 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 109.548 179.954 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.4 m -85.18 119.39 25.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.78 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.479 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 72.37 2.17 53.64 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.639 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.494 ' CG ' ' CB ' ' A' ' 21' ' ' LYS . 2.1 m-20 -69.7 129.44 39.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.299 . . . . 0.0 109.123 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.908 HD21 ' HB1' ' A' ' 49' ' ' ALA . 1.0 OUTLIER -90.93 144.14 25.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.413 -0.805 . . . . 0.0 109.728 -179.697 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.987 HD12 ' CA ' ' A' ' 50' ' ' GLY . 1.3 mt -114.58 -170.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.776 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -100.46 172.45 7.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.079 -1.013 . . . . 0.0 109.405 179.963 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.743 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.8 p -83.89 68.64 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.497 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 163.03 -29.73 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -60.13 151.59 26.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.517 179.959 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -67.06 163.61 44.84 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.705 HD22 ' CD1' ' A' ' 70' ' ' ILE . 0.2 OUTLIER -125.75 -38.81 2.18 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.537 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.777 HG12 ' CD1' ' A' ' 18' ' ' LEU . 28.7 m -152.23 171.64 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.8 HG12 HD12 ' A' ' 16' ' ' ILE . 60.7 t -127.91 95.67 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.309 -0.87 . . . . 0.0 109.417 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 mt -89.88 162.14 15.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.922 . . . . 0.0 109.558 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.53 ' CA ' HD11 ' A' ' 16' ' ' ILE . 8.2 tt0 -114.99 164.13 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -135.43 -177.07 4.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -56.49 -44.06 80.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -0.886 . . . . 0.0 109.471 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.47 48.42 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -176.0 124.03 0.19 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.522 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.0 125.68 32.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.342 -0.849 . . . . 0.0 109.484 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.462 ' SD ' ' HG2' ' A' ' 7' ' ' PRO . 2.3 ptm -115.98 129.9 56.58 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -96.64 167.18 11.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.208 -0.933 . . . . 0.0 109.415 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 2.7 t -144.37 100.1 4.86 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.242 -0.911 . . . . 0.0 109.366 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.2 Cg_endo -77.68 -170.03 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.411 2.074 . . . . 0.0 110.359 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.458 ' HB2' HD12 ' A' ' 32' ' ' LEU . 6.3 t -85.96 142.66 36.61 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.432 -0.792 . . . . 0.0 109.364 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.617 ' HD2' HD13 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.37 -10.94 16.07 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.484 2.122 . . . . 0.0 110.174 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.37 -91.73 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.559 -0.713 . . . . 0.0 109.121 179.887 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.908 ' HB1' HD21 ' A' ' 25' ' ' LEU . . . -85.2 -92.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.29 -0.882 . . . . 0.0 109.229 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.987 ' CA ' HD12 ' A' ' 26' ' ' ILE . . . 139.98 41.04 0.08 OUTLIER Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.1 p -95.56 115.15 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.1 -1.235 . . . . 0.0 109.346 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' A' ' 23' ' ' GLY . 40.6 t -69.26 116.15 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.443 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -108.21 -25.25 11.16 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.174 -0.954 . . . . 0.0 109.513 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.85 123.33 1.73 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.514 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 70' ' ' ILE . 90.1 t -112.58 135.27 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.464 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -126.38 39.73 3.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.52 HG11 HG23 ' A' ' 69' ' ' ILE . 27.1 m -149.91 167.23 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.734 ' O ' HG11 ' A' ' 15' ' ' VAL . 4.2 tttt -125.39 167.99 14.18 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.43 87.42 7.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.6 -11.87 4.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -75.45 146.67 40.5 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -1.118 . . . . 0.0 109.566 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.407 ' C ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -105.14 146.62 28.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.209 -0.932 . . . . 0.0 109.484 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 62' ' ' LYS . 13.8 mt -141.47 178.42 7.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.477 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' GLU . 8.7 tttp -118.58 149.32 41.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.181 -0.949 . . . . 0.0 109.537 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.3 pt-20 -42.71 150.33 0.16 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.337 -0.852 . . . . 0.0 109.627 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.68 -15.33 55.41 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -82.28 132.26 35.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -1.148 . . . . 0.0 109.544 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -63.85 161.59 15.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.432 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.52 HG23 HG11 ' A' ' 57' ' ' VAL . 43.9 mm -128.01 -59.71 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.887 . . . . 0.0 109.522 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.705 ' CD1' HD22 ' A' ' 32' ' ' LEU . 3.4 pt -141.44 -171.94 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.51 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 3' ' ' ILE . 1.7 mt-10 -145.8 109.2 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.602 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.668 HD23 ' C ' ' A' ' 72' ' ' LEU . 2.0 tt -90.02 145.42 25.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.3 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.47 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 1.4 mt-10 -106.09 146.27 32.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.694 ' O ' ' HB3' ' A' ' 75' ' ' ALA . 36.1 Cg_endo -78.34 -22.39 9.61 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.587 2.191 . . . . 0.0 110.431 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.694 ' HB3' ' O ' ' A' ' 74' ' ' PRO . . . 76.08 50.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.496 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -137.2 78.97 1.72 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -167.39 -92.11 0.08 OUTLIER Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -53.45 178.03 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.51 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.6 mtm105 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.429 -179.987 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.485 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 2.5 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mt-10 -125.2 169.19 12.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.24 -0.913 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mt -99.61 137.34 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.535 HG21 ' HG3' ' A' ' 47' ' ' PRO . 31.6 mm -113.82 119.05 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.239 -0.913 . . . . 0.0 109.485 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.701 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -106.23 -177.96 3.51 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.476 -179.927 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.6 t -81.0 142.27 51.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.355 -0.841 . . . . 0.0 109.342 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.07 -170.74 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.607 2.205 . . . . 0.0 110.433 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -84.51 104.69 14.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.224 -0.923 . . . . 0.0 109.437 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.97 -21.65 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.281 -0.887 . . . . 0.0 109.295 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.78 21.63 76.29 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.0 -165.92 25.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -97.2 140.34 31.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -1.168 . . . . 0.0 109.459 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -111.14 105.17 1.83 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.8 mm-40 -97.22 130.22 44.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.542 ' HA ' HD23 ' A' ' 35' ' ' LEU . 60.3 t -72.91 119.42 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.981 HG22 ' O ' ' A' ' 34' ' ' VAL . 1.6 tt -112.55 -24.33 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -145.99 140.44 26.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.51 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.55 127.37 34.96 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.54 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -120.7 47.32 1.82 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.897 . . . . 0.0 109.414 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.465 HG11 ' CD1' ' A' ' 32' ' ' LEU . 3.2 m -150.07 158.19 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.6 mmtt -138.05 -174.0 3.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.9 m -84.4 141.18 31.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.481 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.7 1.83 62.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.89 130.27 34.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -1.196 . . . . 0.0 109.485 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -86.12 119.3 26.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.88 . . . . 0.0 109.387 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.053 HD13 HD21 ' A' ' 32' ' ' LEU . 2.4 mt -90.01 -171.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.209 -0.932 . . . . 0.0 109.201 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.717 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -150.17 163.34 38.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.433 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.49 147.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.161 -0.962 . . . . 0.0 109.411 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 83.07 -43.61 0.11 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.688 -0.632 . . . . 0.0 109.863 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.524 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -55.41 144.27 26.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.078 -1.014 . . . . 0.0 109.43 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.32 172.38 38.27 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 1.053 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -133.04 -51.84 0.9 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.542 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.9 m -153.6 175.75 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.141 -0.974 . . . . 0.0 109.617 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.981 ' O ' HG22 ' A' ' 16' ' ' ILE . 84.4 t -130.8 94.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.87 . . . . 0.0 109.425 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.542 HD23 ' HA ' ' A' ' 15' ' ' VAL . 13.2 mt -90.14 151.86 21.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -106.05 112.02 24.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.291 -0.881 . . . . 0.0 109.432 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.64 -172.12 3.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -0.907 . . . . 0.0 109.525 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.32 6.64 13.67 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.51 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -112.47 -36.89 5.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.178 -0.951 . . . . 0.0 109.518 179.93 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.524 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.44 -152.37 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.243 -0.911 . . . . 0.0 109.429 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 8.3 t -106.05 112.55 25.64 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.251 -0.906 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -106.95 151.81 24.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -110.31 150.43 28.77 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.176 -0.952 . . . . 0.0 109.452 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.8 t -132.73 118.24 15.51 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.897 . . . . 0.0 109.261 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.1 Cg_endo -77.7 -168.65 0.63 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.33 2.02 . . . . 0.0 110.451 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.518 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -85.35 126.32 67.34 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.345 -0.847 . . . . 0.0 109.339 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.535 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.9 Cg_endo -78.44 -0.9 11.12 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.377 2.052 . . . . 0.0 110.374 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.499 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.18 127.31 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.76 99.54 5.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 109.46 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.902 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.93 -137.79 2.42 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 9.5 p -137.19 146.94 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.202 -1.176 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 52.2 t -69.73 133.39 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.303 -0.873 . . . . 0.0 109.518 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.404 ' CD ' ' HB2' ' A' ' 73' ' ' GLU . 0.3 OUTLIER -110.79 -58.23 2.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.313 -0.867 . . . . 0.0 109.482 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 14.1 m -124.52 164.95 18.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.498 ' HA ' HG22 ' A' ' 70' ' ' ILE . 53.7 t -124.74 118.98 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.268 -0.895 . . . . 0.0 109.452 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.21 15.25 27.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.448 HG11 HD11 ' A' ' 63' ' ' LEU . 21.0 m -149.85 173.44 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.241 -0.912 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.42 ' HB3' ' OD2' ' A' ' 61' ' ' ASP . 6.0 tptt -134.47 173.67 11.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.253 -0.905 . . . . 0.0 109.46 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.73 124.29 31.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.65 -10.71 57.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.42 ' OD2' ' HB3' ' A' ' 58' ' ' LYS . 3.0 m-20 -81.74 165.35 21.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -1.093 . . . . 0.0 109.571 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 165.12 13.06 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.499 ' HA ' HD23 ' A' ' 63' ' ' LEU . 5.3 mt -149.35 104.97 3.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.8 OUTLIER -86.99 137.89 31.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 10.3 pt-20 -42.77 151.57 0.12 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.19 -19.75 37.31 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -84.87 144.9 28.1 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.246 -1.15 . . . . 0.0 109.483 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -72.56 -178.8 2.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.701 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.0 mp -139.82 -68.08 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.412 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.498 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.0 OUTLIER -148.9 -177.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.448 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -132.89 117.83 18.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.987 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.8 tt -93.78 143.33 26.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.204 -0.935 . . . . 0.0 109.526 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.404 ' HB2' ' CD ' ' A' ' 53' ' ' LYS . 0.1 OUTLIER -113.53 91.03 19.15 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.363 -0.836 . . . . 0.0 109.381 179.988 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.987 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.02 177.9 8.23 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.668 2.246 . . . . 0.0 110.441 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -170.76 153.08 3.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.27 -0.894 . . . . 0.0 109.385 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -93.25 155.07 17.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.392 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.34 -48.15 5.18 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 47.13 55.72 7.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -1.168 . . . . 0.0 109.495 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.482 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 76.8 p . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.284 0.564 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.6 mt-10 -139.37 160.61 39.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.48 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.519 ' H ' HD12 ' A' ' 3' ' ' ILE . 2.5 mp -85.17 136.07 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.905 . . . . 0.0 109.528 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.751 HD13 ' HG2' ' A' ' 47' ' ' PRO . 10.3 mt -105.49 120.21 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.92 168.55 10.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.189 -0.944 . . . . 0.0 109.486 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 78.3 t -49.68 142.48 12.17 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.268 -0.895 . . . . 0.0 109.322 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.69 -174.72 2.34 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.462 2.108 . . . . 0.0 110.393 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.91 100.86 8.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.712 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.41 -14.91 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.272 -0.892 . . . . 0.0 109.291 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.38 -21.26 32.87 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -128.82 -145.5 5.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.95 142.3 30.63 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -1.163 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.15 103.29 2.13 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.458 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.1 mt-10 -101.7 119.75 39.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.296 -1.12 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.97 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.7 t -78.83 131.93 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.464 179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.442 ' O ' ' HG3' ' A' ' 17' ' ' GLU . 8.8 mm -108.93 -40.48 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.9 . . . . 0.0 109.498 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.442 ' HG3' ' O ' ' A' ' 16' ' ' ILE . 64.9 mt-10 -157.17 -177.77 6.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.426 -179.967 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.501 HD12 HG12 ' A' ' 33' ' ' VAL . 11.3 tp -137.03 145.96 44.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.471 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.467 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -136.8 36.35 2.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.554 -179.95 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 32' ' ' LEU . 3.7 m -149.94 156.61 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.29 -0.881 . . . . 0.0 109.558 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.24 175.71 5.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.181 -0.949 . . . . 0.0 109.469 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.6 m -84.95 146.39 27.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.546 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.525 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 78.48 3.32 86.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.02 133.14 34.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -1.165 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.602 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -83.65 108.12 16.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.197 -0.939 . . . . 0.0 109.432 -179.991 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.53 -171.4 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.1 mt-10 -147.03 -178.95 6.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.421 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.725 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.4 p -82.7 73.67 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.87 -42.36 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.334 -0.853 . . . . 0.0 109.435 179.836 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.43 ' HB3' HG22 ' A' ' 26' ' ' ILE . 18.6 tt0 -50.81 135.69 23.49 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.174 -0.954 . . . . 0.0 109.455 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.467 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -52.88 179.99 0.08 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.592 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -146.24 -67.99 0.28 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.21 -1.171 . . . . 0.0 109.535 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.501 HG12 HD12 ' A' ' 18' ' ' LEU . 30.9 m -133.01 169.63 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.523 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.9 HG22 ' HG2' ' A' ' 43' ' ' GLU . 24.4 t -119.09 79.2 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.261 -0.899 . . . . 0.0 109.452 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.97 HD23 ' HA ' ' A' ' 15' ' ' VAL . 5.9 mt -90.05 151.73 21.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.53 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.424 ' HG3' ' OG ' ' A' ' 41' ' ' SER . 2.3 tm-20 -140.79 141.84 34.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.33 -0.857 . . . . 0.0 109.495 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.03 -177.95 3.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -0.896 . . . . 0.0 109.523 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.95 -12.46 37.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.278 -0.889 . . . . 0.0 109.472 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.51 -67.96 0.77 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.264 -0.897 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.19 175.41 14.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -0.937 . . . . 0.0 109.461 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.424 ' OG ' ' HG3' ' A' ' 36' ' ' GLU . 0.9 OUTLIER -95.01 137.21 34.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 109.473 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.22 124.83 11.76 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.916 . . . . 0.0 109.5 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.9 ' HG2' HG22 ' A' ' 34' ' ' VAL . 7.1 mt-10 -84.52 166.86 16.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.488 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.496 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 54.1 t -137.03 134.59 19.09 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.24 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.23 -168.4 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.412 2.075 . . . . 0.0 110.316 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.1 130.88 50.4 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.302 -0.874 . . . . 0.0 109.353 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.751 ' HG2' HD13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.53 -1.48 11.64 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.416 2.078 . . . . 0.0 110.394 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.755 ' HD2' HD22 ' A' ' 72' ' ' LEU . 33.6 ttmt -160.28 140.69 11.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 109.561 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.09 101.21 12.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.925 . . . . 0.0 109.493 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.909 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -158.58 -162.35 11.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.525 HG22 ' HA2' ' A' ' 23' ' ' GLY . 9.9 p -111.03 129.17 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.295 -1.12 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -54.02 138.63 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.49 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.12 -35.67 4.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 t -174.78 149.48 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.175 -0.953 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.772 HG13 HG22 ' A' ' 70' ' ' ILE . 11.1 t -108.53 148.45 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.452 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 59.4 m -113.35 18.22 17.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.641 ' H ' HG12 ' A' ' 55' ' ' VAL . 30.2 m -147.12 158.47 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.503 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.448 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -120.17 -175.21 2.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 -179.946 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.484 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -77.04 147.75 36.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.265 -0.897 . . . . 0.0 109.416 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.33 11.62 53.05 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.448 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -84.74 132.25 34.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.186 -1.185 . . . . 0.0 109.492 179.997 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.56 118.37 36.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.561 HD23 ' HB3' ' A' ' 67' ' ' ASP . 3.1 mp -122.6 162.55 21.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.1 tttp -102.75 146.79 27.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.431 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.5 OUTLIER -42.9 148.04 0.27 Allowed 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.312 -0.868 . . . . 0.0 109.661 -179.877 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.7 -8.07 74.0 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.561 ' HB3' HD23 ' A' ' 63' ' ' LEU . 1.2 m-20 -83.96 140.18 32.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -1.103 . . . . 0.0 109.487 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.408 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.36 164.16 0.21 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.422 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.596 HG22 HG23 ' A' ' 70' ' ' ILE . 17.7 mm -141.13 -54.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.182 -0.948 . . . . 0.0 109.449 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG13 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -150.65 -178.23 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.931 . . . . 0.0 109.585 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -139.43 135.61 33.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.93 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.5 tt -116.44 146.76 42.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 23.6 tt0 -118.35 88.62 33.73 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.486 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.93 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -77.95 106.76 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.568 2.178 . . . . 0.0 110.466 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -99.64 178.62 4.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.253 -0.904 . . . . 0.0 109.461 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -160.67 143.03 12.76 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 179.949 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -142.57 140.75 10.12 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -69.9 103.76 2.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.184 -1.186 . . . . 0.0 109.443 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.452 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.4 p . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 3' ' ' ILE . 20.9 mp0 -89.43 161.81 16.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.34 -0.85 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.741 ' N ' HD12 ' A' ' 3' ' ' ILE . 3.2 mp -110.74 139.26 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.903 . . . . 0.0 109.466 -179.978 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -111.19 138.27 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.228 -0.92 . . . . 0.0 109.451 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.448 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 3.0 ptt180 -121.55 166.66 13.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.734 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.3 t -48.5 142.2 8.68 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.244 -0.91 . . . . 0.0 109.36 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.734 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.09 -171.45 1.21 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.483 2.122 . . . . 0.0 110.423 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.09 101.54 12.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.492 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.11 -26.36 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.24 -0.912 . . . . 0.0 109.255 -179.922 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 34.9 5.47 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 153.04 -133.58 4.09 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -118.08 168.2 10.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -1.112 . . . . 0.0 109.463 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.1 128.61 2.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.461 ' OE2' ' O ' ' A' ' 15' ' ' VAL . 3.3 tm-20 -89.2 134.65 33.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -1.144 . . . . 0.0 109.427 179.956 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.461 ' O ' ' OE2' ' A' ' 14' ' ' GLU . 19.2 t -74.72 156.57 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.505 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -115.56 -58.49 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.492 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.71 161.91 41.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.0 111.54 20.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -0.88 . . . . 0.0 109.472 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.16 32.91 1.62 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.03 161.98 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.467 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.426 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.24 -177.07 4.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.205 -0.934 . . . . 0.0 109.469 179.999 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.0 m -81.34 143.18 32.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.234 -0.916 . . . . 0.0 109.504 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.58 90.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.426 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 22.7 m-20 -85.07 139.45 31.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -1.198 . . . . 0.0 109.435 -179.961 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.542 ' O ' HD23 ' A' ' 25' ' ' LEU . 6.8 tt -103.43 108.97 20.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.9 OUTLIER -90.15 -171.39 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.212 -0.93 . . . . 0.0 109.234 179.985 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.4 pt-20 -138.22 -178.28 5.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.119 -0.988 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 28' ' ' VAL . 9.9 p -82.27 74.57 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.48 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER 162.91 -55.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.901 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 29' ' ' GLU . 1.4 tt0 -44.41 141.01 2.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.87 . . . . 0.0 109.494 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.455 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -70.77 178.67 32.1 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.521 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -141.35 -42.18 0.37 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -1.169 . . . . 0.0 109.453 179.926 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.6 HG22 ' HB ' ' A' ' 44' ' ' VAL . 20.3 m -152.04 155.29 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 -179.986 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 16' ' ' ILE . 58.7 t -114.84 107.75 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.232 -0.918 . . . . 0.0 109.451 -179.903 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 15' ' ' VAL . 1.8 mp -98.11 -178.38 4.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -147.54 140.08 24.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.938 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.4 p -107.07 -177.67 3.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.58 -65.45 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.238 -0.913 . . . . 0.0 109.425 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 mppt? -129.54 55.91 1.74 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.496 -179.952 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -170.85 -161.56 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.278 -0.889 . . . . 0.0 109.512 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.09 149.73 30.71 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.296 -0.877 . . . . 0.0 109.448 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' HG22 ' A' ' 9' ' ' ILE . 69.5 mmm -146.06 104.42 3.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -0.947 . . . . 0.0 109.383 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.95 171.98 13.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -0.921 . . . . 0.0 109.538 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.6 ' HB ' HG22 ' A' ' 33' ' ' VAL . 48.9 t -146.15 98.48 4.35 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.263 -0.898 . . . . 0.0 109.389 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.5 Cg_endo -77.5 -168.09 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.492 2.128 . . . . 0.0 110.527 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.489 ' CB ' ' HB ' ' A' ' 26' ' ' ILE . 6.5 t -85.09 113.65 51.37 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.45 -179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.4 Cg_endo -78.06 3.01 7.41 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.364 2.043 . . . . 0.0 110.329 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.588 ' O ' HD13 ' A' ' 72' ' ' LEU . 6.0 mttt -160.01 114.94 2.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.312 -0.868 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.1 91.95 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.944 . . . . 0.0 109.533 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 1.01 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.39 -171.86 22.41 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 10.9 p -100.77 155.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -1.185 . . . . 0.0 109.517 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.2 t -81.37 138.62 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -0.923 . . . . 0.0 109.536 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -104.34 -66.9 0.93 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -137.92 148.7 45.55 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.474 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.56 HG12 ' H ' ' A' ' 57' ' ' VAL . 12.0 t -101.65 133.65 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -112.87 13.98 19.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.142 -0.974 . . . . 0.0 109.567 179.962 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.6 HG11 HD13 ' A' ' 69' ' ' ILE . 2.0 m -137.46 158.77 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.219 -0.926 . . . . 0.0 109.478 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.15 158.68 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.238 -0.914 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.8 pp -82.68 137.64 34.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.931 . . . . 0.0 109.53 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.95 -14.52 65.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -83.68 168.07 16.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.14 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.795 ' O ' HD23 ' A' ' 63' ' ' LEU . 8.5 mtmt -97.38 140.77 31.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -0.855 . . . . 0.0 109.442 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 62' ' ' LYS . 6.5 mt -123.97 116.05 22.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.497 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 65' ' ' GLU . 4.3 tttt -90.48 139.69 30.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.303 -0.873 . . . . 0.0 109.472 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.445 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 15.6 pt-20 -42.76 149.19 0.2 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.313 -0.867 . . . . 0.0 109.645 -179.896 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.71 -14.88 58.88 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 91.6 m-20 -85.01 140.06 31.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.285 -1.126 . . . . 0.0 109.471 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -62.37 -179.43 0.24 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.213 -0.929 . . . . 0.0 109.506 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.684 HG22 HG23 ' A' ' 70' ' ' ILE . 28.6 mm -147.95 -72.19 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.447 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.684 HG23 HG22 ' A' ' 69' ' ' ILE . 3.8 pt -142.37 -172.52 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.932 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -140.29 112.2 7.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.011 HD23 ' HD3' ' A' ' 74' ' ' PRO . 3.6 tt -90.06 141.96 28.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -113.24 91.69 20.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.21 -0.932 . . . . 0.0 109.535 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 1.011 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.1 Cg_endo -78.13 115.24 3.71 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.602 2.201 . . . . 0.0 110.35 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -77.6 -81.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.31 -0.869 . . . . 0.0 109.46 179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 118.63 14.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.468 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -153.78 -135.49 2.13 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -105.57 72.56 0.97 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.245 -1.15 . . . . 0.0 109.544 179.944 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.451 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 68.8 p . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -147.42 150.48 34.74 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.635 HD12 ' HB2' ' A' ' 71' ' ' GLU . 1.4 tp -93.03 130.73 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.6 mm -93.81 124.22 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.388 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 3.5 ptt-85 -118.52 159.16 24.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 9' ' ' ILE . 84.3 t -43.33 103.51 0.32 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.344 -0.847 . . . . 0.0 109.442 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.472 ' O ' HG12 ' A' ' 9' ' ' ILE . 35.9 Cg_endo -77.78 -169.54 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.511 2.14 . . . . 0.0 110.45 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -68.26 99.7 0.95 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.283 -0.886 . . . . 0.0 109.413 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.883 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.0 -43.0 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.305 -179.877 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.55 34.61 0.65 Allowed Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 147.21 -132.74 4.45 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -101.5 135.27 43.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.65 115.78 4.31 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.476 ' HG2' ' CB ' ' A' ' 62' ' ' LYS . 12.9 mt-10 -112.36 104.32 12.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -1.152 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.649 ' O ' HD13 ' A' ' 16' ' ' ILE . 42.7 t -54.17 136.23 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.515 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.649 HD13 ' O ' ' A' ' 15' ' ' VAL . 29.2 mm -128.04 -37.42 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.83 155.27 43.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.59 123.59 46.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 32' ' ' LEU . 6.3 mt -93.77 9.36 37.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.535 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.7 m -146.42 175.42 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 179.949 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.423 ' O ' HG21 ' A' ' 52' ' ' VAL . 5.2 ttpp -139.31 -164.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.272 -0.892 . . . . 0.0 109.49 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.4 m -84.83 139.41 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.918 . . . . 0.0 109.509 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.87 10.56 51.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -85.04 134.72 34.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.195 -1.179 . . . . 0.0 109.454 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.629 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -88.24 118.25 27.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.804 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -97.04 -171.41 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.239 -0.913 . . . . 0.0 109.234 -179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.707 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.3 tt0 -147.81 153.99 39.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 28' ' ' VAL . 6.3 p -72.03 84.35 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.248 -0.907 . . . . 0.0 109.506 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.79 -32.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.336 -0.853 . . . . 0.0 109.473 179.877 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -78.66 153.27 31.14 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.233 -0.917 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.38 -160.07 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.804 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -160.01 -72.74 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -1.166 . . . . 0.0 109.459 179.983 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.54 HG21 HD11 ' A' ' 35' ' ' LEU . 8.5 m -119.45 150.92 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.792 HG22 ' OE1' ' A' ' 43' ' ' GLU . 23.9 t -117.91 83.22 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.54 HD11 HG21 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -91.13 147.52 23.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.44 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.39 152.84 21.13 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.169 -0.957 . . . . 0.0 109.411 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -98.72 -175.62 3.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.28 -0.888 . . . . 0.0 109.481 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.61 94.78 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.6 mttm -142.4 48.33 1.56 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.413 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -177.13 -158.76 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.51 152.94 37.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.388 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtp -159.26 142.47 14.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.792 ' OE1' HG22 ' A' ' 34' ' ' VAL . 24.0 mt-10 -132.65 162.8 30.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.7 t -131.02 140.08 37.57 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.309 -0.869 . . . . 0.0 109.345 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.515 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.21 -168.59 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.581 2.188 . . . . 0.0 110.421 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.483 ' HB2' HG21 ' A' ' 26' ' ' ILE . 28.9 t -85.27 113.64 51.6 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.398 -0.814 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.03 0.49 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.348 2.032 . . . . 0.0 110.425 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.76 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.09 104.75 1.51 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.338 -0.851 . . . . 0.0 109.491 179.951 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.35 101.87 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.467 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.943 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -159.36 -150.19 5.75 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.867 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.524 ' HB ' HD21 ' A' ' 25' ' ' LEU . 8.1 p -116.51 132.35 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -1.14 . . . . 0.0 109.478 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 21' ' ' LYS . 63.7 t -56.3 126.84 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.01 -50.1 5.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.163 -0.96 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -169.64 153.26 4.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.349 -0.844 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.753 HG12 ' H ' ' A' ' 57' ' ' VAL . 25.9 t -111.69 136.34 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.301 -0.874 . . . . 0.0 109.457 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -94.79 17.4 13.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.271 -0.893 . . . . 0.0 109.471 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.788 HG11 HD22 ' A' ' 63' ' ' LEU . 1.6 m -145.28 176.88 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.274 -0.891 . . . . 0.0 109.386 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -112.34 -178.91 3.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.19 -0.944 . . . . 0.0 109.522 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -82.3 136.85 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.93 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.41 18.08 76.65 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 4.4 m-20 -83.68 144.14 29.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -103.66 120.94 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.515 179.961 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.788 HD22 HG11 ' A' ' 57' ' ' VAL . 1.3 mp -121.73 175.57 6.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.907 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' GLU . 3.5 tttp -118.31 145.75 44.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 3.2 pt-20 -42.85 137.48 2.3 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.341 -0.849 . . . . 0.0 109.584 -179.884 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.53 -25.93 16.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -84.89 140.76 30.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -1.124 . . . . 0.0 109.448 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -65.04 -174.11 0.14 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.423 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 69' ' ' ILE . 28.7 mm -143.3 -65.33 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.264 -0.897 . . . . 0.0 109.49 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.699 ' CG2' HG13 ' A' ' 55' ' ' VAL . 1.8 pt -141.95 -175.11 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.899 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.635 ' HB2' HD12 ' A' ' 3' ' ' ILE . 1.8 tt0 -149.56 114.37 5.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.296 -0.877 . . . . 0.0 109.498 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.943 HD21 ' HA3' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -93.27 148.02 22.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.423 -179.911 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.413 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 3.6 tt0 -132.91 91.22 29.67 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.493 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.839 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -77.96 176.41 10.02 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.627 2.218 . . . . 0.0 110.44 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -80.37 179.37 7.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.201 -0.937 . . . . 0.0 109.501 -179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -172.7 107.81 0.18 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.18 -0.95 . . . . 0.0 109.471 179.946 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.633 ' O ' ' HB3' ' A' ' 78' ' ' ALA . . . 87.31 78.22 1.25 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.633 ' HB3' ' O ' ' A' ' 77' ' ' GLY . . . 71.24 115.27 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -1.136 . . . . 0.0 109.489 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.419 -179.989 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 89.1 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -122.35 151.07 41.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.476 ' C ' HD12 ' A' ' 4' ' ' ILE . 4.3 mp -90.94 154.36 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.513 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.1 mp -120.81 107.57 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.479 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -101.55 170.64 8.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.385 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.719 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -61.26 142.27 93.6 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.374 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.719 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.08 -169.77 0.83 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.561 2.174 . . . . 0.0 110.458 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -82.88 105.15 13.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.416 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.8 -59.5 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.389 -179.954 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.04 -11.68 10.78 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.05 -141.28 4.22 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.414 ' OD1' ' HE2' ' A' ' 64' ' ' LYS . 0.1 OUTLIER -98.66 164.17 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -1.127 . . . . 0.0 109.516 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.59 95.47 0.47 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -97.0 126.16 41.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.282 -1.128 . . . . 0.0 109.428 -179.953 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.643 HG22 ' CD2' ' A' ' 35' ' ' LEU . 19.2 t -77.09 133.6 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.93 . . . . 0.0 109.512 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.559 HD11 ' HB2' ' A' ' 36' ' ' GLU . 19.2 mt -121.38 -37.58 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.395 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.56 137.6 43.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.192 -0.942 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.423 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -122.43 119.29 30.56 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -117.81 50.34 1.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.431 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -147.36 159.34 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -148.74 -176.3 5.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.427 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.5 m -84.63 126.47 33.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.449 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.88 6.9 64.94 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 180.0 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 57.2 m-20 -83.66 131.9 34.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.46 HD12 ' HB ' ' A' ' 51' ' ' VAL . 7.2 tp -92.94 106.48 18.43 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.534 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.714 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -91.77 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.215 -0.928 . . . . 0.0 109.151 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.714 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.7 mt-10 -144.7 176.51 9.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.925 . . . . 0.0 109.412 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.768 HG13 ' O ' ' A' ' 28' ' ' VAL . 14.4 p -81.96 72.95 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.205 -0.934 . . . . 0.0 109.535 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.83 -44.57 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.331 -0.856 . . . . 0.0 109.397 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -51.13 142.42 12.53 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.209 -0.932 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.457 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.61 175.47 4.68 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.724 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.6 OUTLIER -138.51 -62.24 0.57 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.358 -179.979 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.38 159.86 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.932 . . . . 0.0 109.457 -179.943 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 65.1 t -114.66 84.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.643 ' CD2' HG22 ' A' ' 15' ' ' VAL . 7.3 mt -94.68 159.55 15.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.559 ' HB2' HD11 ' A' ' 16' ' ' ILE . 0.3 OUTLIER -124.15 161.23 26.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.913 . . . . 0.0 109.49 -179.96 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -139.44 172.02 13.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.465 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.02 -13.39 62.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.312 -0.867 . . . . 0.0 109.54 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.535 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mptt -87.42 -38.84 15.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.535 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.07 -174.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.514 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.49 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 0.0 OUTLIER -99.15 134.98 41.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.237 -0.915 . . . . 0.0 109.453 -179.975 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.447 ' O ' ' HG3' ' A' ' 42' ' ' MET . 0.4 OUTLIER -155.16 132.26 10.89 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.449 -179.959 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -94.53 -179.71 4.99 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.5 t -144.36 128.94 9.24 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.224 -0.923 . . . . 0.0 109.304 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.457 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.5 -168.62 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.334 2.023 . . . . 0.0 110.326 179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.724 ' HA ' HD13 ' A' ' 32' ' ' LEU . 1.9 t -85.31 136.41 37.83 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.362 -0.836 . . . . 0.0 109.359 179.891 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HG2' HG12 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.73 -5.73 14.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.516 2.144 . . . . 0.0 110.495 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.33 139.17 10.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 109.488 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.86 101.57 8.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.444 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.849 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -157.7 -147.75 4.91 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 14.5 p -126.66 152.02 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.219 -1.165 . . . . 0.0 109.502 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 54.3 t -68.66 140.47 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.249 -0.907 . . . . 0.0 109.459 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -109.04 -53.88 2.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -0.933 . . . . 0.0 109.457 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.87 177.95 7.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 57' ' ' VAL . 92.9 t -124.35 125.15 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 21.6 t -105.53 1.67 27.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.198 -0.939 . . . . 0.0 109.645 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 55' ' ' VAL . 3.3 m -147.28 176.3 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.481 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.481 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -129.79 150.4 51.11 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.488 -179.943 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.667 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -61.79 140.67 58.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.889 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.75 -11.96 60.64 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.481 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 8.0 m-20 -78.01 152.62 32.97 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.194 -1.18 . . . . 0.0 109.444 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.426 ' O ' ' HG2' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -114.11 146.26 40.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.971 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.2 mp -147.75 -178.41 6.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -120.22 149.74 41.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.459 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.441 ' N ' ' CD ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -42.87 149.17 0.21 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.839 . . . . 0.0 109.591 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.69 -14.29 65.34 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -84.65 137.73 33.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.25 -1.147 . . . . 0.0 109.491 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.43 ' O ' HG13 ' A' ' 69' ' ' ILE . . . -66.25 176.93 1.59 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.479 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.3 mp -142.1 -61.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.253 -0.904 . . . . 0.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -142.9 -172.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.199 -0.938 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -142.41 106.94 4.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.291 -0.881 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.849 HD11 ' N ' ' A' ' 50' ' ' GLY . 2.7 tt -91.18 135.58 33.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.203 -0.936 . . . . 0.0 109.49 179.929 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.524 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 20.6 tt0 -116.66 142.11 29.15 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.227 -0.921 . . . . 0.0 109.423 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 36.0 Cg_endo -78.27 100.02 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.568 2.179 . . . . 0.0 110.403 179.942 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.605 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . -81.36 161.63 23.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.231 -0.918 . . . . 0.0 109.412 -179.939 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 69.89 19.55 6.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.164 -0.96 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -159.82 133.76 3.44 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.998 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -174.28 145.04 0.98 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -1.163 . . . . 0.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.8 mtp180 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.471 -179.953 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.463 ' HB3' ' HG3' ' A' ' 73' ' ' GLU . 9.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -128.12 133.42 48.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.484 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.492 HD12 ' HB2' ' A' ' 71' ' ' GLU . 2.1 tp -79.95 140.27 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.436 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.68 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.4 mp -101.61 142.41 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 179.991 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -113.95 179.74 3.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.854 . . . . 0.0 109.478 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.68 ' CG1' HD11 ' A' ' 9' ' ' ILE . 49.1 t -61.35 134.4 93.35 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 109.292 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.418 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -170.04 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.457 2.105 . . . . 0.0 110.483 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -79.93 101.41 8.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.473 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.68 HD11 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.24 -49.73 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.284 -179.938 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.64 -17.37 6.89 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.938 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.42 -171.88 28.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.83 148.88 42.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -1.159 . . . . 0.0 109.53 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.53 150.23 18.54 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.9 OUTLIER -118.38 142.33 47.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.176 -1.19 . . . . 0.0 109.465 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.479 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -76.48 135.41 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.521 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.84 HD12 HG12 ' A' ' 34' ' ' VAL . 80.5 mt -100.33 -38.33 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.447 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -172.47 170.12 5.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.533 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 tp -117.15 125.16 50.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.444 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.1 pp -104.7 31.25 4.85 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' CD2' ' A' ' 32' ' ' LEU . 17.2 m -150.0 166.67 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.6 mtmt -128.51 179.06 5.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.902 . . . . 0.0 109.498 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 35.1 m -84.96 141.63 30.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.89 63.34 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -84.89 138.45 32.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -1.22 . . . . 0.0 109.502 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -79.98 131.11 35.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 109.431 179.911 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.84 HD13 HD11 ' A' ' 32' ' ' LEU . 2.4 mt -92.95 -171.56 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.176 -0.952 . . . . 0.0 109.278 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.7 OUTLIER -126.98 175.84 7.78 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.206 -0.933 . . . . 0.0 109.433 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 28' ' ' VAL . 8.3 p -76.55 124.46 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.497 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 4.1 mt-10 63.05 11.92 5.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.245 -0.909 . . . . 0.0 109.656 179.859 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.473 ' HG3' ' HB2' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -74.13 122.57 22.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.356 179.923 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.464 ' N ' ' HB3' ' A' ' 45' ' ' PRO . . . -43.19 152.88 0.28 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.86 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.84 HD11 HD13 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -132.56 -39.25 1.01 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -1.153 . . . . 0.0 109.496 179.943 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -140.92 165.1 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.174 -0.954 . . . . 0.0 109.528 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.84 HG12 HD12 ' A' ' 16' ' ' ILE . 78.4 t -130.59 95.51 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.92 163.57 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.711 ' HB2' HD11 ' A' ' 16' ' ' ILE . 21.2 tt0 -122.94 123.45 40.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.892 . . . . 0.0 109.515 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.443 ' HB2' ' HB3' ' A' ' 40' ' ' ALA . 0.4 OUTLIER -79.91 -173.82 4.08 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.58 -42.1 32.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.539 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.81 18.48 0.69 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' HB2' ' A' ' 37' ' ' SER . . . -120.34 -169.74 1.85 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -158.04 101.75 1.78 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.531 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.432 ' N ' ' SD ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -114.34 143.16 45.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.212 -0.93 . . . . 0.0 109.452 -179.984 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -100.97 164.07 11.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.281 -0.887 . . . . 0.0 109.521 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.07 102.88 10.81 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.362 179.951 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.464 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -77.4 -169.58 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.419 2.079 . . . . 0.0 110.428 -179.823 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.73 139.52 35.39 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.473 179.906 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.437 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.4 Cg_endo -78.96 -10.65 15.28 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.409 2.072 . . . . 0.0 110.328 179.841 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.484 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.5 146.84 15.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.477 -0.764 . . . . 0.0 109.364 179.962 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.97 116.95 17.17 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -0.946 . . . . 0.0 109.399 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 1.003 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -164.36 -149.25 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.4 p -126.34 145.43 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -1.113 . . . . 0.0 109.433 -179.945 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.7 t -65.13 140.41 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.891 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.2 tptp -117.16 -47.11 2.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.401 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.49 163.61 32.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 80.4 t -121.52 118.19 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.0 t -108.22 22.59 15.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.557 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.409 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 34.5 m -144.13 160.35 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.532 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.67 169.2 18.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -0.903 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.424 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -84.97 103.08 13.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.218 -0.926 . . . . 0.0 109.476 -179.955 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.1 -14.06 19.14 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.57 138.62 38.46 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.198 -1.178 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -80.48 152.83 28.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -0.868 . . . . 0.0 109.44 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.479 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 63.2 mt -140.97 136.53 32.27 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 14.3 tttm -105.87 149.05 26.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 0.0 109.486 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.0 OUTLIER -42.88 147.31 0.32 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.37 -0.831 . . . . 0.0 109.583 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 82.57 -4.34 78.79 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 2.5 m-20 -83.09 130.87 35.16 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.289 -1.124 . . . . 0.0 109.423 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -50.5 178.34 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.26 -0.9 . . . . 0.0 109.475 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.433 HG22 HG23 ' A' ' 70' ' ' ILE . 29.5 mm -146.97 -71.48 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.461 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.433 HG23 HG22 ' A' ' 69' ' ' ILE . 0.8 OUTLIER -138.81 -174.58 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.489 180.0 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.492 ' HB2' HD12 ' A' ' 3' ' ' ILE . 0.3 OUTLIER -150.0 102.0 3.07 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.907 . . . . 0.0 109.507 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 1.003 HD11 ' CA ' ' A' ' 50' ' ' GLY . 4.0 tt -91.3 129.01 37.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.289 -0.882 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.534 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -90.07 144.96 32.07 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.367 -179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.5 Cg_endo -78.02 151.87 27.63 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.623 2.215 . . . . 0.0 110.432 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -85.59 -45.54 11.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.902 . . . . 0.0 109.461 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 48.57 -171.62 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.465 -179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -118.81 -71.46 0.37 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 46.35 41.7 9.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.362 -1.081 . . . . 0.0 109.476 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.479 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 84.6 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -107.8 147.26 31.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.587 HD11 ' HB1' ' A' ' 68' ' ' ALA . 13.8 tt -79.93 169.13 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -0.883 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.937 ' O ' HD12 ' A' ' 69' ' ' ILE . 24.6 mm -125.39 119.78 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 -179.938 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.537 ' C ' HD11 ' A' ' 69' ' ' ILE . 3.9 ptm180 -94.93 163.83 13.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.648 ' N ' HD11 ' A' ' 69' ' ' ILE . 86.9 t -69.25 140.03 90.25 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.379 -179.903 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.573 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.73 -168.7 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.589 2.193 . . . . 0.0 110.432 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -75.19 117.67 17.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 109.268 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.448 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -108.57 -47.26 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 109.482 -179.736 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 149.61 -38.9 0.92 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.996 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . 172.29 117.64 0.45 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.92 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' A' ' 11' ' ' GLY . 0.7 OUTLIER 50.33 178.66 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -1.091 . . . . 0.0 109.623 179.892 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.35 111.69 0.36 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.439 ' HB2' ' HD3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -95.95 137.12 35.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.283 -1.128 . . . . 0.0 109.539 179.963 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.539 HG22 HD23 ' A' ' 35' ' ' LEU . 59.9 t -85.12 134.97 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.556 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.707 HD11 ' HG3' ' A' ' 36' ' ' GLU . 44.6 mt -104.31 -30.63 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.204 -0.935 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.423 ' HB2' ' O ' ' A' ' 16' ' ' ILE . 0.5 OUTLIER 175.22 131.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.545 179.976 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.491 HD12 ' H ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -103.12 172.08 7.02 Favored 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -145.32 63.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.473 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.411 HG11 ' CD1' ' A' ' 32' ' ' LEU . 18.0 m -146.36 158.92 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.534 179.972 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.432 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 75.9 mttt -123.47 167.75 13.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.875 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 22' ' ' THR . 11.0 t -79.12 126.82 31.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.428 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 89.29 9.36 67.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' OD1' ' HB2' ' A' ' 21' ' ' LYS . 0.8 OUTLIER -85.02 135.06 34.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.158 -1.201 . . . . 0.0 109.506 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.446 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.7 tt -97.25 104.37 16.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -0.916 . . . . 0.0 109.475 179.959 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.7 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.89 -171.45 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.2 -0.937 . . . . 0.0 109.246 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.7 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.7 mt-10 -137.94 176.5 8.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.749 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.1 p -81.39 79.07 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.455 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 167.49 -55.9 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.42 -0.8 . . . . 0.0 109.319 179.874 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.447 ' OE1' HG23 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -44.66 145.79 0.85 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.946 . . . . 0.0 109.497 179.965 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.45 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.34 -162.74 0.09 OUTLIER Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.03 -71.77 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 109.516 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.464 ' O ' ' HB2' ' A' ' 43' ' ' GLU . 9.5 m -129.9 170.24 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.975 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.453 HG22 ' HB3' ' A' ' 43' ' ' GLU . 77.2 t -129.53 92.12 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 180.0 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.539 HD23 HG22 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -97.04 169.83 9.56 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 179.999 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.707 ' HG3' HD11 ' A' ' 16' ' ' ILE . 0.9 OUTLIER -103.12 178.74 4.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.247 -0.908 . . . . 0.0 109.486 -180.0 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -139.57 -173.09 3.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.28 -0.888 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -53.65 -57.61 10.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.932 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mttt -138.45 58.46 1.66 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.246 -0.909 . . . . 0.0 109.526 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.95 174.17 0.16 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.0 127.88 39.23 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.248 -0.907 . . . . 0.0 109.44 -179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.5 mtt -138.19 142.97 40.01 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -105.97 164.12 12.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.284 -0.885 . . . . 0.0 109.352 179.969 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.5 t -122.31 137.83 28.19 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.309 179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.3 Cg_endo -79.13 -167.99 0.57 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.465 2.11 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.05 116.35 65.05 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.395 -0.816 . . . . 0.0 109.36 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' HG21 ' A' ' 4' ' ' ILE . 35.8 Cg_endo -77.77 4.54 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.381 2.054 . . . . 0.0 110.45 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.679 ' HB3' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.01 111.68 2.0 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.522 -179.976 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.45 95.89 2.3 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.307 -0.871 . . . . 0.0 109.435 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.975 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -164.29 -164.08 18.73 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.428 HG23 ' C ' ' A' ' 23' ' ' GLY . 14.9 p -100.91 133.82 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.229 -1.16 . . . . 0.0 109.519 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 80.4 t -58.82 147.88 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 -30.75 6.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -169.6 159.38 8.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.532 ' HA ' HG22 ' A' ' 70' ' ' ILE . 75.2 t -116.66 106.74 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.137 -0.977 . . . . 0.0 109.47 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.91 21.88 8.08 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.261 -0.899 . . . . 0.0 109.417 179.955 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.525 HG21 HG22 ' A' ' 69' ' ' ILE . 15.8 m -144.1 160.51 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.57 171.15 12.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 179.966 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.07 119.2 22.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.424 -179.963 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.77 -10.02 48.4 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.17 159.93 33.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.269 -1.136 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.868 ' O ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -113.52 135.07 54.29 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.507 179.958 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.868 HD12 ' O ' ' A' ' 62' ' ' LYS . 1.2 mp -142.68 155.05 44.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.175 -0.953 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.437 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.43 147.96 26.98 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.522 -179.933 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 64' ' ' LYS . 4.1 pt-20 -43.04 141.24 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.77 -8.89 73.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.494 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -84.49 132.06 34.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -1.169 . . . . 0.0 109.519 179.974 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.587 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -56.08 156.1 5.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.396 -0.815 . . . . 0.0 109.44 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.937 HD12 ' O ' ' A' ' 4' ' ' ILE . 1.4 mp -129.82 -43.8 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.489 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 69' ' ' ILE . 4.9 pt -159.9 -173.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.6 tt0 -135.66 159.0 42.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.252 -0.905 . . . . 0.0 109.474 180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.975 HD11 ' N ' ' A' ' 50' ' ' GLY . 8.0 tt -140.54 145.32 36.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -116.68 87.77 22.58 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.906 . . . . 0.0 109.447 -179.979 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.883 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.05 137.52 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.622 2.215 . . . . 0.0 110.458 179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -117.38 173.0 6.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -136.75 -44.92 0.59 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.369 -0.832 . . . . 0.0 109.459 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -168.6 72.06 0.14 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -95.78 18.38 13.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.206 -1.173 . . . . 0.0 109.381 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.424 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.461 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 86.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -141.86 144.7 33.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.6 mm -90.45 136.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.488 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 mt -110.57 124.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.403 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 11.6 ptt180 -105.18 171.45 7.31 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.907 . . . . 0.0 109.489 -179.945 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.0 t -62.13 142.48 95.57 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -78.56 -170.38 0.97 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.496 2.13 . . . . 0.0 110.375 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -84.9 110.74 19.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.392 179.927 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.59 -10.08 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.298 -0.876 . . . . 0.0 109.389 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.8 26.62 74.45 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.906 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 12' ' ' ASP . . . 171.61 160.55 20.41 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -44.45 155.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.239 -1.153 . . . . 0.0 109.485 -179.996 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.65 109.28 1.45 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -101.72 114.41 28.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -1.159 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 15' ' ' VAL . 14.3 t -60.24 129.93 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.891 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.1 mt -104.86 -35.57 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.243 -0.91 . . . . 0.0 109.502 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.465 ' HA ' ' HB2' ' A' ' 59' ' ' LEU . 6.5 tp10 -165.37 135.47 3.64 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.48 127.49 55.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -0.923 . . . . 0.0 109.411 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -116.03 57.68 0.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.444 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.81 HG11 ' CD2' ' A' ' 32' ' ' LEU . 35.6 m -137.19 157.24 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -129.93 157.51 42.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.511 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' THR . 12.1 t -80.64 128.98 34.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 109.419 179.939 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.71 -8.92 79.09 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -82.26 132.61 35.23 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.229 -1.16 . . . . 0.0 109.427 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -79.9 125.63 29.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.264 -0.897 . . . . 0.0 109.488 -179.959 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.784 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.52 -171.38 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.276 -0.89 . . . . 0.0 109.201 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.72 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 pm0 -142.2 159.68 41.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.119 -0.988 . . . . 0.0 109.477 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.783 HG13 ' O ' ' A' ' 28' ' ' VAL . 13.3 p -81.41 79.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.244 -0.91 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.75 -36.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.397 179.893 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.507 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 39.6 tt0 -67.33 155.47 38.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -0.925 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.441 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -77.32 168.4 54.53 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.81 ' CD2' HG11 ' A' ' 20' ' ' VAL . 1.3 tt -129.5 -40.5 1.42 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.263 -1.14 . . . . 0.0 109.49 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.659 HG22 ' HB ' ' A' ' 44' ' ' VAL . 5.2 m -154.7 166.84 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.506 -179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.4 t -134.66 96.55 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.325 179.931 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -94.62 163.83 13.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.564 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -105.42 173.87 6.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.407 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.1 m -135.32 -174.13 3.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -44.73 -42.58 7.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 109.441 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 ttpp -158.89 39.76 0.22 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.485 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -151.0 -156.9 0.76 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.84 107.26 2.1 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' GLU . 2.4 ttm -100.2 149.66 23.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' MET . 10.6 mt-10 -113.2 164.51 13.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.659 ' HB ' HG22 ' A' ' 33' ' ' VAL . 21.6 t -143.9 101.74 4.93 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.25 -0.906 . . . . 0.0 109.269 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.536 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.4 Cg_endo -77.16 -168.75 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.393 2.062 . . . . 0.0 110.55 -179.824 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.784 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.6 t -85.26 117.64 69.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.272 -0.892 . . . . 0.0 109.502 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.12 3.35 7.13 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.332 2.021 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.703 ' HG2' HD12 ' A' ' 72' ' ' LEU . 1.8 tptt -159.88 131.2 5.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.892 . . . . 0.0 109.415 179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.41 88.36 7.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.818 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.836 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -140.05 -152.35 5.81 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 73' ' ' GLU . 9.9 p -113.59 129.99 68.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -1.169 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.4 t -55.55 126.75 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.09 -44.68 9.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.44 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 54.7 p -171.82 138.44 1.07 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.614 ' HA ' HG22 ' A' ' 70' ' ' ILE . 4.8 t -92.98 117.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 109.539 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.22 13.52 18.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.479 ' H ' HG12 ' A' ' 55' ' ' VAL . 2.8 m -140.83 172.09 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.73 151.74 44.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.465 ' HB2' ' HA ' ' A' ' 17' ' ' GLU . 1.6 pp -56.83 139.91 49.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.87 -7.53 81.56 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -70.57 -179.95 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.212 -1.169 . . . . 0.0 109.438 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -153.12 115.74 4.48 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.186 -0.946 . . . . 0.0 109.441 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mp -131.3 -175.05 3.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.473 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.3 tttp -118.56 144.65 45.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 1.6 pt-20 -42.82 141.23 1.13 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.302 -0.874 . . . . 0.0 109.585 -179.861 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.76 -22.62 36.52 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -78.79 138.14 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.46 179.99 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.44 170.12 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.433 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.653 HD11 ' CG2' ' A' ' 6' ' ' VAL . 27.7 mm -139.11 -59.56 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.614 HG22 ' HA ' ' A' ' 55' ' ' VAL . 2.3 pt -143.44 -173.75 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.268 -0.895 . . . . 0.0 109.409 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -139.07 113.16 8.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.836 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 119.92 30.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.592 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -111.14 95.42 25.16 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.202 -0.936 . . . . 0.0 109.451 -179.926 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.5 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo -77.74 173.67 13.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.594 2.196 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -165.2 -179.84 5.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.465 -179.928 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -79.4 -41.59 27.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.21 -0.931 . . . . 0.0 109.48 179.987 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -153.76 113.43 0.57 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -45.91 -74.18 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.25 -1.147 . . . . 0.0 109.462 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.451 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.484 ' HB3' ' HG2' ' A' ' 73' ' ' GLU . 24.8 p . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -157.19 140.61 15.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.453 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.5 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 2.9 mt -80.48 154.56 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.93 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.5 mt -122.25 97.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.571 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.72 -172.36 3.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.914 . . . . 0.0 109.379 179.968 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.714 HG11 HD11 ' A' ' 9' ' ' ILE . 54.6 t -80.88 139.09 49.86 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.128 -0.983 . . . . 0.0 109.284 -179.957 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.625 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.56 -169.89 0.87 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.499 2.133 . . . . 0.0 110.399 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -81.69 104.11 11.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.847 . . . . 0.0 109.37 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.714 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.77 -42.71 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.989 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.77 -23.37 6.28 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.95 -140.29 4.0 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.2 p30 -99.29 153.08 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.185 -1.185 . . . . 0.0 109.401 179.883 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -107.69 105.95 2.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.99 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.447 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.9 mt-10 -99.96 137.64 38.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -1.145 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 99.6 t -76.5 127.22 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.49 -179.934 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.407 HD11 ' CB ' ' A' ' 36' ' ' GLU . 83.7 mt -107.8 -35.47 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.356 -0.84 . . . . 0.0 109.368 -179.952 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -152.09 127.36 9.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.506 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.409 ' O ' HD23 ' A' ' 18' ' ' LEU . 3.9 tt -110.14 126.07 53.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.893 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.95 54.56 1.51 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.502 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.855 HG11 ' CD1' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -148.55 162.59 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.511 -179.943 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.556 ' O ' HG21 ' A' ' 52' ' ' VAL . 4.0 tptp -141.29 176.75 8.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.6 m -81.76 144.91 30.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.207 -0.933 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.404 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 69.29 8.07 58.43 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -85.02 132.61 34.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -1.151 . . . . 0.0 109.515 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.636 HD13 ' N ' ' A' ' 26' ' ' ILE . 0.7 OUTLIER -88.48 118.9 28.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 179.855 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.959 HD13 HD21 ' A' ' 32' ' ' LEU . 3.2 mt -95.62 -171.33 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 O-C-N 121.222 -0.924 . . . . 0.0 109.328 -179.784 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.3 pt-20 -145.47 167.69 22.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.397 179.975 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.742 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.6 p -83.83 72.73 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.934 . . . . 0.0 109.522 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.486 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 170.82 -35.03 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.334 -0.854 . . . . 0.0 109.459 179.826 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -72.67 153.76 41.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.47 179.985 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.75 175.06 44.94 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -134.85 -44.84 0.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 109.501 179.965 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.443 HG23 ' HB ' ' A' ' 44' ' ' VAL . 2.1 m -153.91 170.88 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.227 -0.92 . . . . 0.0 109.513 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.456 HG12 ' O ' ' A' ' 34' ' ' VAL . 94.0 t -129.75 76.87 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.23 -0.918 . . . . 0.0 109.444 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 4.9 mp -89.91 135.13 33.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.471 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.407 ' CB ' HD11 ' A' ' 16' ' ' ILE . 5.0 tm-20 -111.43 140.36 46.09 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.895 . . . . 0.0 109.492 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.707 ' OG ' HG21 ' A' ' 9' ' ' ILE . 1.4 m -112.52 173.7 6.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.532 179.989 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.89 -13.51 25.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 21.2 mttt -84.26 -45.44 12.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 178.94 165.21 0.88 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.407 ' HA ' ' CG ' ' A' ' 36' ' ' GLU . 8.5 t -81.48 118.56 22.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.541 179.919 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 23.9 mtm -121.63 -178.97 3.95 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 109.415 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.7 174.29 10.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.286 -0.884 . . . . 0.0 109.484 -179.957 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.1 t -149.21 103.05 3.32 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.212 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.465 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.6 Cg_endo -77.39 -168.64 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.343 2.029 . . . . 0.0 110.407 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.438 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.42 113.57 51.48 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.43 -179.905 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.7 Cg_endo -78.18 0.36 9.96 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.343 2.028 . . . . 0.0 110.308 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.47 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.12 131.15 5.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.314 -0.866 . . . . 0.0 109.397 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.59 108.11 5.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.862 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.96 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.86 -172.76 28.6 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 9.8 p -104.87 150.92 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 109.494 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.556 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.1 t -68.88 130.78 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 54' ' ' SER . 0.3 OUTLIER -86.51 -42.59 13.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 109.448 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 53' ' ' LYS . 4.8 t -179.51 139.95 0.14 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.183 -0.948 . . . . 0.0 109.566 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 57' ' ' VAL . 9.0 t -80.87 109.53 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.88 . . . . 0.0 109.423 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.8 p -89.5 7.84 34.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.299 -0.875 . . . . 0.0 109.632 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.996 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.03 -177.59 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.941 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.5 tptp -131.87 171.27 13.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -0.916 . . . . 0.0 109.499 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.402 HD12 ' C ' ' A' ' 59' ' ' LEU . 2.7 pp -84.56 132.33 34.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.899 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.63 74.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -81.38 141.58 33.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -1.158 . . . . 0.0 109.402 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.876 ' C ' HD12 ' A' ' 63' ' ' LEU . 10.8 pttp -99.73 151.61 21.04 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.195 -0.941 . . . . 0.0 109.465 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.876 HD12 ' C ' ' A' ' 62' ' ' LYS . 6.0 mp -138.17 168.9 18.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.238 -0.914 . . . . 0.0 109.504 179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -107.11 146.66 30.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.467 -179.974 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.434 ' N ' ' HD2' ' A' ' 64' ' ' LYS . 5.4 mt-10 -42.96 138.9 1.89 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.292 -0.88 . . . . 0.0 109.635 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.79 -6.44 73.58 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.12 145.73 29.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -1.176 . . . . 0.0 109.48 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.536 ' C ' HD12 ' A' ' 69' ' ' ILE . . . -81.15 163.57 23.01 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.437 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.996 HG23 HG21 ' A' ' 57' ' ' VAL . 4.3 mp -133.85 -55.57 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.18 -0.95 . . . . 0.0 109.546 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.779 HG23 HG22 ' A' ' 69' ' ' ILE . 18.1 pt -145.96 -173.42 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.269 -0.894 . . . . 0.0 109.49 -179.93 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.5 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 1.0 OUTLIER -146.49 155.63 42.67 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.235 -0.915 . . . . 0.0 109.505 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.96 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.5 tt -130.69 126.74 37.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.484 ' HG2' ' HB3' ' A' ' 1' ' ' SER . 0.1 OUTLIER -96.71 149.33 35.65 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.238 -0.914 . . . . 0.0 109.54 -179.959 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.688 ' O ' ' HB3' ' A' ' 75' ' ' ALA . 35.5 Cg_endo -78.15 -27.38 5.61 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.633 2.222 . . . . 0.0 110.412 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.693 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . 75.25 137.29 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.17 -0.956 . . . . 0.0 109.438 179.972 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.693 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 75.81 17.08 2.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -112.43 79.48 0.26 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -55.63 107.68 0.36 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 0.0 109.486 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.514 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 65.6 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.61 172.59 13.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.8 mt -100.5 155.5 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.907 . . . . 0.0 109.486 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.681 HD12 ' HG2' ' A' ' 47' ' ' PRO . 36.2 mm -118.17 91.75 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.895 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.443 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -95.33 175.8 6.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.488 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.891 HG11 HD11 ' A' ' 9' ' ' ILE . 76.4 t -84.25 142.33 40.78 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -169.44 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.517 2.145 . . . . 0.0 110.433 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -78.55 105.41 9.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -0.873 . . . . 0.0 109.411 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.891 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.46 -11.07 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.307 -179.859 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.16 -14.99 56.16 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -144.92 -176.29 18.8 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.967 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -71.06 142.59 50.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -1.148 . . . . 0.0 109.472 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.92 107.55 3.25 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -99.61 113.42 25.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.459 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.0 t -68.91 131.81 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -0.934 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 19.5 mm -116.94 -22.16 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -0.897 . . . . 0.0 109.431 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.93 138.04 19.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.293 -0.879 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.499 ' HG ' HG22 ' A' ' 20' ' ' VAL . 12.8 tp -113.48 101.97 9.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 0.6 OUTLIER -108.84 56.65 0.62 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.499 HG22 ' HG ' ' A' ' 18' ' ' LEU . 2.3 m -134.28 160.28 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.224 -0.922 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.463 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 1.2 mtpp -137.43 156.98 47.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.27 -0.894 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.1 m -84.55 129.65 34.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.47 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.451 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 84.31 -9.4 64.27 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.997 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.463 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 0.9 OUTLIER -77.41 131.87 38.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -1.205 . . . . 0.0 109.462 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.0 OUTLIER -85.95 120.57 27.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.217 -0.927 . . . . 0.0 109.467 179.961 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.26 -171.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.229 -0.92 . . . . 0.0 109.204 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 11.0 mt-10 -145.44 163.02 35.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.693 HG13 ' O ' ' A' ' 28' ' ' VAL . 7.2 p -78.14 79.57 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.367 -0.833 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.81 -34.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.471 179.924 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 14.3 tt0 -70.35 141.07 52.29 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.318 -0.864 . . . . 0.0 109.499 -179.988 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.474 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -51.32 -177.17 0.03 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.661 HD13 ' HA ' ' A' ' 46' ' ' SER . 3.8 tp -151.41 -67.78 0.18 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.198 -1.178 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.07 138.66 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.512 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 42.2 t -97.64 89.12 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.439 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.89 150.36 22.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.206 -0.934 . . . . 0.0 109.481 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 41' ' ' SER . 2.0 tt0 -115.24 167.23 11.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.303 -0.873 . . . . 0.0 109.547 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.96 -172.6 3.88 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.48 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -84.52 10.31 11.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.509 179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 5.4 mttp -121.0 -30.83 4.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.333 -0.854 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 169.75 -171.78 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.321 -0.862 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 36' ' ' GLU . 10.5 t -103.96 134.07 47.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.181 -0.949 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtt -138.73 107.2 5.84 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.251 -0.906 . . . . 0.0 109.487 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.29 166.04 21.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.182 -0.949 . . . . 0.0 109.465 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 45' ' ' PRO . 72.0 t -136.38 142.15 38.49 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.305 -0.872 . . . . 0.0 109.342 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 44' ' ' VAL . 35.8 Cg_endo -77.96 -168.27 0.59 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.512 2.142 . . . . 0.0 110.448 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.661 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.8 OUTLIER -85.21 124.09 72.45 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.374 -0.829 . . . . 0.0 109.392 -179.913 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.681 ' HG2' HD12 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -78.45 0.55 9.83 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.306 2.004 . . . . 0.0 110.29 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.466 ' HE3' ' HG3' ' A' ' 74' ' ' PRO . 0.4 OUTLIER -160.15 116.73 2.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.941 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.76 80.93 2.7 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.467 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.996 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -136.37 -159.71 8.51 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 51' ' ' VAL . 11.7 p -103.4 124.1 57.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.201 -1.176 . . . . 0.0 109.519 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.2 t -49.94 140.02 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.455 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.7 tptm -96.94 -70.22 0.73 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.201 -0.937 . . . . 0.0 109.442 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 52.0 p -158.32 135.23 9.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 57' ' ' VAL . 20.9 t -83.31 117.45 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 8.9 t -94.21 19.99 8.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.453 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.833 HG21 HG23 ' A' ' 69' ' ' ILE . 0.7 OUTLIER -143.06 179.58 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.292 -0.88 . . . . 0.0 109.441 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.514 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -130.0 167.39 18.33 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.537 -179.978 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.22 151.63 35.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.48 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.29 9.0 80.77 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.514 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 4.4 m-20 -85.04 150.77 24.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.215 -1.167 . . . . 0.0 109.487 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -112.44 104.99 13.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.491 ' HA ' HD13 ' A' ' 63' ' ' LEU . 3.2 mm? -110.35 173.56 6.27 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.333 -0.855 . . . . 0.0 109.487 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 18.2 ttpt -108.57 142.04 39.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.925 . . . . 0.0 109.499 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 12.7 pt-20 -42.79 138.58 1.91 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.336 -0.852 . . . . 0.0 109.628 -179.884 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.27 -12.86 61.86 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.458 ' CG ' HD12 ' A' ' 63' ' ' LEU . 4.3 m-20 -79.87 153.56 28.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -1.16 . . . . 0.0 109.423 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -83.09 161.91 21.51 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.222 -0.924 . . . . 0.0 109.508 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.95 HG22 HG23 ' A' ' 70' ' ' ILE . 2.8 mp -132.68 -54.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.23 -0.918 . . . . 0.0 109.481 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.95 HG23 HG22 ' A' ' 69' ' ' ILE . 36.4 pt -144.06 -172.37 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.915 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -138.02 115.39 11.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.23 -0.919 . . . . 0.0 109.474 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.996 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 137.62 32.19 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.294 -0.878 . . . . 0.0 109.365 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.942 ' N ' HD13 ' A' ' 72' ' ' LEU . 10.7 tt0 -111.41 95.12 25.04 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.352 -0.842 . . . . 0.0 109.342 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.7 Cg_endo -77.67 125.88 7.8 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.206 . . . . 0.0 110.489 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -168.07 82.47 0.18 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.304 -0.872 . . . . 0.0 109.364 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 78' ' ' ALA . . . -89.36 122.06 32.22 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 -179.97 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' A' ' 78' ' ' ALA . . . 43.32 -98.71 0.01 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 76' ' ' ALA . . . 61.59 22.57 13.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -1.152 . . . . 0.0 109.462 -179.914 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.5 ttt180 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.44 179.956 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 52.4 p . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -138.06 141.28 40.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.321 -0.862 . . . . 0.0 109.478 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.575 HD12 ' CG ' ' A' ' 71' ' ' GLU . 3.8 tt -89.45 151.46 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.516 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.8 mm -115.79 107.8 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.527 ' NH1' ' HA2' ' A' ' 66' ' ' GLY . 0.0 OUTLIER -92.28 168.13 11.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.504 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.75 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.2 t -44.28 142.27 2.32 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.75 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.23 -170.64 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.447 2.098 . . . . 0.0 110.371 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.85 101.91 12.67 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.542 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.35 -61.66 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 109.253 -179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.75 12.5 6.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.02 -139.49 2.65 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 31.8 t0 -111.14 136.86 49.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -1.152 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -105.48 139.72 14.81 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.443 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.2 mt-10 -122.54 135.08 54.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.176 -1.19 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.401 HG23 ' CD1' ' A' ' 63' ' ' LEU . 13.3 t -81.52 130.64 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.91 . . . . 0.0 109.399 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -97.05 -42.8 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.176 -0.953 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.39 151.5 15.38 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.881 . . . . 0.0 109.493 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 2.5 tp -110.87 110.26 20.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.421 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -101.98 49.76 0.85 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.882 . . . . 0.0 109.407 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.506 HG11 ' HG ' ' A' ' 32' ' ' LEU . 0.8 OUTLIER -146.89 157.47 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.4 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -122.66 173.64 7.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.21 -0.931 . . . . 0.0 109.524 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.402 ' HA ' HG11 ' A' ' 52' ' ' VAL . 15.0 t -85.05 147.27 26.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 71.14 7.8 63.75 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 6.0 m-20 -85.04 130.62 34.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.43 111.48 20.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.453 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 27' ' ' GLU . 3.1 mt -94.31 -171.42 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.3 -0.875 . . . . 0.0 109.185 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.73 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.2 mt-10 -149.05 134.92 18.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.421 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' HG13 ' A' ' 28' ' ' VAL . 3.0 p -50.28 91.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.491 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.78 -60.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.348 -0.845 . . . . 0.0 109.534 179.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.429 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.7 tt0 -57.19 162.79 2.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.567 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.456 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -80.08 -179.11 52.31 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -143.43 -40.45 0.3 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -1.164 . . . . 0.0 109.567 179.962 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.8 m -158.63 173.65 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.171 -0.956 . . . . 0.0 109.523 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 16' ' ' ILE . 88.1 t -132.27 104.7 8.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.268 -0.895 . . . . 0.0 109.494 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.93 164.75 14.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.431 ' CG ' ' N ' ' A' ' 37' ' ' SER . 14.5 tt0 -117.22 158.79 23.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.431 ' N ' ' CG ' ' A' ' 36' ' ' GLU . 2.3 t -130.12 179.76 5.7 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.308 -0.87 . . . . 0.0 109.449 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.19 -59.06 2.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 109.415 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.86 54.55 1.58 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.522 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.65 146.16 0.97 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 78.6 p -105.36 137.22 43.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.1 mmt -120.67 178.81 4.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.209 -0.932 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -138.42 161.4 37.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.892 . . . . 0.0 109.529 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 1.8 t -141.66 96.99 6.7 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.376 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.7 Cg_endo -77.56 -168.4 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.476 2.117 . . . . 0.0 110.452 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 28' ' ' VAL . 1.6 t -85.26 113.71 52.03 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.14 1.9 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.37 2.047 . . . . 0.0 110.256 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.8 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.5 OUTLIER -160.17 138.12 9.93 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.88 . . . . 0.0 109.334 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.9 102.19 11.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.184 -0.948 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.921 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -159.11 -167.82 20.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.467 HG22 ' HA2' ' A' ' 23' ' ' GLY . 14.4 p -110.59 138.28 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -1.137 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.402 HG11 ' HA ' ' A' ' 22' ' ' THR . 61.6 t -56.29 122.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 109.527 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.59 -49.37 5.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.457 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 t -149.95 163.66 37.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.578 HG12 ' H ' ' A' ' 57' ' ' VAL . 43.5 t -121.35 131.84 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.25 -0.906 . . . . 0.0 109.428 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.06 21.43 13.74 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.614 HG11 ' HA ' ' A' ' 69' ' ' ILE . 27.5 m -148.23 162.56 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 ttpt -123.73 155.13 38.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.453 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.458 ' HB3' ' HB2' ' A' ' 18' ' ' LEU . 1.7 pp -72.09 139.27 48.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.524 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.59 -13.85 57.2 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -82.79 148.78 27.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -1.162 . . . . 0.0 109.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.448 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 pttp -104.59 141.12 36.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.175 -0.953 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.781 HD12 ' N ' ' A' ' 63' ' ' LEU . 1.5 mp -130.26 164.26 24.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -0.888 . . . . 0.0 109.531 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -115.32 154.11 29.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.987 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.3 OUTLIER -42.72 130.72 4.11 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.285 -0.884 . . . . 0.0 109.663 -179.939 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.527 ' HA2' ' NH1' ' A' ' 5' ' ' ARG . . . 107.83 -12.58 38.32 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -84.23 131.0 34.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -1.16 . . . . 0.0 109.471 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.26 147.13 48.49 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.289 -0.882 . . . . 0.0 109.448 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.723 HG22 HG23 ' A' ' 70' ' ' ILE . 19.8 mm -103.34 -71.46 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.229 -0.919 . . . . 0.0 109.457 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.723 HG23 HG22 ' A' ' 69' ' ' ILE . 0.9 OUTLIER -142.15 171.14 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -0.912 . . . . 0.0 109.5 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.575 ' CG ' HD12 ' A' ' 3' ' ' ILE . 2.6 mp0 -122.7 117.44 25.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.339 -0.851 . . . . 0.0 109.475 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.921 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -89.99 142.18 27.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.247 -0.908 . . . . 0.0 109.424 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.506 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -115.61 91.86 31.23 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.488 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.526 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.541 0 C-N-CA 122.597 2.198 . . . . 0.0 110.401 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 80.6 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.33 164.24 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 57.0 mt -97.43 140.9 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -0.918 . . . . 0.0 109.456 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.73 114.21 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.505 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.744 ' HA ' HD12 ' A' ' 69' ' ' ILE . 1.5 ptt180 -110.29 164.68 12.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.253 -0.904 . . . . 0.0 109.434 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.746 HG13 ' HD2' ' A' ' 7' ' ' PRO . 74.9 t -65.99 142.28 97.94 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.175 -0.953 . . . . 0.0 109.393 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.746 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.5 Cg_endo -78.16 -171.72 1.29 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.515 2.143 . . . . 0.0 110.39 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -68.04 112.86 5.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.427 ' O ' HG13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -110.18 -29.25 2.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.224 -0.923 . . . . 0.0 108.741 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.62 -47.34 2.32 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.74 -144.96 7.18 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -99.63 146.98 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.2 -1.176 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.02 148.35 18.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 44.2 tt0 -127.78 146.6 50.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -1.108 . . . . 0.0 109.424 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.734 HG22 HD23 ' A' ' 35' ' ' LEU . 3.6 t -84.33 156.96 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.182 -0.949 . . . . 0.0 109.489 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.675 HD11 ' HB2' ' A' ' 36' ' ' GLU . 3.6 mp -123.79 -36.61 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.279 -0.888 . . . . 0.0 109.496 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -151.44 151.39 31.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.22 -0.925 . . . . 0.0 109.449 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 1.011 HD12 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -108.52 118.46 36.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.455 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 mt -90.26 30.55 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.498 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 1.011 HG22 HD12 ' A' ' 18' ' ' LEU . 31.8 m -149.69 156.66 7.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.429 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.3 OUTLIER -130.26 176.3 8.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 22' ' ' THR . 14.7 t -75.15 124.57 27.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.223 -0.923 . . . . 0.0 109.504 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.84 1.05 89.08 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.429 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -84.61 142.17 30.14 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.145 -1.209 . . . . 0.0 109.474 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 5.0 tt -108.66 121.38 44.9 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.207 -0.933 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.718 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.5 mt -90.29 -171.41 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.268 -0.895 . . . . 0.0 109.177 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -145.28 172.69 12.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 28' ' ' VAL . 9.7 p -74.06 82.27 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 162.94 -58.55 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.298 -0.876 . . . . 0.0 109.48 179.918 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.41 ' C ' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -44.29 157.88 0.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.509 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.23 -153.56 0.99 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.755 HD23 ' CA ' ' A' ' 46' ' ' SER . 0.1 OUTLIER -159.87 -73.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -1.148 . . . . 0.0 109.517 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.436 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 25.8 m -135.37 135.09 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HG3' ' A' ' 43' ' ' GLU . 20.5 t -107.09 92.82 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.343 -0.848 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.734 HD23 HG22 ' A' ' 15' ' ' VAL . 0.4 OUTLIER -89.97 -173.69 3.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.945 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.675 ' HB2' HD11 ' A' ' 16' ' ' ILE . 8.7 tt0 -130.41 167.58 18.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.4 m -126.61 172.25 10.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.57 -58.8 3.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 11.6 pttm -132.27 53.38 2.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.432 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.1 -166.58 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.249 -0.907 . . . . 0.0 109.46 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.8 155.68 38.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 4.5 mmt -138.71 145.55 40.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HG3' HG22 ' A' ' 34' ' ' VAL . 14.3 tm-20 -159.99 150.13 18.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.268 -0.895 . . . . 0.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.548 HG13 ' HD2' ' A' ' 45' ' ' PRO . 49.4 t -135.77 140.1 32.64 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.448 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.548 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.28 -168.65 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.442 2.095 . . . . 0.0 110.368 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.755 ' CA ' HD23 ' A' ' 32' ' ' LEU . 0.3 OUTLIER -85.52 113.38 50.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.481 ' O ' ' HG2' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -78.31 -3.17 13.16 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.256 1.971 . . . . 0.0 110.381 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.641 ' CB ' HD22 ' A' ' 72' ' ' LEU . 3.6 mtmm -160.37 130.92 5.44 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.344 -0.847 . . . . 0.0 109.406 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.51 90.67 7.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.439 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.486 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -146.25 -166.24 11.98 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.5 p -109.97 160.26 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.28 -1.13 . . . . 0.0 109.482 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.428 ' N ' HG22 ' A' ' 51' ' ' VAL . 55.0 t -76.04 123.6 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.967 . . . . 0.0 109.443 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -94.23 -49.41 5.74 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.495 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 t -158.35 118.21 3.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.465 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.92 HG13 HG22 ' A' ' 70' ' ' ILE . 5.8 t -87.66 133.17 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 56' ' ' SER . 8.2 t -113.31 29.18 8.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.496 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.445 HG11 ' HA ' ' A' ' 69' ' ' ILE . 35.6 m -149.47 175.6 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -136.5 157.57 46.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.467 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.447 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -68.22 138.87 55.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.448 -179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.45 -10.67 68.47 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.441 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 41.6 m-20 -80.9 144.95 31.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -1.144 . . . . 0.0 109.482 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 14.2 ptmt -110.52 148.09 32.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 63' ' ' LEU . 4.3 mp -138.95 166.68 23.85 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.244 -0.91 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 5.0 mtpt -99.58 148.4 24.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 23.8 pt-20 -42.81 142.76 0.82 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.666 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.83 -9.48 76.68 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.98 137.21 35.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -1.156 . . . . 0.0 109.516 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -67.81 176.83 2.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.844 HG22 HG23 ' A' ' 70' ' ' ILE . 2.1 mp -140.9 -67.24 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.92 HG22 HG13 ' A' ' 55' ' ' VAL . 30.1 pt -139.45 173.24 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 109.472 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -127.83 108.47 10.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.641 HD22 ' CB ' ' A' ' 48' ' ' LYS . 0.6 OUTLIER -90.09 142.24 27.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.436 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.407 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 60.6 tt0 -116.54 88.32 23.84 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HG3' ' HD2' ' A' ' 48' ' ' LYS . 35.7 Cg_endo . . . . . 0 C--N 1.31 -1.492 0 C-N-CA 122.652 2.235 . . . . 0.0 110.409 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 53.6 p . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -82.44 171.64 13.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 41.0 mm -107.0 143.91 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.859 HG21 ' HG3' ' A' ' 47' ' ' PRO . 38.8 mm -107.16 118.59 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.53 ' CG ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -103.73 -171.13 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.185 -0.947 . . . . 0.0 109.541 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.752 HG13 ' HD2' ' A' ' 7' ' ' PRO . 65.7 t -79.47 142.72 58.39 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.319 -0.863 . . . . 0.0 109.311 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.752 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.06 -168.79 0.65 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.599 2.199 . . . . 0.0 110.509 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -82.74 111.18 18.43 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.395 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.91 -10.93 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.935 . . . . 0.0 109.345 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.98 39.63 58.53 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.07 -153.72 24.88 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -89.34 174.15 7.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.289 -1.124 . . . . 0.0 109.497 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -147.51 104.8 0.3 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.463 ' N ' ' CD ' ' A' ' 14' ' ' GLU . 6.2 mp0 -92.82 112.92 25.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -1.153 . . . . 0.0 109.442 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 40.3 t -54.33 134.75 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.5 mm -108.56 -50.88 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.228 -0.92 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -144.19 153.03 41.68 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.454 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.85 HD23 HG23 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -120.82 116.08 24.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.924 . . . . 0.0 109.5 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.767 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.3 pp -106.1 52.15 0.73 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.354 -0.841 . . . . 0.0 109.525 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.85 HG23 HD23 ' A' ' 18' ' ' LEU . 0.8 OUTLIER -140.2 169.54 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . 3.5 tptt -144.32 169.28 18.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.211 -0.931 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.435 HG23 ' O ' ' A' ' 22' ' ' THR . 15.2 t -84.11 132.56 34.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 84.26 -1.43 88.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.44 ' CG ' ' HB3' ' A' ' 21' ' ' LYS . 5.7 m-20 -84.05 134.29 34.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.115 -1.227 . . . . 0.0 109.527 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -94.36 116.37 28.73 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.881 . . . . 0.0 109.41 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.1 mt -90.52 -171.35 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.228 -0.92 . . . . 0.0 109.157 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.6 mt-10 -146.37 159.47 43.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.706 ' O ' HG13 ' A' ' 28' ' ' VAL . 7.5 p -72.95 83.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.88 . . . . 0.0 109.47 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 162.83 -32.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.3 -0.875 . . . . 0.0 109.518 179.914 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.413 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 39.4 tt0 -76.28 148.64 37.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.462 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.44 -175.66 1.28 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.888 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.9 OUTLIER -148.22 -68.59 0.23 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -1.105 . . . . 0.0 109.463 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -131.71 171.42 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.584 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 43' ' ' GLU . 75.4 t -134.14 92.72 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.419 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.4 mp -90.0 149.82 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -0.873 . . . . 0.0 109.423 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -115.17 139.1 50.21 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.24 -179.21 5.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 109.515 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -69.76 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -92.17 -49.69 6.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.892 . . . . 0.0 109.47 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.528 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.89 173.63 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.28 -0.887 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.65 128.94 34.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.294 -0.879 . . . . 0.0 109.501 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.7 mtt -127.2 105.73 8.76 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -80.01 156.76 27.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.547 HG13 ' HD2' ' A' ' 45' ' ' PRO . 44.9 t -133.96 140.45 36.39 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.389 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.547 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.0 Cg_endo -78.44 -168.44 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.599 2.199 . . . . 0.0 110.434 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.888 ' HA ' HD13 ' A' ' 32' ' ' LEU . 7.7 t -85.23 129.93 53.84 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.404 -0.81 . . . . 0.0 109.332 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.859 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.0 Cg_endo -78.59 -1.88 11.98 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.366 2.044 . . . . 0.0 110.513 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.729 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.18 128.57 4.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.533 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.09 86.33 5.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.794 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -146.62 -166.12 12.03 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.456 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.0 p -104.88 139.47 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -1.167 . . . . 0.0 109.466 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 70.5 t -56.98 127.85 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' SER . 18.4 tptm -100.7 -15.91 17.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.202 -0.936 . . . . 0.0 109.485 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.412 ' CB ' ' O ' ' A' ' 53' ' ' LYS . 0.5 OUTLIER 171.12 145.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.464 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.559 HG12 ' H ' ' A' ' 57' ' ' VAL . 76.1 t -101.11 142.19 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.458 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 61.6 m -121.84 13.58 10.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.89 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 69' ' ' ILE . 10.8 m -147.76 166.99 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 109.504 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -125.52 171.23 10.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.464 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -79.03 118.78 21.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.51 -11.47 42.82 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -70.86 150.93 45.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.968 ' C ' HD22 ' A' ' 63' ' ' LEU . 10.2 tttm -100.19 120.26 39.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.463 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.968 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.0 mm? -131.14 143.93 51.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -105.04 153.21 21.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.479 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 4.3 pt-20 -42.9 143.63 0.7 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.66 -18.1 58.09 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' ' O ' ' A' ' 68' ' ' ALA . 7.7 m-20 -85.12 129.99 34.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -1.156 . . . . 0.0 109.526 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.53 ' HA ' ' CG ' ' A' ' 5' ' ' ARG . . . -48.5 175.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.599 ' O ' HG23 ' A' ' 70' ' ' ILE . 21.9 mm -146.93 -47.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.463 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 69' ' ' ILE . 0.6 OUTLIER -158.68 -177.11 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.483 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -127.75 161.82 28.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.208 -0.933 . . . . 0.0 109.494 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.794 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.7 OUTLIER -143.15 135.8 27.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.392 -179.948 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 71.3 tt0 -114.68 90.24 21.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.2 Cg_endo . . . . . 0 C--N 1.309 -1.517 0 C-N-CA 122.557 2.171 . . . . 0.0 110.403 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.451 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 18.3 p . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -121.37 152.57 38.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.507 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.7 tt -86.52 152.96 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.821 HG21 ' HG3' ' A' ' 47' ' ' PRO . 5.2 mp -131.92 118.54 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.254 -0.904 . . . . 0.0 109.464 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.79 175.03 7.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.452 179.954 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.654 HG13 ' HD2' ' A' ' 7' ' ' PRO . 53.5 t -55.2 139.88 64.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.323 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.654 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.1 Cg_endo -78.59 -172.94 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.533 2.155 . . . . 0.0 110.359 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -85.11 110.66 19.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 1.009 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.8 -56.47 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.421 -179.917 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.96 -27.32 1.89 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . -179.8 118.42 0.59 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 1.009 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.2 OUTLIER 49.76 -179.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.267 -1.137 . . . . 0.0 109.478 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.762 ' C ' HD23 ' A' ' 35' ' ' LEU . . . -172.24 90.97 0.09 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 19.3 mt-10 -94.98 124.05 38.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.339 -1.095 . . . . 0.0 109.487 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.7 t -73.12 132.33 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.464 HG22 ' O ' ' A' ' 34' ' ' VAL . 4.4 tt -92.34 -28.76 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -174.43 151.2 1.53 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.41 HD23 ' CG2' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -104.18 103.45 13.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.45 15.07 7.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.284 -0.885 . . . . 0.0 109.375 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.838 HG11 ' HG ' ' A' ' 32' ' ' LEU . 11.9 m -113.28 178.02 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.67 158.43 43.78 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.9 t -73.64 141.89 46.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.288 -0.883 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 82.85 -6.61 69.55 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.14 135.62 36.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -1.141 . . . . 0.0 109.446 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.89 HD12 ' C ' ' A' ' 50' ' ' GLY . 22.4 tp -93.24 110.68 22.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.229 -0.92 . . . . 0.0 109.469 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.816 HG23 ' OE1' ' A' ' 30' ' ' GLN . 2.7 mt -91.27 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.248 -0.908 . . . . 0.0 109.201 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 tm-20 -139.36 -178.63 5.46 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.208 -0.933 . . . . 0.0 109.443 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.752 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.2 p -84.79 69.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.554 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.491 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 169.21 -40.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.366 -0.834 . . . . 0.0 109.435 179.884 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.816 ' OE1' HG23 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -56.73 138.49 52.82 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 109.364 179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.44 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -69.5 166.05 49.15 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.838 ' HG ' HG11 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -127.42 -42.01 1.69 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.366 -1.079 . . . . 0.0 109.446 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 25.6 m -158.63 174.33 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.154 -0.966 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.464 ' O ' HG22 ' A' ' 16' ' ' ILE . 70.7 t -128.77 102.53 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.227 -0.921 . . . . 0.0 109.449 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.762 HD23 ' C ' ' A' ' 13' ' ' GLY . 3.5 mp -89.98 141.67 28.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.216 -0.928 . . . . 0.0 109.4 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.407 ' OE2' ' OG ' ' A' ' 41' ' ' SER . 6.0 tt0 -115.79 134.31 55.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.23 -0.919 . . . . 0.0 109.513 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.9 m -132.03 -177.77 4.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.894 . . . . 0.0 109.446 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.04 -16.54 60.2 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.467 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.8 mttt -84.16 -55.27 4.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.94 . . . . 0.0 109.439 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.467 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.15 -179.54 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.889 . . . . 0.0 109.454 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.407 ' OG ' ' OE2' ' A' ' 36' ' ' GLU . 2.4 m -95.84 103.72 15.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.5 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -93.78 -173.34 3.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.186 -0.946 . . . . 0.0 109.5 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -124.89 162.16 25.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.201 -0.937 . . . . 0.0 109.477 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 35' ' ' LEU . 18.7 t -144.17 97.11 5.28 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.515 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.6 Cg_endo -77.43 -168.69 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.566 2.177 . . . . 0.0 110.476 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.3 135.24 39.21 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.411 -0.806 . . . . 0.0 109.307 179.89 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.821 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.56 -4.63 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.466 2.111 . . . . 0.0 110.433 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 46' ' ' SER . 26.0 tttt -160.31 142.13 12.69 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.403 -0.81 . . . . 0.0 109.468 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.92 94.22 5.19 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.179 -0.951 . . . . 0.0 109.394 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.897 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.94 -174.7 22.15 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 23' ' ' GLY . 10.8 p -103.66 137.98 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -1.149 . . . . 0.0 109.522 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.8 t -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.05 -27.7 13.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.206 -0.934 . . . . 0.0 109.524 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -167.04 171.57 10.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.16 -0.963 . . . . 0.0 109.544 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.787 ' HA ' HG22 ' A' ' 70' ' ' ILE . 55.6 t -131.86 113.25 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 56' ' ' SER . 5.6 t -99.32 22.64 10.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.47 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.414 ' H ' HG12 ' A' ' 55' ' ' VAL . 31.3 m -144.03 169.55 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.198 -0.939 . . . . 0.0 109.451 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.68 171.93 12.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.728 ' O ' HD12 ' A' ' 59' ' ' LEU . 4.0 pp -80.04 139.15 37.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.315 -0.866 . . . . 0.0 109.536 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.79 -11.14 62.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -70.53 137.46 50.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -1.16 . . . . 0.0 109.39 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.544 ' O ' HD22 ' A' ' 63' ' ' LEU . 18.7 mttm -98.5 117.18 32.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.27 -0.894 . . . . 0.0 109.46 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.722 HD12 ' CB ' ' A' ' 67' ' ' ASP . 3.5 mm? -117.92 159.74 22.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.429 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.3 tttt -112.09 142.82 44.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 64' ' ' LYS . 9.7 mt-10 -42.84 129.78 4.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.306 -0.871 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 113.96 -19.95 17.63 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.722 ' CB ' HD12 ' A' ' 63' ' ' LEU . 26.8 m-20 -85.12 136.06 33.71 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.231 -1.158 . . . . 0.0 109.41 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -58.92 167.85 1.47 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.226 -0.921 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.51 HD11 ' CG2' ' A' ' 6' ' ' VAL . 39.1 mm -134.13 -67.28 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.787 HG22 ' HA ' ' A' ' 55' ' ' VAL . 0.7 OUTLIER -144.9 -173.56 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.459 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -133.48 120.93 21.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.303 -0.873 . . . . 0.0 109.477 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.976 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.4 tt -94.05 135.47 35.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.433 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.451 ' OE2' ' HB3' ' A' ' 1' ' ' SER . 5.9 tt0 -114.45 89.17 17.26 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.157 -0.964 . . . . 0.0 109.499 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.976 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.308 -1.592 0 C-N-CA 122.564 2.176 . . . . 0.0 110.365 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.469 ' HB3' ' HB2' ' A' ' 73' ' ' GLU . 95.0 p . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -87.04 137.03 32.69 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -0.883 . . . . 0.0 109.472 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.765 HD13 ' N ' ' A' ' 4' ' ' ILE . 0.0 OUTLIER -101.87 121.49 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.4 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.765 ' N ' HD13 ' A' ' 3' ' ' ILE . 49.8 mm -95.82 115.08 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.424 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.444 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 0.0 OUTLIER -112.4 160.24 17.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.203 -0.935 . . . . 0.0 109.686 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.8 HG13 HD11 ' A' ' 9' ' ' ILE . 85.6 t -44.83 104.47 0.39 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.338 -0.851 . . . . 0.0 109.545 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.1 Cg_endo -77.58 -170.43 0.94 Allowed 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.433 2.089 . . . . 0.0 110.438 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -72.31 99.92 2.52 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.209 -0.932 . . . . 0.0 109.466 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.8 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.26 -10.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.372 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.41 -17.63 11.27 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.04 -119.28 0.81 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.37 170.0 9.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.07 120.14 1.07 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 6.2 mt-10 -100.58 122.46 43.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -1.158 . . . . 0.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.2 t -63.2 124.15 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.905 . . . . 0.0 109.509 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.3 mm -99.54 -18.06 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.34 -0.85 . . . . 0.0 109.454 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.98 149.06 1.83 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.53 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.924 ' HG ' HG22 ' A' ' 20' ' ' VAL . 6.6 tp -118.73 102.39 8.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.545 HD23 ' H ' ' A' ' 19' ' ' LEU . 0.3 OUTLIER -90.71 48.62 1.56 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.527 179.973 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.924 HG22 ' HG ' ' A' ' 18' ' ' LEU . 18.7 m -145.86 168.47 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.409 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.35 171.27 14.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.98 132.02 35.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.554 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 79.57 -4.57 63.81 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.4 134.99 36.57 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.16 -1.2 . . . . 0.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -82.64 127.54 33.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.853 . . . . 0.0 109.429 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.792 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -91.53 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.278 -0.889 . . . . 0.0 109.269 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.715 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.2 tm-20 -142.57 136.68 29.49 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.204 -0.935 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.661 HG13 ' HG3' ' A' ' 29' ' ' GLU . 9.3 p -45.73 140.72 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.248 -0.907 . . . . 0.0 109.475 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.661 ' HG3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER 82.99 -43.69 0.11 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.64 -0.663 . . . . 0.0 109.9 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.523 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -47.35 133.82 12.12 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.035 -1.041 . . . . 0.0 109.482 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.34 162.32 49.74 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.902 ' CD2' HG11 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -125.98 -38.53 2.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -1.158 . . . . 0.0 109.465 179.972 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.705 HG12 HD12 ' A' ' 18' ' ' LEU . 33.0 m -158.73 158.59 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.522 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.2 t -124.44 98.22 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.314 -0.866 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 1.9 mp -90.23 140.24 29.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.305 -0.872 . . . . 0.0 109.526 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -126.89 127.58 45.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.416 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.627 ' HB3' ' HB3' ' A' ' 40' ' ' ALA . 0.3 OUTLIER -102.99 174.87 5.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.893 . . . . 0.0 109.477 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' N ' ' OG ' ' A' ' 37' ' ' SER . . . -44.88 -34.48 2.38 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.6 pttt -156.21 50.87 0.52 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.254 -0.903 . . . . 0.0 109.524 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.627 ' HB3' ' HB3' ' A' ' 37' ' ' SER . . . -158.56 91.72 1.09 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.32 129.62 40.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.421 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.9 mtm -149.25 174.46 12.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.259 -0.9 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 31.6 mp0 -127.97 164.58 22.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -143.9 96.92 5.43 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.57 -169.1 0.68 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.537 2.158 . . . . 0.0 110.478 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.792 ' HB2' HG21 ' A' ' 26' ' ' ILE . 19.0 t -85.55 126.24 67.11 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.436 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.547 ' CG ' ' CD1' ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.59 -2.2 12.26 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.44 2.093 . . . . 0.0 110.383 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.593 ' HB3' HD12 ' A' ' 72' ' ' LEU . 3.3 tptt -160.16 127.35 4.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.386 -0.821 . . . . 0.0 109.432 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.7 88.66 1.74 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.209 -0.932 . . . . 0.0 109.469 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -144.99 -153.71 5.94 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.674 ' O ' HD22 ' A' ' 72' ' ' LEU . 5.9 p -108.45 151.65 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -1.127 . . . . 0.0 109.408 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.2 t -75.97 123.8 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.187 -0.946 . . . . 0.0 109.522 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -81.38 -59.13 2.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.285 -0.884 . . . . 0.0 109.489 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 31.3 p -161.29 126.3 3.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.457 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.69 HG12 ' H ' ' A' ' 57' ' ' VAL . 57.9 t -81.38 126.21 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.287 -0.883 . . . . 0.0 109.486 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 t -103.66 26.0 9.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.216 -0.927 . . . . 0.0 109.48 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.69 ' H ' HG12 ' A' ' 55' ' ' VAL . 15.6 m -148.72 164.87 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.887 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.451 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 9.2 tttt -132.89 164.12 27.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.522 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.34 138.18 55.21 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.454 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.14 -18.22 54.64 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.451 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 1.7 m-20 -82.87 143.61 30.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 109.437 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.577 ' C ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -102.18 136.99 41.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.215 -0.928 . . . . 0.0 109.438 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.1 mm? -111.34 177.94 4.5 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.471 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.449 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.5 ttpp -139.39 152.21 46.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 7.3 mt-10 -44.28 139.9 2.44 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.172 -0.955 . . . . 0.0 109.513 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.34 -47.52 3.65 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -48.75 130.19 17.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.298 -1.119 . . . . 0.0 109.521 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -60.44 161.99 6.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.326 -0.859 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.787 HD11 HG23 ' A' ' 6' ' ' VAL . 19.9 mm -135.41 -55.55 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.304 -0.872 . . . . 0.0 109.466 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.672 HG23 HG22 ' A' ' 69' ' ' ILE . 11.4 pt -156.57 -174.52 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.311 -0.868 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 0.6 OUTLIER -144.17 139.04 28.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.856 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -119.61 118.81 31.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.196 -0.94 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.516 ' N ' HD13 ' A' ' 72' ' ' LEU . 5.7 tt0 -111.74 94.91 25.78 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.575 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo . . . . . 0 C--N 1.308 -1.578 0 C-N-CA 122.616 2.211 . . . . 0.0 110.381 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 94.7 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -99.45 149.21 23.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.941 . . . . 0.0 109.426 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.2 tt -83.48 159.16 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.31 -0.868 . . . . 0.0 109.468 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.18 111.62 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.192 -0.942 . . . . 0.0 109.407 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.466 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.36 170.13 10.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.538 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -44.19 142.32 2.25 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.419 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.27 171.51 16.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.554 2.169 . . . . 0.0 110.37 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -84.92 99.13 10.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.56 -11.19 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.258 -0.901 . . . . 0.0 109.396 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.88 -10.8 68.24 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -158.98 -161.32 11.02 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 -83.74 143.32 30.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -1.179 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.77 150.16 18.7 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -129.44 119.17 23.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -1.154 . . . . 0.0 109.481 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.6 t -67.37 152.22 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.419 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.404 HD12 HG23 ' A' ' 16' ' ' ILE . 49.3 mm -120.06 -34.24 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -175.47 137.91 0.39 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 109.452 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.97 140.6 37.03 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 121.154 -0.966 . . . . 0.0 109.371 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.46 35.23 3.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 m -144.13 -179.7 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.432 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.27 -179.68 6.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 0.0 109.441 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.472 HG23 ' O ' ' A' ' 22' ' ' THR . 14.2 t -79.9 129.58 34.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.41 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.55 -0.13 61.22 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -81.35 133.29 35.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 109.489 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -89.78 107.82 19.32 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.461 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.724 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.88 -171.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.184 -0.948 . . . . 0.0 109.26 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -147.31 176.76 9.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.51 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.748 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.2 p -81.18 74.34 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.515 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.506 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.92 -27.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.313 -0.867 . . . . 0.0 109.402 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -72.99 136.01 45.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.456 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.24 176.18 2.85 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.973 HD23 HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -137.15 -62.93 0.61 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -1.147 . . . . 0.0 109.452 180.0 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.973 HG13 HD23 ' A' ' 32' ' ' LEU . 16.5 m -137.66 172.03 15.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -125.69 105.95 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.246 -0.909 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.1 mp -97.95 153.61 18.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.84 149.98 39.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.6 m -126.65 177.96 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.99 -41.41 59.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.483 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -157.95 37.04 0.26 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -152.69 88.33 1.34 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.401 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.465 ' O ' ' HG2' ' A' ' 42' ' ' MET . 34.6 t -83.45 127.58 33.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.242 -0.911 . . . . 0.0 109.451 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 41' ' ' SER . 11.9 mtt -147.45 136.46 22.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.468 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -93.0 169.93 10.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.162 -0.961 . . . . 0.0 109.437 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 40.7 t -135.88 127.83 17.46 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.36 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.456 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.4 -168.15 0.58 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.43 2.086 . . . . 0.0 110.389 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.529 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.1 OUTLIER -85.14 135.92 38.78 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.869 . . . . 0.0 109.19 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.43 -2.39 12.45 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.434 2.089 . . . . 0.0 110.533 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.775 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.03 140.53 11.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.376 -0.828 . . . . 0.0 109.4 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.68 95.95 9.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.773 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.71 -153.0 6.79 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 73' ' ' GLU . 12.2 p -110.81 141.63 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -1.124 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 71.0 t -63.87 142.6 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.42 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -106.77 -55.35 2.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.31 118.87 7.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 70' ' ' ILE . 13.1 t -84.87 106.73 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 p -90.16 9.2 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.459 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.809 HG11 HG23 ' A' ' 69' ' ' ILE . 20.6 m -124.87 158.27 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.451 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.403 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 2.8 tptp -137.43 -173.38 3.46 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.22 -0.925 . . . . 0.0 109.524 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.453 ' N ' HD21 ' A' ' 18' ' ' LEU . 2.2 pp -85.05 134.36 34.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 77.23 9.08 87.0 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.403 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 37.0 m-20 -84.87 145.46 27.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.244 -1.15 . . . . 0.0 109.438 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -107.41 132.48 53.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.521 -179.981 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.427 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -139.59 130.14 25.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.41 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 31.4 tttm -93.82 145.74 24.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.202 -0.936 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.463 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -42.86 124.29 3.05 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.353 -0.842 . . . . 0.0 109.638 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 123.46 -26.37 6.04 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 68' ' ' ALA . 1.2 m-20 -85.11 131.23 34.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -1.147 . . . . 0.0 109.442 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -49.66 178.55 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.284 -0.885 . . . . 0.0 109.509 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.809 HG23 HG11 ' A' ' 57' ' ' VAL . 23.1 mm -145.08 -65.21 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.237 -0.914 . . . . 0.0 109.414 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.591 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.2 pt -151.51 177.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.478 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -143.48 140.42 30.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.942 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.3 tt -107.75 142.8 37.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.411 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.431 ' O ' HG12 ' A' ' 51' ' ' VAL . 1.3 tp10 -131.34 89.84 39.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.432 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.942 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.55 0 C-N-CA 122.59 2.193 . . . . 0.0 110.406 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 60.4 p . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 16.5 mt-10 -135.78 137.24 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.496 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.618 HD11 ' HB1' ' A' ' 68' ' ' ALA . 1.2 tt -82.14 151.94 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.5 mm -117.37 97.03 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.76 163.3 14.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.843 HG23 HD11 ' A' ' 69' ' ' ILE . 71.4 t -57.88 142.05 79.61 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.737 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -77.98 -174.46 2.24 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.587 2.191 . . . . 0.0 110.386 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -58.78 103.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.602 HG23 ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -110.17 -37.75 3.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.238 -0.913 . . . . 0.0 108.767 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.85 52.98 21.65 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.89 -136.57 4.37 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -116.65 138.4 51.47 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.22 -1.165 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -110.74 118.93 5.1 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.01 130.91 47.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.278 -1.131 . . . . 0.0 109.476 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.3 t -80.67 147.31 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.469 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.838 HD12 HG12 ' A' ' 34' ' ' VAL . 60.4 mt -113.49 -57.02 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -0.942 . . . . 0.0 109.474 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -160.8 162.64 32.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.305 -0.872 . . . . 0.0 109.463 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.1 tp -101.2 141.53 33.94 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.721 HD12 ' N ' ' A' ' 32' ' ' LEU . 12.7 mt -99.0 18.67 16.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.488 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -150.04 172.22 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.422 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -120.01 -178.29 3.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.459 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.22 113.92 19.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.501 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.31 0.5 65.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.84 145.89 27.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -1.138 . . . . 0.0 109.434 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.469 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.1 tp -89.81 132.27 35.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.184 -0.947 . . . . 0.0 109.449 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.822 HD13 ' CD1' ' A' ' 32' ' ' LEU . 2.7 mt -91.79 -171.41 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.184 -0.947 . . . . 0.0 109.135 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -149.96 126.01 10.59 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.246 -0.908 . . . . 0.0 109.488 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.567 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 8.4 p -44.98 149.61 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.567 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 16.3 tt0 83.05 -43.67 0.11 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.666 -0.646 . . . . 0.0 109.8 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.546 ' HB2' ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -62.29 153.81 29.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.101 -0.999 . . . . 0.0 109.48 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.476 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -62.46 -176.94 3.03 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.822 ' CD1' HD13 ' A' ' 26' ' ' ILE . 10.0 tp -153.98 -56.88 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -1.176 . . . . 0.0 109.558 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.19 152.7 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.175 -0.953 . . . . 0.0 109.65 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.838 HG12 HD12 ' A' ' 16' ' ' ILE . 22.6 t -120.97 83.96 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.282 -0.886 . . . . 0.0 109.367 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.01 170.86 9.99 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -0.905 . . . . 0.0 109.478 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.516 ' CG ' ' O ' ' A' ' 40' ' ' ALA . 21.8 tt0 -114.08 154.22 28.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -104.7 -177.05 3.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -45.31 -37.69 5.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.314 -0.866 . . . . 0.0 109.446 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -158.74 63.52 0.42 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.516 ' O ' ' CG ' ' A' ' 36' ' ' GLU . . . 178.13 -167.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.425 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.8 m -135.85 116.36 13.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.243 -0.91 . . . . 0.0 109.455 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -116.78 132.68 56.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.164 -0.96 . . . . 0.0 109.43 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.569 ' HG2' HG22 ' A' ' 34' ' ' VAL . 2.0 mt-10 -112.57 161.59 16.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 3.4 t -139.31 140.3 25.52 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.279 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.31 -169.12 0.71 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.379 2.053 . . . . 0.0 110.38 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.754 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.53 134.71 39.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.32 -0.862 . . . . 0.0 109.302 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.582 ' HD3' HD22 ' A' ' 32' ' ' LEU . 36.2 Cg_endo -78.68 -12.64 15.0 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.435 2.09 . . . . 0.0 110.233 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.453 ' CD ' ' HB3' ' A' ' 74' ' ' PRO . 1.3 ttmp? -160.64 132.11 5.75 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.7 84.54 2.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.4 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.742 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -135.21 -144.11 4.9 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' VAL . 11.3 p -118.74 157.24 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.404 ' N ' HG22 ' A' ' 51' ' ' VAL . 24.1 t -84.82 136.69 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.239 -0.913 . . . . 0.0 109.468 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.38 -60.89 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.433 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.8 m -175.36 157.62 2.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.16 -0.963 . . . . 0.0 109.501 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 57' ' ' VAL . 3.5 t -87.11 121.38 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 m -80.93 5.85 15.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.573 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.871 HG11 HD11 ' A' ' 63' ' ' LEU . 35.6 m -150.11 -172.26 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.436 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.4 OUTLIER -114.05 153.28 29.7 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.453 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -65.81 150.3 48.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.466 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 69.25 9.1 60.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.436 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 5.1 m-20 -84.99 154.79 21.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -101.92 123.18 45.4 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.898 . . . . 0.0 109.427 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 57' ' ' VAL . 83.0 mt -123.2 152.72 40.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 109.453 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.8 ttpt -94.0 147.28 23.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.286 -0.883 . . . . 0.0 109.509 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.602 ' HB3' HG23 ' A' ' 9' ' ' ILE . 10.7 pt-20 -43.05 139.59 1.72 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.35 -0.844 . . . . 0.0 109.605 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.55 -4.61 79.83 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.04 143.37 29.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -1.106 . . . . 0.0 109.452 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.618 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -74.98 157.74 34.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.312 -0.868 . . . . 0.0 109.461 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.843 HD11 HG23 ' A' ' 6' ' ' VAL . 3.2 mp -131.07 -51.77 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.94 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.0 pt -147.4 -179.69 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 2' ' ' GLU . 22.9 tt0 -150.06 129.24 12.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.224 -0.923 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.742 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -95.82 145.07 25.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.473 179.931 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.52 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -112.4 93.32 22.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.328 -0.858 . . . . 0.0 109.404 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.56 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.562 0 C-N-CA 122.631 2.221 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 26.9 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -92.87 169.41 10.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.89 . . . . 0.0 109.476 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.7 mt -106.48 146.58 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.875 . . . . 0.0 109.439 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.595 HD12 ' HG2' ' A' ' 47' ' ' PRO . 27.9 mm -104.93 114.68 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.566 ' HA ' HD12 ' A' ' 69' ' ' ILE . 6.0 ptp180 -107.07 177.71 4.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.238 -0.914 . . . . 0.0 109.459 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 72.6 t -73.77 142.06 79.77 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.219 -0.926 . . . . 0.0 109.459 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.0 Cg_endo -78.45 -170.15 0.92 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.497 2.131 . . . . 0.0 110.441 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -85.02 102.86 13.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.164 -0.96 . . . . 0.0 109.423 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.529 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.3 -49.03 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.352 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.63 30.28 2.44 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' OE1' ' A' ' 65' ' ' GLU . . . 168.3 -166.19 39.34 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -94.95 115.65 27.72 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.264 -1.139 . . . . 0.0 109.531 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.38 168.39 54.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 4.6 tt0 -142.99 117.27 9.58 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.2 -1.177 . . . . 0.0 109.496 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.556 HG11 ' HA ' ' A' ' 59' ' ' LEU . 62.4 t -62.52 119.78 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 34' ' ' VAL . 2.1 pt -113.99 -20.26 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.416 ' N ' HG13 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -155.41 136.76 14.02 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.299 -0.875 . . . . 0.0 109.499 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.425 HD13 HG11 ' A' ' 15' ' ' VAL . 0.2 OUTLIER -129.09 123.57 32.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.937 . . . . 0.0 109.4 -179.965 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.492 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -125.22 63.13 1.17 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 0.0 109.478 -179.923 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.608 HG11 ' HG ' ' A' ' 32' ' ' LEU . 16.7 m -144.96 169.24 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.22 160.07 42.04 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 53' ' ' LYS . 94.8 m -84.5 133.85 34.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.495 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.85 -10.77 73.81 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -81.1 136.42 35.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -1.137 . . . . 0.0 109.505 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.56 115.96 22.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 109.5 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -91.02 -171.54 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.187 -0.945 . . . . 0.0 109.234 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 mt-10 -145.67 174.87 10.81 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.736 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.0 p -84.98 76.22 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.42 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 167.21 -41.98 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.431 -0.793 . . . . 0.0 109.251 179.867 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.526 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 61.5 tt0 -59.65 146.44 41.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.19 168.17 54.4 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.608 ' HG ' HG11 ' A' ' 20' ' ' VAL . 5.0 tp -128.46 -43.79 1.41 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -1.154 . . . . 0.0 109.567 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.526 HG13 ' C ' ' A' ' 32' ' ' LEU . 15.7 m -158.56 159.08 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 16' ' ' ILE . 62.9 t -124.37 103.47 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.184 -0.947 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.08 163.08 15.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -118.05 145.29 44.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -121.69 -177.39 3.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.915 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.36 -56.01 9.25 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.582 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -143.98 59.77 1.36 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 109.523 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.582 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 170.42 112.01 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 33.8 t -100.73 115.15 29.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.483 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 26.2 ttp -102.98 154.73 18.94 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.178 -0.952 . . . . 0.0 109.403 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -100.6 169.61 8.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 69.9 t -146.12 99.57 4.27 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.526 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.4 Cg_endo -77.13 -167.96 0.53 Allowed 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.432 2.088 . . . . 0.0 110.479 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 2.6 t -84.82 125.98 69.5 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.348 -0.845 . . . . 0.0 109.385 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.595 ' HG2' HD12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.54 -1.16 11.35 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.382 2.055 . . . . 0.0 110.404 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 46' ' ' SER . 4.7 tttt -160.15 140.95 12.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.304 -0.872 . . . . 0.0 109.574 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.67 102.84 12.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 0.0 109.402 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 1.002 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -152.92 -168.93 17.54 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.63 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.4 p -104.18 120.19 54.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -1.105 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 50.9 t -49.09 142.36 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.532 ' O ' HG23 ' A' ' 22' ' ' THR . 3.1 ttpp -104.87 -59.77 1.7 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.01 140.99 14.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.572 HG12 ' H ' ' A' ' 57' ' ' VAL . 10.7 t -90.37 126.36 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.506 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.6 m -100.38 20.47 14.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.251 -0.906 . . . . 0.0 109.394 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.795 HG21 HG23 ' A' ' 69' ' ' ILE . 1.4 m -143.62 163.39 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -120.1 141.47 49.77 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.474 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.556 ' HA ' HG11 ' A' ' 15' ' ' VAL . 2.1 pp -60.26 128.37 36.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.466 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.39 -21.9 21.04 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -83.43 158.45 22.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.187 -1.184 . . . . 0.0 109.502 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 5.8 pttt -86.8 165.11 16.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.574 HD21 HG11 ' A' ' 57' ' ' VAL . 0.3 OUTLIER -132.02 110.66 10.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.324 -0.86 . . . . 0.0 109.45 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.84 136.28 36.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.232 -0.918 . . . . 0.0 109.282 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' O ' ' A' ' 11' ' ' GLY . 1.8 mt-10 -48.85 149.04 1.94 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.31 -0.869 . . . . 0.0 109.958 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.79 -14.66 46.75 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.64 141.62 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.198 -1.178 . . . . 0.0 109.621 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -74.61 176.07 7.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 109.342 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.882 HG22 HG23 ' A' ' 70' ' ' ILE . 2.9 mp -139.37 -64.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.156 -0.965 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.882 HG23 HG22 ' A' ' 69' ' ' ILE . 2.3 pp -139.18 173.59 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.605 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -129.31 137.51 51.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.874 . . . . 0.0 109.428 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.002 HD11 ' CA ' ' A' ' 50' ' ' GLY . 3.5 tt -108.52 137.88 45.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.893 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -113.38 92.17 22.19 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.975 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.501 0 C-N-CA 122.598 2.198 . . . . 0.0 110.391 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.529 ' CB ' ' HG2' ' A' ' 73' ' ' GLU . 53.2 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.271 0.558 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 1' ' ' SER . 2.0 mm-40 -154.09 148.81 26.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.231 -0.918 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.7 mp -80.05 143.1 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.412 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.477 HD13 HD11 ' A' ' 70' ' ' ILE . 2.1 mp -114.82 97.88 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.428 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.07 176.67 6.69 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.735 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.0 t -65.68 142.43 98.21 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.735 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.7 Cg_endo -78.24 -178.68 4.8 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.528 2.152 . . . . 0.0 110.374 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -85.05 96.64 9.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.22 -0.925 . . . . 0.0 109.41 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.99 -17.64 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.31 -0.869 . . . . 0.0 109.299 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.29 -8.95 62.46 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.82 -133.14 3.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -113.6 170.8 7.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -134.06 108.44 0.73 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.471 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.3 OUTLIER -99.8 120.33 39.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -1.112 . . . . 0.0 109.371 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.2 t -67.26 123.31 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.88 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.954 HG22 ' O ' ' A' ' 34' ' ' VAL . 8.3 tp -103.37 -25.19 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.196 -0.94 . . . . 0.0 109.494 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -178.62 138.83 0.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.485 ' H ' HD12 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -102.75 152.47 21.2 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.304 -0.872 . . . . 0.0 109.399 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.682 HD12 ' C ' ' A' ' 32' ' ' LEU . 0.7 OUTLIER -112.06 27.29 9.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.446 HG21 HD11 ' A' ' 32' ' ' LEU . 24.3 m -149.98 167.48 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.529 ' O ' HG21 ' A' ' 52' ' ' VAL . 0.0 OUTLIER -132.97 -167.59 1.94 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 80.3 m -84.96 130.34 34.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.447 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 79.79 2.16 87.98 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -84.61 135.3 34.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.191 -1.182 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.4 tp -89.24 127.84 35.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.221 -0.924 . . . . 0.0 109.493 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.012 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -98.5 -171.22 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.285 -0.885 . . . . 0.0 109.148 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 40.0 mm-40 -140.81 164.99 28.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.492 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.772 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.7 p -80.47 75.62 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -0.901 . . . . 0.0 109.404 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 2.4 mt-10 162.7 -31.01 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.283 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 6.2 tt0 -71.01 151.0 45.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.449 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.445 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -70.4 165.94 51.35 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 1.012 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -125.84 -49.54 1.61 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -1.124 . . . . 0.0 109.559 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.428 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.5 m -146.74 158.11 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.482 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.954 ' O ' HG22 ' A' ' 16' ' ' ILE . 82.6 t -126.05 88.25 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.14 -0.975 . . . . 0.0 109.439 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.471 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -90.04 152.34 21.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.541 -179.943 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.53 -178.92 5.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.495 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.418 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -140.87 175.9 9.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.458 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.4 -49.94 9.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.514 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -147.09 32.92 0.9 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.77 169.1 25.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.865 . . . . 0.0 109.464 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 58.7 m -123.56 135.3 53.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.3 mmt -133.59 135.63 44.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' N ' ' A' ' 44' ' ' VAL . 24.9 tt0 -106.92 166.03 10.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.515 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 6.4 t -145.9 111.64 4.48 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.314 -0.866 . . . . 0.0 109.283 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.5 Cg_endo -77.26 -169.11 0.68 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.364 2.043 . . . . 0.0 110.437 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.5 OUTLIER -85.46 130.44 51.36 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 -179.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.405 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.88 -6.6 15.21 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.417 2.078 . . . . 0.0 110.482 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -160.37 149.26 17.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.529 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.433 ' O ' ' HB3' ' A' ' 74' ' ' PRO . . . -79.85 96.43 6.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.762 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -144.78 177.11 23.5 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.447 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.3 p -104.12 137.83 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -1.148 . . . . 0.0 109.483 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.529 HG21 ' O ' ' A' ' 21' ' ' LYS . 49.0 t -53.3 129.62 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.455 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.77 -18.14 10.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.301 -0.874 . . . . 0.0 109.44 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -164.88 150.05 9.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.195 -0.941 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.458 HG12 ' H ' ' A' ' 57' ' ' VAL . 61.0 t -129.88 117.93 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.413 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.07 15.4 29.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.419 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 69' ' ' ILE . 33.3 m -138.71 161.73 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.478 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.93 -165.0 1.8 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.86 123.99 28.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.33 -3.96 86.55 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.88 135.52 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.15 -1.206 . . . . 0.0 109.392 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -107.8 125.06 50.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.533 HD23 ' HB3' ' A' ' 67' ' ' ASP . 1.9 mp -131.35 154.02 49.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.46 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -111.03 150.37 29.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.469 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.7 OUTLIER -42.88 141.46 1.1 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 109.643 -179.825 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.14 -26.47 23.76 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.533 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -85.07 137.33 33.12 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -1.183 . . . . 0.0 109.546 -179.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -64.57 164.18 12.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 70' ' ' ILE . 44.2 mm -122.25 -68.24 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.122 -0.986 . . . . 0.0 109.534 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 69' ' ' ILE . 1.6 pp -138.91 179.87 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.237 -0.914 . . . . 0.0 109.471 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.433 ' N ' HD12 ' A' ' 70' ' ' ILE . 46.3 tt0 -134.03 127.83 33.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.762 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.9 tp -107.03 123.91 48.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.529 ' HG2' ' CB ' ' A' ' 1' ' ' SER . 0.0 OUTLIER -120.92 91.4 47.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.301 -0.874 . . . . 0.0 109.424 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.468 ' HD2' ' CA ' ' A' ' 1' ' ' SER . 35.2 Cg_endo . . . . . 0 C--N 1.308 -1.593 0 C-N-CA 122.644 2.229 . . . . 0.0 110.395 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.475 ' HB3' ' HD3' ' A' ' 74' ' ' PRO . 83.4 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.445 ' OE2' ' HG3' ' A' ' 48' ' ' LYS . 20.2 pt-20 -155.9 172.51 18.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.433 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.846 HD13 ' HG2' ' A' ' 71' ' ' GLU . 16.7 mm -116.52 134.39 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.304 -0.873 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -98.0 110.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.402 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.47 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -110.44 169.56 8.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.21 -0.931 . . . . 0.0 109.573 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG13 HD11 ' A' ' 9' ' ' ILE . 51.6 t -43.58 106.03 0.47 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.893 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.43 -170.5 0.95 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.486 2.124 . . . . 0.0 110.41 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -75.68 100.45 4.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.506 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.614 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.05 -24.81 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.286 -0.883 . . . . 0.0 109.313 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.9 -30.76 4.75 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -173.56 169.43 42.51 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -48.07 113.53 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.488 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.25 149.41 16.86 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.475 ' HB2' ' HG2' ' A' ' 62' ' ' LYS . 55.8 tt0 -115.27 126.37 54.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -1.144 . . . . 0.0 109.548 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.406 ' O ' ' HA2' ' A' ' 60' ' ' GLY . 40.6 t -55.93 148.41 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.883 HD11 ' HB2' ' A' ' 36' ' ' GLU . 50.4 mt -120.41 -50.4 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -159.3 143.55 15.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.286 -0.883 . . . . 0.0 109.413 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.771 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.84 155.2 18.5 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.297 -0.877 . . . . 0.0 109.384 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.612 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -122.83 35.83 4.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -146.13 -179.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.452 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.35 176.12 8.39 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.191 -0.943 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.1 m -77.6 148.41 35.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.445 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 68.49 7.53 53.43 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -85.01 143.1 29.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 0.0 109.515 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -102.21 116.02 31.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.446 179.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.8 OUTLIER -92.92 -171.57 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.194 -0.941 . . . . 0.0 109.245 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 mt-10 -140.56 172.91 12.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.186 -0.946 . . . . 0.0 109.391 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.691 ' O ' HG13 ' A' ' 28' ' ' VAL . 7.1 p -78.86 77.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.52 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.99 -41.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.312 -0.868 . . . . 0.0 109.485 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -61.43 146.6 47.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.464 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -63.13 -174.67 2.68 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.642 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -147.54 -71.9 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.147 -1.207 . . . . 0.0 109.518 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.506 HG13 HD22 ' A' ' 32' ' ' LEU . 8.0 m -131.52 175.84 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.943 . . . . 0.0 109.576 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.876 HG22 ' HB3' ' A' ' 43' ' ' GLU . 87.8 t -132.24 99.73 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.345 -0.847 . . . . 0.0 109.421 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.19 153.37 17.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.881 . . . . 0.0 109.486 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.883 ' HB2' HD11 ' A' ' 16' ' ' ILE . 1.5 tt0 -107.8 153.1 23.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.347 -0.845 . . . . 0.0 109.395 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.66 -179.37 3.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.462 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.45 -22.97 66.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.653 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 10.2 pttp -159.39 65.47 0.39 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.419 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 166.62 174.6 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.176 -0.953 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.4 m -154.95 93.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.397 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 55.7 mtp -116.65 138.82 51.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.275 -0.891 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.876 ' HB3' HG22 ' A' ' 34' ' ' VAL . 4.3 pt-20 -95.36 -176.31 3.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.24 -0.913 . . . . 0.0 109.389 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' A' ' 45' ' ' PRO . 68.0 t -143.33 139.38 16.49 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.1 Cg_endo -78.92 -168.14 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.554 2.169 . . . . 0.0 110.373 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.642 ' HA ' HD12 ' A' ' 32' ' ' LEU . 28.0 t -85.04 124.31 72.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.247 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HD3' HD12 ' A' ' 32' ' ' LEU . 35.8 Cg_endo -78.17 0.37 9.95 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.366 2.044 . . . . 0.0 110.434 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.646 ' HB3' HD13 ' A' ' 72' ' ' LEU . 3.5 mmtm -160.15 121.36 3.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.248 -0.908 . . . . 0.0 109.517 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.15 83.91 1.01 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.14 -170.03 16.96 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 23' ' ' GLY . 8.0 p -95.94 148.59 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -1.145 . . . . 0.0 109.531 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.0 t -75.94 137.69 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.472 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.454 ' HB3' ' O ' ' A' ' 71' ' ' GLU . 0.0 OUTLIER -90.73 -46.21 8.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.462 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.49 144.14 0.12 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.155 -0.965 . . . . 0.0 109.445 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.459 ' HA ' HG22 ' A' ' 70' ' ' ILE . 5.1 t -86.3 112.87 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.496 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.8 m -90.82 15.75 10.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.518 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.652 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.55 157.65 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.81 147.04 28.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.588 ' HB3' HD21 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -60.02 140.21 56.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.453 ' O ' ' OE2' ' A' ' 14' ' ' GLU . . . 90.7 -11.31 72.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -73.23 140.99 47.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -1.134 . . . . 0.0 109.434 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 14' ' ' GLU . 0.4 OUTLIER -98.38 133.78 42.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -140.11 162.3 35.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.454 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.7 tmtt? -128.71 159.71 34.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.557 ' N ' HG11 ' A' ' 6' ' ' VAL . 8.6 mt-10 -42.7 111.83 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.426 -0.796 . . . . 0.0 109.695 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.94 -33.85 2.15 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -84.22 142.51 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -1.149 . . . . 0.0 109.405 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.633 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -78.26 159.54 28.42 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.391 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.652 HG23 HG21 ' A' ' 57' ' ' VAL . 34.5 mm -123.7 -60.72 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.511 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.555 HG23 HG22 ' A' ' 69' ' ' ILE . 11.3 pt -142.54 -176.47 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 109.49 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.846 ' HG2' HD13 ' A' ' 3' ' ' ILE . 1.7 tm-20 -138.16 108.04 6.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.241 -0.912 . . . . 0.0 109.475 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.725 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.4 tt -89.94 140.99 29.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.468 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -110.22 157.89 36.73 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 0.0 109.499 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.475 ' HD3' ' HB3' ' A' ' 1' ' ' SER . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.534 0 C-N-CA 122.57 2.18 . . . . 0.0 110.45 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 79.5 p . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -123.2 178.59 5.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.465 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 71' ' ' GLU . 7.0 mt -120.15 127.71 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.197 -0.939 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.447 HG21 ' HG3' ' A' ' 47' ' ' PRO . 3.3 mt -98.98 126.62 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.439 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -111.03 161.01 16.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.903 HG23 HD11 ' A' ' 69' ' ' ILE . 72.8 t -50.23 142.08 14.85 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.346 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.73 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.22 -170.31 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.632 2.221 . . . . 0.0 110.493 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.95 102.32 10.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.388 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.84 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.3 -10.76 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 109.382 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.16 35.85 91.04 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.5 -173.48 43.79 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -82.96 172.88 12.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -1.153 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.51 146.71 18.69 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.496 ' O ' HD13 ' A' ' 35' ' ' LEU . 25.0 tt0 -132.03 118.24 19.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.288 -1.125 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.71 ' CG2' HD11 ' A' ' 63' ' ' LEU . 9.8 t -67.84 141.17 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.206 -0.934 . . . . 0.0 109.538 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.437 ' CG1' ' HB2' ' A' ' 36' ' ' GLU . 30.3 mm -112.22 -51.27 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.268 -0.895 . . . . 0.0 109.444 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -150.05 140.93 22.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.657 HD23 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -101.83 149.09 24.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.502 179.946 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.472 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.6 OUTLIER -140.69 50.77 1.66 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.269 -0.894 . . . . 0.0 109.533 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.845 HG21 ' CD2' ' A' ' 32' ' ' LEU . 0.9 OUTLIER -150.05 163.27 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.248 -0.908 . . . . 0.0 109.455 -179.956 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.29 165.39 23.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.221 -0.924 . . . . 0.0 109.441 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.524 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 72.4 m -81.16 141.25 34.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 109.513 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.3 -10.83 69.74 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 1.0 OUTLIER -82.86 133.65 35.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.494 179.975 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.5 OUTLIER -85.97 117.58 24.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -90.01 -171.57 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.719 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.6 pt-20 -147.78 166.38 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -0.933 . . . . 0.0 109.479 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.779 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.8 p -77.72 79.05 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.449 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 163.0 -35.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.517 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -70.0 140.55 52.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.2 -0.937 . . . . 0.0 109.437 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.45 165.05 47.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -128.01 -40.49 1.68 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -1.15 . . . . 0.0 109.506 -179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.478 HG12 ' HG ' ' A' ' 18' ' ' LEU . 30.0 m -157.27 174.49 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.482 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.71 104.3 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 14' ' ' GLU . 4.5 mm? -89.96 152.55 21.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.256 -0.903 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.437 ' HB2' ' CG1' ' A' ' 16' ' ' ILE . 0.3 OUTLIER -131.74 116.19 16.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 -179.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.61 -172.62 3.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.47 -57.38 8.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.268 -0.895 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.3 mttt -140.4 49.66 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -154.88 104.67 2.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.339 -0.851 . . . . 0.0 109.478 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.97 119.28 31.56 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.87 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 5.4 ptp -136.51 162.35 33.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.325 -0.859 . . . . 0.0 109.418 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -106.42 172.36 6.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 22.9 t -142.75 95.89 6.25 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.409 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.517 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.9 Cg_endo -77.47 -168.73 0.63 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.481 2.12 . . . . 0.0 110.52 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.527 ' HB2' HG21 ' A' ' 26' ' ' ILE . 11.6 t -85.42 130.68 50.52 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.356 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.447 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.61 -3.04 12.99 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.401 2.067 . . . . 0.0 110.43 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -160.3 145.77 15.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 -179.997 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.93 93.22 8.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.475 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.864 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -143.52 -155.14 6.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.9 p -117.04 142.3 31.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.307 -1.114 . . . . 0.0 109.465 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.524 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 55.0 t -65.37 110.29 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.441 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.58 -35.38 27.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.494 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.8 t -169.86 158.13 7.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.552 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.41 HG12 ' H ' ' A' ' 57' ' ' VAL . 77.7 t -117.44 115.23 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.14 17.87 20.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.551 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.431 HG13 ' O ' ' A' ' 69' ' ' ILE . 29.2 m -123.1 162.23 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 109.483 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 tptt -134.26 172.58 12.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.442 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -81.86 124.33 29.61 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.156 -0.965 . . . . 0.0 109.513 179.959 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 98.33 -9.55 63.0 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -75.87 153.93 36.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -1.176 . . . . 0.0 109.482 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -99.3 121.11 40.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.71 HD11 ' CG2' ' A' ' 15' ' ' VAL . 11.1 mt -102.59 95.16 6.05 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.428 ' O ' ' C ' ' A' ' 65' ' ' GLU . 26.8 ttpt -85.43 138.64 32.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 109.386 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.473 ' HB3' HG13 ' A' ' 9' ' ' ILE . 11.5 pt-20 -43.06 150.63 0.16 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.67 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.26 -26.37 13.79 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -85.17 146.02 27.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.502 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -61.64 -175.15 0.05 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.274 -0.891 . . . . 0.0 109.404 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.903 HD11 HG23 ' A' ' 6' ' ' VAL . 39.8 mm -146.95 -70.37 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.538 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -143.96 -172.33 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.214 -0.929 . . . . 0.0 109.451 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.422 ' HG2' ' HA ' ' A' ' 3' ' ' ILE . 9.6 mt-10 -137.81 105.05 5.46 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.205 -0.935 . . . . 0.0 109.585 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.864 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -90.63 135.14 33.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.179 -0.951 . . . . 0.0 109.484 179.893 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.409 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 27.7 tt0 -113.45 91.33 19.79 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.504 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.507 0 C-N-CA 122.635 2.223 . . . . 0.0 110.423 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.411 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 31.3 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -122.87 155.92 35.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.406 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 4' ' ' ILE . 2.1 mp -117.12 146.89 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 37.9 mm -124.46 112.95 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -100.8 172.83 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.745 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.8 t -61.89 142.26 95.09 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.399 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.745 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.16 -171.24 1.15 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.505 2.137 . . . . 0.0 110.431 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -85.01 102.82 13.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.417 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.486 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.76 -40.19 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.282 -179.925 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.9 29.85 30.62 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.84 -128.52 0.96 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.488 ' OD2' ' CE ' ' A' ' 62' ' ' LYS . 18.3 p-10 -136.31 135.81 39.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.202 -1.176 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.59 111.43 2.55 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.401 ' HG3' ' CG ' ' A' ' 62' ' ' LYS . 3.0 tt0 -101.25 133.85 45.19 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -1.158 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.8 t -72.18 140.01 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.534 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.704 HD12 HG12 ' A' ' 34' ' ' VAL . 20.1 mt -100.8 -39.34 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.372 -0.83 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -164.64 -173.94 3.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.506 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.4 tp -136.7 102.05 4.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.442 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.2 pp -95.88 29.33 2.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.479 HG11 ' HG ' ' A' ' 32' ' ' LEU . 34.2 m -133.23 159.54 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -125.4 174.87 7.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -84.99 141.0 30.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.488 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.456 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 76.6 8.59 86.16 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.95 131.99 34.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.254 -1.145 . . . . 0.0 109.441 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.457 ' HA ' HD22 ' A' ' 25' ' ' LEU . 0.3 OUTLIER -86.01 111.7 20.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.716 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.36 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.288 -0.883 . . . . 0.0 109.25 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 31.8 mt-10 -147.56 -174.51 4.56 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.925 . . . . 0.0 109.446 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.752 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.4 p -84.83 72.76 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.9 -40.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.459 179.955 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.525 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.6 tt0 -54.11 142.49 25.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.62 168.32 54.61 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.66 ' O ' HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -129.31 -40.26 1.46 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.234 -1.157 . . . . 0.0 109.56 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 32' ' ' LEU . 13.0 m -161.01 176.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.112 -0.993 . . . . 0.0 109.534 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.704 HG12 HD12 ' A' ' 16' ' ' ILE . 98.9 t -131.9 97.9 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.422 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.07 146.25 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.439 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.95 177.84 6.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.0 m -136.33 160.91 37.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.87 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.11 -28.85 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.214 -0.929 . . . . 0.0 109.405 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.471 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 3.0 tttm -160.02 52.62 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 176.93 -166.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.174 -0.954 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.2 t -152.73 140.8 20.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.46 150.53 42.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -0.893 . . . . 0.0 109.509 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -98.14 169.71 9.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 55.5 t -146.47 98.39 4.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.235 -0.915 . . . . 0.0 109.422 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.63 -169.05 0.67 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.437 2.091 . . . . 0.0 110.412 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.4 134.17 40.92 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.454 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.489 ' HG2' HG13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.96 -5.37 14.53 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.425 2.083 . . . . 0.0 110.399 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.469 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -160.41 144.99 14.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.326 -0.859 . . . . 0.0 109.513 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.5 99.18 3.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.421 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.862 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -153.79 175.65 32.02 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.456 HG22 ' HA2' ' A' ' 23' ' ' GLY . 11.3 p -95.78 145.16 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -1.131 . . . . 0.0 109.574 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -63.87 114.24 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' A' ' 73' ' ' GLU . 2.8 tttp -85.21 -56.74 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.5 m -143.86 127.44 17.02 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.498 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 t -96.23 128.78 47.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.448 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.9 m -119.59 34.0 5.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.425 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.676 HG13 ' O ' ' A' ' 69' ' ' ILE . 27.2 m -137.54 157.5 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.47 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -141.08 149.53 41.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.918 . . . . 0.0 109.46 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.77 128.58 35.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.497 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.1 -23.2 29.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -80.78 148.89 29.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.184 -1.186 . . . . 0.0 109.489 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.488 ' CE ' ' OD2' ' A' ' 12' ' ' ASP . 3.1 tttt -103.14 112.99 26.11 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.916 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.744 HD22 ' HB3' ' A' ' 67' ' ' ASP . 12.6 mt -102.01 135.32 43.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.287 -0.883 . . . . 0.0 109.434 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -100.51 152.47 20.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.31 -0.869 . . . . 0.0 109.439 -179.956 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.9 pt-20 -42.88 150.49 0.16 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.55 -17.58 51.45 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.744 ' HB3' HD22 ' A' ' 63' ' ' LEU . 1.1 m-20 -84.0 131.21 34.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -1.131 . . . . 0.0 109.436 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -57.4 159.78 4.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.238 -0.914 . . . . 0.0 109.475 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.726 HD11 ' CG2' ' A' ' 6' ' ' VAL . 33.0 mm -117.6 -58.15 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.486 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 69' ' ' ILE . 2.4 pp -158.36 -177.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.239 -0.913 . . . . 0.0 109.43 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.424 ' HG2' HG13 ' A' ' 3' ' ' ILE . 57.5 mt-10 -133.58 127.46 33.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.971 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -99.5 142.47 30.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.484 -179.954 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.481 ' HB2' ' HD2' ' A' ' 53' ' ' LYS . 0.2 OUTLIER -118.85 90.06 39.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.186 -0.946 . . . . 0.0 109.47 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.971 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.533 0 C-N-CA 122.625 2.217 . . . . 0.0 110.413 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 96.5 p . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.244 0.545 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -93.31 140.7 29.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 109.52 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.448 HD13 ' HG3' ' A' ' 71' ' ' GLU . 18.0 mm -80.44 160.35 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 96.6 mt -122.97 96.6 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.333 -0.855 . . . . 0.0 109.415 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.655 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -92.01 -178.76 5.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.289 -0.882 . . . . 0.0 109.558 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.731 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.8 t -70.93 142.7 88.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.369 -0.832 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.03 -170.02 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.494 2.13 . . . . 0.0 110.377 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.85 104.12 14.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.252 -0.905 . . . . 0.0 109.477 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.585 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.19 -41.68 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.208 -0.932 . . . . 0.0 109.273 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.88 -21.04 12.69 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.77 -142.25 3.91 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 3.1 m-20 -102.84 165.94 10.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.289 -1.124 . . . . 0.0 109.415 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.33 165.44 21.25 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -146.44 121.39 10.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.199 -1.177 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.559 HG23 HD13 ' A' ' 63' ' ' LEU . 21.6 t -70.23 149.49 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' ' OE1' ' A' ' 17' ' ' GLU . 69.1 mt -127.15 -40.01 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.284 -0.885 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -156.51 126.44 6.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.489 -179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.427 HD13 HG11 ' A' ' 15' ' ' VAL . 0.7 OUTLIER -102.41 141.53 35.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.428 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.732 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -132.61 61.54 1.67 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.498 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.78 164.42 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 28.6 mmtt -122.98 157.2 33.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 22' ' ' THR . 13.3 t -84.74 128.9 34.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.96 -9.17 73.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.472 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 1.6 m-20 -83.53 136.8 34.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -1.157 . . . . 0.0 109.551 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.448 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -86.18 126.5 34.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.491 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.2 mt -90.33 -171.32 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.294 -0.879 . . . . 0.0 109.193 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 5.6 mt-10 -137.39 156.12 48.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.205 -0.934 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.735 ' O ' HG13 ' A' ' 28' ' ' VAL . 9.6 p -79.03 82.08 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.85 -35.89 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.395 -0.816 . . . . 0.0 109.433 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -71.59 152.13 43.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.44 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.47 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.32 -169.31 0.29 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.536 HD11 ' CD1' ' A' ' 26' ' ' ILE . 8.1 tp -153.31 -70.18 0.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -1.154 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.7 m -134.02 173.56 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.486 HG22 ' HB3' ' A' ' 43' ' ' GLU . 97.1 t -133.73 102.33 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.29 170.07 8.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.311 -0.868 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.85 137.25 51.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.482 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.64 176.89 5.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.21 -0.931 . . . . 0.0 109.5 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.55 -45.82 13.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.403 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.4 mttm -152.3 67.55 0.84 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.492 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 167.66 99.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.208 -0.932 . . . . 0.0 109.479 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.5 t -80.02 126.53 31.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.452 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -147.2 159.46 43.61 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -0.875 . . . . 0.0 109.512 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.486 ' HB3' HG22 ' A' ' 34' ' ' VAL . 3.5 pt-20 -109.4 169.3 8.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.39 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' A' ' 45' ' ' PRO . 94.7 t -132.5 139.36 34.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.405 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.97 -168.23 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.432 0 C-N-CA 122.549 2.166 . . . . 0.0 110.361 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.4 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.0 OUTLIER -85.16 113.55 50.93 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.385 -0.822 . . . . 0.0 109.365 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 36.0 Cg_endo -77.87 3.37 7.02 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.332 2.021 . . . . 0.0 110.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 1.024 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -160.02 110.28 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.465 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.2 90.62 1.6 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.939 . . . . 0.0 109.601 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.83 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -143.69 -157.73 7.29 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 73' ' ' GLU . 11.1 p -111.48 128.53 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -1.148 . . . . 0.0 109.509 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 48.8 t -58.27 134.83 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.474 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.87 -33.28 7.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.291 -0.881 . . . . 0.0 109.458 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 173.27 144.31 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.509 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 57' ' ' VAL . 52.2 t -99.68 135.11 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.6 m -105.63 16.19 25.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.346 -0.846 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 1.009 HG11 HD21 ' A' ' 63' ' ' LEU . 1.5 m -136.47 157.34 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.443 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -110.37 167.17 10.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.02 137.2 38.84 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.493 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.1 -11.07 68.41 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -79.21 148.4 32.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.5 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.712 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 mttp -82.64 165.37 20.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 HG11 ' A' ' 57' ' ' VAL . 3.4 mp -148.77 113.42 5.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -86.03 137.78 32.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.241 -0.912 . . . . 0.0 109.455 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 64' ' ' LYS . 25.7 pt-20 -42.88 151.41 0.13 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 109.672 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.08 -18.2 41.99 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -85.0 141.68 30.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.262 -1.14 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.19 172.42 9.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.914 HG22 HG23 ' A' ' 70' ' ' ILE . 2.0 mp -134.76 -58.49 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.914 HG23 HG22 ' A' ' 69' ' ' ILE . 7.4 pt -147.23 -179.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.461 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.448 ' HG3' HD13 ' A' ' 3' ' ' ILE . 32.4 tt0 -131.18 117.33 18.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.024 HD22 ' HB3' ' A' ' 48' ' ' LYS . 0.7 OUTLIER -97.54 147.08 24.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -0.863 . . . . 0.0 109.486 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.522 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 2.5 tp10 -120.09 89.7 43.24 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo . . . . . 0 C--N 1.308 -1.571 0 C-N-CA 122.651 2.234 . . . . 0.0 110.375 -179.936 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -86.69 111.01 20.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.253 -0.904 . . . . 0.0 109.285 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.679 HD12 ' OE2' ' A' ' 71' ' ' GLU . 2.2 tt -79.96 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.448 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 40.2 mm -122.78 122.77 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.564 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -92.11 -176.13 4.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.554 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.986 ' CG2' HD11 ' A' ' 69' ' ' ILE . 53.4 t -74.75 139.99 74.31 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.347 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.648 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.39 -174.37 2.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.549 2.166 . . . . 0.0 110.438 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -85.19 108.88 17.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.413 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.415 ' CD1' ' HA3' ' A' ' 13' ' ' GLY . 0.0 OUTLIER -104.79 -7.27 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.281 -0.887 . . . . 0.0 109.396 -179.768 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.58 21.95 13.54 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 150.2 -133.53 4.4 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -85.54 170.85 12.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.243 -1.151 . . . . 0.0 109.464 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.415 ' HA3' ' CD1' ' A' ' 9' ' ' ILE . . . -141.05 148.25 19.9 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.454 ' HG3' ' HA ' ' A' ' 62' ' ' LYS . 1.0 OUTLIER -135.73 130.43 34.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -1.17 . . . . 0.0 109.484 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.53 ' HA ' HD23 ' A' ' 35' ' ' LEU . 38.2 t -70.1 147.2 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.899 HD11 ' HB2' ' A' ' 36' ' ' GLU . 42.7 mt -118.95 -53.91 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.326 -0.859 . . . . 0.0 109.558 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -134.34 133.81 41.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.402 HD12 ' CG1' ' A' ' 33' ' ' VAL . 0.4 OUTLIER -115.24 102.47 9.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.496 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.487 HD23 ' H ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -93.66 41.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 m -143.74 156.08 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.533 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.405 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.07 -176.83 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.9 m -84.08 133.92 34.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.482 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.2 5.38 89.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.405 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.3 m-20 -84.94 135.49 34.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -1.175 . . . . 0.0 109.532 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.57 115.7 27.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.269 -0.895 . . . . 0.0 109.471 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.712 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.6 mt -90.46 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.322 -0.861 . . . . 0.0 109.219 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.712 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.8 mt-10 -135.37 177.68 7.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.645 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.3 p -85.4 59.89 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.588 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 3.3 tt0 167.5 -32.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.249 -0.907 . . . . 0.0 109.228 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -52.35 145.41 11.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.414 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.449 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.03 171.03 39.88 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.54 ' CD1' HD13 ' A' ' 26' ' ' ILE . 0.6 OUTLIER -130.11 -56.04 1.11 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -1.156 . . . . 0.0 109.546 -179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 18' ' ' LEU . 36.0 m -151.56 -176.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.496 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.503 HG12 HD12 ' A' ' 16' ' ' ILE . 46.2 t -139.01 97.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 15' ' ' VAL . 3.1 mt -90.08 158.9 17.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.899 ' HB2' HD11 ' A' ' 16' ' ' ILE . 2.0 tt0 -123.27 153.04 40.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.408 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.6 m -130.25 -176.58 4.0 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.464 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.98 -34.62 65.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.249 -0.907 . . . . 0.0 109.484 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 20.9 tttp -159.9 61.19 0.36 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.402 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.14 88.21 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 109.491 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.436 ' HB3' ' CG ' ' A' ' 36' ' ' GLU . 99.6 p -105.1 112.97 26.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.383 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.2 mtt -130.02 -175.5 3.64 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.479 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -114.23 162.19 16.87 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.25 -0.906 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 59.2 t -137.53 117.57 10.35 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.33 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.96 -168.69 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.28 1.987 . . . . 0.0 110.434 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.497 ' HA ' HD13 ' A' ' 32' ' ' LEU . 6.0 t -85.27 138.08 36.7 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.402 -0.811 . . . . 0.0 109.328 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.82 -4.82 14.3 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.417 2.078 . . . . 0.0 110.478 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.573 ' O ' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.35 128.1 4.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -0.859 . . . . 0.0 109.521 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.86 98.51 1.58 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.903 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.491 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -152.12 -135.98 2.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.0 p -132.27 151.36 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.189 -1.183 . . . . 0.0 109.439 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.5 t -73.49 119.95 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -91.97 -43.21 9.57 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.916 . . . . 0.0 109.407 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.8 t -149.48 142.84 25.23 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 57' ' ' VAL . 21.0 t -105.02 106.79 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.86 10.56 13.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.288 -0.883 . . . . 0.0 109.436 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.426 ' H ' HG12 ' A' ' 55' ' ' VAL . 17.2 m -124.98 177.73 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.305 -0.872 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.479 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -128.48 -156.02 0.73 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.87 80.67 9.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.43 ' HA2' ' HB ' ' A' ' 15' ' ' VAL . . . 74.89 46.22 18.03 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 4.9 m-20 -84.96 172.24 11.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.296 -1.12 . . . . 0.0 109.435 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.454 ' HA ' ' HG3' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -97.62 145.3 26.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.196 -0.94 . . . . 0.0 109.447 -179.92 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.92 -172.52 4.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.467 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -138.45 147.08 42.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.86 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.485 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 4.2 pt-20 -45.39 148.86 0.6 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.273 -0.892 . . . . 0.0 109.694 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 5' ' ' ARG . . . 85.86 -43.51 3.25 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 68' ' ' ALA . 0.9 OUTLIER -50.76 134.46 24.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -1.128 . . . . 0.0 109.602 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -48.21 174.04 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -0.886 . . . . 0.0 109.535 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.986 HD11 ' CG2' ' A' ' 6' ' ' VAL . 26.9 mm -143.51 -58.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.238 -0.914 . . . . 0.0 109.498 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.656 ' C ' HD12 ' A' ' 70' ' ' ILE . 2.4 pp -150.98 179.56 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.482 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.679 ' OE2' HD12 ' A' ' 3' ' ' ILE . 22.3 mt-10 -145.56 97.25 2.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.511 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 48' ' ' LYS . 0.4 OUTLIER -90.76 124.86 35.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.238 -0.914 . . . . 0.0 109.433 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.527 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 37.1 tt0 -91.42 140.99 25.6 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.254 -0.903 . . . . 0.0 109.374 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.6 Cg_endo . . . . . 0 C--N 1.31 -1.455 0 C-N-CA 122.486 2.124 . . . . 0.0 110.373 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.433 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 23.4 p . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -126.77 147.55 49.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 109.403 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.531 HG22 ' N ' ' A' ' 4' ' ' ILE . 3.5 mp -85.11 162.88 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.211 -0.931 . . . . 0.0 109.484 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.531 ' N ' HG22 ' A' ' 3' ' ' ILE . 3.0 mp -127.75 104.27 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 4.3 ptp85 -93.03 -172.44 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.145 -0.972 . . . . 0.0 109.473 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 42.0 t -73.99 136.59 76.4 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.297 -0.877 . . . . 0.0 109.389 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.51 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.94 -176.61 3.38 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.481 2.121 . . . . 0.0 110.383 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -85.18 101.21 12.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.183 -0.948 . . . . 0.0 109.322 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.71 -45.95 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.249 -0.907 . . . . 0.0 109.259 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.78 16.07 11.25 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.7 -159.42 16.64 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 7.5 m-20 -104.31 119.82 39.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -1.167 . . . . 0.0 109.516 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.4 151.62 23.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.5 mp0 -131.58 119.82 22.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.246 -1.149 . . . . 0.0 109.442 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.8 t -65.37 134.67 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.495 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 16' ' ' ILE . 18.2 mm -115.19 -52.74 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.438 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -129.09 123.47 32.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.499 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.709 ' HG ' HG22 ' A' ' 20' ' ' VAL . 5.9 tp -99.84 115.37 29.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.893 . . . . 0.0 109.465 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -113.55 57.18 0.68 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.482 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.777 HG11 ' HG ' ' A' ' 32' ' ' LEU . 29.3 m -139.73 158.44 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.263 -0.898 . . . . 0.0 109.435 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.26 162.6 33.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -0.956 . . . . 0.0 109.46 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.423 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 0.2 OUTLIER -84.93 125.61 32.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.259 -0.901 . . . . 0.0 109.512 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.489 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.03 -8.95 67.88 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -78.63 132.05 36.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -1.138 . . . . 0.0 109.5 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.573 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -85.35 115.71 23.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.75 ' CD1' HD11 ' A' ' 32' ' ' LEU . 2.6 mt -91.99 -171.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.3 -0.875 . . . . 0.0 109.211 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 20.0 pt-20 -146.3 172.33 13.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.733 ' O ' HG13 ' A' ' 28' ' ' VAL . 11.6 p -81.12 74.83 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.211 -0.93 . . . . 0.0 109.357 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.4 tm-20 167.87 -39.37 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.332 -0.855 . . . . 0.0 109.299 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -62.47 144.64 55.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.393 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.32 164.34 54.51 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.777 ' HG ' HG11 ' A' ' 20' ' ' VAL . 2.6 tp -124.61 -38.37 2.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -1.166 . . . . 0.0 109.398 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.502 HG13 ' C ' ' A' ' 32' ' ' LEU . 9.3 m -157.77 167.26 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.582 HG22 ' HG3' ' A' ' 43' ' ' GLU . 97.9 t -131.47 105.04 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.468 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.511 ' N ' HD12 ' A' ' 35' ' ' LEU . 9.8 mp -90.23 148.69 22.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -138.56 116.78 11.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.547 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.0 m -100.1 -175.74 3.03 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.26 -0.9 . . . . 0.0 109.449 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.79 -42.22 16.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -154.62 57.45 0.69 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -167.87 97.12 0.45 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.926 . . . . 0.0 109.51 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.5 m -99.7 120.64 40.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.436 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 17.2 mtp -128.63 134.25 48.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.582 ' HG3' HG22 ' A' ' 34' ' ' VAL . 26.0 tt0 -91.56 162.73 14.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.2 -0.937 . . . . 0.0 109.387 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -144.45 99.17 4.91 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.33 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.528 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.7 Cg_endo -77.42 -168.6 0.61 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.526 2.151 . . . . 0.0 110.477 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 1.1 t -85.34 127.45 63.64 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.22 -0.925 . . . . 0.0 109.377 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.43 -2.51 12.56 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.345 2.03 . . . . 0.0 110.43 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 2.4 mtmt -160.19 143.11 13.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.389 -0.819 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.81 97.95 7.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -147.0 -172.51 17.34 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' O ' ' A' ' 73' ' ' GLU . 2.5 p -104.63 127.47 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.456 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.423 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 50.5 t -50.57 133.91 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.411 ' HG2' ' OG ' ' A' ' 54' ' ' SER . 18.1 tttt -101.99 -58.8 1.81 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -0.922 . . . . 0.0 109.496 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.411 ' OG ' ' HG2' ' A' ' 53' ' ' LYS . 0.7 OUTLIER -150.56 153.87 36.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 109.474 -179.969 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' A' ' 70' ' ' ILE . 9.1 t -103.16 131.68 51.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.266 -0.896 . . . . 0.0 109.493 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.0 m -113.62 19.83 16.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.244 -0.91 . . . . 0.0 109.462 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.671 HG11 HG23 ' A' ' 69' ' ' ILE . 17.8 m -132.71 -178.62 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.945 . . . . 0.0 109.396 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.6 ttpt -138.91 158.6 43.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 59' ' ' LEU . 3.4 pp -76.68 123.02 25.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.243 -0.911 . . . . 0.0 109.492 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.97 -8.35 73.28 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -78.01 144.16 36.91 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.268 -1.136 . . . . 0.0 109.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -91.13 122.91 34.18 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.24 -0.913 . . . . 0.0 109.507 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.81 HD13 ' CD1' ' A' ' 69' ' ' ILE . 19.2 mt -102.74 152.14 21.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.895 . . . . 0.0 109.442 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -122.54 152.45 40.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.436 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.53 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 77.2 mt-10 -47.7 148.11 1.64 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.245 -0.909 . . . . 0.0 109.725 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.03 -40.19 3.09 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -61.97 131.6 50.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -1.158 . . . . 0.0 109.549 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.573 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -62.1 -174.88 0.06 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.81 ' CD1' HD13 ' A' ' 63' ' ' LEU . 44.2 mm -146.45 -64.99 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.874 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.661 HD11 ' CD2' ' A' ' 32' ' ' LEU . 2.8 pt -148.56 -172.45 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.297 -0.877 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 3' ' ' ILE . 1.7 tt0 -142.99 117.48 9.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.589 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.896 HD23 ' HD3' ' A' ' 74' ' ' PRO . 0.5 OUTLIER -95.47 137.38 34.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.382 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.52 ' O ' HG12 ' A' ' 51' ' ' VAL . 3.4 tt0 -115.71 85.84 14.81 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.896 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.539 0 C-N-CA 122.654 2.236 . . . . 0.0 110.371 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.71 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.793 HD22 ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.71 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.793 HD22 ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo . . . . . 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.422 ' O ' ' HG2' ' A' ' 2' ' ' GLU . 48.4 p . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.295 0.569 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 1' ' ' SER . 14.0 mt-10 -145.28 145.35 31.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.2 mt -85.13 148.89 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.197 -0.939 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.517 HD13 HD11 ' A' ' 70' ' ' ILE . 2.3 mp -116.14 108.01 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 1.2 ptp85 -98.71 176.73 5.53 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.836 HG23 HD11 ' A' ' 69' ' ' ILE . 78.9 t -74.04 142.43 79.36 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.319 -0.863 . . . . 0.0 109.359 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.738 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.82 -171.53 1.22 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.463 2.109 . . . . 0.0 110.435 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -85.03 104.88 15.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.462 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.59 -31.13 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.226 -0.921 . . . . 0.0 109.215 -179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.68 -11.41 59.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.03 145.07 15.09 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -45.96 151.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.505 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.17 119.9 3.58 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -86.77 129.01 35.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.479 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.3 t -76.5 131.94 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.857 HD11 ' HB2' ' A' ' 36' ' ' GLU . 39.5 mt -95.04 -51.17 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.169 -0.957 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -174.07 163.5 3.96 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.474 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.717 HD23 HG23 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -108.41 139.21 43.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 109.449 -179.99 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.7 15.11 11.68 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.717 HG23 HD23 ' A' ' 18' ' ' LEU . 1.9 m -149.87 164.22 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.887 . . . . 0.0 109.527 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -114.9 -163.87 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.337 -0.852 . . . . 0.0 109.493 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.4 t -84.96 139.86 31.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.302 -0.874 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.01 8.37 61.2 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.449 ' C ' HG23 ' A' ' 51' ' ' VAL . 11.7 m-20 -84.95 133.02 34.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.207 -1.173 . . . . 0.0 109.522 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 1.1 tp -79.98 125.49 29.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.268 -0.895 . . . . 0.0 109.475 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.747 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.04 -171.41 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.251 -0.906 . . . . 0.0 109.204 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.722 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.4 mt-10 -135.16 175.39 9.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.432 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.77 ' O ' HG13 ' A' ' 28' ' ' VAL . 11.6 p -85.15 64.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.505 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.88 -43.68 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.496 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.9 tt0 -45.25 149.59 0.5 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.518 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.442 ' N ' ' HG2' ' A' ' 30' ' ' GLN . . . -74.39 166.89 54.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.823 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -126.94 -37.5 2.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -1.175 . . . . 0.0 109.561 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.624 HG22 ' HB ' ' A' ' 44' ' ' VAL . 23.5 m -152.85 154.32 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.561 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.592 HG22 ' OE2' ' A' ' 43' ' ' GLU . 60.5 t -125.74 91.93 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.307 -0.871 . . . . 0.0 109.419 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mp -89.98 153.75 20.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.51 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.857 ' HB2' HD11 ' A' ' 16' ' ' ILE . 38.3 tt0 -143.36 134.46 25.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.274 -0.891 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.61 174.24 7.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.881 . . . . 0.0 109.547 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.0 -13.18 57.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.46 -56.27 3.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -0.935 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -164.72 -149.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.927 . . . . 0.0 109.401 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.7 p -136.34 144.59 44.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -136.85 -175.97 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.592 ' OE2' HG22 ' A' ' 34' ' ' VAL . 6.4 tt0 -150.24 162.18 40.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.52 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.624 ' HB ' HG22 ' A' ' 33' ' ' VAL . 38.2 t -147.5 101.37 3.76 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.262 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.525 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.6 Cg_endo -77.2 -168.94 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.399 2.066 . . . . 0.0 110.506 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.823 ' HA ' HD12 ' A' ' 32' ' ' LEU . 3.8 t -85.28 132.52 44.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.441 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.503 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.87 -5.28 14.55 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 C-N-CA 122.489 2.126 . . . . 0.0 110.402 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' A' ' 46' ' ' SER . 5.6 tptt -160.23 144.71 14.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.35 -0.844 . . . . 0.0 109.491 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.95 91.05 4.17 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.791 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -139.69 -135.19 3.22 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.554 ' N ' HD11 ' A' ' 72' ' ' LEU . 7.2 p -149.08 150.57 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -1.178 . . . . 0.0 109.535 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.0 t -73.01 129.45 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 3.5 tttp -113.63 -27.59 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.266 -0.896 . . . . 0.0 109.564 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -154.61 128.28 8.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.176 -0.953 . . . . 0.0 109.508 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.553 HG12 ' H ' ' A' ' 57' ' ' VAL . 75.8 t -113.08 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.465 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.37 34.79 4.95 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.553 ' H ' HG12 ' A' ' 55' ' ' VAL . 3.4 m -140.75 170.18 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.26 -0.9 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.443 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -132.59 157.77 43.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.926 . . . . 0.0 109.454 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -83.09 131.79 35.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.496 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.81 -11.48 68.72 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.443 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.7 OUTLIER -81.65 163.93 22.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -1.182 . . . . 0.0 109.435 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 mttt -104.13 120.24 40.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.475 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.434 HD13 ' HA ' ' A' ' 63' ' ' LEU . 1.2 mm? -105.47 137.28 43.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.467 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -101.47 140.32 35.93 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.278 -0.888 . . . . 0.0 109.469 179.964 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.2 OUTLIER -42.76 151.6 0.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.29 -0.881 . . . . 0.0 109.675 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.09 -24.54 21.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.47 134.49 34.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.289 -1.124 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.49 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -59.23 179.23 0.11 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.513 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.836 HD11 HG23 ' A' ' 6' ' ' VAL . 31.8 mm -134.73 -67.63 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.178 -0.951 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.748 HG23 HG22 ' A' ' 69' ' ' ILE . 2.6 pp -147.82 -172.1 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.73 ' N ' HD12 ' A' ' 70' ' ' ILE . 14.5 mt-10 -144.62 136.48 25.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.791 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.3 tp -113.01 112.32 23.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 53' ' ' LYS . 23.7 tt0 -113.78 90.38 18.48 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.493 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.8 Cg_endo . . . . . 0 C--N 1.309 -1.547 0 C-N-CA 122.612 2.208 . . . . 0.0 110.484 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 48.6 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -97.02 175.75 6.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.473 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.561 ' H ' HD12 ' A' ' 3' ' ' ILE . 3.7 mp -104.76 146.97 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.2 mt -104.25 99.26 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.44 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -91.26 165.62 13.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.344 -0.847 . . . . 0.0 109.458 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.8 t -55.0 142.22 57.05 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.888 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.14 -172.58 1.53 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.489 2.126 . . . . 0.0 110.387 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -84.03 104.33 14.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.902 . . . . 0.0 109.503 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.465 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.79 -41.42 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.297 -0.877 . . . . 0.0 109.354 -179.929 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.69 10.73 52.5 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -146.04 -125.14 1.68 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.65 123.67 38.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.15 . . . . 0.0 109.393 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.68 147.43 50.94 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.07 101.79 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -1.119 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.734 HG11 ' O ' ' A' ' 58' ' ' LYS . 38.4 t -48.44 149.76 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.8 HD12 HG12 ' A' ' 34' ' ' VAL . 43.9 mt -127.16 -62.22 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 109.454 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -150.11 149.74 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.777 ' CD1' HG12 ' A' ' 33' ' ' VAL . 2.8 tp -119.47 138.84 52.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 HG13 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -127.98 54.35 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.516 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.621 HG13 HD12 ' A' ' 19' ' ' LEU . 15.3 m -144.42 159.8 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.17 -0.956 . . . . 0.0 109.399 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.494 ' CB ' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -111.37 -171.18 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 109.548 179.954 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.4 m -85.18 119.39 25.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.78 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.479 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 72.37 2.17 53.64 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.639 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.494 ' CG ' ' CB ' ' A' ' 21' ' ' LYS . 2.1 m-20 -69.7 129.44 39.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.299 . . . . 0.0 109.123 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.908 HD21 ' HB1' ' A' ' 49' ' ' ALA . 1.0 OUTLIER -90.93 144.14 25.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.413 -0.805 . . . . 0.0 109.728 -179.697 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.987 HD12 ' CA ' ' A' ' 50' ' ' GLY . 1.3 mt -114.58 -170.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.776 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -100.46 172.45 7.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.079 -1.013 . . . . 0.0 109.405 179.963 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.743 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.8 p -83.89 68.64 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.497 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 163.03 -29.73 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -60.13 151.59 26.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.517 179.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -67.06 163.61 44.84 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.705 HD22 ' CD1' ' A' ' 70' ' ' ILE . 0.2 OUTLIER -125.75 -38.81 2.18 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.537 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.777 HG12 ' CD1' ' A' ' 18' ' ' LEU . 28.7 m -152.23 171.64 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.8 HG12 HD12 ' A' ' 16' ' ' ILE . 60.7 t -127.91 95.67 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.309 -0.87 . . . . 0.0 109.417 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 mt -89.88 162.14 15.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.922 . . . . 0.0 109.558 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.53 ' CA ' HD11 ' A' ' 16' ' ' ILE . 8.2 tt0 -114.99 164.13 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -135.43 -177.07 4.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -56.49 -44.06 80.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -0.886 . . . . 0.0 109.471 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.47 48.42 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -176.0 124.03 0.19 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.522 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.0 125.68 32.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.342 -0.849 . . . . 0.0 109.484 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.462 ' SD ' ' HG2' ' A' ' 7' ' ' PRO . 2.3 ptm -115.98 129.9 56.58 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -96.64 167.18 11.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.208 -0.933 . . . . 0.0 109.415 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 2.7 t -144.37 100.1 4.86 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.242 -0.911 . . . . 0.0 109.366 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.2 Cg_endo -77.68 -170.03 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.411 2.074 . . . . 0.0 110.359 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.458 ' HB2' HD12 ' A' ' 32' ' ' LEU . 6.3 t -85.96 142.66 36.61 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.432 -0.792 . . . . 0.0 109.364 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.617 ' HD2' HD13 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.37 -10.94 16.07 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.484 2.122 . . . . 0.0 110.174 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.37 -91.73 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.559 -0.713 . . . . 0.0 109.121 179.887 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.908 ' HB1' HD21 ' A' ' 25' ' ' LEU . . . -85.2 -92.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.29 -0.882 . . . . 0.0 109.229 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.987 ' CA ' HD12 ' A' ' 26' ' ' ILE . . . 139.98 41.04 0.08 OUTLIER Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.1 p -95.56 115.15 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.1 -1.235 . . . . 0.0 109.346 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' A' ' 23' ' ' GLY . 40.6 t -69.26 116.15 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.443 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -108.21 -25.25 11.16 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.174 -0.954 . . . . 0.0 109.513 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.85 123.33 1.73 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.514 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 70' ' ' ILE . 90.1 t -112.58 135.27 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.464 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -126.38 39.73 3.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.52 HG11 HG23 ' A' ' 69' ' ' ILE . 27.1 m -149.91 167.23 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.734 ' O ' HG11 ' A' ' 15' ' ' VAL . 4.2 tttt -125.39 167.99 14.18 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.43 87.42 7.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.6 -11.87 4.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -75.45 146.67 40.5 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -1.118 . . . . 0.0 109.566 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.407 ' C ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -105.14 146.62 28.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.209 -0.932 . . . . 0.0 109.484 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 62' ' ' LYS . 13.8 mt -141.47 178.42 7.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.477 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' GLU . 8.7 tttp -118.58 149.32 41.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.181 -0.949 . . . . 0.0 109.537 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.3 pt-20 -42.71 150.33 0.16 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.337 -0.852 . . . . 0.0 109.627 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.68 -15.33 55.41 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -82.28 132.26 35.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -1.148 . . . . 0.0 109.544 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -63.85 161.59 15.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.432 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.52 HG23 HG11 ' A' ' 57' ' ' VAL . 43.9 mm -128.01 -59.71 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.887 . . . . 0.0 109.522 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.705 ' CD1' HD22 ' A' ' 32' ' ' LEU . 3.4 pt -141.44 -171.94 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.51 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 3' ' ' ILE . 1.7 mt-10 -145.8 109.2 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.602 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.668 ' C ' HD23 ' A' ' 72' ' ' LEU . 2.0 tt -90.02 145.42 25.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.3 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.47 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 1.4 mt-10 -106.09 146.27 32.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.47 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 36.1 Cg_endo . . . . . 0 C--N 1.309 -1.508 0 C-N-CA 122.587 2.191 . . . . 0.0 110.431 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.485 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 2.5 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mt-10 -125.2 169.19 12.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.24 -0.913 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mt -99.61 137.34 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.535 HG21 ' HG3' ' A' ' 47' ' ' PRO . 31.6 mm -113.82 119.05 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.239 -0.913 . . . . 0.0 109.485 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.701 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -106.23 -177.96 3.51 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.476 -179.927 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.6 t -81.0 142.27 51.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.355 -0.841 . . . . 0.0 109.342 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.07 -170.74 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.607 2.205 . . . . 0.0 110.433 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -84.51 104.69 14.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.224 -0.923 . . . . 0.0 109.437 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.97 -21.65 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.281 -0.887 . . . . 0.0 109.295 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.78 21.63 76.29 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.0 -165.92 25.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -97.2 140.34 31.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -1.168 . . . . 0.0 109.459 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -111.14 105.17 1.83 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.8 mm-40 -97.22 130.22 44.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.542 ' HA ' HD23 ' A' ' 35' ' ' LEU . 60.3 t -72.91 119.42 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.981 HG22 ' O ' ' A' ' 34' ' ' VAL . 1.6 tt -112.55 -24.33 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -145.99 140.44 26.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.51 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.55 127.37 34.96 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.54 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -120.7 47.32 1.82 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.897 . . . . 0.0 109.414 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.465 HG11 ' CD1' ' A' ' 32' ' ' LEU . 3.2 m -150.07 158.19 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.6 mmtt -138.05 -174.0 3.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.9 m -84.4 141.18 31.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.481 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.7 1.83 62.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.89 130.27 34.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -1.196 . . . . 0.0 109.485 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -86.12 119.3 26.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.88 . . . . 0.0 109.387 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.053 HD13 HD21 ' A' ' 32' ' ' LEU . 2.4 mt -90.01 -171.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.209 -0.932 . . . . 0.0 109.201 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.717 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -150.17 163.34 38.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.433 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.49 147.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.161 -0.962 . . . . 0.0 109.411 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 83.07 -43.61 0.11 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.688 -0.632 . . . . 0.0 109.863 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.524 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -55.41 144.27 26.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.078 -1.014 . . . . 0.0 109.43 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.32 172.38 38.27 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 1.053 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -133.04 -51.84 0.9 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.542 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.9 m -153.6 175.75 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.141 -0.974 . . . . 0.0 109.617 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.981 ' O ' HG22 ' A' ' 16' ' ' ILE . 84.4 t -130.8 94.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.87 . . . . 0.0 109.425 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.542 HD23 ' HA ' ' A' ' 15' ' ' VAL . 13.2 mt -90.14 151.86 21.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -106.05 112.02 24.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.291 -0.881 . . . . 0.0 109.432 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.64 -172.12 3.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -0.907 . . . . 0.0 109.525 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.32 6.64 13.67 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.51 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -112.47 -36.89 5.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.178 -0.951 . . . . 0.0 109.518 179.93 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.524 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.44 -152.37 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.243 -0.911 . . . . 0.0 109.429 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 8.3 t -106.05 112.55 25.64 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.251 -0.906 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -106.95 151.81 24.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -110.31 150.43 28.77 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.176 -0.952 . . . . 0.0 109.452 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.8 t -132.73 118.24 15.51 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.897 . . . . 0.0 109.261 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.1 Cg_endo -77.7 -168.65 0.63 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.33 2.02 . . . . 0.0 110.451 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.518 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -85.35 126.32 67.34 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.345 -0.847 . . . . 0.0 109.339 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.535 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.9 Cg_endo -78.44 -0.9 11.12 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.377 2.052 . . . . 0.0 110.374 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.499 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.18 127.31 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.76 99.54 5.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 109.46 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.902 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.93 -137.79 2.42 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 9.5 p -137.19 146.94 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.202 -1.176 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 52.2 t -69.73 133.39 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.303 -0.873 . . . . 0.0 109.518 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.404 ' CD ' ' HB2' ' A' ' 73' ' ' GLU . 0.3 OUTLIER -110.79 -58.23 2.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.313 -0.867 . . . . 0.0 109.482 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 14.1 m -124.52 164.95 18.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.498 ' HA ' HG22 ' A' ' 70' ' ' ILE . 53.7 t -124.74 118.98 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.268 -0.895 . . . . 0.0 109.452 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.21 15.25 27.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.448 HG11 HD11 ' A' ' 63' ' ' LEU . 21.0 m -149.85 173.44 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.241 -0.912 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.42 ' HB3' ' OD2' ' A' ' 61' ' ' ASP . 6.0 tptt -134.47 173.67 11.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.253 -0.905 . . . . 0.0 109.46 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.73 124.29 31.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.65 -10.71 57.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.42 ' OD2' ' HB3' ' A' ' 58' ' ' LYS . 3.0 m-20 -81.74 165.35 21.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -1.093 . . . . 0.0 109.571 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 165.12 13.06 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.499 ' HA ' HD23 ' A' ' 63' ' ' LEU . 5.3 mt -149.35 104.97 3.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.8 OUTLIER -86.99 137.89 31.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 10.3 pt-20 -42.77 151.57 0.12 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.19 -19.75 37.31 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -84.87 144.9 28.1 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.246 -1.15 . . . . 0.0 109.483 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -72.56 -178.8 2.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.701 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.0 mp -139.82 -68.08 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.412 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.498 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.0 OUTLIER -148.9 -177.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.448 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -132.89 117.83 18.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.987 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.8 tt -93.78 143.33 26.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.204 -0.935 . . . . 0.0 109.526 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.404 ' HB2' ' CD ' ' A' ' 53' ' ' LYS . 0.1 OUTLIER -113.53 91.03 19.15 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.363 -0.836 . . . . 0.0 109.381 179.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.987 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.603 0 C-N-CA 122.668 2.246 . . . . 0.0 110.441 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 76.8 p . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.284 0.564 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.6 mt-10 -139.37 160.61 39.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.48 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.519 ' H ' HD12 ' A' ' 3' ' ' ILE . 2.5 mp -85.17 136.07 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.905 . . . . 0.0 109.528 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.751 HD13 ' HG2' ' A' ' 47' ' ' PRO . 10.3 mt -105.49 120.21 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.92 168.55 10.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.189 -0.944 . . . . 0.0 109.486 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 78.3 t -49.68 142.48 12.17 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.268 -0.895 . . . . 0.0 109.322 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.69 -174.72 2.34 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.462 2.108 . . . . 0.0 110.393 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.91 100.86 8.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.712 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.41 -14.91 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.272 -0.892 . . . . 0.0 109.291 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.38 -21.26 32.87 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -128.82 -145.5 5.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.95 142.3 30.63 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -1.163 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.15 103.29 2.13 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.458 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.1 mt-10 -101.7 119.75 39.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.296 -1.12 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.97 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.7 t -78.83 131.93 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.464 179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.442 ' O ' ' HG3' ' A' ' 17' ' ' GLU . 8.8 mm -108.93 -40.48 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.9 . . . . 0.0 109.498 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.442 ' HG3' ' O ' ' A' ' 16' ' ' ILE . 64.9 mt-10 -157.17 -177.77 6.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.426 -179.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.501 HD12 HG12 ' A' ' 33' ' ' VAL . 11.3 tp -137.03 145.96 44.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.471 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.467 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -136.8 36.35 2.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.554 -179.95 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 32' ' ' LEU . 3.7 m -149.94 156.61 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.29 -0.881 . . . . 0.0 109.558 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.24 175.71 5.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.181 -0.949 . . . . 0.0 109.469 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.6 m -84.95 146.39 27.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.546 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.525 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 78.48 3.32 86.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.02 133.14 34.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -1.165 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.602 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -83.65 108.12 16.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.197 -0.939 . . . . 0.0 109.432 -179.991 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.53 -171.4 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.1 mt-10 -147.03 -178.95 6.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.421 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.725 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.4 p -82.7 73.67 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.87 -42.36 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.334 -0.853 . . . . 0.0 109.435 179.836 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.43 ' HB3' HG22 ' A' ' 26' ' ' ILE . 18.6 tt0 -50.81 135.69 23.49 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.174 -0.954 . . . . 0.0 109.455 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.467 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -52.88 179.99 0.08 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.592 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -146.24 -67.99 0.28 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.21 -1.171 . . . . 0.0 109.535 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.501 HG12 HD12 ' A' ' 18' ' ' LEU . 30.9 m -133.01 169.63 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.523 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.9 HG22 ' HG2' ' A' ' 43' ' ' GLU . 24.4 t -119.09 79.2 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.261 -0.899 . . . . 0.0 109.452 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.97 HD23 ' HA ' ' A' ' 15' ' ' VAL . 5.9 mt -90.05 151.73 21.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.53 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.424 ' HG3' ' OG ' ' A' ' 41' ' ' SER . 2.3 tm-20 -140.79 141.84 34.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.33 -0.857 . . . . 0.0 109.495 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.03 -177.95 3.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -0.896 . . . . 0.0 109.523 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.95 -12.46 37.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.278 -0.889 . . . . 0.0 109.472 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.51 -67.96 0.77 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.264 -0.897 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.19 175.41 14.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -0.937 . . . . 0.0 109.461 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.424 ' OG ' ' HG3' ' A' ' 36' ' ' GLU . 0.9 OUTLIER -95.01 137.21 34.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 109.473 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.22 124.83 11.76 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.916 . . . . 0.0 109.5 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.9 ' HG2' HG22 ' A' ' 34' ' ' VAL . 7.1 mt-10 -84.52 166.86 16.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.488 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.496 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 54.1 t -137.03 134.59 19.09 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.24 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.23 -168.4 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.412 2.075 . . . . 0.0 110.316 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.1 130.88 50.4 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.302 -0.874 . . . . 0.0 109.353 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.751 ' HG2' HD13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.53 -1.48 11.64 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.416 2.078 . . . . 0.0 110.394 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.755 ' HD2' HD22 ' A' ' 72' ' ' LEU . 33.6 ttmt -160.28 140.69 11.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 109.561 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.09 101.21 12.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.925 . . . . 0.0 109.493 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.909 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -158.58 -162.35 11.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.525 HG22 ' HA2' ' A' ' 23' ' ' GLY . 9.9 p -111.03 129.17 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.295 -1.12 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -54.02 138.63 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.49 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.12 -35.67 4.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 t -174.78 149.48 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.175 -0.953 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.772 HG13 HG22 ' A' ' 70' ' ' ILE . 11.1 t -108.53 148.45 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.452 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 59.4 m -113.35 18.22 17.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.641 ' H ' HG12 ' A' ' 55' ' ' VAL . 30.2 m -147.12 158.47 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.503 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.448 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -120.17 -175.21 2.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 -179.946 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.484 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -77.04 147.75 36.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.265 -0.897 . . . . 0.0 109.416 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.33 11.62 53.05 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.448 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -84.74 132.25 34.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.186 -1.185 . . . . 0.0 109.492 179.997 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.56 118.37 36.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.561 HD23 ' HB3' ' A' ' 67' ' ' ASP . 3.1 mp -122.6 162.55 21.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.1 tttp -102.75 146.79 27.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.431 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.5 OUTLIER -42.9 148.04 0.27 Allowed 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.312 -0.868 . . . . 0.0 109.661 -179.877 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.7 -8.07 74.0 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.561 ' HB3' HD23 ' A' ' 63' ' ' LEU . 1.2 m-20 -83.96 140.18 32.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -1.103 . . . . 0.0 109.487 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.408 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.36 164.16 0.21 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.422 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.596 HG22 HG23 ' A' ' 70' ' ' ILE . 17.7 mm -141.13 -54.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.182 -0.948 . . . . 0.0 109.449 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG13 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -150.65 -178.23 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.931 . . . . 0.0 109.585 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -139.43 135.61 33.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.93 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.5 tt -116.44 146.76 42.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 23.6 tt0 -118.35 88.62 33.73 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.486 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.93 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.309 -1.529 0 C-N-CA 122.568 2.178 . . . . 0.0 110.466 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.4 p . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 3' ' ' ILE . 20.9 mp0 -89.43 161.81 16.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.34 -0.85 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.741 HD12 ' N ' ' A' ' 3' ' ' ILE . 3.2 mp -110.74 139.26 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.903 . . . . 0.0 109.466 -179.978 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -111.19 138.27 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.228 -0.92 . . . . 0.0 109.451 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.448 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 3.0 ptt180 -121.55 166.66 13.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.734 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.3 t -48.5 142.2 8.68 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.244 -0.91 . . . . 0.0 109.36 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.734 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.09 -171.45 1.21 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.483 2.122 . . . . 0.0 110.423 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.09 101.54 12.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.492 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.11 -26.36 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.24 -0.912 . . . . 0.0 109.255 -179.922 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 34.9 5.47 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 153.04 -133.58 4.09 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -118.08 168.2 10.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -1.112 . . . . 0.0 109.463 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.1 128.61 2.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.461 ' OE2' ' O ' ' A' ' 15' ' ' VAL . 3.3 tm-20 -89.2 134.65 33.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -1.144 . . . . 0.0 109.427 179.956 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.461 ' O ' ' OE2' ' A' ' 14' ' ' GLU . 19.2 t -74.72 156.57 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.505 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -115.56 -58.49 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.492 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.71 161.91 41.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.0 111.54 20.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -0.88 . . . . 0.0 109.472 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.16 32.91 1.62 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.03 161.98 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.467 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.426 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.24 -177.07 4.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.205 -0.934 . . . . 0.0 109.469 179.999 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.0 m -81.34 143.18 32.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.234 -0.916 . . . . 0.0 109.504 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.58 90.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.426 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 22.7 m-20 -85.07 139.45 31.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -1.198 . . . . 0.0 109.435 -179.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.542 HD23 ' O ' ' A' ' 25' ' ' LEU . 6.8 tt -103.43 108.97 20.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.9 OUTLIER -90.15 -171.39 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.212 -0.93 . . . . 0.0 109.234 179.985 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.4 pt-20 -138.22 -178.28 5.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.119 -0.988 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.724 ' O ' HG13 ' A' ' 28' ' ' VAL . 9.9 p -82.27 74.57 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.48 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER 162.91 -55.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.901 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 29' ' ' GLU . 1.4 tt0 -44.41 141.01 2.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.87 . . . . 0.0 109.494 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.455 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -70.77 178.67 32.1 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.521 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -141.35 -42.18 0.37 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -1.169 . . . . 0.0 109.453 179.926 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.6 HG22 ' HB ' ' A' ' 44' ' ' VAL . 20.3 m -152.04 155.29 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 -179.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 16' ' ' ILE . 58.7 t -114.84 107.75 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.232 -0.918 . . . . 0.0 109.451 -179.903 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 15' ' ' VAL . 1.8 mp -98.11 -178.38 4.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -147.54 140.08 24.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.938 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.4 p -107.07 -177.67 3.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.58 -65.45 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.238 -0.913 . . . . 0.0 109.425 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 mppt? -129.54 55.91 1.74 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.496 -179.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -170.85 -161.56 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.278 -0.889 . . . . 0.0 109.512 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.09 149.73 30.71 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.296 -0.877 . . . . 0.0 109.448 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' HG22 ' A' ' 9' ' ' ILE . 69.5 mmm -146.06 104.42 3.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -0.947 . . . . 0.0 109.383 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.95 171.98 13.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -0.921 . . . . 0.0 109.538 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.6 ' HB ' HG22 ' A' ' 33' ' ' VAL . 48.9 t -146.15 98.48 4.35 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.263 -0.898 . . . . 0.0 109.389 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.5 Cg_endo -77.5 -168.09 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.492 2.128 . . . . 0.0 110.527 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.489 ' CB ' ' HB ' ' A' ' 26' ' ' ILE . 6.5 t -85.09 113.65 51.37 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.45 -179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.4 Cg_endo -78.06 3.01 7.41 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.364 2.043 . . . . 0.0 110.329 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.588 ' O ' HD13 ' A' ' 72' ' ' LEU . 6.0 mttt -160.01 114.94 2.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.312 -0.868 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.1 91.95 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.944 . . . . 0.0 109.533 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 1.01 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.39 -171.86 22.41 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 10.9 p -100.77 155.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -1.185 . . . . 0.0 109.517 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.2 t -81.37 138.62 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -0.923 . . . . 0.0 109.536 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -104.34 -66.9 0.93 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -137.92 148.7 45.55 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.474 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.56 HG12 ' H ' ' A' ' 57' ' ' VAL . 12.0 t -101.65 133.65 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -112.87 13.98 19.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.142 -0.974 . . . . 0.0 109.567 179.962 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.6 HG11 HD13 ' A' ' 69' ' ' ILE . 2.0 m -137.46 158.77 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.219 -0.926 . . . . 0.0 109.478 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.15 158.68 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.238 -0.914 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.8 pp -82.68 137.64 34.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.931 . . . . 0.0 109.53 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.95 -14.52 65.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -83.68 168.07 16.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.14 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.795 ' O ' HD23 ' A' ' 63' ' ' LEU . 8.5 mtmt -97.38 140.77 31.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -0.855 . . . . 0.0 109.442 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 62' ' ' LYS . 6.5 mt -123.97 116.05 22.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.497 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 65' ' ' GLU . 4.3 tttt -90.48 139.69 30.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.303 -0.873 . . . . 0.0 109.472 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.445 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 15.6 pt-20 -42.76 149.19 0.2 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.313 -0.867 . . . . 0.0 109.645 -179.896 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.71 -14.88 58.88 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 91.6 m-20 -85.01 140.06 31.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.285 -1.126 . . . . 0.0 109.471 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -62.37 -179.43 0.24 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.213 -0.929 . . . . 0.0 109.506 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.684 HG22 HG23 ' A' ' 70' ' ' ILE . 28.6 mm -147.95 -72.19 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.447 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.684 HG23 HG22 ' A' ' 69' ' ' ILE . 3.8 pt -142.37 -172.52 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.932 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -140.29 112.2 7.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.011 HD23 ' HD3' ' A' ' 74' ' ' PRO . 3.6 tt -90.06 141.96 28.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -113.24 91.69 20.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.21 -0.932 . . . . 0.0 109.535 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 1.011 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.1 Cg_endo . . . . . 0 C--N 1.308 -1.56 0 C-N-CA 122.602 2.201 . . . . 0.0 110.35 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 68.8 p . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -147.42 150.48 34.74 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.635 HD12 ' HB2' ' A' ' 71' ' ' GLU . 1.4 tp -93.03 130.73 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.6 mm -93.81 124.22 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.388 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 3.5 ptt-85 -118.52 159.16 24.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 9' ' ' ILE . 84.3 t -43.33 103.51 0.32 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.344 -0.847 . . . . 0.0 109.442 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.472 ' O ' HG12 ' A' ' 9' ' ' ILE . 35.9 Cg_endo -77.78 -169.54 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.511 2.14 . . . . 0.0 110.45 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -68.26 99.7 0.95 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.283 -0.886 . . . . 0.0 109.413 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.883 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.0 -43.0 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.305 -179.877 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.55 34.61 0.65 Allowed Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 147.21 -132.74 4.45 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -101.5 135.27 43.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.65 115.78 4.31 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.476 ' HG2' ' CB ' ' A' ' 62' ' ' LYS . 12.9 mt-10 -112.36 104.32 12.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -1.152 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.649 ' O ' HD13 ' A' ' 16' ' ' ILE . 42.7 t -54.17 136.23 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.515 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.649 HD13 ' O ' ' A' ' 15' ' ' VAL . 29.2 mm -128.04 -37.42 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.83 155.27 43.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.59 123.59 46.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 32' ' ' LEU . 6.3 mt -93.77 9.36 37.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.535 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.7 m -146.42 175.42 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 179.949 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.423 ' O ' HG21 ' A' ' 52' ' ' VAL . 5.2 ttpp -139.31 -164.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.272 -0.892 . . . . 0.0 109.49 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.4 m -84.83 139.41 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.918 . . . . 0.0 109.509 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.87 10.56 51.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -85.04 134.72 34.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.195 -1.179 . . . . 0.0 109.454 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.629 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -88.24 118.25 27.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.804 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -97.04 -171.41 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.239 -0.913 . . . . 0.0 109.234 -179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.707 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.3 tt0 -147.81 153.99 39.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 28' ' ' VAL . 6.3 p -72.03 84.35 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.248 -0.907 . . . . 0.0 109.506 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.79 -32.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.336 -0.853 . . . . 0.0 109.473 179.877 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -78.66 153.27 31.14 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.233 -0.917 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.463 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.38 -160.07 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.804 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -160.01 -72.74 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -1.166 . . . . 0.0 109.459 179.983 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.54 HG21 HD11 ' A' ' 35' ' ' LEU . 8.5 m -119.45 150.92 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.792 HG22 ' OE1' ' A' ' 43' ' ' GLU . 23.9 t -117.91 83.22 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.54 HD11 HG21 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -91.13 147.52 23.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.44 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.39 152.84 21.13 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.169 -0.957 . . . . 0.0 109.411 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -98.72 -175.62 3.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.28 -0.888 . . . . 0.0 109.481 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.61 94.78 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.6 mttm -142.4 48.33 1.56 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.413 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -177.13 -158.76 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.51 152.94 37.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.388 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtp -159.26 142.47 14.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.792 ' OE1' HG22 ' A' ' 34' ' ' VAL . 24.0 mt-10 -132.65 162.8 30.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.7 t -131.02 140.08 37.57 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.309 -0.869 . . . . 0.0 109.345 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.515 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.21 -168.59 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.581 2.188 . . . . 0.0 110.421 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.483 ' HB2' HG21 ' A' ' 26' ' ' ILE . 28.9 t -85.27 113.64 51.6 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.398 -0.814 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.03 0.49 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.348 2.032 . . . . 0.0 110.425 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.76 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.09 104.75 1.51 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.338 -0.851 . . . . 0.0 109.491 179.951 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.35 101.87 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.467 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.943 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -159.36 -150.19 5.75 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.867 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.524 ' HB ' HD21 ' A' ' 25' ' ' LEU . 8.1 p -116.51 132.35 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -1.14 . . . . 0.0 109.478 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 21' ' ' LYS . 63.7 t -56.3 126.84 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.01 -50.1 5.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.163 -0.96 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -169.64 153.26 4.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.349 -0.844 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.753 HG12 ' H ' ' A' ' 57' ' ' VAL . 25.9 t -111.69 136.34 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.301 -0.874 . . . . 0.0 109.457 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -94.79 17.4 13.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.271 -0.893 . . . . 0.0 109.471 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.788 HG11 HD22 ' A' ' 63' ' ' LEU . 1.6 m -145.28 176.88 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.274 -0.891 . . . . 0.0 109.386 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -112.34 -178.91 3.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.19 -0.944 . . . . 0.0 109.522 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -82.3 136.85 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.93 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.41 18.08 76.65 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 4.4 m-20 -83.68 144.14 29.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -103.66 120.94 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.515 179.961 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.788 HD22 HG11 ' A' ' 57' ' ' VAL . 1.3 mp -121.73 175.57 6.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.907 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' GLU . 3.5 tttp -118.31 145.75 44.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 3.2 pt-20 -42.85 137.48 2.3 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.341 -0.849 . . . . 0.0 109.584 -179.884 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.53 -25.93 16.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -84.89 140.76 30.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -1.124 . . . . 0.0 109.448 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -65.04 -174.11 0.14 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.423 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 69' ' ' ILE . 28.7 mm -143.3 -65.33 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.264 -0.897 . . . . 0.0 109.49 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.699 ' CG2' HG13 ' A' ' 55' ' ' VAL . 1.8 pt -141.95 -175.11 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.899 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.635 ' HB2' HD12 ' A' ' 3' ' ' ILE . 1.8 tt0 -149.56 114.37 5.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.296 -0.877 . . . . 0.0 109.498 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.943 HD21 ' HA3' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -93.27 148.02 22.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.423 -179.911 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.413 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 3.6 tt0 -132.91 91.22 29.67 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.493 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.839 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo . . . . . 0 C--N 1.308 -1.553 0 C-N-CA 122.627 2.218 . . . . 0.0 110.44 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 89.1 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -122.35 151.07 41.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.476 ' C ' HD12 ' A' ' 4' ' ' ILE . 4.3 mp -90.94 154.36 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.513 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.1 mp -120.81 107.57 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.479 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -101.55 170.64 8.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.385 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.719 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -61.26 142.27 93.6 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.374 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.719 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.08 -169.77 0.83 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.561 2.174 . . . . 0.0 110.458 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -82.88 105.15 13.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.416 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.8 -59.5 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.389 -179.954 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.04 -11.68 10.78 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.05 -141.28 4.22 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.414 ' OD1' ' HE2' ' A' ' 64' ' ' LYS . 0.1 OUTLIER -98.66 164.17 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -1.127 . . . . 0.0 109.516 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.59 95.47 0.47 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -97.0 126.16 41.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.282 -1.128 . . . . 0.0 109.428 -179.953 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.643 HG22 ' CD2' ' A' ' 35' ' ' LEU . 19.2 t -77.09 133.6 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.93 . . . . 0.0 109.512 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.559 HD11 ' HB2' ' A' ' 36' ' ' GLU . 19.2 mt -121.38 -37.58 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.395 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.56 137.6 43.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.192 -0.942 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.423 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -122.43 119.29 30.56 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -117.81 50.34 1.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.431 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -147.36 159.34 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -148.74 -176.3 5.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.427 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.5 m -84.63 126.47 33.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.449 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.88 6.9 64.94 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 180.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 57.2 m-20 -83.66 131.9 34.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.46 HD12 ' HB ' ' A' ' 51' ' ' VAL . 7.2 tp -92.94 106.48 18.43 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.534 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.714 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -91.77 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.215 -0.928 . . . . 0.0 109.151 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.714 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.7 mt-10 -144.7 176.51 9.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.925 . . . . 0.0 109.412 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.768 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.4 p -81.96 72.95 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.205 -0.934 . . . . 0.0 109.535 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.83 -44.57 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.331 -0.856 . . . . 0.0 109.397 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -51.13 142.42 12.53 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.209 -0.932 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.457 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.61 175.47 4.68 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.724 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.6 OUTLIER -138.51 -62.24 0.57 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.358 -179.979 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.38 159.86 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.932 . . . . 0.0 109.457 -179.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 65.1 t -114.66 84.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.643 ' CD2' HG22 ' A' ' 15' ' ' VAL . 7.3 mt -94.68 159.55 15.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.559 ' HB2' HD11 ' A' ' 16' ' ' ILE . 0.3 OUTLIER -124.15 161.23 26.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.913 . . . . 0.0 109.49 -179.96 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -139.44 172.02 13.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.465 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.02 -13.39 62.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.312 -0.867 . . . . 0.0 109.54 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.535 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mptt -87.42 -38.84 15.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.535 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.07 -174.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.514 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.49 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 0.0 OUTLIER -99.15 134.98 41.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.237 -0.915 . . . . 0.0 109.453 -179.975 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.447 ' O ' ' HG3' ' A' ' 42' ' ' MET . 0.4 OUTLIER -155.16 132.26 10.89 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.449 -179.959 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -94.53 -179.71 4.99 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.5 t -144.36 128.94 9.24 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.224 -0.923 . . . . 0.0 109.304 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.457 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.5 -168.62 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.334 2.023 . . . . 0.0 110.326 179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.724 ' HA ' HD13 ' A' ' 32' ' ' LEU . 1.9 t -85.31 136.41 37.83 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.362 -0.836 . . . . 0.0 109.359 179.891 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HG2' HG12 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.73 -5.73 14.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.516 2.144 . . . . 0.0 110.495 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.33 139.17 10.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 109.488 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.86 101.57 8.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.444 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.849 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -157.7 -147.75 4.91 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 14.5 p -126.66 152.02 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.219 -1.165 . . . . 0.0 109.502 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 54.3 t -68.66 140.47 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.249 -0.907 . . . . 0.0 109.459 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -109.04 -53.88 2.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -0.933 . . . . 0.0 109.457 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.87 177.95 7.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 57' ' ' VAL . 92.9 t -124.35 125.15 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 21.6 t -105.53 1.67 27.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.198 -0.939 . . . . 0.0 109.645 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 55' ' ' VAL . 3.3 m -147.28 176.3 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.481 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.481 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -129.79 150.4 51.11 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.488 -179.943 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.667 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -61.79 140.67 58.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.889 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.75 -11.96 60.64 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.481 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 8.0 m-20 -78.01 152.62 32.97 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.194 -1.18 . . . . 0.0 109.444 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.426 ' O ' ' HG2' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -114.11 146.26 40.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.971 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.2 mp -147.75 -178.41 6.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -120.22 149.74 41.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.459 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.441 ' CD ' ' N ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -42.87 149.17 0.21 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.839 . . . . 0.0 109.591 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.69 -14.29 65.34 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -84.65 137.73 33.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.25 -1.147 . . . . 0.0 109.491 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.43 ' O ' HG13 ' A' ' 69' ' ' ILE . . . -66.25 176.93 1.59 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.479 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.3 mp -142.1 -61.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.253 -0.904 . . . . 0.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -142.9 -172.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.199 -0.938 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -142.41 106.94 4.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.291 -0.881 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.849 HD11 ' N ' ' A' ' 50' ' ' GLY . 2.7 tt -91.18 135.58 33.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.203 -0.936 . . . . 0.0 109.49 179.929 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.524 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 20.6 tt0 -116.66 142.11 29.15 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.227 -0.921 . . . . 0.0 109.423 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 36.0 Cg_endo . . . . . 0 C--N 1.309 -1.519 0 C-N-CA 122.568 2.179 . . . . 0.0 110.403 179.942 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.463 ' HB3' ' HG3' ' A' ' 73' ' ' GLU . 9.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -128.12 133.42 48.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.484 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.492 HD12 ' HB2' ' A' ' 71' ' ' GLU . 2.1 tp -79.95 140.27 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.436 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.68 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.4 mp -101.61 142.41 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 179.991 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -113.95 179.74 3.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.854 . . . . 0.0 109.478 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.68 ' CG1' HD11 ' A' ' 9' ' ' ILE . 49.1 t -61.35 134.4 93.35 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 109.292 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.418 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -170.04 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.457 2.105 . . . . 0.0 110.483 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -79.93 101.41 8.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.473 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.68 HD11 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.24 -49.73 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.284 -179.938 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.64 -17.37 6.89 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.938 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.42 -171.88 28.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.83 148.88 42.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -1.159 . . . . 0.0 109.53 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.53 150.23 18.54 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.9 OUTLIER -118.38 142.33 47.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.176 -1.19 . . . . 0.0 109.465 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.479 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -76.48 135.41 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.521 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.84 HD12 HG12 ' A' ' 34' ' ' VAL . 80.5 mt -100.33 -38.33 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.447 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -172.47 170.12 5.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.533 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 tp -117.15 125.16 50.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.444 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.1 pp -104.7 31.25 4.85 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' CD2' ' A' ' 32' ' ' LEU . 17.2 m -150.0 166.67 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.6 mtmt -128.51 179.06 5.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.902 . . . . 0.0 109.498 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 35.1 m -84.96 141.63 30.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.89 63.34 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -84.89 138.45 32.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -1.22 . . . . 0.0 109.502 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -79.98 131.11 35.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 109.431 179.911 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.84 HD13 HD11 ' A' ' 32' ' ' LEU . 2.4 mt -92.95 -171.56 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.176 -0.952 . . . . 0.0 109.278 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.7 OUTLIER -126.98 175.84 7.78 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.206 -0.933 . . . . 0.0 109.433 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.576 ' O ' HG13 ' A' ' 28' ' ' VAL . 8.3 p -76.55 124.46 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.497 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 4.1 mt-10 63.05 11.92 5.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.245 -0.909 . . . . 0.0 109.656 179.859 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.473 ' HG3' ' HB2' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -74.13 122.57 22.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.356 179.923 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.464 ' N ' ' HB3' ' A' ' 45' ' ' PRO . . . -43.19 152.88 0.28 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.86 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.84 HD11 HD13 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -132.56 -39.25 1.01 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -1.153 . . . . 0.0 109.496 179.943 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -140.92 165.1 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.174 -0.954 . . . . 0.0 109.528 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.84 HG12 HD12 ' A' ' 16' ' ' ILE . 78.4 t -130.59 95.51 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.92 163.57 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.711 ' HB2' HD11 ' A' ' 16' ' ' ILE . 21.2 tt0 -122.94 123.45 40.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.892 . . . . 0.0 109.515 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.443 ' HB2' ' HB3' ' A' ' 40' ' ' ALA . 0.4 OUTLIER -79.91 -173.82 4.08 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.58 -42.1 32.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.539 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.81 18.48 0.69 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' HB2' ' A' ' 37' ' ' SER . . . -120.34 -169.74 1.85 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -158.04 101.75 1.78 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.531 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.432 ' N ' ' SD ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -114.34 143.16 45.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.212 -0.93 . . . . 0.0 109.452 -179.984 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -100.97 164.07 11.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.281 -0.887 . . . . 0.0 109.521 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.07 102.88 10.81 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.362 179.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.464 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -77.4 -169.58 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.419 2.079 . . . . 0.0 110.428 -179.823 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.73 139.52 35.39 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.473 179.906 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.437 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.4 Cg_endo -78.96 -10.65 15.28 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.409 2.072 . . . . 0.0 110.328 179.841 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.484 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.5 146.84 15.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.477 -0.764 . . . . 0.0 109.364 179.962 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.97 116.95 17.17 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -0.946 . . . . 0.0 109.399 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 1.003 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -164.36 -149.25 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.4 p -126.34 145.43 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -1.113 . . . . 0.0 109.433 -179.945 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.7 t -65.13 140.41 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.891 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.2 tptp -117.16 -47.11 2.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.401 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.49 163.61 32.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 80.4 t -121.52 118.19 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.0 t -108.22 22.59 15.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.557 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.409 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 34.5 m -144.13 160.35 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.532 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.67 169.2 18.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -0.903 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.424 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -84.97 103.08 13.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.218 -0.926 . . . . 0.0 109.476 -179.955 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.1 -14.06 19.14 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.57 138.62 38.46 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.198 -1.178 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -80.48 152.83 28.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -0.868 . . . . 0.0 109.44 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.479 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 63.2 mt -140.97 136.53 32.27 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 14.3 tttm -105.87 149.05 26.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 0.0 109.486 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.0 OUTLIER -42.88 147.31 0.32 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.37 -0.831 . . . . 0.0 109.583 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 82.57 -4.34 78.79 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 2.5 m-20 -83.09 130.87 35.16 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.289 -1.124 . . . . 0.0 109.423 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -50.5 178.34 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.26 -0.9 . . . . 0.0 109.475 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.433 HG22 HG23 ' A' ' 70' ' ' ILE . 29.5 mm -146.97 -71.48 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.461 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.433 HG23 HG22 ' A' ' 69' ' ' ILE . 0.8 OUTLIER -138.81 -174.58 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.489 180.0 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.492 ' HB2' HD12 ' A' ' 3' ' ' ILE . 0.3 OUTLIER -150.0 102.0 3.07 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.907 . . . . 0.0 109.507 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 1.003 HD11 ' CA ' ' A' ' 50' ' ' GLY . 4.0 tt -91.3 129.01 37.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.289 -0.882 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.534 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -90.07 144.96 32.07 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.367 -179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.53 0 C-N-CA 122.623 2.215 . . . . 0.0 110.432 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 84.6 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -107.8 147.26 31.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.587 HD11 ' HB1' ' A' ' 68' ' ' ALA . 13.8 tt -79.93 169.13 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -0.883 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.937 ' O ' HD12 ' A' ' 69' ' ' ILE . 24.6 mm -125.39 119.78 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 -179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.537 ' C ' HD11 ' A' ' 69' ' ' ILE . 3.9 ptm180 -94.93 163.83 13.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.648 ' N ' HD11 ' A' ' 69' ' ' ILE . 86.9 t -69.25 140.03 90.25 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.379 -179.903 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.573 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.73 -168.7 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.589 2.193 . . . . 0.0 110.432 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -75.19 117.67 17.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 109.268 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.448 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -108.57 -47.26 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 109.482 -179.736 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 149.61 -38.9 0.92 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . 172.29 117.64 0.45 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.92 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' A' ' 11' ' ' GLY . 0.7 OUTLIER 50.33 178.66 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -1.091 . . . . 0.0 109.623 179.892 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.35 111.69 0.36 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.439 ' HB2' ' HD3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -95.95 137.12 35.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.283 -1.128 . . . . 0.0 109.539 179.963 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.539 HG22 HD23 ' A' ' 35' ' ' LEU . 59.9 t -85.12 134.97 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.556 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.707 HD11 ' HG3' ' A' ' 36' ' ' GLU . 44.6 mt -104.31 -30.63 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.204 -0.935 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.423 ' HB2' ' O ' ' A' ' 16' ' ' ILE . 0.5 OUTLIER 175.22 131.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.545 179.976 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.491 ' H ' HD12 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -103.12 172.08 7.02 Favored 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -145.32 63.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.473 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.411 HG11 ' CD1' ' A' ' 32' ' ' LEU . 18.0 m -146.36 158.92 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.534 179.972 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.432 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 75.9 mttt -123.47 167.75 13.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.875 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 22' ' ' THR . 11.0 t -79.12 126.82 31.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.428 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 89.29 9.36 67.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' OD1' ' HB2' ' A' ' 21' ' ' LYS . 0.8 OUTLIER -85.02 135.06 34.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.158 -1.201 . . . . 0.0 109.506 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.446 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.7 tt -97.25 104.37 16.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -0.916 . . . . 0.0 109.475 179.959 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.7 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.89 -171.45 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.2 -0.937 . . . . 0.0 109.246 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.7 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.7 mt-10 -137.94 176.5 8.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 28' ' ' VAL . 11.1 p -81.39 79.07 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.455 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 167.49 -55.9 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.42 -0.8 . . . . 0.0 109.319 179.874 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.591 ' NE2' HG23 ' A' ' 26' ' ' ILE . 0.0 OUTLIER -44.66 145.79 0.85 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.946 . . . . 0.0 109.497 179.965 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.45 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.34 -162.74 0.09 OUTLIER Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.03 -71.77 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 109.516 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.464 ' O ' ' HB2' ' A' ' 43' ' ' GLU . 9.5 m -129.9 170.24 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.453 HG22 ' HB3' ' A' ' 43' ' ' GLU . 77.2 t -129.53 92.12 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 180.0 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.539 HD23 HG22 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -97.04 169.83 9.56 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 179.999 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.707 ' HG3' HD11 ' A' ' 16' ' ' ILE . 0.9 OUTLIER -103.12 178.74 4.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.247 -0.908 . . . . 0.0 109.486 -180.0 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -139.57 -173.09 3.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.28 -0.888 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -53.65 -57.61 10.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.932 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mttt -138.45 58.46 1.66 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.246 -0.909 . . . . 0.0 109.526 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.95 174.17 0.16 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.0 127.88 39.23 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.248 -0.907 . . . . 0.0 109.44 -179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.5 mtt -138.19 142.97 40.01 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -105.97 164.12 12.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.284 -0.885 . . . . 0.0 109.352 179.969 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.5 t -122.31 137.83 28.19 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.309 179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.3 Cg_endo -79.13 -167.99 0.57 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.465 2.11 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.05 116.35 65.05 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.395 -0.816 . . . . 0.0 109.36 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' HG21 ' A' ' 4' ' ' ILE . 35.8 Cg_endo -77.77 4.54 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.381 2.054 . . . . 0.0 110.45 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.679 ' HB3' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.01 111.68 2.0 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.522 -179.976 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.45 95.89 2.3 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.307 -0.871 . . . . 0.0 109.435 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.975 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -164.29 -164.08 18.73 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.428 HG23 ' C ' ' A' ' 23' ' ' GLY . 14.9 p -100.91 133.82 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.229 -1.16 . . . . 0.0 109.519 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 80.4 t -58.82 147.88 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 -30.75 6.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -169.6 159.38 8.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.532 ' HA ' HG22 ' A' ' 70' ' ' ILE . 75.2 t -116.66 106.74 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.137 -0.977 . . . . 0.0 109.47 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.91 21.88 8.08 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.261 -0.899 . . . . 0.0 109.417 179.955 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.525 HG21 HG22 ' A' ' 69' ' ' ILE . 15.8 m -144.1 160.51 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.57 171.15 12.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 179.966 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.07 119.2 22.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.424 -179.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.77 -10.02 48.4 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.17 159.93 33.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.269 -1.136 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.868 ' O ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -113.52 135.07 54.29 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.507 179.958 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.868 HD12 ' O ' ' A' ' 62' ' ' LYS . 1.2 mp -142.68 155.05 44.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.175 -0.953 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.437 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.43 147.96 26.98 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.522 -179.933 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 64' ' ' LYS . 4.1 pt-20 -43.04 141.24 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.77 -8.89 73.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.494 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -84.49 132.06 34.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -1.169 . . . . 0.0 109.519 179.974 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.587 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -56.08 156.1 5.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.396 -0.815 . . . . 0.0 109.44 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.937 HD12 ' O ' ' A' ' 4' ' ' ILE . 1.4 mp -129.82 -43.8 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.489 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 69' ' ' ILE . 4.9 pt -159.9 -173.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.6 tt0 -135.66 159.0 42.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.252 -0.905 . . . . 0.0 109.474 180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.975 HD11 ' N ' ' A' ' 50' ' ' GLY . 8.0 tt -140.54 145.32 36.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -116.68 87.77 22.58 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.906 . . . . 0.0 109.447 -179.979 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.883 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.552 0 C-N-CA 122.622 2.215 . . . . 0.0 110.458 179.974 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.461 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 86.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -141.86 144.7 33.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.6 mm -90.45 136.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.488 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 mt -110.57 124.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.403 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 11.6 ptt180 -105.18 171.45 7.31 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.907 . . . . 0.0 109.489 -179.945 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.0 t -62.13 142.48 95.57 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -78.56 -170.38 0.97 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.496 2.13 . . . . 0.0 110.375 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -84.9 110.74 19.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.392 179.927 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.59 -10.08 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.298 -0.876 . . . . 0.0 109.389 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.8 26.62 74.45 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.906 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 12' ' ' ASP . . . 171.61 160.55 20.41 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -44.45 155.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.239 -1.153 . . . . 0.0 109.485 -179.996 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.65 109.28 1.45 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -101.72 114.41 28.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -1.159 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 15' ' ' VAL . 14.3 t -60.24 129.93 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.891 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.1 mt -104.86 -35.57 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.243 -0.91 . . . . 0.0 109.502 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.465 ' HA ' ' HB2' ' A' ' 59' ' ' LEU . 6.5 tp10 -165.37 135.47 3.64 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.48 127.49 55.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -0.923 . . . . 0.0 109.411 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -116.03 57.68 0.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.444 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.81 HG11 ' CD2' ' A' ' 32' ' ' LEU . 35.6 m -137.19 157.24 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -129.93 157.51 42.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.511 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' THR . 12.1 t -80.64 128.98 34.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 109.419 179.939 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.71 -8.92 79.09 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -82.26 132.61 35.23 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.229 -1.16 . . . . 0.0 109.427 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -79.9 125.63 29.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.264 -0.897 . . . . 0.0 109.488 -179.959 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.784 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.52 -171.38 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.276 -0.89 . . . . 0.0 109.201 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.72 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 pm0 -142.2 159.68 41.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.119 -0.988 . . . . 0.0 109.477 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.783 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.3 p -81.41 79.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.244 -0.91 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.75 -36.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.397 179.893 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.507 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 39.6 tt0 -67.33 155.47 38.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -0.925 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.441 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -77.32 168.4 54.53 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.81 ' CD2' HG11 ' A' ' 20' ' ' VAL . 1.3 tt -129.5 -40.5 1.42 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.263 -1.14 . . . . 0.0 109.49 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.659 HG22 ' HB ' ' A' ' 44' ' ' VAL . 5.2 m -154.7 166.84 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.506 -179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.4 t -134.66 96.55 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.325 179.931 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -94.62 163.83 13.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.564 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -105.42 173.87 6.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.407 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.1 m -135.32 -174.13 3.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -44.73 -42.58 7.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 109.441 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 ttpp -158.89 39.76 0.22 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.485 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -151.0 -156.9 0.76 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.84 107.26 2.1 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' GLU . 2.4 ttm -100.2 149.66 23.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' MET . 10.6 mt-10 -113.2 164.51 13.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.659 ' HB ' HG22 ' A' ' 33' ' ' VAL . 21.6 t -143.9 101.74 4.93 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.25 -0.906 . . . . 0.0 109.269 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.536 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.4 Cg_endo -77.16 -168.75 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.393 2.062 . . . . 0.0 110.55 -179.824 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.784 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.6 t -85.26 117.64 69.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.272 -0.892 . . . . 0.0 109.502 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.12 3.35 7.13 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.332 2.021 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.703 ' HG2' HD12 ' A' ' 72' ' ' LEU . 1.8 tptt -159.88 131.2 5.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.892 . . . . 0.0 109.415 179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.41 88.36 7.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.818 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.836 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -140.05 -152.35 5.81 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 73' ' ' GLU . 9.9 p -113.59 129.99 68.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -1.169 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.4 t -55.55 126.75 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.09 -44.68 9.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.44 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 54.7 p -171.82 138.44 1.07 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.614 ' HA ' HG22 ' A' ' 70' ' ' ILE . 4.8 t -92.98 117.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 109.539 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.22 13.52 18.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.479 ' H ' HG12 ' A' ' 55' ' ' VAL . 2.8 m -140.83 172.09 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.73 151.74 44.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.465 ' HB2' ' HA ' ' A' ' 17' ' ' GLU . 1.6 pp -56.83 139.91 49.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.87 -7.53 81.56 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -70.57 -179.95 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.212 -1.169 . . . . 0.0 109.438 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -153.12 115.74 4.48 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.186 -0.946 . . . . 0.0 109.441 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mp -131.3 -175.05 3.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.473 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.3 tttp -118.56 144.65 45.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 1.6 pt-20 -42.82 141.23 1.13 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.302 -0.874 . . . . 0.0 109.585 -179.861 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.76 -22.62 36.52 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -78.79 138.14 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.46 179.99 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.44 170.12 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.433 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.653 HD11 ' CG2' ' A' ' 6' ' ' VAL . 27.7 mm -139.11 -59.56 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.614 HG22 ' HA ' ' A' ' 55' ' ' VAL . 2.3 pt -143.44 -173.75 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.268 -0.895 . . . . 0.0 109.409 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -139.07 113.16 8.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.836 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 119.92 30.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.592 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -111.14 95.42 25.16 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.202 -0.936 . . . . 0.0 109.451 -179.926 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.5 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.527 0 C-N-CA 122.594 2.196 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.484 ' HB3' ' HG2' ' A' ' 73' ' ' GLU . 24.8 p . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -157.19 140.61 15.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.453 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.5 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 2.9 mt -80.48 154.56 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.93 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.5 mt -122.25 97.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.571 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.72 -172.36 3.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.914 . . . . 0.0 109.379 179.968 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.714 HG11 HD11 ' A' ' 9' ' ' ILE . 54.6 t -80.88 139.09 49.86 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.128 -0.983 . . . . 0.0 109.284 -179.957 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.625 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.56 -169.89 0.87 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.499 2.133 . . . . 0.0 110.399 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -81.69 104.11 11.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.847 . . . . 0.0 109.37 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.714 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.77 -42.71 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.989 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.77 -23.37 6.28 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.95 -140.29 4.0 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.2 p30 -99.29 153.08 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.185 -1.185 . . . . 0.0 109.401 179.883 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -107.69 105.95 2.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.99 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.447 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.9 mt-10 -99.96 137.64 38.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -1.145 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 99.6 t -76.5 127.22 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.49 -179.934 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.407 HD11 ' CB ' ' A' ' 36' ' ' GLU . 83.7 mt -107.8 -35.47 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.356 -0.84 . . . . 0.0 109.368 -179.952 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -152.09 127.36 9.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.506 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.409 ' O ' HD23 ' A' ' 18' ' ' LEU . 3.9 tt -110.14 126.07 53.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.893 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.95 54.56 1.51 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.502 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.855 HG11 ' CD1' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -148.55 162.59 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.511 -179.943 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.556 ' O ' HG21 ' A' ' 52' ' ' VAL . 4.0 tptp -141.29 176.75 8.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.6 m -81.76 144.91 30.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.207 -0.933 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.404 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 69.29 8.07 58.43 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -85.02 132.61 34.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -1.151 . . . . 0.0 109.515 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.636 HD13 ' N ' ' A' ' 26' ' ' ILE . 0.7 OUTLIER -88.48 118.9 28.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 179.855 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.959 HD13 HD21 ' A' ' 32' ' ' LEU . 3.2 mt -95.62 -171.33 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 O-C-N 121.222 -0.924 . . . . 0.0 109.328 -179.784 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.3 pt-20 -145.47 167.69 22.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.397 179.975 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.742 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.6 p -83.83 72.73 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.934 . . . . 0.0 109.522 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.486 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 170.82 -35.03 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.334 -0.854 . . . . 0.0 109.459 179.826 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -72.67 153.76 41.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.47 179.985 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.75 175.06 44.94 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -134.85 -44.84 0.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 109.501 179.965 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.443 HG23 ' HB ' ' A' ' 44' ' ' VAL . 2.1 m -153.91 170.88 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.227 -0.92 . . . . 0.0 109.513 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.456 ' O ' HG12 ' A' ' 34' ' ' VAL . 94.0 t -129.75 76.87 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.23 -0.918 . . . . 0.0 109.444 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 4.9 mp -89.91 135.13 33.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.471 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.407 ' CB ' HD11 ' A' ' 16' ' ' ILE . 5.0 tm-20 -111.43 140.36 46.09 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.895 . . . . 0.0 109.492 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.707 ' OG ' HG21 ' A' ' 9' ' ' ILE . 1.4 m -112.52 173.7 6.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.532 179.989 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.89 -13.51 25.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 21.2 mttt -84.26 -45.44 12.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 178.94 165.21 0.88 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.407 ' HA ' ' CG ' ' A' ' 36' ' ' GLU . 8.5 t -81.48 118.56 22.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.541 179.919 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 23.9 mtm -121.63 -178.97 3.95 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 109.415 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.7 174.29 10.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.286 -0.884 . . . . 0.0 109.484 -179.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.1 t -149.21 103.05 3.32 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.212 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.465 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.6 Cg_endo -77.39 -168.64 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.343 2.029 . . . . 0.0 110.407 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.438 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.42 113.57 51.48 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.43 -179.905 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.7 Cg_endo -78.18 0.36 9.96 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.343 2.028 . . . . 0.0 110.308 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.47 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.12 131.15 5.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.314 -0.866 . . . . 0.0 109.397 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.59 108.11 5.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.862 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.96 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.86 -172.76 28.6 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 9.8 p -104.87 150.92 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 109.494 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.556 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.1 t -68.88 130.78 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 54' ' ' SER . 0.3 OUTLIER -86.51 -42.59 13.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 109.448 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 53' ' ' LYS . 4.8 t -179.51 139.95 0.14 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.183 -0.948 . . . . 0.0 109.566 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 57' ' ' VAL . 9.0 t -80.87 109.53 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.88 . . . . 0.0 109.423 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.8 p -89.5 7.84 34.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.299 -0.875 . . . . 0.0 109.632 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.996 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.03 -177.59 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.941 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.5 tptp -131.87 171.27 13.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -0.916 . . . . 0.0 109.499 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.402 HD12 ' C ' ' A' ' 59' ' ' LEU . 2.7 pp -84.56 132.33 34.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.899 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.63 74.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -81.38 141.58 33.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -1.158 . . . . 0.0 109.402 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.876 ' C ' HD12 ' A' ' 63' ' ' LEU . 10.8 pttp -99.73 151.61 21.04 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.195 -0.941 . . . . 0.0 109.465 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.876 HD12 ' C ' ' A' ' 62' ' ' LYS . 6.0 mp -138.17 168.9 18.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.238 -0.914 . . . . 0.0 109.504 179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -107.11 146.66 30.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.467 -179.974 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.434 ' N ' ' HD2' ' A' ' 64' ' ' LYS . 5.4 mt-10 -42.96 138.9 1.89 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.292 -0.88 . . . . 0.0 109.635 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.79 -6.44 73.58 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.12 145.73 29.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -1.176 . . . . 0.0 109.48 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.536 ' C ' HD12 ' A' ' 69' ' ' ILE . . . -81.15 163.57 23.01 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.437 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.996 HG23 HG21 ' A' ' 57' ' ' VAL . 4.3 mp -133.85 -55.57 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.18 -0.95 . . . . 0.0 109.546 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.779 HG23 HG22 ' A' ' 69' ' ' ILE . 18.1 pt -145.96 -173.42 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.269 -0.894 . . . . 0.0 109.49 -179.93 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.5 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 1.0 OUTLIER -146.49 155.63 42.67 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.235 -0.915 . . . . 0.0 109.505 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.96 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.5 tt -130.69 126.74 37.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.484 ' HG2' ' HB3' ' A' ' 1' ' ' SER . 0.1 OUTLIER -96.71 149.33 35.65 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.238 -0.914 . . . . 0.0 109.54 -179.959 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD2' ' HG2' ' A' ' 73' ' ' GLU . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.51 0 C-N-CA 122.633 2.222 . . . . 0.0 110.412 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 65.6 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.61 172.59 13.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.8 mt -100.5 155.5 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.907 . . . . 0.0 109.486 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.681 HD12 ' HG2' ' A' ' 47' ' ' PRO . 36.2 mm -118.17 91.75 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.895 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.443 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -95.33 175.8 6.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.488 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.891 HG11 HD11 ' A' ' 9' ' ' ILE . 76.4 t -84.25 142.33 40.78 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -169.44 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.517 2.145 . . . . 0.0 110.433 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -78.55 105.41 9.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -0.873 . . . . 0.0 109.411 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.891 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.46 -11.07 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.307 -179.859 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.16 -14.99 56.16 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -144.92 -176.29 18.8 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.967 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -71.06 142.59 50.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -1.148 . . . . 0.0 109.472 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.92 107.55 3.25 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -99.61 113.42 25.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.459 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.0 t -68.91 131.81 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -0.934 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 19.5 mm -116.94 -22.16 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -0.897 . . . . 0.0 109.431 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.93 138.04 19.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.293 -0.879 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.499 ' HG ' HG22 ' A' ' 20' ' ' VAL . 12.8 tp -113.48 101.97 9.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 0.6 OUTLIER -108.84 56.65 0.62 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.499 HG22 ' HG ' ' A' ' 18' ' ' LEU . 2.3 m -134.28 160.28 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.224 -0.922 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.463 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 1.2 mtpp -137.43 156.98 47.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.27 -0.894 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.1 m -84.55 129.65 34.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.47 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.451 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 84.31 -9.4 64.27 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.997 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.463 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 0.9 OUTLIER -77.41 131.87 38.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -1.205 . . . . 0.0 109.462 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.0 OUTLIER -85.95 120.57 27.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.217 -0.927 . . . . 0.0 109.467 179.961 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.26 -171.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.229 -0.92 . . . . 0.0 109.204 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 11.0 mt-10 -145.44 163.02 35.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.693 ' O ' HG13 ' A' ' 28' ' ' VAL . 7.2 p -78.14 79.57 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.367 -0.833 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.81 -34.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.471 179.924 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.481 ' NE2' HG23 ' A' ' 26' ' ' ILE . 28.4 tt0 -70.35 141.07 52.29 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.318 -0.864 . . . . 0.0 109.499 -179.988 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.474 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -51.32 -177.17 0.03 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.661 HD13 ' HA ' ' A' ' 46' ' ' SER . 3.8 tp -151.41 -67.78 0.18 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.198 -1.178 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.07 138.66 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.512 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 42.2 t -97.64 89.12 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.439 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.89 150.36 22.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.206 -0.934 . . . . 0.0 109.481 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 41' ' ' SER . 2.0 tt0 -115.24 167.23 11.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.303 -0.873 . . . . 0.0 109.547 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.96 -172.6 3.88 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.48 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -84.52 10.31 11.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.509 179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 5.4 mttp -121.0 -30.83 4.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.333 -0.854 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 169.75 -171.78 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.321 -0.862 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 36' ' ' GLU . 10.5 t -103.96 134.07 47.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.181 -0.949 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtt -138.73 107.2 5.84 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.251 -0.906 . . . . 0.0 109.487 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.29 166.04 21.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.182 -0.949 . . . . 0.0 109.465 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 45' ' ' PRO . 72.0 t -136.38 142.15 38.49 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.305 -0.872 . . . . 0.0 109.342 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 44' ' ' VAL . 35.8 Cg_endo -77.96 -168.27 0.59 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.512 2.142 . . . . 0.0 110.448 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.661 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.8 OUTLIER -85.21 124.09 72.45 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.374 -0.829 . . . . 0.0 109.392 -179.913 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.681 ' HG2' HD12 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -78.45 0.55 9.83 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.306 2.004 . . . . 0.0 110.29 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.466 ' HE3' ' HG3' ' A' ' 74' ' ' PRO . 0.4 OUTLIER -160.15 116.73 2.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.941 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.76 80.93 2.7 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.467 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.996 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -136.37 -159.71 8.51 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 51' ' ' VAL . 11.7 p -103.4 124.1 57.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.201 -1.176 . . . . 0.0 109.519 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.2 t -49.94 140.02 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.455 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.7 tptm -96.94 -70.22 0.73 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.201 -0.937 . . . . 0.0 109.442 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 52.0 p -158.32 135.23 9.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 57' ' ' VAL . 20.9 t -83.31 117.45 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 8.9 t -94.21 19.99 8.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.453 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.833 HG21 HG23 ' A' ' 69' ' ' ILE . 0.7 OUTLIER -143.06 179.58 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.292 -0.88 . . . . 0.0 109.441 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.514 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -130.0 167.39 18.33 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.537 -179.978 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.22 151.63 35.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.48 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.29 9.0 80.77 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.514 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 4.4 m-20 -85.04 150.77 24.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.215 -1.167 . . . . 0.0 109.487 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -112.44 104.99 13.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.491 HD13 ' HA ' ' A' ' 63' ' ' LEU . 3.2 mm? -110.35 173.56 6.27 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.333 -0.855 . . . . 0.0 109.487 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 18.2 ttpt -108.57 142.04 39.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.925 . . . . 0.0 109.499 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 12.7 pt-20 -42.79 138.58 1.91 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.336 -0.852 . . . . 0.0 109.628 -179.884 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.27 -12.86 61.86 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.458 ' CG ' HD12 ' A' ' 63' ' ' LEU . 4.3 m-20 -79.87 153.56 28.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -1.16 . . . . 0.0 109.423 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -83.09 161.91 21.51 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.222 -0.924 . . . . 0.0 109.508 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.95 HG22 HG23 ' A' ' 70' ' ' ILE . 2.8 mp -132.68 -54.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.23 -0.918 . . . . 0.0 109.481 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.95 HG23 HG22 ' A' ' 69' ' ' ILE . 36.4 pt -144.06 -172.37 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.915 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -138.02 115.39 11.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.23 -0.919 . . . . 0.0 109.474 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.996 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 137.62 32.19 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.294 -0.878 . . . . 0.0 109.365 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.942 ' N ' HD13 ' A' ' 72' ' ' LEU . 10.7 tt0 -111.41 95.12 25.04 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.352 -0.842 . . . . 0.0 109.342 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.7 Cg_endo . . . . . 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.206 . . . . 0.0 110.489 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 52.4 p . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -138.06 141.28 40.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.321 -0.862 . . . . 0.0 109.478 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.575 HD12 ' CG ' ' A' ' 71' ' ' GLU . 3.8 tt -89.45 151.46 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.209 -0.932 . . . . 0.0 109.516 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.8 mm -115.79 107.8 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.527 ' NH1' ' HA2' ' A' ' 66' ' ' GLY . 0.0 OUTLIER -92.28 168.13 11.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.306 -0.871 . . . . 0.0 109.504 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.75 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.2 t -44.28 142.27 2.32 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.75 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.23 -170.64 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.447 2.098 . . . . 0.0 110.371 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.85 101.91 12.67 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.542 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.35 -61.66 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 109.253 -179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 119.75 12.5 6.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.02 -139.49 2.65 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 31.8 t0 -111.14 136.86 49.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -1.152 . . . . 0.0 109.475 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -105.48 139.72 14.81 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.443 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.2 mt-10 -122.54 135.08 54.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.176 -1.19 . . . . 0.0 109.43 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.401 HG23 ' CD1' ' A' ' 63' ' ' LEU . 13.3 t -81.52 130.64 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.91 . . . . 0.0 109.399 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -97.05 -42.8 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.176 -0.953 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -162.39 151.5 15.38 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.881 . . . . 0.0 109.493 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 2.5 tp -110.87 110.26 20.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.421 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -101.98 49.76 0.85 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.882 . . . . 0.0 109.407 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.506 HG11 ' HG ' ' A' ' 32' ' ' LEU . 0.8 OUTLIER -146.89 157.47 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.4 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -122.66 173.64 7.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.21 -0.931 . . . . 0.0 109.524 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.402 ' HA ' HG11 ' A' ' 52' ' ' VAL . 15.0 t -85.05 147.27 26.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.199 -0.938 . . . . 0.0 109.457 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 71.14 7.8 63.75 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 6.0 m-20 -85.04 130.62 34.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -86.43 111.48 20.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.453 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 27' ' ' GLU . 3.1 mt -94.31 -171.42 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.3 -0.875 . . . . 0.0 109.185 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.73 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.2 mt-10 -149.05 134.92 18.91 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.421 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' HG13 ' A' ' 28' ' ' VAL . 3.0 p -50.28 91.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.491 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CG ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.78 -60.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.348 -0.845 . . . . 0.0 109.534 179.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.429 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.7 tt0 -57.19 162.79 2.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.567 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.456 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -80.08 -179.11 52.31 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -143.43 -40.45 0.3 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.221 -1.164 . . . . 0.0 109.567 179.962 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 30.8 m -158.63 173.65 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.171 -0.956 . . . . 0.0 109.523 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 16' ' ' ILE . 88.1 t -132.27 104.7 8.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.268 -0.895 . . . . 0.0 109.494 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.93 164.75 14.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.233 -0.917 . . . . 0.0 109.478 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.431 ' CG ' ' N ' ' A' ' 37' ' ' SER . 14.5 tt0 -117.22 158.79 23.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.431 ' N ' ' CG ' ' A' ' 36' ' ' GLU . 2.3 t -130.12 179.76 5.7 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.308 -0.87 . . . . 0.0 109.449 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.19 -59.06 2.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 109.415 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.86 54.55 1.58 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.522 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.65 146.16 0.97 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 78.6 p -105.36 137.22 43.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.1 mmt -120.67 178.81 4.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.209 -0.932 . . . . 0.0 109.476 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -138.42 161.4 37.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.892 . . . . 0.0 109.529 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 1.8 t -141.66 96.99 6.7 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.376 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.7 Cg_endo -77.56 -168.4 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.476 2.117 . . . . 0.0 110.452 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 28' ' ' VAL . 1.6 t -85.26 113.71 52.03 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.14 1.9 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.37 2.047 . . . . 0.0 110.256 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.8 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.5 OUTLIER -160.17 138.12 9.93 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.88 . . . . 0.0 109.334 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.9 102.19 11.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.184 -0.948 . . . . 0.0 109.516 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.921 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -159.11 -167.82 20.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.467 HG22 ' HA2' ' A' ' 23' ' ' GLY . 14.4 p -110.59 138.28 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -1.137 . . . . 0.0 109.496 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.402 HG11 ' HA ' ' A' ' 22' ' ' THR . 61.6 t -56.29 122.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.9 . . . . 0.0 109.527 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.59 -49.37 5.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.457 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 t -149.95 163.66 37.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.578 HG12 ' H ' ' A' ' 57' ' ' VAL . 43.5 t -121.35 131.84 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.25 -0.906 . . . . 0.0 109.428 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.06 21.43 13.74 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.614 HG11 ' HA ' ' A' ' 69' ' ' ILE . 27.5 m -148.23 162.56 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.9 ttpt -123.73 155.13 38.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.886 . . . . 0.0 109.453 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.458 ' HB3' ' HB2' ' A' ' 18' ' ' LEU . 1.7 pp -72.09 139.27 48.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.239 -0.913 . . . . 0.0 109.524 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.59 -13.85 57.2 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 -82.79 148.78 27.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -1.162 . . . . 0.0 109.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.448 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 pttp -104.59 141.12 36.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.175 -0.953 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.781 HD12 ' N ' ' A' ' 63' ' ' LEU . 1.5 mp -130.26 164.26 24.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -0.888 . . . . 0.0 109.531 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -115.32 154.11 29.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.987 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.3 OUTLIER -42.72 130.72 4.11 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.285 -0.884 . . . . 0.0 109.663 -179.939 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.527 ' HA2' ' NH1' ' A' ' 5' ' ' ARG . . . 107.83 -12.58 38.32 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -84.23 131.0 34.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -1.16 . . . . 0.0 109.471 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.26 147.13 48.49 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.289 -0.882 . . . . 0.0 109.448 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.723 HG22 HG23 ' A' ' 70' ' ' ILE . 19.8 mm -103.34 -71.46 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.229 -0.919 . . . . 0.0 109.457 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.723 HG23 HG22 ' A' ' 69' ' ' ILE . 0.9 OUTLIER -142.15 171.14 11.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -0.912 . . . . 0.0 109.5 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.575 ' CG ' HD12 ' A' ' 3' ' ' ILE . 2.6 mp0 -122.7 117.44 25.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.339 -0.851 . . . . 0.0 109.475 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.921 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -89.99 142.18 27.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.247 -0.908 . . . . 0.0 109.424 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.506 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -115.61 91.86 31.23 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.488 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.61 ' O ' ' HB3' ' A' ' 75' ' ' ALA . 35.4 Cg_endo -78.07 2.91 7.5 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.597 2.198 . . . . 0.0 110.401 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 74' ' ' PRO . . . 70.26 -169.07 0.16 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.474 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -74.17 -49.26 24.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.359 -0.838 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -146.36 170.57 27.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -141.67 145.94 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -1.162 . . . . 0.0 109.455 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.47 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 80.6 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.33 164.24 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.89 . . . . 0.0 109.451 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 57.0 mt -97.43 140.9 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -0.918 . . . . 0.0 109.456 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.73 114.21 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.505 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.744 ' HA ' HD12 ' A' ' 69' ' ' ILE . 1.5 ptt180 -110.29 164.68 12.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.253 -0.904 . . . . 0.0 109.434 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.746 HG13 ' HD2' ' A' ' 7' ' ' PRO . 74.9 t -65.99 142.28 97.94 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.175 -0.953 . . . . 0.0 109.393 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.746 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.5 Cg_endo -78.16 -171.72 1.29 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.515 2.143 . . . . 0.0 110.39 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -68.04 112.86 5.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.427 ' O ' HG13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -110.18 -29.25 2.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.224 -0.923 . . . . 0.0 108.741 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 93.62 -47.34 2.32 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.74 -144.96 7.18 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -99.63 146.98 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.2 -1.176 . . . . 0.0 109.5 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.02 148.35 18.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 44.2 tt0 -127.78 146.6 50.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -1.108 . . . . 0.0 109.424 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.734 HG22 HD23 ' A' ' 35' ' ' LEU . 3.6 t -84.33 156.96 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.182 -0.949 . . . . 0.0 109.489 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.675 HD11 ' HB2' ' A' ' 36' ' ' GLU . 3.6 mp -123.79 -36.61 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.279 -0.888 . . . . 0.0 109.496 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -151.44 151.39 31.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.22 -0.925 . . . . 0.0 109.449 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 1.011 HD12 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -108.52 118.46 36.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.455 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 mt -90.26 30.55 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.299 -0.876 . . . . 0.0 109.498 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 1.011 HG22 HD12 ' A' ' 18' ' ' LEU . 31.8 m -149.69 156.66 7.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.429 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.3 OUTLIER -130.26 176.3 8.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 22' ' ' THR . 14.7 t -75.15 124.57 27.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.223 -0.923 . . . . 0.0 109.504 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.84 1.05 89.08 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.429 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -84.61 142.17 30.14 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.145 -1.209 . . . . 0.0 109.474 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 5.0 tt -108.66 121.38 44.9 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.207 -0.933 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.718 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.5 mt -90.29 -171.41 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.268 -0.895 . . . . 0.0 109.177 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -145.28 172.69 12.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.932 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 28' ' ' VAL . 9.7 p -74.06 82.27 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.307 -0.871 . . . . 0.0 109.422 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 162.94 -58.55 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.298 -0.876 . . . . 0.0 109.48 179.918 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.41 ' C ' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -44.29 157.88 0.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.509 179.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 45' ' ' PRO . . . -70.23 -153.56 0.99 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.755 HD23 ' CA ' ' A' ' 46' ' ' SER . 0.1 OUTLIER -159.87 -73.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -1.148 . . . . 0.0 109.517 179.895 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.436 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 25.8 m -135.37 135.09 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HG3' ' A' ' 43' ' ' GLU . 20.5 t -107.09 92.82 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.343 -0.848 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.734 HD23 HG22 ' A' ' 15' ' ' VAL . 0.4 OUTLIER -89.97 -173.69 3.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.445 -179.945 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.675 ' HB2' HD11 ' A' ' 16' ' ' ILE . 8.7 tt0 -130.41 167.58 18.35 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.4 m -126.61 172.25 10.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.57 -58.8 3.13 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 11.6 pttm -132.27 53.38 2.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.432 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -174.1 -166.58 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.249 -0.907 . . . . 0.0 109.46 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.8 155.68 38.99 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 4.5 mmt -138.71 145.55 40.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.447 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HG3' HG22 ' A' ' 34' ' ' VAL . 14.3 tm-20 -159.99 150.13 18.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.268 -0.895 . . . . 0.0 109.435 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.548 HG13 ' HD2' ' A' ' 45' ' ' PRO . 49.4 t -135.77 140.1 32.64 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.448 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.548 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.28 -168.65 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.442 2.095 . . . . 0.0 110.368 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.755 ' CA ' HD23 ' A' ' 32' ' ' LEU . 0.3 OUTLIER -85.52 113.38 50.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.481 ' O ' ' HG2' ' A' ' 48' ' ' LYS . 35.6 Cg_endo -78.31 -3.17 13.16 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.256 1.971 . . . . 0.0 110.381 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.641 ' CB ' HD22 ' A' ' 72' ' ' LEU . 3.6 mtmm -160.37 130.92 5.44 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.344 -0.847 . . . . 0.0 109.406 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.51 90.67 7.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.439 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.486 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -146.25 -166.24 11.98 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.5 p -109.97 160.26 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.28 -1.13 . . . . 0.0 109.482 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.428 ' N ' HG22 ' A' ' 51' ' ' VAL . 55.0 t -76.04 123.6 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.967 . . . . 0.0 109.443 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -94.23 -49.41 5.74 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.495 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.7 t -158.35 118.21 3.24 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.197 -0.939 . . . . 0.0 109.465 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.92 HG13 HG22 ' A' ' 70' ' ' ILE . 5.8 t -87.66 133.17 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.453 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 56' ' ' SER . 8.2 t -113.31 29.18 8.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -0.919 . . . . 0.0 109.496 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.445 HG11 ' HA ' ' A' ' 69' ' ' ILE . 35.6 m -149.47 175.6 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.441 ' O ' ' HB2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -136.5 157.57 46.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.467 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.447 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -68.22 138.87 55.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.448 -179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.45 -10.67 68.47 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.441 ' HB2' ' O ' ' A' ' 58' ' ' LYS . 41.6 m-20 -80.9 144.95 31.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -1.144 . . . . 0.0 109.482 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 14.2 ptmt -110.52 148.09 32.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 63' ' ' LEU . 4.3 mp -138.95 166.68 23.85 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.244 -0.91 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 5.0 mtpt -99.58 148.4 24.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 23.8 pt-20 -42.81 142.76 0.82 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.666 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.83 -9.48 76.68 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.98 137.21 35.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -1.156 . . . . 0.0 109.516 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -67.81 176.83 2.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.844 HG22 HG23 ' A' ' 70' ' ' ILE . 2.1 mp -140.9 -67.24 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.92 HG22 HG13 ' A' ' 55' ' ' VAL . 30.1 pt -139.45 173.24 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 109.472 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -127.83 108.47 10.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.503 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.641 HD22 ' CB ' ' A' ' 48' ' ' LYS . 0.6 OUTLIER -90.09 142.24 27.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.436 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.407 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 60.6 tt0 -116.54 88.32 23.84 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 109.469 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HG3' ' HD2' ' A' ' 48' ' ' LYS . 35.7 Cg_endo -78.11 71.4 6.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.652 2.235 . . . . 0.0 110.409 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.407 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . 49.6 -172.05 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.242 -0.911 . . . . 0.0 109.421 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 60.63 36.69 19.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -98.05 130.65 10.31 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -51.35 104.62 0.08 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -1.118 . . . . 0.0 109.474 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.481 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 53.6 p . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -82.44 171.64 13.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.476 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 41.0 mm -107.0 143.91 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.859 HG21 ' HG3' ' A' ' 47' ' ' PRO . 38.8 mm -107.16 118.59 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.491 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.53 ' CG ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -103.73 -171.13 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.185 -0.947 . . . . 0.0 109.541 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.752 HG13 ' HD2' ' A' ' 7' ' ' PRO . 65.7 t -79.47 142.72 58.39 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.319 -0.863 . . . . 0.0 109.311 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.752 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.06 -168.79 0.65 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.599 2.199 . . . . 0.0 110.509 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -82.74 111.18 18.43 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.395 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.91 -10.93 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.935 . . . . 0.0 109.345 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 71.98 39.63 58.53 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.07 -153.72 24.88 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -89.34 174.15 7.98 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.289 -1.124 . . . . 0.0 109.497 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -147.51 104.8 0.3 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.463 ' N ' ' CD ' ' A' ' 14' ' ' GLU . 6.2 mp0 -92.82 112.92 25.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -1.153 . . . . 0.0 109.442 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 40.3 t -54.33 134.75 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.5 mm -108.56 -50.88 7.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.228 -0.92 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -144.19 153.03 41.68 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.454 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.85 HD23 HG23 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -120.82 116.08 24.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.924 . . . . 0.0 109.5 179.97 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.767 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.3 pp -106.1 52.15 0.73 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.354 -0.841 . . . . 0.0 109.525 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.85 HG23 HD23 ' A' ' 18' ' ' LEU . 0.8 OUTLIER -140.2 169.54 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . 3.5 tptt -144.32 169.28 18.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.211 -0.931 . . . . 0.0 109.512 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.435 HG23 ' O ' ' A' ' 22' ' ' THR . 15.2 t -84.11 132.56 34.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 84.26 -1.43 88.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.44 ' CG ' ' HB3' ' A' ' 21' ' ' LYS . 5.7 m-20 -84.05 134.29 34.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.115 -1.227 . . . . 0.0 109.527 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -94.36 116.37 28.73 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.881 . . . . 0.0 109.41 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.1 mt -90.52 -171.35 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.228 -0.92 . . . . 0.0 109.157 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.6 mt-10 -146.37 159.47 43.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.706 ' O ' HG13 ' A' ' 28' ' ' VAL . 7.5 p -72.95 83.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.293 -0.88 . . . . 0.0 109.47 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 162.83 -32.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.3 -0.875 . . . . 0.0 109.518 179.914 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.413 ' O ' ' HA ' ' A' ' 45' ' ' PRO . 39.4 tt0 -76.28 148.64 37.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.462 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.44 -175.66 1.28 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.888 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.9 OUTLIER -148.22 -68.59 0.23 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -1.105 . . . . 0.0 109.463 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -131.71 171.42 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.584 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 43' ' ' GLU . 75.4 t -134.14 92.72 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.227 -0.921 . . . . 0.0 109.419 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.4 mp -90.0 149.82 22.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.303 -0.873 . . . . 0.0 109.423 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -115.17 139.1 50.21 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.24 -179.21 5.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.271 -0.893 . . . . 0.0 109.515 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -69.76 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.505 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -92.17 -49.69 6.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.892 . . . . 0.0 109.47 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.528 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.89 173.63 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.28 -0.887 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.65 128.94 34.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.294 -0.879 . . . . 0.0 109.501 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 1.7 mtt -127.2 105.73 8.76 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.597 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -80.01 156.76 27.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.547 HG13 ' HD2' ' A' ' 45' ' ' PRO . 44.9 t -133.96 140.45 36.39 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.389 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.547 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.0 Cg_endo -78.44 -168.44 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.599 2.199 . . . . 0.0 110.434 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.888 ' HA ' HD13 ' A' ' 32' ' ' LEU . 7.7 t -85.23 129.93 53.84 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.404 -0.81 . . . . 0.0 109.332 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.859 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.0 Cg_endo -78.59 -1.88 11.98 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.366 2.044 . . . . 0.0 110.513 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.729 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.18 128.57 4.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.533 -179.984 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.09 86.33 5.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.251 -0.906 . . . . 0.0 109.439 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.794 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -146.62 -166.12 12.03 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.456 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.0 p -104.88 139.47 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -1.167 . . . . 0.0 109.466 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 70.5 t -56.98 127.85 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.212 -0.93 . . . . 0.0 109.484 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' SER . 18.4 tptm -100.7 -15.91 17.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.202 -0.936 . . . . 0.0 109.485 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.412 ' CB ' ' O ' ' A' ' 53' ' ' LYS . 0.5 OUTLIER 171.12 145.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.464 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.559 HG12 ' H ' ' A' ' 57' ' ' VAL . 76.1 t -101.11 142.19 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.458 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 61.6 m -121.84 13.58 10.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.89 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 69' ' ' ILE . 10.8 m -147.76 166.99 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 109.504 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -125.52 171.23 10.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.464 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -79.03 118.78 21.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.51 -11.47 42.82 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -70.86 150.93 45.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.968 ' C ' HD22 ' A' ' 63' ' ' LEU . 10.2 tttm -100.19 120.26 39.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.463 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.968 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.0 mm? -131.14 143.93 51.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -105.04 153.21 21.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.269 -0.894 . . . . 0.0 109.458 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.479 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 4.3 pt-20 -42.9 143.63 0.7 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.392 -0.817 . . . . 0.0 109.655 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.66 -18.1 58.09 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' ' O ' ' A' ' 68' ' ' ALA . 7.7 m-20 -85.12 129.99 34.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -1.156 . . . . 0.0 109.526 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.53 ' HA ' ' CG ' ' A' ' 5' ' ' ARG . . . -48.5 175.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.599 ' O ' HG23 ' A' ' 70' ' ' ILE . 21.9 mm -146.93 -47.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.199 -0.938 . . . . 0.0 109.463 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.599 HG23 ' O ' ' A' ' 69' ' ' ILE . 0.6 OUTLIER -158.68 -177.11 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.483 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -127.75 161.82 28.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.208 -0.933 . . . . 0.0 109.494 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.794 HD11 ' N ' ' A' ' 50' ' ' GLY . 0.7 OUTLIER -143.15 135.8 27.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.392 -179.948 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 71.3 tt0 -114.68 90.24 21.33 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.451 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.2 Cg_endo -78.07 111.31 3.06 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.557 2.171 . . . . 0.0 110.403 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.418 ' O ' ' C ' ' A' ' 76' ' ' ALA . . . -123.9 -79.6 0.61 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.19 -0.943 . . . . 0.0 109.508 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 75' ' ' ALA . . . 44.71 81.65 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.434 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 89.19 -138.86 14.93 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.46 ' O ' ' HB3' ' A' ' 79' ' ' ARG . . . -168.96 166.91 11.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.325 -1.103 . . . . 0.0 109.49 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.46 ' HB3' ' O ' ' A' ' 78' ' ' ALA . 14.8 ttp180 . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.413 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.451 ' HB3' ' OE2' ' A' ' 73' ' ' GLU . 18.3 p . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -121.37 152.57 38.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.507 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.7 tt -86.52 152.96 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.821 HG21 ' HG3' ' A' ' 47' ' ' PRO . 5.2 mp -131.92 118.54 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.254 -0.904 . . . . 0.0 109.464 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.79 175.03 7.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.452 179.954 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.654 HG13 ' HD2' ' A' ' 7' ' ' PRO . 53.5 t -55.2 139.88 64.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.234 -0.916 . . . . 0.0 109.323 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.654 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.1 Cg_endo -78.59 -172.94 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.533 2.155 . . . . 0.0 110.359 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -85.11 110.66 19.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 1.009 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.8 -56.47 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.19 -0.944 . . . . 0.0 109.421 -179.917 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.96 -27.32 1.89 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . -179.8 118.42 0.59 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 1.009 ' O ' HD12 ' A' ' 9' ' ' ILE . 0.2 OUTLIER 49.76 -179.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.267 -1.137 . . . . 0.0 109.478 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.762 ' C ' HD23 ' A' ' 35' ' ' LEU . . . -172.24 90.97 0.09 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.453 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 19.3 mt-10 -94.98 124.05 38.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.339 -1.095 . . . . 0.0 109.487 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.7 t -73.12 132.33 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 109.512 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.464 HG22 ' O ' ' A' ' 34' ' ' VAL . 4.4 tt -92.34 -28.76 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -174.43 151.2 1.53 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.41 HD23 ' CG2' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -104.18 103.45 13.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.45 15.07 7.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.284 -0.885 . . . . 0.0 109.375 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.838 HG11 ' HG ' ' A' ' 32' ' ' LEU . 11.9 m -113.28 178.02 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.67 158.43 43.78 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 8.9 t -73.64 141.89 46.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.288 -0.883 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 82.85 -6.61 69.55 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.14 135.62 36.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -1.141 . . . . 0.0 109.446 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.89 HD12 ' C ' ' A' ' 50' ' ' GLY . 22.4 tp -93.24 110.68 22.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.229 -0.92 . . . . 0.0 109.469 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.816 HG23 ' OE1' ' A' ' 30' ' ' GLN . 2.7 mt -91.27 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.248 -0.908 . . . . 0.0 109.201 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 tm-20 -139.36 -178.63 5.46 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.208 -0.933 . . . . 0.0 109.443 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.752 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.2 p -84.79 69.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.554 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.491 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 169.21 -40.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.366 -0.834 . . . . 0.0 109.435 179.884 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.816 ' OE1' HG23 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -56.73 138.49 52.82 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 109.364 179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.44 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -69.5 166.05 49.15 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.838 ' HG ' HG11 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -127.42 -42.01 1.69 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.366 -1.079 . . . . 0.0 109.446 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 32' ' ' LEU . 25.6 m -158.63 174.33 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.154 -0.966 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.464 ' O ' HG22 ' A' ' 16' ' ' ILE . 70.7 t -128.77 102.53 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.227 -0.921 . . . . 0.0 109.449 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.762 HD23 ' C ' ' A' ' 13' ' ' GLY . 3.5 mp -89.98 141.67 28.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.216 -0.928 . . . . 0.0 109.4 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.407 ' OE2' ' OG ' ' A' ' 41' ' ' SER . 6.0 tt0 -115.79 134.31 55.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.23 -0.919 . . . . 0.0 109.513 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.9 m -132.03 -177.77 4.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.269 -0.894 . . . . 0.0 109.446 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.04 -16.54 60.2 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.25 -0.906 . . . . 0.0 109.524 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.8 mttt -84.16 -55.27 4.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.94 . . . . 0.0 109.439 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.467 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.15 -179.54 0.2 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.889 . . . . 0.0 109.454 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.407 ' OG ' ' OE2' ' A' ' 36' ' ' GLU . 2.4 m -95.84 103.72 15.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.5 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -93.78 -173.34 3.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.186 -0.946 . . . . 0.0 109.5 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -124.89 162.16 25.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.201 -0.937 . . . . 0.0 109.477 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 35' ' ' LEU . 18.7 t -144.17 97.11 5.28 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.515 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.6 Cg_endo -77.43 -168.69 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.566 2.177 . . . . 0.0 110.476 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.3 135.24 39.21 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.411 -0.806 . . . . 0.0 109.307 179.89 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.821 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.7 Cg_endo -78.56 -4.63 14.28 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.466 2.111 . . . . 0.0 110.433 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 46' ' ' SER . 26.0 tttt -160.31 142.13 12.69 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.403 -0.81 . . . . 0.0 109.468 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.92 94.22 5.19 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.179 -0.951 . . . . 0.0 109.394 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.897 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.94 -174.7 22.15 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 23' ' ' GLY . 10.8 p -103.66 137.98 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -1.149 . . . . 0.0 109.522 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 55.8 t -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.05 -27.7 13.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.206 -0.934 . . . . 0.0 109.524 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -167.04 171.57 10.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.16 -0.963 . . . . 0.0 109.544 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.787 ' HA ' HG22 ' A' ' 70' ' ' ILE . 55.6 t -131.86 113.25 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.26 -0.9 . . . . 0.0 109.481 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 56' ' ' SER . 5.6 t -99.32 22.64 10.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.47 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.414 ' H ' HG12 ' A' ' 55' ' ' VAL . 31.3 m -144.03 169.55 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.198 -0.939 . . . . 0.0 109.451 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.68 171.93 12.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.728 ' O ' HD12 ' A' ' 59' ' ' LEU . 4.0 pp -80.04 139.15 37.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.315 -0.866 . . . . 0.0 109.536 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.79 -11.14 62.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -70.53 137.46 50.16 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -1.16 . . . . 0.0 109.39 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.544 ' O ' HD22 ' A' ' 63' ' ' LEU . 18.7 mttm -98.5 117.18 32.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.27 -0.894 . . . . 0.0 109.46 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.722 HD12 ' CB ' ' A' ' 67' ' ' ASP . 3.5 mm? -117.92 159.74 22.62 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.429 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.3 tttt -112.09 142.82 44.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 64' ' ' LYS . 9.7 mt-10 -42.84 129.78 4.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.306 -0.871 . . . . 0.0 109.603 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 113.96 -19.95 17.63 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.722 ' CB ' HD12 ' A' ' 63' ' ' LEU . 26.8 m-20 -85.12 136.06 33.71 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.231 -1.158 . . . . 0.0 109.41 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -58.92 167.85 1.47 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.226 -0.921 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.51 HD11 ' CG2' ' A' ' 6' ' ' VAL . 39.1 mm -134.13 -67.28 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.787 HG22 ' HA ' ' A' ' 55' ' ' VAL . 0.7 OUTLIER -144.9 -173.56 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.459 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -133.48 120.93 21.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.303 -0.873 . . . . 0.0 109.477 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.976 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.4 tt -94.05 135.47 35.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.278 -0.889 . . . . 0.0 109.433 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.451 ' OE2' ' HB3' ' A' ' 1' ' ' SER . 5.9 tt0 -114.45 89.17 17.26 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.157 -0.964 . . . . 0.0 109.499 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.976 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo -78.28 173.24 14.13 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.564 2.176 . . . . 0.0 110.365 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -137.89 -54.0 0.65 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.501 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -174.87 133.3 0.34 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.426 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.28 81.98 0.2 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -87.51 134.31 33.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -1.178 . . . . 0.0 109.447 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.446 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.469 ' HB3' ' HB2' ' A' ' 73' ' ' GLU . 95.0 p . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -87.04 137.03 32.69 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -0.883 . . . . 0.0 109.472 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.765 HD13 ' N ' ' A' ' 4' ' ' ILE . 0.0 OUTLIER -101.87 121.49 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.4 -179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.765 ' N ' HD13 ' A' ' 3' ' ' ILE . 49.8 mm -95.82 115.08 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.424 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.444 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 0.0 OUTLIER -112.4 160.24 17.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.203 -0.935 . . . . 0.0 109.686 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.8 HG13 HD11 ' A' ' 9' ' ' ILE . 85.6 t -44.83 104.47 0.39 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.338 -0.851 . . . . 0.0 109.545 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 5' ' ' ARG . 35.1 Cg_endo -77.58 -170.43 0.94 Allowed 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.433 2.089 . . . . 0.0 110.438 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -72.31 99.92 2.52 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.209 -0.932 . . . . 0.0 109.466 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.8 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.26 -10.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.372 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.41 -17.63 11.27 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.04 -119.28 0.81 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.37 170.0 9.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.245 -1.15 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.07 120.14 1.07 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 6.2 mt-10 -100.58 122.46 43.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.231 -1.158 . . . . 0.0 109.441 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.2 t -63.2 124.15 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.905 . . . . 0.0 109.509 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.3 mm -99.54 -18.06 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.34 -0.85 . . . . 0.0 109.454 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -172.98 149.06 1.83 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.23 -0.919 . . . . 0.0 109.53 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.924 ' HG ' HG22 ' A' ' 20' ' ' VAL . 6.6 tp -118.73 102.39 8.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.545 HD23 ' H ' ' A' ' 19' ' ' LEU . 0.3 OUTLIER -90.71 48.62 1.56 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.253 -0.904 . . . . 0.0 109.527 179.973 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.924 HG22 ' HG ' ' A' ' 18' ' ' LEU . 18.7 m -145.86 168.47 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.409 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.35 171.27 14.73 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -82.98 132.02 35.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.384 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.554 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 79.57 -4.57 63.81 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.4 134.99 36.57 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.16 -1.2 . . . . 0.0 109.401 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -82.64 127.54 33.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.853 . . . . 0.0 109.429 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.792 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.6 mt -91.53 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.278 -0.889 . . . . 0.0 109.269 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.715 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.2 tm-20 -142.57 136.68 29.49 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.204 -0.935 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.661 HG13 ' HG3' ' A' ' 29' ' ' GLU . 9.3 p -45.73 140.72 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.248 -0.907 . . . . 0.0 109.475 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.661 ' HG3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER 82.99 -43.69 0.11 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.64 -0.663 . . . . 0.0 109.9 179.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.523 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -47.35 133.82 12.12 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.035 -1.041 . . . . 0.0 109.482 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.34 162.32 49.74 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.902 ' CD2' HG11 ' A' ' 20' ' ' VAL . 0.7 OUTLIER -125.98 -38.53 2.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -1.158 . . . . 0.0 109.465 179.972 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.705 HG12 HD12 ' A' ' 18' ' ' LEU . 33.0 m -158.73 158.59 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.522 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.2 t -124.44 98.22 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.314 -0.866 . . . . 0.0 109.484 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 1.9 mp -90.23 140.24 29.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.305 -0.872 . . . . 0.0 109.526 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -126.89 127.58 45.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.416 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.627 ' HB3' ' HB3' ' A' ' 40' ' ' ALA . 0.3 OUTLIER -102.99 174.87 5.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.272 -0.893 . . . . 0.0 109.477 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' N ' ' OG ' ' A' ' 37' ' ' SER . . . -44.88 -34.48 2.38 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.6 pttt -156.21 50.87 0.52 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.254 -0.903 . . . . 0.0 109.524 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.627 ' HB3' ' HB3' ' A' ' 37' ' ' SER . . . -158.56 91.72 1.09 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.32 129.62 40.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.421 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.9 mtm -149.25 174.46 12.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.259 -0.9 . . . . 0.0 109.503 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 31.6 mp0 -127.97 164.58 22.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.521 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -143.9 96.92 5.43 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.57 -169.1 0.68 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.537 2.158 . . . . 0.0 110.478 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.792 ' HB2' HG21 ' A' ' 26' ' ' ILE . 19.0 t -85.55 126.24 67.11 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.436 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.547 ' CG ' ' CD1' ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.59 -2.2 12.26 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.44 2.093 . . . . 0.0 110.383 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.593 ' HB3' HD12 ' A' ' 72' ' ' LEU . 3.3 tptt -160.16 127.35 4.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.386 -0.821 . . . . 0.0 109.432 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.7 88.66 1.74 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.209 -0.932 . . . . 0.0 109.469 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -144.99 -153.71 5.94 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.674 ' O ' HD22 ' A' ' 72' ' ' LEU . 5.9 p -108.45 151.65 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -1.127 . . . . 0.0 109.408 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.2 t -75.97 123.8 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.187 -0.946 . . . . 0.0 109.522 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -81.38 -59.13 2.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.285 -0.884 . . . . 0.0 109.489 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 31.3 p -161.29 126.3 3.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.28 -0.888 . . . . 0.0 109.457 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.69 HG12 ' H ' ' A' ' 57' ' ' VAL . 57.9 t -81.38 126.21 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.287 -0.883 . . . . 0.0 109.486 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 35.5 t -103.66 26.0 9.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.216 -0.927 . . . . 0.0 109.48 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.69 ' H ' HG12 ' A' ' 55' ' ' VAL . 15.6 m -148.72 164.87 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.887 . . . . 0.0 109.449 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.451 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 9.2 tttt -132.89 164.12 27.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.208 -0.933 . . . . 0.0 109.522 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.34 138.18 55.21 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 109.454 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.14 -18.22 54.64 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.451 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 1.7 m-20 -82.87 143.61 30.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 109.437 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.577 ' C ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -102.18 136.99 41.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.215 -0.928 . . . . 0.0 109.438 179.986 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 62' ' ' LYS . 4.1 mm? -111.34 177.94 4.5 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.471 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.449 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 2.5 ttpp -139.39 152.21 46.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.207 -0.933 . . . . 0.0 109.464 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 7.3 mt-10 -44.28 139.9 2.44 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.172 -0.955 . . . . 0.0 109.513 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.34 -47.52 3.65 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -48.75 130.19 17.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.298 -1.119 . . . . 0.0 109.521 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -60.44 161.99 6.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.326 -0.859 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.787 HD11 HG23 ' A' ' 6' ' ' VAL . 19.9 mm -135.41 -55.55 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.304 -0.872 . . . . 0.0 109.466 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.672 HG23 HG22 ' A' ' 69' ' ' ILE . 11.4 pt -156.57 -174.52 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.311 -0.868 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.433 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 0.6 OUTLIER -144.17 139.04 28.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.856 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -119.61 118.81 31.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.196 -0.94 . . . . 0.0 109.509 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.516 ' N ' HD13 ' A' ' 72' ' ' LEU . 5.7 tt0 -111.74 94.91 25.78 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.575 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo -78.05 2.74 7.66 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.616 2.211 . . . . 0.0 110.381 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -87.82 164.57 15.85 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.213 -0.93 . . . . 0.0 109.576 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -91.66 108.83 20.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.457 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -94.28 -139.47 9.85 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -158.03 24.04 0.26 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.2 -1.176 . . . . 0.0 109.486 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.451 -179.986 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 94.7 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -99.45 149.21 23.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.941 . . . . 0.0 109.426 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.2 tt -83.48 159.16 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.31 -0.868 . . . . 0.0 109.468 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.18 111.62 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.192 -0.942 . . . . 0.0 109.407 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.466 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.36 170.13 10.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.538 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -44.19 142.32 2.25 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.278 -0.889 . . . . 0.0 109.419 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.9 Cg_endo -78.27 171.51 16.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.554 2.169 . . . . 0.0 110.37 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -84.92 99.13 10.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.234 -0.916 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.56 -11.19 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.258 -0.901 . . . . 0.0 109.396 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.88 -10.8 68.24 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -158.98 -161.32 11.02 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 -83.74 143.32 30.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -1.179 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.77 150.16 18.7 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -129.44 119.17 23.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -1.154 . . . . 0.0 109.481 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.6 t -67.37 152.22 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.419 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.404 HD12 HG23 ' A' ' 16' ' ' ILE . 49.3 mm -120.06 -34.24 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -175.47 137.91 0.39 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 109.452 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.781 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.97 140.6 37.03 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 121.154 -0.966 . . . . 0.0 109.371 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.46 35.23 3.26 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.6 m -144.13 -179.7 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.432 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -145.27 -179.68 6.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 0.0 109.441 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.472 HG23 ' O ' ' A' ' 22' ' ' THR . 14.2 t -79.9 129.58 34.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.5 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.41 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.55 -0.13 61.22 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -81.35 133.29 35.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 109.489 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -89.78 107.82 19.32 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -0.903 . . . . 0.0 109.461 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.724 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.88 -171.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.184 -0.948 . . . . 0.0 109.26 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.724 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.8 OUTLIER -147.31 176.76 9.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.151 -0.968 . . . . 0.0 109.51 179.978 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.748 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.2 p -81.18 74.34 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.273 -0.892 . . . . 0.0 109.515 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.506 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 162.92 -27.03 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.313 -0.867 . . . . 0.0 109.402 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 6.2 tt0 -72.99 136.01 45.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.456 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.24 176.18 2.85 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.973 HD23 HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -137.15 -62.93 0.61 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.25 -1.147 . . . . 0.0 109.452 180.0 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.973 HG13 HD23 ' A' ' 32' ' ' LEU . 16.5 m -137.66 172.03 15.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.2 t -125.69 105.95 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.246 -0.909 . . . . 0.0 109.488 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.1 mp -97.95 153.61 18.24 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.84 149.98 39.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.6 m -126.65 177.96 6.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.99 -41.41 59.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.483 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -157.95 37.04 0.26 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.266 -0.896 . . . . 0.0 109.512 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -152.69 88.33 1.34 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.18 -0.95 . . . . 0.0 109.401 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.465 ' O ' ' HG2' ' A' ' 42' ' ' MET . 34.6 t -83.45 127.58 33.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.242 -0.911 . . . . 0.0 109.451 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 41' ' ' SER . 11.9 mtt -147.45 136.46 22.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.468 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -93.0 169.93 10.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.162 -0.961 . . . . 0.0 109.437 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 40.7 t -135.88 127.83 17.46 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.36 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.456 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.4 -168.15 0.58 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.43 2.086 . . . . 0.0 110.389 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.529 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.1 OUTLIER -85.14 135.92 38.78 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.309 -0.869 . . . . 0.0 109.19 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.43 -2.39 12.45 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.434 2.089 . . . . 0.0 110.533 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.775 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.03 140.53 11.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.376 -0.828 . . . . 0.0 109.4 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.68 95.95 9.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.773 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.71 -153.0 6.79 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 73' ' ' GLU . 12.2 p -110.81 141.63 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -1.124 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 71.0 t -63.87 142.6 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.25 -0.906 . . . . 0.0 109.42 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -106.77 -55.35 2.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 109.48 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.31 118.87 7.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.223 -0.923 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 70' ' ' ILE . 13.1 t -84.87 106.73 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 p -90.16 9.2 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.265 -0.897 . . . . 0.0 109.459 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.809 HG11 HG23 ' A' ' 69' ' ' ILE . 20.6 m -124.87 158.27 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.451 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.403 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 2.8 tptp -137.43 -173.38 3.46 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.22 -0.925 . . . . 0.0 109.524 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.453 ' N ' HD21 ' A' ' 18' ' ' LEU . 2.2 pp -85.05 134.36 34.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 77.23 9.08 87.0 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.403 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 37.0 m-20 -84.87 145.46 27.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.244 -1.15 . . . . 0.0 109.438 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -107.41 132.48 53.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.272 -0.893 . . . . 0.0 109.521 -179.981 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.427 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -139.59 130.14 25.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.41 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 31.4 tttm -93.82 145.74 24.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.202 -0.936 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.463 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -42.86 124.29 3.05 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.353 -0.842 . . . . 0.0 109.638 -179.875 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 123.46 -26.37 6.04 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.446 ' O ' ' O ' ' A' ' 68' ' ' ALA . 1.2 m-20 -85.11 131.23 34.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -1.147 . . . . 0.0 109.442 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -49.66 178.55 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.284 -0.885 . . . . 0.0 109.509 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.809 HG23 HG11 ' A' ' 57' ' ' VAL . 23.1 mm -145.08 -65.21 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.237 -0.914 . . . . 0.0 109.414 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.591 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.2 pt -151.51 177.18 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.478 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -143.48 140.42 30.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.942 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.3 tt -107.75 142.8 37.2 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 109.411 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.431 ' O ' HG12 ' A' ' 51' ' ' VAL . 1.3 tp10 -131.34 89.84 39.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.432 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.942 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.05 91.08 1.21 Allowed 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.59 2.193 . . . . 0.0 110.406 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -152.87 -54.16 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.248 -0.907 . . . . 0.0 109.419 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -160.42 146.39 15.21 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.92 . . . . 0.0 109.472 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.59 -100.86 0.01 OUTLIER Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -79.84 178.31 8.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.472 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.487 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 60.4 p . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' A' ' 71' ' ' GLU . 16.5 mt-10 -135.78 137.24 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.496 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.618 HD11 ' HB1' ' A' ' 68' ' ' ALA . 1.2 tt -82.14 151.94 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.5 mm -117.37 97.03 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.76 163.3 14.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.843 HG23 HD11 ' A' ' 69' ' ' ILE . 71.4 t -57.88 142.05 79.61 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.737 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -77.98 -174.46 2.24 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.587 2.191 . . . . 0.0 110.386 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -58.78 103.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.541 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.602 HG23 ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -110.17 -37.75 3.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.238 -0.913 . . . . 0.0 108.767 179.934 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.85 52.98 21.65 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.89 -136.57 4.37 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -116.65 138.4 51.47 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.22 -1.165 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -110.74 118.93 5.1 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.01 130.91 47.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.278 -1.131 . . . . 0.0 109.476 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.3 t -80.67 147.31 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.469 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.838 HD12 HG12 ' A' ' 34' ' ' VAL . 60.4 mt -113.49 -57.02 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.193 -0.942 . . . . 0.0 109.474 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -160.8 162.64 32.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.305 -0.872 . . . . 0.0 109.463 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.1 tp -101.2 141.53 33.94 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.721 HD12 ' N ' ' A' ' 32' ' ' LEU . 12.7 mt -99.0 18.67 16.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.488 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.5 m -150.04 172.22 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.422 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -120.01 -178.29 3.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.459 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.22 113.92 19.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.501 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.31 0.5 65.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.84 145.89 27.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.265 -1.138 . . . . 0.0 109.434 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.469 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.1 tp -89.81 132.27 35.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.184 -0.947 . . . . 0.0 109.449 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.822 HD13 ' CD1' ' A' ' 32' ' ' LEU . 2.7 mt -91.79 -171.41 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.184 -0.947 . . . . 0.0 109.135 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -149.96 126.01 10.59 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.246 -0.908 . . . . 0.0 109.488 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.567 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 8.4 p -44.98 149.61 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.567 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 16.3 tt0 83.05 -43.67 0.11 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.666 -0.646 . . . . 0.0 109.8 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.546 ' HB2' ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -62.29 153.81 29.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.101 -0.999 . . . . 0.0 109.48 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.476 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -62.46 -176.94 3.03 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.822 ' CD1' HD13 ' A' ' 26' ' ' ILE . 10.0 tp -153.98 -56.88 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -1.176 . . . . 0.0 109.558 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.19 152.7 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.175 -0.953 . . . . 0.0 109.65 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.838 HG12 HD12 ' A' ' 16' ' ' ILE . 22.6 t -120.97 83.96 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.282 -0.886 . . . . 0.0 109.367 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.01 170.86 9.99 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -0.905 . . . . 0.0 109.478 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.516 ' CG ' ' O ' ' A' ' 40' ' ' ALA . 21.8 tt0 -114.08 154.22 28.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -104.7 -177.05 3.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -45.31 -37.69 5.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.314 -0.866 . . . . 0.0 109.446 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -158.74 63.52 0.42 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.516 ' O ' ' CG ' ' A' ' 36' ' ' GLU . . . 178.13 -167.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.425 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.8 m -135.85 116.36 13.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.243 -0.91 . . . . 0.0 109.455 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -116.78 132.68 56.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.164 -0.96 . . . . 0.0 109.43 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.569 ' HG2' HG22 ' A' ' 34' ' ' VAL . 2.0 mt-10 -112.57 161.59 16.61 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.54 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 3.4 t -139.31 140.3 25.52 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.22 -0.925 . . . . 0.0 109.279 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.54 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.31 -169.12 0.71 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.379 2.053 . . . . 0.0 110.38 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.754 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.53 134.71 39.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.32 -0.862 . . . . 0.0 109.302 179.911 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.582 ' HD3' HD22 ' A' ' 32' ' ' LEU . 36.2 Cg_endo -78.68 -12.64 15.0 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.435 2.09 . . . . 0.0 110.233 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.453 ' CD ' ' HB3' ' A' ' 74' ' ' PRO . 1.3 ttmp? -160.64 132.11 5.75 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.7 84.54 2.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.4 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.742 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -135.21 -144.11 4.9 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' VAL . 11.3 p -118.74 157.24 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.404 ' N ' HG22 ' A' ' 51' ' ' VAL . 24.1 t -84.82 136.69 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.239 -0.913 . . . . 0.0 109.468 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.38 -60.89 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.433 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.8 m -175.36 157.62 2.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.16 -0.963 . . . . 0.0 109.501 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 57' ' ' VAL . 3.5 t -87.11 121.38 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.2 m -80.93 5.85 15.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.573 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.871 HG11 HD11 ' A' ' 63' ' ' LEU . 35.6 m -150.11 -172.26 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.499 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.436 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.4 OUTLIER -114.05 153.28 29.7 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.453 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -65.81 150.3 48.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.466 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 69.25 9.1 60.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.436 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 5.1 m-20 -84.99 154.79 21.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -1.156 . . . . 0.0 109.492 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -101.92 123.18 45.4 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.264 -0.898 . . . . 0.0 109.427 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 57' ' ' VAL . 83.0 mt -123.2 152.72 40.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 109.453 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.416 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.8 ttpt -94.0 147.28 23.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.286 -0.883 . . . . 0.0 109.509 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.602 ' HB3' HG23 ' A' ' 9' ' ' ILE . 10.7 pt-20 -43.05 139.59 1.72 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.35 -0.844 . . . . 0.0 109.605 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.55 -4.61 79.83 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.04 143.37 29.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.32 -1.106 . . . . 0.0 109.452 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.618 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -74.98 157.74 34.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.312 -0.868 . . . . 0.0 109.461 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.843 HD11 HG23 ' A' ' 6' ' ' VAL . 3.2 mp -131.07 -51.77 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.195 -0.94 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.0 pt -147.4 -179.69 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 2' ' ' GLU . 22.9 tt0 -150.06 129.24 12.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.224 -0.923 . . . . 0.0 109.489 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.742 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.6 OUTLIER -95.82 145.07 25.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.473 179.931 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.52 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -112.4 93.32 22.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.328 -0.858 . . . . 0.0 109.404 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.56 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -77.97 -170.33 0.94 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.631 2.221 . . . . 0.0 110.461 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.42 ' C ' ' O ' ' A' ' 74' ' ' PRO . . . -43.69 97.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.317 -0.865 . . . . 0.0 109.454 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 74' ' ' PRO . . . -81.63 -14.1 57.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -165.6 -76.85 0.03 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -161.76 94.93 0.97 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.221 -1.164 . . . . 0.0 109.528 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 26.9 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -92.87 169.41 10.48 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.89 . . . . 0.0 109.476 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 16.7 mt -106.48 146.58 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.875 . . . . 0.0 109.439 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.595 HD12 ' HG2' ' A' ' 47' ' ' PRO . 27.9 mm -104.93 114.68 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.566 ' HA ' HD12 ' A' ' 69' ' ' ILE . 6.0 ptp180 -107.07 177.71 4.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.238 -0.914 . . . . 0.0 109.459 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 72.6 t -73.77 142.06 79.77 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.219 -0.926 . . . . 0.0 109.459 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.0 Cg_endo -78.45 -170.15 0.92 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.497 2.131 . . . . 0.0 110.441 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -85.02 102.86 13.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.164 -0.96 . . . . 0.0 109.423 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.529 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.3 -49.03 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.352 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.63 30.28 2.44 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' OE1' ' A' ' 65' ' ' GLU . . . 168.3 -166.19 39.34 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -94.95 115.65 27.72 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.264 -1.139 . . . . 0.0 109.531 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.38 168.39 54.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 62' ' ' LYS . 4.6 tt0 -142.99 117.27 9.58 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.2 -1.177 . . . . 0.0 109.496 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.556 HG11 ' HA ' ' A' ' 59' ' ' LEU . 62.4 t -62.52 119.78 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.513 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 34' ' ' VAL . 2.1 pt -113.99 -20.26 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.416 ' N ' HG13 ' A' ' 16' ' ' ILE . 0.1 OUTLIER -155.41 136.76 14.02 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.299 -0.875 . . . . 0.0 109.499 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.425 HD13 HG11 ' A' ' 15' ' ' VAL . 0.2 OUTLIER -129.09 123.57 32.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.937 . . . . 0.0 109.4 -179.965 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.492 ' CG ' ' O ' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -125.22 63.13 1.17 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 0.0 109.478 -179.923 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.608 HG11 ' HG ' ' A' ' 32' ' ' LEU . 16.7 m -144.96 169.24 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.22 160.07 42.04 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 53' ' ' LYS . 94.8 m -84.5 133.85 34.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.495 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.85 -10.77 73.81 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -81.1 136.42 35.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -1.137 . . . . 0.0 109.505 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.56 115.96 22.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 109.5 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.704 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -91.02 -171.54 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.187 -0.945 . . . . 0.0 109.234 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 mt-10 -145.67 174.87 10.81 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.736 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.0 p -84.98 76.22 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.892 . . . . 0.0 109.42 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.8 OUTLIER 167.21 -41.98 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.431 -0.793 . . . . 0.0 109.251 179.867 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.526 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 61.5 tt0 -59.65 146.44 41.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.19 168.17 54.4 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.608 ' HG ' HG11 ' A' ' 20' ' ' VAL . 5.0 tp -128.46 -43.79 1.41 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -1.154 . . . . 0.0 109.567 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.526 HG13 ' C ' ' A' ' 32' ' ' LEU . 15.7 m -158.56 159.08 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 16' ' ' ILE . 62.9 t -124.37 103.47 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.184 -0.947 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.08 163.08 15.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -118.05 145.29 44.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 0.1 OUTLIER -121.69 -177.39 3.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.915 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.36 -56.01 9.25 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.582 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -143.98 59.77 1.36 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 109.523 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.582 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 170.42 112.01 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 33.8 t -100.73 115.15 29.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.483 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 26.2 ttp -102.98 154.73 18.94 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.178 -0.952 . . . . 0.0 109.403 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -100.6 169.61 8.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 69.9 t -146.12 99.57 4.27 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.526 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.4 Cg_endo -77.13 -167.96 0.53 Allowed 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.432 2.088 . . . . 0.0 110.479 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 2.6 t -84.82 125.98 69.5 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.348 -0.845 . . . . 0.0 109.385 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.595 ' HG2' HD12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.54 -1.16 11.35 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.382 2.055 . . . . 0.0 110.404 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 46' ' ' SER . 4.7 tttt -160.15 140.95 12.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.304 -0.872 . . . . 0.0 109.574 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.67 102.84 12.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 0.0 109.402 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 1.002 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -152.92 -168.93 17.54 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.63 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.4 p -104.18 120.19 54.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -1.105 . . . . 0.0 109.499 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 50.9 t -49.09 142.36 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.532 ' O ' HG23 ' A' ' 22' ' ' THR . 3.1 ttpp -104.87 -59.77 1.7 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.218 -0.926 . . . . 0.0 109.486 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.01 140.99 14.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.572 HG12 ' H ' ' A' ' 57' ' ' VAL . 10.7 t -90.37 126.36 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.506 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.6 m -100.38 20.47 14.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.251 -0.906 . . . . 0.0 109.394 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.795 HG21 HG23 ' A' ' 69' ' ' ILE . 1.4 m -143.62 163.39 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.413 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 17.1 ttpt -120.1 141.47 49.77 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.474 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.556 ' HA ' HG11 ' A' ' 15' ' ' VAL . 2.1 pp -60.26 128.37 36.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.466 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.39 -21.9 21.04 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -83.43 158.45 22.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.187 -1.184 . . . . 0.0 109.502 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 14' ' ' GLU . 5.8 pttt -86.8 165.11 16.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.574 HD21 HG11 ' A' ' 57' ' ' VAL . 0.3 OUTLIER -132.02 110.66 10.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.324 -0.86 . . . . 0.0 109.45 -179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.84 136.28 36.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.232 -0.918 . . . . 0.0 109.282 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.459 ' OE1' ' O ' ' A' ' 11' ' ' GLY . 1.8 mt-10 -48.85 149.04 1.94 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.31 -0.869 . . . . 0.0 109.958 -179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.79 -14.66 46.75 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.64 141.62 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.198 -1.178 . . . . 0.0 109.621 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.453 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -74.61 176.07 7.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 109.342 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.882 HG22 HG23 ' A' ' 70' ' ' ILE . 2.9 mp -139.37 -64.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.156 -0.965 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.882 HG23 HG22 ' A' ' 69' ' ' ILE . 2.3 pp -139.18 173.59 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.931 . . . . 0.0 109.605 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -129.31 137.51 51.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.874 . . . . 0.0 109.428 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.002 HD11 ' CA ' ' A' ' 50' ' ' GLY . 3.5 tt -108.52 137.88 45.75 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.272 -0.893 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -113.38 92.17 22.19 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.975 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.4 Cg_endo -78.05 75.05 5.02 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.598 2.198 . . . . 0.0 110.391 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . 53.7 97.95 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.399 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -107.25 16.11 24.36 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.454 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.16 -106.13 0.22 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -87.42 -166.77 1.67 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.32 -1.106 . . . . 0.0 109.404 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.2 mtm180 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.049 -0.976 . . . . 0.0 109.467 179.917 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.529 ' CB ' ' HG2' ' A' ' 73' ' ' GLU . 53.2 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.271 0.558 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 1' ' ' SER . 2.0 mm-40 -154.09 148.81 26.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.231 -0.918 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.7 mp -80.05 143.1 12.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.412 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.477 HD13 HD11 ' A' ' 70' ' ' ILE . 2.1 mp -114.82 97.88 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.428 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.444 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.07 176.67 6.69 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.735 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.0 t -65.68 142.43 98.21 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.288 -0.882 . . . . 0.0 109.387 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.735 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.7 Cg_endo -78.24 -178.68 4.8 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.528 2.152 . . . . 0.0 110.374 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -85.05 96.64 9.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.22 -0.925 . . . . 0.0 109.41 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.99 -17.64 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.31 -0.869 . . . . 0.0 109.299 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.29 -8.95 62.46 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.82 -133.14 3.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -113.6 170.8 7.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -134.06 108.44 0.73 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.471 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.3 OUTLIER -99.8 120.33 39.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -1.112 . . . . 0.0 109.371 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.2 t -67.26 123.31 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.88 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.954 HG22 ' O ' ' A' ' 34' ' ' VAL . 8.3 tp -103.37 -25.19 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.196 -0.94 . . . . 0.0 109.494 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -178.62 138.83 0.17 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.485 ' H ' HD12 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -102.75 152.47 21.2 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.304 -0.872 . . . . 0.0 109.399 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.682 HD12 ' C ' ' A' ' 32' ' ' LEU . 0.7 OUTLIER -112.06 27.29 9.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.446 HG21 HD11 ' A' ' 32' ' ' LEU . 24.3 m -149.98 167.48 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -0.903 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.529 ' O ' HG21 ' A' ' 52' ' ' VAL . 0.0 OUTLIER -132.97 -167.59 1.94 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 80.3 m -84.96 130.34 34.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.479 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.447 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 79.79 2.16 87.98 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -84.61 135.3 34.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.191 -1.182 . . . . 0.0 109.466 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.4 tp -89.24 127.84 35.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.221 -0.924 . . . . 0.0 109.493 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.012 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -98.5 -171.22 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.285 -0.885 . . . . 0.0 109.148 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 40.0 mm-40 -140.81 164.99 28.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.492 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.772 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.7 p -80.47 75.62 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.259 -0.901 . . . . 0.0 109.404 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 2.4 mt-10 162.7 -31.01 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.352 -0.842 . . . . 0.0 109.283 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 6.2 tt0 -71.01 151.0 45.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.24 -0.913 . . . . 0.0 109.449 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.445 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -70.4 165.94 51.35 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 1.012 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -125.84 -49.54 1.61 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -1.124 . . . . 0.0 109.559 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.428 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.5 m -146.74 158.11 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.482 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.954 ' O ' HG22 ' A' ' 16' ' ' ILE . 82.6 t -126.05 88.25 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.14 -0.975 . . . . 0.0 109.439 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.471 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.5 OUTLIER -90.04 152.34 21.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.541 -179.943 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -92.53 -178.92 5.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.495 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.418 ' O ' ' C ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -140.87 175.9 9.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.458 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.418 ' C ' ' O ' ' A' ' 37' ' ' SER . . . -44.4 -49.94 9.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.514 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -147.09 32.92 0.9 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.77 169.1 25.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.865 . . . . 0.0 109.464 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 58.7 m -123.56 135.3 53.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.428 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.3 mmt -133.59 135.63 44.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' N ' ' A' ' 44' ' ' VAL . 24.9 tt0 -106.92 166.03 10.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.515 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 6.4 t -145.9 111.64 4.48 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.314 -0.866 . . . . 0.0 109.283 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.5 Cg_endo -77.26 -169.11 0.68 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.364 2.043 . . . . 0.0 110.437 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.5 OUTLIER -85.46 130.44 51.36 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 -179.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.405 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.88 -6.6 15.21 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.417 2.078 . . . . 0.0 110.482 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -160.37 149.26 17.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.529 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.433 ' O ' ' HB3' ' A' ' 74' ' ' PRO . . . -79.85 96.43 6.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.762 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -144.78 177.11 23.5 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.447 HG23 ' C ' ' A' ' 23' ' ' GLY . 7.3 p -104.12 137.83 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -1.148 . . . . 0.0 109.483 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.529 HG21 ' O ' ' A' ' 21' ' ' LYS . 49.0 t -53.3 129.62 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.455 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.77 -18.14 10.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.301 -0.874 . . . . 0.0 109.44 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.2 p -164.88 150.05 9.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.195 -0.941 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.458 HG12 ' H ' ' A' ' 57' ' ' VAL . 61.0 t -129.88 117.93 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.413 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.07 15.4 29.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.419 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 69' ' ' ILE . 33.3 m -138.71 161.73 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.288 -0.883 . . . . 0.0 109.478 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.93 -165.0 1.8 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.1 pp -80.86 123.99 28.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.33 -3.96 86.55 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.88 135.52 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.15 -1.206 . . . . 0.0 109.392 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -107.8 125.06 50.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.533 HD23 ' HB3' ' A' ' 67' ' ' ASP . 1.9 mp -131.35 154.02 49.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.46 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -111.03 150.37 29.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.238 -0.914 . . . . 0.0 109.518 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.469 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 0.7 OUTLIER -42.88 141.46 1.1 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 109.643 -179.825 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.14 -26.47 23.76 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.533 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -85.07 137.33 33.12 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -1.183 . . . . 0.0 109.546 -179.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -64.57 164.18 12.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.381 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 70' ' ' ILE . 44.2 mm -122.25 -68.24 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.122 -0.986 . . . . 0.0 109.534 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 69' ' ' ILE . 1.6 pp -138.91 179.87 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.237 -0.914 . . . . 0.0 109.471 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.433 ' N ' HD12 ' A' ' 70' ' ' ILE . 46.3 tt0 -134.03 127.83 33.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.762 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.9 tp -107.03 123.91 48.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.884 ' OE1' ' HB2' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -120.92 91.4 47.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.301 -0.874 . . . . 0.0 109.424 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.468 ' HD2' ' CA ' ' A' ' 1' ' ' SER . 35.2 Cg_endo -77.99 98.16 1.19 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.644 2.229 . . . . 0.0 110.395 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.441 ' O ' ' O ' ' A' ' 74' ' ' PRO . . . 61.13 120.72 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -0.893 . . . . 0.0 109.486 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.884 ' HB2' ' OE1' ' A' ' 73' ' ' GLU . . . -112.94 94.69 5.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -104.94 -49.3 1.01 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -50.45 -23.95 2.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.252 -1.146 . . . . 0.0 109.521 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 7.9 ttt180 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.504 179.99 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.475 ' HB3' ' HD3' ' A' ' 74' ' ' PRO . 83.4 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.445 ' OE2' ' HG3' ' A' ' 48' ' ' LYS . 20.2 pt-20 -155.9 172.51 18.24 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.433 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.846 HD13 ' HG2' ' A' ' 71' ' ' GLU . 16.7 mm -116.52 134.39 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.304 -0.873 . . . . 0.0 109.47 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -98.0 110.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.402 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.47 ' HA ' HG12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -110.44 169.56 8.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.21 -0.931 . . . . 0.0 109.573 -179.944 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.614 HG13 HD11 ' A' ' 9' ' ' ILE . 51.6 t -43.58 106.03 0.47 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.272 -0.893 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.43 -170.5 0.95 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.486 2.124 . . . . 0.0 110.41 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -75.68 100.45 4.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.506 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.614 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -107.05 -24.81 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.286 -0.883 . . . . 0.0 109.313 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 123.9 -30.76 4.75 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -173.56 169.43 42.51 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -48.07 113.53 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.287 -1.125 . . . . 0.0 109.488 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.25 149.41 16.86 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.475 ' HB2' ' HG2' ' A' ' 62' ' ' LYS . 55.8 tt0 -115.27 126.37 54.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.255 -1.144 . . . . 0.0 109.548 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.406 ' O ' ' HA2' ' A' ' 60' ' ' GLY . 40.6 t -55.93 148.41 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.324 -0.86 . . . . 0.0 109.495 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.883 HD11 ' HB2' ' A' ' 36' ' ' GLU . 50.4 mt -120.41 -50.4 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -0.886 . . . . 0.0 109.455 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -159.3 143.55 15.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.286 -0.883 . . . . 0.0 109.413 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.771 HD23 ' N ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -102.84 155.2 18.5 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.297 -0.877 . . . . 0.0 109.384 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.612 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -122.83 35.83 4.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -146.13 -179.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.193 -0.942 . . . . 0.0 109.452 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.35 176.12 8.39 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.191 -0.943 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.1 m -77.6 148.41 35.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.445 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 68.49 7.53 53.43 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -85.01 143.1 29.14 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 0.0 109.515 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -102.21 116.02 31.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.446 179.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.8 OUTLIER -92.92 -171.57 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.194 -0.941 . . . . 0.0 109.245 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.1 mt-10 -140.56 172.91 12.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.186 -0.946 . . . . 0.0 109.391 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.691 ' O ' HG13 ' A' ' 28' ' ' VAL . 7.1 p -78.86 77.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.268 -0.895 . . . . 0.0 109.52 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.515 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.99 -41.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.312 -0.868 . . . . 0.0 109.485 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -61.43 146.6 47.86 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.464 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -63.13 -174.67 2.68 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.642 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -147.54 -71.9 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.147 -1.207 . . . . 0.0 109.518 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.506 HG13 HD22 ' A' ' 32' ' ' LEU . 8.0 m -131.52 175.84 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.943 . . . . 0.0 109.576 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.876 HG22 ' HB3' ' A' ' 43' ' ' GLU . 87.8 t -132.24 99.73 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.345 -0.847 . . . . 0.0 109.421 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.19 153.37 17.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.881 . . . . 0.0 109.486 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.883 ' HB2' HD11 ' A' ' 16' ' ' ILE . 1.5 tt0 -107.8 153.1 23.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.347 -0.845 . . . . 0.0 109.395 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.66 -179.37 3.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.211 -0.931 . . . . 0.0 109.462 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.45 -22.97 66.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.653 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 10.2 pttp -159.39 65.47 0.39 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.419 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 166.62 174.6 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.176 -0.953 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.4 m -154.95 93.06 1.51 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.912 . . . . 0.0 109.397 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 55.7 mtp -116.65 138.82 51.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.275 -0.891 . . . . 0.0 109.494 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.876 ' HB3' HG22 ' A' ' 34' ' ' VAL . 4.3 pt-20 -95.36 -176.31 3.75 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.24 -0.913 . . . . 0.0 109.389 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.561 HG13 ' HD2' ' A' ' 45' ' ' PRO . 68.0 t -143.33 139.38 16.49 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.496 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.561 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.1 Cg_endo -78.92 -168.14 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.554 2.169 . . . . 0.0 110.373 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.642 ' HA ' HD12 ' A' ' 32' ' ' LEU . 28.0 t -85.04 124.31 72.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.247 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HD3' HD12 ' A' ' 32' ' ' LEU . 35.8 Cg_endo -78.17 0.37 9.95 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.366 2.044 . . . . 0.0 110.434 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.646 ' HB3' HD13 ' A' ' 72' ' ' LEU . 3.5 mmtm -160.15 121.36 3.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.248 -0.908 . . . . 0.0 109.517 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.15 83.91 1.01 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.249 -0.907 . . . . 0.0 109.422 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -150.14 -170.03 16.96 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 23' ' ' GLY . 8.0 p -95.94 148.59 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -1.145 . . . . 0.0 109.531 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.0 t -75.94 137.69 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.225 -0.922 . . . . 0.0 109.472 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.454 ' HB3' ' O ' ' A' ' 71' ' ' GLU . 0.0 OUTLIER -90.73 -46.21 8.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.462 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.49 144.14 0.12 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.155 -0.965 . . . . 0.0 109.445 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.459 ' HA ' HG22 ' A' ' 70' ' ' ILE . 5.1 t -86.3 112.87 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.182 -0.949 . . . . 0.0 109.496 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.8 m -90.82 15.75 10.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.518 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.652 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.55 157.65 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.81 147.04 28.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.588 ' HB3' HD21 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -60.02 140.21 56.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.462 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.453 ' O ' ' OE2' ' A' ' 14' ' ' GLU . . . 90.7 -11.31 72.13 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -73.23 140.99 47.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -1.134 . . . . 0.0 109.434 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 14' ' ' GLU . 0.4 OUTLIER -98.38 133.78 42.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 62' ' ' LYS . 1.1 mt -140.11 162.3 35.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.454 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.7 tmtt? -128.71 159.71 34.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.557 ' N ' HG11 ' A' ' 6' ' ' VAL . 8.6 mt-10 -42.7 111.83 0.29 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.426 -0.796 . . . . 0.0 109.695 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.94 -33.85 2.15 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -84.22 142.51 30.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.247 -1.149 . . . . 0.0 109.405 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.633 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -78.26 159.54 28.42 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.391 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.652 HG23 HG21 ' A' ' 57' ' ' VAL . 34.5 mm -123.7 -60.72 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.511 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.555 HG23 HG22 ' A' ' 69' ' ' ILE . 11.3 pt -142.54 -176.47 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 109.49 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.846 ' HG2' HD13 ' A' ' 3' ' ' ILE . 1.7 tm-20 -138.16 108.04 6.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.241 -0.912 . . . . 0.0 109.475 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.725 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.4 tt -89.94 140.99 29.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.477 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.468 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -110.22 157.89 36.73 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 0.0 109.499 179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.475 ' HD3' ' HB3' ' A' ' 1' ' ' SER . 35.9 Cg_endo -77.97 117.48 4.19 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.57 2.18 . . . . 0.0 110.45 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -149.99 87.94 1.5 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.429 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -93.59 40.71 1.07 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.12 -30.55 8.2 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 56.34 20.64 4.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -1.148 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 40.7 mtp85 . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.982 -1.008 . . . . 0.0 109.484 179.969 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 79.5 p . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -123.2 178.59 5.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.465 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.422 ' HA ' ' HG2' ' A' ' 71' ' ' GLU . 7.0 mt -120.15 127.71 75.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.197 -0.939 . . . . 0.0 109.479 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.447 HG21 ' HG3' ' A' ' 47' ' ' PRO . 3.3 mt -98.98 126.62 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.247 -0.908 . . . . 0.0 109.439 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -111.03 161.01 16.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.903 HG23 HD11 ' A' ' 69' ' ' ILE . 72.8 t -50.23 142.08 14.85 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.346 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.73 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.22 -170.31 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.632 2.221 . . . . 0.0 110.493 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.95 102.32 10.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.255 -0.903 . . . . 0.0 109.388 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.84 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.3 -10.76 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -0.859 . . . . 0.0 109.382 -179.915 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.16 35.85 91.04 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 169.5 -173.48 43.79 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -82.96 172.88 12.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.239 -1.153 . . . . 0.0 109.432 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -136.51 146.71 18.69 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.496 ' O ' HD13 ' A' ' 35' ' ' LEU . 25.0 tt0 -132.03 118.24 19.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.288 -1.125 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.71 ' CG2' HD11 ' A' ' 63' ' ' LEU . 9.8 t -67.84 141.17 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.206 -0.934 . . . . 0.0 109.538 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.437 ' CG1' ' HB2' ' A' ' 36' ' ' GLU . 30.3 mm -112.22 -51.27 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.268 -0.895 . . . . 0.0 109.444 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -150.05 140.93 22.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.657 HD23 HG22 ' A' ' 20' ' ' VAL . 0.2 OUTLIER -101.83 149.09 24.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.502 179.946 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.472 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.6 OUTLIER -140.69 50.77 1.66 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.269 -0.894 . . . . 0.0 109.533 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.845 HG21 ' CD2' ' A' ' 32' ' ' LEU . 0.9 OUTLIER -150.05 163.27 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.248 -0.908 . . . . 0.0 109.455 -179.956 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.29 165.39 23.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.221 -0.924 . . . . 0.0 109.441 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.524 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 72.4 m -81.16 141.25 34.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 109.513 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.3 -10.83 69.74 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 1.0 OUTLIER -82.86 133.65 35.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.494 179.975 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.5 OUTLIER -85.97 117.58 24.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.4 mt -90.01 -171.57 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.719 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.6 pt-20 -147.78 166.38 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.207 -0.933 . . . . 0.0 109.479 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.779 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.8 p -77.72 79.05 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.449 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.7 OUTLIER 163.0 -35.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.517 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -70.0 140.55 52.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.2 -0.937 . . . . 0.0 109.437 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -68.45 165.05 47.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.845 ' CD2' HG21 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -128.01 -40.49 1.68 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.245 -1.15 . . . . 0.0 109.506 -179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.478 HG12 ' HG ' ' A' ' 18' ' ' LEU . 30.0 m -157.27 174.49 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.482 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.71 104.3 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.258 -0.901 . . . . 0.0 109.393 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.496 HD13 ' O ' ' A' ' 14' ' ' GLU . 4.5 mm? -89.96 152.55 21.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.256 -0.903 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.437 ' HB2' ' CG1' ' A' ' 16' ' ' ILE . 0.3 OUTLIER -131.74 116.19 16.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 -179.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.61 -172.62 3.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -50.47 -57.38 8.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.268 -0.895 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 10.3 mttt -140.4 49.66 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -154.88 104.67 2.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.339 -0.851 . . . . 0.0 109.478 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.97 119.28 31.56 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.87 . . . . 0.0 109.462 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 5.4 ptp -136.51 162.35 33.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.325 -0.859 . . . . 0.0 109.418 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -106.42 172.36 6.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 22.9 t -142.75 95.89 6.25 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.902 . . . . 0.0 109.409 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.517 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.9 Cg_endo -77.47 -168.73 0.63 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.481 2.12 . . . . 0.0 110.52 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.527 ' HB2' HG21 ' A' ' 26' ' ' ILE . 11.6 t -85.42 130.68 50.52 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.356 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.447 ' HG3' HG21 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.61 -3.04 12.99 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.401 2.067 . . . . 0.0 110.43 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.463 ' O ' ' OG ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -160.3 145.77 15.02 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 -179.997 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.93 93.22 8.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.475 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.864 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -143.52 -155.14 6.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 7.9 p -117.04 142.3 31.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.307 -1.114 . . . . 0.0 109.465 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.524 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 55.0 t -65.37 110.29 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.441 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.58 -35.38 27.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.494 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.8 t -169.86 158.13 7.16 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.552 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.41 HG12 ' H ' ' A' ' 57' ' ' VAL . 77.7 t -117.44 115.23 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.14 17.87 20.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.551 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.431 HG13 ' O ' ' A' ' 69' ' ' ILE . 29.2 m -123.1 162.23 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 109.483 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.3 tptt -134.26 172.58 12.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.442 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -81.86 124.33 29.61 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.156 -0.965 . . . . 0.0 109.513 179.959 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 98.33 -9.55 63.0 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -75.87 153.93 36.43 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -1.176 . . . . 0.0 109.482 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -99.3 121.11 40.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.71 HD11 ' CG2' ' A' ' 15' ' ' VAL . 11.1 mt -102.59 95.16 6.05 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.428 ' O ' ' C ' ' A' ' 65' ' ' GLU . 26.8 ttpt -85.43 138.64 32.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 109.386 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.473 ' HB3' HG13 ' A' ' 9' ' ' ILE . 11.5 pt-20 -43.06 150.63 0.16 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.67 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.26 -26.37 13.79 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -85.17 146.02 27.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 109.465 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.502 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -61.64 -175.15 0.05 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.274 -0.891 . . . . 0.0 109.404 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.903 HD11 HG23 ' A' ' 6' ' ' VAL . 39.8 mm -146.95 -70.37 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.538 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -143.96 -172.33 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.214 -0.929 . . . . 0.0 109.451 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.422 ' HG2' ' HA ' ' A' ' 3' ' ' ILE . 9.6 mt-10 -137.81 105.05 5.46 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.205 -0.935 . . . . 0.0 109.585 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.864 HD11 ' CA ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -90.63 135.14 33.9 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.179 -0.951 . . . . 0.0 109.484 179.893 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.409 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 27.7 tt0 -113.45 91.33 19.79 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.484 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.504 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -78.02 -18.29 13.06 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.635 2.223 . . . . 0.0 110.423 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.516 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . -59.34 -66.01 0.58 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.413 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 65.46 -168.85 0.21 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.447 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 98.94 18.45 24.8 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -114.07 -74.38 0.62 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.329 -1.101 . . . . 0.0 109.464 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.2 mtt85 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.423 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.411 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 31.3 p . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -122.87 155.92 35.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.406 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.562 ' O ' HD13 ' A' ' 4' ' ' ILE . 2.1 mp -117.12 146.89 20.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.482 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 37.9 mm -124.46 112.95 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -100.8 172.83 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.745 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.8 t -61.89 142.26 95.09 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.399 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.745 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.16 -171.24 1.15 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.505 2.137 . . . . 0.0 110.431 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -85.01 102.82 13.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.417 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.486 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.76 -40.19 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.282 -179.925 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.9 29.85 30.62 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -163.84 -128.52 0.96 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.488 ' OD2' ' CE ' ' A' ' 62' ' ' LYS . 18.3 p-10 -136.31 135.81 39.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.202 -1.176 . . . . 0.0 109.5 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.59 111.43 2.55 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.401 ' HG3' ' CG ' ' A' ' 62' ' ' LYS . 3.0 tt0 -101.25 133.85 45.19 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -1.158 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.8 t -72.18 140.01 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.534 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.704 HD12 HG12 ' A' ' 34' ' ' VAL . 20.1 mt -100.8 -39.34 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.372 -0.83 . . . . 0.0 109.461 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -164.64 -173.94 3.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.506 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.4 tp -136.7 102.05 4.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.442 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.2 pp -95.88 29.33 2.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.479 HG11 ' HG ' ' A' ' 32' ' ' LEU . 34.2 m -133.23 159.54 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -125.4 174.87 7.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -84.99 141.0 30.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.488 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.456 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 76.6 8.59 86.16 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.95 131.99 34.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.254 -1.145 . . . . 0.0 109.441 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.457 ' HA ' HD22 ' A' ' 25' ' ' LEU . 0.3 OUTLIER -86.01 111.7 20.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.302 -0.873 . . . . 0.0 109.466 179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.716 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.36 -171.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.288 -0.883 . . . . 0.0 109.25 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.716 ' H ' HG22 ' A' ' 26' ' ' ILE . 31.8 mt-10 -147.56 -174.51 4.56 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.925 . . . . 0.0 109.446 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.752 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.4 p -84.83 72.76 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.9 -40.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.459 179.955 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.525 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 22.6 tt0 -54.11 142.49 25.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.168 -0.957 . . . . 0.0 109.552 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.62 168.32 54.61 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.66 ' O ' HG13 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -129.31 -40.26 1.46 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.234 -1.157 . . . . 0.0 109.56 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 32' ' ' LEU . 13.0 m -161.01 176.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.112 -0.993 . . . . 0.0 109.534 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.704 HG12 HD12 ' A' ' 16' ' ' ILE . 98.9 t -131.9 97.9 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.422 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.07 146.25 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.439 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.95 177.84 6.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.0 m -136.33 160.91 37.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.87 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.11 -28.85 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.214 -0.929 . . . . 0.0 109.405 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.471 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 3.0 tttm -160.02 52.62 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.444 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 176.93 -166.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.174 -0.954 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.2 t -152.73 140.8 20.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.274 -0.891 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.46 150.53 42.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.272 -0.893 . . . . 0.0 109.509 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -98.14 169.71 9.41 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.519 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 55.5 t -146.47 98.39 4.25 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.235 -0.915 . . . . 0.0 109.422 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 35.7 Cg_endo -77.63 -169.05 0.67 Allowed 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.437 2.091 . . . . 0.0 110.412 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.4 134.17 40.92 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.454 179.958 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.489 ' HG2' HG13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.96 -5.37 14.53 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.425 2.083 . . . . 0.0 110.399 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.469 ' O ' ' CD1' ' A' ' 72' ' ' LEU . 0.7 OUTLIER -160.41 144.99 14.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.326 -0.859 . . . . 0.0 109.513 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -74.5 99.18 3.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -0.933 . . . . 0.0 109.421 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.862 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -153.79 175.65 32.02 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.456 HG22 ' HA2' ' A' ' 23' ' ' GLY . 11.3 p -95.78 145.16 8.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -1.131 . . . . 0.0 109.574 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -63.87 114.24 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.481 ' HD2' ' HB2' ' A' ' 73' ' ' GLU . 2.8 tttp -85.21 -56.74 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.5 m -143.86 127.44 17.02 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.498 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 11.9 t -96.23 128.78 47.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.448 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.9 m -119.59 34.0 5.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.425 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.676 HG13 ' O ' ' A' ' 69' ' ' ILE . 27.2 m -137.54 157.5 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.175 -0.953 . . . . 0.0 109.47 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -141.08 149.53 41.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.23 -0.918 . . . . 0.0 109.46 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.77 128.58 35.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 109.497 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 106.1 -23.2 29.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -80.78 148.89 29.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.184 -1.186 . . . . 0.0 109.489 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.488 ' CE ' ' OD2' ' A' ' 12' ' ' ASP . 3.1 tttt -103.14 112.99 26.11 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.916 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.744 HD22 ' HB3' ' A' ' 67' ' ' ASP . 12.6 mt -102.01 135.32 43.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.287 -0.883 . . . . 0.0 109.434 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -100.51 152.47 20.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.31 -0.869 . . . . 0.0 109.439 -179.956 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.9 pt-20 -42.88 150.49 0.16 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.519 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.55 -17.58 51.45 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.744 ' HB3' HD22 ' A' ' 63' ' ' LEU . 1.1 m-20 -84.0 131.21 34.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -1.131 . . . . 0.0 109.436 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -57.4 159.78 4.53 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.238 -0.914 . . . . 0.0 109.475 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.726 HD11 ' CG2' ' A' ' 6' ' ' VAL . 33.0 mm -117.6 -58.15 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.486 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 69' ' ' ILE . 2.4 pp -158.36 -177.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.239 -0.913 . . . . 0.0 109.43 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.424 ' HG2' HG13 ' A' ' 3' ' ' ILE . 57.5 mt-10 -133.58 127.46 33.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.971 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -99.5 142.47 30.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.484 -179.954 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.481 ' HB2' ' HD2' ' A' ' 53' ' ' LYS . 0.2 OUTLIER -118.85 90.06 39.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.186 -0.946 . . . . 0.0 109.47 179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.971 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -78.26 174.57 12.24 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.625 2.217 . . . . 0.0 110.413 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -69.92 -170.86 0.36 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 109.422 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -96.94 25.96 4.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.435 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -45.54 -38.45 7.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -89.39 -176.73 5.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.281 -1.129 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.474 ' HB3' ' CZ ' ' A' ' 79' ' ' ARG . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.484 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 96.5 p . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.244 0.545 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -93.31 140.7 29.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 109.52 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.448 HD13 ' HG3' ' A' ' 71' ' ' GLU . 18.0 mm -80.44 160.35 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 96.6 mt -122.97 96.6 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.333 -0.855 . . . . 0.0 109.415 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.655 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -92.01 -178.76 5.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.289 -0.882 . . . . 0.0 109.558 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.731 HG13 ' HD2' ' A' ' 7' ' ' PRO . 75.8 t -70.93 142.7 88.18 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.369 -0.832 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.03 -170.02 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.494 2.13 . . . . 0.0 110.377 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.85 104.12 14.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.252 -0.905 . . . . 0.0 109.477 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.585 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.19 -41.68 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.208 -0.932 . . . . 0.0 109.273 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.88 -21.04 12.69 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.77 -142.25 3.91 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 3.1 m-20 -102.84 165.94 10.76 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.289 -1.124 . . . . 0.0 109.415 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.33 165.44 21.25 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -146.44 121.39 10.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.199 -1.177 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.559 HG23 HD13 ' A' ' 63' ' ' LEU . 21.6 t -70.23 149.49 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' ' OE1' ' A' ' 17' ' ' GLU . 69.1 mt -127.15 -40.01 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.284 -0.885 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -156.51 126.44 6.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.489 -179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.427 HD13 HG11 ' A' ' 15' ' ' VAL . 0.7 OUTLIER -102.41 141.53 35.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.428 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.732 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -132.61 61.54 1.67 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.214 -0.929 . . . . 0.0 109.498 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.78 164.42 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 28.6 mmtt -122.98 157.2 33.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 22' ' ' THR . 13.3 t -84.74 128.9 34.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.26 -0.9 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.96 -9.17 73.33 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.472 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 1.6 m-20 -83.53 136.8 34.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -1.157 . . . . 0.0 109.551 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.448 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -86.18 126.5 34.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.491 -179.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.2 mt -90.33 -171.32 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.294 -0.879 . . . . 0.0 109.193 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 5.6 mt-10 -137.39 156.12 48.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.205 -0.934 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.735 ' O ' HG13 ' A' ' 28' ' ' VAL . 9.6 p -79.03 82.08 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.85 -35.89 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.395 -0.816 . . . . 0.0 109.433 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -71.59 152.13 43.2 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.44 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.47 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.32 -169.31 0.29 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.536 HD11 ' CD1' ' A' ' 26' ' ' ILE . 8.1 tp -153.31 -70.18 0.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.238 -1.154 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.7 m -134.02 173.56 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.486 HG22 ' HB3' ' A' ' 43' ' ' GLU . 97.1 t -133.73 102.33 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.29 170.07 8.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.311 -0.868 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.85 137.25 51.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.482 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.64 176.89 5.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.21 -0.931 . . . . 0.0 109.5 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -45.55 -45.82 13.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.403 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.655 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 1.4 mttm -152.3 67.55 0.84 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.492 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 167.66 99.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.208 -0.932 . . . . 0.0 109.479 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 2.5 t -80.02 126.53 31.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.452 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -147.2 159.46 43.61 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -0.875 . . . . 0.0 109.512 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.486 ' HB3' HG22 ' A' ' 34' ' ' VAL . 3.5 pt-20 -109.4 169.3 8.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.39 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.597 HG13 ' HD2' ' A' ' 45' ' ' PRO . 94.7 t -132.5 139.36 34.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.405 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.597 ' HD2' HG13 ' A' ' 44' ' ' VAL . 36.2 Cg_endo -78.97 -168.23 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.432 0 C-N-CA 122.549 2.166 . . . . 0.0 110.361 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.4 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.0 OUTLIER -85.16 113.55 50.93 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.385 -0.822 . . . . 0.0 109.365 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 36.0 Cg_endo -77.87 3.37 7.02 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.332 2.021 . . . . 0.0 110.346 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 1.024 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.2 OUTLIER -160.02 110.28 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -0.868 . . . . 0.0 109.465 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.2 90.62 1.6 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.939 . . . . 0.0 109.601 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.83 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -143.69 -157.73 7.29 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 73' ' ' GLU . 11.1 p -111.48 128.53 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -1.148 . . . . 0.0 109.509 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 48.8 t -58.27 134.83 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.474 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.87 -33.28 7.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.291 -0.881 . . . . 0.0 109.458 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 173.27 144.31 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.509 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 57' ' ' VAL . 52.2 t -99.68 135.11 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.6 m -105.63 16.19 25.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.346 -0.846 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 1.009 HG11 HD21 ' A' ' 63' ' ' LEU . 1.5 m -136.47 157.34 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.226 -0.921 . . . . 0.0 109.443 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -110.37 167.17 10.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.458 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.02 137.2 38.84 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.297 -0.877 . . . . 0.0 109.493 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.1 -11.07 68.41 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -79.21 148.4 32.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.5 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.712 ' C ' HD12 ' A' ' 63' ' ' LEU . 1.2 mttp -82.64 165.37 20.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.382 -0.824 . . . . 0.0 109.533 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 HG11 ' A' ' 57' ' ' VAL . 3.4 mp -148.77 113.42 5.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.433 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -86.03 137.78 32.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.241 -0.912 . . . . 0.0 109.455 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 64' ' ' LYS . 25.7 pt-20 -42.88 151.41 0.13 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 109.672 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.08 -18.2 41.99 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 39.5 m-20 -85.0 141.68 30.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.262 -1.14 . . . . 0.0 109.532 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -71.19 172.42 9.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.914 HG22 HG23 ' A' ' 70' ' ' ILE . 2.0 mp -134.76 -58.49 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.914 HG23 HG22 ' A' ' 69' ' ' ILE . 7.4 pt -147.23 -179.91 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.461 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.448 ' HG3' HD13 ' A' ' 3' ' ' ILE . 32.4 tt0 -131.18 117.33 18.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.024 HD22 ' HB3' ' A' ' 48' ' ' LYS . 0.7 OUTLIER -97.54 147.08 24.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -0.863 . . . . 0.0 109.486 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.522 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 2.5 tp10 -120.09 89.7 43.24 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.13 173.4 13.97 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.651 2.234 . . . . 0.0 110.375 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.702 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . -60.32 -84.97 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.164 -0.96 . . . . 0.0 109.447 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.702 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 75.39 -168.3 0.09 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.285 -0.884 . . . . 0.0 109.515 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.81 153.77 52.44 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.04 119.17 12.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -1.186 . . . . 0.0 109.467 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.467 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -86.69 111.01 20.26 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.253 -0.904 . . . . 0.0 109.285 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.679 HD12 ' OE2' ' A' ' 71' ' ' GLU . 2.2 tt -79.96 140.36 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.238 -0.914 . . . . 0.0 109.448 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.562 HD13 ' O ' ' A' ' 3' ' ' ILE . 40.2 mm -122.78 122.77 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.564 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -92.11 -176.13 4.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 0.0 109.554 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.986 ' CG2' HD11 ' A' ' 69' ' ' ILE . 53.4 t -74.75 139.99 74.31 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.28 -0.888 . . . . 0.0 109.347 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.648 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.39 -174.37 2.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.549 2.166 . . . . 0.0 110.438 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -85.19 108.88 17.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.413 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.415 ' CD1' ' HA3' ' A' ' 13' ' ' GLY . 0.0 OUTLIER -104.79 -7.27 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.281 -0.887 . . . . 0.0 109.396 -179.768 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.58 21.95 13.54 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 150.2 -133.53 4.4 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -85.54 170.85 12.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.243 -1.151 . . . . 0.0 109.464 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.415 ' HA3' ' CD1' ' A' ' 9' ' ' ILE . . . -141.05 148.25 19.9 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.454 ' HG3' ' HA ' ' A' ' 62' ' ' LYS . 1.0 OUTLIER -135.73 130.43 34.15 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.21 -1.17 . . . . 0.0 109.484 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.53 ' HA ' HD23 ' A' ' 35' ' ' LEU . 38.2 t -70.1 147.2 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.899 HD11 ' HB2' ' A' ' 36' ' ' GLU . 42.7 mt -118.95 -53.91 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.326 -0.859 . . . . 0.0 109.558 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -134.34 133.81 41.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.402 HD12 ' CG1' ' A' ' 33' ' ' VAL . 0.4 OUTLIER -115.24 102.47 9.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.496 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.487 HD23 ' H ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -93.66 41.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 m -143.74 156.08 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.271 -0.893 . . . . 0.0 109.533 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.405 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.07 -176.83 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.9 m -84.08 133.92 34.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.233 -0.917 . . . . 0.0 109.482 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.2 5.38 89.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.405 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 1.3 m-20 -84.94 135.49 34.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.203 -1.175 . . . . 0.0 109.532 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.57 115.7 27.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.269 -0.895 . . . . 0.0 109.471 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.712 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.6 mt -90.46 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.322 -0.861 . . . . 0.0 109.219 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.712 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.8 mt-10 -135.37 177.68 7.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.458 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.645 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.3 p -85.4 59.89 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.588 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.488 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 3.3 tt0 167.5 -32.34 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.249 -0.907 . . . . 0.0 109.228 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -52.35 145.41 11.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.414 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.449 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.03 171.03 39.88 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.54 ' CD1' HD13 ' A' ' 26' ' ' ILE . 0.6 OUTLIER -130.11 -56.04 1.11 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -1.156 . . . . 0.0 109.546 -179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 18' ' ' LEU . 36.0 m -151.56 -176.51 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.496 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.503 HG12 HD12 ' A' ' 16' ' ' ILE . 46.2 t -139.01 97.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.292 -0.88 . . . . 0.0 109.437 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 15' ' ' VAL . 3.1 mt -90.08 158.9 17.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.899 ' HB2' HD11 ' A' ' 16' ' ' ILE . 2.0 tt0 -123.27 153.04 40.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -0.9 . . . . 0.0 109.408 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.6 m -130.25 -176.58 4.0 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.464 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.98 -34.62 65.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.249 -0.907 . . . . 0.0 109.484 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 20.9 tttp -159.9 61.19 0.36 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.402 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 177.14 88.21 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 109.491 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.436 ' HB3' ' CG ' ' A' ' 36' ' ' GLU . 99.6 p -105.1 112.97 26.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.383 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.2 mtt -130.02 -175.5 3.64 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.479 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -114.23 162.19 16.87 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.25 -0.906 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 59.2 t -137.53 117.57 10.35 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.33 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.0 Cg_endo -77.96 -168.69 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.28 1.987 . . . . 0.0 110.434 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.497 ' HA ' HD13 ' A' ' 32' ' ' LEU . 6.0 t -85.27 138.08 36.7 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.402 -0.811 . . . . 0.0 109.328 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.82 -4.82 14.3 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.417 2.078 . . . . 0.0 110.478 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.573 ' O ' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.35 128.1 4.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -0.859 . . . . 0.0 109.521 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.86 98.51 1.58 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.903 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.491 ' H ' HD11 ' A' ' 72' ' ' LEU . . . -152.12 -135.98 2.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.0 p -132.27 151.36 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.189 -1.183 . . . . 0.0 109.439 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.5 t -73.49 119.95 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 109.466 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -91.97 -43.21 9.57 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.234 -0.916 . . . . 0.0 109.407 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.8 t -149.48 142.84 25.23 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.265 -0.897 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 57' ' ' VAL . 21.0 t -105.02 106.79 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.459 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.86 10.56 13.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.288 -0.883 . . . . 0.0 109.436 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.426 ' H ' HG12 ' A' ' 55' ' ' VAL . 17.2 m -124.98 177.73 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.305 -0.872 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.479 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -128.48 -156.02 0.73 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.209 -0.932 . . . . 0.0 109.53 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.87 80.67 9.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.43 ' HA2' ' HB ' ' A' ' 15' ' ' VAL . . . 74.89 46.22 18.03 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 4.9 m-20 -84.96 172.24 11.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.296 -1.12 . . . . 0.0 109.435 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.454 ' HA ' ' HG3' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -97.62 145.3 26.42 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.196 -0.94 . . . . 0.0 109.447 -179.92 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.92 -172.52 4.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.467 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -138.45 147.08 42.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.323 -0.86 . . . . 0.0 109.44 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.485 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 4.2 pt-20 -45.39 148.86 0.6 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.273 -0.892 . . . . 0.0 109.694 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 5' ' ' ARG . . . 85.86 -43.51 3.25 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.425 ' O ' ' O ' ' A' ' 68' ' ' ALA . 0.9 OUTLIER -50.76 134.46 24.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -1.128 . . . . 0.0 109.602 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -48.21 174.04 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -0.886 . . . . 0.0 109.535 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.986 HD11 ' CG2' ' A' ' 6' ' ' VAL . 26.9 mm -143.51 -58.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.238 -0.914 . . . . 0.0 109.498 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.656 ' C ' HD12 ' A' ' 70' ' ' ILE . 2.4 pp -150.98 179.56 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.2 -0.938 . . . . 0.0 109.482 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.679 ' OE2' HD12 ' A' ' 3' ' ' ILE . 22.3 mt-10 -145.56 97.25 2.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.222 -0.924 . . . . 0.0 109.511 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 48' ' ' LYS . 0.4 OUTLIER -90.76 124.86 35.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.238 -0.914 . . . . 0.0 109.433 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.527 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 37.1 tt0 -91.42 140.99 25.6 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.254 -0.903 . . . . 0.0 109.374 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.6 Cg_endo -78.38 -54.97 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.486 2.124 . . . . 0.0 110.373 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.433 ' HB2' ' O ' ' A' ' 74' ' ' PRO . . . 178.9 168.99 0.92 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.47 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -142.3 -57.29 0.45 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.4 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 64.88 161.75 0.61 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -98.41 172.25 7.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.485 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.415 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 5.4 ttt180 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.464 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.433 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 23.4 p . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -126.77 147.55 49.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 109.403 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.531 HG22 ' N ' ' A' ' 4' ' ' ILE . 3.5 mp -85.11 162.88 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.211 -0.931 . . . . 0.0 109.484 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.531 ' N ' HG22 ' A' ' 3' ' ' ILE . 3.0 mp -127.75 104.27 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -0.904 . . . . 0.0 109.453 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 4.3 ptp85 -93.03 -172.44 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.145 -0.972 . . . . 0.0 109.473 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' HA ' ' A' ' 65' ' ' GLU . 42.0 t -73.99 136.59 76.4 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.297 -0.877 . . . . 0.0 109.389 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.51 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.94 -176.61 3.38 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.481 2.121 . . . . 0.0 110.383 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -85.18 101.21 12.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.183 -0.948 . . . . 0.0 109.322 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -102.71 -45.95 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.249 -0.907 . . . . 0.0 109.259 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.78 16.07 11.25 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.7 -159.42 16.64 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 7.5 m-20 -104.31 119.82 39.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -1.167 . . . . 0.0 109.516 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.4 151.62 23.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.5 mp0 -131.58 119.82 22.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.246 -1.149 . . . . 0.0 109.442 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.8 t -65.37 134.67 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.495 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 16' ' ' ILE . 18.2 mm -115.19 -52.74 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.438 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -129.09 123.47 32.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.499 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.709 ' HG ' HG22 ' A' ' 20' ' ' VAL . 5.9 tp -99.84 115.37 29.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.893 . . . . 0.0 109.465 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -113.55 57.18 0.68 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.317 -0.864 . . . . 0.0 109.482 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.777 HG11 ' HG ' ' A' ' 32' ' ' LEU . 29.3 m -139.73 158.44 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.263 -0.898 . . . . 0.0 109.435 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.26 162.6 33.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -0.956 . . . . 0.0 109.46 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.423 ' HA ' ' CG1' ' A' ' 52' ' ' VAL . 0.2 OUTLIER -84.93 125.61 32.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.259 -0.901 . . . . 0.0 109.512 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.489 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 96.03 -8.95 67.88 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -78.63 132.05 36.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -1.138 . . . . 0.0 109.5 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.573 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -85.35 115.71 23.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.255 -0.903 . . . . 0.0 109.448 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.75 ' CD1' HD11 ' A' ' 32' ' ' LEU . 2.6 mt -91.99 -171.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.3 -0.875 . . . . 0.0 109.211 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.711 ' H ' HG22 ' A' ' 26' ' ' ILE . 20.0 pt-20 -146.3 172.33 13.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.415 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.733 ' O ' HG13 ' A' ' 28' ' ' VAL . 11.6 p -81.12 74.83 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.211 -0.93 . . . . 0.0 109.357 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.4 tm-20 167.87 -39.37 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.332 -0.855 . . . . 0.0 109.299 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.519 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -62.47 144.64 55.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.393 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.437 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.32 164.34 54.51 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.777 ' HG ' HG11 ' A' ' 20' ' ' VAL . 2.6 tp -124.61 -38.37 2.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -1.166 . . . . 0.0 109.398 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.502 HG13 ' C ' ' A' ' 32' ' ' LEU . 9.3 m -157.77 167.26 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.506 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.582 HG22 ' HG3' ' A' ' 43' ' ' GLU . 97.9 t -131.47 105.04 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.254 -0.904 . . . . 0.0 109.468 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.511 ' N ' HD12 ' A' ' 35' ' ' LEU . 9.8 mp -90.23 148.69 22.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.901 . . . . 0.0 109.413 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -138.56 116.78 11.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.238 -0.914 . . . . 0.0 109.547 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.0 m -100.1 -175.74 3.03 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.26 -0.9 . . . . 0.0 109.449 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.79 -42.22 16.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -154.62 57.45 0.69 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.452 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -167.87 97.12 0.45 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.926 . . . . 0.0 109.51 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 4.5 m -99.7 120.64 40.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.436 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 17.2 mtp -128.63 134.25 48.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.271 -0.893 . . . . 0.0 109.506 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.582 ' HG3' HG22 ' A' ' 34' ' ' VAL . 26.0 tt0 -91.56 162.73 14.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.2 -0.937 . . . . 0.0 109.387 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.0 t -144.45 99.17 4.91 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.33 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.528 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.7 Cg_endo -77.42 -168.6 0.61 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.526 2.151 . . . . 0.0 110.477 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 1.1 t -85.34 127.45 63.64 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.22 -0.925 . . . . 0.0 109.377 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.43 -2.51 12.56 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.345 2.03 . . . . 0.0 110.43 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' O ' ' OG ' ' A' ' 46' ' ' SER . 2.4 mtmt -160.19 143.11 13.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.389 -0.819 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.81 97.95 7.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 109.445 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.725 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -147.0 -172.51 17.34 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' O ' ' A' ' 73' ' ' GLU . 2.5 p -104.63 127.47 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.456 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.423 ' CG1' ' HA ' ' A' ' 22' ' ' THR . 50.5 t -50.57 133.91 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.411 ' HG2' ' OG ' ' A' ' 54' ' ' SER . 18.1 tttt -101.99 -58.8 1.81 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -0.922 . . . . 0.0 109.496 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.411 ' OG ' ' HG2' ' A' ' 53' ' ' LYS . 0.7 OUTLIER -150.56 153.87 36.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.881 . . . . 0.0 109.474 -179.969 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.648 ' HA ' HG22 ' A' ' 70' ' ' ILE . 9.1 t -103.16 131.68 51.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.266 -0.896 . . . . 0.0 109.493 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.0 m -113.62 19.83 16.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.244 -0.91 . . . . 0.0 109.462 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.671 HG11 HG23 ' A' ' 69' ' ' ILE . 17.8 m -132.71 -178.62 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.945 . . . . 0.0 109.396 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 1.6 ttpt -138.91 158.6 43.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.453 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 59' ' ' LEU . 3.4 pp -76.68 123.02 25.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.243 -0.911 . . . . 0.0 109.492 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.97 -8.35 73.28 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -78.01 144.16 36.91 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.268 -1.136 . . . . 0.0 109.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -91.13 122.91 34.18 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.24 -0.913 . . . . 0.0 109.507 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.81 HD13 ' CD1' ' A' ' 69' ' ' ILE . 19.2 mt -102.74 152.14 21.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.895 . . . . 0.0 109.442 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -122.54 152.45 40.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.436 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.53 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 77.2 mt-10 -47.7 148.11 1.64 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.245 -0.909 . . . . 0.0 109.725 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.03 -40.19 3.09 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -61.97 131.6 50.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -1.158 . . . . 0.0 109.549 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.573 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -62.1 -174.88 0.06 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.81 ' CD1' HD13 ' A' ' 63' ' ' LEU . 44.2 mm -146.45 -64.99 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.874 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.661 HD11 ' CD2' ' A' ' 32' ' ' LEU . 2.8 pt -148.56 -172.45 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.297 -0.877 . . . . 0.0 109.532 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.513 ' CG ' HG13 ' A' ' 3' ' ' ILE . 1.7 tt0 -142.99 117.48 9.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.589 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.896 HD23 ' HD3' ' A' ' 74' ' ' PRO . 0.5 OUTLIER -95.47 137.38 34.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.382 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.52 ' O ' HG12 ' A' ' 51' ' ' VAL . 3.4 tt0 -115.71 85.84 14.81 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.896 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.08 131.83 11.18 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.654 2.236 . . . . 0.0 110.371 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -138.31 110.49 7.34 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.217 -0.927 . . . . 0.0 109.516 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -141.81 95.5 2.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 109.478 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.557 ' O ' ' HB3' ' A' ' 78' ' ' ALA . . . 148.06 157.14 7.35 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 77' ' ' GLY . . . 67.28 19.83 10.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.316 -1.109 . . . . 0.0 109.486 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.444 -179.929 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.71 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.793 HD22 ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo -78.19 131.14 10.62 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -92.45 123.69 35.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.11 -63.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.54 76.87 0.07 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -99.88 134.51 42.68 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.226 -1.161 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.456 -179.994 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -116.07 136.1 53.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.458 HD12 ' CG ' ' A' ' 71' ' ' GLU . 12.5 mm -90.0 139.1 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.424 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.595 HG21 ' CG ' ' A' ' 47' ' ' PRO . 1.8 mt -106.46 136.08 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.249 -0.907 . . . . 0.0 109.5 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 0.6 OUTLIER -129.06 143.42 50.86 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.169 -0.957 . . . . 0.0 109.668 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.641 HG11 ' CG ' ' A' ' 65' ' ' GLU . 5.5 t -63.01 141.53 97.69 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.379 -0.825 . . . . 0.0 109.027 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.554 ' HD2' ' CG1' ' A' ' 6' ' ' VAL . 34.5 Cg_endo -77.03 178.17 7.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.42 2.08 . . . . 0.0 110.957 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -57.53 148.55 23.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.861 -179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.691 HD12 ' OE2' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -119.86 -40.68 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -179.665 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.16 11.8 30.97 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -177.06 -115.38 0.43 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.94 171.07 14.43 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.245 -1.15 . . . . 0.0 109.449 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 63' ' ' LEU . . . -147.31 148.86 20.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -127.17 139.22 53.11 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.389 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.71 140.4 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.6 mm -99.0 -71.16 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.517 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -151.11 169.33 22.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.922 . . . . 0.0 109.49 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.7 133.54 54.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.891 . . . . 0.0 109.442 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 12.63 19.48 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -0.908 . . . . 0.0 109.555 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -136.14 168.44 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.454 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.459 ' HB2' ' OD2' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -131.54 179.52 6.0 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.267 -0.896 . . . . 0.0 109.434 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.478 ' HA ' ' HB ' ' A' ' 52' ' ' VAL . 10.9 t -85.15 148.9 25.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.224 -0.922 . . . . 0.0 109.46 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.04 -8.18 64.29 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' OD2' ' HB2' ' A' ' 21' ' ' LYS . 11.6 m-20 -85.1 139.53 31.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -1.129 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -85.7 125.44 33.19 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.434 -179.994 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.967 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.08 -171.61 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.235 -0.916 . . . . 0.0 109.271 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.704 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -138.79 174.33 10.64 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 109.413 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.71 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.6 p -85.06 64.56 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.191 -0.943 . . . . 0.0 109.514 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 162.67 -42.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.389 -0.819 . . . . 0.0 109.454 179.869 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.508 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -44.22 149.75 0.34 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.263 -0.898 . . . . 0.0 109.5 -179.975 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -74.84 168.35 54.73 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.827 HD11 HD13 ' A' ' 26' ' ' ILE . 6.0 tp -128.06 -46.08 1.39 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -1.195 . . . . 0.0 109.493 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 32' ' ' LEU . 29.4 m -157.59 -175.16 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.494 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.2 t -135.34 105.17 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.224 -0.922 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.793 HD22 ' N ' ' A' ' 35' ' ' LEU . 2.8 mm? -90.22 168.91 11.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 41' ' ' SER . 33.8 tt0 -119.37 132.52 55.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ALA . 50.4 m -112.23 177.61 4.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -0.93 30.9 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.516 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -124.19 -28.86 3.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.245 -0.909 . . . . 0.0 109.57 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 37' ' ' SER . . . -178.23 164.37 1.76 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.119 -0.988 . . . . 0.0 109.542 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 36' ' ' GLU . 2.5 t -86.47 112.61 21.68 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.419 ' O ' ' HG3' ' A' ' 42' ' ' MET . 2.5 ppp? -93.31 135.37 34.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.309 -0.869 . . . . 0.0 109.364 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -84.78 158.94 20.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.556 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 61.7 t -136.74 104.66 9.05 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.215 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.512 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.2 Cg_endo -77.17 -168.88 0.64 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.399 2.066 . . . . 0.0 110.555 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.967 ' HB2' HG21 ' A' ' 26' ' ' ILE . 13.1 t -85.36 118.37 70.62 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.325 -0.859 . . . . 0.0 109.526 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.595 ' CG ' HG21 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -77.98 2.77 7.61 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.327 2.018 . . . . 0.0 110.343 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 16.5 mtmm -159.54 137.65 10.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.257 -0.902 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.43 109.23 15.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.912 . . . . 0.0 109.537 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 1.038 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -162.85 -173.91 32.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.547 ' HB ' HD21 ' A' ' 25' ' ' LEU . 9.8 p -103.97 129.45 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -1.149 . . . . 0.0 109.478 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.478 ' HB ' ' HA ' ' A' ' 22' ' ' THR . 41.2 t -54.6 136.89 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.303 -0.873 . . . . 0.0 109.494 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -103.7 -50.16 3.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.9 p -164.93 168.25 17.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.904 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.705 ' HA ' HG22 ' A' ' 70' ' ' ILE . 22.0 t -114.39 116.54 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.186 -0.946 . . . . 0.0 109.456 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 t -86.73 12.3 11.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.195 -0.941 . . . . 0.0 109.481 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.646 ' H ' HG12 ' A' ' 55' ' ' VAL . 35.4 m -139.22 -175.77 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.36 150.21 45.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.353 -0.842 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.43 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 1.4 pp -81.53 140.85 34.29 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.79 -9.9 64.12 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -85.03 163.42 18.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -1.154 . . . . 0.0 109.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.04 152.49 21.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.209 -0.932 . . . . 0.0 109.398 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 13' ' ' GLY . 7.6 mt -148.67 -171.77 3.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.19 -0.944 . . . . 0.0 109.358 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 66' ' ' GLY . 1.1 ttpm? -130.18 107.24 9.15 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.909 . . . . 0.0 109.386 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.691 ' OE2' HD12 ' A' ' 9' ' ' ILE . 0.3 OUTLIER -41.93 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.46 -0.775 . . . . 0.0 109.472 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 64' ' ' LYS . . . 157.71 -20.08 0.37 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 -179.55 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 27.0 m-20 -85.23 -174.83 5.44 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.375 -1.073 . . . . 0.0 109.498 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -82.71 178.08 8.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.928 . . . . 0.0 109.505 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.588 HD11 ' N ' ' A' ' 6' ' ' VAL . 2.6 mt -136.42 -63.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.899 . . . . 0.0 109.483 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.705 HG22 ' HA ' ' A' ' 55' ' ' VAL . 11.2 pt -148.94 -172.98 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.563 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.458 ' CG ' HD12 ' A' ' 3' ' ' ILE . 8.1 mt-10 -128.46 108.86 10.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.24 -0.913 . . . . 0.0 109.441 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.038 HD11 ' N ' ' A' ' 50' ' ' GLY . 1.9 tt -90.06 139.6 30.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.445 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -113.27 91.7 20.18 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.561 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.926 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.3 Cg_endo -78.19 131.14 10.62 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.554 2.169 . . . . 0.0 110.339 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -92.45 123.69 35.94 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.493 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.11 -63.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.457 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.54 76.87 0.07 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -99.88 134.51 42.68 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.226 -1.161 . . . . 0.0 109.483 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.991 -1.004 . . . . 0.0 109.456 -179.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.422 ' O ' ' HG2' ' A' ' 2' ' ' GLU . 48.4 p . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.295 0.569 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 1' ' ' SER . 14.0 mt-10 -145.28 145.35 31.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.267 -0.896 . . . . 0.0 109.479 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.2 mt -85.13 148.89 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.197 -0.939 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.517 HD13 HD11 ' A' ' 70' ' ' ILE . 2.3 mp -116.14 108.01 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 1.2 ptp85 -98.71 176.73 5.53 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.836 HG23 HD11 ' A' ' 69' ' ' ILE . 78.9 t -74.04 142.43 79.36 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.319 -0.863 . . . . 0.0 109.359 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.738 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.82 -171.53 1.22 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.463 2.109 . . . . 0.0 110.435 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -85.03 104.88 15.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.462 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.59 -31.13 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.226 -0.921 . . . . 0.0 109.215 -179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.68 -11.41 59.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.03 145.07 15.09 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -45.96 151.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.505 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -126.17 119.9 3.58 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -86.77 129.01 35.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.216 -1.167 . . . . 0.0 109.479 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.3 t -76.5 131.94 33.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 0.0 109.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.857 HD11 ' HB2' ' A' ' 36' ' ' GLU . 39.5 mt -95.04 -51.17 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.169 -0.957 . . . . 0.0 109.521 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -174.07 163.5 3.96 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.356 -0.84 . . . . 0.0 109.474 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.717 HD23 HG23 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -108.41 139.21 43.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 109.449 -179.99 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.7 15.11 11.68 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.717 HG23 HD23 ' A' ' 18' ' ' LEU . 1.9 m -149.87 164.22 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.282 -0.887 . . . . 0.0 109.527 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -114.9 -163.87 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.337 -0.852 . . . . 0.0 109.493 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.4 t -84.96 139.86 31.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.302 -0.874 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.01 8.37 61.2 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.449 ' C ' HG23 ' A' ' 51' ' ' VAL . 11.7 m-20 -84.95 133.02 34.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.207 -1.173 . . . . 0.0 109.522 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 1.1 tp -79.98 125.49 29.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.268 -0.895 . . . . 0.0 109.475 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.747 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.04 -171.41 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 O-C-N 121.251 -0.906 . . . . 0.0 109.204 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.722 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.4 mt-10 -135.16 175.39 9.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.432 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.77 ' O ' HG13 ' A' ' 28' ' ' VAL . 11.6 p -85.15 64.11 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.284 -0.885 . . . . 0.0 109.505 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.88 -43.68 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.496 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 4.9 tt0 -45.25 149.59 0.5 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.297 -0.877 . . . . 0.0 109.518 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.442 ' N ' ' HG2' ' A' ' 30' ' ' GLN . . . -74.39 166.89 54.79 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.823 HD12 ' HA ' ' A' ' 46' ' ' SER . 0.4 OUTLIER -126.94 -37.5 2.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -1.175 . . . . 0.0 109.561 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.624 HG22 ' HB ' ' A' ' 44' ' ' VAL . 23.5 m -152.85 154.32 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.946 . . . . 0.0 109.561 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.592 HG22 ' OE2' ' A' ' 43' ' ' GLU . 60.5 t -125.74 91.93 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.307 -0.871 . . . . 0.0 109.419 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mp -89.98 153.75 20.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.51 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.857 ' HB2' HD11 ' A' ' 16' ' ' ILE . 38.3 tt0 -143.36 134.46 25.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.274 -0.891 . . . . 0.0 109.467 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.61 174.24 7.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.291 -0.881 . . . . 0.0 109.547 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.0 -13.18 57.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.46 -56.27 3.99 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -0.935 . . . . 0.0 109.464 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -164.72 -149.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.927 . . . . 0.0 109.401 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 1.7 p -136.34 144.59 44.71 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.263 -0.898 . . . . 0.0 109.51 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -136.85 -175.97 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.592 ' OE2' HG22 ' A' ' 34' ' ' VAL . 6.4 tt0 -150.24 162.18 40.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.908 . . . . 0.0 109.52 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.624 ' HB ' HG22 ' A' ' 33' ' ' VAL . 38.2 t -147.5 101.37 3.76 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.262 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.525 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.6 Cg_endo -77.2 -168.94 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.399 2.066 . . . . 0.0 110.506 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.823 ' HA ' HD12 ' A' ' 32' ' ' LEU . 3.8 t -85.28 132.52 44.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.441 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.503 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.2 Cg_endo -78.87 -5.28 14.55 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 C-N-CA 122.489 2.126 . . . . 0.0 110.402 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' A' ' 46' ' ' SER . 5.6 tptt -160.23 144.71 14.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.35 -0.844 . . . . 0.0 109.491 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.95 91.05 4.17 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.791 ' C ' HD11 ' A' ' 72' ' ' LEU . . . -139.69 -135.19 3.22 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.554 ' N ' HD11 ' A' ' 72' ' ' LEU . 7.2 p -149.08 150.57 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -1.178 . . . . 0.0 109.535 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.0 t -73.01 129.45 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 3.5 tttp -113.63 -27.59 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.266 -0.896 . . . . 0.0 109.564 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -154.61 128.28 8.65 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.176 -0.953 . . . . 0.0 109.508 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.553 HG12 ' H ' ' A' ' 57' ' ' VAL . 75.8 t -113.08 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.465 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.37 34.79 4.95 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.553 ' H ' HG12 ' A' ' 55' ' ' VAL . 3.4 m -140.75 170.18 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.26 -0.9 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.443 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -132.59 157.77 43.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.926 . . . . 0.0 109.454 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -83.09 131.79 35.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.496 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.81 -11.48 68.72 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.443 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.7 OUTLIER -81.65 163.93 22.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -1.182 . . . . 0.0 109.435 -179.973 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 mttt -104.13 120.24 40.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 109.475 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.434 HD13 ' HA ' ' A' ' 63' ' ' LEU . 1.2 mm? -105.47 137.28 43.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.467 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -101.47 140.32 35.93 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.278 -0.888 . . . . 0.0 109.469 179.964 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.2 OUTLIER -42.76 151.6 0.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.29 -0.881 . . . . 0.0 109.675 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.09 -24.54 21.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.47 134.49 34.85 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.289 -1.124 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.49 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -59.23 179.23 0.11 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.513 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.836 HD11 HG23 ' A' ' 6' ' ' VAL . 31.8 mm -134.73 -67.63 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.178 -0.951 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.748 HG23 HG22 ' A' ' 69' ' ' ILE . 2.6 pp -147.82 -172.1 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.73 ' N ' HD12 ' A' ' 70' ' ' ILE . 14.5 mt-10 -144.62 136.48 25.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.514 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.791 HD11 ' C ' ' A' ' 50' ' ' GLY . 1.3 tp -113.01 112.32 23.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.447 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 53' ' ' LYS . 23.7 tt0 -113.78 90.38 18.48 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.602 ' O ' ' HB2' ' A' ' 75' ' ' ALA . 35.8 Cg_endo -78.1 -85.54 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.612 2.208 . . . . 0.0 110.484 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.602 ' HB2' ' O ' ' A' ' 74' ' ' PRO . . . 170.39 67.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.425 ' O ' ' O ' ' A' ' 77' ' ' GLY . . . -77.13 147.97 36.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . -47.44 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 77' ' ' GLY . . . 179.81 -161.51 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -1.171 . . . . 0.0 109.452 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.928 -1.034 . . . . 0.0 109.409 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 48.6 p . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -97.02 175.75 6.21 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.201 -0.937 . . . . 0.0 109.473 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.561 ' H ' HD12 ' A' ' 3' ' ' ILE . 3.7 mp -104.76 146.97 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 60.2 mt -104.25 99.26 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.273 -0.892 . . . . 0.0 109.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.44 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -91.26 165.62 13.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.344 -0.847 . . . . 0.0 109.458 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.732 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.8 t -55.0 142.22 57.05 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.28 -0.888 . . . . 0.0 109.336 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.732 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.14 -172.58 1.53 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.489 2.126 . . . . 0.0 110.387 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -84.03 104.33 14.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.256 -0.902 . . . . 0.0 109.503 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.465 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.79 -41.42 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.297 -0.877 . . . . 0.0 109.354 -179.929 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.69 10.73 52.5 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -146.04 -125.14 1.68 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.65 123.67 38.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.15 . . . . 0.0 109.393 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.68 147.43 50.94 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.07 101.79 3.32 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -1.119 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.734 HG11 ' O ' ' A' ' 58' ' ' LYS . 38.4 t -48.44 149.76 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.238 -0.914 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.8 HD12 HG12 ' A' ' 34' ' ' VAL . 43.9 mt -127.16 -62.22 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 109.454 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -150.11 149.74 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.777 ' CD1' HG12 ' A' ' 33' ' ' VAL . 2.8 tp -119.47 138.84 52.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 HG13 ' A' ' 20' ' ' VAL . 0.6 OUTLIER -127.98 54.35 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.516 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.621 HG13 HD12 ' A' ' 19' ' ' LEU . 15.3 m -144.42 159.8 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.17 -0.956 . . . . 0.0 109.399 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.494 ' CB ' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -111.37 -171.18 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 109.548 179.954 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 94.4 m -85.18 119.39 25.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.905 . . . . 0.0 109.78 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.479 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 72.37 2.17 53.64 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.639 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.494 ' CG ' ' CB ' ' A' ' 21' ' ' LYS . 2.1 m-20 -69.7 129.44 39.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.299 . . . . 0.0 109.123 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.908 HD21 ' HB1' ' A' ' 49' ' ' ALA . 1.0 OUTLIER -90.93 144.14 25.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.413 -0.805 . . . . 0.0 109.728 -179.697 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.987 HD12 ' CA ' ' A' ' 50' ' ' GLY . 1.3 mt -114.58 -170.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.776 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -100.46 172.45 7.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.079 -1.013 . . . . 0.0 109.405 179.963 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.743 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.8 p -83.89 68.64 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.497 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.2 OUTLIER 163.03 -29.73 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.516 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -60.13 151.59 26.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.517 179.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -67.06 163.61 44.84 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.705 HD22 ' CD1' ' A' ' 70' ' ' ILE . 0.2 OUTLIER -125.75 -38.81 2.18 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -1.129 . . . . 0.0 109.537 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.777 HG12 ' CD1' ' A' ' 18' ' ' LEU . 28.7 m -152.23 171.64 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.183 -0.948 . . . . 0.0 109.538 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.8 HG12 HD12 ' A' ' 16' ' ' ILE . 60.7 t -127.91 95.67 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.309 -0.87 . . . . 0.0 109.417 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 mt -89.88 162.14 15.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.922 . . . . 0.0 109.558 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.53 ' CA ' HD11 ' A' ' 16' ' ' ILE . 8.2 tt0 -114.99 164.13 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 109.5 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -135.43 -177.07 4.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.226 -0.921 . . . . 0.0 109.484 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -56.49 -44.06 80.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -0.886 . . . . 0.0 109.471 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -153.47 48.42 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.519 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -176.0 124.03 0.19 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.522 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -85.0 125.68 32.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.342 -0.849 . . . . 0.0 109.484 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.462 ' SD ' ' HG2' ' A' ' 7' ' ' PRO . 2.3 ptm -115.98 129.9 56.58 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -96.64 167.18 11.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.208 -0.933 . . . . 0.0 109.415 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.465 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 2.7 t -144.37 100.1 4.86 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.242 -0.911 . . . . 0.0 109.366 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.516 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.2 Cg_endo -77.68 -170.03 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.411 2.074 . . . . 0.0 110.359 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.458 ' HB2' HD12 ' A' ' 32' ' ' LEU . 6.3 t -85.96 142.66 36.61 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.432 -0.792 . . . . 0.0 109.364 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.617 ' HD2' HD13 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.37 -10.94 16.07 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.484 2.122 . . . . 0.0 110.174 179.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.37 -91.73 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.559 -0.713 . . . . 0.0 109.121 179.887 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.908 ' HB1' HD21 ' A' ' 25' ' ' LEU . . . -85.2 -92.54 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.29 -0.882 . . . . 0.0 109.229 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.987 ' CA ' HD12 ' A' ' 26' ' ' ILE . . . 139.98 41.04 0.08 OUTLIER Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 51' ' ' VAL . 7.1 p -95.56 115.15 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.1 -1.235 . . . . 0.0 109.346 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.465 ' O ' ' HA2' ' A' ' 23' ' ' GLY . 40.6 t -69.26 116.15 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.269 -0.894 . . . . 0.0 109.443 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.2 tttt -108.21 -25.25 11.16 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.174 -0.954 . . . . 0.0 109.513 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.85 123.33 1.73 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.223 -0.923 . . . . 0.0 109.514 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 70' ' ' ILE . 90.1 t -112.58 135.27 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.464 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -126.38 39.73 3.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.52 HG11 HG23 ' A' ' 69' ' ' ILE . 27.1 m -149.91 167.23 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.734 ' O ' HG11 ' A' ' 15' ' ' VAL . 4.2 tttt -125.39 167.99 14.18 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.43 87.42 7.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.185 -0.947 . . . . 0.0 109.481 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.6 -11.87 4.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -75.45 146.67 40.5 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -1.118 . . . . 0.0 109.566 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.407 ' C ' ' HG ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -105.14 146.62 28.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.209 -0.932 . . . . 0.0 109.484 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 62' ' ' LYS . 13.8 mt -141.47 178.42 7.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.477 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' GLU . 8.7 tttp -118.58 149.32 41.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.181 -0.949 . . . . 0.0 109.537 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' LYS . 1.3 pt-20 -42.71 150.33 0.16 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.337 -0.852 . . . . 0.0 109.627 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.68 -15.33 55.41 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -82.28 132.26 35.23 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -1.148 . . . . 0.0 109.544 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -63.85 161.59 15.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.432 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.52 HG23 HG11 ' A' ' 57' ' ' VAL . 43.9 mm -128.01 -59.71 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.887 . . . . 0.0 109.522 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.705 ' CD1' HD22 ' A' ' 32' ' ' LEU . 3.4 pt -141.44 -171.94 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.51 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 3' ' ' ILE . 1.7 mt-10 -145.8 109.2 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.602 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.668 ' C ' HD23 ' A' ' 72' ' ' LEU . 2.0 tt -90.02 145.42 25.11 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.3 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.47 ' HG2' ' HD2' ' A' ' 74' ' ' PRO . 1.4 mt-10 -106.09 146.27 32.59 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.694 ' O ' ' HB3' ' A' ' 75' ' ' ALA . 36.1 Cg_endo -78.34 -22.39 9.61 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.587 2.191 . . . . 0.0 110.431 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.694 ' HB3' ' O ' ' A' ' 74' ' ' PRO . . . 76.08 50.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.496 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -137.2 78.97 1.72 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -167.39 -92.11 0.08 OUTLIER Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -53.45 178.03 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.51 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 2.6 mtm105 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.429 -179.987 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.485 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 2.5 p . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 80.1 mt-10 -125.2 169.19 12.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.24 -0.913 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 mt -99.61 137.34 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.535 HG21 ' HG3' ' A' ' 47' ' ' PRO . 31.6 mm -113.82 119.05 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.239 -0.913 . . . . 0.0 109.485 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.701 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -106.23 -177.96 3.51 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.476 -179.927 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.6 t -81.0 142.27 51.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.355 -0.841 . . . . 0.0 109.342 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.07 -170.74 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.607 2.205 . . . . 0.0 110.433 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -84.51 104.69 14.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.224 -0.923 . . . . 0.0 109.437 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.97 -21.65 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.281 -0.887 . . . . 0.0 109.295 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 75.78 21.63 76.29 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.0 -165.92 25.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -97.2 140.34 31.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -1.168 . . . . 0.0 109.459 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -111.14 105.17 1.83 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.8 mm-40 -97.22 130.22 44.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -1.138 . . . . 0.0 109.447 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.542 ' HA ' HD23 ' A' ' 35' ' ' LEU . 60.3 t -72.91 119.42 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.216 -0.928 . . . . 0.0 109.445 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.981 HG22 ' O ' ' A' ' 34' ' ' VAL . 1.6 tt -112.55 -24.33 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -145.99 140.44 26.87 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.51 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.55 127.37 34.96 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.54 HD23 ' N ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -120.7 47.32 1.82 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.897 . . . . 0.0 109.414 -179.962 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.465 HG11 ' CD1' ' A' ' 32' ' ' LEU . 3.2 m -150.07 158.19 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.468 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 18.6 mmtt -138.05 -174.0 3.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.9 m -84.4 141.18 31.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.481 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.7 1.83 62.86 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -84.89 130.27 34.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -1.196 . . . . 0.0 109.485 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 51' ' ' VAL . 0.0 OUTLIER -86.12 119.3 26.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.291 -0.88 . . . . 0.0 109.387 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.053 HD13 HD21 ' A' ' 32' ' ' LEU . 2.4 mt -90.01 -171.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.209 -0.932 . . . . 0.0 109.201 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.717 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.3 OUTLIER -150.17 163.34 38.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.264 -0.897 . . . . 0.0 109.433 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.565 ' O ' ' CB ' ' A' ' 29' ' ' GLU . 7.5 p -72.49 147.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.161 -0.962 . . . . 0.0 109.411 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER 83.07 -43.61 0.11 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.688 -0.632 . . . . 0.0 109.863 -179.915 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.524 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 0.0 OUTLIER -55.41 144.27 26.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.078 -1.014 . . . . 0.0 109.43 -179.994 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -69.32 172.38 38.27 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 1.053 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -133.04 -51.84 0.9 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.251 -1.147 . . . . 0.0 109.542 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.9 m -153.6 175.75 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.141 -0.974 . . . . 0.0 109.617 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.981 ' O ' HG22 ' A' ' 16' ' ' ILE . 84.4 t -130.8 94.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.307 -0.87 . . . . 0.0 109.425 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.542 HD23 ' HA ' ' A' ' 15' ' ' VAL . 13.2 mt -90.14 151.86 21.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -106.05 112.02 24.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.291 -0.881 . . . . 0.0 109.432 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -88.64 -172.12 3.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.249 -0.907 . . . . 0.0 109.525 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -81.32 6.64 13.67 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.51 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 0.0 OUTLIER -112.47 -36.89 5.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.178 -0.951 . . . . 0.0 109.518 179.93 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.524 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.44 -152.37 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.243 -0.911 . . . . 0.0 109.429 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 8.3 t -106.05 112.55 25.64 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.251 -0.906 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -106.95 151.81 24.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -110.31 150.43 28.77 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.176 -0.952 . . . . 0.0 109.452 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 21.8 t -132.73 118.24 15.51 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.897 . . . . 0.0 109.261 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 30' ' ' GLN . 36.1 Cg_endo -77.7 -168.65 0.63 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.33 2.02 . . . . 0.0 110.451 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.518 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -85.35 126.32 67.34 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.345 -0.847 . . . . 0.0 109.339 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.535 ' HG3' HG21 ' A' ' 4' ' ' ILE . 35.9 Cg_endo -78.44 -0.9 11.12 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.377 2.052 . . . . 0.0 110.374 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.499 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.18 127.31 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -77.76 99.54 5.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.931 . . . . 0.0 109.46 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.902 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.93 -137.79 2.42 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 25' ' ' LEU . 9.5 p -137.19 146.94 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.202 -1.176 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 52.2 t -69.73 133.39 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.303 -0.873 . . . . 0.0 109.518 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.404 ' CD ' ' HB2' ' A' ' 73' ' ' GLU . 0.3 OUTLIER -110.79 -58.23 2.12 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.313 -0.867 . . . . 0.0 109.482 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 14.1 m -124.52 164.95 18.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.498 ' HA ' HG22 ' A' ' 70' ' ' ILE . 53.7 t -124.74 118.98 54.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.268 -0.895 . . . . 0.0 109.452 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.21 15.25 27.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.448 HG11 HD11 ' A' ' 63' ' ' LEU . 21.0 m -149.85 173.44 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.241 -0.912 . . . . 0.0 109.457 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.42 ' HB3' ' OD2' ' A' ' 61' ' ' ASP . 6.0 tptt -134.47 173.67 11.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.253 -0.905 . . . . 0.0 109.46 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -84.73 124.29 31.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 101.65 -10.71 57.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.42 ' OD2' ' HB3' ' A' ' 58' ' ' LYS . 3.0 m-20 -81.74 165.35 21.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -1.093 . . . . 0.0 109.571 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 165.12 13.06 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.499 ' HA ' HD23 ' A' ' 63' ' ' LEU . 5.3 mt -149.35 104.97 3.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.429 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.8 OUTLIER -86.99 137.89 31.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.301 -0.874 . . . . 0.0 109.449 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 64' ' ' LYS . 10.3 pt-20 -42.77 151.57 0.12 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 89.19 -19.75 37.31 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -84.87 144.9 28.1 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.246 -1.15 . . . . 0.0 109.483 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -72.56 -178.8 2.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.249 -0.907 . . . . 0.0 109.553 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.701 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.0 mp -139.82 -68.08 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.412 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.498 HG22 ' HA ' ' A' ' 55' ' ' VAL . 1.0 OUTLIER -148.9 -177.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.448 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -132.89 117.83 18.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.987 HD23 ' HD3' ' A' ' 74' ' ' PRO . 2.8 tt -93.78 143.33 26.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.204 -0.935 . . . . 0.0 109.526 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.404 ' HB2' ' CD ' ' A' ' 53' ' ' LYS . 0.1 OUTLIER -113.53 91.03 19.15 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.363 -0.836 . . . . 0.0 109.381 179.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.987 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.6 Cg_endo -78.02 177.9 8.23 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.668 2.246 . . . . 0.0 110.441 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -170.76 153.08 3.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.27 -0.894 . . . . 0.0 109.385 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -93.25 155.07 17.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.392 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.34 -48.15 5.18 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 47.13 55.72 7.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -1.168 . . . . 0.0 109.495 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.482 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 76.8 p . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.284 0.564 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.6 mt-10 -139.37 160.61 39.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.48 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.519 ' H ' HD12 ' A' ' 3' ' ' ILE . 2.5 mp -85.17 136.07 23.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.905 . . . . 0.0 109.528 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.751 HD13 ' HG2' ' A' ' 47' ' ' PRO . 10.3 mt -105.49 120.21 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.92 168.55 10.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.189 -0.944 . . . . 0.0 109.486 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.749 HG13 ' HD2' ' A' ' 7' ' ' PRO . 78.3 t -49.68 142.48 12.17 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.268 -0.895 . . . . 0.0 109.322 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.749 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -77.69 -174.72 2.34 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.462 2.108 . . . . 0.0 110.393 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -79.91 100.86 8.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.234 -0.916 . . . . 0.0 109.46 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.712 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.41 -14.91 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.272 -0.892 . . . . 0.0 109.291 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.38 -21.26 32.87 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -128.82 -145.5 5.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.95 142.3 30.63 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -1.163 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.15 103.29 2.13 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.458 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.1 mt-10 -101.7 119.75 39.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.296 -1.12 . . . . 0.0 109.559 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.97 ' HA ' HD23 ' A' ' 35' ' ' LEU . 39.7 t -78.83 131.93 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.464 179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.442 ' O ' ' HG3' ' A' ' 17' ' ' GLU . 8.8 mm -108.93 -40.48 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.9 . . . . 0.0 109.498 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.442 ' HG3' ' O ' ' A' ' 16' ' ' ILE . 64.9 mt-10 -157.17 -177.77 6.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.426 -179.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.501 HD12 HG12 ' A' ' 33' ' ' VAL . 11.3 tp -137.03 145.96 44.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.471 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.467 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -136.8 36.35 2.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.554 -179.95 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 32' ' ' LEU . 3.7 m -149.94 156.61 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.29 -0.881 . . . . 0.0 109.558 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.24 175.71 5.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.181 -0.949 . . . . 0.0 109.469 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 5.6 m -84.95 146.39 27.26 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.546 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.525 ' HA2' HG22 ' A' ' 51' ' ' VAL . . . 78.48 3.32 86.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.02 133.14 34.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -1.165 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.602 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -83.65 108.12 16.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.197 -0.939 . . . . 0.0 109.432 -179.991 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.728 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.53 -171.4 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.728 ' H ' HG22 ' A' ' 26' ' ' ILE . 15.1 mt-10 -147.03 -178.95 6.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.165 -0.959 . . . . 0.0 109.421 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.725 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.4 p -82.7 73.67 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 162.87 -42.36 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.334 -0.853 . . . . 0.0 109.435 179.836 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.43 ' HB3' HG22 ' A' ' 26' ' ' ILE . 18.6 tt0 -50.81 135.69 23.49 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.174 -0.954 . . . . 0.0 109.455 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.467 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -52.88 179.99 0.08 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.592 HD21 HD13 ' A' ' 26' ' ' ILE . 0.2 OUTLIER -146.24 -67.99 0.28 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.21 -1.171 . . . . 0.0 109.535 -180.0 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.501 HG12 HD12 ' A' ' 18' ' ' LEU . 30.9 m -133.01 169.63 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.523 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.9 HG22 ' HG2' ' A' ' 43' ' ' GLU . 24.4 t -119.09 79.2 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.261 -0.899 . . . . 0.0 109.452 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.97 HD23 ' HA ' ' A' ' 15' ' ' VAL . 5.9 mt -90.05 151.73 21.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.53 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.424 ' HG3' ' OG ' ' A' ' 41' ' ' SER . 2.3 tm-20 -140.79 141.84 34.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.33 -0.857 . . . . 0.0 109.495 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.03 -177.95 3.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.267 -0.896 . . . . 0.0 109.523 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.95 -12.46 37.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.278 -0.889 . . . . 0.0 109.472 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.51 -67.96 0.77 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.264 -0.897 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -156.19 175.41 14.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -0.937 . . . . 0.0 109.461 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.424 ' OG ' ' HG3' ' A' ' 36' ' ' GLU . 0.9 OUTLIER -95.01 137.21 34.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 109.473 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -147.22 124.83 11.76 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.235 -0.916 . . . . 0.0 109.5 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.9 ' HG2' HG22 ' A' ' 34' ' ' VAL . 7.1 mt-10 -84.52 166.86 16.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.488 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.496 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 54.1 t -137.03 134.59 19.09 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.24 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.1 Cg_endo -78.23 -168.4 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.412 2.075 . . . . 0.0 110.316 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.1 130.88 50.4 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.302 -0.874 . . . . 0.0 109.353 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.751 ' HG2' HD13 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.53 -1.48 11.64 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.416 2.078 . . . . 0.0 110.394 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.755 ' HD2' HD22 ' A' ' 72' ' ' LEU . 33.6 ttmt -160.28 140.69 11.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.28 -0.888 . . . . 0.0 109.561 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.09 101.21 12.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.925 . . . . 0.0 109.493 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.909 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -158.58 -162.35 11.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.525 HG22 ' HA2' ' A' ' 23' ' ' GLY . 9.9 p -111.03 129.17 66.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.295 -1.12 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -54.02 138.63 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.49 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.12 -35.67 4.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 t -174.78 149.48 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.175 -0.953 . . . . 0.0 109.44 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.772 HG13 HG22 ' A' ' 70' ' ' ILE . 11.1 t -108.53 148.45 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.452 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 59.4 m -113.35 18.22 17.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.641 ' H ' HG12 ' A' ' 55' ' ' VAL . 30.2 m -147.12 158.47 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.503 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.448 ' HB3' ' OD1' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -120.17 -175.21 2.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 -179.946 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.484 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -77.04 147.75 36.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.265 -0.897 . . . . 0.0 109.416 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.33 11.62 53.05 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.448 ' OD1' ' HB3' ' A' ' 58' ' ' LYS . 0.9 OUTLIER -84.74 132.25 34.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.186 -1.185 . . . . 0.0 109.492 179.997 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.56 118.37 36.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.561 HD23 ' HB3' ' A' ' 67' ' ' ASP . 3.1 mp -122.6 162.55 21.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 65' ' ' GLU . 2.1 tttp -102.75 146.79 27.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.431 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.5 OUTLIER -42.9 148.04 0.27 Allowed 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.312 -0.868 . . . . 0.0 109.661 -179.877 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.7 -8.07 74.0 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.561 ' HB3' HD23 ' A' ' 63' ' ' LEU . 1.2 m-20 -83.96 140.18 32.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -1.103 . . . . 0.0 109.487 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.408 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.36 164.16 0.21 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.422 179.999 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.596 HG22 HG23 ' A' ' 70' ' ' ILE . 17.7 mm -141.13 -54.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.182 -0.948 . . . . 0.0 109.449 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG13 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -150.65 -178.23 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.21 -0.931 . . . . 0.0 109.585 -179.984 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -139.43 135.61 33.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.93 HD23 ' HD3' ' A' ' 74' ' ' PRO . 1.5 tt -116.44 146.76 42.3 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.257 -0.902 . . . . 0.0 109.46 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 23.6 tt0 -118.35 88.62 33.73 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.486 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.93 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -77.95 106.76 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.568 2.178 . . . . 0.0 110.466 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -99.64 178.62 4.79 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.253 -0.904 . . . . 0.0 109.461 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -160.67 143.03 12.76 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.277 -0.889 . . . . 0.0 109.503 179.949 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -142.57 140.75 10.12 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -69.9 103.76 2.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.184 -1.186 . . . . 0.0 109.443 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.452 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.4 p . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.511 ' C ' HD12 ' A' ' 3' ' ' ILE . 20.9 mp0 -89.43 161.81 16.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.34 -0.85 . . . . 0.0 109.459 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.741 HD12 ' N ' ' A' ' 3' ' ' ILE . 3.2 mp -110.74 139.26 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.254 -0.903 . . . . 0.0 109.466 -179.978 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -111.19 138.27 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.228 -0.92 . . . . 0.0 109.451 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.448 ' HB2' ' O ' ' A' ' 67' ' ' ASP . 3.0 ptt180 -121.55 166.66 13.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.734 HG13 ' HD2' ' A' ' 7' ' ' PRO . 76.3 t -48.5 142.2 8.68 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.244 -0.91 . . . . 0.0 109.36 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.734 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.4 Cg_endo -78.09 -171.45 1.21 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.483 2.122 . . . . 0.0 110.423 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.09 101.54 12.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.492 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -103.11 -26.36 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.24 -0.912 . . . . 0.0 109.255 -179.922 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 34.9 5.47 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 153.04 -133.58 4.09 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -118.08 168.2 10.77 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -1.112 . . . . 0.0 109.463 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.1 128.61 2.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.461 ' OE2' ' O ' ' A' ' 15' ' ' VAL . 3.3 tm-20 -89.2 134.65 33.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.256 -1.144 . . . . 0.0 109.427 179.956 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.461 ' O ' ' OE2' ' A' ' 14' ' ' GLU . 19.2 t -74.72 156.57 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.505 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 34' ' ' VAL . 32.2 mm -115.56 -58.49 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 0.0 109.492 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.71 161.91 41.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.0 111.54 20.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -0.88 . . . . 0.0 109.472 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -95.16 32.91 1.62 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.03 161.98 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.467 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.426 ' CB ' ' OD2' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -133.24 -177.07 4.36 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.205 -0.934 . . . . 0.0 109.469 179.999 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.0 m -81.34 143.18 32.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.234 -0.916 . . . . 0.0 109.504 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.58 90.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.426 ' OD2' ' CB ' ' A' ' 21' ' ' LYS . 22.7 m-20 -85.07 139.45 31.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -1.198 . . . . 0.0 109.435 -179.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.542 HD23 ' O ' ' A' ' 25' ' ' LEU . 6.8 tt -103.43 108.97 20.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 27' ' ' GLU . 0.9 OUTLIER -90.15 -171.39 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.212 -0.93 . . . . 0.0 109.234 179.985 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.725 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.4 pt-20 -138.22 -178.28 5.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.119 -0.988 . . . . 0.0 109.491 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.724 ' O ' HG13 ' A' ' 28' ' ' VAL . 9.9 p -82.27 74.57 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.48 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER 162.91 -55.97 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.901 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 29' ' ' GLU . 1.4 tt0 -44.41 141.01 2.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.307 -0.87 . . . . 0.0 109.494 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.455 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -70.77 178.67 32.1 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.521 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -141.35 -42.18 0.37 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.212 -1.169 . . . . 0.0 109.453 179.926 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.6 HG22 ' HB ' ' A' ' 44' ' ' VAL . 20.3 m -152.04 155.29 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 -179.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 16' ' ' ILE . 58.7 t -114.84 107.75 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.232 -0.918 . . . . 0.0 109.451 -179.903 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 15' ' ' VAL . 1.8 mp -98.11 -178.38 4.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -147.54 140.08 24.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.2 -0.938 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.4 p -107.07 -177.67 3.42 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -46.58 -65.45 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.238 -0.913 . . . . 0.0 109.425 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.4 mppt? -129.54 55.91 1.74 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.496 -179.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -170.85 -161.56 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.278 -0.889 . . . . 0.0 109.512 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.09 149.73 30.71 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.296 -0.877 . . . . 0.0 109.448 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' HG22 ' A' ' 9' ' ' ILE . 69.5 mmm -146.06 104.42 3.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -0.947 . . . . 0.0 109.383 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.95 171.98 13.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -0.921 . . . . 0.0 109.538 179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.6 ' HB ' HG22 ' A' ' 33' ' ' VAL . 48.9 t -146.15 98.48 4.35 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.263 -0.898 . . . . 0.0 109.389 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.5 Cg_endo -77.5 -168.09 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.492 2.128 . . . . 0.0 110.527 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.489 ' CB ' ' HB ' ' A' ' 26' ' ' ILE . 6.5 t -85.09 113.65 51.37 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.45 -179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.4 Cg_endo -78.06 3.01 7.41 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.364 2.043 . . . . 0.0 110.329 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.588 ' O ' HD13 ' A' ' 72' ' ' LEU . 6.0 mttt -160.01 114.94 2.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.312 -0.868 . . . . 0.0 109.427 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.1 91.95 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.944 . . . . 0.0 109.533 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 1.01 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -155.39 -171.86 22.41 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 10.9 p -100.77 155.49 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.185 -1.185 . . . . 0.0 109.517 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.2 t -81.37 138.62 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -0.923 . . . . 0.0 109.536 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -104.34 -66.9 0.93 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -137.92 148.7 45.55 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.474 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.56 HG12 ' H ' ' A' ' 57' ' ' VAL . 12.0 t -101.65 133.65 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -112.87 13.98 19.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.142 -0.974 . . . . 0.0 109.567 179.962 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.6 HG11 HD13 ' A' ' 69' ' ' ILE . 2.0 m -137.46 158.77 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.219 -0.926 . . . . 0.0 109.478 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.15 158.68 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.238 -0.914 . . . . 0.0 109.489 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.8 pp -82.68 137.64 34.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.931 . . . . 0.0 109.53 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.95 -14.52 65.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -83.68 168.07 16.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.14 . . . . 0.0 109.44 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.795 ' O ' HD23 ' A' ' 63' ' ' LEU . 8.5 mtmt -97.38 140.77 31.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -0.855 . . . . 0.0 109.442 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.795 HD23 ' O ' ' A' ' 62' ' ' LYS . 6.5 mt -123.97 116.05 22.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.497 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.434 ' O ' ' C ' ' A' ' 65' ' ' GLU . 4.3 tttt -90.48 139.69 30.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.303 -0.873 . . . . 0.0 109.472 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.445 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 15.6 pt-20 -42.76 149.19 0.2 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.313 -0.867 . . . . 0.0 109.645 -179.896 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.71 -14.88 58.88 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 5' ' ' ARG . 91.6 m-20 -85.01 140.06 31.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.285 -1.126 . . . . 0.0 109.471 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -62.37 -179.43 0.24 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.213 -0.929 . . . . 0.0 109.506 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.684 HG22 HG23 ' A' ' 70' ' ' ILE . 28.6 mm -147.95 -72.19 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.447 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.684 HG23 HG22 ' A' ' 69' ' ' ILE . 3.8 pt -142.37 -172.52 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.932 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -140.29 112.2 7.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.011 HD23 ' HD3' ' A' ' 74' ' ' PRO . 3.6 tt -90.06 141.96 28.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.33 -0.856 . . . . 0.0 109.392 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -113.24 91.69 20.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.21 -0.932 . . . . 0.0 109.535 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 1.011 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.1 Cg_endo -78.13 115.24 3.71 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.602 2.201 . . . . 0.0 110.35 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -77.6 -81.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.31 -0.869 . . . . 0.0 109.46 179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 118.63 14.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.468 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -153.78 -135.49 2.13 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -105.57 72.56 0.97 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.245 -1.15 . . . . 0.0 109.544 179.944 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.451 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 68.8 p . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -147.42 150.48 34.74 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.505 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.635 HD12 ' HB2' ' A' ' 71' ' ' GLU . 1.4 tp -93.03 130.73 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.6 mm -93.81 124.22 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.388 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 3.5 ptt-85 -118.52 159.16 24.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.21 -0.931 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 9' ' ' ILE . 84.3 t -43.33 103.51 0.32 Allowed Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.344 -0.847 . . . . 0.0 109.442 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.472 ' O ' HG12 ' A' ' 9' ' ' ILE . 35.9 Cg_endo -77.78 -169.54 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.511 2.14 . . . . 0.0 110.45 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -68.26 99.7 0.95 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.283 -0.886 . . . . 0.0 109.413 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.883 HD11 HG13 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -106.0 -43.0 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.305 -179.877 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.55 34.61 0.65 Allowed Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 147.21 -132.74 4.45 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -101.5 135.27 43.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.65 115.78 4.31 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.476 ' HG2' ' CB ' ' A' ' 62' ' ' LYS . 12.9 mt-10 -112.36 104.32 12.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -1.152 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.649 ' O ' HD13 ' A' ' 16' ' ' ILE . 42.7 t -54.17 136.23 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.515 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.649 HD13 ' O ' ' A' ' 15' ' ' VAL . 29.2 mm -128.04 -37.42 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.83 155.27 43.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.59 123.59 46.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 32' ' ' LEU . 6.3 mt -93.77 9.36 37.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.535 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.7 m -146.42 175.42 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 179.949 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.423 ' O ' HG21 ' A' ' 52' ' ' VAL . 5.2 ttpp -139.31 -164.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.272 -0.892 . . . . 0.0 109.49 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 26.4 m -84.83 139.41 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.918 . . . . 0.0 109.509 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.87 10.56 51.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -85.04 134.72 34.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.195 -1.179 . . . . 0.0 109.454 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.629 HD13 ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -88.24 118.25 27.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.247 -0.908 . . . . 0.0 109.454 179.96 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.804 HD13 HD21 ' A' ' 32' ' ' LEU . 3.7 mt -97.04 -171.41 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.239 -0.913 . . . . 0.0 109.234 -179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.707 ' H ' HG22 ' A' ' 26' ' ' ILE . 3.3 tt0 -147.81 153.99 39.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 28' ' ' VAL . 6.3 p -72.03 84.35 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.248 -0.907 . . . . 0.0 109.506 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.79 -32.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.336 -0.853 . . . . 0.0 109.473 179.877 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -78.66 153.27 31.14 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.233 -0.917 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.38 -160.07 0.05 OUTLIER Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.804 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -160.01 -72.74 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -1.166 . . . . 0.0 109.459 179.983 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.54 HG21 HD11 ' A' ' 35' ' ' LEU . 8.5 m -119.45 150.92 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.239 -0.913 . . . . 0.0 109.519 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.792 HG22 ' OE1' ' A' ' 43' ' ' GLU . 23.9 t -117.91 83.22 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.54 HD11 HG21 ' A' ' 33' ' ' VAL . 0.4 OUTLIER -91.13 147.52 23.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.44 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.39 152.84 21.13 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.169 -0.957 . . . . 0.0 109.411 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -98.72 -175.62 3.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.28 -0.888 . . . . 0.0 109.481 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.65 -39.61 94.78 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 0.0 109.476 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.6 mttm -142.4 48.33 1.56 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.413 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -177.13 -158.76 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.51 152.94 37.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.881 . . . . 0.0 109.388 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtp -159.26 142.47 14.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.792 ' OE1' HG22 ' A' ' 34' ' ' VAL . 24.0 mt-10 -132.65 162.8 30.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.418 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.523 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.7 t -131.02 140.08 37.57 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.309 -0.869 . . . . 0.0 109.345 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.515 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 36.5 Cg_endo -79.21 -168.59 0.65 Allowed 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.581 2.188 . . . . 0.0 110.421 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.483 ' HB2' HG21 ' A' ' 26' ' ' ILE . 28.9 t -85.27 113.64 51.6 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.398 -0.814 . . . . 0.0 109.409 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.5 Cg_endo -78.03 0.49 9.81 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.348 2.032 . . . . 0.0 110.425 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.76 ' HB3' HD22 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.09 104.75 1.51 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.338 -0.851 . . . . 0.0 109.491 179.951 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -65.35 101.87 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 109.467 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.943 ' HA3' HD21 ' A' ' 72' ' ' LEU . . . -159.36 -150.19 5.75 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.867 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.524 ' HB ' HD21 ' A' ' 25' ' ' LEU . 8.1 p -116.51 132.35 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -1.14 . . . . 0.0 109.478 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 21' ' ' LYS . 63.7 t -56.3 126.84 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.913 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -93.01 -50.1 5.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.163 -0.96 . . . . 0.0 109.416 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -169.64 153.26 4.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.349 -0.844 . . . . 0.0 109.464 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.753 HG12 ' H ' ' A' ' 57' ' ' VAL . 25.9 t -111.69 136.34 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.301 -0.874 . . . . 0.0 109.457 -179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -94.79 17.4 13.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.271 -0.893 . . . . 0.0 109.471 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.788 HG11 HD22 ' A' ' 63' ' ' LEU . 1.6 m -145.28 176.88 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.274 -0.891 . . . . 0.0 109.386 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HB2' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -112.34 -178.91 3.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.19 -0.944 . . . . 0.0 109.522 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -82.3 136.85 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.913 . . . . 0.0 109.501 179.93 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 71.41 18.08 76.65 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 58' ' ' LYS . 4.4 m-20 -83.68 144.14 29.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 109.431 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.476 ' CB ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -103.66 120.94 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.515 179.961 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.788 HD22 HG11 ' A' ' 57' ' ' VAL . 1.3 mp -121.73 175.57 6.19 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.248 -0.907 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' GLU . 3.5 tttp -118.31 145.75 44.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 3.2 pt-20 -42.85 137.48 2.3 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.341 -0.849 . . . . 0.0 109.584 -179.884 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 109.53 -25.93 16.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -84.89 140.76 30.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -1.124 . . . . 0.0 109.448 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -65.04 -174.11 0.14 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.423 179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 69' ' ' ILE . 28.7 mm -143.3 -65.33 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.264 -0.897 . . . . 0.0 109.49 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.699 ' CG2' HG13 ' A' ' 55' ' ' VAL . 1.8 pt -141.95 -175.11 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.899 . . . . 0.0 109.463 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.635 ' HB2' HD12 ' A' ' 3' ' ' ILE . 1.8 tt0 -149.56 114.37 5.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.296 -0.877 . . . . 0.0 109.498 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.943 HD21 ' HA3' ' A' ' 50' ' ' GLY . 0.9 OUTLIER -93.27 148.02 22.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.284 -0.885 . . . . 0.0 109.423 -179.911 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.413 ' N ' ' HG ' ' A' ' 72' ' ' LEU . 3.6 tt0 -132.91 91.22 29.67 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.493 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.839 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.9 Cg_endo -77.96 176.41 10.02 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.627 2.218 . . . . 0.0 110.44 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -80.37 179.37 7.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.201 -0.937 . . . . 0.0 109.501 -179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -172.7 107.81 0.18 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.18 -0.95 . . . . 0.0 109.471 179.946 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.633 ' O ' ' HB3' ' A' ' 78' ' ' ALA . . . 87.31 78.22 1.25 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.633 ' HB3' ' O ' ' A' ' 77' ' ' GLY . . . 71.24 115.27 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.268 -1.136 . . . . 0.0 109.489 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.419 -179.989 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 89.1 p . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -122.35 151.07 41.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -0.916 . . . . 0.0 109.512 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.476 ' C ' HD12 ' A' ' 4' ' ' ILE . 4.3 mp -90.94 154.36 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.513 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.1 mp -120.81 107.57 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.479 ' HA ' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -101.55 170.64 8.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 0.0 109.385 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.719 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.6 t -61.26 142.27 93.6 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.374 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.719 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.8 Cg_endo -78.08 -169.77 0.83 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.561 2.174 . . . . 0.0 110.458 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -82.88 105.15 13.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.416 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.8 -59.5 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.389 -179.954 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.04 -11.68 10.78 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.05 -141.28 4.22 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.414 ' OD1' ' HE2' ' A' ' 64' ' ' LYS . 0.1 OUTLIER -98.66 164.17 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -1.127 . . . . 0.0 109.516 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -125.59 95.47 0.47 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -97.0 126.16 41.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.282 -1.128 . . . . 0.0 109.428 -179.953 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.643 HG22 ' CD2' ' A' ' 35' ' ' LEU . 19.2 t -77.09 133.6 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -0.93 . . . . 0.0 109.512 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.559 HD11 ' HB2' ' A' ' 36' ' ' GLU . 19.2 mt -121.38 -37.58 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.395 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.56 137.6 43.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.192 -0.942 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.423 ' HB2' ' HB3' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -122.43 119.29 30.56 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.22 -0.925 . . . . 0.0 109.558 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -117.81 50.34 1.15 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.431 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -147.36 159.34 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.492 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -148.74 -176.3 5.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.918 . . . . 0.0 109.427 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.5 m -84.63 126.47 33.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.256 -0.903 . . . . 0.0 109.449 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.88 6.9 64.94 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 180.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 51' ' ' VAL . 57.2 m-20 -83.66 131.9 34.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.232 -1.158 . . . . 0.0 109.441 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.46 HD12 ' HB ' ' A' ' 51' ' ' VAL . 7.2 tp -92.94 106.48 18.43 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.534 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.714 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -91.77 -171.4 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.215 -0.928 . . . . 0.0 109.151 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.714 ' H ' HG22 ' A' ' 26' ' ' ILE . 2.7 mt-10 -144.7 176.51 9.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.925 . . . . 0.0 109.412 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.768 ' O ' HG13 ' A' ' 28' ' ' VAL . 14.4 p -81.96 72.95 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.205 -0.934 . . . . 0.0 109.535 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.83 -44.57 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.331 -0.856 . . . . 0.0 109.397 179.986 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -51.13 142.42 12.53 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.209 -0.932 . . . . 0.0 109.441 179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.457 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -60.61 175.47 4.68 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.724 HD13 ' HA ' ' A' ' 46' ' ' SER . 0.6 OUTLIER -138.51 -62.24 0.57 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.358 -179.979 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.38 159.86 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.932 . . . . 0.0 109.457 -179.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 65.1 t -114.66 84.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.643 ' CD2' HG22 ' A' ' 15' ' ' VAL . 7.3 mt -94.68 159.55 15.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.559 ' HB2' HD11 ' A' ' 16' ' ' ILE . 0.3 OUTLIER -124.15 161.23 26.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.913 . . . . 0.0 109.49 -179.96 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -139.44 172.02 13.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.198 -0.939 . . . . 0.0 109.465 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.02 -13.39 62.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.312 -0.867 . . . . 0.0 109.54 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.535 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mptt -87.42 -38.84 15.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.489 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.535 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 174.07 -174.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.514 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.49 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 0.0 OUTLIER -99.15 134.98 41.22 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.237 -0.915 . . . . 0.0 109.453 -179.975 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.447 ' O ' ' HG3' ' A' ' 42' ' ' MET . 0.4 OUTLIER -155.16 132.26 10.89 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.449 -179.959 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -94.53 -179.71 4.99 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.243 -0.91 . . . . 0.0 109.491 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 48.5 t -144.36 128.94 9.24 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.224 -0.923 . . . . 0.0 109.304 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.457 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -78.5 -168.62 0.64 Allowed 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.334 2.023 . . . . 0.0 110.326 179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.724 ' HA ' HD13 ' A' ' 32' ' ' LEU . 1.9 t -85.31 136.41 37.83 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.362 -0.836 . . . . 0.0 109.359 179.891 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HG2' HG12 ' A' ' 4' ' ' ILE . 36.1 Cg_endo -78.73 -5.73 14.88 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.516 2.144 . . . . 0.0 110.495 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -160.33 139.17 10.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 109.488 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.86 101.57 8.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.234 -0.916 . . . . 0.0 109.444 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.849 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -157.7 -147.75 4.91 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 24' ' ' ASP . 14.5 p -126.66 152.02 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.219 -1.165 . . . . 0.0 109.502 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 54.3 t -68.66 140.47 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.249 -0.907 . . . . 0.0 109.459 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -109.04 -53.88 2.59 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -0.933 . . . . 0.0 109.457 -179.977 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.87 177.95 7.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 57' ' ' VAL . 92.9 t -124.35 125.15 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 21.6 t -105.53 1.67 27.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.198 -0.939 . . . . 0.0 109.645 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 55' ' ' VAL . 3.3 m -147.28 176.3 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.231 -0.918 . . . . 0.0 109.481 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.481 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -129.79 150.4 51.11 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.488 -179.943 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.667 HD23 ' H ' ' A' ' 59' ' ' LEU . 0.5 OUTLIER -61.79 140.67 58.22 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.889 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.75 -11.96 60.64 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.481 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 8.0 m-20 -78.01 152.62 32.97 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.194 -1.18 . . . . 0.0 109.444 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.426 ' O ' ' HG2' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -114.11 146.26 40.53 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.971 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.2 mp -147.75 -178.41 6.25 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.432 ' O ' ' C ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -120.22 149.74 41.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.459 -179.987 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.441 ' CD ' ' N ' ' A' ' 65' ' ' GLU . 0.1 OUTLIER -42.87 149.17 0.21 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.839 . . . . 0.0 109.591 -179.89 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.69 -14.29 65.34 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -84.65 137.73 33.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.25 -1.147 . . . . 0.0 109.491 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.43 ' O ' HG13 ' A' ' 69' ' ' ILE . . . -66.25 176.93 1.59 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.523 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.479 HD12 ' HA ' ' A' ' 5' ' ' ARG . 2.3 mp -142.1 -61.25 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.253 -0.904 . . . . 0.0 109.449 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -142.9 -172.21 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.199 -0.938 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -142.41 106.94 4.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.291 -0.881 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.849 HD11 ' N ' ' A' ' 50' ' ' GLY . 2.7 tt -91.18 135.58 33.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.203 -0.936 . . . . 0.0 109.49 179.929 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.524 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 20.6 tt0 -116.66 142.11 29.15 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.227 -0.921 . . . . 0.0 109.423 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 36.0 Cg_endo -78.27 100.02 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.568 2.179 . . . . 0.0 110.403 179.942 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.605 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . -81.36 161.63 23.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.231 -0.918 . . . . 0.0 109.412 -179.939 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 69.89 19.55 6.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.164 -0.96 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -159.82 133.76 3.44 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.998 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -174.28 145.04 0.98 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -1.163 . . . . 0.0 109.512 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 5.8 mtp180 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.471 -179.953 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.463 ' HB3' ' HG3' ' A' ' 73' ' ' GLU . 9.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -128.12 133.42 48.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.906 . . . . 0.0 109.484 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.492 HD12 ' HB2' ' A' ' 71' ' ' GLU . 2.1 tp -79.95 140.27 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.255 -0.903 . . . . 0.0 109.436 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.68 ' N ' HD12 ' A' ' 4' ' ' ILE . 4.4 mp -101.61 142.41 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 179.991 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -113.95 179.74 3.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.854 . . . . 0.0 109.478 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.68 ' CG1' HD11 ' A' ' 9' ' ' ILE . 49.1 t -61.35 134.4 93.35 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 109.292 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.418 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -170.04 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.457 2.105 . . . . 0.0 110.483 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -79.93 101.41 8.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.473 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.68 HD11 ' CG1' ' A' ' 6' ' ' VAL . 0.0 OUTLIER -104.24 -49.73 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.284 -179.938 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 125.64 -17.37 6.89 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.938 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.42 -171.88 28.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.83 148.88 42.0 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -1.159 . . . . 0.0 109.53 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -128.53 150.23 18.54 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.9 OUTLIER -118.38 142.33 47.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.176 -1.19 . . . . 0.0 109.465 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.479 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -76.48 135.41 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.521 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.84 HD12 HG12 ' A' ' 34' ' ' VAL . 80.5 mt -100.33 -38.33 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.447 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -172.47 170.12 5.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.243 -0.911 . . . . 0.0 109.533 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.5 tp -117.15 125.16 50.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.444 ' O ' HD12 ' A' ' 19' ' ' LEU . 1.1 pp -104.7 31.25 4.85 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' CD2' ' A' ' 32' ' ' LEU . 17.2 m -150.0 166.67 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.6 mtmt -128.51 179.06 5.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.902 . . . . 0.0 109.498 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 35.1 m -84.96 141.63 30.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.89 63.34 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -84.89 138.45 32.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -1.22 . . . . 0.0 109.502 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.2 OUTLIER -79.98 131.11 35.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 109.431 179.911 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.84 HD13 HD11 ' A' ' 32' ' ' LEU . 2.4 mt -92.95 -171.56 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.176 -0.952 . . . . 0.0 109.278 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 0.7 OUTLIER -126.98 175.84 7.78 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.206 -0.933 . . . . 0.0 109.433 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.576 ' O ' HG13 ' A' ' 28' ' ' VAL . 8.3 p -76.55 124.46 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.497 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 4.1 mt-10 63.05 11.92 5.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.245 -0.909 . . . . 0.0 109.656 179.859 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.473 ' HG3' ' HB2' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -74.13 122.57 22.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.356 179.923 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.464 ' N ' ' HB3' ' A' ' 45' ' ' PRO . . . -43.19 152.88 0.28 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.86 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.84 HD11 HD13 ' A' ' 26' ' ' ILE . 0.5 OUTLIER -132.56 -39.25 1.01 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -1.153 . . . . 0.0 109.496 179.943 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -140.92 165.1 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.174 -0.954 . . . . 0.0 109.528 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.84 HG12 HD12 ' A' ' 16' ' ' ILE . 78.4 t -130.59 95.51 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 0.9 OUTLIER -89.92 163.57 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.462 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.711 ' HB2' HD11 ' A' ' 16' ' ' ILE . 21.2 tt0 -122.94 123.45 40.95 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.892 . . . . 0.0 109.515 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.443 ' HB2' ' HB3' ' A' ' 40' ' ' ALA . 0.4 OUTLIER -79.91 -173.82 4.08 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.47 -179.959 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -48.58 -42.1 32.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.361 -0.837 . . . . 0.0 109.539 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.81 18.48 0.69 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 179.936 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' HB2' ' A' ' 37' ' ' SER . . . -120.34 -169.74 1.85 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -158.04 101.75 1.78 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.531 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.432 ' N ' ' SD ' ' A' ' 42' ' ' MET . 0.0 OUTLIER -114.34 143.16 45.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.212 -0.93 . . . . 0.0 109.452 -179.984 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -100.97 164.07 11.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.281 -0.887 . . . . 0.0 109.521 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.07 102.88 10.81 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.362 179.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.464 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 36.2 Cg_endo -77.4 -169.58 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.419 2.079 . . . . 0.0 110.428 -179.823 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 48' ' ' LYS . 0.3 OUTLIER -85.73 139.52 35.39 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.473 179.906 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.437 ' HG3' HG12 ' A' ' 4' ' ' ILE . 36.4 Cg_endo -78.96 -10.65 15.28 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.409 2.072 . . . . 0.0 110.328 179.841 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.484 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.5 146.84 15.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.477 -0.764 . . . . 0.0 109.364 179.962 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.97 116.95 17.17 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -0.946 . . . . 0.0 109.399 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 1.003 ' CA ' HD11 ' A' ' 72' ' ' LEU . . . -164.36 -149.25 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.4 p -126.34 145.43 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -1.113 . . . . 0.0 109.433 -179.945 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.7 t -65.13 140.41 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.891 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.2 tptp -117.16 -47.11 2.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.401 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.49 163.61 32.37 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 80.4 t -121.52 118.19 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.0 t -108.22 22.59 15.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.251 -0.906 . . . . 0.0 109.557 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.409 ' CG1' ' HA ' ' A' ' 69' ' ' ILE . 34.5 m -144.13 160.35 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.906 . . . . 0.0 109.532 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.67 169.2 18.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -0.903 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.424 ' O ' ' HG ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER -84.97 103.08 13.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.218 -0.926 . . . . 0.0 109.476 -179.955 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 115.1 -14.06 19.14 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.57 138.62 38.46 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.198 -1.178 . . . . 0.0 109.49 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -80.48 152.83 28.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -0.868 . . . . 0.0 109.44 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.479 ' CD1' ' CG2' ' A' ' 15' ' ' VAL . 63.2 mt -140.97 136.53 32.27 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 14.3 tttm -105.87 149.05 26.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 0.0 109.486 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.438 ' C ' ' O ' ' A' ' 64' ' ' LYS . 0.0 OUTLIER -42.88 147.31 0.32 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.37 -0.831 . . . . 0.0 109.583 -179.901 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 82.57 -4.34 78.79 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 64' ' ' LYS . 2.5 m-20 -83.09 130.87 35.16 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.289 -1.124 . . . . 0.0 109.423 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -50.5 178.34 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.26 -0.9 . . . . 0.0 109.475 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.433 HG22 HG23 ' A' ' 70' ' ' ILE . 29.5 mm -146.97 -71.48 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.221 -0.924 . . . . 0.0 109.461 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.433 HG23 HG22 ' A' ' 69' ' ' ILE . 0.8 OUTLIER -138.81 -174.58 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.489 180.0 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.492 ' HB2' HD12 ' A' ' 3' ' ' ILE . 0.3 OUTLIER -150.0 102.0 3.07 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.907 . . . . 0.0 109.507 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 1.003 HD11 ' CA ' ' A' ' 50' ' ' GLY . 4.0 tt -91.3 129.01 37.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.289 -0.882 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.534 ' CG ' ' HD2' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -90.07 144.96 32.07 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.367 -179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 73' ' ' GLU . 35.5 Cg_endo -78.02 151.87 27.63 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.623 2.215 . . . . 0.0 110.432 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -85.59 -45.54 11.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.902 . . . . 0.0 109.461 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 48.57 -171.62 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.465 -179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -118.81 -71.46 0.37 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . 46.35 41.7 9.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.362 -1.081 . . . . 0.0 109.476 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.479 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 84.6 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -107.8 147.26 31.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.587 HD11 ' HB1' ' A' ' 68' ' ' ALA . 13.8 tt -79.93 169.13 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -0.883 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.937 ' O ' HD12 ' A' ' 69' ' ' ILE . 24.6 mm -125.39 119.78 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.456 -179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.537 ' C ' HD11 ' A' ' 69' ' ' ILE . 3.9 ptm180 -94.93 163.83 13.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.648 ' N ' HD11 ' A' ' 69' ' ' ILE . 86.9 t -69.25 140.03 90.25 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.379 -179.903 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.573 ' HD2' HG13 ' A' ' 6' ' ' VAL . 36.2 Cg_endo -78.73 -168.7 0.66 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.589 2.193 . . . . 0.0 110.432 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -75.19 117.67 17.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 109.268 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.448 HD12 ' O ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -108.57 -47.26 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 109.482 -179.736 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 149.61 -38.9 0.92 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 12' ' ' ASP . . . 172.29 117.64 0.45 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.92 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.461 ' O ' ' O ' ' A' ' 11' ' ' GLY . 0.7 OUTLIER 50.33 178.66 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -1.091 . . . . 0.0 109.623 179.892 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.35 111.69 0.36 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.439 ' HB2' ' HD3' ' A' ' 62' ' ' LYS . 0.0 OUTLIER -95.95 137.12 35.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.283 -1.128 . . . . 0.0 109.539 179.963 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.539 HG22 HD23 ' A' ' 35' ' ' LEU . 59.9 t -85.12 134.97 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.556 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.707 HD11 ' HG3' ' A' ' 36' ' ' GLU . 44.6 mt -104.31 -30.63 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.204 -0.935 . . . . 0.0 109.514 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.423 ' HB2' ' O ' ' A' ' 16' ' ' ILE . 0.5 OUTLIER 175.22 131.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.545 179.976 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.491 ' H ' HD12 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -103.12 172.08 7.02 Favored 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -145.32 63.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.473 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.411 HG11 ' CD1' ' A' ' 32' ' ' LEU . 18.0 m -146.36 158.92 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.237 -0.914 . . . . 0.0 109.534 179.972 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.432 ' HB2' ' OD1' ' A' ' 24' ' ' ASP . 75.9 mttt -123.47 167.75 13.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.301 -0.875 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 22' ' ' THR . 11.0 t -79.12 126.82 31.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.428 ' C ' HG23 ' A' ' 51' ' ' VAL . . . 89.29 9.36 67.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' OD1' ' HB2' ' A' ' 21' ' ' LYS . 0.8 OUTLIER -85.02 135.06 34.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.158 -1.201 . . . . 0.0 109.506 179.994 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.446 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 1.7 tt -97.25 104.37 16.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.234 -0.916 . . . . 0.0 109.475 179.959 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.7 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.7 mt -91.89 -171.45 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.2 -0.937 . . . . 0.0 109.246 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.7 ' H ' HG22 ' A' ' 26' ' ' ILE . 6.7 mt-10 -137.94 176.5 8.65 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 28' ' ' VAL . 11.1 p -81.39 79.07 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 109.455 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER 167.49 -55.9 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.42 -0.8 . . . . 0.0 109.319 179.874 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.591 ' NE2' HG23 ' A' ' 26' ' ' ILE . 0.0 OUTLIER -44.66 145.79 0.85 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.946 . . . . 0.0 109.497 179.965 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.45 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -59.34 -162.74 0.09 OUTLIER Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.522 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -160.03 -71.77 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 109.516 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.464 ' O ' ' HB2' ' A' ' 43' ' ' GLU . 9.5 m -129.9 170.24 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.453 HG22 ' HB3' ' A' ' 43' ' ' GLU . 77.2 t -129.53 92.12 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 180.0 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.539 HD23 HG22 ' A' ' 15' ' ' VAL . 0.5 OUTLIER -97.04 169.83 9.56 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.26 -0.9 . . . . 0.0 109.478 179.999 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.707 ' HG3' HD11 ' A' ' 16' ' ' ILE . 0.9 OUTLIER -103.12 178.74 4.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.247 -0.908 . . . . 0.0 109.486 -180.0 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -139.57 -173.09 3.52 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.28 -0.888 . . . . 0.0 109.469 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -53.65 -57.61 10.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.932 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 2.2 mttt -138.45 58.46 1.66 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.246 -0.909 . . . . 0.0 109.526 -179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 173.95 174.17 0.16 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.0 127.88 39.23 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.248 -0.907 . . . . 0.0 109.44 -179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 6.5 mtt -138.19 142.97 40.01 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.545 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -105.97 164.12 12.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.284 -0.885 . . . . 0.0 109.352 179.969 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 3.5 t -122.31 137.83 28.19 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.309 179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HA ' ' C ' ' A' ' 31' ' ' GLY . 36.3 Cg_endo -79.13 -167.99 0.57 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.465 2.11 . . . . 0.0 110.458 179.981 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.05 116.35 65.05 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.395 -0.816 . . . . 0.0 109.36 179.961 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' HG21 ' A' ' 4' ' ' ILE . 35.8 Cg_endo -77.77 4.54 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.381 2.054 . . . . 0.0 110.45 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.679 ' HB3' HD13 ' A' ' 72' ' ' LEU . 0.0 OUTLIER -160.01 111.68 2.0 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.522 -179.976 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.45 95.89 2.3 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.307 -0.871 . . . . 0.0 109.435 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.975 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -164.29 -164.08 18.73 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.428 HG23 ' C ' ' A' ' 23' ' ' GLY . 14.9 p -100.91 133.82 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.229 -1.16 . . . . 0.0 109.519 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 80.4 t -58.82 147.88 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.84 -30.75 6.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 109.445 -179.961 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -169.6 159.38 8.29 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 109.451 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.532 ' HA ' HG22 ' A' ' 70' ' ' ILE . 75.2 t -116.66 106.74 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.137 -0.977 . . . . 0.0 109.47 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -95.91 21.88 8.08 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.261 -0.899 . . . . 0.0 109.417 179.955 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.525 HG21 HG22 ' A' ' 69' ' ' ILE . 15.8 m -144.1 160.51 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.449 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.57 171.15 12.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 179.966 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.07 119.2 22.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.424 -179.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 104.77 -10.02 48.4 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.17 159.93 33.29 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.269 -1.136 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.868 ' O ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -113.52 135.07 54.29 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.507 179.958 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.868 HD12 ' O ' ' A' ' 62' ' ' LYS . 1.2 mp -142.68 155.05 44.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.175 -0.953 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.437 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 0.0 OUTLIER -104.43 147.96 26.98 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.522 -179.933 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 64' ' ' LYS . 4.1 pt-20 -43.04 141.24 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.77 -8.89 73.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.494 ' HB3' HD23 ' A' ' 63' ' ' LEU . 0.9 OUTLIER -84.49 132.06 34.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -1.169 . . . . 0.0 109.519 179.974 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.587 ' HB1' HD11 ' A' ' 3' ' ' ILE . . . -56.08 156.1 5.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.396 -0.815 . . . . 0.0 109.44 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.937 HD12 ' O ' ' A' ' 4' ' ' ILE . 1.4 mp -129.82 -43.8 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.489 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 69' ' ' ILE . 4.9 pt -159.9 -173.47 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.471 179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.6 tt0 -135.66 159.0 42.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.252 -0.905 . . . . 0.0 109.474 180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.975 HD11 ' N ' ' A' ' 50' ' ' GLY . 8.0 tt -140.54 145.32 36.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -116.68 87.77 22.58 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.251 -0.906 . . . . 0.0 109.447 -179.979 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.883 ' HD3' HD23 ' A' ' 72' ' ' LEU . 35.7 Cg_endo -78.05 137.52 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.622 2.215 . . . . 0.0 110.458 179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -117.38 173.0 6.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -0.927 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -136.75 -44.92 0.59 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.369 -0.832 . . . . 0.0 109.459 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -168.6 72.06 0.14 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -95.78 18.38 13.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.206 -1.173 . . . . 0.0 109.381 -179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.424 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.461 ' HA ' ' HD2' ' A' ' 74' ' ' PRO . 86.5 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -141.86 144.7 33.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.412 179.994 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.6 mm -90.45 136.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.488 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 mt -110.57 124.48 67.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.403 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 11.6 ptt180 -105.18 171.45 7.31 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.907 . . . . 0.0 109.489 -179.945 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.713 HG13 ' HD2' ' A' ' 7' ' ' PRO . 77.0 t -62.13 142.48 95.57 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.46 -179.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.713 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.3 Cg_endo -78.56 -170.38 0.97 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.496 2.13 . . . . 0.0 110.375 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -84.9 110.74 19.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.392 179.927 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.59 -10.08 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.298 -0.876 . . . . 0.0 109.389 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 68.8 26.62 74.45 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.906 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 12' ' ' ASP . . . 171.61 160.55 20.41 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -44.45 155.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.239 -1.153 . . . . 0.0 109.485 -179.996 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.65 109.28 1.45 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -101.72 114.41 28.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.229 -1.159 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.402 ' H ' HG23 ' A' ' 15' ' ' VAL . 14.3 t -60.24 129.93 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.891 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 60.1 mt -104.86 -35.57 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.243 -0.91 . . . . 0.0 109.502 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.465 ' HA ' ' HB2' ' A' ' 59' ' ' LEU . 6.5 tp10 -165.37 135.47 3.64 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.48 127.49 55.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -0.923 . . . . 0.0 109.411 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -116.03 57.68 0.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -0.908 . . . . 0.0 109.444 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.81 HG11 ' CD2' ' A' ' 32' ' ' LEU . 35.6 m -137.19 157.24 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -129.93 157.51 42.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.511 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 22' ' ' THR . 12.1 t -80.64 128.98 34.24 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 109.419 179.939 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.71 -8.92 79.09 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -82.26 132.61 35.23 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.229 -1.16 . . . . 0.0 109.427 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 50' ' ' GLY . 0.4 OUTLIER -79.9 125.63 29.97 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.264 -0.897 . . . . 0.0 109.488 -179.959 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.784 HG21 ' HB2' ' A' ' 46' ' ' SER . 2.7 mt -92.52 -171.38 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.276 -0.89 . . . . 0.0 109.201 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.72 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.7 pm0 -142.2 159.68 41.74 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.119 -0.988 . . . . 0.0 109.477 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.783 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.3 p -81.41 79.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.244 -0.91 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 162.75 -36.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.397 179.893 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.507 ' O ' ' CB ' ' A' ' 45' ' ' PRO . 39.6 tt0 -67.33 155.47 38.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -0.925 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.441 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -77.32 168.4 54.53 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.81 ' CD2' HG11 ' A' ' 20' ' ' VAL . 1.3 tt -129.5 -40.5 1.42 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.263 -1.14 . . . . 0.0 109.49 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.659 HG22 ' HB ' ' A' ' 44' ' ' VAL . 5.2 m -154.7 166.84 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.506 -179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 88.4 t -134.66 96.55 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.325 179.931 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -94.62 163.83 13.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.223 -0.923 . . . . 0.0 109.564 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -105.42 173.87 6.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.407 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.1 m -135.32 -174.13 3.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.298 -0.876 . . . . 0.0 109.51 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -44.73 -42.58 7.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 109.441 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 ttpp -158.89 39.76 0.22 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.485 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -151.0 -156.9 0.76 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.466 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.84 107.26 2.1 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -0.914 . . . . 0.0 109.511 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . 0.437 ' HG3' ' N ' ' A' ' 43' ' ' GLU . 2.4 ttm -100.2 149.66 23.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' N ' ' HG3' ' A' ' 42' ' ' MET . 10.6 mt-10 -113.2 164.51 13.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.659 ' HB ' HG22 ' A' ' 33' ' ' VAL . 21.6 t -143.9 101.74 4.93 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.25 -0.906 . . . . 0.0 109.269 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.536 ' HA ' ' N ' ' A' ' 32' ' ' LEU . 35.4 Cg_endo -77.16 -168.75 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.393 2.062 . . . . 0.0 110.55 -179.824 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.784 ' HB2' HG21 ' A' ' 26' ' ' ILE . 1.6 t -85.26 117.64 69.18 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.272 -0.892 . . . . 0.0 109.502 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.12 3.35 7.13 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.332 2.021 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.703 ' HG2' HD12 ' A' ' 72' ' ' LEU . 1.8 tptt -159.88 131.2 5.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.892 . . . . 0.0 109.415 179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -84.41 88.36 7.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 -179.818 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.836 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -140.05 -152.35 5.81 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 73' ' ' GLU . 9.9 p -113.59 129.99 68.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -1.169 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.4 t -55.55 126.75 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.901 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.09 -44.68 9.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.261 -0.9 . . . . 0.0 109.44 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 54.7 p -171.82 138.44 1.07 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.614 ' HA ' HG22 ' A' ' 70' ' ' ILE . 4.8 t -92.98 117.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.308 -0.87 . . . . 0.0 109.539 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.22 13.52 18.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.479 ' H ' HG12 ' A' ' 55' ' ' VAL . 2.8 m -140.83 172.09 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.463 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.73 151.74 44.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.465 ' HB2' ' HA ' ' A' ' 17' ' ' GLU . 1.6 pp -56.83 139.91 49.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.87 -7.53 81.56 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -70.57 -179.95 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.212 -1.169 . . . . 0.0 109.438 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 6.9 ptpp? -153.12 115.74 4.48 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.186 -0.946 . . . . 0.0 109.441 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mp -131.3 -175.05 3.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.473 179.942 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' O ' ' C ' ' A' ' 65' ' ' GLU . 1.3 tttp -118.56 144.65 45.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.22 -0.925 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HA ' ' HB ' ' A' ' 6' ' ' VAL . 1.6 pt-20 -42.82 141.23 1.13 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.302 -0.874 . . . . 0.0 109.585 -179.861 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.76 -22.62 36.52 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -78.79 138.14 38.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.46 179.99 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.44 170.12 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.433 -179.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.653 HD11 ' CG2' ' A' ' 6' ' ' VAL . 27.7 mm -139.11 -59.56 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.244 -0.91 . . . . 0.0 109.4 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.614 HG22 ' HA ' ' A' ' 55' ' ' VAL . 2.3 pt -143.44 -173.75 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.268 -0.895 . . . . 0.0 109.409 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -139.07 113.16 8.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.236 -0.915 . . . . 0.0 109.512 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.836 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 119.92 30.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.592 ' O ' HG12 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -111.14 95.42 25.16 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.202 -0.936 . . . . 0.0 109.451 -179.926 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.5 ' HD3' HD13 ' A' ' 72' ' ' LEU . 35.5 Cg_endo -77.74 173.67 13.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.594 2.196 . . . . 0.0 110.363 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -165.2 -179.84 5.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.465 -179.928 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -79.4 -41.59 27.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.21 -0.931 . . . . 0.0 109.48 179.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -153.76 113.43 0.57 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -45.91 -74.18 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.25 -1.147 . . . . 0.0 109.462 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.451 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.484 ' HB3' ' HG2' ' A' ' 73' ' ' GLU . 24.8 p . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -157.19 140.61 15.67 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.453 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.5 ' HA ' ' HG3' ' A' ' 71' ' ' GLU . 2.9 mt -80.48 154.56 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.93 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.5 mt -122.25 97.55 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.571 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -90.72 -172.36 3.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -0.914 . . . . 0.0 109.379 179.968 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.714 HG11 HD11 ' A' ' 9' ' ' ILE . 54.6 t -80.88 139.09 49.86 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.128 -0.983 . . . . 0.0 109.284 -179.957 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.625 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.56 -169.89 0.87 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.499 2.133 . . . . 0.0 110.399 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -81.69 104.11 11.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.344 -0.847 . . . . 0.0 109.37 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.714 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.77 -42.71 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.989 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 124.77 -23.37 6.28 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -137.95 -140.29 4.0 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.2 p30 -99.29 153.08 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.185 -1.185 . . . . 0.0 109.401 179.883 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -107.69 105.95 2.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.99 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.447 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.9 mt-10 -99.96 137.64 38.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -1.145 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 99.6 t -76.5 127.22 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.49 -179.934 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.407 HD11 ' CB ' ' A' ' 36' ' ' GLU . 83.7 mt -107.8 -35.47 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.356 -0.84 . . . . 0.0 109.368 -179.952 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -152.09 127.36 9.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.506 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.409 ' O ' HD23 ' A' ' 18' ' ' LEU . 3.9 tt -110.14 126.07 53.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.893 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.95 54.56 1.51 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.502 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.855 HG11 ' CD1' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -148.55 162.59 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.511 -179.943 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.556 ' O ' HG21 ' A' ' 52' ' ' VAL . 4.0 tptp -141.29 176.75 8.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.6 m -81.76 144.91 30.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.207 -0.933 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.404 ' HA2' ' CG2' ' A' ' 51' ' ' VAL . . . 69.29 8.07 58.43 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -85.02 132.61 34.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -1.151 . . . . 0.0 109.515 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.636 HD13 ' N ' ' A' ' 26' ' ' ILE . 0.7 OUTLIER -88.48 118.9 28.44 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.212 -0.93 . . . . 0.0 109.41 179.855 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.959 HD13 HD21 ' A' ' 32' ' ' LEU . 3.2 mt -95.62 -171.33 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 O-C-N 121.222 -0.924 . . . . 0.0 109.328 -179.784 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.718 ' H ' HG22 ' A' ' 26' ' ' ILE . 1.3 pt-20 -145.47 167.69 22.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.397 179.975 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.742 ' O ' HG13 ' A' ' 28' ' ' VAL . 12.6 p -83.83 72.73 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -0.934 . . . . 0.0 109.522 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.486 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 0.9 OUTLIER 170.82 -35.03 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.334 -0.854 . . . . 0.0 109.459 179.826 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.421 ' OE1' ' O ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -72.67 153.76 41.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.47 179.985 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA2' ' HB3' ' A' ' 45' ' ' PRO . . . -72.75 175.06 44.94 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD21 HD13 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -134.85 -44.84 0.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -1.115 . . . . 0.0 109.501 179.965 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.443 HG23 ' HB ' ' A' ' 44' ' ' VAL . 2.1 m -153.91 170.88 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.227 -0.92 . . . . 0.0 109.513 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.456 ' O ' HG12 ' A' ' 34' ' ' VAL . 94.0 t -129.75 76.87 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.23 -0.918 . . . . 0.0 109.444 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 14' ' ' GLU . 4.9 mp -89.91 135.13 33.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.471 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.407 ' CB ' HD11 ' A' ' 16' ' ' ILE . 5.0 tm-20 -111.43 140.36 46.09 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.895 . . . . 0.0 109.492 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.707 ' OG ' HG21 ' A' ' 9' ' ' ILE . 1.4 m -112.52 173.7 6.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.532 179.989 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.89 -13.51 25.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.46 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 21.2 mttt -84.26 -45.44 12.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 178.94 165.21 0.88 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.407 ' HA ' ' CG ' ' A' ' 36' ' ' GLU . 8.5 t -81.48 118.56 22.82 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.541 179.919 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 23.9 mtm -121.63 -178.97 3.95 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 109.415 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.7 174.29 10.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.286 -0.884 . . . . 0.0 109.484 -179.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 32' ' ' LEU . 18.1 t -149.21 103.05 3.32 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.212 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.465 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.6 Cg_endo -77.39 -168.64 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.343 2.029 . . . . 0.0 110.407 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.438 ' HB2' HG21 ' A' ' 26' ' ' ILE . 0.9 OUTLIER -85.42 113.57 51.48 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.43 -179.905 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 45' ' ' PRO . 35.7 Cg_endo -78.18 0.36 9.96 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.343 2.028 . . . . 0.0 110.308 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.47 ' O ' HD13 ' A' ' 72' ' ' LEU . 0.1 OUTLIER -160.12 131.15 5.74 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.314 -0.866 . . . . 0.0 109.397 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.59 108.11 5.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.862 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.96 ' N ' HD11 ' A' ' 72' ' ' LEU . . . -160.86 -172.76 28.6 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 9.8 p -104.87 150.92 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 109.494 -179.923 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.556 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.1 t -68.88 130.78 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.225 -0.922 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 54' ' ' SER . 0.3 OUTLIER -86.51 -42.59 13.42 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 109.448 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 53' ' ' LYS . 4.8 t -179.51 139.95 0.14 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.183 -0.948 . . . . 0.0 109.566 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 57' ' ' VAL . 9.0 t -80.87 109.53 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.88 . . . . 0.0 109.423 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.8 p -89.5 7.84 34.11 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.299 -0.875 . . . . 0.0 109.632 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.996 HG21 HG23 ' A' ' 69' ' ' ILE . 2.8 m -139.03 -177.59 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.195 -0.941 . . . . 0.0 109.508 -179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.5 tptp -131.87 171.27 13.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.235 -0.916 . . . . 0.0 109.499 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.402 HD12 ' C ' ' A' ' 59' ' ' LEU . 2.7 pp -84.56 132.33 34.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.899 . . . . 0.0 109.468 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.57 -10.63 74.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -81.38 141.58 33.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -1.158 . . . . 0.0 109.402 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.876 ' C ' HD12 ' A' ' 63' ' ' LEU . 10.8 pttp -99.73 151.61 21.04 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.195 -0.941 . . . . 0.0 109.465 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.876 HD12 ' C ' ' A' ' 62' ' ' LYS . 6.0 mp -138.17 168.9 18.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.238 -0.914 . . . . 0.0 109.504 179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 65' ' ' GLU . 0.5 OUTLIER -107.11 146.66 30.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.467 -179.974 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.434 ' N ' ' HD2' ' A' ' 64' ' ' LYS . 5.4 mt-10 -42.96 138.9 1.89 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.292 -0.88 . . . . 0.0 109.635 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.79 -6.44 73.58 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.12 145.73 29.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -1.176 . . . . 0.0 109.48 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.536 ' C ' HD12 ' A' ' 69' ' ' ILE . . . -81.15 163.57 23.01 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.267 -0.896 . . . . 0.0 109.437 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.996 HG23 HG21 ' A' ' 57' ' ' VAL . 4.3 mp -133.85 -55.57 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.18 -0.95 . . . . 0.0 109.546 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.779 HG23 HG22 ' A' ' 69' ' ' ILE . 18.1 pt -145.96 -173.42 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.269 -0.894 . . . . 0.0 109.49 -179.93 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.5 ' HG3' ' HA ' ' A' ' 3' ' ' ILE . 1.0 OUTLIER -146.49 155.63 42.67 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.235 -0.915 . . . . 0.0 109.505 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.96 HD11 ' N ' ' A' ' 50' ' ' GLY . 4.5 tt -130.69 126.74 37.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.484 ' HG2' ' HB3' ' A' ' 1' ' ' SER . 0.1 OUTLIER -96.71 149.33 35.65 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.238 -0.914 . . . . 0.0 109.54 -179.959 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.688 ' O ' ' HB3' ' A' ' 75' ' ' ALA . 35.5 Cg_endo -78.15 -27.38 5.61 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.633 2.222 . . . . 0.0 110.412 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.693 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . 75.25 137.29 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.17 -0.956 . . . . 0.0 109.438 179.972 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.693 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 75.81 17.08 2.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -112.43 79.48 0.26 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -55.63 107.68 0.36 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 0.0 109.486 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.514 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' LEU . 65.6 p . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.61 172.59 13.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.325 -0.859 . . . . 0.0 109.512 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.8 mt -100.5 155.5 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.907 . . . . 0.0 109.486 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.681 HD12 ' HG2' ' A' ' 47' ' ' PRO . 36.2 mm -118.17 91.75 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.267 -0.895 . . . . 0.0 109.457 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.443 ' HA ' ' HA ' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -95.33 175.8 6.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.488 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.891 HG11 HD11 ' A' ' 9' ' ' ILE . 76.4 t -84.25 142.33 40.78 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.357 -179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.731 ' HD2' HG13 ' A' ' 6' ' ' VAL . 35.6 Cg_endo -78.04 -169.44 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.517 2.145 . . . . 0.0 110.433 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -78.55 105.41 9.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -0.873 . . . . 0.0 109.411 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.891 HD11 HG11 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -105.46 -11.07 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.307 -179.859 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.16 -14.99 56.16 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -144.92 -176.29 18.8 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.967 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -71.06 142.59 50.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -1.148 . . . . 0.0 109.472 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.92 107.55 3.25 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -99.61 113.42 25.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -1.129 . . . . 0.0 109.459 -179.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.0 t -68.91 131.81 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -0.934 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 19.5 mm -116.94 -22.16 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.265 -0.897 . . . . 0.0 109.431 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.93 138.04 19.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.293 -0.879 . . . . 0.0 109.512 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.499 ' HG ' HG22 ' A' ' 20' ' ' VAL . 12.8 tp -113.48 101.97 9.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 32' ' ' LEU . 0.6 OUTLIER -108.84 56.65 0.62 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.444 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.499 HG22 ' HG ' ' A' ' 18' ' ' LEU . 2.3 m -134.28 160.28 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.224 -0.922 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.463 ' HB3' ' OD1' ' A' ' 24' ' ' ASP . 1.2 mtpp -137.43 156.98 47.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.27 -0.894 . . . . 0.0 109.466 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.1 m -84.55 129.65 34.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.271 -0.893 . . . . 0.0 109.47 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.451 ' O ' HG23 ' A' ' 51' ' ' VAL . . . 84.31 -9.4 64.27 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.997 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.463 ' OD1' ' HB3' ' A' ' 21' ' ' LYS . 0.9 OUTLIER -77.41 131.87 38.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -1.205 . . . . 0.0 109.462 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 50' ' ' GLY . 0.0 OUTLIER -85.95 120.57 27.5 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.217 -0.927 . . . . 0.0 109.467 179.961 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.705 HG22 ' H ' ' A' ' 27' ' ' GLU . 2.8 mt -92.26 -171.44 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.229 -0.92 . . . . 0.0 109.204 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 26' ' ' ILE . 11.0 mt-10 -145.44 163.02 35.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 109.461 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.693 ' O ' HG13 ' A' ' 28' ' ' VAL . 7.2 p -78.14 79.57 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.367 -0.833 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.504 ' CB ' ' O ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER 162.81 -34.43 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.471 179.924 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.481 ' NE2' HG23 ' A' ' 26' ' ' ILE . 28.4 tt0 -70.35 141.07 52.29 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.318 -0.864 . . . . 0.0 109.499 -179.988 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.474 ' C ' ' HA ' ' A' ' 45' ' ' PRO . . . -51.32 -177.17 0.03 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.661 HD13 ' HA ' ' A' ' 46' ' ' SER . 3.8 tp -151.41 -67.78 0.18 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.198 -1.178 . . . . 0.0 109.442 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.07 138.66 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.214 -0.929 . . . . 0.0 109.512 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 42.2 t -97.64 89.12 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.439 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.89 150.36 22.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.206 -0.934 . . . . 0.0 109.481 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 41' ' ' SER . 2.0 tt0 -115.24 167.23 11.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.303 -0.873 . . . . 0.0 109.547 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.96 -172.6 3.88 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.209 -0.932 . . . . 0.0 109.48 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -84.52 10.31 11.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.509 179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 5.4 mttp -121.0 -30.83 4.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.333 -0.854 . . . . 0.0 109.44 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 39' ' ' LYS . . . 169.75 -171.78 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.321 -0.862 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 36' ' ' GLU . 10.5 t -103.96 134.07 47.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.181 -0.949 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' MET . . . . . . . . . . . . . 2.2 mtt -138.73 107.2 5.84 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.251 -0.906 . . . . 0.0 109.487 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.29 166.04 21.75 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.182 -0.949 . . . . 0.0 109.465 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 45' ' ' PRO . 72.0 t -136.38 142.15 38.49 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.305 -0.872 . . . . 0.0 109.342 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 44' ' ' VAL . 35.8 Cg_endo -77.96 -168.27 0.59 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.512 2.142 . . . . 0.0 110.448 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.661 ' HA ' HD13 ' A' ' 32' ' ' LEU . 0.8 OUTLIER -85.21 124.09 72.45 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.374 -0.829 . . . . 0.0 109.392 -179.913 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.681 ' HG2' HD12 ' A' ' 4' ' ' ILE . 35.6 Cg_endo -78.45 0.55 9.83 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.306 2.004 . . . . 0.0 110.29 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.466 ' HE3' ' HG3' ' A' ' 74' ' ' PRO . 0.4 OUTLIER -160.15 116.73 2.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.941 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.76 80.93 2.7 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.19 -0.944 . . . . 0.0 109.467 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.996 ' HA3' HD11 ' A' ' 72' ' ' LEU . . . -136.37 -159.71 8.51 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 51' ' ' VAL . 11.7 p -103.4 124.1 57.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.201 -1.176 . . . . 0.0 109.519 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 21' ' ' LYS . 60.2 t -49.94 140.02 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.325 -0.859 . . . . 0.0 109.455 -179.991 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.7 tptm -96.94 -70.22 0.73 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.201 -0.937 . . . . 0.0 109.442 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 52.0 p -158.32 135.23 9.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.903 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 57' ' ' VAL . 20.9 t -83.31 117.45 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.292 -0.88 . . . . 0.0 109.452 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 8.9 t -94.21 19.99 8.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.453 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.833 HG21 HG23 ' A' ' 69' ' ' ILE . 0.7 OUTLIER -143.06 179.58 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.292 -0.88 . . . . 0.0 109.441 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.514 ' CB ' ' OD2' ' A' ' 61' ' ' ASP . 0.0 OUTLIER -130.0 167.39 18.33 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.537 -179.978 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -77.22 151.63 35.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.48 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.29 9.0 80.77 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.514 ' OD2' ' CB ' ' A' ' 58' ' ' LYS . 4.4 m-20 -85.04 150.77 24.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.215 -1.167 . . . . 0.0 109.487 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -112.44 104.99 13.13 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.491 HD13 ' HA ' ' A' ' 63' ' ' LEU . 3.2 mm? -110.35 173.56 6.27 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.333 -0.855 . . . . 0.0 109.487 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' O ' ' C ' ' A' ' 65' ' ' GLU . 18.2 ttpt -108.57 142.04 39.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.221 -0.925 . . . . 0.0 109.499 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 64' ' ' LYS . 12.7 pt-20 -42.79 138.58 1.91 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.336 -0.852 . . . . 0.0 109.628 -179.884 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.27 -12.86 61.86 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.458 ' CG ' HD12 ' A' ' 63' ' ' LEU . 4.3 m-20 -79.87 153.56 28.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -1.16 . . . . 0.0 109.423 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 5' ' ' ARG . . . -83.09 161.91 21.51 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.222 -0.924 . . . . 0.0 109.508 179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.95 HG22 HG23 ' A' ' 70' ' ' ILE . 2.8 mp -132.68 -54.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.23 -0.918 . . . . 0.0 109.481 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.95 HG23 HG22 ' A' ' 69' ' ' ILE . 36.4 pt -144.06 -172.37 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.915 . . . . 0.0 109.515 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -138.02 115.39 11.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.23 -0.919 . . . . 0.0 109.474 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.996 HD11 ' HA3' ' A' ' 50' ' ' GLY . 3.4 tm? -90.05 137.62 32.19 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.294 -0.878 . . . . 0.0 109.365 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.942 ' N ' HD13 ' A' ' 72' ' ' LEU . 10.7 tt0 -111.41 95.12 25.04 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.352 -0.842 . . . . 0.0 109.342 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 72' ' ' LEU . 35.7 Cg_endo -77.67 125.88 7.8 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.61 2.206 . . . . 0.0 110.489 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -168.07 82.47 0.18 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.304 -0.872 . . . . 0.0 109.364 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 78' ' ' ALA . . . -89.36 122.06 32.22 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 -179.97 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' A' ' 78' ' ' ALA . . . 43.32 -98.71 0.01 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 76' ' ' ALA . . . 61.59 22.57 13.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -1.152 . . . . 0.0 109.462 -179.914 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 3.5 ttt180 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.44 179.956 . . . . . . . . 0 0 . 1 stop_ save_